<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="0" size="12" family="Times" color="#231f20"/>
	<fontspec id="1" size="10" family="Times" color="#231f20"/>
	<fontspec id="2" size="10" family="Times" color="#231f20"/>
	<fontspec id="3" size="10" family="Times" color="#231f20"/>
	<fontspec id="4" size="10" family="Times" color="#231f20"/>
	<fontspec id="5" size="25" family="Times" color="#231f20"/>
	<fontspec id="6" size="20" family="Times" color="#231f20"/>
	<fontspec id="7" size="13" family="Times" color="#231f20"/>
	<fontspec id="8" size="26" family="Times" color="#ffffff"/>
	<fontspec id="9" size="10" family="Times" color="#000000"/>
<text top="1128" left="425" width="28" height="16" font="0"><i><b>e506</b></i></text>
<text top="1070" left="83" width="373" height="14" font="1"><b>(<i>Circulation</i></b><b>. 2016;133:e506-e574. DOI: 10.1161/CIR.0000000000000311.)</b></text>
<text top="1084" left="83" width="626" height="13" font="3">© 2016 by the American College of Cardiology Foundation, the American Heart Association, Inc.,  and the Heart Rhythm Society.</text>
<text top="1103" left="83" width="271" height="14" font="2"><i><b>Circulation</b> </i><b>is available at http://circ.ahajournals.org </b></text>
<text top="1103" left="616" width="193" height="14" font="1"><b>DOI: 10.1161/CIR.0000000000000311</b></text>
<text top="120" left="106" width="676" height="32" font="5"><b>2015 ACC/AHA/HRS Guideline for the Management of </b></text>
<text top="150" left="136" width="608" height="32" font="5"><b>Adult Patients With Supraventricular Tachycardia</b></text>
<text top="184" left="151" width="589" height="26" font="6"><b>A Report of the American College of Cardiology/American  </b></text>
<text top="208" left="120" width="651" height="26" font="6"><b>Heart Association Task Force on Clinical Practice Guidelines and  </b></text>
<text top="232" left="312" width="255" height="26" font="6"><b>the Heart Rhythm Society</b></text>
<text top="269" left="311" width="258" height="18" font="7">WRITING COMMITTEE MEMBERS*</text>
<text top="287" left="271" width="341" height="18" font="7">Richard L. Page, MD, FACC, FAHA, FHRS, Chair; </text>
<text top="305" left="261" width="360" height="18" font="7">José A. Joglar, MD, FACC, FAHA, FHRS, Vice Chair; </text>
<text top="323" left="148" width="593" height="18" font="7">Mary A. Caldwell, RN, MBA, PhD, FAHA; Hugh Calkins, MD, FACC, FAHA, FHRS*†;  </text>
<text top="341" left="258" width="372" height="18" font="7">Jamie B. Conti, MD, FACC*‡§; Barbara J. Deal, MD‡;  </text>
<text top="359" left="143" width="602" height="18" font="7">N.A. Mark Estes III, MD, FACC, FAHA, FHRS*‡; Michael E. Field, MD, FACC, FHRS‡;  </text>
<text top="377" left="251" width="386" height="18" font="7">Zachary D. Goldberger, MD, MS, FACC, FAHA, FHRS‡;  </text>
<text top="395" left="137" width="615" height="18" font="7">Stephen C. Hammill, MD, FACC, FHRS†; Julia H. Indik, MD, PhD, FACC, FAHA, FHRS†;  </text>
<text top="413" left="149" width="591" height="18" font="7">Bruce D. Lindsay, MD, FACC, FHRS*†; Brian Olshansky, MD, FACC, FAHA, FHRS*‡;  </text>
<text top="431" left="151" width="566" height="18" font="7">Andrea M. Russo, MD, FACC, FHRS*§; Win-Kuang Shen, MD, FACC, FAHA, FHRS</text>
<text top="435" left="716" width="7" height="13" font="3">║</text>
<text top="431" left="724" width="14" height="18" font="7">;  </text>
<text top="449" left="155" width="578" height="18" font="7">Cynthia M. Tracy, MD, FACC‡; Sana M. Al-Khatib, MD, MHS, FACC, FAHA, FHRS,  </text>
<text top="467" left="322" width="235" height="18" font="7">Evidence Review Committee Chair‡</text>
<text top="497" left="313" width="254" height="18" font="7">ACC/AHA TASK FORCE MEMBERS</text>
<text top="515" left="280" width="329" height="18" font="7">Jonathan L. Halperin, MD, FACC, FAHA, Chair;  </text>
<text top="533" left="275" width="339" height="18" font="7">Glenn N. Levine, MD, FACC, FAHA, Chair-Elect;  </text>
<text top="551" left="228" width="433" height="18" font="7">Jeffrey L. Anderson, MD, FACC, FAHA, Immediate Past Chair¶;  </text>
<text top="569" left="164" width="561" height="18" font="7">Nancy M. Albert, PhD, RN, FAHA¶; Sana M. Al-Khatib, MD, MHS, FACC, FAHA;  </text>
<text top="587" left="184" width="521" height="18" font="7">Kim K. Birtcher, PharmD, AACC; Biykem Bozkurt, MD, PhD, FACC, FAHA;  </text>
<text top="605" left="204" width="480" height="18" font="7">Ralph G. Brindis, MD, MPH, MACC; Joaquin E. Cigarroa, MD, FACC;  </text>
<text top="623" left="218" width="453" height="18" font="7">Lesley H. Curtis, PhD, FAHA; Lee A. Fleisher, MD, FACC, FAHA;  </text>
<text top="641" left="145" width="599" height="18" font="7">Federico Gentile, MD, FACC; Samuel Gidding, MD, FAHA; Mark A. Hlatky, MD, FACC;  </text>
<text top="659" left="215" width="459" height="18" font="7">John Ikonomidis, MD, PhD, FAHA; Jose Joglar, MD, FACC, FAHA;  </text>
<text top="677" left="197" width="495" height="18" font="7">Richard J. Kovacs, MD, FACC, FAHA¶; E. Magnus Ohman, MD, FACC¶;  </text>
<text top="695" left="196" width="497" height="18" font="7">Susan J. Pressler, PhD, RN, FAHA; Frank W. Sellke, MD, FACC, FAHA¶;  </text>
<text top="713" left="187" width="506" height="18" font="7">Win-Kuang Shen, MD, FACC, FAHA¶; Duminda N. Wijeysundera, MD, PhD</text>
<text top="195" left="-203" width="73" height="33" font="8"><b>LWW</b></text>
<text top="403" left="-329" width="30" height="13" font="3">10163</text>
<text top="760" left="83" width="729" height="13" font="3">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities </text>
<text top="774" left="71" width="742" height="13" font="3">may apply; see Appendix 1 for recusal information. †HRS Representative. ‡ACC/AHA Representative. §ACC/AHA Task Force on Performance Measures </text>
<text top="787" left="71" width="701" height="14" font="3">Liaison. ║ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ¶Former Task Force member; current member during this writing effort.</text>
<text top="801" left="83" width="730" height="13" font="3">This document was approved by the American College of Cardiology Board of Trustees and Executive Committee, the American Heart Association </text>
<text top="814" left="71" width="742" height="13" font="3">Science Advisory and Coordinating Committee, and the Heart Rhythm Society Board of Trustees in August 2015 and the American Heart Association </text>
<text top="828" left="71" width="200" height="13" font="3">Executive Committee in September 2015.</text>
<text top="841" left="83" width="726" height="14" font="1"><b>The Author Comprehensive Relationships Data Supplement is av<a href="">ailable with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/</a></b></text>
<text top="854" left="71" width="158" height="14" font="1"><a href=""><b>CIR.0000000000000311/-/DC1.</b></a></text>
<text top="868" left="83" width="726" height="14" font="1"><b>The Data Supplement files are available with this article <a href="">at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000311/-/DC2.</a></b></text>
<text top="882" left="83" width="730" height="13" font="3">The American Heart Association requests that this document be cited as follows: Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes </text>
<text top="895" left="71" width="738" height="13" font="3">NAM 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen W-K, Tracy CM, Al-Khatib SM. 2015 ACC/AHA/</text>
<text top="909" left="71" width="741" height="13" font="3">HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association  </text>
<text top="922" left="71" width="711" height="13" font="3">Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2016;133;e506-e574. doi: 10.1161/CIR.0000000000000311.</text>
<text top="936" left="83" width="553" height="13" font="3">This article has been copublished in the <i>Journal of the American College of Cardiology</i> and <i><b>Heart</b>Rhythm Journal</i>. </text>
<text top="949" left="83" width="731" height="13" font="3">Copies: This document is available on the World Wide Web sites of the American Colle<a href="">ge of Cardiology (www.acc.org), the </a>American Heart </text>
<text top="963" left="71" width="738" height="13" font="3"><a href="">Association (professional.heart.org), and the Heart Rhythm Society (www.hrsonline.org). </a>A copy of the document is av<a href="">ailable at http://professional.heart.</a></text>
<text top="976" left="71" width="741" height="13" font="3"><a href="">org/statements by using either “Search for Guidelines &amp; Statements” or the “Bro</a>wse By Topic” area. To purchase additional reprints, call 843-216-2533 </text>
<text top="990" left="71" width="213" height="13" font="3"><a href="mailto:kelle.ramsay@wolterskluwer.com">or e-mail kelle.ramsay@wolterskluwer.com.</a></text>
<text top="1003" left="83" width="729" height="13" font="3">Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines </text>
<text top="1017" left="71" width="738" height="13" font="3">dev<a href="">elopment, visit http://professional.heart.org/statements. Select the “Guidelines &amp; Statements” drop-do</a>wn menu, then click “Publication Development.”</text>
<text top="1030" left="83" width="731" height="13" font="3">Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express </text>
<text top="1044" left="71" width="738" height="13" font="3">permission of the American Heart <a href="">Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-</a></text>
<text top="1057" left="71" width="680" height="13" font="3"><a href="">Permission-Guidelines_UCM_300404_Article.jsp. </a>A link to the “Copyright Permissions Request Form” appears on the right side of the page.</text>
<text top="56" left="278" width="324" height="33" font="8"><b>ACC/AHA/HRS Guideline</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="10" size="13" family="Times" color="#231f20"/>
	<fontspec id="11" size="13" family="Times" color="#231f20"/>
	<fontspec id="12" size="15" family="Times" color="#231f20"/>
	<fontspec id="13" size="12" family="Times" color="#231f20"/>
	<fontspec id="14" size="6" family="Times" color="#231f20"/>
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e507</i></b></text>
<text top="96" left="180" width="130" height="20" font="12"><b>Table of Contents</b></text>
<text top="116" left="69" width="351" height="16" font="13">Preamble  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e507</text>
<text top="133" left="69" width="351" height="16" font="13">1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e508</text>
<text top="150" left="69" width="351" height="16" font="13">    1.1.  Methodology and Evidence Review . . . . . . . . . . e508</text>
<text top="166" left="69" width="351" height="16" font="13">    1.2.  Organization of the GWC . . . . . . . . . . . . . . . . . . e510</text>
<text top="183" left="69" width="351" height="16" font="13">    1.3.  Document  Review  and Approval  . . . . . . . . . . . . e510</text>
<text top="200" left="69" width="351" height="16" font="13">    1.4.  Scope of the Guideline  . . . . . . . . . . . . . . . . . . . . e510</text>
<text top="217" left="69" width="351" height="16" font="13">2.  General Principles. . . . . . . . . . . . . . . . . . . . . . . . . . . . e510</text>
<text top="233" left="69" width="351" height="16" font="13">    2.1.  Mechanisms  and  Definitions. . . . . . . . . . . . . . . . e510</text>
<text top="250" left="69" width="251" height="16" font="13">    2.2.   Epidemiology,  Demographics,  and   </text>
<text top="267" left="115" width="305" height="16" font="13">Public Health Impact. . . . . . . . . . . . . . . . . . . . . . e510</text>
<text top="283" left="69" width="287" height="16" font="13">    2.3.   Evaluation of the Patient With Suspected  </text>
<text top="300" left="115" width="305" height="16" font="13">or Documented SVT . . . . . . . . . . . . . . . . . . . . . . e511</text>
<text top="317" left="69" width="302" height="16" font="13">        2.3.1.   Clinical Presentation and Differential </text>
<text top="333" left="155" width="266" height="16" font="13">Diagnosis on the Basis of Symptoms. . . . e511</text>
<text top="350" left="69" width="351" height="16" font="13">        2.3.2.  Evaluation of the ECG . . . . . . . . . . . . . . . e514</text>
<text top="367" left="69" width="351" height="16" font="13">    2.4.  Principles  of  Medical Therapy  . . . . . . . . . . . . . . e515</text>
<text top="383" left="69" width="29" height="16" font="13">  </text>
<text top="383" left="85" width="29" height="16" font="13">  </text>
<text top="383" left="101" width="101" height="16" font="13"> 2.4.1. Acute </text>
<text top="383" left="191" width="76" height="16" font="13">Treatment: </text>
<text top="383" left="257" width="163" height="16" font="13">Recommendations . . . . e515</text>
<text top="400" left="69" width="29" height="16" font="13">  </text>
<text top="400" left="85" width="29" height="16" font="13">  </text>
<text top="400" left="101" width="68" height="16" font="13"> 2.4.2.  </text>
<text top="400" left="155" width="64" height="16" font="13">Ongoing </text>
<text top="400" left="208" width="93" height="16" font="13">Management: </text>
<text top="400" left="290" width="4" height="16" font="13"> </text>
<text top="417" left="155" width="266" height="16" font="13">Recommendations  . . . . . . . . . . . . . . . . . . e517</text>
<text top="433" left="69" width="283" height="16" font="13">    2.5.   Basic Principles of Electrophysiological  </text>
<text top="450" left="115" width="305" height="16" font="13">Study, Mapping, and Ablation  . . . . . . . . . . . . . . e518</text>
<text top="467" left="69" width="294" height="16" font="13">        2.5.1.   Mapping With Multiple and Roving </text>
<text top="483" left="155" width="266" height="16" font="13">Electrodes. . . . . . . . . . . . . . . . . . . . . . . . . e518</text>
<text top="500" left="69" width="309" height="16" font="13">        2.5.2.   Tools to Facilitate Ablation, Including  </text>
<text top="517" left="154" width="266" height="16" font="13">3-Dimensional Electroanatomic Mapping. . . .e518</text>
<text top="534" left="69" width="29" height="16" font="13">  </text>
<text top="534" left="85" width="29" height="16" font="13">  </text>
<text top="534" left="101" width="68" height="16" font="13"> 2.5.3.  </text>
<text top="534" left="155" width="66" height="16" font="13">Mapping </text>
<text top="534" left="210" width="35" height="16" font="13">and </text>
<text top="534" left="233" width="64" height="16" font="13">Ablation </text>
<text top="534" left="286" width="42" height="16" font="13">With </text>
<text top="534" left="317" width="32" height="16" font="13">No </text>
<text top="534" left="338" width="4" height="16" font="13"> </text>
<text top="550" left="155" width="266" height="16" font="13">or Minimal Radiation. . . . . . . . . . . . . . . . e519</text>
<text top="567" left="69" width="29" height="16" font="13">  </text>
<text top="567" left="85" width="29" height="16" font="13">  </text>
<text top="567" left="101" width="117" height="16" font="13"> 2.5.4. Ablation </text>
<text top="567" left="207" width="55" height="16" font="13">Energy </text>
<text top="567" left="252" width="168" height="16" font="13">Sources  . . . . . . . . . . . . . e519</text>
<text top="584" left="69" width="351" height="16" font="13">3.  Sinus Tachyarrhythmias  . . . . . . . . . . . . . . . . . . . . . . . e520</text>
<text top="600" left="69" width="351" height="16" font="13">    3.1.  Physiological  Sinus Tachycardia. . . . . . . . . . . . . e521</text>
<text top="617" left="69" width="351" height="16" font="13">    3.2.  Inappropriate  Sinus Tachycardia. . . . . . . . . . . . . e521</text>
<text top="634" left="69" width="29" height="16" font="13">  </text>
<text top="634" left="85" width="29" height="16" font="13">  </text>
<text top="634" left="101" width="101" height="16" font="13"> 3.2.1. Acute </text>
<text top="634" left="191" width="229" height="16" font="13">Treatment. . . . . . . . . . . . . . . . . . . . e521</text>
<text top="650" left="69" width="28" height="16" font="13">  </text>
<text top="650" left="84" width="28" height="16" font="13">  </text>
<text top="650" left="99" width="109" height="16" font="13"> 3.2.2. Ongoing </text>
<text top="650" left="197" width="86" height="16" font="13">Management: </text>
<text top="650" left="272" width="148" height="16" font="13">Recommendations. . . .e521</text>
<text top="667" left="69" width="351" height="16" font="13">4.  Nonsinus Focal Atrial Tachycardia and MAT. . . . . . . e523</text>
<text top="684" left="69" width="351" height="16" font="13">    4.1.   Focal Atrial Tachycardia . . . . . . . . . . . . . . . . . . . e523</text>
<text top="700" left="69" width="29" height="16" font="13">  </text>
<text top="700" left="85" width="29" height="16" font="13">  </text>
<text top="700" left="101" width="101" height="16" font="13"> 4.1.1. Acute </text>
<text top="700" left="191" width="76" height="16" font="13">Treatment: </text>
<text top="700" left="257" width="163" height="16" font="13">Recommendations . . . . e526</text>
<text top="717" left="69" width="29" height="16" font="13">  </text>
<text top="717" left="84" width="29" height="16" font="13">  </text>
<text top="717" left="100" width="112" height="16" font="13"> 4.1.2. Ongoing </text>
<text top="717" left="200" width="87" height="16" font="13">Management: </text>
<text top="717" left="275" width="145" height="16" font="13">Recommendations  . . .e527</text>
<text top="734" left="69" width="351" height="16" font="13">    4.2.  Multifocal Atrial Tachycardia . . . . . . . . . . . . . . . e527</text>
<text top="750" left="69" width="29" height="16" font="13">  </text>
<text top="750" left="85" width="29" height="16" font="13">  </text>
<text top="750" left="101" width="101" height="16" font="13"> 4.2.1. Acute </text>
<text top="750" left="191" width="76" height="16" font="13">Treatment: </text>
<text top="750" left="257" width="163" height="16" font="13">Recommendation. . . . . e531</text>
<text top="767" left="69" width="29" height="16" font="13">  </text>
<text top="767" left="85" width="29" height="16" font="13">  </text>
<text top="767" left="101" width="116" height="16" font="13"> 4.2.2. Ongoing </text>
<text top="767" left="206" width="90" height="16" font="13">Management: </text>
<text top="767" left="284" width="136" height="16" font="13">Recommendations  e531</text>
<text top="784" left="69" width="351" height="16" font="13">5.  Atrioventricular Nodal Reentrant Tachycardia . . . . . . e531</text>
<text top="801" left="69" width="351" height="16" font="13">    5.1.  Acute Treatment:  Recommendations  . . . . . . . . . e532</text>
<text top="817" left="69" width="351" height="16" font="13">    5.2.  Ongoing  Management:  Recommendations. . . . . e533</text>
<text top="834" left="69" width="351" height="16" font="13">6.  Manifest and Concealed Accessory Pathways  . . . . . . e534</text>
<text top="851" left="69" width="302" height="16" font="13">    6.1.   Management of Patients With Symptomatic  </text>
<text top="867" left="115" width="305" height="16" font="13">Manifest or Concealed Accessory Pathways  . . . e535</text>
<text top="884" left="69" width="29" height="16" font="13">  </text>
<text top="884" left="85" width="29" height="16" font="13">  </text>
<text top="884" left="101" width="101" height="16" font="13"> 6.1.1. Acute </text>
<text top="884" left="191" width="76" height="16" font="13">Treatment: </text>
<text top="884" left="257" width="163" height="16" font="13">Recommendations . . . . e535</text>
<text top="901" left="69" width="29" height="16" font="13">  </text>
<text top="901" left="84" width="29" height="16" font="13">  </text>
<text top="901" left="100" width="112" height="16" font="13"> 6.1.2. Ongoing </text>
<text top="901" left="200" width="87" height="16" font="13">Management: </text>
<text top="901" left="275" width="145" height="16" font="13">Recommendations  . . .e536</text>
<text top="917" left="69" width="351" height="16" font="13">    6.2.  Management  of Asymptomatic  Pre-Excitation. . e537</text>
<text top="934" left="69" width="29" height="16" font="13">  </text>
<text top="934" left="85" width="29" height="16" font="13">  </text>
<text top="934" left="101" width="116" height="16" font="13"> 6.2.1. PICOTS </text>
<text top="934" left="207" width="57" height="16" font="13">Critical </text>
<text top="934" left="253" width="167" height="16" font="13">Questions  . . . . . . . . . . . e537</text>
<text top="951" left="69" width="29" height="16" font="13">  </text>
<text top="951" left="85" width="29" height="16" font="13">  </text>
<text top="951" left="101" width="67" height="16" font="13"> 6.2.2.  </text>
<text top="951" left="154" width="98" height="16" font="13">Asymptomatic </text>
<text top="951" left="241" width="59" height="16" font="13">Patients </text>
<text top="951" left="289" width="42" height="16" font="13">With </text>
<text top="951" left="321" width="4" height="16" font="13"> </text>
<text top="967" left="154" width="266" height="16" font="13">Pre-Excitation: Recommendations. . . . . . e538</text>
<text top="984" left="69" width="354" height="16" font="13">    6.3.   Risk Stratification of Symptomatic Patients With Manifest </text>
<text top="1001" left="112" width="308" height="16" font="13">Accessory Pathways: Recommendations. . . . . . . . . . e539</text>
<text top="1017" left="69" width="351" height="16" font="13">7.  Atrial Flutter  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e539</text>
<text top="1034" left="69" width="351" height="16" font="13">    7.1.  Cavotricuspid Isthmus–Dependent Atrial Flutter . e539</text>
<text top="1051" left="69" width="351" height="16" font="13">    7.2.  Non–Isthmus-Dependent Atrial  Flutters . . . . . . . e540</text>
<text top="1068" left="69" width="351" height="16" font="13">    7.3.  Acute Treatment:  Recommendations  . . . . . . . . . e541</text>
<text top="1084" left="69" width="185" height="16" font="13">    7.4.   Ongoing  Management:   </text>
<text top="1101" left="115" width="305" height="16" font="13">Recommendations. . . . . . . . . . . . . . . . . . . . . . . . e542</text>
<text top="97" left="456" width="351" height="16" font="13">8.  Junctional Tachycardia  . . . . . . . . . . . . . . . . . . . . . . . . e544</text>
<text top="114" left="456" width="351" height="16" font="13">    8.1.  Acute Treatment:  Recommendations  . . . . . . . . . e544</text>
<text top="131" left="456" width="351" height="16" font="13">    8.2.  Ongoing  Management:  Recommendations. . . . . e545</text>
<text top="147" left="456" width="351" height="16" font="13">9.  Special Populations. . . . . . . . . . . . . . . . . . . . . . . . . . . e545</text>
<text top="164" left="456" width="351" height="16" font="13">    9.1.  Pediatrics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e545</text>
<text top="181" left="456" width="351" height="16" font="13">    9.2.  Patients With Adult Congenital Heart Disease . . . . e549</text>
<text top="197" left="456" width="29" height="16" font="13">  </text>
<text top="197" left="472" width="29" height="16" font="13">  </text>
<text top="197" left="488" width="113" height="16" font="13"> 9.2.1. Clinical </text>
<text top="197" left="590" width="217" height="16" font="13">Features  . . . . . . . . . . . . . . . . . . . e549</text>
<text top="214" left="456" width="29" height="16" font="13">  </text>
<text top="214" left="472" width="29" height="16" font="13">  </text>
<text top="214" left="488" width="101" height="16" font="13"> 9.2.2. Acute </text>
<text top="214" left="578" width="76" height="16" font="13">Treatment: </text>
<text top="214" left="644" width="163" height="16" font="13">Recommendations . . . . e550</text>
<text top="231" left="456" width="29" height="16" font="13">  </text>
<text top="231" left="471" width="28" height="16" font="13">  </text>
<text top="231" left="487" width="110" height="16" font="13"> 9.2.3. Ongoing </text>
<text top="231" left="585" width="85" height="16" font="13">Management: </text>
<text top="231" left="658" width="149" height="16" font="13">Recommendations. . . . e551</text>
<text top="248" left="456" width="351" height="16" font="13">    9.3.  Pregnancy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e553</text>
<text top="264" left="456" width="29" height="16" font="13">  </text>
<text top="264" left="472" width="29" height="16" font="13">  </text>
<text top="264" left="488" width="101" height="16" font="13"> 9.3.1. Acute </text>
<text top="264" left="578" width="76" height="16" font="13">Treatment: </text>
<text top="264" left="644" width="163" height="16" font="13">Recommendations . . . . e553</text>
<text top="281" left="456" width="29" height="16" font="13">  </text>
<text top="281" left="472" width="29" height="16" font="13">  </text>
<text top="281" left="488" width="60" height="16" font="13"> 9.3.2. </text>
<text top="281" left="540" width="60" height="16" font="13">Ongoing </text>
<text top="281" left="589" width="86" height="16" font="13">Management: </text>
<text top="281" left="663" width="144" height="16" font="13">Recommendations  . . . e554</text>
<text top="298" left="456" width="351" height="16" font="13">    9.4.  SVT in Older Populations. . . . . . . . . . . . . . . . . . e555</text>
<text top="315" left="456" width="29" height="16" font="13">  </text>
<text top="315" left="472" width="29" height="16" font="13">  </text>
<text top="315" left="488" width="67" height="16" font="13"> 9.4.1.  </text>
<text top="315" left="541" width="48" height="16" font="13">Acute </text>
<text top="315" left="578" width="72" height="16" font="13">Treatment </text>
<text top="315" left="640" width="35" height="16" font="13">and </text>
<text top="315" left="664" width="64" height="16" font="13">Ongoing </text>
<text top="315" left="717" width="4" height="16" font="13"> </text>
<text top="331" left="541" width="266" height="16" font="13">Management: Recommendation. . . . . . . . e555</text>
<text top="348" left="456" width="351" height="16" font="13">10.  Quality-of-Life Considerations. . . . . . . . . . . . . . . . . e555</text>
<text top="365" left="456" width="351" height="16" font="13">11. Cost-Effectiveness. . . . . . . . . . . . . . . . . . . . . . . . . . . e555</text>
<text top="381" left="456" width="351" height="16" font="13">12.  Shared Decision Making. . . . . . . . . . . . . . . . . . . . . . e556</text>
<text top="398" left="456" width="351" height="16" font="13">13.  Evidence Gaps and Future Research Needs  . . . . . . . e556</text>
<text top="415" left="456" width="351" height="16" font="13">References  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e557</text>
<text top="432" left="456" width="312" height="16" font="13">Appendix 1.   Author Relationships With Industry and  </text>
<text top="448" left="533" width="274" height="16" font="13">Other Entities (Relevant)  . . . . . . . . . . . . . . e570</text>
<text top="465" left="456" width="322" height="16" font="13">Appendix 2.   Reviewer Relationships With Industry and </text>
<text top="482" left="534" width="273" height="16" font="13">Other Entities (Relevant)  . . . . . . . . . . . . . . e571</text>
<text top="498" left="456" width="351" height="16" font="13">Appendix  3.   Abbreviations . . . . . . . . . . . . . . . . . . . . . . . e574</text>
<text top="533" left="596" width="71" height="20" font="12"><b>Preamble</b></text>
<text top="554" left="456" width="357" height="16" font="13">Since 1980, the American College of Cardiology (ACC) </text>
<text top="571" left="456" width="358" height="16" font="13">and American Heart Association (AHA) have translated </text>
<text top="589" left="456" width="358" height="16" font="13">scientific evidence into clinical practice guidelines with </text>
<text top="606" left="456" width="356" height="16" font="13">recommendations to improve cardiovascular health. These </text>
<text top="624" left="456" width="357" height="16" font="13">guidelines, based on systematic methods to evaluate and </text>
<text top="641" left="456" width="351" height="16" font="13">classify evidence, provide a cornerstone of quality cardio-</text>
<text top="659" left="456" width="81" height="16" font="13">vascular care.</text>
<text top="676" left="477" width="295" height="16" font="13">In response to reports from the Institute of Medicine</text>
<text top="677" left="773" width="10" height="9" font="14">1,2</text>
<text top="676" left="783" width="27" height="16" font="13"> and </text>
<text top="694" left="456" width="355" height="16" font="13">a mandate to evaluate new knowledge and maintain relevance </text>
<text top="711" left="456" width="357" height="16" font="13">at the point of care, the ACC/AHA Task Force on Clinical </text>
<text top="729" left="456" width="339" height="16" font="13">Practice Guidelines (Task Force) modified its methodology.</text>
<text top="729" left="795" width="12" height="9" font="14">3–5</text>
<text top="729" left="807" width="4" height="16" font="13"> </text>
<text top="746" left="456" width="351" height="16" font="13">The relationships between guidelines, data standards, appro-</text>
<text top="764" left="456" width="356" height="16" font="13">priate use criteria, and performance measures are addressed </text>
<text top="781" left="456" width="60" height="16" font="13">elsewhere.</text>
<text top="782" left="516" width="4" height="9" font="14">4</text>
<text top="817" left="456" width="89" height="18" font="10"><b>Intended Use</b></text>
<text top="836" left="456" width="362" height="16" font="13">Practice guidelines provide recommendations applicable </text>
<text top="854" left="456" width="351" height="16" font="13">to patients with or at risk of developing cardiovascular dis-</text>
<text top="871" left="456" width="356" height="16" font="13">ease. The focus is on medical practice in the United States, </text>
<text top="889" left="456" width="351" height="16" font="13">but guidelines developed in collaboration with other organi-</text>
<text top="906" left="456" width="356" height="16" font="13">zations may have a broader target. Although guidelines may </text>
<text top="924" left="456" width="358" height="16" font="13">inform regulatory or payer decisions, they are intended to </text>
<text top="941" left="456" width="281" height="16" font="13">improve quality of care in the interest of patients.</text>
<text top="977" left="456" width="114" height="18" font="10"><b>Evidence Review</b></text>
<text top="996" left="456" width="351" height="16" font="13">Guideline Writing Committee (GWC) members review the lit-</text>
<text top="1014" left="456" width="354" height="16" font="13">erature; weigh the quality of evidence for or against particular </text>
<text top="1031" left="456" width="355" height="16" font="13">tests, treatments, or procedures; and estimate expected health </text>
<text top="1049" left="456" width="357" height="16" font="13">outcomes. In developing recommendations, the GWC uses </text>
<text top="1066" left="456" width="355" height="16" font="13">evidence-based methodologies that are based on all available </text>
<text top="1084" left="456" width="27" height="16" font="13">data.</text>
<text top="1084" left="483" width="12" height="9" font="14">4–6</text>
<text top="1084" left="496" width="317" height="16" font="13"> Literature searches focus on randomized controlled </text>
<text top="1101" left="456" width="360" height="16" font="13">trials (RCTs) but also include registries, nonrandomized </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="15" size="12" family="Times" color="#3c4ba7"/>
	<fontspec id="16" size="12" family="Times" color="#231f20"/>
<text top="47" left="71" width="243" height="17" font="11"><i><b>e508  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="351" height="16" font="13">comparative and descriptive studies, case series, cohort stud-</text>
<text top="115" left="71" width="351" height="16" font="13">ies, systematic reviews, and expert opinion. Only selected ref-</text>
<text top="132" left="71" width="99" height="16" font="13">erences are cited.</text>
<text top="150" left="92" width="330" height="16" font="13">The Task Force recognizes the need for objective, indepen-</text>
<text top="167" left="71" width="351" height="16" font="13">dent Evidence Review Committees (ERCs) that include meth-</text>
<text top="184" left="71" width="356" height="16" font="13">odologists, epidemiologists, clinicians, and biostatisticians </text>
<text top="202" left="71" width="356" height="16" font="13">who systematically survey, abstract, and assess the evidence </text>
<text top="219" left="71" width="355" height="16" font="13">to address key clinical questions posed in the PICOTS format </text>
<text top="237" left="71" width="359" height="16" font="13">(P=population, I=intervention, C=comparator, O=outcome, </text>
<text top="254" left="71" width="128" height="16" font="13">T=timing, S=setting).</text>
<text top="254" left="198" width="10" height="9" font="14">4,5</text>
<text top="254" left="208" width="221" height="16" font="13"> Practical considerations, including </text>
<text top="271" left="70" width="354" height="16" font="13">time and resource constraints, limit the ERCs to evidence that </text>
<text top="289" left="70" width="351" height="16" font="13">is relevant to key clinical questions and lends itself to sys-</text>
<text top="306" left="70" width="355" height="16" font="13">tematic review and analysis that could affect the strength of </text>
<text top="323" left="70" width="351" height="16" font="13">corresponding recommendations. Recommendations devel-</text>
<text top="341" left="70" width="355" height="16" font="13">oped by the GWC on the basis of the systematic review are </text>
<text top="358" left="70" width="54" height="16" font="13">marked “</text>
<text top="359" left="125" width="10" height="9" font="14">SR</text>
<text top="358" left="135" width="10" height="16" font="13">”.</text>
<text top="394" left="71" width="248" height="18" font="10"><b>Guideline-Directed Medical Therapy</b></text>
<text top="413" left="71" width="357" height="16" font="13">The term guideline-directed medical therapy refers to care </text>
<text top="431" left="71" width="360" height="16" font="13">defined mainly by ACC/AHA Class I recommendations. </text>
<text top="448" left="71" width="358" height="16" font="13">For these and all recommended drug treatment regimens, </text>
<text top="465" left="71" width="351" height="16" font="13">the reader should confirm dosage with product insert mate-</text>
<text top="483" left="71" width="351" height="16" font="13">rial and carefully evaluate for contraindications and interac-</text>
<text top="500" left="71" width="355" height="16" font="13">tions. Recommendations are limited to treatments, drugs, and </text>
<text top="518" left="71" width="306" height="16" font="13">devices approved for clinical use in the United States.</text>
<text top="553" left="71" width="327" height="18" font="10"><b>Class of Recommendation and Level of Evidence</b></text>
<text top="573" left="71" width="351" height="16" font="13">The Class of Recommendation (COR; ie, the strength of the rec-</text>
<text top="590" left="71" width="351" height="16" font="13">ommendation) encompasses the anticipated magnitude and cer-</text>
<text top="607" left="71" width="354" height="16" font="13">tainty of benefit in proportion to risk. The Level of Evidence (LOE) </text>
<text top="625" left="71" width="354" height="16" font="13">rates evidence supporting the effect of the intervention on the basis </text>
<text top="642" left="71" width="355" height="16" font="13">of the type, quality, quantity, and consistency of data from clinical </text>
<text top="660" left="71" width="171" height="16" font="13">trials and other reports (Table 1).</text>
<text top="660" left="241" width="10" height="9" font="14">5,7</text>
<text top="660" left="250" width="171" height="16" font="13"> Unless otherwise stated, recom-</text>
<text top="677" left="71" width="351" height="16" font="13">mendations are sequenced by COR and then by LOE. Where com-</text>
<text top="694" left="71" width="355" height="16" font="13">parative data exist, preferred strategies take precedence. When &gt;1 </text>
<text top="712" left="71" width="354" height="16" font="13">drug, strategy, or therapy exists within the same COR and LOE and </text>
<text top="729" left="71" width="129" height="16" font="13">no comparative data are </text>
<text top="729" left="199" width="226" height="17" font="13">­available, options are listed alphabetically. </text>
<text top="747" left="71" width="355" height="16" font="13">Each recommendation is followed by supplemental text linked to </text>
<text top="764" left="71" width="224" height="16" font="13">supporting references and evidence tables.</text>
<text top="803" left="71" width="320" height="18" font="10"><b>Relationships With Industry and Other Entities</b></text>
<text top="823" left="71" width="351" height="16" font="13">The ACC and AHA sponsor the guidelines without com-</text>
<text top="840" left="71" width="356" height="16" font="13">mercial support, and members volunteer their time. The Task </text>
<text top="858" left="71" width="351" height="16" font="13">Force zealously avoids actual, potential, or perceived con-</text>
<text top="875" left="71" width="358" height="16" font="13">flicts of interest that might arise through relationships with </text>
<text top="892" left="71" width="359" height="16" font="13">industry or other entities (RWI). All GWC members and </text>
<text top="910" left="71" width="351" height="16" font="13">reviewers are required to disclose current industry relation-</text>
<text top="927" left="71" width="357" height="16" font="13">ships or personal interests from 12 months before initiation </text>
<text top="945" left="71" width="356" height="16" font="13">of the writing effort. Management of RWI involves selecting </text>
<text top="962" left="71" width="357" height="16" font="13">a balanced GWC and assuring that the chair and a majority </text>
<text top="979" left="71" width="357" height="16" font="13">of committee members have no relevant RWI (Appendix 1).  </text>
<text top="997" left="71" width="351" height="16" font="13">Members are restricted with regard to writing or voting on sec-</text>
<text top="1014" left="71" width="357" height="16" font="13">tions to which their RWI apply. For transparency, members’ </text>
<text top="1032" left="71" width="313" height="16" font="13">comprehensive disclosure information is av<a href="">ailable </a></text>
<text top="1032" left="383" width="35" height="16" font="15"><a href="">online</a></text>
<text top="1032" left="418" width="7" height="16" font="13"><a href="">. </a></text>
<text top="1049" left="71" width="357" height="16" font="13">Comprehensive disclosure information for the Task Force is </text>
<text top="1066" left="71" width="82" height="16" font="13">also av<a href="">ailable </a></text>
<text top="1066" left="152" width="35" height="16" font="15"><a href="">online</a></text>
<text top="1066" left="187" width="240" height="16" font="13"><a href="">. </a>The Task Force strives to avoid bias by </text>
<text top="1084" left="71" width="351" height="16" font="13">selecting experts from a broad array of backgrounds represent-</text>
<text top="1101" left="71" width="355" height="16" font="13">ing different geographic regions, sexes, ethnicities, intellectual </text>
<text top="97" left="458" width="358" height="16" font="13">perspectives/biases, and scopes of clinical practice, and by </text>
<text top="115" left="458" width="357" height="16" font="13">inviting organizations and professional societies with related </text>
<text top="133" left="458" width="351" height="16" font="13">interests and expertise to participate as partners or collaborators.</text>
<text top="172" left="458" width="330" height="18" font="10"><b>Individualizing Care in Patients With Associated </b></text>
<text top="190" left="458" width="203" height="18" font="10"><b>Conditions and Comorbidities</b></text>
<text top="209" left="458" width="358" height="16" font="13">Managing patients with multiple conditions can be complex, </text>
<text top="227" left="458" width="351" height="16" font="13">especially when recommendations applicable to coexisting ill-</text>
<text top="244" left="458" width="194" height="16" font="13">nesses are discordant or interacting.</text>
<text top="245" left="651" width="4" height="9" font="14">8</text>
<text top="244" left="655" width="157" height="16" font="13"> The guidelines are intended </text>
<text top="262" left="458" width="355" height="16" font="13">to define practices meeting the needs of patients in most, but not </text>
<text top="279" left="458" width="358" height="16" font="13">all, circumstances. The recommendations should not replace </text>
<text top="297" left="458" width="98" height="16" font="13">clinical judgment.</text>
<text top="336" left="458" width="164" height="18" font="10"><b>Clinical Implementation</b></text>
<text top="356" left="458" width="354" height="16" font="13">Management in accordance with guideline recommendations is </text>
<text top="373" left="458" width="355" height="16" font="13">effective only when followed. Adherence to recommendations </text>
<text top="391" left="458" width="355" height="16" font="13">can be enhanced by shared decision making between clinicians </text>
<text top="408" left="458" width="354" height="16" font="13">and patients, with patient engagement in selecting interventions </text>
<text top="426" left="458" width="351" height="16" font="13">based on individual values, preferences, and associated con-</text>
<text top="443" left="458" width="357" height="16" font="13">ditions and comorbidities. Consequently, circumstances may </text>
<text top="461" left="458" width="351" height="16" font="13">arise in which deviations from these guidelines are appropriate.</text>
<text top="497" left="458" width="41" height="18" font="10"><b>Policy</b></text>
<text top="516" left="458" width="356" height="16" font="13">The recommendations in this guideline represent the official </text>
<text top="534" left="458" width="356" height="16" font="13">policy of the ACC and AHA until superseded by published </text>
<text top="551" left="458" width="360" height="16" font="13">addenda, statements of clarification, focused updates, or </text>
<text top="569" left="458" width="355" height="16" font="13">revised full-text guidelines. To ensure that guidelines remain </text>
<text top="586" left="458" width="360" height="16" font="13">current, new data are reviewed biannually to determine </text>
<text top="604" left="458" width="354" height="16" font="13">whether recommendations should be modified. In general, full </text>
<text top="621" left="458" width="210" height="16" font="13">revisions are posted in 5-year cycles.</text>
<text top="622" left="667" width="10" height="9" font="14">3,5</text>
<text top="651" left="573" width="235" height="16" font="16"><i>Jonathan L. Halperin, MD, FACC, FAHA</i></text>
<text top="669" left="478" width="330" height="16" font="16"><i>Chair, ACC/AHA Task Force on Clinical Practice Guidelines</i></text>
<text top="703" left="578" width="111" height="20" font="12"><b>1. Introduction</b></text>
<text top="729" left="458" width="263" height="18" font="10"><b>1.1. Methodology and Evidence Review</b></text>
<text top="750" left="458" width="356" height="16" font="13">The recommendations listed in this guideline are, whenever </text>
<text top="768" left="458" width="356" height="16" font="13">possible, evidence based. An extensive evidence review was </text>
<text top="785" left="458" width="358" height="16" font="13">conducted in April 2014 that included literature published </text>
<text top="803" left="458" width="355" height="16" font="13">through September 2014. Other selected references published </text>
<text top="820" left="458" width="354" height="16" font="13">through May 2015 were incorporated by the GWC. Literature </text>
<text top="838" left="458" width="354" height="16" font="13">included was derived from research involving human subjects, </text>
<text top="856" left="458" width="358" height="16" font="13">published in English, and indexed in MEDLINE (through </text>
<text top="873" left="458" width="357" height="16" font="13">PubMed), EMBASE, the Cochrane Library, the Agency for </text>
<text top="891" left="458" width="354" height="16" font="13">Healthcare Research and Quality, and other selected databases </text>
<text top="908" left="458" width="356" height="16" font="13">relevant to this guideline. The relevant data are included in </text>
<text top="926" left="458" width="133" height="16" font="13">evidence tables in the </text>
<text top="926" left="591" width="144" height="16" font="15"><a href="">Online Data Supplement</a></text>
<text top="926" left="735" width="79" height="16" font="13"><a href="">. K</a>ey search </text>
<text top="943" left="458" width="351" height="16" font="13">words included but were not limited to the following<i>: abla-</i></text>
<text top="961" left="458" width="359" height="16" font="16"><i>tion therapy (catheter and radiofrequency; fast and slow </i></text>
<text top="978" left="458" width="361" height="16" font="16"><i>pathway), accessory pathway (manifest and concealed), </i></text>
<text top="996" left="458" width="357" height="16" font="16"><i>antiarrhythmic drugs, atrial fibrillation, atrial tachycardia, </i></text>
<text top="1014" left="458" width="363" height="16" font="16"><i>atrioventricular nodal reentrant (reentry, reciprocating) </i></text>
<text top="1031" left="458" width="351" height="16" font="16"><i>tachycardia, atrioventricular reentrant (reentry, reciprocat-</i></text>
<text top="1049" left="458" width="358" height="16" font="16"><i>ing) tachycardia, beta blockers, calcium channel blockers, </i></text>
<text top="1066" left="458" width="351" height="16" font="16"><i>cardiac imaging, cardioversion, cost effectiveness, cryother-</i></text>
<text top="1084" left="458" width="355" height="16" font="16"><i>apy, echocardiography, elderly (aged and older), focal atrial </i></text>
<text top="1101" left="458" width="354" height="16" font="16"><i>tachycardia, Holter monitor, inappropriate sinus tachycardia, </i></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="17" size="11" family="Times" color="#231f20"/>
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e509</i></b></text>
<text top="962" left="69" width="351" height="16" font="16"><i>junctional tachycardia, multifocal atrial tachycardia, parox-</i></text>
<text top="980" left="69" width="351" height="16" font="16"><i>ysmal supraventricular tachycardia, permanent form of junc-</i></text>
<text top="997" left="69" width="358" height="16" font="16"><i>tional reciprocating tachycardia, pre-excitation, pregnancy, </i></text>
<text top="1015" left="69" width="359" height="16" font="16"><i>quality of life, sinoatrial node, sinus node reentry, sinus </i></text>
<text top="1032" left="69" width="357" height="16" font="16"><i>tachycardia, supraventricular tachycardia, supraventricular </i></text>
<text top="1049" left="69" width="356" height="16" font="16"><i>arrhythmia, tachycardia, tachyarrhythmia, vagal maneuvers </i></text>
<text top="1067" left="69" width="120" height="16" font="16"><i>(Valsalva maneuver)</i></text>
<text top="1066" left="189" width="234" height="16" font="13">, and <i>Wolff-Parkinson-White syndrome</i>. </text>
<text top="1084" left="69" width="351" height="16" font="13">Additionally, the GWC reviewed documents related to supra-</text>
<text top="1101" left="69" width="358" height="16" font="13">ventricular tachycardia (SVT) previously published by the </text>
<text top="962" left="456" width="357" height="16" font="13">ACC, AHA, and Heart Rhythm Society (HRS). References </text>
<text top="980" left="456" width="354" height="16" font="13">selected and published in this document are representative and </text>
<text top="997" left="456" width="95" height="16" font="13">not all-inclusive.</text>
<text top="1014" left="477" width="339" height="16" font="13">An independent ERC was commissioned to perform </text>
<text top="1032" left="456" width="356" height="16" font="13">a systematic review of key clinical questions, the results of </text>
<text top="1049" left="456" width="354" height="16" font="13">which were considered by the GWC for incorporation into this </text>
<text top="1066" left="456" width="354" height="16" font="13">guideline. The systematic review report on the management of </text>
<text top="1084" left="456" width="357" height="16" font="13">asymptomatic patients with Wolff-Parkinson-White (WPW) </text>
<text top="1101" left="456" width="327" height="16" font="13">syndrome is published in conjunction with this guideline.</text>
<text top="1102" left="783" width="4" height="9" font="14">9</text>
<text top="107" left="69" width="735" height="16" font="17"><b>Table 1.  Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic </b></text>
<text top="122" left="69" width="132" height="16" font="17"><b>Testing in Patient Care*</b></text>
<text top="147" left="78" width="3" height="14" font="3"> </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e510  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="202" height="18" font="10"><b>1.2. Organization of the GWC</b></text>
<text top="116" left="71" width="351" height="16" font="13">The GWC consisted of clinicians, cardiologists, electrophysi-</text>
<text top="133" left="71" width="354" height="16" font="13">ologists (including those specialized in pediatrics), and a nurse </text>
<text top="151" left="71" width="351" height="16" font="13">(in the role of patient representative) and included representa-</text>
<text top="168" left="71" width="210" height="16" font="13">tives from the ACC, AHA, and HRS.</text>
<text top="204" left="71" width="245" height="18" font="10"><b>1.3. Document Review and Approval</b></text>
<text top="224" left="71" width="351" height="16" font="13">This document was reviewed by 8 official reviewers nomi-</text>
<text top="241" left="71" width="355" height="16" font="13">nated by the ACC, AHA, and HRS, and 25 individual content </text>
<text top="259" left="71" width="354" height="16" font="13">reviewers. Reviewers’ RWI information was distributed to the </text>
<text top="276" left="71" width="312" height="16" font="13">GWC and is published in this document (Appendix 2).</text>
<text top="294" left="92" width="330" height="16" font="13">This document was approved for publication by the gov-</text>
<text top="311" left="71" width="287" height="16" font="13">erning bodies of the ACC, the AHA, and the HRS.</text>
<text top="347" left="71" width="179" height="18" font="10"><b>1.4. Scope of the Guideline</b></text>
<text top="366" left="71" width="357" height="16" font="13">The purpose of this joint ACC/AHA/HRS document is to </text>
<text top="384" left="71" width="357" height="16" font="13">provide a contemporary guideline for the management of </text>
<text top="401" left="71" width="357" height="16" font="13">adults with all types of SVT other than atrial fibrillation </text>
<text top="419" left="71" width="356" height="16" font="13">(AF). Although AF is, strictly speaking, an SVT, the term </text>
<text top="436" left="71" width="356" height="16" font="13">SVT generally does not refer to AF. AF is addressed in the </text>
<text top="454" left="71" width="359" height="16" font="13">2014 ACC/AHA/HRS Guideline for the Management of </text>
<text top="471" left="71" width="229" height="16" font="13">Atrial Fibrillation (2014 AF guideline).</text>
<text top="472" left="300" width="8" height="9" font="14">10</text>
<text top="471" left="309" width="113" height="16" font="13"> The present guide-</text>
<text top="489" left="70" width="357" height="16" font="13">line addresses other SVTs, including regular narrow–QRS </text>
<text top="506" left="70" width="356" height="16" font="13">complex tachycardias, as well as other, irregular SVTs (eg, </text>
<text top="524" left="70" width="351" height="16" font="13">atrial flutter with irregular ventricular response and multi-</text>
<text top="541" left="70" width="356" height="16" font="13">focal atrial tachycardia [MAT]). This guideline supersedes </text>
<text top="559" left="70" width="356" height="16" font="13">the “2003 ACC/AHA/ESC Guidelines for the Management </text>
<text top="576" left="70" width="288" height="16" font="13">of Patients With Supraventricular Arrhythmias.”</text>
<text top="577" left="358" width="8" height="9" font="14">11</text>
<text top="576" left="367" width="55" height="16" font="13"> It incor-</text>
<text top="594" left="70" width="355" height="16" font="13">porates new and existing knowledge derived from published </text>
<text top="611" left="70" width="351" height="16" font="13">clinical trials, basic science, and comprehensive review arti-</text>
<text top="629" left="70" width="354" height="16" font="13">cles, along with evolving treatment strategies and new drugs. </text>
<text top="646" left="70" width="354" height="16" font="13">Some recommendations from the earlier guideline have been </text>
<text top="664" left="70" width="351" height="16" font="13">updated as warranted by new evidence or a better under-</text>
<text top="681" left="70" width="86" height="16" font="13">standing of  </text>
<text top="681" left="148" width="281" height="16" font="13">existing evidence, whereas other inaccurate, </text>
<text top="699" left="70" width="358" height="16" font="13">irrelevant, or overlapping recommendations were deleted </text>
<text top="716" left="70" width="147" height="16" font="13">or modified. Whenever  </text>
<text top="716" left="209" width="217" height="16" font="13">possible, we reference data from the </text>
<text top="734" left="70" width="354" height="16" font="13">acute clinical care environment; however, in some cases, the </text>
<text top="751" left="70" width="351" height="16" font="13">reference studies from the invasive electrophysiology labo-</text>
<text top="769" left="70" width="354" height="16" font="13">ratory inform our understanding of arrhythmia diagnosis and </text>
<text top="786" left="70" width="356" height="16" font="13">management. Although this document is aimed at the adult </text>
<text top="804" left="70" width="71" height="16" font="13">population (</text>
<text top="803" left="142" width="280" height="17" font="13">≥18 years of age) and offers no specific recom-</text>
<text top="821" left="70" width="356" height="16" font="13">mendations for pediatric patients, as per the reference list, </text>
<text top="839" left="70" width="357" height="16" font="13">we examined literature that included pediatric patients. In </text>
<text top="856" left="70" width="354" height="16" font="13">some cases, the data from noninfant pediatric patients helped </text>
<text top="874" left="70" width="126" height="16" font="13">inform this guideline.</text>
<text top="891" left="92" width="330" height="16" font="13">In the current healthcare environment, cost consider-</text>
<text top="909" left="70" width="356" height="16" font="13">ation cannot be isolated from shared decision making and </text>
<text top="926" left="70" width="351" height="16" font="13">patient-centered care. The AHA and ACC have acknowl-</text>
<text top="943" left="70" width="357" height="16" font="13">edged the importance of value in health care, calling for </text>
<text top="961" left="70" width="351" height="16" font="13">eventual development of a Level of Value for practice rec-</text>
<text top="978" left="70" width="351" height="16" font="13">ommendations in the “2014 ACC/AHA Statement on Cost/</text>
<text top="996" left="70" width="359" height="16" font="13">Value Methodology in Clinical Practice Guidelines and </text>
<text top="1013" left="70" width="144" height="16" font="13">Performance Measures.”</text>
<text top="1014" left="215" width="4" height="9" font="14">6</text>
<text top="1014" left="219" width="202" height="16" font="13"> Although quality-of-life and cost-</text>
<text top="1031" left="71" width="351" height="16" font="13">effectiveness data were not sufficient to allow for devel-</text>
<text top="1049" left="71" width="359" height="16" font="13">opment of specific recommendations, the GWC agreed </text>
<text top="1066" left="71" width="357" height="16" font="13">the data warranted brief discussion (Sections 10 and 11). </text>
<text top="1084" left="71" width="351" height="16" font="13">Throughout this document, and associated with all rec-</text>
<text top="1101" left="71" width="358" height="16" font="13">ommendations and algorithms, the importance of shared </text>
<text top="97" left="458" width="356" height="16" font="13">decision making should be acknowledged. Each approach, </text>
<text top="115" left="458" width="358" height="16" font="13">ranging from observation to drug treatment to ablation, </text>
<text top="132" left="458" width="355" height="16" font="13">must be considered in the setting of a clear discussion with </text>
<text top="149" left="458" width="356" height="16" font="13">the patient regarding risk, benefit and personal preference. </text>
<text top="167" left="458" width="249" height="16" font="13">See Section 12 for additional information.</text>
<text top="184" left="479" width="330" height="16" font="13">In developing this guideline, the GWC reviewed prior pub-</text>
<text top="201" left="458" width="354" height="16" font="13">lished guidelines and related statements. Table 2 contains a list </text>
<text top="219" left="458" width="355" height="16" font="13">of guidelines and statements deemed pertinent to this writing </text>
<text top="236" left="458" width="276" height="16" font="13">effort and is intended for use as a resource, thus </text>
<text top="235" left="734" width="78" height="17" font="13">­obviating the </text>
<text top="253" left="458" width="132" height="16" font="13">need to repeat existing </text>
<text top="253" left="589" width="161" height="17" font="13">­guideline recommendations.</text>
<text top="288" left="556" width="155" height="20" font="12"><b>2. General Principles</b></text>
<text top="313" left="458" width="217" height="18" font="10"><b>2.1. Mechanisms and Definitions</b></text>
<text top="335" left="458" width="356" height="16" font="13">For the purposes of this guideline, SVT is defined as per </text>
<text top="352" left="457" width="356" height="16" font="13">Table 3, which provides definitions and the mechanism(s)  </text>
<text top="369" left="458" width="357" height="16" font="13">of each type of SVT. The term SVT does not generally </text>
<text top="387" left="458" width="351" height="16" font="13">include AF, and this document does not discuss the manage-</text>
<text top="404" left="458" width="69" height="16" font="13">ment of AF.</text>
<text top="440" left="458" width="308" height="18" font="10"><b>2.2. Epidemiology, Demographics, and Public </b></text>
<text top="457" left="458" width="98" height="18" font="10"><b>Health Impact</b></text>
<text top="476" left="458" width="351" height="16" font="13">The epidemiology of SVT, including its frequency, pat-</text>
<text top="494" left="458" width="357" height="16" font="13">terns, causes, and effects, is imprecisely defined because </text>
<text top="511" left="458" width="356" height="16" font="13">of incomplete data and failure to discriminate among AF, </text>
<text top="529" left="458" width="357" height="16" font="13">atrial flutter, and other supraventricular arrhythmias. The </text>
<text top="546" left="458" width="354" height="16" font="13">best available evidence indicates that the prevalence of SVT </text>
<text top="563" left="458" width="304" height="16" font="13">in the general population is 2.29 per 1000 persons.</text>
<text top="564" left="761" width="8" height="9" font="14">32</text>
<text top="563" left="770" width="42" height="16" font="13"> When </text>
<text top="581" left="457" width="354" height="16" font="13">adjusted by age and sex in the US population, the incidence </text>
<text top="598" left="457" width="351" height="16" font="13">of paroxysmal supraventricular tachycardia (PSVT) is esti-</text>
<text top="615" left="457" width="279" height="16" font="13">mated to be 36 per 100 000 persons per year.</text>
<text top="616" left="737" width="8" height="9" font="14">32</text>
<text top="615" left="745" width="69" height="16" font="13"> There are </text>
<text top="633" left="457" width="351" height="16" font="13">approximately 89 000 new cases per year and 570 000 per-</text>
<text top="650" left="457" width="100" height="16" font="13">sons with PSVT.</text>
<text top="651" left="557" width="8" height="9" font="14">32</text>
<text top="650" left="566" width="243" height="16" font="13"> Compared with patients with cardiovas-</text>
<text top="667" left="457" width="355" height="16" font="13">cular disease, those with PSVT without any cardiovascular </text>
<text top="685" left="457" width="357" height="16" font="13">disease are younger (37 versus 69 years; <i>P</i>=0.0002) and </text>
<text top="702" left="457" width="354" height="16" font="13">have faster PSVT (186 bpm versus 155 bpm; <i>P</i>=0.0006). </text>
<text top="719" left="457" width="342" height="16" font="13">Women have twice the risk of men of developing PSVT.</text>
<text top="720" left="800" width="8" height="9" font="14">32</text>
<text top="719" left="809" width="4" height="16" font="13"> </text>
<text top="737" left="457" width="358" height="16" font="13">Individuals &gt;65 years of age have &gt;5 times the risk of </text>
<text top="754" left="457" width="224" height="16" font="13">younger persons of developing PSVT.</text>
<text top="755" left="681" width="8" height="9" font="14">32</text>
<text top="771" left="479" width="330" height="16" font="13">Patients with PSVT who are referred to specialized cen-</text>
<text top="789" left="458" width="358" height="16" font="13">ters for management with ablation are younger, have an </text>
<text top="806" left="458" width="351" height="16" font="13">equal sex distribution, and have a low frequency of cardio-</text>
<text top="823" left="458" width="98" height="16" font="13">vascular disease.</text>
<text top="824" left="555" width="21" height="9" font="14">33–47</text>
<text top="823" left="576" width="236" height="16" font="13"> The frequency of atrioventricular nodal </text>
<text top="841" left="457" width="357" height="16" font="13">reentrant tachycardia (AVNRT) is greater in women than </text>
<text top="858" left="457" width="356" height="16" font="13">in men. This may be due to an actual higher incidence in </text>
<text top="875" left="457" width="356" height="16" font="13">women, or it may reflect referral bias. In persons who are </text>
<text top="893" left="457" width="355" height="16" font="13">middle-aged or older, AVNRT is more common, whereas in </text>
<text top="910" left="457" width="355" height="16" font="13">adolescents, the prevalence may be more balanced between </text>
<text top="928" left="457" width="356" height="16" font="13">atrioventricular reentrant tachycardia (AVRT) and AVNRT, </text>
<text top="945" left="457" width="202" height="16" font="13">or AVRT may be more prevalent.</text>
<text top="945" left="660" width="8" height="9" font="14">32</text>
<text top="945" left="668" width="146" height="16" font="13"> The relative frequency </text>
<text top="962" left="457" width="355" height="16" font="13">of tachycardia mediated by an accessory pathway decreases </text>
<text top="980" left="457" width="355" height="16" font="13">with age. The incidence of manifest pre-excitation or WPW </text>
<text top="997" left="457" width="356" height="16" font="13">pattern on ECG tracings in the general population is 0.1% </text>
<text top="1014" left="457" width="351" height="16" font="13">to 0.3%. However, not all patients with manifest ventricu-</text>
<text top="1032" left="457" width="191" height="16" font="13">lar pre-excitation develop PSVT.</text>
<text top="1032" left="649" width="21" height="9" font="14">47–49</text>
<text top="1032" left="670" width="142" height="16" font="13"> The limited data on the </text>
<text top="1049" left="457" width="355" height="16" font="13">public health impact of SVT indicate that the arrhythmia is </text>
<text top="1066" left="457" width="355" height="16" font="13">commonly a reason for emergency department and primary </text>
<text top="1084" left="457" width="356" height="16" font="13">care physician visits but is infrequently the primary reason </text>
<text top="1101" left="457" width="133" height="16" font="13">for hospital admission.</text>
<text top="1102" left="591" width="30" height="9" font="14">11,50,51</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="18" size="4" family="Times" color="#231f20"/>
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e511</i></b></text>
<text top="97" left="456" width="311" height="18" font="10"><b>2.3. Evaluation of the Patient With Suspected  </b></text>
<text top="114" left="456" width="138" height="18" font="10"><b>or Documented SVT</b></text>
<text top="141" left="456" width="327" height="16" font="0"><i><b>2.3.1. Clinical Presentation and Differential Diagnosis  </b></i></text>
<text top="157" left="456" width="151" height="16" font="0"><i><b>on the Basis of Symptoms</b></i></text>
<text top="174" left="456" width="358" height="16" font="13">Patients seen in consultation for palpitations often describe </text>
<text top="192" left="456" width="356" height="16" font="13">symptoms with characteristic features suggestive of SVT that </text>
<text top="209" left="456" width="357" height="16" font="13">may guide physicians to appropriate testing and a definitive </text>
<text top="226" left="456" width="354" height="16" font="13">diagnosis. The diagnosis of SVT is often made in the emergency </text>
<text top="243" left="456" width="357" height="16" font="13">department, but it is common to elicit symptoms suggestive </text>
<text top="261" left="456" width="358" height="16" font="13">of SVT before initial electrocardiogram/electrocardiographic </text>
<text top="278" left="456" width="357" height="16" font="13">(ECG) documentation. SVT symptom onset often begins in </text>
<text top="295" left="456" width="354" height="16" font="13">adulthood; in 1 study in adults, the mean age of symptom onset </text>
<text top="312" left="456" width="355" height="16" font="13">was 32±18 years of age for AVNRT, versus 23±14 years of age </text>
<text top="330" left="456" width="57" height="16" font="13">for AVRT.</text>
<text top="330" left="513" width="8" height="9" font="14">52</text>
<text top="330" left="521" width="286" height="16" font="13"> In contrast, in a study conducted in pediatric popu-</text>
<text top="347" left="456" width="355" height="16" font="13">lations, the mean ages of symptom onset of AVRT and AVNRT </text>
<text top="364" left="456" width="189" height="16" font="13">were 8 and 11 years, respectively.</text>
<text top="365" left="645" width="8" height="9" font="14">53</text>
<text top="364" left="653" width="158" height="16" font="13"> In comparison with AVRT, </text>
<text top="381" left="456" width="355" height="16" font="13">patients with AVNRT are more likely to be female, with an age </text>
<text top="399" left="456" width="107" height="16" font="13">of onset &gt;30 years.</text>
<text top="399" left="563" width="31" height="9" font="14">49,54–56</text>
<text top="399" left="593" width="218" height="16" font="13"> AVNRT onset has been reported after </text>
<text top="416" left="456" width="356" height="16" font="13">the age of 50 years in 16% and before the age of 20 years in </text>
<text top="433" left="456" width="29" height="16" font="13">18%.</text>
<text top="434" left="485" width="8" height="9" font="14">57</text>
<text top="433" left="493" width="319" height="16" font="13"> Among women with SVT and no other cardiovascular </text>
<text top="450" left="456" width="356" height="16" font="13">disease, the onset of symptoms occurred during childbearing </text>
<text top="468" left="456" width="203" height="16" font="13">years (eg, 15 to 50 years) in 58%.</text>
<text top="468" left="659" width="8" height="9" font="14">32</text>
<text top="468" left="667" width="145" height="16" font="13"> The first onset of SVT </text>
<text top="485" left="456" width="355" height="16" font="13">occurred in only 3.9% of women during pregnancy, but among </text>
<text top="502" left="456" width="355" height="16" font="13">women with an established history of SVT, 22% reported that </text>
<text top="519" left="456" width="221" height="16" font="13">pregnancy exacerbated their symptoms.</text>
<text top="520" left="676" width="8" height="9" font="14">58</text>
<text top="537" left="477" width="333" height="16" font="13">SVT has an impact on quality of life, which varies according </text>
<text top="554" left="456" width="355" height="16" font="13">to the frequency of episodes, the duration of SVT, and whether </text>
<text top="571" left="456" width="307" height="16" font="13">symptoms occur not only with exercise but also at rest.</text>
<text top="572" left="762" width="18" height="9" font="14">53,59</text>
<text top="571" left="781" width="31" height="16" font="13"> In 1 </text>
<text top="588" left="456" width="356" height="16" font="13">retrospective study in which the records of patients &lt;21 years </text>
<text top="606" left="456" width="356" height="16" font="13">of age with WPW pattern on the ECG were reviewed, 64% of </text>
<text top="623" left="456" width="356" height="16" font="13">patients had symptoms at presentation, and an additional 20% </text>
<text top="640" left="456" width="217" height="16" font="13">developed symptoms during follow-up.</text>
<text top="641" left="672" width="8" height="9" font="14">60</text>
<text top="640" left="680" width="130" height="16" font="13"> Modes of presentation </text>
<text top="657" left="456" width="356" height="16" font="13">included documented SVT in 38%, palpitations in 22%, chest </text>
<text top="675" left="456" width="357" height="16" font="13">pain in 5%, syncope in 4%, AF in 0.4%, and sudden cardiac </text>
<text top="692" left="456" width="117" height="16" font="13">death (SCD) in 0.2%.</text>
<text top="692" left="573" width="8" height="9" font="14">60</text>
<text top="692" left="581" width="229" height="16" font="13"> Although this was a pediatric population, </text>
<text top="709" left="456" width="355" height="16" font="13">it provided symptom data that are likely applicable to adults. A </text>
<text top="726" left="456" width="351" height="16" font="13">confounding factor in diagnosing SVT is the need to differen-</text>
<text top="744" left="456" width="356" height="16" font="13">tiate symptoms of SVT from symptoms of panic and anxiety </text>
<text top="761" left="456" width="357" height="16" font="13">disorders or any condition of heightened awareness of sinus </text>
<text top="778" left="456" width="354" height="16" font="13">tachycardia (such as postural orthostatic tachycardia syndrome). </text>
<text top="795" left="456" width="356" height="16" font="13">In 1 study, the criteria for panic disorder were fulfilled in 67% </text>
<text top="813" left="456" width="351" height="16" font="13">of patients with SVT that remained unrecognized after their ini-</text>
<text top="830" left="456" width="354" height="16" font="13">tial evaluation. Physicians attributed symptoms of SVT to panic, </text>
<text top="847" left="456" width="355" height="16" font="13">anxiety, or stress in 54% of patients, with women more likely to </text>
<text top="864" left="456" width="243" height="16" font="13">be mislabeled with panic disorder than men.</text>
<text top="865" left="699" width="8" height="9" font="14">61</text>
<text top="882" left="477" width="334" height="16" font="13">When AVNRT and AVRT are compared, symptoms appear </text>
<text top="899" left="456" width="357" height="16" font="13">to differ substantially. Patients with AVNRT more frequently </text>
<text top="916" left="456" width="333" height="16" font="13">describe symptoms of “shirt flapping” or “neck pounding”</text>
<text top="917" left="789" width="18" height="9" font="14">54,62</text>
<text top="916" left="807" width="4" height="16" font="13"> </text>
<text top="933" left="456" width="356" height="16" font="13">that may be related to pulsatile reversed flow when the right </text>
<text top="951" left="456" width="360" height="16" font="13">atrium contracts against a closed tricuspid valve (cannon </text>
<text top="968" left="456" width="358" height="16" font="13">a-waves). During 1 invasive study of patients with AVNRT </text>
<text top="985" left="456" width="357" height="16" font="13">and AVRT, both arrhythmias decreased arterial pressure and </text>
<text top="1002" left="456" width="351" height="16" font="13">increased left atrial pressure, but simulation of SVT mecha-</text>
<text top="1020" left="456" width="356" height="16" font="13">nism by timing the pacing of the atria and ventricles showed </text>
<text top="1037" left="456" width="357" height="16" font="13">significantly higher left atrial pressure in simulated AVNRT </text>
<text top="1054" left="456" width="135" height="16" font="13">than in simulated AVRT.</text>
<text top="1055" left="590" width="8" height="9" font="14">62</text>
<text top="1054" left="599" width="211" height="16" font="13"> Polyuria is particularly common with </text>
<text top="1071" left="456" width="351" height="16" font="13">AVNRT and is related to higher right atrial pressures and ele-</text>
<text top="1089" left="456" width="354" height="16" font="13">vated levels of atrial natriuretic protein in patients with AVNRT </text>
<text top="1106" left="456" width="318" height="16" font="13">compared with patients who have AVRT or atrial flutter.</text>
<text top="1106" left="774" width="8" height="9" font="14">63</text>
<text top="97" left="69" width="272" height="16" font="17"><b>Table 2.  Associated Guidelines and Statements</b></text>
<text top="139" left="80" width="19" height="14" font="3">Title</text>
<text top="139" left="250" width="56" height="14" font="3">Organization</text>
<text top="124" left="338" width="74" height="14" font="3">Publication Year </text>
<text top="139" left="348" width="51" height="14" font="3">(Reference)</text>
<text top="161" left="80" width="46" height="14" font="3">Guidelines</text>
<text top="184" left="92" width="70" height="14" font="3">Atrial fibrillation</text>
<text top="184" left="246" width="62" height="14" font="3">AHA/ACC/HRS</text>
<text top="184" left="358" width="23" height="14" font="3">2014</text>
<text top="184" left="381" width="7" height="8" font="18">10</text>
<text top="206" left="92" width="76" height="14" font="3">Stable ischemic  </text>
<text top="221" left="92" width="60" height="14" font="3">heart disease</text>
<text top="206" left="245" width="68" height="14" font="3">ACC/AHA/ACP/ </text>
<text top="221" left="249" width="61" height="14" font="3">AATS/ PCNA/ </text>
<text top="236" left="257" width="42" height="14" font="3">SCAI/STS</text>
<text top="206" left="342" width="23" height="14" font="3">2014</text>
<text top="207" left="365" width="7" height="8" font="18">12</text>
<text top="206" left="372" width="26" height="14" font="3"> 2012</text>
<text top="207" left="398" width="7" height="8" font="18">13</text>
<text top="259" left="92" width="97" height="14" font="3">Valvular heart disease</text>
<text top="259" left="257" width="40" height="14" font="3">AHA/ACC</text>
<text top="259" left="358" width="23" height="14" font="3">2014</text>
<text top="260" left="381" width="7" height="8" font="18">14</text>
<text top="282" left="92" width="71" height="14" font="3">Assessment of  </text>
<text top="297" left="92" width="83" height="14" font="3">cardiovascular risk</text>
<text top="282" left="257" width="40" height="14" font="3">ACC/AHA</text>
<text top="282" left="358" width="23" height="14" font="3">2013</text>
<text top="282" left="381" width="7" height="8" font="18">15</text>
<text top="319" left="92" width="54" height="14" font="3">Heart failure</text>
<text top="319" left="257" width="40" height="14" font="3">ACC/AHA</text>
<text top="319" left="358" width="23" height="14" font="3">2013</text>
<text top="320" left="381" width="7" height="8" font="18">16</text>
<text top="342" left="92" width="107" height="14" font="3">Antithrombotic therapy  </text>
<text top="357" left="92" width="112" height="14" font="3">for valvular heart disease</text>
<text top="342" left="265" width="24" height="14" font="3">ACCP</text>
<text top="342" left="358" width="23" height="14" font="3">2012</text>
<text top="343" left="381" width="7" height="8" font="18">17</text>
<text top="380" left="92" width="70" height="14" font="3">Atrial fibrillation</text>
<text top="380" left="269" width="18" height="14" font="3">ESC</text>
<text top="380" left="342" width="23" height="14" font="3">2012</text>
<text top="380" left="365" width="7" height="8" font="18">18</text>
<text top="380" left="372" width="26" height="14" font="3"> 2010</text>
<text top="380" left="398" width="7" height="8" font="18">19</text>
<text top="402" left="92" width="97" height="14" font="3">Device-based therapy</text>
<text top="402" left="246" width="62" height="14" font="3">ACC/AHA/HRS</text>
<text top="402" left="358" width="23" height="14" font="3">2012</text>
<text top="403" left="381" width="7" height="8" font="18">20</text>
<text top="425" left="92" width="70" height="14" font="3">Atrial fibrillation</text>
<text top="425" left="268" width="18" height="14" font="3">CCS</text>
<text top="425" left="342" width="23" height="14" font="3">2014</text>
<text top="426" left="365" width="7" height="8" font="18">21</text>
<text top="425" left="372" width="26" height="14" font="3"> 2011</text>
<text top="426" left="398" width="7" height="8" font="18">22</text>
<text top="448" left="92" width="125" height="14" font="3">Hypertrophic cardiomyopathy</text>
<text top="448" left="257" width="40" height="14" font="3">ACC/AHA</text>
<text top="448" left="358" width="23" height="14" font="3">2011</text>
<text top="448" left="381" width="7" height="8" font="18">23</text>
<text top="470" left="92" width="121" height="14" font="3">Secondary prevention and  </text>
<text top="485" left="92" width="115" height="14" font="3">risk reduction therapy for </text>
<text top="500" left="92" width="104" height="14" font="3">patients with coronary  </text>
<text top="515" left="92" width="113" height="14" font="3">and other atherosclerotic </text>
<text top="530" left="92" width="74" height="14" font="3">vascular disease</text>
<text top="470" left="257" width="40" height="14" font="3">AHA/ACC</text>
<text top="470" left="358" width="23" height="14" font="3">2011</text>
<text top="471" left="381" width="7" height="8" font="18">24</text>
<text top="553" left="92" width="77" height="14" font="3">Adult congenital  </text>
<text top="568" left="92" width="60" height="14" font="3">heart disease</text>
<text top="553" left="257" width="40" height="14" font="3">ACC/AHA</text>
<text top="553" left="356" width="23" height="14" font="3">2008</text>
<text top="554" left="379" width="7" height="8" font="18">25</text>
<text top="553" left="386" width="4" height="14" font="3">*</text>
<text top="591" left="92" width="99" height="14" font="3">Seventh Report of the </text>
<text top="606" left="92" width="115" height="14" font="3">Joint National Committee </text>
<text top="621" left="92" width="114" height="14" font="3">on Prevention, Detection, </text>
<text top="636" left="92" width="124" height="14" font="3">Evaluation, and Treatment of </text>
<text top="651" left="92" width="123" height="14" font="3">High Blood Pressure (JNC VII)</text>
<text top="591" left="264" width="27" height="14" font="3">NHLBI</text>
<text top="591" left="358" width="23" height="14" font="3">2003</text>
<text top="591" left="381" width="7" height="8" font="18">26</text>
<text top="673" left="80" width="50" height="14" font="3">Statements</text>
<text top="696" left="92" width="128" height="14" font="3">Catheter ablation in children </text>
<text top="711" left="92" width="128" height="14" font="3">and patients with congenital </text>
<text top="726" left="92" width="60" height="14" font="3">heart disease</text>
<text top="696" left="252" width="52" height="14" font="3">PACES/HRS</text>
<text top="696" left="337" width="67" height="14" font="3">2015 (in press)</text>
<text top="697" left="403" width="7" height="8" font="18">27</text>
<text top="749" left="92" width="93" height="14" font="3">Postural tachycardia </text>
<text top="764" left="92" width="114" height="14" font="3">syndrome, inappropriate  </text>
<text top="779" left="92" width="103" height="14" font="3">sinus tachycardia, and </text>
<text top="794" left="92" width="83" height="14" font="3">vasovagal syncope</text>
<text top="749" left="268" width="19" height="14" font="3">HRS</text>
<text top="749" left="358" width="23" height="14" font="3">2015</text>
<text top="749" left="381" width="7" height="8" font="18">28</text>
<text top="816" left="92" width="92" height="14" font="3">Arrhythmias in adult </text>
<text top="831" left="92" width="108" height="14" font="3">congenital heart disease</text>
<text top="816" left="252" width="52" height="14" font="3">PACES/HRS</text>
<text top="816" left="358" width="23" height="14" font="3">2014</text>
<text top="817" left="381" width="7" height="8" font="18">29</text>
<text top="854" left="92" width="100" height="14" font="3">Catheter and surgical  </text>
<text top="869" left="92" width="118" height="14" font="3">ablation of atrial fibrillation</text>
<text top="854" left="241" width="73" height="14" font="3">HRS/EHRA/ECAS</text>
<text top="854" left="358" width="23" height="14" font="3">2012</text>
<text top="855" left="381" width="7" height="8" font="18">30</text>
<text top="892" left="92" width="93" height="14" font="3">CPR and emergency </text>
<text top="907" left="92" width="87" height="14" font="3">cardiovascular care</text>
<text top="892" left="268" width="18" height="14" font="3">AHA</text>
<text top="892" left="356" width="23" height="14" font="3">2010</text>
<text top="892" left="379" width="7" height="8" font="18">31</text>
<text top="892" left="386" width="4" height="14" font="3">*</text>
<text top="927" left="81" width="345" height="14" font="3">*A revision to the current document is being prepared, with publication </text>
<text top="942" left="69" width="99" height="14" font="3">expected in late 2015.</text>
<text top="957" left="81" width="342" height="14" font="3">AATS indicates American Association for Thoracic Surgery; ACC, American </text>
<text top="972" left="69" width="356" height="14" font="3">College of Cardiology; ACCP, American College of Chest Physicians; ACP, </text>
<text top="987" left="69" width="357" height="14" font="3">American College of Physicians; AHA, American Heart Association; CCS, </text>
<text top="1002" left="69" width="359" height="14" font="3">Canadian Cardiovascular Society; CPR, cardiopulmonary resuscitation; </text>
<text top="1017" left="69" width="355" height="14" font="3">ECAS, European Cardiac Arrhythmia Society; EHRA, European Heart Rhythm </text>
<text top="1032" left="69" width="358" height="14" font="3">Association; ESC, European Society of Cardiology; HRS, Heart Rhythm </text>
<text top="1047" left="69" width="356" height="14" font="3">Society; JNC, Joint National Committee; NHLBI, National Heart, Lung, and </text>
<text top="1062" left="69" width="355" height="14" font="3">Blood Institute; PACES, Pediatric and Congenital Electrophysiology Society; </text>
<text top="1077" left="69" width="358" height="14" font="3">PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for </text>
<text top="1092" left="69" width="354" height="14" font="3">Cardiovascular Angiography and Interventions; and STS, Society of Thoracic </text>
<text top="1107" left="69" width="47" height="14" font="3">Surgeons.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e512  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="232" height="16" font="17"><b>Table 3.  Relevant Terms and Definitions</b></text>
<text top="124" left="81" width="75" height="14" font="3">Arrhythmia/Term</text>
<text top="124" left="538" width="42" height="14" font="3">Definition</text>
<text top="146" left="81" width="153" height="14" font="3">Supraventricular tachycardia (SVT)</text>
<text top="146" left="317" width="484" height="14" font="3">An umbrella term used to describe tachycardias (atrial and/or ventricular rates in excess of 100 bpm at rest), </text>
<text top="161" left="317" width="464" height="14" font="3">the mechanism of which involves tissue from the His bundle or above. These SVTs include inappropriate </text>
<text top="176" left="317" width="477" height="14" font="3">sinus tachycardia, AT (including focal and multifocal AT), macroreentrant AT (including typical atrial flutter), </text>
<text top="191" left="317" width="482" height="14" font="3">junctional tachycardia, AVNRT, and various forms of accessory pathway-mediated reentrant tachycardias. In </text>
<text top="206" left="317" width="195" height="14" font="3">this guideline, the term does not include AF.</text>
<text top="228" left="81" width="211" height="14" font="3">Paroxysmal supraventricular tachycardia (PSVT)</text>
<text top="228" left="317" width="489" height="14" font="3">A clinical syndrome characterized by the presence of a regular and rapid tachycardia of abrupt onset and termination. </text>
<text top="243" left="317" width="485" height="14" font="3">These features are characteristic of AVNRT or AVRT, and, less frequently, AT. PSVT represents a subset of SVT.</text>
<text top="266" left="81" width="90" height="14" font="3">Atrial fibrillation (AF)</text>
<text top="266" left="317" width="453" height="14" font="3">A supraventricular arrhythmia with uncoordinated atrial activation and, consequently, ineffective atrial </text>
<text top="281" left="317" width="467" height="14" font="3">contraction. ECG characteristics include: 1) irregular atrial activity, 2) absence of distinct P waves, and 3) </text>
<text top="296" left="317" width="470" height="14" font="3">irregular R-R intervals (when atrioventricular conduction is present). AF is not addressed in this document.</text>
<text top="318" left="81" width="79" height="14" font="3">Sinus tachycardia</text>
<text top="318" left="317" width="374" height="14" font="3">Rhythm arising from the sinus node in which the rate of impulses exceeds 100 bpm.</text>
<text top="340" left="81" width="154" height="14" font="3">  •  Physiologic sinus tachycardia</text>
<text top="340" left="317" width="482" height="14" font="3">Appropriate increased sinus rate in response to exercise and other situations that increase sympathetic tone.</text>
<text top="363" left="81" width="163" height="14" font="3">  •  Inappropriate sinus tachycardia</text>
<text top="363" left="317" width="430" height="14" font="3">Sinus heart rate &gt;100 bpm at rest, with a mean 24-h heart rate &gt;90 bpm not due to appropriate </text>
<text top="378" left="317" width="349" height="14" font="3">physiological responses or primary causes such as hyperthyroidism or anemia.</text>
<text top="400" left="81" width="97" height="14" font="3">Atrial tachycardia (AT)</text>
<text top="422" left="81" width="62" height="14" font="3">  •  Focal AT</text>
<text top="422" left="317" width="466" height="14" font="3">An SVT arising from a localized atrial site, characterized by regular, organized atrial activity with discrete </text>
<text top="437" left="317" width="472" height="14" font="3">P waves and typically an isoelectric segment between P waves. At times, irregularity is seen, especially at </text>
<text top="452" left="317" width="432" height="14" font="3">onset (“warm-up”) and termination (“warm-down”). Atrial mapping reveals a focal point of origin.</text>
<text top="475" left="81" width="161" height="14" font="3">  •  Sinus node reentry tachycardia</text>
<text top="475" left="317" width="481" height="14" font="3">A specific type of focal AT that is due to microreentry arising from the sinus node complex, characterized by </text>
<text top="490" left="317" width="477" height="14" font="3">abrupt onset and termination, resulting in a P-wave morphology that is indistinguishable from sinus rhythm.</text>
<text top="512" left="81" width="175" height="14" font="3">  •  Multifocal atrial tachycardia (MAT)</text>
<text top="512" left="317" width="151" height="14" font="3">An irregular SVT characterized by </text>
<text top="512" left="468" width="314" height="14" font="3">≥3 distinct P-wave morphologies and/or patterns of atrial activation at </text>
<text top="527" left="317" width="205" height="14" font="3">different rates. The rhythm is always irregular.</text>
<text top="550" left="81" width="52" height="14" font="3">Atrial flutter</text>
<text top="572" left="81" width="206" height="14" font="3">  •    Cavotricuspid isthmus–dependent atrial </text>
<text top="587" left="108" width="61" height="14" font="3">flutter: typical</text>
<text top="572" left="317" width="465" height="14" font="3">Macroreentrant AT propagating around the tricuspid annulus, proceeding superiorly along the atrial </text>
<text top="587" left="317" width="450" height="14" font="3">septum, inferiorly along the right atrial wall, and through the cavotricuspid isthmus between the </text>
<text top="602" left="317" width="444" height="14" font="3">tricuspid valve annulus and the Eustachian valve and ridge. This activation sequence produces </text>
<text top="617" left="317" width="478" height="14" font="3">predominantly negative “sawtooth” flutter waves on the ECG in leads 2, 3, and aVF and a late positive </text>
<text top="632" left="317" width="468" height="14" font="3">deflection in V1. The atrial rate can be slower than the typical 300 bpm (cycle length 200 ms) in the </text>
<text top="647" left="317" width="475" height="14" font="3">presence of antiarrhythmic drugs or scarring. It is also known as “typical atrial flutter” or “cavotricuspid </text>
<text top="662" left="317" width="323" height="14" font="3">isthmus–dependent atrial flutter” or “counterclockwise atrial flutter.”</text>
<text top="684" left="81" width="203" height="14" font="3">  •   Cavotricuspid isthmus–dependent atrial </text>
<text top="699" left="105" width="97" height="14" font="3">flutter: reverse typical</text>
<text top="684" left="317" width="479" height="14" font="3">Macroreentrant AT that propagates around in the direction reverse that of typical atrial flutter. Flutter waves </text>
<text top="699" left="317" width="488" height="14" font="3">typically appear positive in the inferior leads and negative in V1. This type of atrial flutter is also referred to as </text>
<text top="714" left="317" width="286" height="14" font="3">“reverse typical” atrial flutter or “clockwise typical atrial flutter.”</text>
<text top="737" left="81" width="202" height="14" font="3">  •   Atypical or non–cavotricuspid isthmus– </text>
<text top="752" left="105" width="101" height="14" font="3">dependent atrial flutter</text>
<text top="737" left="317" width="481" height="14" font="3">Macroreentrant ATs that do not involve the cavotricuspid isthmus. A variety of reentrant circuits may include reentry </text>
<text top="752" left="317" width="486" height="14" font="3">around the mitral valve annulus or scar tissue within the left or right atrium. A variety of terms have been applied to </text>
<text top="767" left="317" width="486" height="14" font="3">these arrhythmias according to the re-entry circuit location, including particular forms, such as “LA flutter” and “LA </text>
<text top="782" left="317" width="481" height="14" font="3">macroreentrant tachycardia” or incisional atrial re-entrant tachycardia due to re-entry around surgical scars.</text>
<text top="804" left="81" width="100" height="14" font="3">Junctional tachycardia</text>
<text top="804" left="317" width="346" height="14" font="3">A nonreentrant SVT that arises from the AV junction (including the His bundle).</text>
<text top="826" left="81" width="195" height="14" font="3">Atrioventricular nodal reentrant tachycardia </text>
<text top="841" left="81" width="36" height="14" font="3">(AVNRT)</text>
<text top="826" left="317" width="481" height="14" font="3">A reentrant tachycardia involving 2 functionally distinct pathways, generally referred to as “fast” and “slow” </text>
<text top="841" left="317" width="452" height="14" font="3">pathways. Most commonly, the fast pathway is located near the apex of Koch’s triangle, and the slow </text>
<text top="856" left="317" width="479" height="14" font="3">pathway inferoposterior to the compact AV node tissue. Variant pathways have been described, allowing for </text>
<text top="871" left="317" width="91" height="14" font="3">“slow-slow” AVNRT.</text>
<text top="894" left="81" width="88" height="14" font="3">  •  Typical AVNRT</text>
<text top="894" left="317" width="484" height="14" font="3">AVNRT in which a slow pathway serves as the anterograde limb of the circuit and the fast pathway serves as </text>
<text top="909" left="317" width="230" height="14" font="3">the retrograde limb (also called “slow-fast AVNRT”).</text>
<text top="931" left="81" width="92" height="14" font="3">  •  Atypical AVNRT</text>
<text top="931" left="317" width="484" height="14" font="3">AVNRT in which the fast pathway serves as the anterograde limb of the circuit and a slow pathway serves as </text>
<text top="946" left="317" width="472" height="14" font="3">the retrograde limb (also called “fast-slow AV node reentry”) or a slow pathway serves as the anterograde </text>
<text top="961" left="317" width="427" height="14" font="3">limb and a second slow pathway serves as the retrograde limb (also called “slow-slow AVNRT”).</text>
<text top="983" left="81" width="85" height="14" font="3">Accessory pathway</text>
<text top="983" left="317" width="447" height="14" font="3">For the purpose of this guideline, an accessory pathway is defined as an extranodal AV pathway that </text>
<text top="998" left="317" width="457" height="14" font="3">connects the myocardium of the atrium to the ventricle across the AV groove. Accessory pathways can </text>
<text top="1013" left="317" width="470" height="14" font="3">be classified by their location, type of conduction (decremental or nondecremental), and whether they are </text>
<text top="1028" left="317" width="462" height="14" font="3">capable of conducting anterogradely, retrogradely, or in both directions. Of note, accessory pathways of </text>
<text top="1043" left="317" width="488" height="14" font="3">other types (such as atriofascicular, nodo-fascicular, nodo-ventricular, and fasciculoventricular pathways) are </text>
<text top="1058" left="317" width="314" height="14" font="3">uncommon and are discussed only briefly in this document (Section 7).</text>
<text top="1081" left="81" width="155" height="14" font="3">  •  Manifest accessory pathways</text>
<text top="1081" left="317" width="417" height="14" font="3">A pathway that conducts anterogradely to cause ventricular pre-excitation pattern on the ECG.</text>
<text top="1100" left="757" width="52" height="14" font="3">(Continued )</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e513</i></b></text>
<text top="669" left="90" width="333" height="16" font="13">True syncope is infrequent with SVT, but complaints of </text>
<text top="686" left="69" width="351" height="16" font="13">light-headedness are common. In patients with WPW syn-</text>
<text top="703" left="69" width="351" height="16" font="13">drome, syncope should be taken seriously but is not neces-</text>
<text top="721" left="69" width="271" height="16" font="13">sarily associated with increased risk of SCD.</text>
<text top="721" left="341" width="8" height="9" font="14">64</text>
<text top="721" left="349" width="75" height="16" font="13"> The rate of </text>
<text top="738" left="69" width="342" height="16" font="13">AVRT is faster when AVRT is induced during exercise,</text>
<text top="738" left="412" width="8" height="9" font="14">65</text>
<text top="738" left="420" width="4" height="16" font="13"> </text>
<text top="755" left="69" width="351" height="16" font="13">yet the rate alone does not explain symptoms of near-</text>
<text top="773" left="69" width="356" height="16" font="13">syncope. Elderly patients with AVNRT are more prone to </text>
<text top="790" left="69" width="355" height="16" font="13">syncope or near-syncope than are younger patients, but the </text>
<text top="807" left="69" width="304" height="16" font="13">tachycardia rate is generally slower in the elderly.</text>
<text top="808" left="373" width="19" height="9" font="14">66,67</text>
<text top="807" left="393" width="32" height="16" font="13"> The </text>
<text top="824" left="69" width="355" height="16" font="13">drop in blood pressure (BP) during SVT is greatest in the </text>
<text top="842" left="69" width="355" height="16" font="13">first 10 to 30 seconds and somewhat normalizes within 30 </text>
<text top="859" left="69" width="283" height="16" font="13">to 60 seconds, despite minimal changes in rate.</text>
<text top="860" left="353" width="19" height="9" font="14">68,69</text>
<text top="859" left="372" width="52" height="16" font="13"> Shorter </text>
<text top="876" left="69" width="354" height="16" font="13">ventriculoatrial intervals are associated with a greater mean </text>
<text top="894" left="69" width="92" height="16" font="13">decrease in BP.</text>
<text top="894" left="161" width="8" height="9" font="14">69</text>
<text top="894" left="170" width="254" height="16" font="13"> Studies have demonstrated a relationship </text>
<text top="911" left="69" width="356" height="16" font="13">between hemodynamic changes and the relative timing of </text>
<text top="928" left="69" width="355" height="16" font="13">atrial and ventricular activation. In a study of patients with </text>
<text top="945" left="69" width="357" height="16" font="13">AVNRT with short versus long ventriculoatrial intervals, </text>
<text top="963" left="69" width="358" height="16" font="13">there was no significant difference in tachycardia cycle </text>
<text top="980" left="69" width="37" height="16" font="13">length</text>
<text top="981" left="106" width="8" height="9" font="14">70</text>
<text top="980" left="115" width="309" height="16" font="13">; however, the induction of typical AVNRT caused </text>
<text top="997" left="69" width="358" height="16" font="13">a marked initial fall in systemic BP, followed by only </text>
<text top="1015" left="69" width="358" height="16" font="13">partial recovery that resulted in stable hypotension and </text>
<text top="1032" left="69" width="356" height="16" font="13">a reduction in cardiac output due to a decrease in stroke </text>
<text top="1049" left="69" width="356" height="16" font="13">volume. In comparison, atypical AVNRT, having a longer </text>
<text top="1066" left="69" width="355" height="16" font="13">ventriculoatrial interval, exhibited a lesser degree of initial </text>
<text top="1084" left="69" width="355" height="16" font="13">hypotension, a complete recovery of BP, and no significant </text>
<text top="1101" left="69" width="150" height="16" font="13">change in cardiac output.</text>
<text top="1102" left="219" width="8" height="9" font="14">70</text>
<text top="669" left="477" width="330" height="16" font="13">The contrasting hemodynamic responses without sig-</text>
<text top="686" left="456" width="355" height="16" font="13">nificant differences in heart rate during SVT confirm that rate </text>
<text top="703" left="456" width="354" height="16" font="13">alone does not account for these hemodynamic changes. Atrial </text>
<text top="721" left="456" width="351" height="16" font="13">contraction on a closed valve might impair pulmonary drain-</text>
<text top="738" left="456" width="351" height="16" font="13">age and lead to neural factors that account for these observa-</text>
<text top="755" left="456" width="355" height="16" font="13">tions. These findings were confirmed in a study performed in </text>
<text top="773" left="456" width="358" height="16" font="13">the electrophysiological (EP) laboratory: When pacing was </text>
<text top="790" left="456" width="355" height="16" font="13">used to replicate the timing of ventricular and atrial activation </text>
<text top="807" left="456" width="351" height="16" font="13">during SVT, the decrease in BP was greatest with simultane-</text>
<text top="824" left="456" width="354" height="16" font="13">ous ventriculoatrial timing, smaller with a short vertriculoatrial </text>
<text top="842" left="456" width="323" height="16" font="13">interval, and smallest with a long ventriculoatrial interval.</text>
<text top="842" left="779" width="8" height="9" font="14">71</text>
<text top="842" left="787" width="22" height="16" font="13"> An </text>
<text top="859" left="456" width="356" height="16" font="13">increase in central venous pressure followed the same trend. </text>
<text top="876" left="456" width="351" height="16" font="13">Sympathetic nerve activity increased with all 3 pacing modali-</text>
<text top="894" left="456" width="357" height="16" font="13">ties but was most pronounced with simultaneous atrial and </text>
<text top="911" left="456" width="301" height="16" font="13">ventricular pacing or a short ventriculoatrial interval.</text>
<text top="928" left="477" width="333" height="16" font="13">In a study of the relationship of SVT with driving, 57% of </text>
<text top="945" left="456" width="355" height="16" font="13">patients with SVT experienced an episode while driving, and </text>
<text top="963" left="456" width="314" height="16" font="13">24% of these considered it to be an obstacle to driving.</text>
<text top="963" left="770" width="8" height="9" font="14">72</text>
<text top="963" left="778" width="32" height="16" font="13"> This </text>
<text top="980" left="456" width="354" height="16" font="13">sentiment was most common in patients who had experienced </text>
<text top="997" left="456" width="357" height="16" font="13">syncope or near-syncope. Among patients who experienced </text>
<text top="1015" left="456" width="356" height="16" font="13">SVT while driving, 77% felt fatigue, 50% had symptoms of </text>
<text top="1032" left="456" width="358" height="16" font="13">near-syncope, and 14% experienced syncope. Women had </text>
<text top="1049" left="456" width="191" height="16" font="13">more symptoms in each category.</text>
<text top="1067" left="477" width="20" height="16" font="16"><i>See</i></text>
<text top="1067" left="497" width="4" height="16" font="13"> </text>
<text top="1067" left="504" width="161" height="16" font="15"><a href="">Online Data Supplement 1</a></text>
<text top="1067" left="665" width="149" height="16" font="13">  <i>for additional data on </i></text>
<text top="1084" left="456" width="356" height="16" font="16"><i>clinical presentation and differential diagnosis on the basis </i></text>
<text top="1101" left="456" width="74" height="16" font="16"><i>of symptoms.</i></text>
<text top="146" left="80" width="158" height="14" font="3">  •  Concealed accessory pathway</text>
<text top="146" left="316" width="442" height="14" font="3">A pathway that conducts only retrogradely and does not affect the ECG pattern during sinus rhythm.</text>
<text top="169" left="80" width="120" height="14" font="3">  •  Pre-excitation pattern</text>
<text top="169" left="316" width="475" height="14" font="3">An ECG pattern reflecting the presence of a manifest accessory pathway connecting the atrium to the </text>
<text top="184" left="316" width="484" height="14" font="3">ventricle. Pre-excited ventricular activation over the accessory pathway competes with the anterograde </text>
<text top="199" left="316" width="482" height="14" font="3">conduction over the AV node and spreads from the accessory pathway insertion point in the ventricular </text>
<text top="214" left="316" width="452" height="14" font="3">myocardium. Depending on the relative contribution from ventricular activation by the normal AV </text>
<text top="229" left="316" width="480" height="14" font="3">nodal/His Purkinje system versus the manifest accessory pathway, a variable degree of pre-excitation, </text>
<text top="244" left="316" width="461" height="14" font="3">with its characteristic pattern of a short P-R interval with slurring of the initial upstroke of the QRS </text>
<text top="259" left="316" width="486" height="14" font="3">complex (delta wave), is observed. Pre-excitation can be intermittent or not easily appreciated for some </text>
<text top="274" left="316" width="471" height="14" font="3">pathways capable of anterograde conduction; this is usually associated with a low-risk pathway, but </text>
<text top="289" left="316" width="82" height="14" font="3">exceptions occur.</text>
<text top="311" left="80" width="194" height="14" font="3">  •   Asymptomatic pre-excitation (isolated </text>
<text top="326" left="104" width="64" height="14" font="3">pre-excitation)</text>
<text top="311" left="316" width="472" height="14" font="3">The abnormal pre-excitation ECG pattern in the absence of documented SVT or symptoms consistent with SVT.</text>
<text top="348" left="80" width="171" height="14" font="3">  •  Wolff-Parkinson-White syndrome</text>
<text top="348" left="316" width="476" height="14" font="3">Syndrome characterized by documented SVT or symptoms consistent with SVT in a patient with ventricular </text>
<text top="363" left="316" width="156" height="14" font="3">pre-excitation during sinus rhythm.</text>
<text top="386" left="80" width="197" height="14" font="3">Atrioventricular reentrant tachycardia (AVRT)</text>
<text top="386" left="316" width="445" height="14" font="3">A reentrant tachycardia, the electrical pathway of which requires an accessory pathway, the atrium, </text>
<text top="401" left="316" width="297" height="14" font="3">atrioventricular node (or second accessory pathway), and ventricle.</text>
<text top="423" left="80" width="105" height="14" font="3">  •  Orthodromic AVRT</text>
<text top="423" left="316" width="465" height="14" font="3">An AVRT in which the reentrant impulse uses the accessory pathway in the retrograde direction from the </text>
<text top="438" left="316" width="487" height="14" font="3">ventricle to the atrium, and the AV node in the anterograde direction. The QRS complex is generally narrow or </text>
<text top="453" left="316" width="364" height="14" font="3">may be wide because of pre-existing bundle-branch block or aberrant conduction.</text>
<text top="476" left="80" width="98" height="14" font="3">  •  Antidromic AVRT</text>
<text top="476" left="316" width="473" height="14" font="3">An AVRT in which the reentrant impulse uses the accessory pathway in the anterograde direction from the </text>
<text top="491" left="316" width="470" height="14" font="3">atrium to the ventricle, and the AV node for the retrograde direction. Occasionally, instead of the AV node, </text>
<text top="506" left="316" width="487" height="14" font="3">another accessory pathway can be used in the retrograde direction, which is referred to as pre-excited AVRT. </text>
<text top="521" left="316" width="223" height="14" font="3">The QRS complex is wide (maximally pre-excited).</text>
<text top="543" left="80" width="193" height="14" font="3">Permanent form of junctional reciprocating </text>
<text top="558" left="80" width="83" height="14" font="3">tachycardia (PJRT)</text>
<text top="543" left="316" width="442" height="14" font="3">A rare form of nearly incessant orthodromic AVRT involving a slowly conducting, concealed, usually </text>
<text top="558" left="316" width="150" height="14" font="3">posteroseptal accessory pathway.</text>
<text top="580" left="80" width="65" height="14" font="3">Pre-excited AF</text>
<text top="580" left="316" width="271" height="14" font="3">AF with ventricular pre-excitation caused by conduction over </text>
<text top="580" left="587" width="114" height="14" font="3">≥1 accessory pathway(s).</text>
<text top="601" left="81" width="731" height="14" font="3">AF indicates atrial fibrillation; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant </text>
<text top="616" left="69" width="741" height="14" font="3">tachycardia; bpm, beats per minute; ECG, electrocardiogram/electrocardiographic; LA, left atrial; MAT, multifocal atrial tachycardia; PJRT, permanent form of junctional </text>
<text top="631" left="69" width="638" height="14" font="3">reciprocating tachycardia; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; and WPW, Wolff-Parkinson-White.</text>
<text top="97" left="69" width="114" height="16" font="17"><b>Table 3.  Continued</b></text>
<text top="124" left="80" width="75" height="14" font="3">Arrhythmia/Term</text>
<text top="124" left="537" width="42" height="14" font="3">Definition</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e514  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="171" height="16" font="0"><i><b>2.3.2. Evaluation of the ECG</b></i></text>
<text top="115" left="71" width="357" height="16" font="13">Figures 1 to 6 provide representative ECGs, with Figure 1 </text>
<text top="132" left="71" width="358" height="16" font="13">showing ventricular tachycardia (VT) and Figures 2 to 5 </text>
<text top="149" left="71" width="324" height="16" font="13">showing some of the most common types of these SVTs.</text>
<text top="166" left="92" width="335" height="16" font="13">A 12-lead ECG obtained during tachycardia and during </text>
<text top="184" left="71" width="355" height="16" font="13">sinus rhythm may reveal the etiology of tachycardia. For the </text>
<text top="201" left="71" width="358" height="16" font="13">patient who describes prior, but not current, symptoms of </text>
<text top="218" left="71" width="356" height="16" font="13">palpitations, the resting ECG can identify pre-excitation that </text>
<text top="236" left="71" width="323" height="16" font="13">should prompt a referral to a cardiac electrophysiologist.</text>
<text top="253" left="92" width="337" height="16" font="13">A wide-complex tachycardia (QRS duration &gt;120 ms) </text>
<text top="270" left="71" width="357" height="16" font="13">may represent either VT or a supraventricular rhythm with </text>
<text top="287" left="71" width="361" height="16" font="13">abnormal conduction. Conduction abnormalities may be </text>
<text top="305" left="71" width="351" height="16" font="13">due to rate-related aberrant conduction, pre-existing bundle-</text>
<text top="322" left="71" width="356" height="16" font="13">branch block seen in sinus rhythm, or an accessory pathway </text>
<text top="339" left="71" width="351" height="16" font="13">that results in pre-excitation (Table 4). The presence of atrio-</text>
<text top="357" left="71" width="354" height="16" font="13">ventricular (AV) dissociation (with ventricular rate faster than </text>
<text top="374" left="71" width="356" height="16" font="13">atrial rate) or fusion complexes–representing dissociation of </text>
<text top="391" left="71" width="302" height="16" font="13">supraventricular impulses from a ventricular rhythm–</text>
<text top="391" left="373" width="52" height="17" font="13">­provides </text>
<text top="408" left="71" width="356" height="16" font="13">the diagnosis of VT (Figure 1). Other criteria are useful but </text>
<text top="426" left="71" width="351" height="16" font="13">not diagnostic. Concordance of the precordial QRS com-</text>
<text top="443" left="71" width="356" height="16" font="13">plexes such that all are positive or negative suggests VT or </text>
<text top="460" left="71" width="357" height="16" font="13">pre-excitation, whereas QRS complexes in tachycardia that </text>
<text top="478" left="71" width="355" height="16" font="13">are identical to those seen in sinus rhythm are consistent with </text>
<text top="495" left="71" width="357" height="16" font="13">SVT. Other, more complicated ECG algorithms have been </text>
<text top="512" left="71" width="355" height="16" font="13">developed to distinguish VT from SVT, such as the Brugada </text>
<text top="529" left="71" width="351" height="16" font="13">criteria, which rely on an examination of the QRS morphol-</text>
<text top="547" left="71" width="169" height="16" font="13">ogy in the precordial leads,</text>
<text top="547" left="239" width="8" height="9" font="14">73</text>
<text top="547" left="247" width="181" height="16" font="13"> and the Vereckei algorithm, </text>
<text top="564" left="71" width="354" height="16" font="13">which is based on an examination of the QRS complex in lead </text>
<text top="581" left="71" width="26" height="16" font="13">aVR</text>
<text top="582" left="97" width="8" height="9" font="14">74</text>
<text top="581" left="105" width="321" height="16" font="13"> (Table 5). The failure to correctly identify VT can be </text>
<text top="97" left="458" width="354" height="16" font="13">potentially life threatening, particularly if misdiagnosis results </text>
<text top="115" left="458" width="354" height="16" font="13">in VT being treated with verapamil or diltiazem. Adenosine is </text>
<text top="132" left="458" width="354" height="16" font="13">suggested in the “2010 AHA Guidelines for Cardiopulmonary </text>
<text top="149" left="458" width="358" height="16" font="13">Resuscitation and Emergency Cardiovascular Care–Part 8: </text>
<text top="167" left="458" width="357" height="16" font="13">Adult Advanced Cardiovascular Life Support” (2010 Adult </text>
<text top="184" left="458" width="99" height="16" font="13">ACLS guideline)</text>
<text top="185" left="557" width="8" height="9" font="14">75</text>
<text top="184" left="565" width="243" height="16" font="13"> if a wide-complex tachycardia is mono-</text>
<text top="201" left="457" width="358" height="16" font="13">morphic, regular, and hemodynamically tolerated, because </text>
<text top="219" left="457" width="354" height="16" font="13">adenosine may help convert the rhythm to sinus and may help </text>
<text top="236" left="457" width="357" height="16" font="13">in the diagnosis. When doubt exists, it is safest to assume </text>
<text top="253" left="457" width="356" height="16" font="13">any wide-complex tachycardia is VT, particularly in patients </text>
<text top="270" left="457" width="355" height="16" font="13">with known cardiovascular disease, such as prior myocardial </text>
<text top="288" left="457" width="59" height="16" font="13">infarction.</text>
<text top="305" left="479" width="336" height="16" font="13">For a patient presenting in SVT, the 12-lead ECG can </text>
<text top="322" left="457" width="354" height="16" font="13">potentially identify the arrhythmia mechanism (Figure 7). The </text>
<text top="340" left="457" width="358" height="16" font="13">tachycardia should first be classified according to whether </text>
<text top="357" left="457" width="351" height="16" font="13">there is a regular or irregular ventricular rate. An irregular ven-</text>
<text top="374" left="457" width="356" height="16" font="13">tricular rate suggests AF, MAT, or atrial flutter with variable </text>
<text top="392" left="457" width="351" height="16" font="13">AV conduction. When AF is associated with a rapid ventricu-</text>
<text top="409" left="457" width="354" height="16" font="13">lar response, the irregularity of the ventricular response is less </text>
<text top="426" left="457" width="343" height="16" font="13">easily detected and can be misdiagnosed as a regular SVT.</text>
<text top="427" left="800" width="8" height="9" font="14">76</text>
<text top="426" left="809" width="4" height="16" font="13"> </text>
<text top="444" left="457" width="355" height="16" font="13">If the atrial rate exceeds the ventricular rate, then atrial flutter </text>
<text top="461" left="457" width="356" height="16" font="13">or AT (focal or multifocal) is usually present (rare cases of </text>
<text top="478" left="457" width="282" height="16" font="13">AVNRT with 2:1 conduction have been described</text>
<text top="479" left="740" width="8" height="9" font="14">77</text>
<text top="478" left="748" width="8" height="16" font="13">).</text>
<text top="496" left="479" width="330" height="16" font="13">If the SVT is regular, this may represent AT with 1:1 con-</text>
<text top="513" left="457" width="351" height="16" font="13">duction or an SVT that involves the AV node. Junctional tachy-</text>
<text top="530" left="457" width="355" height="16" font="13">cardias, which originate in the AV junction (including the His </text>
<text top="548" left="457" width="355" height="16" font="13">bundle), can be regular or irregular, with variable conduction </text>
<text top="565" left="457" width="351" height="16" font="13">to the atria. SVTs that involve the AV node as a required com-</text>
<text top="582" left="457" width="357" height="16" font="13">ponent of the tachycardia reentrant circuit include AVNRT </text>
<text top="600" left="457" width="355" height="16" font="13">(Section 6: Figures 2 and 3) and AVRT (Section 7: Figures 4 </text>
<text top="617" left="457" width="351" height="16" font="13">and 6). In these reentrant tachycardias, the retrogradely con-</text>
<text top="634" left="457" width="351" height="16" font="13">ducted P wave may be difficult to discern, especially if bundle-</text>
<text top="651" left="457" width="355" height="16" font="13">branch block is present. In typical AVNRT, atrial activation is </text>
<text top="669" left="457" width="355" height="16" font="13">nearly simultaneous with the QRS, so the terminal portion of </text>
<text top="686" left="457" width="355" height="16" font="13">the P wave is usually located at the end of the QRS complex, </text>
<text top="703" left="457" width="356" height="16" font="13">appearing as a narrow and negative deflection in the inferior </text>
<text top="721" left="457" width="356" height="16" font="13">leads (a pseudo S wave) and a slightly positive deflection at </text>
<text top="738" left="457" width="285" height="16" font="13">the end of the QRS complex in lead V1 (pseudo R</text>
<text top="737" left="743" width="66" height="17" font="13">′). In ortho-</text>
<text top="755" left="457" width="358" height="16" font="13">dromic AVRT (with anterograde conduction down the AV </text>
<text top="773" left="457" width="355" height="16" font="13">node), the P wave can usually be seen in the early part of the </text>
<text top="790" left="457" width="354" height="16" font="13">ST-T segment. In typical forms of AVNRT and AVRT, because </text>
<text top="807" left="457" width="354" height="16" font="13">the P wave is located closer to the prior QRS complex than the </text>
<text top="825" left="457" width="355" height="16" font="13">subsequent QRS complex, the tachycardias are referred to as </text>
<text top="842" left="457" width="354" height="16" font="13">having a “short RP.” They also have a 1:1 relationship between </text>
<text top="859" left="457" width="354" height="16" font="13">the P wave and QRS complex, except in rare cases of AVNRT </text>
<text top="877" left="457" width="356" height="16" font="13">in which 2:1 AV block or various degrees of AV block can </text>
<text top="894" left="457" width="355" height="16" font="13">occur. In unusual cases of AVNRT (such as “fast-slow”), the </text>
<text top="911" left="457" width="356" height="16" font="13">P wave is closer to the subsequent QRS complex, providing </text>
<text top="928" left="457" width="355" height="16" font="13">a long RP. The RP is also long during an uncommon form of </text>
<text top="946" left="457" width="351" height="16" font="13">AVRT, referred to as the permanent form of junctional recip-</text>
<text top="963" left="457" width="356" height="16" font="13">rocating tachycardia (PJRT), in which an unusual accessory </text>
<text top="980" left="457" width="351" height="16" font="13">bypass tract with “decremental” (slowly conducting) retro-</text>
<text top="998" left="457" width="354" height="16" font="13">grade conduction during orthodromic AVRT produces delayed </text>
<text top="1015" left="457" width="223" height="16" font="13">atrial activation and a long RP interval.</text>
<text top="1032" left="479" width="334" height="16" font="13">A long RP interval is typical of AT because the rhythm is </text>
<text top="1050" left="457" width="355" height="16" font="13">driven by the atrium and conducts normally to the ventricles. </text>
<text top="1067" left="457" width="351" height="16" font="13">In AT, the ECG will typically show a P wave with a morphol-</text>
<text top="1084" left="457" width="354" height="16" font="13">ogy that differs from sinus that is usually seen near the end of </text>
<text top="1102" left="457" width="356" height="16" font="13">or shortly after the T wave (Figure 5). In sinus node reentry </text>
<text top="1048" left="71" width="332" height="14" font="1"><b>Figure 1.</b> ECG showing AV dissociation during VT in a patient </text>
<text top="1062" left="71" width="330" height="14" font="3">with a wide–QRS complex tachycardia. *P waves are marked </text>
<text top="1075" left="71" width="330" height="14" font="3">with arrows. AV indicates atrioventricular; ECG, electrocardio-</text>
<text top="1089" left="71" width="342" height="14" font="3">gram; and VT, ventricular tachycardia. Reproduced with permis-</text>
<text top="1102" left="71" width="199" height="14" font="3">sion from Blomström-Lundqvist et al.</text>
<text top="1103" left="269" width="8" height="8" font="18">11</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e515</i></b></text>
<text top="945" left="69" width="357" height="16" font="13">tachycardia, a form of focal AT, the P-wave morphology is </text>
<text top="962" left="69" width="225" height="16" font="13">identical to the P wave in sinus rhythm.</text>
<text top="995" left="69" width="231" height="18" font="10"><b>2.4. Principles of Medical Therapy</b></text>
<text top="1014" left="69" width="351" height="16" font="13">See Figure 8 for the algorithm for acute treatment of tachy-</text>
<text top="1032" left="69" width="355" height="16" font="13">cardia of unknown mechanism; Figure 9 for the algorithm for </text>
<text top="1049" left="69" width="354" height="16" font="13">ongoing management of tachycardia of unknown mechanism; </text>
<text top="1066" left="69" width="351" height="16" font="13">Table 6 for acute drug therapy for SVT (intravenous adminis-</text>
<text top="1083" left="69" width="355" height="16" font="13">tration); and Table 7 for ongoing drug therapy for SVT (oral </text>
<text top="1101" left="69" width="91" height="16" font="13">administration).</text>
<text top="944" left="456" width="250" height="16" font="0"><i><b>2.4.1. Acute Treatment: Recommendations</b></i></text>
<text top="962" left="456" width="359" height="16" font="13">Because patients with SVT account for approximately </text>
<text top="979" left="456" width="300" height="16" font="13">50 000 emergency department visits each year,</text>
<text top="980" left="756" width="8" height="9" font="14">81</text>
<text top="979" left="765" width="42" height="16" font="13"> emer-</text>
<text top="997" left="456" width="359" height="16" font="13">gency physicians may be the first to evaluate patients </text>
<text top="1014" left="456" width="355" height="16" font="13">whose tachycardia mechanism is unknown and to have the </text>
<text top="1032" left="456" width="354" height="16" font="13">opportunity to diagnose the mechanism of arrhythmia. It is </text>
<text top="1049" left="456" width="351" height="16" font="13">important to record a 12-lead ECG to differentiate tachy-</text>
<text top="1066" left="456" width="354" height="16" font="13">cardia mechanisms according to whether the AV node is an </text>
<text top="1084" left="456" width="354" height="16" font="13">obligate component (Section 2.3.2), because treatment that </text>
<text top="1101" left="456" width="354" height="16" font="13">targets the AV node will not reliably terminate tachycardias </text>
<text top="846" left="69" width="740" height="14" font="1"><b>Figure 2.</b> Typical AVNRT and normal sinus rhythm after conversion. <b>Upper panel</b>: The arrow points to the P waves, which are inscribed at </text>
<text top="860" left="69" width="730" height="14" font="3">the end of the QRS complex, seen best in the inferior leads and as a slightly positive R′ (pseudo r prime) in lead V1. The reentrant circuit </text>
<text top="873" left="69" width="724" height="14" font="3">involves anterograde conduction over a slow atrioventricular node pathway, followed by retrograde conduction in a fast atrioventricular </text>
<text top="887" left="69" width="345" height="14" font="3">node pathway. Typical AVNRT is a type of short RP tachycardia. </text>
<text top="887" left="414" width="380" height="14" font="1"><b>Middle panel</b>: When the patient is in sinus rhythm, the arrow indicates </text>
<text top="900" left="69" width="725" height="14" font="3">where the R′ is absent in V1. <b>Bottom panels</b>: Magnified portions of lead V1 in AVNRT <b>(left)</b> and sinus rhythm <b>(right)</b> are shown. AVNRT </text>
<text top="914" left="69" width="284" height="14" font="3">indicates atrioventricular nodal reentrant tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="19" size="11" family="Times" color="#ffffff"/>
	<fontspec id="20" size="4" family="Times" color="#231f20"/>
	<fontspec id="21" size="10" family="Times" color="#3c4ba7"/>
<text top="47" left="71" width="243" height="17" font="11"><i><b>e516  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="519" left="71" width="355" height="16" font="13">that are not AV node dependent. Also, if the QRS duration </text>
<text top="537" left="71" width="355" height="16" font="13">is &gt;120 ms, it is crucial to distinguish VT from SVT with </text>
<text top="554" left="71" width="356" height="16" font="13">aberrant conduction, pre-existing bundle-branch block, or </text>
<text top="571" left="71" width="357" height="16" font="13">pre-excitation (Table 4). In particular, the administration </text>
<text top="519" left="458" width="356" height="16" font="13">of verapamil or diltiazem for treatment of either VT or a </text>
<text top="537" left="458" width="356" height="16" font="13">pre-excited AF may lead to hemodynamic compromise or </text>
<text top="554" left="458" width="356" height="16" font="13">may accelerate the ventricular rate and lead to ventricular </text>
<text top="571" left="458" width="67" height="16" font="13">fibrillation.</text>
<text top="621" left="80" width="395" height="16" font="19"><b>Recommendations for Acute Treatment of SVT of Unknown Mechanism</b></text>
<text top="643" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="643" left="130" width="18" height="14" font="1"><b>LOE</b></text>
<text top="643" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="668" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="668" left="130" width="18" height="14" font="1"><b>B-R</b></text>
<text top="668" left="171" width="419" height="14" font="1"><b>1.   Vagal maneuvers are recommended for acute treatment in patients with regular SVT.</b></text>
<text top="669" left="590" width="17" height="8" font="20"><b>82–84</b></text>
<text top="754" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="754" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="769" left="80" width="70" height="14" font="21"><a href="">Supplements 2 </a></text>
<text top="784" left="80" width="25" height="14" font="21"><a href="">and 3</a></text>
<text top="784" left="105" width="3" height="14" font="3"><a href="">.</a></text>
<text top="694" left="171" width="615" height="14" font="3">For acute conversion of SVT, vagal maneuvers, including Valsalva and carotid sinus massage, can be performed quickly and should </text>
<text top="709" left="171" width="612" height="14" font="3">be the first-line intervention to terminate SVT. These maneuvers should be performed with the patient in the supine position. Vagal </text>
<text top="724" left="171" width="613" height="14" font="3">maneuvers typically will not be effective if the rhythm does not involve the AV node as a requisite component of a reentrant circuit. </text>
<text top="739" left="171" width="601" height="14" font="3">There is no “gold standard” for proper Valsalva maneuver technique but, in general, the patient raises intrathoracic pressure by  </text>
<text top="754" left="171" width="493" height="14" font="3">bearing down against a closed glottis for 10 to 30 seconds, equivalent to at least 30 mm Hg to 40 mm Hg.</text>
<text top="755" left="664" width="16" height="8" font="18">82,84</text>
<text top="754" left="680" width="95" height="14" font="3"> Carotid massage is </text>
<text top="769" left="171" width="619" height="14" font="3">performed after absence of bruit has been confirmed by auscultation, by applying steady pressure over the right or left carotid sinus </text>
<text top="784" left="171" width="93" height="14" font="3">for 5 to 10 seconds.</text>
<text top="785" left="265" width="16" height="8" font="18">83,84</text>
<text top="784" left="281" width="510" height="14" font="3"> Another vagal maneuver based on the classic diving reflex consists of applying an ice-cold, wet towel to the </text>
<text top="799" left="171" width="20" height="14" font="3">face</text>
<text top="800" left="191" width="7" height="8" font="18">85</text>
<text top="799" left="198" width="568" height="14" font="3">; in a laboratory setting, facial immersion in water at 10°C (50°F) has proved effective in terminating tachycardia, as well.</text>
<text top="800" left="766" width="7" height="8" font="18">86</text>
<text top="799" left="773" width="24" height="14" font="3"> One </text>
<text top="814" left="171" width="636" height="14" font="3">study involving 148 patients with SVT demonstrated that Valsalva was more successful than carotid sinus massage, and switching from </text>
<text top="829" left="171" width="323" height="14" font="3">1 technique to the other resulted in an overall success rate of 27.7%.</text>
<text top="830" left="495" width="7" height="8" font="18">82</text>
<text top="829" left="502" width="290" height="14" font="3"> The practice of applying pressure to the eyeball is potentially </text>
<text top="844" left="171" width="172" height="14" font="3">dangerous and has been abandoned.</text>
<text top="865" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="865" left="130" width="18" height="14" font="1"><b>B-R</b></text>
<text top="865" left="171" width="380" height="14" font="1"><b>2.   Adenosine is recommended for acute treatment in patients with regular SVT.</b></text>
<text top="866" left="551" width="42" height="8" font="20"><b>42,51,83,87–92</b></text>
<text top="917" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="917" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="932" left="80" width="70" height="14" font="21"><a href="">Supplements 2 </a></text>
<text top="947" left="80" width="25" height="14" font="21"><a href="">and 3</a></text>
<text top="947" left="105" width="3" height="14" font="3"><a href="">.</a></text>
<text top="887" left="171" width="616" height="14" font="3">Adenosine has been shown in nonrandomized trials in the emergency department or prehospital setting to effectively terminate SVT that is </text>
<text top="902" left="171" width="613" height="14" font="3">due to either AVNRT or AVRT, with success rates ranging from 78% to 96%. Although patients may experience side effects, such as chest </text>
<text top="917" left="171" width="530" height="14" font="3">discomfort, shortness of breath, and flushing, serious adverse effects are rare because of the drug’s very short half-life.</text>
<text top="917" left="702" width="7" height="8" font="18">93</text>
<text top="917" left="708" width="94" height="14" font="3"> Adenosine may also </text>
<text top="932" left="171" width="558" height="14" font="3">be useful diagnostically, to unmask atrial flutter or AT, but it is uncommon for adenosine to terminate these atrial arrhythmias.</text>
<text top="932" left="730" width="7" height="8" font="18">91</text>
<text top="932" left="736" width="57" height="14" font="3"> It should be </text>
<text top="947" left="171" width="621" height="14" font="3">administered via proximal IV as a rapid bolus infusion followed by a saline flush. Continuous ECG recording during adenosine administration </text>
<text top="962" left="171" width="618" height="14" font="3">may help diagnostically and can also distinguish drug failure due to failure to terminate the arrhythmias versus successful termination with </text>
<text top="977" left="171" width="150" height="14" font="3">immediate arrhythmia reinitiation.</text>
<text top="1005" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="1005" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="997" left="171" width="613" height="14" font="1"><b>3.   Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically unstable SVT when vagal </b></text>
<text top="1012" left="186" width="262" height="14" font="1"><b>maneuvers or adenosine are ineffective or not feasible.</b></text>
<text top="1013" left="448" width="7" height="8" font="20"><b>94</b></text>
<text top="1056" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1056" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1071" left="80" width="62" height="14" font="21"><a href="">Supplement 3</a></text>
<text top="1071" left="141" width="3" height="14" font="3">.</text>
<text top="1033" left="171" width="615" height="14" font="3">Sinus rhythm must be promptly restored in patients with SVT who are hemodynamically unstable. The safety and effectiveness of cardioversion in </text>
<text top="1048" left="171" width="627" height="14" font="3">the prehospital setting was analyzed in a cohort of patients with hemodynamically unstable SVT who had failed to convert with vagal maneuvers and </text>
<text top="1063" left="171" width="445" height="14" font="3">intravenous pharmacological therapy, and cardioversion successfully restored sinus rhythm in all patients.</text>
<text top="1064" left="616" width="7" height="8" font="18">94</text>
<text top="1063" left="622" width="133" height="14" font="3"> The 2010 adult ACLS guideline</text>
<text top="1064" left="755" width="7" height="8" font="18">75</text>
<text top="1063" left="761" width="37" height="14" font="3"> advises </text>
<text top="1078" left="171" width="619" height="14" font="3">synchronized cardioversion for any persistent SVT resulting in hypotension, acutely altered mental status, signs of shock, chest pain, or acute heart </text>
<text top="1093" left="171" width="547" height="14" font="3">failure symptoms but recommends that adenosine be considered first if the tachycardia is regular and has a narrow QRS complex.</text>
<text top="419" left="70" width="725" height="14" font="1"><b>Figure 3.</b> Atypical AVNRT. Arrows point to the P wave. The reentrant circuit involves anterograde conduction over a fast atrioventricular </text>
<text top="433" left="70" width="709" height="14" font="3">node pathway, followed by retrograde conduction in a slow atrioventricular node pathway, resulting in a retrograde P wave (negative </text>
<text top="446" left="70" width="734" height="14" font="3">polarity in inferior leads) with long RP interval. This ECG does not exclude PJRT or a low septal atrial tachycardia, which can appear very </text>
<text top="460" left="70" width="732" height="14" font="3">similar to this ECG. AVNRT indicates atrioventricular nodal reentrant tachycardia; ECG, electrocardiogram; and PJRT, permanent form of </text>
<text top="473" left="70" width="194" height="14" font="3">junctional reciprocating tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e517</i></b></text>
<text top="474" left="69" width="285" height="16" font="0"><i><b>2.4.2. Ongoing Management: Recommendations</b></i></text>
<text top="491" left="69" width="354" height="16" font="13">The recommendations and algorithm (Figure 9) for ongoing </text>
<text top="508" left="69" width="351" height="16" font="13">management, along with other recommendations and algo-</text>
<text top="526" left="69" width="356" height="16" font="13">rithms for specific SVTs that follow, are meant to include </text>
<text top="543" left="69" width="355" height="16" font="13">consideration of patient preferences and clinical judgment; </text>
<text top="560" left="69" width="351" height="16" font="13">this may include consideration of consultation with a car-</text>
<text top="578" left="69" width="358" height="16" font="13">diologist or clinical cardiac electrophyisiologist, as well </text>
<text top="474" left="456" width="358" height="16" font="13">as patient comfort with possible invasive diagnostic and </text>
<text top="491" left="456" width="358" height="16" font="13">therapeutic intervention. Recommendations for treatment </text>
<text top="509" left="456" width="357" height="16" font="13">options (including drug therapy, ablation, or observation) </text>
<text top="526" left="456" width="351" height="16" font="13">must be considered in the context of frequency and dura-</text>
<text top="543" left="456" width="357" height="16" font="13">tion of the SVT, along with clinical manifestations, such </text>
<text top="560" left="456" width="355" height="16" font="13">as symptoms or adverse consequences (eg, development of </text>
<text top="578" left="456" width="104" height="16" font="13">cardiomyopathy).</text>
<text top="619" left="78" width="424" height="16" font="19"><b>Recommendations for Ongoing Management of SVT of Unknown Mechanism</b></text>
<text top="643" left="78" width="20" height="14" font="1"><b>COR</b></text>
<text top="643" left="132" width="18" height="14" font="1"><b>LOE</b></text>
<text top="643" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="672" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="672" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="664" left="170" width="630" height="14" font="1"><b>1.   Oral beta blockers, diltiazem, or verapamil is useful for ongoing management in patients with symptomatic SVT who do not have </b></text>
<text top="679" left="184" width="223" height="14" font="1"><b>ventricular pre-excitation during sinus rhythm.</b></text>
<text top="680" left="408" width="24" height="8" font="20"><b>46,98,99</b></text>
<text top="746" left="78" width="20" height="14" font="3">See </text>
<text top="746" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="761" left="78" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="761" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="701" left="170" width="617" height="14" font="3">Although many patients prefer to undergo potentially curative therapy with ablation, given its high success rate, and although ablation may </text>
<text top="716" left="170" width="629" height="14" font="3">be mandatory therapy for patients in certain occupations (eg, pilots, bus drivers), patients may prefer not to undergo ablation or may not have </text>
<text top="731" left="170" width="610" height="14" font="3">access to a cardiac electrophysiologist. In these latter cases, pharmacological therapy with AV nodal blockers is an appropriate option for </text>
<text top="746" left="170" width="635" height="14" font="3">long-term prophylactic therapy. Pharmacological therapy with verapamil (dosage up to 480 mg/day) has been studied in RCTs, with reductions </text>
<text top="761" left="170" width="611" height="14" font="3">documented in SVT episode frequency and duration as recorded by Holter monitoring or subjective episode frequency recording in diaries.</text>
<text top="762" left="781" width="7" height="8" font="18">98</text>
<text top="761" left="788" width="3" height="14" font="3"> </text>
<text top="776" left="170" width="624" height="14" font="3">Evidence for beta blockers is limited. One small study randomized patients with SVT to digoxin (0.375 mg/day), propranolol (240 mg/day), or </text>
<text top="791" left="170" width="366" height="14" font="3">verapamil (480 mg/day), with 1 week of placebo washout between drug regimens.</text>
<text top="792" left="536" width="7" height="8" font="18">99</text>
<text top="791" left="542" width="258" height="14" font="3"> Reduction in the number of episodes and duration of SVT </text>
<text top="806" left="170" width="576" height="14" font="3">(ascertained by diary and weekly 24-h Holter) was similar among the treatment groups, and all 3 medications were well tolerated.</text>
<text top="807" left="746" width="7" height="8" font="18">99</text>
<text top="827" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="827" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="827" left="170" width="461" height="14" font="1"><b>2.   EP study with the option of ablation is useful for the diagnosis and potential treatment of SVT.</b></text>
<text top="828" left="631" width="32" height="8" font="20"><b>36,100–106</b></text>
<text top="856" left="78" width="20" height="14" font="3">See </text>
<text top="856" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="871" left="78" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="871" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="849" left="170" width="627" height="14" font="3">EP testing with the option of ablation is useful as first-line therapy for treatment of symptomatic SVT, as it provides the potential for definitive </text>
<text top="864" left="170" width="618" height="14" font="3">cure without the need for chronic pharmacological therapy. Large registry studies report high success rates for ablation of both AVNRT and </text>
<text top="879" left="170" width="316" height="14" font="3">AVRT, with low frequency of potentially serious complications (Table 8).</text>
<text top="901" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="901" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="901" left="170" width="528" height="14" font="1"><b>3.   Patients with SVT should be educated on how to perform vagal maneuvers for ongoing management of SVT.</b></text>
<text top="902" left="698" width="7" height="8" font="20"><b>82</b></text>
<text top="941" left="78" width="20" height="14" font="3">See </text>
<text top="941" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="956" left="78" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="956" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="926" left="170" width="587" height="14" font="3">When properly performed, vagal maneuvers can terminate SVT, so patient education on this maneuver may help to avoid a more prolonged </text>
<text top="941" left="170" width="615" height="14" font="3">tachycardia episode and reduce the need to seek medical attention. Vagal maneuvers should be performed with the patient in the supine position. </text>
<text top="956" left="170" width="621" height="14" font="3">Patients can be taught to perform a Valsalva maneuver by forcefully exhaling against a closed airway for 10 to 30 seconds, equivalent to at least 30 </text>
<text top="971" left="170" width="89" height="14" font="3">mm Hg to 40 mm Hg.</text>
<text top="972" left="258" width="15" height="8" font="18">82,84</text>
<text top="971" left="273" width="478" height="14" font="3"> Another vagal maneuver based on the classic diving reflex consists of applying an ice-cold, wet towel to the face.</text>
<text top="972" left="751" width="7" height="8" font="18">85</text>
<text top="1002" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="1002" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="995" left="170" width="626" height="14" font="1"><b>1.   Flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart </b></text>
<text top="1010" left="184" width="509" height="14" font="1"><b>disease who have symptomatic SVT and are not candidates for, or prefer not to undergo, catheter ablation.</b></text>
<text top="1011" left="693" width="40" height="8" font="20"><b>45,46,107–112</b></text>
<text top="1057" left="78" width="20" height="14" font="3">See </text>
<text top="1057" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1072" left="78" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="1072" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="1035" left="170" width="621" height="14" font="3">Several RCTs have demonstrated the efficacy of daily therapy with propafenone (450 mg/day to 900 mg/day) or flecainide (100 mg/day to 300 mg/day) </text>
<text top="1050" left="170" width="224" height="14" font="3">to prevent recurrences of SVT in symptomatic patients.</text>
<text top="1050" left="394" width="38" height="8" font="18">45,46,107–112</text>
<text top="1050" left="432" width="362" height="14" font="3"> In 1 RCT, the probability of 12 months of effective (defined as &lt;2 attacks of arrhythmia) </text>
<text top="1065" left="170" width="285" height="14" font="3">and safe treatment was 86% for propafenone and 93% for flecainide.</text>
<text top="1065" left="454" width="10" height="8" font="18">109</text>
<text top="1065" left="463" width="340" height="14" font="3"> However, flecainide and propafenone have a risk of proarrhythmia in patients with </text>
<text top="1080" left="170" width="448" height="14" font="3">structural heart disease or ischemic heart disease, so these drugs are contraindicated in these patient groups.</text>
<text top="1080" left="618" width="10" height="8" font="18">113</text>
<text top="1080" left="627" width="175" height="14" font="3"> These drugs, though often effective, have </text>
<text top="1095" left="170" width="625" height="14" font="3">potential side effects and as such should be reserved for patients for whom beta blockers, diltiazem, or verapamil are ineffective or cannot be prescribed.</text>
<text top="153" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="153" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="145" left="169" width="573" height="14" font="1"><b>4.   Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically stable SVT when </b></text>
<text top="160" left="184" width="276" height="14" font="1"><b>pharmacological therapy is ineffective or contraindicated.</b></text>
<text top="161" left="460" width="15" height="8" font="20"><b>87,95</b></text>
<text top="197" left="77" width="20" height="14" font="3">See </text>
<text top="197" left="97" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="212" left="77" width="70" height="14" font="21"><a href="">Supplements 3 </a></text>
<text top="227" left="77" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="227" left="108" width="3" height="14" font="3">.</text>
<text top="182" left="169" width="636" height="14" font="3">Synchronized cardioversion is highly effective in terminating SVT (including AVRT and AVNRT), and when the patient is stable, this is performed </text>
<text top="197" left="169" width="170" height="14" font="3">after adequate sedation or anesthesia.</text>
<text top="197" left="339" width="7" height="8" font="18">94</text>
<text top="197" left="346" width="450" height="14" font="3"> Most stable patients with SVT respond to pharmacological therapy, with conversion success rates of </text>
<text top="212" left="169" width="631" height="14" font="3">80% to 98% for agents such as verapamil, diltiazem, or adenosine. In some resistant cases, a second drug bolus or higher dose of initial drug </text>
<text top="227" left="169" width="124" height="14" font="3">agent might prove effective.</text>
<text top="227" left="293" width="15" height="8" font="18">87,96</text>
<text top="227" left="308" width="490" height="14" font="3"> Nevertheless, in rare instances, drugs may fail to successfully restore sinus rhythm, and cardioversion will be </text>
<text top="242" left="169" width="492" height="14" font="3">necessary. Synchronized cardioversion is inappropriate if the SVT is terminating and reinitiating spontaneously.</text>
<text top="262" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="262" left="127" width="18" height="14" font="1"><b>B-R</b></text>
<text top="262" left="169" width="574" height="14" font="1"><b>1.   Intravenous diltiazem or verapamil can be effective for acute treatment in patients with hemodynamically stable SVT.</b></text>
<text top="263" left="743" width="32" height="8" font="20"><b>87,89,92,97</b></text>
<text top="306" left="77" width="20" height="14" font="3">See </text>
<text top="306" left="97" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="321" left="77" width="70" height="14" font="21"><a href="">Supplements 2 </a></text>
<text top="336" left="77" width="25" height="14" font="21"><a href="">and 3</a></text>
<text top="336" left="103" width="3" height="14" font="3"><a href="">.</a></text>
<text top="284" left="169" width="601" height="14" font="3">Intravenous diltiazem and verapamil have been shown to terminate SVT in 64% to 98% of patients. These drugs should be used only in </text>
<text top="299" left="169" width="544" height="14" font="3">hemodynamically stable patients. A slow infusion of either drug up to 20 minutes may lessen the potential for hypotension.</text>
<text top="299" left="713" width="7" height="8" font="18">97</text>
<text top="299" left="720" width="67" height="14" font="3"> It is important </text>
<text top="314" left="169" width="602" height="14" font="3">to ensure that tachycardia is not due to VT or pre-excited AF because patients with these rhythms who are given diltiazem or verapamil </text>
<text top="329" left="169" width="611" height="14" font="3">may become hemodynamically unstable or may have accelerated ventricular rate, which may lead to ventricular fibrillation. These agents </text>
<text top="344" left="169" width="620" height="14" font="3">are especially useful in patients who cannot tolerate beta blockers or experience recurrence after conversion with adenosine. Diltiazem and </text>
<text top="359" left="169" width="349" height="14" font="3">verapamil are not appropriate for patients with suspected systolic heart failure.</text>
<text top="379" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="379" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="379" left="169" width="527" height="14" font="1"><b>2.   Intravenous beta blockers are reasonable for acute treatment in patients with hemodynamically stable SVT.</b></text>
<text top="380" left="696" width="7" height="8" font="20"><b>96</b></text>
<text top="409" left="77" width="20" height="14" font="3">See </text>
<text top="409" left="97" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="424" left="77" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="424" left="139" width="3" height="14" font="3">.</text>
<text top="401" left="169" width="615" height="14" font="3">Evidence for the effectiveness of beta blockers in terminating SVT is limited. In a trial that compared esmolol with diltiazem, diltiazem was </text>
<text top="416" left="169" width="151" height="14" font="3">more effective in terminating SVT.</text>
<text top="417" left="320" width="7" height="8" font="18">96</text>
<text top="416" left="326" width="459" height="14" font="3"> Nonetheless, beta blockers have an excellent safety profile, so it is reasonable to use intravenous beta </text>
<text top="431" left="169" width="324" height="14" font="3">blockers to attempt to terminate SVT in hemodynamically stable patients.</text>
<text top="103" left="77" width="463" height="16" font="19"><b>Recommendations for Acute Treatment of SVT of Unknown Mechanism (Continued)</b></text>
<text top="125" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="125" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="125" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e518  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="728" left="71" width="342" height="18" font="10"><b>2.5. Basic Principles of Electrophysiological Study, </b></text>
<text top="745" left="71" width="156" height="18" font="10"><b>Mapping, and Ablation</b></text>
<text top="772" left="71" width="309" height="16" font="0"><i><b>2.5.1. Mapping With Multiple and Roving Electrodes</b></i></text>
<text top="790" left="71" width="357" height="16" font="13">An invasive EP study permits the precise diagnosis of the </text>
<text top="807" left="71" width="355" height="16" font="13">underlying arrhythmia mechanism and localization of the site </text>
<text top="824" left="71" width="357" height="16" font="13">of origin and provides definitive treatment if coupled with </text>
<text top="842" left="71" width="351" height="16" font="13">catheter ablation. There are standards that define the equip-</text>
<text top="859" left="71" width="357" height="16" font="13">ment and training of personnel for optimal performance of </text>
<text top="876" left="71" width="56" height="16" font="13">EP study.</text>
<text top="877" left="126" width="12" height="9" font="14">141</text>
<text top="876" left="138" width="288" height="16" font="13"> EP studies involve placement of multielectrode </text>
<text top="894" left="70" width="147" height="16" font="13">catheters in the heart at </text>
<text top="893" left="218" width="210" height="17" font="13">≥1 sites in the atria, ventricles, or </text>
<text top="911" left="70" width="354" height="16" font="13">coronary sinus. Pacing and programmed electrical stimulation </text>
<text top="928" left="70" width="351" height="16" font="13">may be performed with or without pharmacological provoca-</text>
<text top="945" left="70" width="354" height="16" font="13">tion. Making a precise and correct diagnosis of the mechanism </text>
<text top="963" left="70" width="356" height="16" font="13">of SVT is the key to successful outcome, particularly when </text>
<text top="980" left="70" width="351" height="16" font="13">multiple arrhythmia mechanisms are possible; as such, appro-</text>
<text top="997" left="70" width="351" height="16" font="13">priate diagnostic maneuvers should be performed before pro-</text>
<text top="1015" left="70" width="355" height="16" font="13">ceeding with ablation. By using diagnostic maneuvers during </text>
<text top="1032" left="70" width="355" height="16" font="13">the EP study, the mechanism of SVT can be defined in most </text>
<text top="1049" left="70" width="34" height="16" font="13">cases.</text>
<text top="1050" left="104" width="23" height="9" font="14">80,142</text>
<text top="1049" left="127" width="298" height="16" font="13"> Complications of diagnostic EP studies are rare but </text>
<text top="1066" left="71" width="131" height="16" font="13">can be life threatening.</text>
<text top="1067" left="201" width="12" height="9" font="14">143</text>
<text top="1084" left="92" width="330" height="16" font="13">Cardiac mapping is performed during EP studies to iden-</text>
<text top="1101" left="71" width="357" height="16" font="13">tify the site of origin of an arrhythmia or areas of critical </text>
<text top="729" left="458" width="354" height="16" font="13">conduction to allow targeting of ablation. Multiple techniques </text>
<text top="746" left="458" width="355" height="16" font="13">have been developed to characterize the temporal and spatial </text>
<text top="763" left="458" width="201" height="16" font="13">distribution of electrical activation.</text>
<text top="764" left="659" width="12" height="9" font="14">144</text>
<text top="763" left="671" width="142" height="16" font="13"> The simplest technique </text>
<text top="781" left="457" width="357" height="16" font="13">uses several multipole catheters plus a roving catheter that </text>
<text top="798" left="457" width="356" height="16" font="13">is sequentially positioned in different regions of interest and </text>
<text top="816" left="457" width="351" height="16" font="13">measures local activation time. Electroanatomic mapping sys-</text>
<text top="833" left="457" width="354" height="16" font="13">tems and specialized multielectrode catheters, such as circular </text>
<text top="850" left="457" width="351" height="16" font="13">or multispline catheters, can map simultaneously from mul-</text>
<text top="868" left="457" width="343" height="16" font="13">tiple sites and improve the speed and resolution of mapping.</text>
<text top="893" left="457" width="353" height="16" font="0"><i><b>2.5.2. Tools to Facilitate Ablation, Including 3-Dimensional </b></i></text>
<text top="909" left="457" width="154" height="16" font="0"><i><b>Electroanatomic Mapping</b></i></text>
<text top="927" left="457" width="358" height="16" font="13">Several tools have been developed to facilitate arrhythmia </text>
<text top="944" left="457" width="351" height="16" font="13">mapping and ablation, including electroanatomic 3-dimen-</text>
<text top="962" left="457" width="354" height="16" font="13">sional mapping and magnetic navigation. Potential benefits of </text>
<text top="979" left="457" width="351" height="16" font="13">these technologies include more precise definition or localiza-</text>
<text top="997" left="457" width="354" height="16" font="13">tion of arrhythmia mechanism, spatial display of catheters and </text>
<text top="1014" left="457" width="356" height="16" font="13">arrhythmia activation, reduction in fluoroscopy exposure for </text>
<text top="1031" left="457" width="351" height="16" font="13">the patient and staff, and shortened procedure times, particu-</text>
<text top="1049" left="457" width="250" height="16" font="13">larly for complex arrhythmias or anatomy.</text>
<text top="1049" left="708" width="12" height="9" font="14">145</text>
<text top="1049" left="720" width="94" height="16" font="13"> Disadvantages </text>
<text top="1066" left="458" width="357" height="16" font="13">include higher cost, as well as additional training, support, </text>
<text top="1084" left="458" width="351" height="16" font="13">and procedure preparation time. Several studies have dem-</text>
<text top="1101" left="458" width="357" height="16" font="13">onstrated the advantages of electroanatomic mapping, with </text>
<text top="155" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="155" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="147" left="171" width="625" height="14" font="1"><b>1.   Sotalol may be reasonable for ongoing management in patients with symptomatic SVT who are not candidates for, or prefer not </b></text>
<text top="162" left="186" width="141" height="14" font="1"><b>to undergo, catheter ablation.</b></text>
<text top="163" left="327" width="10" height="8" font="20"><b>114</b></text>
<text top="217" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="217" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="232" left="80" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="232" left="141" width="3" height="14" font="3">.</text>
<text top="187" left="171" width="606" height="14" font="3">Sotalol is a class III antiarrhythmic agent with beta-blocker properties. Unlike flecainide and propafenone, it can be used in patients with </text>
<text top="202" left="171" width="592" height="14" font="3">structural heart disease or ischemic heart disease. One study randomized patients with reentrant SVT (AVNRT or AVRT) or other atrial </text>
<text top="217" left="171" width="625" height="14" font="3">tachyarrhythmias (eg, AF, atrial flutter, AT) to sotalol at a dose of 80 mg or 160 mg twice daily or placebo and found significant reductions in </text>
<text top="232" left="171" width="428" height="14" font="3">recurrence risk, including for patients with reentrant SVT, with no proarrhythmic adverse effects.</text>
<text top="233" left="599" width="10" height="8" font="18">114</text>
<text top="232" left="609" width="196" height="14" font="3"> Because of the potential for proarrhythmia, </text>
<text top="247" left="171" width="622" height="14" font="3">sotalol should be reserved for patients who are not candidates for catheter ablation and for whom beta blockers, diltiazem, or verapamil are </text>
<text top="262" left="171" width="157" height="14" font="3">ineffective or cannot be prescribed.</text>
<text top="301" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="301" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="286" left="171" width="620" height="14" font="1"><b>2.   Dofetilide may be reasonable for ongoing management in patients with symptomatic SVT who are not candidates for, or prefer </b></text>
<text top="301" left="186" width="609" height="14" font="1"><b>not to undergo, catheter ablation and in whom beta blockers, diltiazem, flecainide, propafenone, or verapamil are ineffective or </b></text>
<text top="316" left="186" width="78" height="14" font="1"><b>contraindicated.</b></text>
<text top="317" left="264" width="10" height="8" font="20"><b>107</b></text>
<text top="369" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="369" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="384" left="80" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="384" left="141" width="3" height="14" font="3">.</text>
<text top="339" left="171" width="621" height="14" font="3">Dofetilide is a class III antiarrhythmic agent that, unlike sotalol, does not have beta-blocker properties. It may be reasonable in patients with </text>
<text top="354" left="171" width="627" height="14" font="3">structural heart disease or ischemic heart disease. In a trial of 122 patients randomized to dofetilide, propafenone, or placebo, the probability </text>
<text top="369" left="171" width="611" height="14" font="3">of remaining free of SVT after 6 months of treatment was 50% for dofetilide, 54% for propafenone, and 6% for placebo, with P&lt;0.001 for </text>
<text top="384" left="171" width="249" height="14" font="3">either dofetilide or propafenone compared with placebo.</text>
<text top="385" left="420" width="10" height="8" font="18">107</text>
<text top="384" left="430" width="341" height="14" font="3"> Because of the potential for proarrhythmia, dofetilide should be reserved for </text>
<text top="399" left="171" width="598" height="14" font="3">patients who are not candidates for catheter ablation and for whom beta blockers, diltiazem, flecainide, verapamil, or propafenone are </text>
<text top="414" left="171" width="157" height="14" font="3">ineffective or cannot be prescribed.</text>
<text top="450" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="450" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="435" left="171" width="622" height="14" font="1"><b>3.   Oral amiodarone may be considered for ongoing management in patients with symptomatic SVT who are not candidates for, or </b></text>
<text top="450" left="186" width="594" height="14" font="1"><b>prefer not to undergo, catheter ablation and in whom beta blockers, diltiazem, dofetilide, flecainide, propafenone, sotalol, or </b></text>
<text top="465" left="186" width="212" height="14" font="1"><b>verapamil are ineffective or contraindicated.</b></text>
<text top="466" left="397" width="10" height="8" font="20"><b>115</b></text>
<text top="502" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="502" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="517" left="80" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="517" left="141" width="3" height="14" font="3">.</text>
<text top="487" left="171" width="631" height="14" font="3">Evidence for amiodarone for the ongoing management of SVT is limited. The drug was evaluated in a small retrospective study and was found </text>
<text top="502" left="171" width="289" height="14" font="3">to be effective in suppressing AVNRT during outpatient follow-up.</text>
<text top="503" left="460" width="10" height="8" font="18">115</text>
<text top="502" left="470" width="323" height="14" font="3"> Amiodarone is a second-line agent for patients who are not able to take </text>
<text top="517" left="171" width="612" height="14" font="3">beta blockers, diltiazem, dofetilide, flecainide, propafenone, sotalol, or verapamil given the toxicity and side effects that may develop with </text>
<text top="532" left="171" width="138" height="14" font="3">long-term amiodarone therapy.</text>
<text top="561" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="561" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="553" left="171" width="622" height="14" font="1"><b>4.   Oral digoxin may be reasonable for ongoing management in patients with symptomatic SVT without pre-excitation who are not </b></text>
<text top="568" left="186" width="278" height="14" font="1"><b>candidates for, or prefer not to undergo, catheter ablation.</b></text>
<text top="569" left="464" width="7" height="8" font="20"><b>99</b></text>
<text top="627" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="627" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="642" left="80" width="62" height="14" font="21"><a href="">Supplement 2</a></text>
<text top="642" left="141" width="3" height="14" font="3">.</text>
<text top="590" left="171" width="631" height="14" font="3">Evidence for the use of digoxin is limited. One small study randomized patients with SVT to digoxin (0.375 mg/day), propranolol (240 mg/day), </text>
<text top="605" left="171" width="385" height="14" font="3">and verapamil (480 mg/day), with 1 week of placebo washout between drug regimens.</text>
<text top="605" left="556" width="7" height="8" font="18">99</text>
<text top="605" left="563" width="229" height="14" font="3"> Overall, episodes and duration of SVT (ascertained </text>
<text top="620" left="171" width="393" height="14" font="3">by diary and weekly 24-h Holter) were similar, and all 3 medications were well tolerated.</text>
<text top="620" left="564" width="7" height="8" font="18">99</text>
<text top="620" left="571" width="210" height="14" font="3"> However, the dose of digoxin used was higher </text>
<text top="635" left="171" width="629" height="14" font="3">than that commonly used in clinical practice today, and in view of the risk of toxicity, digoxin should be reserved for patients who cannot take </text>
<text top="650" left="171" width="622" height="14" font="3">beta blockers, diltiazem, or verapamil or a class Ic agent (flecainide or propafenone) and must be used with caution in the presence of renal </text>
<text top="665" left="171" width="629" height="14" font="3">dysfunction. In some clinical studies, digoxin levels &gt;1.2 ng/mL were associated with worse clinical outcomes, while levels &lt;0.8 ng/mL were </text>
<text top="680" left="171" width="218" height="14" font="3">considered optimal; therefore, caution is advised.</text>
<text top="680" left="390" width="10" height="8" font="18">116</text>
<text top="103" left="80" width="493" height="16" font="19"><b>Recommendations for Ongoing Management of SVT of Unknown Mechanism (Continued)</b></text>
<text top="125" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="125" left="130" width="18" height="14" font="1"><b>LOE</b></text>
<text top="125" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e519</i></b></text>
<text top="487" left="69" width="354" height="16" font="13">success rates comparable to conventional approaches yet with </text>
<text top="505" left="69" width="240" height="16" font="13">significant reduction in fluoroscopy times.</text>
<text top="505" left="309" width="29" height="9" font="14">145–148</text>
<text top="530" left="69" width="351" height="16" font="0"><i><b>2.5.3. Mapping and Ablation With No or Minimal Radiation</b></i></text>
<text top="547" left="69" width="351" height="16" font="13">Fluoroscopy has historically been the primary imaging modal-</text>
<text top="565" left="69" width="357" height="16" font="13">ity used for EP studies. The use of ionizing radiation puts </text>
<text top="582" left="69" width="355" height="16" font="13">patient, operator, and laboratory staff at risk of the short- and </text>
<text top="599" left="69" width="356" height="16" font="13">long-term effects of radiation exposure. Attention to optimal </text>
<text top="616" left="69" width="359" height="16" font="13">fluoroscopic technique and adoption of radiation-reducing </text>
<text top="634" left="69" width="351" height="16" font="13">strategies can minimize radiation dose to the patient and oper-</text>
<text top="651" left="69" width="355" height="16" font="13">ator. The current standard is to use the “as low as reasonably </text>
<text top="668" left="69" width="355" height="16" font="13">achievable” (ALARA) principle on the assumption that there </text>
<text top="685" left="69" width="356" height="16" font="13">is no threshold below which ionizing radiation is free from </text>
<text top="703" left="69" width="356" height="16" font="13">harmful biological effect. Alternative imaging systems, such </text>
<text top="720" left="69" width="351" height="16" font="13">as electroanatomic mapping and intracardiac echocardiogra-</text>
<text top="737" left="69" width="355" height="16" font="13">phy, have led to the ability to perform SVT ablation with no </text>
<text top="487" left="456" width="356" height="16" font="13">or minimal fluoroscopy, with success and complication rates </text>
<text top="505" left="456" width="186" height="16" font="13">similar to standard techniques.</text>
<text top="505" left="642" width="44" height="9" font="14">147,149–152</text>
<text top="505" left="685" width="129" height="16" font="13"> Radiation exposure </text>
<text top="522" left="456" width="351" height="16" font="13">may be further reduced by using robotic or magnetic naviga-</text>
<text top="539" left="456" width="356" height="16" font="13">tion of catheters that use a 3-dimensional anatomic tracking </text>
<text top="556" left="456" width="356" height="16" font="13">system superimposed on traditional fluoroscopy imaging. A </text>
<text top="574" left="456" width="358" height="16" font="13">reduced- fluoroscopy approach is particularly important in </text>
<text top="591" left="456" width="228" height="16" font="13">pediatric patients and during pregnancy.</text>
<text top="591" left="684" width="27" height="9" font="14">153,154</text>
<text top="616" left="456" width="182" height="16" font="0"><i><b>2.5.4. Ablation Energy Sources</b></i></text>
<text top="634" left="456" width="356" height="16" font="13">Radiofrequency current is the most commonly used energy </text>
<text top="651" left="456" width="145" height="16" font="13">source for SVT ablation.</text>
<text top="651" left="601" width="13" height="9" font="14">155</text>
<text top="651" left="614" width="193" height="16" font="13"> Cryoablation is used as an alter-</text>
<text top="668" left="456" width="356" height="16" font="13">native to radiofrequency ablation to minimize injury to the </text>
<text top="685" left="456" width="357" height="16" font="13">AV node during ablation of specific arrhythmias, such as </text>
<text top="703" left="456" width="351" height="16" font="13">AVNRT, para-Hisian AT, and para-Hisian accessory path-</text>
<text top="720" left="456" width="357" height="16" font="13">ways, particularly in specific patient populations, such as </text>
<text top="737" left="456" width="357" height="16" font="13">children and young adults. Selection of the energy source </text>
<text top="420" left="69" width="740" height="14" font="1"><b>Figure 4.</b> Orthodromic atrioventricular reentrant tachycardia. Arrows point to the P waves, which are inscribed in the ST-segment after the </text>
<text top="434" left="69" width="721" height="14" font="3">QRS complex. The reentrant circuit involves anterograde conduction over the atrioventricular node, followed by retrograde conduction </text>
<text top="447" left="69" width="467" height="14" font="3">over an accessory pathway, which results in a retrograde P wave with short RP interval.</text>
<text top="1089" left="69" width="729" height="14" font="1"><b>Figure 5.</b> Atrial tachycardia. Arrows point to the P wave, which is inscribed before the QRS complex. The focus of this atrial tachycardia </text>
<text top="1102" left="69" width="502" height="14" font="3">was mapped during electrophysiological study to an area near the left inferior pulmonary vein.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e520  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="518" left="71" width="355" height="16" font="13">depends on operator experience, arrhythmia target location, </text>
<text top="535" left="71" width="351" height="16" font="13">and patient preference. Published trials, including a meta-</text>
<text top="552" left="71" width="351" height="16" font="13">analysis comparing radiofrequency ablation with cryoabla-</text>
<text top="569" left="71" width="356" height="16" font="13">tion for treatment of AVNRT, have shown a higher rate of </text>
<text top="587" left="71" width="354" height="16" font="13">recurrence with cryoablation but lower risk of permanent AV </text>
<text top="604" left="71" width="72" height="16" font="13">nodal block.</text>
<text top="604" left="143" width="30" height="9" font="14">156–158</text>
<text top="604" left="173" width="249" height="16" font="13"> The rate of AVNRT recurrence with cryo-</text>
<text top="621" left="71" width="356" height="16" font="13">ablation depends on the size of the ablation electrode and </text>
<text top="638" left="71" width="111" height="16" font="13">the endpoint used.</text>
<text top="639" left="182" width="27" height="9" font="14">156,159</text>
<text top="638" left="210" width="212" height="16" font="13"> Ultimately, the choice of technol-</text>
<text top="656" left="70" width="355" height="16" font="13">ogy should be made on the basis of an informed discussion </text>
<text top="673" left="70" width="216" height="16" font="13">between the operator and the patient.</text>
<text top="707" left="147" width="197" height="20" font="12"><b>3. Sinus Tachyarrhythmias</b></text>
<text top="728" left="71" width="359" height="16" font="13">In normal individuals, the sinus rate at rest is generally </text>
<text top="745" left="71" width="287" height="16" font="13">between 50 bpm and 90 bpm, reflecting vagal tone.</text>
<text top="745" left="358" width="29" height="9" font="14">160–163</text>
<text top="745" left="387" width="38" height="16" font="13"> Sinus </text>
<text top="762" left="71" width="355" height="16" font="13">tachycardia refers to the circumstance in which the sinus rate </text>
<text top="779" left="71" width="357" height="16" font="13">exceeds 100 bpm. Sinus tachycardia may be appropriate in </text>
<text top="797" left="71" width="354" height="16" font="13">response to physiological stimuli or other exogenous factors or </text>
<text top="814" left="71" width="354" height="16" font="13">may be inappropriate when the heart rate exceeds what would </text>
<text top="518" left="458" width="356" height="16" font="13">be expected for physical activity or other circumstances. On </text>
<text top="535" left="458" width="356" height="16" font="13">the ECG, the P wave is upright in leads I, II, and aVF and </text>
<text top="552" left="458" width="355" height="16" font="13">is biphasic in lead V1. As the sinus rate increases, activation </text>
<text top="569" left="458" width="354" height="16" font="13">arises from more superior aspects of the right atrium, resulting </text>
<text top="587" left="458" width="282" height="16" font="13">in a larger-amplitude P wave in the inferior leads.</text>
<text top="612" left="458" width="307" height="16" font="17"><b>Table 5.  ECG Criteria to Differentiate VT From SVT in  </b></text>
<text top="628" left="458" width="152" height="16" font="17"><b>Wide-Complex Tachycardia</b></text>
<text top="655" left="468" width="158" height="14" font="3">Findings or Leads on ECG Assessed</text>
<text top="655" left="642" width="59" height="14" font="3">Interpretation</text>
<text top="678" left="468" width="129" height="14" font="3">QRS complex in leads V1-V6 </text>
<text top="693" left="468" width="77" height="14" font="3">(Brugada criteria)</text>
<text top="693" left="545" width="7" height="8" font="18">73</text>
<text top="678" left="642" width="139" height="14" font="3">•   Lack of any R-S complexes  </text>
<text top="693" left="654" width="46" height="14" font="3">implies VT</text>
<text top="710" left="642" width="155" height="14" font="3">•   R-S interval (onset of R wave to </text>
<text top="725" left="654" width="148" height="14" font="3">nadir of S wave) &gt;100 ms in any </text>
<text top="740" left="654" width="114" height="14" font="3">precordial lead implies VT</text>
<text top="763" left="468" width="137" height="14" font="3">QRS complex in aVR (Vereckei </text>
<text top="778" left="468" width="45" height="14" font="3">algorithm)</text>
<text top="778" left="513" width="7" height="8" font="18">74</text>
<text top="763" left="642" width="132" height="14" font="3">•   Presence of initial R wave  </text>
<text top="778" left="654" width="46" height="14" font="3">implies VT</text>
<text top="795" left="642" width="133" height="14" font="3">•   Initial R or Q wave &gt;40 ms </text>
<text top="810" left="654" width="46" height="14" font="3">implies VT</text>
<text top="828" left="642" width="127" height="14" font="3">•   Presence of a notch on the </text>
<text top="843" left="653" width="140" height="14" font="3">descending limb at the onset of </text>
<text top="858" left="653" width="137" height="14" font="3">a predominantly negative QRS </text>
<text top="873" left="653" width="46" height="14" font="3">implies VT</text>
<text top="895" left="468" width="71" height="14" font="3">AV dissociation*</text>
<text top="895" left="642" width="161" height="14" font="3">•   Presence of AV dissociation (with </text>
<text top="910" left="654" width="146" height="14" font="3">ventricular rate faster than atrial </text>
<text top="925" left="654" width="148" height="14" font="3">rate) or fusion complexes implies VT</text>
<text top="947" left="468" width="130" height="14" font="3">QRS complexes in precordial </text>
<text top="962" left="468" width="142" height="14" font="3">leads all positive or all negative </text>
<text top="977" left="468" width="55" height="14" font="3">(concordant)</text>
<text top="947" left="642" width="58" height="14" font="3">•  Implies VT</text>
<text top="1000" left="468" width="157" height="14" font="3">QRS in tachycardia that is identical </text>
<text top="1015" left="468" width="69" height="14" font="3">to sinus rhythm</text>
<text top="1015" left="537" width="7" height="8" font="18">78</text>
<text top="1000" left="642" width="73" height="14" font="3">•  Suggests SVT</text>
<text top="1037" left="468" width="121" height="14" font="3">R-wave peak time in lead II</text>
<text top="1038" left="589" width="7" height="8" font="18">78</text>
<text top="1037" left="642" width="95" height="14" font="3">•   R-wave peak time </text>
<text top="1037" left="737" width="41" height="14" font="3">≥50 ms  </text>
<text top="1052" left="654" width="54" height="14" font="3">suggests VT</text>
<text top="1073" left="470" width="268" height="14" font="3">*AV dissociation is also a component of the Brugada criteria.</text>
<text top="1073" left="737" width="7" height="8" font="18">73</text>
<text top="1088" left="470" width="343" height="14" font="3">AV indicates atrioventricular; ECG, electrocardiogram; SVT, supraventricular </text>
<text top="1103" left="458" width="197" height="14" font="3">tachycardia; and VT, ventricular tachycardia.</text>
<text top="853" left="71" width="295" height="16" font="17"><b>Table 4.  Differential Diagnosis of Wide–QRS Complex </b></text>
<text top="869" left="71" width="65" height="16" font="17"><b>Tachycardia</b></text>
<text top="896" left="81" width="51" height="14" font="3">Mechanism</text>
<text top="918" left="93" width="102" height="14" font="3">Ventricular tachycardia</text>
<text top="940" left="93" width="276" height="14" font="3">SVT with pre-existing bundle-branch block or intraventricular  </text>
<text top="955" left="93" width="79" height="14" font="3">conduction defect</text>
<text top="978" left="93" width="315" height="14" font="3">SVT with aberrant conduction due to tachycardia (normal QRS when in </text>
<text top="993" left="93" width="60" height="14" font="3">sinus rhythm)</text>
<text top="1015" left="93" width="275" height="14" font="3">SVT with wide QRS related to electrolyte or metabolic disorder</text>
<text top="1037" left="93" width="284" height="14" font="3">SVT with conduction over an accessory pathway (pre-excitation)</text>
<text top="1060" left="93" width="61" height="14" font="3">Paced rhythm</text>
<text top="1082" left="93" width="32" height="14" font="3">Artifact</text>
<text top="1103" left="83" width="191" height="14" font="3">SVT indicates supraventricular tachycardia.</text>
<text top="422" left="71" width="724" height="14" font="1"><b>Figure 6.</b> Permanent form of junctional reciprocating tachycardia (PJRT). Tachycardia starts after 2 beats of sinus rhythm. Arrows point </text>
<text top="436" left="71" width="737" height="14" font="3">to the P wave, which is inscribed before the QRS complex. The reentrant circuit involves anterograde conduction over the atrioventricular </text>
<text top="449" left="71" width="720" height="14" font="3">node, followed by retrograde conduction over a slowly conducting (or decremental) accessory pathway, usually located in the postero-</text>
<text top="463" left="71" width="708" height="14" font="3">septal region, to provide a retrograde P wave with long RP interval. This ECG does not exclude atypical AVNRT or a low septal atrial </text>
<text top="476" left="71" width="735" height="14" font="3">tachycardia, which can appear very similar to this ECG. AVNRT indicates atrioventricular nodal reentrant tachycardia; ECG, electrocardio-</text>
<text top="490" left="71" width="389" height="14" font="3">gram; and PJRT, permanent form of junctional reciprocating tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e521</i></b></text>
<text top="803" left="69" width="243" height="18" font="10"><b>3.1. Physiological Sinus Tachycardia</b></text>
<text top="823" left="69" width="356" height="16" font="13">Sinus tachycardia is regarded as physiological when it is the </text>
<text top="840" left="69" width="351" height="16" font="13">result of appropriate autonomic influences, such as in the set-</text>
<text top="857" left="69" width="354" height="16" font="13">ting of physical activity or emotional responses. Physiological </text>
<text top="875" left="69" width="351" height="16" font="13">sinus tachycardia may result from pathological causes, includ-</text>
<text top="892" left="69" width="357" height="16" font="13">ing infection with fever, dehydration, anemia, heart failure, </text>
<text top="909" left="69" width="357" height="16" font="13">and hyperthyroidism, in addition to exogenous substances, </text>
<text top="927" left="69" width="351" height="16" font="13">including caffeine, drugs with a beta-agonist effect (eg, alb-</text>
<text top="944" left="69" width="351" height="16" font="13">uterol, salmeterol), and illicit stimulant drugs (eg, amphet-</text>
<text top="961" left="69" width="356" height="16" font="13">amines, cocaine). In these cases, tachycardia is expected to </text>
<text top="978" left="69" width="272" height="16" font="13">resolve with correction of the underlying cause.</text>
<text top="1013" left="69" width="250" height="18" font="10"><b>3.2. Inappropriate Sinus Tachycardia</b></text>
<text top="1032" left="69" width="359" height="16" font="13">Inappropriate sinus tachycardia (IST) is defined as sinus </text>
<text top="1049" left="69" width="356" height="16" font="13">tachycardia that is unexplained by physiological demands at </text>
<text top="1066" left="69" width="355" height="16" font="13">rest, with minimal exertion, or during recovery from exercise. </text>
<text top="1084" left="69" width="351" height="16" font="13">Crucial to this definition is the presence of associated, some-</text>
<text top="1101" left="69" width="356" height="16" font="13">times debilitating, symptoms that include weakness, fatigue, </text>
<text top="582" left="456" width="355" height="16" font="13">lightheadedness, and uncomfortable sensations, such as heart </text>
<text top="599" left="456" width="355" height="16" font="13">racing. Patients with IST commonly show resting heart rates </text>
<text top="617" left="456" width="356" height="16" font="13">&gt;100 bpm and average rates that are &gt;90 bpm in a 24-hour </text>
<text top="634" left="456" width="40" height="16" font="13">period.</text>
<text top="634" left="496" width="12" height="9" font="14">160</text>
<text top="634" left="508" width="302" height="16" font="13"> The cause of IST is unclear, and mechanisms related </text>
<text top="651" left="456" width="355" height="16" font="13">to dysautonomia, neurohormonal dysregulation, and intrinsic </text>
<text top="669" left="456" width="259" height="16" font="13">sinus node hyperactivity have been proposed.</text>
<text top="686" left="477" width="333" height="16" font="13">It is important to distinguish IST from secondary causes </text>
<text top="703" left="456" width="351" height="16" font="13">of tachycardia, including hyperthyroidism, anemia, dehy-</text>
<text top="721" left="456" width="357" height="16" font="13">dration, pain, and use of exogenous substances and drugs </text>
<text top="738" left="456" width="356" height="16" font="13">of abuse. Anxiety is also an important trigger, and patients </text>
<text top="755" left="456" width="278" height="16" font="13">with IST may have associated anxiety disorders.</text>
<text top="756" left="734" width="13" height="9" font="14">160</text>
<text top="755" left="747" width="63" height="16" font="13"> Structural </text>
<text top="773" left="456" width="360" height="16" font="13">heart disease, such as cardiomyopathies, must also be </text>
<text top="790" left="456" width="359" height="16" font="13">excluded, though the development of a cardiomyopathy </text>
<text top="807" left="456" width="296" height="16" font="13">secondary to sinus tachycardia is extremely rare.</text>
<text top="808" left="752" width="27" height="9" font="14">164,165</text>
<text top="807" left="780" width="33" height="16" font="13"> IST </text>
<text top="825" left="456" width="355" height="16" font="13">must also be distinguished from other forms of tachycardia, </text>
<text top="842" left="456" width="356" height="16" font="13">including AT arising from the superior aspect of the crista </text>
<text top="859" left="456" width="355" height="16" font="13">terminalis and sinus node reentrant tachycardia (Section 4). </text>
<text top="877" left="456" width="351" height="16" font="13">It is also important to distinguish IST from postural ortho-</text>
<text top="894" left="456" width="351" height="16" font="13">static tachycardia syndrome, although overlap may be pres-</text>
<text top="911" left="456" width="356" height="16" font="13">ent within an individual. Patients with postural orthostatic </text>
<text top="929" left="456" width="356" height="16" font="13">tachycardia syndrome have predominant symptoms related </text>
<text top="946" left="456" width="356" height="16" font="13">to a change in posture, and treatment to suppress the sinus </text>
<text top="963" left="456" width="354" height="16" font="13">rate may lead to severe orthostatic hypotension. Thus, IST is </text>
<text top="981" left="456" width="144" height="16" font="13">a diagnosis of exclusion.</text>
<text top="1006" left="456" width="133" height="16" font="0"><i><b>3.2.1. Acute Treatment</b></i></text>
<text top="1024" left="456" width="356" height="16" font="13">There are no specific recommendations for acute treatment </text>
<text top="1041" left="456" width="40" height="16" font="13">of IST.</text>
<text top="1066" left="456" width="285" height="16" font="0"><i><b>3.2.2. Ongoing Management: Recommendations</b></i></text>
<text top="1084" left="456" width="354" height="16" font="13">Because the prognosis of IST is generally benign, treatment is </text>
<text top="1101" left="456" width="355" height="16" font="13">for symptom reduction and may not be necessary. Treatment </text>
<text top="605" left="69" width="338" height="14" font="1"><b>Figure 7.</b> Differential diagnosis for adult narrow QRS tachycar-</text>
<text top="619" left="69" width="323" height="14" font="3">dia. Patients with junctional tachycardia may mimic the pat-</text>
<text top="632" left="69" width="327" height="14" font="3">tern of slow-fast AVNRT and may show AV dissociation and/</text>
<text top="646" left="69" width="328" height="14" font="3">or marked irregularity in the junctional rate. *RP refers to the </text>
<text top="659" left="69" width="341" height="14" font="3">interval from the onset of surface QRS to the onset of visible P </text>
<text top="673" left="69" width="335" height="14" font="3">wave (note that the 90-ms interval is defined from the surface </text>
<text top="686" left="69" width="29" height="14" font="3">ECG,</text>
<text top="687" left="98" width="8" height="8" font="18">79</text>
<text top="686" left="106" width="305" height="14" font="3"> as opposed to the 70-ms ventriculoatrial interval that is </text>
<text top="700" left="69" width="170" height="14" font="3">used for intracardiac diagnosis </text>
<text top="701" left="239" width="8" height="8" font="18">80</text>
<text top="700" left="247" width="152" height="14" font="3">). AV indicates atrioventricu-</text>
<text top="713" left="69" width="338" height="14" font="3">lar; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, </text>
<text top="727" left="69" width="343" height="14" font="3">atrioventricular reentrant tachycardia; ECG, electrocardiogram; </text>
<text top="740" left="69" width="347" height="14" font="3">MAT, multifocal atrial tachycardia; and PJRT, permanent form of </text>
<text top="754" left="69" width="344" height="14" font="3">junctional reentrant tachycardia. Modified with permission from </text>
<text top="767" left="69" width="147" height="14" font="3">Blomström-Lundqvist et al.</text>
<text top="768" left="216" width="8" height="8" font="18">11</text>
<text top="486" left="456" width="352" height="14" font="1"><b>Figure 8.</b> Acute treatment of regular SVT of unknown mechanism. </text>
<text top="500" left="456" width="348" height="14" font="3">Colors correspond to Class of Recommendation in Table 1; drugs </text>
<text top="514" left="456" width="327" height="14" font="3">listed alphabetically. *For rhythms that break or recur spontane-</text>
<text top="527" left="456" width="346" height="14" font="3">ously, synchronized cardioversion is not appropriate. IV indicates </text>
<text top="541" left="456" width="272" height="14" font="3">intravenous; and SVT, supraventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e522  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="625" left="71" width="356" height="16" font="13">of IST is difficult, and it should be recognized that lowering </text>
<text top="642" left="71" width="355" height="16" font="13">the heart rate may not alleviate symptoms. Therapy with beta </text>
<text top="659" left="71" width="356" height="16" font="13">blockers or calcium channel blockers is often ineffective or </text>
<text top="677" left="71" width="355" height="16" font="13">not well tolerated because of cardiovascular side effects, such </text>
<text top="694" left="71" width="356" height="16" font="13">as hypotension. Exercise training may be of benefit, but the </text>
<text top="711" left="71" width="112" height="16" font="13">benefit is unproven.</text>
<text top="729" left="92" width="330" height="16" font="13">Ivabradine is an inhibitor of the “I-funny” or “If” chan-</text>
<text top="746" left="71" width="358" height="16" font="13">nel, which is responsible for normal automaticity of the </text>
<text top="763" left="71" width="358" height="16" font="13">sinus node; therefore, ivabradine reduces the sinus node </text>
<text top="780" left="71" width="357" height="16" font="13">pacemaker activity, which results in slowing of the heart </text>
<text top="798" left="71" width="351" height="16" font="13">rate. On the basis of the results of 2 large, randomized, pla-</text>
<text top="815" left="71" width="357" height="16" font="13">cebo-controlled trials, this drug was recently approved by </text>
<text top="832" left="71" width="357" height="16" font="13">the FDA for use in patients with systolic heart failure. In </text>
<text top="850" left="71" width="358" height="16" font="13">the BEAUTIFUL (Morbidity-Mortality Evaluation of the </text>
<text top="867" left="71" width="357" height="16" font="13">If Inhibitor Ivabradine in Patients With Coronary Disease </text>
<text top="884" left="71" width="243" height="16" font="13">and Left-Ventricular Dysfunction) study,</text>
<text top="885" left="314" width="13" height="9" font="14">166</text>
<text top="884" left="327" width="100" height="16" font="13"> 10 917 patients </text>
<text top="902" left="71" width="351" height="16" font="13">with coronary disease and a left ventricular ejection frac-</text>
<text top="919" left="71" width="357" height="16" font="13">tion &lt;40% were randomized to ivabradine or placebo. In </text>
<text top="936" left="71" width="360" height="16" font="13">the SHIFT (Systolic Heart Failure Treatment With the </text>
<text top="954" left="71" width="176" height="16" font="13">If Inhibitor Ivabradine) trial,</text>
<text top="954" left="247" width="13" height="9" font="14">167</text>
<text top="954" left="260" width="169" height="16" font="13"> 6558 patients with a left </text>
<text top="971" left="71" width="181" height="16" font="13">ventricular ejection fraction </text>
<text top="970" left="252" width="178" height="17" font="13">≤35% were randomized to </text>
<text top="988" left="71" width="356" height="16" font="13">ivabradine or placebo. In both of these trials, therapy with </text>
<text top="1005" left="71" width="354" height="16" font="13">ivabradine resulted in additional heart rate reductions of 6 to </text>
<text top="1023" left="71" width="354" height="16" font="13">8 bpm and proved to be generally safe. The drug has no other </text>
<text top="1040" left="71" width="355" height="16" font="13">hemodynamic effects aside from lowering the heart rate. As </text>
<text top="1057" left="71" width="354" height="16" font="13">such, it has been investigated for use to reduce the sinus rate </text>
<text top="1075" left="71" width="223" height="16" font="13">and improve symptoms related to IST.</text>
<text top="1075" left="293" width="30" height="9" font="14">168–176</text>
<text top="625" left="479" width="336" height="16" font="13">Radiofrequency ablation to modify the sinus node can </text>
<text top="642" left="458" width="357" height="16" font="13">reduce the sinus rate, with acute procedural success rates </text>
<text top="659" left="458" width="357" height="16" font="13">reported in the range of 76% to 100% in nonrandomized </text>
<text top="677" left="458" width="46" height="16" font="13">cohorts.</text>
<text top="677" left="504" width="29" height="9" font="14">177–183</text>
<text top="677" left="533" width="276" height="16" font="13"> Ablation is typically performed with 3-dimen-</text>
<text top="694" left="457" width="358" height="16" font="13">sional electroanatomic or noncontact mapping techniques </text>
<text top="711" left="457" width="354" height="16" font="13">targeting sites of early activation with isoproterenol infusion, </text>
<text top="729" left="457" width="351" height="16" font="13">with or without use of intracardiac ultrasound–guided map-</text>
<text top="746" left="457" width="356" height="16" font="13">ping to image the crista terminalis. Nonetheless, symptoms </text>
<text top="763" left="457" width="354" height="16" font="13">commonly recur after several months, with IST recurrence in </text>
<text top="780" left="457" width="351" height="16" font="13">up to 27% and overall symptomatic recurrence (IST or non-</text>
<text top="798" left="457" width="163" height="16" font="13">IST AT) in 45% of patients.</text>
<text top="798" left="621" width="57" height="9" font="14">177,179,180,182</text>
<text top="798" left="678" width="135" height="16" font="13"> Complications can be </text>
<text top="815" left="458" width="355" height="16" font="13">significant and may include symptomatic sinus or junctional </text>
<text top="832" left="458" width="361" height="16" font="13">bradycardia necessitating pacemaker placement, phrenic </text>
<text top="850" left="458" width="355" height="16" font="13">nerve injury with paralysis of the right hemidiaphragm, and </text>
<text top="867" left="458" width="358" height="16" font="13">significant facial and upper-extremity swelling caused by </text>
<text top="884" left="458" width="354" height="16" font="13">narrowing of the superior vena cava/RA junction, which may </text>
<text top="902" left="458" width="355" height="16" font="13">rarely result in superior vena cava syndrome. In view of the </text>
<text top="919" left="458" width="351" height="16" font="13">modest benefit of this procedure and its potential for sig-</text>
<text top="936" left="458" width="355" height="16" font="13">nificant harm, sinus node modification should be considered </text>
<text top="954" left="458" width="355" height="16" font="13">only for patients who are highly symptomatic and cannot be </text>
<text top="971" left="458" width="351" height="16" font="13">adequately treated by medication, and then only after inform-</text>
<text top="988" left="458" width="357" height="16" font="13">ing the patient that the risks may outweigh the benefits of </text>
<text top="1006" left="458" width="355" height="16" font="13">ablation. Even more aggressive surgical methods to ablate or </text>
<text top="1023" left="458" width="351" height="16" font="13">denervate the sinus node have been described, further high-</text>
<text top="1040" left="458" width="354" height="16" font="13">lighting the risks that highly symptomatic patients are willing </text>
<text top="1057" left="458" width="132" height="16" font="13">to accept to find relief.</text>
<text top="1058" left="589" width="13" height="9" font="14">184</text>
<text top="1057" left="602" width="210" height="16" font="13"> Effective patient communication is </text>
<text top="1075" left="457" width="126" height="16" font="13">key for these patients.</text>
<text top="282" left="536" width="228" height="14" font="1"><b>Figure 9.</b> Ongoing management of SVT of </text>
<text top="295" left="536" width="271" height="14" font="3">unknown mechanism. Colors correspond to Class </text>
<text top="309" left="536" width="270" height="14" font="3">of Recommendation in Table 1; drugs listed alpha-</text>
<text top="322" left="536" width="260" height="14" font="3">betically. *Clinical follow-up without treatment is </text>
<text top="336" left="536" width="266" height="14" font="3">also an option. EP indicates electrophysiological; </text>
<text top="349" left="536" width="262" height="14" font="3">pt, patient; SHD, structural heart disease (includ-</text>
<text top="363" left="536" width="257" height="14" font="3">ing ischemic heart disease); and SVT, supraven-</text>
<text top="376" left="536" width="106" height="14" font="3">tricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e523</i></b></text>
<text top="648" left="71" width="347" height="20" font="12"><b>4. Nonsinus Focal Atrial Tachycardia and MAT</b></text>
<text top="668" left="69" width="351" height="16" font="13">See Figure 10 for the algorithm for acute treatment of sus-</text>
<text top="685" left="69" width="357" height="16" font="13">pected focal atrial tachycardia (AT) and Figure 11 for the </text>
<text top="703" left="69" width="272" height="16" font="13">algorithm for ongoing management of focal AT.</text>
<text top="736" left="69" width="194" height="18" font="10"><b>4.1. Focal Atrial Tachycardia</b></text>
<text top="755" left="69" width="351" height="16" font="13">Focal AT is characterized as a fast rhythm from a discrete ori-</text>
<text top="773" left="69" width="351" height="16" font="13">gin, discharging at a rate that is generally regular, and con-</text>
<text top="790" left="69" width="356" height="16" font="13">ducting in a centrifugal manner throughout the atrial tissue. </text>
<text top="807" left="69" width="355" height="16" font="13">Focal AT represents approximately 3% to 17% of the patients </text>
<text top="824" left="69" width="152" height="16" font="13">referred for SVT ablation.</text>
<text top="825" left="221" width="37" height="9" font="14">49,122,186</text>
<text top="824" left="259" width="166" height="16" font="13"> The demographics of focal </text>
<text top="842" left="69" width="356" height="16" font="13">AT in the adult population will continue to change as SVTs </text>
<text top="859" left="69" width="236" height="16" font="13">are increasingly ablated at a younger age.</text>
<text top="876" left="90" width="336" height="16" font="13">Focal AT can be sustained or nonsustained. The atrial </text>
<text top="894" left="69" width="339" height="16" font="13">rate during focal AT is usually between 100 and 250 bpm.</text>
<text top="894" left="408" width="12" height="9" font="14">186</text>
<text top="894" left="420" width="4" height="16" font="13"> </text>
<text top="911" left="69" width="351" height="16" font="13">Presence and severity of symptoms during focal AT are vari-</text>
<text top="928" left="69" width="351" height="16" font="13">able among patients. Focal AT in the adult population is usu-</text>
<text top="945" left="69" width="354" height="16" font="13">ally associated with a benign prognosis, although AT-mediated </text>
<text top="963" left="69" width="356" height="16" font="13">cardiomyopathy has been reported in up to 10% of patients </text>
<text top="980" left="69" width="239" height="16" font="13">referred for ablation of incessant SVT.</text>
<text top="981" left="308" width="27" height="9" font="14">187,188</text>
<text top="980" left="335" width="93" height="16" font="13"> Nonsustained </text>
<text top="997" left="69" width="328" height="16" font="13">focal AT is common and often does not require treatment.</text>
<text top="1015" left="90" width="335" height="16" font="13">The diagnosis of focal AT is suspected when the ECG </text>
<text top="1032" left="69" width="351" height="16" font="13">criteria are met (Section 2). Algorithms have been devel-</text>
<text top="1049" left="69" width="354" height="16" font="13">oped to estimate the origin of the focal AT from the P-wave </text>
<text top="1066" left="69" width="305" height="16" font="13">morphology recorded on a standard 12-lead ECG.</text>
<text top="1067" left="374" width="28" height="9" font="14">189,190</text>
<text top="1066" left="402" width="23" height="16" font="13"> In </text>
<text top="1084" left="69" width="355" height="16" font="13">general, a positive P wave in lead V1 and negative P waves </text>
<text top="1101" left="69" width="354" height="16" font="13">in leads I and aVL are correlated to ATs arising from the left </text>
<text top="649" left="456" width="354" height="16" font="13">atrium. Positive P waves in leads II, III, and aVF suggest that </text>
<text top="666" left="456" width="356" height="16" font="13">the origin of AT is from the cranial portion of either atria. </text>
<text top="683" left="456" width="354" height="16" font="13">Shorter P-wave duration is correlated to AT arising from the </text>
<text top="701" left="456" width="338" height="16" font="13">paraseptal tissue versus the right or left atrial free wall.</text>
<text top="701" left="794" width="13" height="9" font="14">191</text>
<text top="701" left="807" width="4" height="16" font="13"> </text>
<text top="718" left="456" width="354" height="16" font="13">The precise location of the focal AT is ultimately confirmed </text>
<text top="736" left="456" width="358" height="16" font="13">by mapping during EP studies when successful ablation </text>
<text top="753" left="456" width="71" height="16" font="13">is achieved.</text>
<text top="754" left="527" width="62" height="9" font="14">123–127,192–196</text>
<text top="753" left="589" width="223" height="16" font="13"> Focal AT has been localized to the </text>
<text top="770" left="456" width="355" height="16" font="13">crista terminalis, right or left atrial free wall or appendage, </text>
<text top="788" left="456" width="356" height="16" font="13">tricuspid or mitral annulus, paraseptal or paranodal areas, </text>
<text top="805" left="456" width="354" height="16" font="13">pulmonary veins, coronary sinus, and coronary cusps, but it </text>
<text top="823" left="456" width="355" height="16" font="13">originates more frequently from the right atrium than from </text>
<text top="840" left="456" width="88" height="16" font="13">the left atrium.</text>
<text top="841" left="544" width="28" height="9" font="14">197,198</text>
<text top="857" left="477" width="330" height="16" font="13">The underlying mechanism of focal AT can be auto-</text>
<text top="875" left="456" width="358" height="16" font="13">matic, triggered activity, or microreentry, but methods to </text>
<text top="892" left="456" width="355" height="16" font="13">distinguish the mechanism through pharmacological testing </text>
<text top="910" left="456" width="351" height="16" font="13">or EP study are of modest value because of limited sensi-</text>
<text top="927" left="456" width="125" height="16" font="13">tivity and specificity.</text>
<text top="928" left="581" width="42" height="9" font="14">123,199,200</text>
<text top="927" left="623" width="184" height="16" font="13"> An automatic AT can be tran-</text>
<text top="944" left="456" width="355" height="16" font="13">siently suppressed by adenosine or by overdrive pacing and </text>
<text top="962" left="456" width="354" height="16" font="13">may be terminated by beta blockers, diltiazem, or verapamil. </text>
<text top="979" left="456" width="356" height="16" font="13">Whereas a triggered AT can be terminated by adenosine or </text>
<text top="997" left="456" width="357" height="16" font="13">overdrive pacing, its response to beta blockers, diltiazem, </text>
<text top="1014" left="456" width="356" height="16" font="13">or verapamil may be variable. A microreentrant AT can be </text>
<text top="1031" left="456" width="358" height="16" font="13">induced and terminated by programmed stimulation, but </text>
<text top="1049" left="456" width="351" height="16" font="13">its response to adenosine, beta blockers, diltiazem, or vera-</text>
<text top="1066" left="456" width="351" height="16" font="13">pamil may depend on the location of the microreentrant cir-</text>
<text top="1084" left="456" width="355" height="16" font="13">cuit; the tachycardia can be terminated by these drugs if the </text>
<text top="1101" left="456" width="355" height="16" font="13">microreentrant circuit involves tissue around the sinus node, </text>
<text top="104" left="78" width="286" height="16" font="19"><b>Recommendations for Ongoing Management of IST</b></text>
<text top="128" left="85" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="132" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="150" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="150" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="150" left="170" width="488" height="14" font="1"><b>1.   Evaluation for and treatment of reversible causes are recommended in patients with suspected IST.</b></text>
<text top="151" left="658" width="22" height="8" font="20"><b>160,185</b></text>
<text top="179" left="78" width="20" height="14" font="3">See </text>
<text top="179" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="194" left="78" width="70" height="14" font="21"><a href="">Supplements 4 </a></text>
<text top="209" left="78" width="25" height="14" font="21"><a href="">and 5</a></text>
<text top="209" left="103" width="3" height="14" font="3">.</text>
<text top="172" left="170" width="586" height="14" font="3">It is important to distinguish IST from physiological sinus tachycardia or focal AT from the high right atrium, which can have P-wave </text>
<text top="187" left="170" width="635" height="14" font="3">morphology similar to the sinus P wave. A careful history and physical examination, with further laboratory and imaging studies, are necessary </text>
<text top="202" left="170" width="625" height="14" font="3">to determine reversible causes of tachycardia, such as exogenous substances and drugs, infection, anemia, and hyperthyroidism. A focal AT </text>
<text top="217" left="170" width="353" height="14" font="3">would have sudden onset and termination, which would not be the case for IST.</text>
<text top="238" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="238" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="238" left="170" width="417" height="14" font="1"><b>1.   Ivabradine is reasonable for ongoing management in patients with symptomatic IST.</b></text>
<text top="238" left="587" width="24" height="8" font="20"><b>168–176</b></text>
<text top="297" left="78" width="20" height="14" font="3">See </text>
<text top="297" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="312" left="78" width="70" height="14" font="21"><a href="">Supplements 4 </a></text>
<text top="327" left="78" width="25" height="14" font="21"><a href="">and 5</a></text>
<text top="327" left="103" width="3" height="14" font="3">.</text>
<text top="259" left="170" width="167" height="14" font="3">In 1 small randomized crossover trial,</text>
<text top="260" left="336" width="10" height="8" font="18">168</text>
<text top="259" left="346" width="436" height="14" font="3"> ivabradine given at a dosage of 2.5 to 7.5 mg twice daily significantly reduced daytime heart rate </text>
<text top="274" left="170" width="620" height="14" font="3">from 98.4±11.2 at baseline to 84.7±9.0, compared with 98.6±11.1 on placebo (P&lt;0.001), and improved exercise tolerance and symptoms </text>
<text top="289" left="170" width="514" height="14" font="3">in patients with IST. Similar findings have been observed in several additional nonrandomized observational studies.</text>
<text top="290" left="683" width="24" height="8" font="18">169–176</text>
<text top="289" left="707" width="72" height="14" font="3"> Furthermore, a </text>
<text top="304" left="170" width="618" height="14" font="3">significant number of patients in these studies reported complete resolution of symptoms, with persistent clinical benefit observed in some </text>
<text top="319" left="170" width="621" height="14" font="3">even after discontinuing the drug. In 1 observational study, ivabradine was more effective than metoprolol in reduction of the heart rate and </text>
<text top="334" left="170" width="118" height="14" font="3">amelioration of symptoms.</text>
<text top="335" left="288" width="10" height="8" font="18">170</text>
<text top="334" left="298" width="490" height="14" font="3"> The drug is well tolerated, with an excellent safety profile demonstrated in 2 large RCTs in patients with heart </text>
<text top="349" left="170" width="31" height="14" font="3">failure.</text>
<text top="350" left="200" width="22" height="8" font="18">166,167</text>
<text top="349" left="222" width="547" height="14" font="3"> Ivabradine can cause phosphenes, an enhanced brightness in a portion of the visual field; this side effect, which is usually </text>
<text top="364" left="170" width="330" height="14" font="3">transient, was reported in 3% of patients taking the drug in the SHIFT trial.</text>
<text top="365" left="500" width="10" height="8" font="18">167</text>
<text top="385" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="385" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="385" left="170" width="459" height="14" font="1"><b>1.   Beta blockers may be considered for ongoing management in patients with symptomatic IST.</b></text>
<text top="386" left="628" width="22" height="8" font="20"><b>170,172</b></text>
<text top="422" left="78" width="20" height="14" font="3">See </text>
<text top="422" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="437" left="78" width="65" height="14" font="21"><a href="">Supplement 4 </a></text>
<text top="452" left="78" width="25" height="14" font="21"><a href="">and 5</a></text>
<text top="452" left="103" width="3" height="14" font="3">.</text>
<text top="407" left="170" width="598" height="14" font="3">Beta blockers are modestly effective in lowering the heart rate and improving symptoms that are due to IST. In a small nonrandomized </text>
<text top="422" left="170" width="575" height="14" font="3">observational cohort, metoprolol succinate titrated to a target of 95 mg daily lowered the heart rate over 4 weeks from a baseline.</text>
<text top="423" left="744" width="10" height="8" font="18">172</text>
<text top="422" left="755" width="49" height="14" font="3"> In a small </text>
<text top="437" left="170" width="624" height="14" font="3">nonrandomized study comparing metoprolol with ivabradine, both agents reduced heart rate compared with baseline and improved exercise </text>
<text top="452" left="170" width="40" height="14" font="3">capacity.</text>
<text top="453" left="209" width="10" height="8" font="18">170</text>
<text top="452" left="220" width="567" height="14" font="3"> Although effectiveness of beta blockers is modest and hypotension may limit dose, the overall safety of beta blockers warrants </text>
<text top="467" left="170" width="212" height="14" font="3">their use for treatment of symptomatic patients.</text>
<text top="488" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="488" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="488" left="170" width="561" height="14" font="1"><b>2.   The combination of beta blockers and ivabradine may be considered for ongoing management in patients with IST.</b></text>
<text top="489" left="731" width="10" height="8" font="20"><b>172</b></text>
<text top="540" left="78" width="20" height="14" font="3">See </text>
<text top="540" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="555" left="78" width="65" height="14" font="21"><a href="">Supplement 4 </a></text>
<text top="570" left="78" width="25" height="14" font="21"><a href="">and 5</a></text>
<text top="570" left="103" width="3" height="14" font="3">.</text>
<text top="510" left="170" width="619" height="14" font="3">Some patients with IST may have particularly refractory symptoms, and single-drug efficacy may be limited. In a small observational study, </text>
<text top="525" left="170" width="622" height="14" font="3">the addition of ivabradine (7.5 mg twice daily) to metoprolol succinate (95 mg daily) reduced the heart rate from baseline to a greater extent </text>
<text top="540" left="170" width="116" height="14" font="3">than did metoprolol alone.</text>
<text top="541" left="285" width="10" height="8" font="18">172</text>
<text top="540" left="296" width="495" height="14" font="3"> On combination therapy, symptoms related to IST were resolved in all patients, and the combined therapy was </text>
<text top="555" left="170" width="613" height="14" font="3">well tolerated. In the SHIFT and BEAUTIFUL studies, the majority of patients were taking the combination of ivabradine and a beta blocker, </text>
<text top="570" left="170" width="113" height="14" font="3">which was well tolerated.</text>
<text top="571" left="283" width="22" height="8" font="18">166,167</text>
<text top="570" left="305" width="461" height="14" font="3"> Nevertheless, patients who are considered for combination therapy should be monitored closely for the </text>
<text top="585" left="170" width="617" height="14" font="3">possibility of excess bradycardia. Ivabradine can cause phosphenes, an enhanced brightness in a portion of the visual field; this side effect </text>
<text top="600" left="170" width="286" height="14" font="3">was reported in 3% of patients taking the drug in the SHIFT trial.</text>
<text top="601" left="455" width="10" height="8" font="18">167</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e524  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="375" height="16" font="17"><b>Table 6.  Acute Drug Therapy for SVT, Intravenous Administration*</b></text>
<text top="139" left="81" width="21" height="14" font="3">Drug</text>
<text top="139" left="176" width="49" height="14" font="3">Initial Dose</text>
<text top="124" left="275" width="67" height="14" font="3">Subsequent or </text>
<text top="139" left="266" width="82" height="14" font="3">Maintenance Dose</text>
<text top="124" left="416" width="83" height="14" font="3">Potential Adverse  </text>
<text top="139" left="439" width="30" height="14" font="3">Effects</text>
<text top="124" left="602" width="152" height="14" font="3">Precautions (Exclude or Use With  </text>
<text top="139" left="620" width="110" height="14" font="3">Caution) and Interactions</text>
<text top="161" left="81" width="49" height="14" font="3">Nucleoside</text>
<text top="183" left="93" width="46" height="14" font="3">Adenosine</text>
<text top="183" left="163" width="62" height="14" font="3">6-mg rapid IV </text>
<text top="198" left="163" width="66" height="14" font="3">bolus (injected </text>
<text top="213" left="163" width="82" height="14" font="3">into IV as proximal </text>
<text top="228" left="163" width="77" height="14" font="3">or as close to the </text>
<text top="243" left="163" width="82" height="14" font="3">heart as possible), </text>
<text top="258" left="163" width="81" height="14" font="3">administered over </text>
<text top="273" left="163" width="83" height="14" font="3">1–2 s, followed by </text>
<text top="288" left="163" width="74" height="14" font="3">rapid saline flush</text>
<text top="183" left="254" width="100" height="14" font="3">If no result within 1–2 </text>
<text top="198" left="254" width="81" height="14" font="3">min, 12-mg rapid </text>
<text top="213" left="254" width="90" height="14" font="3">IV bolus; can repeat </text>
<text top="228" left="254" width="91" height="14" font="3">12-mg dose 1 time. </text>
<text top="243" left="254" width="104" height="14" font="3">The safe use of 18-mg </text>
<text top="258" left="254" width="99" height="14" font="3">bolus doses has been </text>
<text top="273" left="254" width="40" height="14" font="3">reported.</text>
<text top="274" left="294" width="10" height="8" font="18">117</text>
<text top="183" left="375" width="156" height="14" font="3">Transient AV block, flushing, chest </text>
<text top="198" left="375" width="139" height="14" font="3">pain, hypotension, or dyspnea, </text>
<text top="213" left="375" width="126" height="14" font="3">AF can be initiated or cause </text>
<text top="228" left="375" width="147" height="14" font="3">decompensation in the presence </text>
<text top="243" left="375" width="154" height="14" font="3">of pre-excitation, PVCs/ventricular </text>
<text top="258" left="375" width="155" height="14" font="3">tachycardia, bronchospasm (rare), </text>
<text top="273" left="375" width="162" height="14" font="3">or coronary steal. Minor side effects </text>
<text top="288" left="375" width="144" height="14" font="3">are usually transient because of </text>
<text top="303" left="375" width="140" height="14" font="3">adenosine’s very short half-life.</text>
<text top="183" left="548" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="198" left="560" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="216" left="548" width="119" height="14" font="3">•  Reactive airway disease</text>
<text top="233" left="548" width="191" height="14" font="3">•  Concomitant use of verapamil or digoxin</text>
<text top="251" left="548" width="35" height="14" font="3">•  WPW</text>
<text top="326" left="81" width="60" height="14" font="3">Beta blockers</text>
<text top="348" left="93" width="35" height="14" font="3">Esmolol</text>
<text top="348" left="163" width="69" height="14" font="3">500-mcg/kg IV </text>
<text top="363" left="163" width="74" height="14" font="3">bolus over 1 min</text>
<text top="348" left="254" width="109" height="14" font="3">Infusion at 50–300 mcg/</text>
<text top="363" left="254" width="89" height="14" font="3">kg/min, with repeat </text>
<text top="378" left="254" width="102" height="14" font="3">boluses between each </text>
<text top="393" left="254" width="70" height="14" font="3">dosing increase</text>
<text top="348" left="375" width="127" height="14" font="3">Hypotension, worsening HF, </text>
<text top="363" left="375" width="123" height="14" font="3">bronchospasm, bradycardia</text>
<text top="348" left="548" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="363" left="560" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="381" left="548" width="134" height="14" font="3">•  Decompensated systolic HF</text>
<text top="398" left="548" width="66" height="14" font="3">•  Hypotension</text>
<text top="416" left="548" width="94" height="14" font="3">•  Cardiogenic shock</text>
<text top="433" left="548" width="119" height="14" font="3">•  Reactive airway disease</text>
<text top="451" left="548" width="91" height="14" font="3">•  Renal dysfunction</text>
<text top="468" left="548" width="239" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="491" left="93" width="53" height="14" font="3">Metoprolol  </text>
<text top="506" left="93" width="32" height="14" font="3">tartrate</text>
<text top="491" left="163" width="67" height="14" font="3">2.5–5.0-mg IV </text>
<text top="506" left="163" width="74" height="14" font="3">bolus over 2 min</text>
<text top="491" left="254" width="103" height="14" font="3">Can repeat 2.5- to 5.0-</text>
<text top="506" left="254" width="116" height="14" font="3">mg IV bolus in 10 min, up </text>
<text top="521" left="254" width="46" height="14" font="3">to 3 doses</text>
<text top="491" left="375" width="127" height="14" font="3">Hypotension, worsening HF, </text>
<text top="506" left="375" width="123" height="14" font="3">bronchospasm, bradycardia</text>
<text top="491" left="548" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="506" left="560" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="523" left="548" width="134" height="14" font="3">•  Decompensated systolic HF</text>
<text top="541" left="548" width="66" height="14" font="3">•  Hypotension</text>
<text top="558" left="548" width="119" height="14" font="3">•  Reactive airway disease</text>
<text top="576" left="548" width="239" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="598" left="93" width="50" height="14" font="3">Propranolol</text>
<text top="598" left="163" width="67" height="14" font="3">1 mg IV over 1 </text>
<text top="613" left="163" width="17" height="14" font="3">min</text>
<text top="598" left="254" width="99" height="14" font="3">Can repeat 1 mg IV at </text>
<text top="613" left="254" width="107" height="14" font="3">2-min intervals, up to 3 </text>
<text top="628" left="254" width="26" height="14" font="3">doses</text>
<text top="598" left="375" width="127" height="14" font="3">Hypotension, worsening HF, </text>
<text top="613" left="375" width="123" height="14" font="3">bronchospasm, bradycardia</text>
<text top="598" left="548" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="613" left="560" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="631" left="548" width="94" height="14" font="3">•  Cardiogenic shock</text>
<text top="648" left="548" width="119" height="14" font="3">•  Reactive airway disease</text>
<text top="666" left="548" width="98" height="14" font="3">•  Decompensated HF</text>
<text top="684" left="548" width="66" height="14" font="3">•  Hypotension</text>
<text top="701" left="548" width="136" height="14" font="3">•  Hepatic or renal dysfunction</text>
<text top="719" left="548" width="224" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="741" left="81" width="202" height="14" font="3">Nondihydropyridine calcium channel antagonists</text>
<text top="763" left="93" width="41" height="14" font="3">Diltiazem</text>
<text top="763" left="163" width="67" height="14" font="3">0.25-mg/kg IV </text>
<text top="778" left="163" width="74" height="14" font="3">bolus over 2 min</text>
<text top="763" left="254" width="107" height="14" font="3">Infusion at 5–10 mg/h,  </text>
<text top="778" left="254" width="63" height="14" font="3">up to 15 mg/h</text>
<text top="763" left="375" width="130" height="14" font="3">Hypotension, worsening HF in </text>
<text top="778" left="375" width="165" height="14" font="3">patients with pre-existing ventricular </text>
<text top="793" left="375" width="159" height="14" font="3">dysfunction, bradycardia, abnormal </text>
<text top="808" left="375" width="160" height="14" font="3">liver function studies, acute hepatic </text>
<text top="823" left="375" width="51" height="14" font="3">injury (rare)</text>
<text top="763" left="548" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="778" left="560" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="796" left="548" width="126" height="14" font="3">•  WPW with AF/atrial flutter</text>
<text top="814" left="548" width="72" height="14" font="3">•  Hypotension†</text>
<text top="831" left="548" width="203" height="14" font="3">•  Decompensated systolic HF/LV dysfunction</text>
<text top="849" left="548" width="239" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="866" left="548" width="136" height="14" font="3">•  Hepatic or renal dysfunction</text>
<text top="884" left="548" width="229" height="14" font="3">•   Diltiazem is a substrate of CYP3A4 (major) and a </text>
<text top="899" left="560" width="119" height="14" font="3">moderate CYP3A4 inhibitor</text>
<text top="916" left="548" width="231" height="14" font="3">•   Apixaban, itraconazole, bosutinib, ceritinib, cilostazol, </text>
<text top="931" left="559" width="202" height="14" font="3">cyclosporine, everolimus, ibrutinib, idelalisib, </text>
<text top="946" left="559" width="211" height="14" font="3">ivabradine, lomitapide, olaparib, posaconazole, </text>
<text top="961" left="559" width="201" height="14" font="3">ranolazine, rifampin, simeprevir, voriconazole</text>
<text top="988" left="757" width="52" height="14" font="3">(Continued )</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e525</i></b></text>
<text top="161" left="92" width="44" height="14" font="3">Verapamil</text>
<text top="161" left="161" width="79" height="14" font="3">5–10-mg (0.075–</text>
<text top="176" left="161" width="72" height="14" font="3">0. 15-mg/kg) IV </text>
<text top="191" left="161" width="74" height="14" font="3">bolus over 2 min</text>
<text top="161" left="252" width="108" height="14" font="3">If no response, can give </text>
<text top="176" left="252" width="91" height="14" font="3">an additional 10 mg </text>
<text top="191" left="252" width="94" height="14" font="3">(0.15 mg/kg) 30 min </text>
<text top="206" left="252" width="93" height="14" font="3">after first dose; then </text>
<text top="221" left="252" width="95" height="14" font="3">infusion at 0.005 mg/</text>
<text top="236" left="252" width="31" height="14" font="3">kg/min</text>
<text top="161" left="374" width="135" height="14" font="3">Hypotension, worsening HF in </text>
<text top="176" left="374" width="165" height="14" font="3">patients with pre-existing ventricular </text>
<text top="191" left="374" width="140" height="14" font="3">dysfunction, pulmonary edema </text>
<text top="206" left="374" width="129" height="14" font="3">in patients with hypertrophic </text>
<text top="221" left="374" width="129" height="14" font="3">cardiomyopathy, bradycardia</text>
<text top="161" left="546" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="176" left="558" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="193" left="546" width="203" height="14" font="3">•  Decompensated systolic HF/LV dysfunction</text>
<text top="209" left="546" width="239" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="226" left="546" width="72" height="14" font="3">•  Hypotension†</text>
<text top="243" left="546" width="94" height="14" font="3">•  Cardiogenic shock</text>
<text top="260" left="546" width="126" height="14" font="3">•  WPW with AF/atrial flutter</text>
<text top="277" left="546" width="136" height="14" font="3">•  Hepatic or renal dysfunction</text>
<text top="294" left="546" width="240" height="14" font="3">•   Verapamil is a moderate CYP3A4 inhibitor and also </text>
<text top="309" left="558" width="99" height="14" font="3">inhibits P-glycoprotein</text>
<text top="326" left="546" width="147" height="14" font="3">•  Contraindicated with dofetilide</text>
<text top="343" left="546" width="256" height="14" font="3">•   Itraconazole, bosutinib, ceritinib, cilostazol, colchicine, </text>
<text top="358" left="558" width="217" height="14" font="3">cyclosporine, everolimus, dabigatran, edoxaban, </text>
<text top="373" left="558" width="249" height="14" font="3">flecainide, ibrutinib, ivabradine, olaparib, posaconazole, </text>
<text top="388" left="558" width="248" height="14" font="3">ranolazine, rivaroxaban, rifampin, silodosin, simeprevir, </text>
<text top="403" left="558" width="206" height="14" font="3">rivaroxaban, rifampin, simvastatin, topotecan, </text>
<text top="418" left="558" width="235" height="14" font="3">trabectedin, vincristine, voriconazole, grapefruit juice</text>
<text top="440" left="80" width="79" height="14" font="3">Cardiac glycosides</text>
<text top="461" left="92" width="33" height="14" font="3">Digoxin</text>
<text top="461" left="161" width="73" height="14" font="3">0.25–0.5-mg IV </text>
<text top="476" left="161" width="24" height="14" font="3">bolus</text>
<text top="461" left="252" width="99" height="14" font="3">Can repeat 0.25-mg IV </text>
<text top="476" left="252" width="97" height="14" font="3">bolus, up to maximum </text>
<text top="491" left="252" width="90" height="14" font="3">dose of 1.0 mg over  </text>
<text top="506" left="252" width="111" height="14" font="3">24 h (ie, maximum loading </text>
<text top="521" left="252" width="92" height="14" font="3">dose 8–12 mcg/kg), </text>
<text top="536" left="252" width="106" height="14" font="3">given at 6–8-h intervals; </text>
<text top="551" left="252" width="109" height="14" font="3">maintenance dose based </text>
<text top="566" left="252" width="113" height="14" font="3">on patient’s age, lean body </text>
<text top="581" left="252" width="99" height="14" font="3">weight, renal function,  </text>
<text top="596" left="252" width="102" height="14" font="3">and concomitant drugs  </text>
<text top="611" left="252" width="92" height="14" font="3">(IV 2.4–3.6 mcg/kg/d)</text>
<text top="461" left="374" width="129" height="14" font="3">Anorexia, nausea, vomiting,  </text>
<text top="476" left="374" width="123" height="14" font="3">visual changes and cardiac </text>
<text top="491" left="374" width="133" height="14" font="3">arrhythmias if digoxin toxicity </text>
<text top="506" left="374" width="153" height="14" font="3">(associated with levels &gt;2 ng/mL, </text>
<text top="521" left="374" width="136" height="14" font="3">although symptoms may also  </text>
<text top="536" left="374" width="94" height="14" font="3">occur at lower levels)</text>
<text top="461" left="546" width="91" height="14" font="3">•  Renal dysfunction</text>
<text top="478" left="546" width="126" height="14" font="3">•  WPW with AF/atrial flutter</text>
<text top="495" left="546" width="215" height="14" font="3">•   AV block greater than first degree or SA node </text>
<text top="510" left="558" width="171" height="14" font="3">dysfunction (in absence of pacemaker)</text>
<text top="527" left="546" width="191" height="14" font="3">•  Drugs with AV nodal-blocking properties</text>
<text top="544" left="546" width="175" height="14" font="3">•  Digoxin is a P-glycoprotein substrate</text>
<text top="561" left="546" width="210" height="14" font="3">•   Dronedarone (reduce dose by at least 50%), </text>
<text top="576" left="558" width="179" height="14" font="3">amiodarone (reduce dose by 30%–50%)</text>
<text top="592" left="546" width="252" height="14" font="3">•   Verapamil, clarithromycin, cyclosporine, erythromycin, </text>
<text top="607" left="558" width="221" height="14" font="3">flecainide, itraconazole, posaconazole, propafenone, </text>
<text top="622" left="558" width="153" height="14" font="3">voriconazole: Monitor digoxin levels</text>
<text top="639" left="546" width="244" height="14" font="3">•   A large retrospective study suggested an increased  </text>
<text top="654" left="558" width="226" height="14" font="3">risk in mortality in patients who were treated with  </text>
<text top="669" left="558" width="213" height="14" font="3">digoxin for newly diagnosed AF or atrial flutter;  </text>
<text top="684" left="558" width="232" height="14" font="3">although the data were collected from a population  </text>
<text top="699" left="558" width="235" height="14" font="3">that was different from SVT patients, digoxin should  </text>
<text top="714" left="558" width="95" height="14" font="3">be used with caution.</text>
<text top="715" left="653" width="10" height="8" font="18">118</text>
<text top="735" left="80" width="134" height="14" font="3">Class III antiarrhythmic agents</text>
<text top="757" left="92" width="53" height="14" font="3">Amiodarone</text>
<text top="757" left="161" width="73" height="14" font="3">150 mg IV over  </text>
<text top="772" left="161" width="31" height="14" font="3">10 min</text>
<text top="757" left="252" width="95" height="14" font="3">Infusion at 1 mg/min </text>
<text top="772" left="252" width="107" height="14" font="3">(360 mg) over next 6 h; </text>
<text top="787" left="252" width="100" height="14" font="3">then 0.5 mg/min (540 </text>
<text top="802" left="252" width="109" height="14" font="3">mg) over remaining 18 h</text>
<text top="757" left="374" width="161" height="14" font="3">Hypotension, bradycardia, phlebitis, </text>
<text top="772" left="374" width="166" height="14" font="3">QT prolongation, torsades de pointes </text>
<text top="787" left="374" width="91" height="14" font="3">(rare), increased INR</text>
<text top="757" left="546" width="219" height="14" font="3">•   Sinus or AV conduction disease (in absence of </text>
<text top="772" left="558" width="52" height="14" font="3">pacemaker)</text>
<text top="789" left="546" width="162" height="14" font="3">•  Inflammatory lung disease (acute)</text>
<text top="805" left="546" width="99" height="14" font="3">•  Hepatic dysfunction</text>
<text top="822" left="546" width="230" height="14" font="3">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="839" left="546" width="196" height="14" font="3">•   Amiodarone is a substrate of and inhibits </text>
<text top="854" left="558" width="217" height="14" font="3">p-glycoprotein and CYP2C9 (moderate), CYP2D6 </text>
<text top="869" left="558" width="202" height="14" font="3">(moderate), and CYP3A4 (weak); amiodarone </text>
<text top="884" left="558" width="207" height="14" font="3">is a substrate for CYP3A4 (major) and CYP2C8 </text>
<text top="899" left="558" width="188" height="14" font="3">(major);amiodarone is an inhibitor of OCT2</text>
<text top="916" left="546" width="241" height="14" font="3">•    Reduce warfarin dose by 50% and reduce digoxin  </text>
<text top="931" left="561" width="85" height="14" font="3">dose by 30%–50%</text>
<text top="948" left="546" width="222" height="14" font="3">•   Agalsidase alfa, agalsidase beta, azithromycin, </text>
<text top="963" left="558" width="239" height="14" font="3">bosutinib, ceritinib, colchicine, dabigatran, edoxaban, </text>
<text top="978" left="558" width="240" height="14" font="3">flecainide, ivabradine, ledipasvir/sofosbuvir, lopinavir, </text>
<text top="993" left="558" width="228" height="14" font="3">lopinavir/ritonavir, lovastatin, nelfinavir, pazopanib, </text>
<text top="1008" left="558" width="217" height="14" font="3">propafenone, simvastatin, ritonavir, rivaroxaban, </text>
<text top="1023" left="558" width="203" height="14" font="3">saquinavir, sofosbuvir, topotecan, vincristine, </text>
<text top="1038" left="558" width="67" height="14" font="3">grapefruit juice</text>
<text top="1061" left="755" width="52" height="14" font="3">(Continued )</text>
<text top="97" left="69" width="114" height="16" font="17"><b>Table 6.  Continued</b></text>
<text top="139" left="80" width="21" height="14" font="3">Drug</text>
<text top="139" left="175" width="49" height="14" font="3">Initial Dose</text>
<text top="124" left="273" width="67" height="14" font="3">Subsequent or </text>
<text top="139" left="264" width="82" height="14" font="3">Maintenance Dose</text>
<text top="124" left="415" width="83" height="14" font="3">Potential Adverse  </text>
<text top="139" left="438" width="30" height="14" font="3">Effects</text>
<text top="124" left="601" width="152" height="14" font="3">Precautions (Exclude or Use With  </text>
<text top="139" left="618" width="110" height="14" font="3">Caution) and Interactions</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e526  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="476" left="71" width="356" height="16" font="13">whereas microreentrant ATs from other locations generally </text>
<text top="494" left="71" width="220" height="16" font="13">will not be terminated by these drugs.</text>
<text top="511" left="92" width="333" height="16" font="13">Sinus node reentrant tachycardia is an uncommon type of </text>
<text top="529" left="71" width="356" height="16" font="13">focal AT that involves a microreentrant circuit in the region </text>
<text top="546" left="71" width="356" height="16" font="13">of the sinoatrial node, causing a P-wave morphology that is </text>
<text top="563" left="71" width="354" height="16" font="13">identical to that of sinus tachycardia (although this is not sinus </text>
<text top="581" left="71" width="351" height="16" font="13">tachycardia). Characteristics that distinguish sinus node reen-</text>
<text top="598" left="71" width="354" height="16" font="13">try from sinus tachycardia are an abrupt onset and termination </text>
<text top="616" left="71" width="351" height="16" font="13">and often a longer RP interval than that observed during nor-</text>
<text top="633" left="71" width="351" height="16" font="13">mal sinus rhythm. Sinus node reentry is characterized by par-</text>
<text top="651" left="71" width="356" height="16" font="13">oxysmal episodes of tachycardia, generally 100 bpm to 150 </text>
<text top="668" left="71" width="29" height="16" font="13">bpm.</text>
<text top="668" left="99" width="29" height="9" font="14">201–203</text>
<text top="668" left="128" width="297" height="16" font="13"> Confirmation of the reentrant mechanism requires </text>
<text top="685" left="71" width="357" height="16" font="13">an EP study. Induction of sinus node reentrant tachycardia </text>
<text top="703" left="71" width="351" height="16" font="13">during programmed stimulation, demonstration of entrain-</text>
<text top="720" left="71" width="355" height="16" font="13">ment, and localization of the tachycardia origin in the region </text>
<text top="738" left="71" width="321" height="16" font="13">of the sinus node are necessary to confirm the diagnosis.</text>
<text top="763" left="71" width="250" height="16" font="0"><i><b>4.1.1. Acute Treatment: Recommendations</b></i></text>
<text top="781" left="71" width="359" height="16" font="13">RCTs of drug therapy for comparative effectiveness in </text>
<text top="798" left="71" width="351" height="16" font="13">patients with focal AT in the acute setting are not avail-</text>
<text top="815" left="71" width="355" height="16" font="13">able. Many of the clinical outcomes are reported from small </text>
<text top="833" left="71" width="360" height="16" font="13">observational studies that included infants or pediatric </text>
<text top="476" left="458" width="49" height="16" font="13">patients.</text>
<text top="477" left="507" width="27" height="9" font="14">204,205</text>
<text top="476" left="534" width="281" height="16" font="13"> The design or execution of these studies is </text>
<text top="494" left="457" width="351" height="16" font="13">frequently suboptimal because of the poorly defined inclu-</text>
<text top="512" left="457" width="358" height="16" font="13">sion criteria or variable clinical settings. Several studies </text>
<text top="530" left="457" width="355" height="16" font="13">included a mix of patients with congenital or postoperative </text>
<text top="548" left="457" width="354" height="16" font="13">AT, and some of these patients likely had macroreentrant AT. </text>
<text top="565" left="457" width="356" height="16" font="13">In many reports, the response to intravenous drug therapy </text>
<text top="583" left="457" width="351" height="16" font="13">was evaluated by EP study rather than in the clinical envi-</text>
<text top="601" left="457" width="52" height="16" font="13">ronment.</text>
<text top="602" left="510" width="59" height="9" font="14">123,200,204–207</text>
<text top="601" left="569" width="243" height="16" font="13"> In the clinical setting, if the diagnosis is </text>
<text top="619" left="458" width="351" height="16" font="13">uncertain, vagal maneuvers may be attempted to better iden-</text>
<text top="637" left="458" width="161" height="16" font="13">tify the mechanism of SVT.</text>
<text top="654" left="479" width="332" height="16" font="13">Digoxin has not been well studied for focal AT. Intravenous </text>
<text top="672" left="458" width="351" height="16" font="13">class Ic drugs (eg, flecainide, propafenone) may be moder-</text>
<text top="690" left="458" width="357" height="16" font="13">ately effective in treating focal AT in the acute setting, as </text>
<text top="708" left="458" width="360" height="16" font="13">reported in earlier, small observational studies, although </text>
<text top="726" left="458" width="355" height="16" font="13">intravenous forms of IC drugs are not available in the United </text>
<text top="743" left="458" width="356" height="16" font="13">States. In patients with an implanted cardiac pacing device, </text>
<text top="761" left="458" width="356" height="16" font="13">it may be possible to perform overdrive pacing through the </text>
<text top="779" left="458" width="356" height="16" font="13">device, although close monitoring is required to prevent any </text>
<text top="797" left="458" width="355" height="16" font="13">significant adverse effect, such as pacing-induced AF or other </text>
<text top="815" left="458" width="355" height="16" font="13">atrial arrhythmias. Equipment should be available to provide </text>
<text top="832" left="458" width="240" height="16" font="13">support for cardioversion of AF if needed.</text>
<text top="161" left="93" width="35" height="14" font="3">Ibutilide</text>
<text top="161" left="163" width="72" height="14" font="3">Contraindicated </text>
<text top="176" left="163" width="75" height="14" font="3">when QTc &gt;440 </text>
<text top="191" left="163" width="73" height="14" font="3">ms‡; 1 mg over </text>
<text top="206" left="163" width="45" height="14" font="3">10 min (if </text>
<text top="206" left="208" width="22" height="14" font="3">≥60 </text>
<text top="221" left="163" width="66" height="14" font="3">kg); if &lt;60 kg, </text>
<text top="236" left="163" width="74" height="14" font="3">then 0.01 mg/kg</text>
<text top="161" left="254" width="104" height="14" font="3">Can repeat 1 mg once, </text>
<text top="176" left="254" width="100" height="14" font="3">if the arrhythmia does </text>
<text top="191" left="254" width="92" height="14" font="3">not terminate within </text>
<text top="206" left="254" width="37" height="14" font="3">10 min§</text>
<text top="161" left="375" width="133" height="14" font="3">QT prolongation, torsades de  </text>
<text top="176" left="375" width="76" height="14" font="3">pointes, AV block</text>
<text top="161" left="548" width="107" height="14" font="3">•  Prolonged QT interval</text>
<text top="179" left="548" width="144" height="14" font="3">•  History of torsades de pointes</text>
<text top="196" left="548" width="193" height="14" font="3">•  Avoid other QT interval–prolonging drugs</text>
<text top="214" left="548" width="249" height="14" font="3">•   Concurrent administration of high-dose magnesium has </text>
<text top="229" left="559" width="215" height="14" font="3">been associated with enhanced efficacy and safety</text>
<text top="230" left="774" width="21" height="8" font="18">119,120</text>
<text top="257" left="83" width="521" height="14" font="3">Note: For this reference table, drugs are presented in alphabetical order within the drug classes, not by COR and LOE.</text>
<text top="272" left="83" width="729" height="14" font="3">*When 1 drug is used in combination with other drugs, appropriate dosing adjustments should be made with consideration of at least additive effects during </text>
<text top="287" left="71" width="741" height="14" font="3">dosage  titration.  All  potential  drug–drug  interactions  are  not  included  in  this  list.  For  a  more  detailed  list  of  drug–drug  interactions,  clinicians  should  consult </text>
<text top="302" left="71" width="95" height="14" font="3">additional resources.</text>
<text top="317" left="83" width="729" height="14" font="3">†If  hypotension  is  a  consideration,  a  slow  infusion  of  diltiazem  (2.5  mg/min)  or  verapamil  (1  mg/min)  for  up  to  20  minutes  may  lessen  the  potential  for </text>
<text top="332" left="71" width="58" height="14" font="3">hypotension.</text>
<text top="333" left="129" width="7" height="8" font="18">92</text>
<text top="347" left="83" width="729" height="14" font="3">‡QTc calculation used the Bazett’s Formula in most clinical studies. Patients should be observed with continuous ECG monitoring for at least 4 h after infusion or until </text>
<text top="362" left="71" width="130" height="14" font="3">QTc has returned to baseline.</text>
<text top="377" left="83" width="729" height="14" font="3">§The infusion should be stopped as soon as the arrhythmia is terminated or in the event of sustained or nonsustained ventricular tachycardia or marked prolongation </text>
<text top="392" left="71" width="134" height="14" font="3">of QT or corrected QT interval.</text>
<text top="407" left="83" width="728" height="14" font="3">AF indicates atrial fibrillation; AV, atrioventricular; BID, twice daily; COR, Class of Recommendation; HF, heart failure; INR, international normalized ratio; IV, intravenous; </text>
<text top="422" left="71" width="742" height="14" font="3">LOE, Level of Evidence; LV, left ventricular; PVC, premature ventricular contraction; QTc, corrected QT interval; SA, sinoatrial; SVT, supraventricular tachycardia; and </text>
<text top="437" left="71" width="132" height="14" font="3">WPW, Wolff-Parkinson-White.</text>
<text top="97" left="71" width="114" height="16" font="17"><b>Table 6.  Continued</b></text>
<text top="139" left="81" width="21" height="14" font="3">Drug</text>
<text top="139" left="176" width="49" height="14" font="3">Initial Dose</text>
<text top="124" left="275" width="67" height="14" font="3">Subsequent or </text>
<text top="139" left="266" width="82" height="14" font="3">Maintenance Dose</text>
<text top="124" left="416" width="83" height="14" font="3">Potential Adverse  </text>
<text top="139" left="439" width="30" height="14" font="3">Effects</text>
<text top="124" left="602" width="152" height="14" font="3">Precautions (Exclude or Use With  </text>
<text top="139" left="620" width="110" height="14" font="3">Caution) and Interactions</text>
<text top="881" left="80" width="434" height="16" font="19"><b>Recommendations for Acute Treatment of Suspected Focal Atrial Tachycardia</b></text>
<text top="906" left="82" width="20" height="14" font="1"><b>COR</b></text>
<text top="906" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="906" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="934" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="934" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="927" left="171" width="617" height="14" font="1"><b>1.   Intravenous beta blockers, diltiazem, or verapamil is useful for acute treatment in hemodynamically stable patients with focal </b></text>
<text top="942" left="186" width="15" height="14" font="1"><b>AT.</b></text>
<text top="943" left="201" width="45" height="8" font="20"><b>123,204,205,207</b></text>
<text top="971" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="971" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="986" left="80" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="986" left="141" width="3" height="14" font="3">.</text>
<text top="964" left="171" width="627" height="14" font="3">Intravenous beta blockers, diltiazem, or verapamil is recommended to treat focal AT. During EP study, propranolol or verapamil is moderately </text>
<text top="979" left="171" width="525" height="14" font="3">effective in either terminating the focal AT or slowing the ventricular rate in approximately 30% to 50% of the patients.</text>
<text top="979" left="696" width="22" height="8" font="18">204,205</text>
<text top="979" left="718" width="72" height="14" font="3"> Although these </text>
<text top="994" left="171" width="605" height="14" font="3">agents are relatively safe, close monitoring is recommended during intravenous drug therapy to evaluate for hypotension or bradycardia.</text>
<text top="1015" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="1015" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1015" left="171" width="576" height="14" font="1"><b>2.   Synchronized cardioversion is recommended for acute treatment in patients with hemodynamically unstable focal AT.</b></text>
<text top="1015" left="747" width="18" height="8" font="20"><b>94,208</b></text>
<text top="1059" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1059" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1074" left="80" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="1074" left="141" width="3" height="14" font="3">.</text>
<text top="1036" left="171" width="596" height="14" font="3">Although minimum data are available on cardioversion of focal AT, synchronized cardioversion is a consideration in patients with drug-</text>
<text top="1051" left="171" width="585" height="14" font="3">resistant arrhythmias associated with signs and symptoms of compromised hemodynamics. Termination of tachycardia is expected </text>
<text top="1066" left="171" width="607" height="14" font="3">when a focal AT is of a microreentrant mechanism. Response of a triggered focal AT to cardioversion can be variable, whereas electrical </text>
<text top="1081" left="171" width="622" height="14" font="3">cardioversion is not likely to be effective in focal AT with an automatic mechanism. In this latter case, antiarrhythmic drug therapy is usually </text>
<text top="1096" left="171" width="40" height="14" font="3">required.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e527</i></b></text>
<text top="379" left="69" width="285" height="16" font="0"><i><b>4.1.2. Ongoing Management: Recommendations</b></i></text>
<text top="157" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="157" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="150" left="169" width="621" height="14" font="1"><b>1.   Adenosine can be useful in the acute setting to either restore sinus rhythm or diagnose the tachycardia mechanism in patients </b></text>
<text top="165" left="184" width="117" height="14" font="1"><b>with suspected focal AT.</b></text>
<text top="166" left="301" width="34" height="8" font="20"><b>123,200,207</b></text>
<text top="194" left="78" width="20" height="14" font="3">See </text>
<text top="194" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="209" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="209" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="187" left="169" width="599" height="14" font="3">Adenosine is usually effective in terminating focal AT of a triggered mechanism but is not expected to be effective in reentrant focal AT.</text>
<text top="187" left="769" width="10" height="8" font="18">207</text>
<text top="187" left="779" width="3" height="14" font="3"> </text>
<text top="202" left="170" width="638" height="14" font="3">Transient suppression can be observed in automatic focal AT. The observation of transient AV block with persistent AT can be helpful in making </text>
<text top="217" left="170" width="286" height="14" font="3">the diagnosis and differentiating focal AT from AVNRT and AVRT.</text>
<text top="245" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="245" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="238" left="170" width="610" height="14" font="1"><b>1.   Intravenous amiodarone may be reasonable in the acute setting to either restore sinus rhythm or slow the ventricular rate in </b></text>
<text top="253" left="184" width="226" height="14" font="1"><b>hemodynamically stable patients with focal AT.</b></text>
<text top="254" left="410" width="22" height="8" font="20"><b>205,206</b></text>
<text top="275" left="78" width="20" height="14" font="3">See </text>
<text top="275" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="290" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="290" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="275" left="169" width="638" height="14" font="3">The therapeutic effect of intravenous amiodarone in the acute setting is likely mediated via blockade of the beta receptors or calcium channels. </text>
<text top="290" left="169" width="475" height="14" font="3">Amiodarone may be preferred in patients with reduced ventricular function or with a history of heart failure.</text>
<text top="310" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="310" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="310" left="169" width="596" height="14" font="1"><b>2.   Ibutilide may be reasonable in the acute setting to restore sinus rhythm in hemodynamically stable patients with focal AT.</b></text>
<text top="311" left="765" width="22" height="8" font="20"><b>205,206</b></text>
<text top="332" left="78" width="20" height="14" font="3">See </text>
<text top="332" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="347" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="347" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="332" left="169" width="619" height="14" font="3">The effectiveness of ibutilide for treatment of focal AT is unclear. In 1 study, intravenous ibutilide terminated AT of single atrial morphology in 19 of  </text>
<text top="347" left="169" width="554" height="14" font="3">39 patients (38.8%), but the proportions of patients with focal AT and macroreentrant AT were not differentiated in this study cohort.</text>
<text top="348" left="724" width="10" height="8" font="18">206</text>
<text top="104" left="78" width="502" height="16" font="19"><b>Recommendations for Acute Treatment of Suspected Focal Atrial Tachycardia (Continued)</b></text>
<text top="128" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="419" left="78" width="463" height="16" font="19"><b>Recommendations for Ongoing Management of Suspected Focal Atrial Tachycardia</b></text>
<text top="443" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="443" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="443" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="465" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="465" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="465" left="170" width="546" height="14" font="1"><b>1.   Catheter ablation is recommended in patients with symptomatic focal AT as an alternative to pharmacological therapy.</b></text>
<text top="466" left="715" width="69" height="8" font="20"><b>122–126,188,191–196,206</b></text>
<text top="534" left="78" width="20" height="14" font="3">See </text>
<text top="534" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="549" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="549" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="487" left="170" width="614" height="14" font="3">A large number of nonrandomized cohort studies on focal AT ablation have accumulated in the past 2 decades. In a 2012 ablation registry </text>
<text top="502" left="170" width="534" height="14" font="3">provided by 74 voluntary medical centers in Spain, AT was found in 333 of 11 042 of the ablation procedures performed.</text>
<text top="502" left="704" width="10" height="8" font="18">122</text>
<text top="502" left="714" width="71" height="14" font="3"> In experienced </text>
<text top="517" left="170" width="601" height="14" font="3">centers, when the AT can be induced in the laboratory, acute success rates above 90% to 95% have consistently been reported, with a </text>
<text top="532" left="170" width="145" height="14" font="3">complication rate of &lt;1% to 2%.</text>
<text top="532" left="315" width="45" height="8" font="18">122,123,125,196</text>
<text top="532" left="360" width="384" height="14" font="3"> See Table 8 for a summary of ablation efficacy, complications, and rate of recurrence.</text>
<text top="551" left="170" width="621" height="14" font="3">Although uncommon, focal AT-mediated cardiomyopathy should be recognized in patients presenting with heart failure, reduced ventricular </text>
<text top="566" left="170" width="579" height="14" font="3">function, and persistent tachycardia. In a case–control study of patients with AT, 10% of patients had evidence of cardiomyopathy.</text>
<text top="567" left="748" width="10" height="8" font="18">125</text>
<text top="566" left="758" width="22" height="14" font="3"> The </text>
<text top="581" left="170" width="633" height="14" font="3">tachycardia in patients with cardiomyopathy was incessant and slower than in the patients without cardiomyopathy (cycle lengths 502 ms and </text>
<text top="596" left="170" width="465" height="14" font="3">402 ms, respectively). Normal ejection fraction was restored in 97% of patients after successful ablation.</text>
<text top="597" left="635" width="10" height="8" font="18">188</text>
<text top="617" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="617" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="617" left="170" width="592" height="14" font="1"><b>1.   Oral beta blockers, diltiazem, or verapamil are reasonable for ongoing management in patients with symptomatic focal AT.</b></text>
<text top="618" left="762" width="33" height="8" font="20"><b>123,204,205</b></text>
<text top="646" left="78" width="20" height="14" font="3">See </text>
<text top="646" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="661" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="661" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="639" left="170" width="607" height="14" font="3">Data on long-term drug therapy of focal AT are limited to observational studies, and some studies did not provide clear inclusion criteria, </text>
<text top="654" left="170" width="609" height="14" font="3">so results for AT were combined with those for other mechanisms of SVT. Nevertheless, these drugs are moderately effective, with a low </text>
<text top="669" left="170" width="176" height="14" font="3">incidence of significant adverse effects.</text>
<text top="670" left="345" width="59" height="8" font="18">123,204,205,209–214</text>
<text top="697" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="697" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="690" left="170" width="610" height="14" font="1"><b>2.   Flecainide or propafenone can be effective for ongoing management in patients without structural heart disease or ischemic </b></text>
<text top="705" left="184" width="157" height="14" font="1"><b>heart disease who have focal AT.</b></text>
<text top="706" left="342" width="24" height="8" font="20"><b>209–213</b></text>
<text top="734" left="78" width="20" height="14" font="3">See </text>
<text top="734" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="749" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="749" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="727" left="170" width="475" height="14" font="3">Small case series studies reported that focal AT suppression was achieved with flecainide in most patients.</text>
<text top="727" left="645" width="22" height="8" font="18">209,210</text>
<text top="727" left="667" width="107" height="14" font="3"> In infants and children, </text>
<text top="742" left="170" width="343" height="14" font="3">propafenone is moderately effective in focal AT suppression during follow-up.</text>
<text top="742" left="513" width="10" height="8" font="18">213</text>
<text top="742" left="523" width="282" height="14" font="3"> Flecainide and propafenone are generally tolerated by patients </text>
<text top="757" left="170" width="555" height="14" font="3">with focal AT. Combinations of a class Ic drug with a beta blocker, diltiazem, or verapamil may improve overall efficacy rates.</text>
<text top="778" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="778" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="778" left="170" width="478" height="14" font="1"><b>1.   Oral sotalol or amiodarone may be reasonable for ongoing management in patients with focal AT.</b></text>
<text top="778" left="648" width="47" height="8" font="20"><b>188,211,215–219</b></text>
<text top="814" left="78" width="20" height="14" font="3">See </text>
<text top="814" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="829" left="78" width="62" height="14" font="21"><a href="">Supplement 6</a></text>
<text top="829" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="799" left="170" width="571" height="14" font="3">Several studies reported moderate efficacies of oral sotalol or amiodarone in maintaining sinus rhythm in long-term treatment in </text>
<text top="814" left="170" width="38" height="14" font="3">children.</text>
<text top="815" left="208" width="47" height="8" font="18">188,211,215–219</text>
<text top="814" left="255" width="377" height="14" font="3"> Although most reports are in children, limited data suggest similar efficacy in adults.</text>
<text top="815" left="632" width="10" height="8" font="18">218</text>
<text top="814" left="642" width="102" height="14" font="3"> Because of the risk of </text>
<text top="829" left="170" width="635" height="14" font="3">proarrhythmia and other complications, before use of these drugs, a balance between anticipated benefit of focal AT suppression and potential </text>
<text top="844" left="170" width="275" height="14" font="3">adverse effects of these drugs should be carefully considered.</text>
<text top="892" left="69" width="227" height="18" font="10"><b>4.2. Multifocal Atrial Tachycardia</b></text>
<text top="911" left="69" width="351" height="16" font="13">MAT is defined as a rapid, irregular rhythm with at least 3 dis-</text>
<text top="929" left="69" width="355" height="16" font="13">tinct morphologies of P waves on the surface ECG. It may be </text>
<text top="946" left="69" width="354" height="16" font="13">difficult to distinguish MAT from AF on physical examination </text>
<text top="963" left="69" width="354" height="16" font="13">or even on a single ECG tracing, so a 12-lead ECG is indicated </text>
<text top="980" left="69" width="355" height="16" font="13">to confirm the diagnosis. On the ECG, the atrial rate is &gt;100 </text>
<text top="998" left="69" width="286" height="16" font="13">bpm (or &gt;90 bpm, as defined in at least 1 report</text>
<text top="998" left="355" width="12" height="9" font="14">220</text>
<text top="998" left="368" width="57" height="16" font="13">). Unlike </text>
<text top="1015" left="69" width="354" height="16" font="13">AF, there is a distinct isoelectric period between P waves. The </text>
<text top="1032" left="69" width="356" height="16" font="13">P-P, P-R, and R-R intervals are variable. The mechanism of </text>
<text top="1049" left="69" width="355" height="16" font="13">MAT is not well established. Although it is assumed that the </text>
<text top="1067" left="69" width="351" height="16" font="13">variability of P-wave morphology implies a multifocal ori-</text>
<text top="1084" left="69" width="279" height="16" font="13">gin, there are very few mapping studies of MAT.</text>
<text top="1084" left="348" width="12" height="9" font="14">221</text>
<text top="1084" left="360" width="63" height="16" font="13"> Similarly, </text>
<text top="1101" left="69" width="356" height="16" font="13">the variability of the P-R interval may relate to decremental </text>
<text top="893" left="456" width="355" height="16" font="13">conduction through the AV node, as opposed to the origin of </text>
<text top="910" left="456" width="355" height="16" font="13">the P wave. Occasional responsiveness to verapamil suggests </text>
<text top="928" left="456" width="251" height="16" font="13">a triggered mechanism, but data are limited.</text>
<text top="928" left="707" width="12" height="9" font="14">222</text>
<text top="945" left="477" width="333" height="16" font="13">MAT is commonly associated with underlying conditions, </text>
<text top="962" left="456" width="351" height="16" font="13">including pulmonary disease, pulmonary hypertension, coro-</text>
<text top="980" left="456" width="223" height="16" font="13">nary disease, and valvular heart disease,</text>
<text top="980" left="679" width="12" height="9" font="14">223</text>
<text top="980" left="691" width="116" height="16" font="13"> as well as hypomag-</text>
<text top="997" left="456" width="193" height="16" font="13">nesemia and theophylline therapy.</text>
<text top="998" left="649" width="12" height="9" font="14">224</text>
<text top="997" left="661" width="149" height="16" font="13"> The first-line treatment is </text>
<text top="1014" left="456" width="351" height="16" font="13">management of the underlying condition. Intravenous mag-</text>
<text top="1032" left="456" width="351" height="16" font="13">nesium may also be helpful in patients with normal magne-</text>
<text top="1049" left="456" width="68" height="16" font="13">sium levels.</text>
<text top="1050" left="524" width="12" height="9" font="14">225</text>
<text top="1049" left="537" width="275" height="16" font="13"> Antiarrhythmic medications in general are not </text>
<text top="1066" left="456" width="227" height="16" font="13">helpful in suppression of multifocal AT.</text>
<text top="1067" left="683" width="12" height="9" font="14">226</text>
<text top="1066" left="696" width="115" height="16" font="13"> Management often </text>
<text top="1084" left="456" width="355" height="16" font="13">involves slowing conduction at the AV nodal level to control </text>
<text top="1101" left="456" width="354" height="16" font="13">heart rate. Verapamil has been shown to have some efficacy in </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="22" size="9" family="Times" color="#231f20"/>
<text top="47" left="71" width="243" height="17" font="11"><i><b>e528  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="346" height="16" font="17"><b>Table 7.  Ongoing Drug Therapy for SVT, Oral Administration*</b></text>
<text top="138" left="81" width="20" height="13" font="22">Drug</text>
<text top="138" left="184" width="79" height="13" font="22">Initial Daily Dose(s)</text>
<text top="124" left="310" width="93" height="13" font="22">Maximum Total Daily  </text>
<text top="138" left="315" width="77" height="13" font="22">Maintenance Dose</text>
<text top="124" left="459" width="77" height="13" font="22">Potential Adverse  </text>
<text top="138" left="481" width="28" height="13" font="22">Effects</text>
<text top="124" left="631" width="121" height="13" font="22">Precautions (Exclude or Use  </text>
<text top="138" left="626" width="125" height="13" font="22">With Caution) and Interactions</text>
<text top="160" left="81" width="57" height="13" font="22">Beta blockers</text>
<text top="182" left="93" width="33" height="13" font="22">Atenolol</text>
<text top="182" left="168" width="58" height="13" font="22">25–50 mg QD</text>
<text top="182" left="294" width="119" height="13" font="22">100 mg QD (reduced dosing </text>
<text top="196" left="294" width="120" height="13" font="22">in patients with severe renal </text>
<text top="210" left="294" width="51" height="13" font="22">dysfunction)</text>
<text top="182" left="429" width="123" height="13" font="22">Hypotension, bronchospasm, </text>
<text top="196" left="429" width="49" height="13" font="22">bradycardia</text>
<text top="182" left="576" width="174" height="13" font="22">•   AV block greater than first degree or SA  </text>
<text top="196" left="587" width="177" height="13" font="22">node dysfunction (in absence of pacemaker)</text>
<text top="213" left="576" width="126" height="13" font="22">•  Decompensated systolic HF</text>
<text top="230" left="576" width="62" height="13" font="22">•  Hypotension</text>
<text top="247" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="264" left="576" width="114" height="13" font="22">•  Severe renal dysfunction</text>
<text top="281" left="576" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="302" left="93" width="47" height="13" font="22">Metoprolol </text>
<text top="317" left="93" width="30" height="13" font="22">tartrate</text>
<text top="302" left="168" width="44" height="13" font="22">25 mg BID</text>
<text top="302" left="294" width="49" height="13" font="22">200 mg BID</text>
<text top="302" left="429" width="123" height="13" font="22">Hypotension, bronchospasm, </text>
<text top="317" left="429" width="49" height="13" font="22">bradycardia</text>
<text top="302" left="576" width="191" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="317" left="587" width="153" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="334" left="576" width="126" height="13" font="22">•  Decompensated systolic HF</text>
<text top="351" left="576" width="62" height="13" font="22">•  Hypotension</text>
<text top="368" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="385" left="576" width="227" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="406" left="93" width="47" height="13" font="22">Metoprolol </text>
<text top="421" left="93" width="42" height="13" font="22">succinate </text>
<text top="435" left="93" width="53" height="13" font="22">(long-acting)</text>
<text top="406" left="168" width="42" height="13" font="22">50 mg QD</text>
<text top="406" left="294" width="47" height="13" font="22">400 mg QD</text>
<text top="406" left="429" width="123" height="13" font="22">Hypotension, bronchospasm, </text>
<text top="421" left="429" width="49" height="13" font="22">bradycardia</text>
<text top="406" left="576" width="201" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="421" left="587" width="161" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="438" left="576" width="126" height="13" font="22">•  Decompensated systolic HF</text>
<text top="454" left="576" width="62" height="13" font="22">•  Hypotension</text>
<text top="471" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="488" left="576" width="224" height="13" font="22">•  Drugs with SA and/or AV nodal–blocking properties</text>
<text top="510" left="93" width="31" height="13" font="22">Nadolol</text>
<text top="510" left="168" width="42" height="13" font="22">40 mg QD</text>
<text top="510" left="294" width="122" height="13" font="22">320 mg QD (reduced dosage </text>
<text top="524" left="294" width="94" height="13" font="22">with renal impairment)</text>
<text top="510" left="429" width="123" height="13" font="22">Hypotension, bronchospasm, </text>
<text top="524" left="429" width="49" height="13" font="22">bradycardia</text>
<text top="510" left="576" width="194" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="524" left="587" width="155" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="541" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="558" left="576" width="88" height="13" font="22">•  Cardiogenic shock</text>
<text top="575" left="576" width="92" height="13" font="22">•  Decompensated HF</text>
<text top="592" left="576" width="62" height="13" font="22">•  Hypotension</text>
<text top="609" left="576" width="85" height="13" font="22">•  Renal dysfunction</text>
<text top="626" left="576" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="648" left="93" width="47" height="13" font="22">Propranolol</text>
<text top="648" left="168" width="91" height="13" font="22">30–60 mg in divided  </text>
<text top="662" left="168" width="103" height="13" font="22">or single dose with long-</text>
<text top="676" left="168" width="80" height="13" font="22">acting formulations</text>
<text top="648" left="294" width="105" height="13" font="22">40–160 mg in divided or </text>
<text top="662" left="294" width="120" height="13" font="22">single dose with long-acting </text>
<text top="677" left="294" width="52" height="13" font="22">formulations</text>
<text top="648" left="429" width="119" height="13" font="22">Hypotension, worsening HF, </text>
<text top="662" left="429" width="116" height="13" font="22">bronchospasm, bradycardia</text>
<text top="648" left="576" width="201" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="662" left="587" width="161" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="679" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="696" left="576" width="126" height="13" font="22">•  Decompensated systolic HF</text>
<text top="713" left="576" width="62" height="13" font="22">•  Hypotension</text>
<text top="730" left="576" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="751" left="81" width="202" height="13" font="22">Nondihydropyridine calcium channel antagonists</text>
<text top="772" left="93" width="39" height="13" font="22">Diltiazem</text>
<text top="772" left="168" width="100" height="13" font="22">120 mg daily in divided </text>
<text top="786" left="168" width="103" height="13" font="22">or single dose with long-</text>
<text top="800" left="168" width="80" height="13" font="22">acting formulations</text>
<text top="772" left="294" width="111" height="13" font="22">360 mg daily in divided or </text>
<text top="786" left="294" width="120" height="13" font="22">single dose with long-acting </text>
<text top="800" left="294" width="52" height="13" font="22">formulations</text>
<text top="772" left="429" width="116" height="13" font="22">Hypotension, worsening HF </text>
<text top="786" left="429" width="119" height="13" font="22">in patients with pre-existing </text>
<text top="800" left="429" width="100" height="13" font="22">ventricular dysfunction, </text>
<text top="815" left="429" width="119" height="13" font="22">bradycardia, abnormal liver  </text>
<text top="829" left="429" width="133" height="13" font="22">function studies, acute hepatic  </text>
<text top="843" left="429" width="48" height="13" font="22">injury (rare)</text>
<text top="772" left="576" width="201" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="786" left="587" width="161" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="802" left="576" width="68" height="13" font="22">•  Hypotension†</text>
<text top="819" left="576" width="220" height="13" font="22">•  Decompensated systolic HF/severe LV dysfunction</text>
<text top="835" left="576" width="118" height="13" font="22">•  WPW with AF/atrial flutter</text>
<text top="851" left="576" width="224" height="13" font="22">•  Drugs with SA and/or AV nodal–blocking properties</text>
<text top="868" left="576" width="215" height="13" font="22">•   Diltiazem is a substrate of CYP3A4 (major) and a </text>
<text top="882" left="587" width="112" height="13" font="22">moderate CYP3A4 inhibitor</text>
<text top="898" left="576" width="192" height="13" font="22">•   Apixaban, itraconazole, bosutinib, ceritinib, </text>
<text top="912" left="587" width="192" height="13" font="22">cilostazol, cyclosporine, everolimus, ibrutinib, </text>
<text top="927" left="587" width="178" height="13" font="22">idelalisib, ivabradine, lomitapide, olaparib, </text>
<text top="941" left="587" width="132" height="13" font="22">ranolazine, rifampin, simeprevir</text>
<text top="959" left="757" width="52" height="14" font="3">(Continued )</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e529</i></b></text>
<text top="159" left="92" width="41" height="13" font="22">Verapamil</text>
<text top="159" left="166" width="100" height="13" font="22">120 mg daily in divided </text>
<text top="174" left="166" width="103" height="13" font="22">or single dose with long-</text>
<text top="188" left="166" width="80" height="13" font="22">acting formulations</text>
<text top="159" left="292" width="108" height="13" font="22">480 mg daily in divided or </text>
<text top="174" left="292" width="118" height="13" font="22">single dose with long-acting </text>
<text top="188" left="292" width="52" height="13" font="22">formulations</text>
<text top="159" left="427" width="59" height="13" font="22">Hypotension,  </text>
<text top="174" left="427" width="106" height="13" font="22">worsening HF in patients </text>
<text top="188" left="427" width="119" height="13" font="22">with pre-existing ventricular </text>
<text top="202" left="427" width="131" height="13" font="22">dysfunction, pulmonary edema </text>
<text top="217" left="427" width="121" height="13" font="22">in patients with hypertrophic </text>
<text top="231" left="427" width="126" height="13" font="22">cardiomyopathy, bradycardia, </text>
<text top="245" left="427" width="128" height="13" font="22">abnormal liver function studies</text>
<text top="160" left="575" width="201" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="174" left="586" width="161" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="190" left="575" width="220" height="13" font="22">•  Decompensated systolic HF/severe LV dysfunction</text>
<text top="206" left="575" width="68" height="13" font="22">•  Hypotension†</text>
<text top="223" left="575" width="118" height="13" font="22">•  WPW with AF/atrial flutter</text>
<text top="239" left="575" width="225" height="13" font="22">•   Verapamil is a moderate CYP3A4 inhibitor and also </text>
<text top="253" left="586" width="93" height="13" font="22">inhibits P-glycoprotein</text>
<text top="269" left="575" width="138" height="13" font="22">•  Contraindicated with dofetilide</text>
<text top="286" left="575" width="193" height="13" font="22">•   Itraconazole, bosutinib, ceritinib, cilostazol, </text>
<text top="300" left="586" width="205" height="13" font="22">colchicine, cyclosporine, everolimus, dabigatran, </text>
<text top="314" left="586" width="218" height="13" font="22">edoxaban, flecainide, ibrutinib, ivabradine, olaparib, </text>
<text top="329" left="586" width="184" height="13" font="22">ranolazine, rivaroxaban, rifampin, silodosin, </text>
<text top="343" left="586" width="196" height="13" font="22">simeprevir, rivaroxaban, rifampin, simvastatin, </text>
<text top="357" left="586" width="209" height="13" font="22">topotecan, trabectedin, vincristine, grapefruit juice</text>
<text top="378" left="80" width="75" height="13" font="22">Cardiac glycosides</text>
<text top="398" left="92" width="31" height="13" font="22">Digoxin</text>
<text top="398" left="166" width="94" height="13" font="22">Loading: 0.5 mg, with </text>
<text top="412" left="166" width="96" height="13" font="22">additional 0.125–0.25-</text>
<text top="427" left="166" width="100" height="13" font="22">mg doses administered </text>
<text top="441" left="166" width="95" height="13" font="22">at 6–8-h intervals until </text>
<text top="455" left="166" width="116" height="13" font="22">evidence of adequate effect </text>
<text top="469" left="166" width="112" height="13" font="22">(maximum dose 8–12 mcg/</text>
<text top="484" left="166" width="55" height="13" font="22">kg over 24 h)</text>
<text top="398" left="292" width="112" height="13" font="22">0.25 mg QD Maintenance: </text>
<text top="412" left="292" width="106" height="13" font="22">0.125–0.25 mg QD, with </text>
<text top="427" left="292" width="109" height="13" font="22">dosing based on patient’s </text>
<text top="441" left="292" width="115" height="13" font="22">age, lean body weight, and </text>
<text top="455" left="292" width="100" height="13" font="22">renal function and drug </text>
<text top="469" left="292" width="107" height="13" font="22">interactions; occasionally </text>
<text top="484" left="292" width="121" height="13" font="22">down to 0.0625 mg in cases </text>
<text top="498" left="292" width="117" height="13" font="22">of renal impairment (trough </text>
<text top="512" left="292" width="110" height="13" font="22">serum digoxin level 0.5 to </text>
<text top="526" left="292" width="37" height="13" font="22">1 ng/mL)</text>
<text top="398" left="427" width="104" height="13" font="22">Bradycardia, heart block, </text>
<text top="412" left="427" width="114" height="13" font="22">anorexia, nausea, vomiting, </text>
<text top="427" left="427" width="113" height="13" font="22">visual changes and cardiac </text>
<text top="441" left="427" width="129" height="13" font="22">arrhythmias in cases of digoxin </text>
<text top="455" left="427" width="125" height="13" font="22">toxicity (associated with levels </text>
<text top="469" left="427" width="129" height="13" font="22">&gt;2 ng/mL, although symptoms </text>
<text top="484" left="427" width="125" height="13" font="22">may also occur at lower levels)</text>
<text top="398" left="575" width="85" height="13" font="22">•  Renal dysfunction</text>
<text top="415" left="575" width="118" height="13" font="22">•  WPW with AF/atrial flutter</text>
<text top="431" left="575" width="201" height="13" font="22">•   AV block greater than first degree or SA node </text>
<text top="445" left="586" width="161" height="13" font="22">dysfunction (in absence of pacemaker)</text>
<text top="461" left="575" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="478" left="575" width="212" height="13" font="22">•   Reduce dose by 30%–50% when administering </text>
<text top="492" left="586" width="210" height="13" font="22">with amiodarone and by 50% when administering </text>
<text top="506" left="586" width="73" height="13" font="22">with dronedarone</text>
<text top="522" left="575" width="209" height="13" font="22">•   Monitor digoxin concentrations with verapamil, </text>
<text top="537" left="586" width="180" height="13" font="22">clarithromycin, erythromycin, itraconazole, </text>
<text top="551" left="586" width="155" height="13" font="22">cyclosporine, propafenone, flecainide</text>
<text top="575" left="80" width="126" height="13" font="22">Class Ic antiarrhythmic agents</text>
<text top="595" left="92" width="42" height="13" font="22">Flecainide</text>
<text top="595" left="166" width="73" height="13" font="22">50 mg every 12 h</text>
<text top="595" left="292" width="84" height="13" font="22">150 mg every 12 h  </text>
<text top="610" left="292" width="96" height="13" font="22">(PR and QRS intervals  </text>
<text top="624" left="292" width="91" height="13" font="22">should be monitored. </text>
<text top="638" left="292" width="106" height="13" font="22">May consider monitoring </text>
<text top="652" left="292" width="103" height="13" font="22">flecainide plasma levels, </text>
<text top="667" left="292" width="122" height="13" font="22">keeping trough plasma levels </text>
<text top="681" left="292" width="100" height="13" font="22">below 0.7–1.0 mcg/mL)</text>
<text top="595" left="427" width="102" height="13" font="22">Atrial flutter with 1:1 AV </text>
<text top="610" left="427" width="128" height="13" font="22">conduction‡, QT prolongation, </text>
<text top="624" left="427" width="133" height="13" font="22">torsades de pointes, worsening </text>
<text top="638" left="427" width="65" height="13" font="22">HF, bradycardia</text>
<text top="595" left="575" width="205" height="13" font="22">•   Sinus or AV conduction disease (in absence of </text>
<text top="610" left="586" width="49" height="13" font="22">pacemaker)</text>
<text top="626" left="575" width="88" height="13" font="22">•  Cardiogenic shock</text>
<text top="642" left="575" width="230" height="13" font="22">•   Avoid in structural heart disease (including ischemic </text>
<text top="657" left="586" width="59" height="13" font="22">heart disease)</text>
<text top="673" left="574" width="222" height="13" font="22">•   Atrial flutter (unless concomitant AV nodal therapy </text>
<text top="687" left="586" width="100" height="13" font="22">to avoid 1:1 conduction)</text>
<text top="703" left="574" width="90" height="13" font="22">•  Brugada syndrome</text>
<text top="720" left="574" width="85" height="13" font="22">•  Renal dysfunction</text>
<text top="736" left="574" width="93" height="13" font="22">•  Hepatic dysfunction</text>
<text top="752" left="574" width="97" height="13" font="22">•  QT-prolonging drugs</text>
<text top="769" left="574" width="189" height="13" font="22">•   Amiodarone, digoxin, ritonavir, saquinavir, </text>
<text top="783" left="586" width="39" height="13" font="22">tipranavir</text>
<text top="803" left="92" width="52" height="13" font="22">Propafenone</text>
<text top="803" left="166" width="76" height="13" font="22">150 mg every 8 h </text>
<text top="818" left="166" width="107" height="13" font="22">(immediate release); 225 </text>
<text top="832" left="166" width="106" height="13" font="22">mg every 12 h (extended </text>
<text top="846" left="166" width="33" height="13" font="22">release)</text>
<text top="803" left="292" width="125" height="13" font="22">300 mg every 8 h (immediate </text>
<text top="818" left="292" width="112" height="13" font="22">release); 425 mg every 12 </text>
<text top="832" left="292" width="104" height="13" font="22">h (extended release) (PR </text>
<text top="846" left="292" width="115" height="13" font="22">and QRS interval should be </text>
<text top="860" left="292" width="119" height="13" font="22">monitored. Consider dosage </text>
<text top="875" left="292" width="95" height="13" font="22">reduction with hepatic </text>
<text top="889" left="292" width="50" height="13" font="22">impairment)</text>
<text top="803" left="427" width="102" height="13" font="22">Atrial flutter with 1:1 AV </text>
<text top="818" left="427" width="128" height="13" font="22">conduction‡, QT prolongation, </text>
<text top="832" left="427" width="87" height="13" font="22">torsades de pointes, </text>
<text top="846" left="427" width="116" height="13" font="22">bradycardia, bronchospasm</text>
<text top="803" left="574" width="205" height="13" font="22">•   Sinus or AV conduction disease (in absence of </text>
<text top="818" left="586" width="49" height="13" font="22">pacemaker)</text>
<text top="834" left="574" width="88" height="13" font="22">•  Cardiogenic shock</text>
<text top="850" left="574" width="62" height="13" font="22">•  Hypotension</text>
<text top="866" left="574" width="216" height="13" font="22">•   Reactive airway disease Avoid in structural heart </text>
<text top="881" left="586" width="176" height="13" font="22">disease (including ischemic heart disease)</text>
<text top="897" left="574" width="222" height="13" font="22">•   Atrial flutter (unless concomitant AV nodal therapy </text>
<text top="911" left="586" width="100" height="13" font="22">to avoid 1:1 conduction)</text>
<text top="928" left="574" width="90" height="13" font="22">•  Brugada syndrome</text>
<text top="944" left="574" width="93" height="13" font="22">•  Hepatic dysfunction</text>
<text top="960" left="574" width="97" height="13" font="22">•  QT-prolonging drugs</text>
<text top="976" left="574" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="993" left="574" width="177" height="13" font="22">•   Amiodarone, ritonavir, saquinavir, tipranavir</text>
<text top="1017" left="755" width="52" height="14" font="3">(Continued )</text>
<text top="97" left="69" width="114" height="16" font="17"><b>Table 7.  Continued</b></text>
<text top="138" left="80" width="20" height="13" font="22">Drug</text>
<text top="138" left="183" width="79" height="13" font="22">Initial Daily Dose(s)</text>
<text top="124" left="309" width="93" height="13" font="22">Maximum Total Daily  </text>
<text top="138" left="314" width="77" height="13" font="22">Maintenance Dose</text>
<text top="124" left="457" width="77" height="13" font="22">Potential Adverse  </text>
<text top="138" left="479" width="28" height="13" font="22">Effects</text>
<text top="124" left="629" width="121" height="13" font="22">Precautions (Exclude or Use  </text>
<text top="138" left="624" width="125" height="13" font="22">With Caution) and Interactions</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e530  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="1117" left="757" width="52" height="14" font="3">(Continued )</text>
<text top="159" left="81" width="125" height="13" font="22">Class III antiarrhythmic agents</text>
<text top="180" left="93" width="50" height="13" font="22">Amiodarone</text>
<text top="180" left="168" width="115" height="13" font="22">400–600 mg QD in divided </text>
<text top="194" left="168" width="111" height="13" font="22">doses for 2–4 wk (loading </text>
<text top="209" left="168" width="100" height="13" font="22">dose); followed by 100–</text>
<text top="223" left="168" width="109" height="13" font="22">200 mg QD (maintenance </text>
<text top="237" left="168" width="22" height="13" font="22">dose)</text>
<text top="180" left="294" width="108" height="13" font="22">Up to 1200 mg QD may be </text>
<text top="194" left="294" width="108" height="13" font="22">considered in an inpatient </text>
<text top="209" left="294" width="114" height="13" font="22">monitoring setting (loading </text>
<text top="223" left="294" width="102" height="13" font="22">dose); up to 200 mg QD </text>
<text top="237" left="294" width="110" height="13" font="22">maintenance (to minimize </text>
<text top="251" left="294" width="110" height="13" font="22">long-term adverse effects)</text>
<text top="180" left="429" width="126" height="13" font="22">Bradycardia, QT prolongation, </text>
<text top="194" left="429" width="112" height="13" font="22">torsades de pointes (rare), </text>
<text top="209" left="429" width="95" height="13" font="22">gastrointestinal upset, </text>
<text top="223" left="429" width="125" height="13" font="22">constipation, hypothyroidism, </text>
<text top="237" left="429" width="119" height="13" font="22">hyperthyroidism, pulmonary </text>
<text top="251" left="429" width="103" height="13" font="22">fibrosis, hepatic toxicity, </text>
<text top="266" left="429" width="133" height="13" font="22">corneal deposits, optic neuritis, </text>
<text top="280" left="429" width="97" height="13" font="22">peripheral neuropathy, </text>
<text top="294" left="429" width="93" height="13" font="22">photosensitivity, adult </text>
<text top="308" left="429" width="126" height="13" font="22">respiratory distress syndrome </text>
<text top="323" left="429" width="115" height="13" font="22">after cardiac or noncardiac </text>
<text top="337" left="429" width="56" height="13" font="22">surgery (rare)</text>
<text top="180" left="576" width="147" height="13" font="22">•   Sinus or AV conduction disease  </text>
<text top="194" left="587" width="110" height="13" font="22">(in absence of pacemaker)</text>
<text top="211" left="576" width="121" height="13" font="22">•  Inflammatory lung disease</text>
<text top="227" left="576" width="93" height="13" font="22">•  Hepatic dysfunction</text>
<text top="243" left="576" width="148" height="13" font="22">•  Hypothyroidism, hyperthyroidism</text>
<text top="260" left="576" width="103" height="13" font="22">•  Peripheral neuropathy</text>
<text top="276" left="576" width="97" height="13" font="22">•  Abnormal gait/ataxia</text>
<text top="292" left="576" width="66" height="13" font="22">•  Optic neuritis</text>
<text top="308" left="576" width="224" height="13" font="22">•   Drugs with SA and/or AV nodal–blocking properties</text>
<text top="325" left="576" width="174" height="13" font="22">•   Amiodarone is a substrate of and inhibits </text>
<text top="339" left="587" width="194" height="13" font="22">P-glycoprotein and CYP2C9 (moderate), CYP2D6 </text>
<text top="353" left="587" width="196" height="13" font="22">(moderate), and CYP3A4 (weak); amiodarone is a </text>
<text top="367" left="587" width="201" height="13" font="22">substrate for CYP3A4 (major) and CYP2C8 (major); </text>
<text top="382" left="587" width="137" height="13" font="22">amiodarone is an inhibitor of OCT2</text>
<text top="398" left="576" width="224" height="13" font="22">•   Reduce warfarin dose by 50%, and reduce digoxin </text>
<text top="412" left="587" width="79" height="13" font="22">dose by 30%–50%</text>
<text top="429" left="576" width="228" height="13" font="22">•   Agalsidase alfa, agalsidase beta, azithromycin, bosutinib, </text>
<text top="443" left="586" width="217" height="13" font="22">ceritinib, colchicine, dabigatran, edoxaban, flecainide, </text>
<text top="457" left="586" width="212" height="13" font="22">ivabradine, ledipasvir/sofosbuvir, lopinavir, lopinavir/</text>
<text top="471" left="586" width="218" height="13" font="22">ritonavir, lovastatin, nelfinavir, pazopanib, propafenone, </text>
<text top="486" left="586" width="216" height="13" font="22">simvastatin, ritonavir, rivaroxaban, saquinavir, sofosbuvir, </text>
<text top="500" left="586" width="157" height="13" font="22">topotecan, vincristine, grapefruit juice</text>
<text top="520" left="93" width="39" height="13" font="22">Dofetilide</text>
<text top="520" left="168" width="84" height="13" font="22">500 mcg every 12 h  </text>
<text top="535" left="168" width="80" height="13" font="22">(if CrCl &gt;60 mL/min)</text>
<text top="553" left="168" width="84" height="13" font="22">250 mcg every 12 h  </text>
<text top="568" left="168" width="89" height="13" font="22">(if CrCl 40–60 mL/min)</text>
<text top="586" left="168" width="84" height="13" font="22">125 mcg every 12 h  </text>
<text top="601" left="168" width="103" height="13" font="22">(if CrCl 20 to &lt;40 mL/min)</text>
<text top="619" left="168" width="78" height="13" font="22">Not recommended  </text>
<text top="634" left="168" width="75" height="13" font="22">if CrCl &lt;20 mL/min</text>
<text top="652" left="168" width="83" height="13" font="22">Adjust dose for renal </text>
<text top="667" left="168" width="109" height="13" font="22">function, body size, and age</text>
<text top="685" left="168" width="106" height="13" font="22">Initiate for minimum of 3 d </text>
<text top="700" left="168" width="109" height="13" font="22">in a facility that can provide </text>
<text top="714" left="168" width="108" height="13" font="22">continuous ECG monitoring </text>
<text top="728" left="168" width="98" height="13" font="22">and cardiac resuscitation</text>
<text top="747" left="168" width="86" height="13" font="22">Contraindicated if the </text>
<text top="761" left="168" width="94" height="13" font="22">baseline QTc interval or </text>
<text top="775" left="168" width="105" height="13" font="22">QTc &gt;440 ms† or 500 ms </text>
<text top="790" left="168" width="105" height="13" font="22">in patients with ventricular </text>
<text top="804" left="168" width="98" height="13" font="22">conduction abnormalities</text>
<text top="520" left="294" width="100" height="13" font="22">Repeat ECG 2–3 h after </text>
<text top="535" left="294" width="116" height="13" font="22">administering the first dose </text>
<text top="549" left="294" width="101" height="13" font="22">to determine QTc; if the </text>
<text top="563" left="294" width="103" height="13" font="22">QTc increased by &gt;15% </text>
<text top="577" left="294" width="113" height="13" font="22">compared with baseline or </text>
<text top="592" left="294" width="120" height="13" font="22">if QTc is &gt;500 ms† (550 ms </text>
<text top="606" left="294" width="113" height="13" font="22">in patients with ventricular </text>
<text top="620" left="294" width="113" height="13" font="22">conduction abnormalities), </text>
<text top="634" left="294" width="111" height="13" font="22">subsequent dosing should </text>
<text top="649" left="294" width="118" height="13" font="22">be down titrated by 50%; at </text>
<text top="663" left="294" width="122" height="13" font="22">2–3 h after each subsequent </text>
<text top="677" left="294" width="106" height="13" font="22">dose, determine QTc (for </text>
<text top="691" left="294" width="117" height="13" font="22">in-hospital doses 2–5); if at </text>
<text top="706" left="294" width="109" height="13" font="22">any time after the second </text>
<text top="720" left="294" width="115" height="13" font="22">dose the QTc is &gt;500 ms║ </text>
<text top="734" left="294" width="103" height="13" font="22">(550 ms in patients with </text>
<text top="748" left="294" width="95" height="13" font="22">ventricular conduction </text>
<text top="763" left="294" width="105" height="13" font="22">abnormalities), dofetilide </text>
<text top="777" left="294" width="96" height="13" font="22">should be discontinued</text>
<text top="521" left="429" width="122" height="13" font="22">QT prolongation, torsades de </text>
<text top="535" left="429" width="30" height="13" font="22">pointes</text>
<text top="521" left="576" width="214" height="13" font="22">•   Severe renal dysfunction (contraindicated if CrCl </text>
<text top="535" left="587" width="55" height="13" font="22">&lt;20 mL/min)</text>
<text top="551" left="576" width="67" height="13" font="22">•  Prolonged QT</text>
<text top="567" left="576" width="135" height="13" font="22">•  History of torsades de pointes</text>
<text top="584" left="576" width="229" height="13" font="22">•   Concomitant use of hydrochlorothiazide, cimetidine, </text>
<text top="598" left="587" width="217" height="13" font="22">dolutegravir, itraconazole, ketoconazole, megestrol, </text>
<text top="612" left="587" width="188" height="13" font="22">trimethoprim, prochlorperazine trimethoprim/</text>
<text top="626" left="587" width="197" height="13" font="22">sulfamethoxazole or verapamil, contraindicated</text>
<text top="643" left="576" width="146" height="13" font="22">•  Avoid other QT-prolonging drugs</text>
<text top="825" left="94" width="28" height="13" font="22">Sotalol</text>
<text top="825" left="168" width="94" height="13" font="22">40–80 mg every 12 h </text>
<text top="840" left="168" width="87" height="13" font="22">(Patients initiated or </text>
<text top="854" left="168" width="88" height="13" font="22">reinitiated on sotalol </text>
<text top="868" left="168" width="92" height="13" font="22">should be placed in a </text>
<text top="882" left="168" width="101" height="13" font="22">facility that can provide </text>
<text top="897" left="168" width="90" height="13" font="22">cardiac resuscitation </text>
<text top="911" left="168" width="67" height="13" font="22">and continuous </text>
<text top="925" left="168" width="89" height="13" font="22">electrocardiographic </text>
<text top="939" left="168" width="112" height="13" font="22">monitoring for a minimum </text>
<text top="954" left="168" width="101" height="13" font="22">of 3 d). Contraindicated </text>
<text top="968" left="168" width="92" height="13" font="22">if the QTc† interval is </text>
<text top="982" left="168" width="41" height="13" font="22">&gt;450 ms.</text>
<text top="1001" left="168" width="103" height="13" font="22">CrCl should be calculated </text>
<text top="1015" left="168" width="88" height="13" font="22">before dosing. If CrCl </text>
<text top="1029" left="168" width="106" height="13" font="22">&gt;60 mL/min, then dosing </text>
<text top="1044" left="168" width="107" height="13" font="22">frequency is twice daily. If </text>
<text top="1058" left="168" width="116" height="13" font="22">CrCl 40–60 mL/min, dosing </text>
<text top="1072" left="168" width="99" height="13" font="22">interval is every 24 h. If </text>
<text top="1086" left="168" width="106" height="13" font="22">CrCl &lt;40 mL/min, should </text>
<text top="1101" left="168" width="53" height="13" font="22">not be used.)</text>
<text top="825" left="294" width="109" height="13" font="22">160 mg every 12 h (During </text>
<text top="840" left="294" width="116" height="13" font="22">initiation and titration, the QT </text>
<text top="854" left="294" width="115" height="13" font="22">interval should be monitored </text>
<text top="868" left="294" width="114" height="13" font="22">2–4 h after each dose. If the </text>
<text top="882" left="294" width="91" height="13" font="22">QT interval prolongs to </text>
<text top="882" left="385" width="25" height="13" font="22">≥500 </text>
<text top="897" left="294" width="123" height="13" font="22">ms, the dose must be reduced </text>
<text top="911" left="294" width="101" height="13" font="22">or the drug discontinued.)</text>
<text top="825" left="429" width="110" height="13" font="22">QT prolongation, torsades </text>
<text top="840" left="429" width="103" height="13" font="22">de pointes, bradycardia, </text>
<text top="854" left="429" width="61" height="13" font="22">bronchospasm</text>
<text top="825" left="576" width="67" height="13" font="22">•  Prolonged QT</text>
<text top="842" left="576" width="85" height="13" font="22">•  Renal dysfunction</text>
<text top="859" left="576" width="65" height="13" font="22">•  Hypokalemia</text>
<text top="876" left="576" width="77" height="13" font="22">•  Diuretic therapy</text>
<text top="893" left="576" width="146" height="13" font="22">•  Avoid other QT-prolonging drugs</text>
<text top="910" left="576" width="198" height="13" font="22">•   Sinus or AV nodal dysfunction (in absence of </text>
<text top="924" left="587" width="49" height="13" font="22">pacemaker)</text>
<text top="941" left="576" width="126" height="13" font="22">•  Decompensated systolic HF</text>
<text top="958" left="576" width="88" height="13" font="22">•  Cardiogenic shock</text>
<text top="975" left="576" width="111" height="13" font="22">•  Reactive airway disease</text>
<text top="992" left="576" width="224" height="13" font="22">•   Drugs with SA and/or AV–nodal blocking properties</text>
<text top="97" left="71" width="114" height="16" font="17"><b>Table 7.  Continued</b></text>
<text top="138" left="81" width="20" height="13" font="22">Drug</text>
<text top="138" left="184" width="79" height="13" font="22">Initial Daily Dose(s)</text>
<text top="124" left="310" width="93" height="13" font="22">Maximum Total Daily  </text>
<text top="138" left="315" width="77" height="13" font="22">Maintenance Dose</text>
<text top="124" left="459" width="77" height="13" font="22">Potential Adverse  </text>
<text top="138" left="481" width="28" height="13" font="22">Effects</text>
<text top="124" left="631" width="121" height="13" font="22">Precautions (Exclude or Use  </text>
<text top="138" left="626" width="125" height="13" font="22">With Caution) and Interactions</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="23" size="10" family="Times" color="#5c60b6"/>
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e531</i></b></text>
<text top="585" left="69" width="355" height="16" font="13">patients with MAT who do not have ventricular dysfunction, </text>
<text top="602" left="69" width="209" height="16" font="13">sinus node dysfunction, or AV block</text>
<text top="603" left="278" width="27" height="9" font="14">227,228</text>
<text top="602" left="305" width="119" height="16" font="13">; although diltiazem </text>
<text top="619" left="69" width="354" height="16" font="13">has not been studied, it may provide a class effect with similar </text>
<text top="636" left="69" width="351" height="16" font="13">mechanism to verapamil. Beta blockers can be used with cau-</text>
<text top="654" left="69" width="351" height="16" font="13">tion to treat MAT in the absence of respiratory decompensa-</text>
<text top="671" left="69" width="249" height="16" font="13">tion, sinus node dysfunction, or AV block.</text>
<text top="672" left="318" width="27" height="9" font="14">229,230</text>
<text top="671" left="345" width="80" height="16" font="13"> Amiodarone </text>
<text top="688" left="69" width="241" height="16" font="13">has been reported to be useful in 1 report.</text>
<text top="689" left="310" width="12" height="9" font="14">231</text>
<text top="688" left="322" width="102" height="16" font="13"> Cardioversion is </text>
<text top="705" left="69" width="107" height="16" font="13">not useful in MAT.</text>
<text top="706" left="176" width="12" height="9" font="14">223</text>
<text top="731" left="69" width="244" height="16" font="0"><i><b>4.2.1. Acute Treatment: Recommendation</b></i></text>
<text top="929" left="69" width="285" height="16" font="0"><i><b>4.2.2. Ongoing Management: Recommendations</b></i></text>
<text top="584" left="461" width="340" height="20" font="12"><b>5. Atrioventricular Nodal Reentrant Tachycardia</b></text>
<text top="604" left="456" width="354" height="16" font="13">See Figure 12 for the algorithm for acute treatment of AVNRT </text>
<text top="622" left="456" width="356" height="16" font="13">and Figure 13 for the algorithm for ongoing management of </text>
<text top="639" left="456" width="49" height="16" font="13">AVNRT.</text>
<text top="656" left="477" width="335" height="16" font="13">AVNRT is the most common SVT. It is usually seen in </text>
<text top="673" left="456" width="358" height="16" font="13">young adults without structural heart disease or ischemic </text>
<text top="691" left="456" width="343" height="16" font="13">heart disease, and &gt;60% of cases are observed in women.</text>
<text top="691" left="799" width="8" height="9" font="14">49</text>
<text top="691" left="807" width="4" height="16" font="13"> </text>
<text top="708" left="456" width="355" height="16" font="13">The ventricular rate is often 180 bpm to 200 bpm but ranges </text>
<text top="725" left="456" width="355" height="16" font="13">from 110 bpm to &gt;250 bpm (and in rare cases, the rate can be  </text>
<text top="160" left="80" width="59" height="13" font="22">Miscellaneous</text>
<text top="182" left="92" width="43" height="13" font="22">Ivabradine</text>
<text top="182" left="204" width="39" height="13" font="22">5 mg BID</text>
<text top="182" left="331" width="47" height="13" font="22">7.5 mg BID</text>
<text top="182" left="462" width="66" height="13" font="22">Phosphenes, AF</text>
<text top="182" left="575" width="189" height="13" font="22">•   Concomitant drugs that can exacerbate  </text>
<text top="196" left="586" width="51" height="13" font="22">bradycardia</text>
<text top="213" left="575" width="169" height="13" font="22">•  Contraindicated in decompensated HF</text>
<text top="230" left="575" width="164" height="13" font="22">•  Contraindicated if BP &lt;90/50 mm Hg</text>
<text top="247" left="575" width="200" height="13" font="22">•  Contraindicated in severe hepatic impairment</text>
<text top="264" left="575" width="66" height="13" font="22">•  Hypertension</text>
<text top="281" left="575" width="191" height="13" font="22">•  Ivabradine is a substrate of CYP3A4 (major)</text>
<text top="298" left="575" width="193" height="13" font="22">•   Avoid use with concomitant strong CYP3A4 </text>
<text top="312" left="586" width="198" height="13" font="22">inhibitors (boceprevir, clarithromycin, indinavir, </text>
<text top="326" left="586" width="177" height="13" font="22">itraconazole, lopinavir/ritonavir, nelfinavir, </text>
<text top="341" left="586" width="194" height="13" font="22">ritonavir, saquinavir, telaprevir, posaconazole, </text>
<text top="355" left="586" width="55" height="13" font="22">voriconazole)</text>
<text top="372" left="575" width="177" height="13" font="22">•   Avoid use with strong CYP3A4 inducers </text>
<text top="386" left="586" width="156" height="13" font="22">(carbamazepine, phenytoin, rifampin,  </text>
<text top="400" left="586" width="64" height="13" font="22">St. John’s wort)</text>
<text top="417" left="575" width="226" height="13" font="22">•   Avoid use with diltiazem, verapamil, grapefruit juice</text>
<text top="437" left="81" width="521" height="14" font="3">Note: For this reference table, drugs are presented in alphabetical order within the drug classes, not by COR and LOE.</text>
<text top="452" left="81" width="728" height="14" font="3">*When 1 drug is used in combination with other drugs, appropriate dosing adjustments should be made with consideration of at least additive effects during dosage </text>
<text top="467" left="69" width="740" height="14" font="3">titration. All potential drug–drug interactions and adverse reactions are not included in this list. For a more detailed list of drug interactions and adverse responses, </text>
<text top="482" left="69" width="265" height="14" font="3"><a href="">clinicians should consult additional resources; for example, </a></text>
<text top="482" left="334" width="103" height="14" font="23"><a href="">www.crediblemeds.org</a></text>
<text top="482" left="437" width="277" height="14" font="3"> may be consulted for potential prolongation of the QT interval.</text>
<text top="497" left="81" width="299" height="14" font="3">†QTc calculation used the Bazett’s Formula in most clinical studies.</text>
<text top="512" left="81" width="478" height="14" font="3">‡Recommended given in conjunction with a beta blocker or nondihydropyridine calcium channel antagonist.</text>
<text top="527" left="81" width="728" height="14" font="3">AF indicates atrial fibrillation; AV, atrioventricular; BID, twice daily; BP, blood pressure; CrCl, creatinine clearance; ECG, electrocardiogram/electrocardiographic; HF, </text>
<text top="542" left="69" width="740" height="14" font="3">heart failure; INR, international normalized ratio; LV, left ventricular; QD, once daily; QID, 4 times a day; QTc, corrected QT interval; SA, sinoatrial; SVT, supraventricular </text>
<text top="557" left="69" width="294" height="14" font="3">tachycardia; TID, 3 times a day; and WPW, Wolff-Parkinson-White.</text>
<text top="97" left="69" width="114" height="16" font="17"><b>Table 7.  Continued</b></text>
<text top="138" left="80" width="20" height="13" font="22">Drug</text>
<text top="138" left="183" width="79" height="13" font="22">Initial Daily Dose(s)</text>
<text top="124" left="309" width="93" height="13" font="22">Maximum Total Daily  </text>
<text top="138" left="314" width="77" height="13" font="22">Maintenance Dose</text>
<text top="124" left="457" width="77" height="13" font="22">Potential Adverse  </text>
<text top="138" left="479" width="28" height="13" font="22">Effects</text>
<text top="124" left="629" width="121" height="13" font="22">Precautions (Exclude or Use  </text>
<text top="138" left="624" width="125" height="13" font="22">With Caution) and Interactions</text>
<text top="963" left="78" width="427" height="16" font="19"><b>Recommendations for Ongoing Management of Multifocal Atrial Tachycardia</b></text>
<text top="987" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="987" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="987" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="1019" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="1009" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="1012" left="169" width="635" height="14" font="1"><b>1.   Oral verapamil (<i>Level of Evidence: B-NR</i></b><b> ) or diltiazem (<i>Level of Evidence: C-LD</i></b><b>) is reasonable for ongoing management in patients </b></text>
<text top="1027" left="184" width="160" height="14" font="1"><b>with recurrent symptomatic MAT.</b></text>
<text top="1027" left="344" width="22" height="8" font="20"><b>227,230</b></text>
<text top="1030" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1067" left="78" width="20" height="14" font="3">See </text>
<text top="1067" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1082" left="78" width="62" height="14" font="21"><a href="">Supplement 8</a></text>
<text top="1082" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="1052" left="170" width="586" height="14" font="3">Long-term management of MAT frequently involves slowing of the ventricular response because arrhythmia termination is often not </text>
<text top="1067" left="170" width="633" height="14" font="3">achievable. Verapamil has the advantage of not exacerbating pulmonary disease. Although it would be expected for diltiazem to have a similar </text>
<text top="1082" left="170" width="621" height="14" font="3">effect, data on its use in patients with MAT are lacking. These drugs should not be used in patients with severe conduction abnormalities or </text>
<text top="1097" left="170" width="391" height="14" font="3">sinus node dysfunction because those conditions can be exacerbated with these agents.</text>
<text top="769" left="78" width="398" height="16" font="19"><b>Recommendations for Acute Treatment of Multifocal Atrial Tachycardia</b></text>
<text top="794" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="794" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="794" left="169" width="83" height="14" font="1"><b>Recommendation</b></text>
<text top="815" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="815" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="815" left="169" width="125" height="14" font="1"><b>1.   Intravenous  metoprolol</b></text>
<text top="816" left="295" width="10" height="8" font="20"><b>229</b></text>
<text top="815" left="305" width="63" height="14" font="1"><b> or verapamil</b></text>
<text top="816" left="368" width="22" height="8" font="20"><b>232,233</b></text>
<text top="815" left="389" width="266" height="14" font="1"><b> can be useful for acute treatment in patients with MAT.</b></text>
<text top="859" left="78" width="20" height="14" font="3">See </text>
<text top="859" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="874" left="78" width="62" height="14" font="21"><a href="">Supplement 7</a></text>
<text top="874" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="837" left="169" width="635" height="14" font="3">The mechanism of MAT can involve triggered activity, and treatment with intravenous verapamil can terminate the arrhythmia with moderate success. In </text>
<text top="852" left="169" width="330" height="14" font="3">1 small study, intravenous verapamil converted MAT in 8 of 16 patients treated.</text>
<text top="852" left="499" width="10" height="8" font="18">233</text>
<text top="852" left="508" width="289" height="14" font="3"> Alternatively, intravenous verapamil may acutely slow the ventricular </text>
<text top="867" left="170" width="266" height="14" font="3">response to MAT. The major potential side effect is hypotension.</text>
<text top="867" left="435" width="10" height="8" font="18">233</text>
<text top="867" left="445" width="348" height="14" font="3"> The relatively cardioselective beta blocker metoprolol can also work by slowing the </text>
<text top="882" left="170" width="632" height="14" font="3">ventricular rate in MAT. Beta blockers are typically avoided in patients with severe underlying pulmonary disease, particularly those with bronchospasm; </text>
<text top="897" left="170" width="585" height="14" font="3">both beta blockers and verapamil are typically avoided in the presence of acute decompensated heart failure and/or hemodynamic instability.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e532  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="270" left="71" width="68" height="16" font="13">&lt;100 bpm).</text>
<text top="271" left="139" width="8" height="9" font="14">54</text>
<text top="270" left="147" width="280" height="16" font="13"> The anatomic substrate of AVNRT is dual AV </text>
<text top="287" left="71" width="157" height="16" font="13">nodal physiology (Table 3).</text>
<text top="304" left="92" width="330" height="16" font="13">AVNRT is often well tolerated and is rarely life threaten-</text>
<text top="322" left="71" width="356" height="16" font="13">ing. Patients will typically present with the sudden onset of </text>
<text top="339" left="71" width="355" height="16" font="13">palpitations and possibly with shortness of breath, dizziness, </text>
<text top="270" left="458" width="359" height="16" font="13">and neck pulsations. Syncope is a rare manifestation of </text>
<text top="287" left="458" width="355" height="16" font="13">AVNRT. AVNRT may occur spontaneously or on provocation </text>
<text top="305" left="458" width="209" height="16" font="13">with exertion, coffee, tea, or alcohol.</text>
<text top="338" left="458" width="273" height="18" font="10"><b>5.1. Acute Treatment: Recommendations</b></text>
<text top="150" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="150" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="150" left="171" width="471" height="14" font="1"><b>2.   Metoprolol is reasonable for ongoing management in patients with recurrent symptomatic MAT.</b></text>
<text top="151" left="642" width="34" height="8" font="20"><b>226,229,230</b></text>
<text top="187" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="187" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="202" left="80" width="70" height="14" font="21"><a href="">Supplements 7 </a></text>
<text top="217" left="80" width="25" height="14" font="21"><a href="">and 8</a></text>
<text top="217" left="105" width="3" height="14" font="3"><a href="">.</a></text>
<text top="172" left="171" width="566" height="14" font="3">Beta blockers are typically avoided in the presence of acute decompensated heart failure or in patients with severe (particularly </text>
<text top="187" left="171" width="612" height="14" font="3">bronchospastic) pulmonary disease. However, metoprolol has been used in small studies in patients with serious pulmonary disease after </text>
<text top="202" left="171" width="626" height="14" font="3">correction of hypoxia or other signs of acute decompensation. In these studies, intravenous or oral metoprolol resulted in conversion to sinus </text>
<text top="217" left="171" width="390" height="14" font="3">rhythm or achieved rate control, and oral metoprolol was used for maintenance therapy.</text>
<text top="217" left="561" width="22" height="8" font="18">226,230</text>
<text top="217" left="583" width="213" height="14" font="3"> Beta blockers are generally avoided in patients </text>
<text top="232" left="171" width="285" height="14" font="3">with severe conduction abnormalities or sinus node dysfunction.</text>
<text top="104" left="80" width="490" height="16" font="19"><b>Recommendations for Ongoing Management of Multifocal Atrial Tachycardia (Continued)</b></text>
<text top="128" left="82" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="374" left="80" width="274" height="16" font="19"><b>Recommendations for Acute Treatment of AVNRT</b></text>
<text top="399" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="399" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="399" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="420" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="420" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="420" left="171" width="396" height="14" font="1"><b>1.   Vagal maneuvers are recommended for acute treatment in patients with AVNRT.</b></text>
<text top="421" left="567" width="40" height="8" font="20"><b>82–84,234,235</b></text>
<text top="494" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="494" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="509" left="80" width="67" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="509" left="147" width="3" height="14" font="3">.</text>
<text top="442" left="171" width="611" height="14" font="3">For acute conversion of AVNRT, vagal maneuvers, including Valsalva and carotid sinus massage, can be performed quickly and should be </text>
<text top="457" left="171" width="619" height="14" font="3">the first-line intervention to terminate SVT. These maneuvers should be performed with the patient in the supine position. There is no “gold </text>
<text top="472" left="171" width="626" height="14" font="3">standard” for proper Valsalva maneuver technique, but in general, the patient raises intrathoracic pressure by bearing down against a closed </text>
<text top="487" left="171" width="330" height="14" font="3">glottis for 10 to 30 seconds, equivalent to at least 30 mm Hg to 40 mm Hg.</text>
<text top="488" left="501" width="15" height="8" font="18">82,84</text>
<text top="487" left="516" width="280" height="14" font="3"> Carotid massage is performed after absence of bruit has been </text>
<text top="502" left="171" width="483" height="14" font="3">confirmed by auscultation, by applying steady pressure over the right or left carotid sinus for 5 to10 seconds.</text>
<text top="503" left="654" width="15" height="8" font="18">83,84</text>
<text top="502" left="669" width="114" height="14" font="3"> Another vagal maneuver </text>
<text top="517" left="171" width="389" height="14" font="3">based on the classic diving reflex consists of applying an ice-cold, wet towel to the face</text>
<text top="518" left="560" width="7" height="8" font="18">85</text>
<text top="517" left="567" width="234" height="14" font="3">; in a laboratory setting, facial immersion in water at </text>
<text top="532" left="171" width="304" height="14" font="3">10°C (50°F) has proved effective in terminating tachycardia, as well.</text>
<text top="533" left="475" width="7" height="8" font="18">86</text>
<text top="532" left="481" width="315" height="14" font="3"> One study involving 148 patients with SVT demonstrated that Valsalva </text>
<text top="547" left="171" width="619" height="14" font="3">was more successful than carotid sinus massage, and switching from 1 technique to the other resulted in an overall success rate of 27.7%.</text>
<text top="548" left="790" width="7" height="8" font="18">82</text>
<text top="547" left="797" width="3" height="14" font="3"> </text>
<text top="562" left="171" width="436" height="14" font="3">The practice of applying pressure to the eyeball is potentially dangerous and has been abandoned.</text>
<text top="583" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="583" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="583" left="171" width="357" height="14" font="1"><b>2.   Adenosine is recommended for acute treatment in patients with AVNRT.</b></text>
<text top="584" left="528" width="35" height="8" font="20"><b>42,51,91,236</b></text>
<text top="605" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="605" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="620" left="80" width="70" height="14" font="21"><a href="">Supplements 9 </a></text>
<text top="635" left="80" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="635" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="612" left="171" width="633" height="14" font="3">Adenosine can be considered as both a therapeutic and diagnostic agent in narrow-complex tachyarrhythmias. It will acutely terminate AVNRT </text>
<text top="627" left="171" width="471" height="14" font="3">in approximately 95% of patients and will unmask atrial activity in arrhythmias, such as atrial flutter or AT.</text>
<text top="628" left="642" width="18" height="8" font="18">91,236</text>
<text top="663" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="663" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="656" left="171" width="604" height="14" font="1"><b>3.   Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with AVNRT when </b></text>
<text top="671" left="185" width="395" height="14" font="1"><b>adenosine and vagal maneuvers do not terminate the tachycardia or are not feasible.</b></text>
<text top="671" left="580" width="18" height="8" font="20"><b>94,208</b></text>
<text top="692" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="692" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="707" left="80" width="67" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="707" left="147" width="3" height="14" font="3">.</text>
<text top="692" left="171" width="626" height="14" font="3">Sinus rhythm must be promptly restored in patients with AVNRT who are hemodynamically unstable. The safety and effectiveness of cardioversion has </text>
<text top="707" left="171" width="619" height="14" font="3">been proven in patients with hemodynamically unstable SVT who had failed to convert with vagal maneuvers and intravenous pharmacological therapy.</text>
<text top="708" left="789" width="7" height="8" font="18">94</text>
<text top="736" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="736" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="728" left="171" width="628" height="14" font="1"><b>4.   Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVNRT when pharmacological </b></text>
<text top="743" left="185" width="290" height="14" font="1"><b>therapy does not terminate the tachycardia or is contraindicated.</b></text>
<text top="744" left="474" width="14" height="8" font="20"><b>87,95</b></text>
<text top="773" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="773" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="788" left="80" width="70" height="14" font="21"><a href="">Supplements 3 </a></text>
<text top="803" left="80" width="25" height="14" font="21"><a href="">and 9</a></text>
<text top="803" left="105" width="3" height="14" font="3"><a href="">.</a></text>
<text top="765" left="171" width="416" height="14" font="3">Synchronized cardioversion is highly effective in terminating SVT (including AVRT and AVNRT).</text>
<text top="766" left="587" width="7" height="8" font="18">94</text>
<text top="765" left="594" width="187" height="14" font="3"> Most stable patients with SVT respond to </text>
<text top="780" left="171" width="623" height="14" font="3">pharmacological therapy, with success rates of 80% to 98% for agents such as verapamil, diltiazem, or adenosine. In some resistant cases, </text>
<text top="795" left="171" width="324" height="14" font="3">a second drug bolus or higher dose of initial drug agent is often effective.</text>
<text top="796" left="495" width="15" height="8" font="18">87,96</text>
<text top="795" left="510" width="280" height="14" font="3"> Nevertheless, in rare instances, drugs may fail to successfully </text>
<text top="810" left="171" width="282" height="14" font="3">restore sinus rhythm, necessitating synchronized cardioversion.</text>
<text top="839" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="839" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="831" left="171" width="636" height="14" font="1"><b>1.   Intravenous beta blockers, diltiazem, or verapamil are reasonable for acute treatment in hemodynamically stable patients with </b></text>
<text top="846" left="186" width="36" height="14" font="1"><b>AVNRT.</b></text>
<text top="847" left="222" width="33" height="8" font="20"><b>96,237–240</b></text>
<text top="898" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="898" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="913" left="80" width="68" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="913" left="147" width="3" height="14" font="3">.</text>
<text top="868" left="171" width="576" height="14" font="3">Intravenous diltiazem and verapamil are particularly effective in converting AVNRT to sinus rhythm. These drugs should be used only in </text>
<text top="883" left="171" width="625" height="14" font="3">hemodynamically stable patients. It is important to ensure the absence of VT or pre-excited AF, because patients with these rhythms may become </text>
<text top="898" left="171" width="627" height="14" font="3">hemodynamically unstable and develop ventricular fibrillation if administered diltiazem or verapamil. Diltiazem or verapamil should also be avoided </text>
<text top="913" left="171" width="592" height="14" font="3">in patients with suspected systolic heart failure. Evidence for the effectiveness of beta blockers to terminate AVNRT is limited. In a trial that </text>
<text top="928" left="171" width="352" height="14" font="3">compared esmolol with diltiazem, diltiazem was more effective in terminating SVT.</text>
<text top="929" left="523" width="10" height="8" font="18">237</text>
<text top="928" left="533" width="271" height="14" font="3"> Nonetheless, beta blockers have an excellent safety profile, so </text>
<text top="943" left="171" width="393" height="14" font="3">it is reasonable to use them to attempt to terminate SVT in hemodynamically stable patients.</text>
<text top="964" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="964" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="964" left="171" width="611" height="14" font="1"><b>1.   Oral beta blockers, diltiazem, or verapamil may be reasonable for acute treatment in hemodynamically stable patients with AVNRT.</b></text>
<text top="965" left="782" width="22" height="8" font="20"><b>241,242</b></text>
<text top="993" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="993" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1008" left="80" width="62" height="14" font="21"><a href="">Supplement 9</a></text>
<text top="1008" left="141" width="3" height="14" font="3">.</text>
<text top="986" left="171" width="629" height="14" font="3">Overall, there are no data specifically studying the effect of oral beta-blocker monotherapy for the acute termination of AVNRT. However, 2 studies have </text>
<text top="1001" left="171" width="442" height="14" font="3">demonstrated success with the combination of oral diltiazem and propranolol to terminate AVNRT or AVRT.</text>
<text top="1001" left="612" width="21" height="8" font="18">241,242</text>
<text top="1001" left="633" width="156" height="14" font="3"> Oral beta blockers have an excellent </text>
<text top="1016" left="171" width="584" height="14" font="3">safety profile, and administration (particularly in patients without intravenous access) can be performed in conjunction with vagal maneuvers.</text>
<text top="1044" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="1044" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1037" left="171" width="609" height="14" font="1"><b>2.   Intravenous amiodarone may be considered for acute treatment in hemodynamically stable patients with AVNRT when other </b></text>
<text top="1052" left="186" width="209" height="14" font="1"><b>therapies are ineffective or contraindicated.</b></text>
<text top="1052" left="395" width="10" height="8" font="20"><b>115</b></text>
<text top="1073" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1073" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1088" left="80" width="68" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="1088" left="147" width="3" height="14" font="3">.</text>
<text top="1073" left="171" width="375" height="14" font="3">In a small cohort study, intravenous amiodarone was effective in terminating AVNRT.</text>
<text top="1074" left="546" width="10" height="8" font="18">115</text>
<text top="1073" left="556" width="214" height="14" font="3"> Long-term toxicity is not seen with intravenous </text>
<text top="1088" left="171" width="203" height="14" font="3">amiodarone if given for a short period of time.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e533</i></b></text>
<text top="97" left="69" width="311" height="18" font="10"><b>5.2. Ongoing Management: Recommendations</b></text>
<text top="133" left="78" width="303" height="16" font="19"><b>Recommendations for Ongoing Management of AVNRT</b></text>
<text top="157" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="157" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="157" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="186" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="186" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="178" left="169" width="610" height="14" font="1"><b>1.   Oral verapamil or diltiazem is recommended for ongoing management in patients with AVNRT who are not candidates for, or </b></text>
<text top="193" left="184" width="191" height="14" font="1"><b>prefer not to undergo, catheter ablation.</b></text>
<text top="194" left="375" width="39" height="8" font="20"><b>98,99,243,244</b></text>
<text top="215" left="78" width="20" height="14" font="3">See </text>
<text top="215" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="230" left="78" width="70" height="14" font="21"><a href="">Supplements 9 </a></text>
<text top="245" left="78" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="245" left="109" width="3" height="14" font="3">.</text>
<text top="215" left="169" width="618" height="14" font="3">Both diltiazem and verapamil are well-tolerated and effective pharmacological alternatives to ablation for the ongoing treatment of patients </text>
<text top="230" left="169" width="55" height="14" font="3">with AVNRT.</text>
<text top="231" left="224" width="18" height="8" font="18">98,243</text>
<text top="230" left="243" width="553" height="14" font="3"> When therapy with these agents is initiated, attention should be directed toward avoiding the potential for bradyarrhythmias </text>
<text top="245" left="170" width="456" height="14" font="3">and hypotension. Diltiazem and verapamil should also be avoided in patients with systolic heart failure.</text>
<text top="266" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="266" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="266" left="170" width="379" height="14" font="1"><b>2.   Catheter ablation of the slow pathway is recommended in patients with AVNRT.</b></text>
<text top="267" left="548" width="56" height="8" font="20"><b>36,100–106,245–249</b></text>
<text top="318" left="78" width="20" height="14" font="3">See </text>
<text top="318" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="333" left="78" width="70" height="14" font="21"><a href="">Supplements 9 </a></text>
<text top="348" left="78" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="348" left="109" width="3" height="14" font="3">.</text>
<text top="288" left="169" width="596" height="14" font="3">Catheter ablation of AVNRT is regarded as first-line therapy for treatment of symptomatic AVNRT. It is potentially curative, and chronic </text>
<text top="303" left="169" width="616" height="14" font="3">pharmacological therapy is usually not needed after the procedure. Slow-pathway ablation (also called modification) is the preferred target </text>
<text top="318" left="169" width="113" height="14" font="3">during ablation of AVNRT.</text>
<text top="333" left="169" width="550" height="14" font="3">Large registry studies report the success rates of slow-pathway ablation to be &gt;95%, with a &lt;1% risk of AV block (Table 8).</text>
<text top="333" left="719" width="57" height="8" font="18">36,100–102,246–248</text>
<text top="333" left="777" width="3" height="14" font="3"> </text>
<text top="348" left="170" width="621" height="14" font="3">Cryoablation of AVNRT is an alternative to radiofrequency ablation. Recent systematic reviews and trials randomizing patients to radiofrequency </text>
<text top="363" left="170" width="615" height="14" font="3">ablation versus cryoablation suggest an equivalent acute success rate, with a lower rate of AV block but a higher rate of recurrence during </text>
<text top="378" left="170" width="91" height="14" font="3">long-term follow-up.</text>
<text top="378" left="261" width="10" height="8" font="18">156</text>
<text top="406" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="406" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="399" left="170" width="622" height="14" font="1"><b>3.   Oral beta blockers are recommended for ongoing management in patients with AVNRT who are not candidates for, or prefer not to </b></text>
<text top="414" left="184" width="126" height="14" font="1"><b>undergo, catheter ablation.</b></text>
<text top="415" left="310" width="7" height="8" font="20"><b>99</b></text>
<text top="451" left="78" width="20" height="14" font="3">See </text>
<text top="451" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="466" left="78" width="62" height="14" font="21"><a href="">Supplement 9</a></text>
<text top="466" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="436" left="169" width="602" height="14" font="3">Evidence for oral beta blockers is limited. One small study randomized patients with AVNRT and AVRT to digoxin (0.375 mg/day), </text>
<text top="451" left="169" width="521" height="14" font="3">propranolol (240 mg/day), or verapamil (480 mg/day), with 1 week of placebo washout between drug regimens.</text>
<text top="451" left="690" width="7" height="8" font="18">99</text>
<text top="451" left="697" width="109" height="14" font="3"> Episodes and duration </text>
<text top="466" left="170" width="635" height="14" font="3">of tachyarrhythmia (ascertained by diary and weekly 24-h Holter) were similar among the treatment groups, and all 3 medications were </text>
<text top="481" left="170" width="66" height="14" font="3">well tolerated.</text>
<text top="517" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="517" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="502" left="170" width="616" height="14" font="1"><b>1.   Flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart </b></text>
<text top="517" left="184" width="579" height="14" font="1"><b>disease who have AVNRT and are not candidates for, or prefer not to undergo, catheter ablation and in whom beta blockers, </b></text>
<text top="532" left="184" width="261" height="14" font="1"><b>diltiazem, or verapamil are ineffective or contraindicated.</b></text>
<text top="532" left="445" width="95" height="8" font="20"><b>45,46,107–112,114,241,242,250,251</b></text>
<text top="576" left="78" width="20" height="14" font="3">See </text>
<text top="576" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="591" left="78" width="70" height="14" font="21"><a href="">Supplements 9 </a></text>
<text top="606" left="78" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="606" left="109" width="3" height="14" font="3">.</text>
<text top="553" left="169" width="569" height="14" font="3">In 1 RCT, the probability of 12 months of effective (defined as &lt;2 attacks of arrhythmia) and safe treatment was 86% for  </text>
<text top="568" left="169" width="170" height="14" font="3">propafenone and 93% for flecainide.</text>
<text top="569" left="340" width="10" height="8" font="18">109</text>
<text top="568" left="350" width="419" height="14" font="3"> Flecainide and propafenone have a risk of proarrhythmia in patients with structural heart </text>
<text top="583" left="170" width="588" height="14" font="3">disease or ischemic heart disease and are contraindicated in these patient groups. In 1 nonrandomized study, flecainide was  </text>
<text top="598" left="170" width="360" height="14" font="3">evaluated as “pill-in-the-pocket” therapy along with diltiazem or propranolol.</text>
<text top="599" left="530" width="23" height="8" font="18">241,242</text>
<text top="598" left="552" width="202" height="14" font="3"> However, all patients were screened with  </text>
<text top="613" left="170" width="611" height="14" font="3">EP studies, and only 5 patients were discharged on flecainide. As such, the merit of flecainide as “pill in the pocket” for outpatient </text>
<text top="628" left="170" width="166" height="14" font="3">therapy for AVNRT remains unclear.</text>
<text top="657" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="657" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="649" left="170" width="594" height="14" font="1"><b>2.   Clinical follow-up without pharmacological therapy or ablation is reasonable for ongoing management in minimally </b></text>
<text top="664" left="185" width="173" height="14" font="1"><b>symptomatic patients with AVNRT.</b></text>
<text top="665" left="358" width="10" height="8" font="20"><b>244</b></text>
<text top="702" left="78" width="20" height="14" font="3">See </text>
<text top="702" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="717" left="78" width="68" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="717" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="687" left="169" width="621" height="14" font="3">In a prospective study of 93 adult patients with AVNRT who were followed for approximately 15 years, nearly half of minimally symptomatic </text>
<text top="702" left="169" width="549" height="14" font="3">patients who received no therapy (versus ablation or antiarrhythmic agents) improved over time and became asymptomatic.</text>
<text top="703" left="718" width="10" height="8" font="18">244</text>
<text top="702" left="728" width="71" height="14" font="3"> Patients with a </text>
<text top="717" left="170" width="632" height="14" font="3">confirmed or suspected diagnosis of AVNRT who choose not to undergo catheter ablation or take medications should be educated about when </text>
<text top="732" left="170" width="328" height="14" font="3">to seek medical attention and be taught how to perform vagal maneuvers.</text>
<text top="760" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="760" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="753" left="170" width="606" height="14" font="1"><b>1.   Oral sotalol or dofetilide may be reasonable for ongoing management in patients with AVNRT who are not candidates for, or </b></text>
<text top="768" left="184" width="191" height="14" font="1"><b>prefer not to undergo, catheter ablation.</b></text>
<text top="769" left="375" width="22" height="8" font="20"><b>107,114</b></text>
<text top="805" left="78" width="20" height="14" font="3">See </text>
<text top="805" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="820" left="78" width="62" height="14" font="21"><a href="">Supplement 9</a></text>
<text top="820" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="790" left="169" width="605" height="14" font="3">Unlike flecainide and propafenone, sotalol and dofetilide can be used in patients with structural heart disease or coronary artery disease.</text>
<text top="790" left="774" width="10" height="8" font="18">113</text>
<text top="790" left="784" width="3" height="14" font="3"> </text>
<text top="805" left="170" width="630" height="14" font="3">Given the potential for significant QT prolongation and torsades de pointes, inpatient monitoring with serial ECGs is generally performed when </text>
<text top="820" left="170" width="631" height="14" font="3">these agents are initiated. Generally, these agents are reserved for patients who are unresponsive to, or are not candidates for, beta blockers, </text>
<text top="835" left="170" width="214" height="14" font="3">diltiazem, flecainide, propafenone, or verapamil.</text>
<text top="863" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="863" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="856" left="170" width="625" height="14" font="1"><b>2.   Oral digoxin or amiodarone may be reasonable for ongoing treatment of AVNRT in patients who are not candidates for, or prefer </b></text>
<text top="871" left="184" width="159" height="14" font="1"><b>not to undergo, catheter ablation.</b></text>
<text top="871" left="344" width="18" height="8" font="20"><b>99,115</b></text>
<text top="915" left="78" width="20" height="14" font="3">See </text>
<text top="915" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="930" left="78" width="70" height="14" font="21"><a href="">Supplements 9 </a></text>
<text top="945" left="78" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="945" left="109" width="3" height="14" font="3">.</text>
<text top="892" left="169" width="605" height="14" font="3">One small study randomized patients with unspecified PSVT to digoxin (0.375 mg/day), propranolol (240 mg/day), or verapamil (480 mg/</text>
<text top="907" left="169" width="171" height="14" font="3">day), with 1 week of placebo washout.</text>
<text top="908" left="340" width="7" height="8" font="18">99</text>
<text top="907" left="347" width="438" height="14" font="3"> Episodes and duration of PSVT (ascertained by diary and weekly 24-h Holter) were largely similar, </text>
<text top="922" left="170" width="185" height="14" font="3">and all 3 medications were well tolerated.</text>
<text top="923" left="355" width="7" height="8" font="18">99</text>
<text top="922" left="362" width="439" height="14" font="3"> However, the dose of digoxin used was higher than that commonly used in clinical practice today. </text>
<text top="937" left="170" width="330" height="14" font="3">Amiodarone is effective in suppressing AVNRT during outpatient follow-up.</text>
<text top="938" left="500" width="10" height="8" font="18">115</text>
<text top="937" left="510" width="282" height="14" font="3"> Given the potential adverse effects of digoxin and amiodarone, </text>
<text top="952" left="169" width="601" height="14" font="3">these agents are generally reserved as third-line therapy for patients who are unresponsive to, or are not candidates for, beta blockers, </text>
<text top="967" left="169" width="214" height="14" font="3">diltiazem, verapamil, flecainide, or propafenone.</text>
<text top="996" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="996" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="988" left="169" width="635" height="14" font="1"><b>3.   Self-administered (“pill-in-the-pocket”) acute doses of oral beta blockers, diltiazem, or verapamil may be reasonable for ongoing </b></text>
<text top="1003" left="184" width="359" height="14" font="1"><b>management in patients with infrequent, well-tolerated episodes of AVNRT.</b></text>
<text top="1004" left="544" width="22" height="8" font="20"><b>241,242</b></text>
<text top="1040" left="78" width="20" height="14" font="3">See </text>
<text top="1040" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1055" left="78" width="62" height="14" font="21"><a href="">Supplement 9</a></text>
<text top="1055" left="140" width="3" height="14" font="3"><a href="">.</a></text>
<text top="1025" left="169" width="607" height="14" font="3">Two studies have demonstrated success with the combination of diltiazem and propranolol as a “pill-in-the-pocket” approach to acutely </text>
<text top="1040" left="169" width="611" height="14" font="3">terminate PSVT caused by AVNRT, but the overall safety of self-administration of these medications remains unclear because episodes of </text>
<text top="1055" left="169" width="106" height="14" font="3">syncope were observed.</text>
<text top="1056" left="276" width="22" height="8" font="18">241,242</text>
<text top="1055" left="297" width="498" height="14" font="3"> If oral therapy with empiric beta blockers, diltiazem, or verapamil fails to terminate the tachyarrhythmia, patients </text>
<text top="1070" left="170" width="135" height="14" font="3">should seek medical attention.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e534  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="525" left="71" width="349" height="14" font="1"><b>Figure 10.</b> Acute treatment of suspected focal atrial tachycardia. </text>
<text top="538" left="71" width="354" height="14" font="3">Colors correspond to Class of Recommendation in Table 1; drugs </text>
<text top="552" left="71" width="340" height="14" font="3">listed alphabetically. *For rhythms that break or recur spontane-</text>
<text top="565" left="71" width="350" height="14" font="3">ously, synchronized cardioversion is not appropriate. IV indicates </text>
<text top="579" left="71" width="66" height="14" font="3">intravenous.</text>
<text top="615" left="148" width="204" height="20" font="12"><b>6. Manifest and Concealed  </b></text>
<text top="634" left="172" width="149" height="20" font="12"><b>Accessory Pathways</b></text>
<text top="655" left="71" width="351" height="16" font="13">Accessory pathways can be manifest or concealed; can con-</text>
<text top="673" left="71" width="358" height="16" font="13">duct in the anterograde direction, retrograde direction, or </text>
<text top="691" left="71" width="351" height="16" font="13">both; and can be associated with several different supraven-</text>
<text top="709" left="71" width="356" height="16" font="13">tricular arrhythmias. Some anterograde pathways may place </text>
<text top="727" left="71" width="355" height="16" font="13">patients at risk of SCD. Typically, pathways directly connect </text>
<text top="744" left="71" width="357" height="16" font="13">the atrium and ventricle, bypassing the normal conduction </text>
<text top="762" left="71" width="355" height="16" font="13">through the AV node and His Purkinje system. The pathways </text>
<text top="780" left="71" width="357" height="16" font="13">are considered manifest if they conduct in the anterograde </text>
<text top="798" left="71" width="356" height="16" font="13">direction, demonstrating pre-excitation with a delta wave on </text>
<text top="816" left="71" width="356" height="16" font="13">the ECG. Manifest pathways occur in 0.1% to 0.3% of the </text>
<text top="834" left="71" width="351" height="16" font="13">population and may conduct in both the anterograde and ret-</text>
<text top="852" left="71" width="355" height="16" font="13">rograde directions or, less commonly, only in the anterograde </text>
<text top="869" left="71" width="54" height="16" font="13">direction.</text>
<text top="870" left="125" width="12" height="9" font="14">252</text>
<text top="869" left="137" width="284" height="16" font="13"> Concealed pathways conduct only in the retro-</text>
<text top="887" left="71" width="356" height="16" font="13">grade direction and therefore do not cause pre-excitation on </text>
<text top="905" left="71" width="151" height="16" font="13">the standard 12-lead ECG.</text>
<text top="923" left="92" width="339" height="16" font="13">The most common tachycardia associated with an </text>
<text top="941" left="71" width="354" height="16" font="13">accessory pathway is orthodromic AVRT, with a circuit that </text>
<text top="959" left="71" width="351" height="16" font="13">uses the AV node and His Purkinje system in the antero-</text>
<text top="977" left="71" width="351" height="16" font="13">grade direction, followed by conduction through the ventri-</text>
<text top="994" left="71" width="354" height="16" font="13">cle, retrograde conduction over the accessory pathway, and </text>
<text top="1012" left="71" width="355" height="16" font="13">completion of the circuit by conduction through the atrium </text>
<text top="1030" left="71" width="357" height="16" font="13">back into the AV node. Orthodromic AVRT accounts for </text>
<text top="1048" left="71" width="356" height="16" font="13">approximately 90% to 95% of AVRT episodes in patients </text>
<text top="1066" left="71" width="359" height="16" font="13">with a manifest accessory pathway. Pre-excited AVRT, </text>
<text top="1084" left="71" width="355" height="16" font="13">including antidromic AVRT, accounts for 5% of the AVRT </text>
<text top="97" left="458" width="355" height="16" font="13">episodes in patients with a manifest pathway and involves </text>
<text top="115" left="458" width="351" height="16" font="13">conduction from the atrium to the ventricle via the acces-</text>
<text top="132" left="458" width="357" height="16" font="13">sory pathway, causing a pre-excited QRS complex. This </text>
<text top="149" left="458" width="358" height="16" font="13">is called antidromic AVRT tachycardia when the return </text>
<text top="167" left="458" width="355" height="16" font="13">reentrant conduction occurs retrogradely via the AV node. </text>
<text top="184" left="458" width="356" height="16" font="13">In rare cases of pre-excited AVRT, the return conduction </text>
<text top="201" left="458" width="356" height="16" font="13">occurs via a second accessory AV pathway. AF can occur </text>
<text top="218" left="458" width="356" height="16" font="13">in patients with accessory pathways, which may result in </text>
<text top="236" left="458" width="354" height="16" font="13">extremely rapid conduction to the ventricle over a manifest </text>
<text top="253" left="458" width="356" height="16" font="13">pathway, which increases the risk of inducing ventricular </text>
<text top="270" left="458" width="357" height="16" font="13">fibrillation and SCD. Other SVTs, such as AVNRT, AT, </text>
<text top="288" left="458" width="355" height="16" font="13">and atrial flutter, can also conduct rapidly over a manifest </text>
<text top="305" left="458" width="351" height="16" font="13">accessory pathway; in these instances, the pathway is con-</text>
<text top="322" left="458" width="351" height="16" font="13">sidered a “bystander” because it is not part of the tachy-</text>
<text top="340" left="458" width="356" height="16" font="13">cardia circuit. Most accessory pathways have conduction </text>
<text top="357" left="458" width="351" height="16" font="13">properties similar to the myocardium and do not demon-</text>
<text top="374" left="458" width="358" height="16" font="13">strate decremental conduction. A unique form of AVRT </text>
<text top="391" left="458" width="357" height="16" font="13">involves a concealed accessory pathway, usually located </text>
<text top="409" left="458" width="357" height="16" font="13">in the posteroseptal region, with retrograde decremental </text>
<text top="426" left="458" width="356" height="16" font="13">conduction properties resulting in a form of orthodromic </text>
<text top="443" left="458" width="357" height="16" font="13">reentrant tachycardia termed PJRT. This tachycardia has </text>
<text top="461" left="458" width="354" height="16" font="13">deeply inverted retrograde P waves in leads II, III, and aVF, </text>
<text top="478" left="458" width="354" height="16" font="13">with a long RP interval due to the location and decremental </text>
<text top="495" left="458" width="354" height="16" font="13">conduction properties of the accessory pathway (Figure 6). </text>
<text top="513" left="458" width="351" height="16" font="13">The incessant nature of PJRT may result in tachycardia-</text>
<text top="530" left="458" width="351" height="16" font="13">induced cardiomyopathy that usually resolves after suc-</text>
<text top="547" left="458" width="357" height="16" font="13">cessful treatment. Another unusual accessory pathway is </text>
<text top="564" left="458" width="356" height="16" font="13">the atriofascicular fiber (also called a Mahaim fiber) that </text>
<text top="582" left="458" width="356" height="16" font="13">connects the right atrium to a fascicle of the distal right </text>
<text top="599" left="458" width="354" height="16" font="13">bundle branch and has decremental anterograde conduction </text>
<text top="616" left="458" width="355" height="16" font="13">while not allowing conduction in the retrograde direction; </text>
<text top="634" left="458" width="351" height="16" font="13">this pathway can allow reentrant tachycardia with a cir-</text>
<text top="651" left="458" width="351" height="16" font="13">cuit that involves anterograde conduction over the acces-</text>
<text top="668" left="458" width="356" height="16" font="13">sory pathway with characteristic left bundle-branch block </text>
<text top="686" left="458" width="358" height="16" font="13">morphology and retrograde conduction through the AV </text>
<text top="703" left="458" width="357" height="16" font="13">node/His Purkinje system. Other rare accessory pathway </text>
<text top="720" left="458" width="357" height="16" font="13">connections that may participate in reentrant tachycardia </text>
<text top="737" left="458" width="355" height="16" font="13">are nodofascicular pathways (connecting the AV node to a </text>
<text top="755" left="458" width="354" height="16" font="13">fascicle) and nodoventricular pathways (connecting the AV </text>
<text top="772" left="458" width="355" height="16" font="13">node to the ventricular myocardium). Fasciculoventricular </text>
<text top="789" left="458" width="357" height="16" font="13">pathways, connecting a fascicle to the proximal right or </text>
<text top="807" left="458" width="354" height="16" font="13">left bundle branch, have also been described, although they </text>
<text top="824" left="458" width="355" height="16" font="13">have never been reported to participate in tachycardia. An </text>
<text top="841" left="458" width="356" height="16" font="13">EP study is necessary to establish the diagnosis of these </text>
<text top="859" left="458" width="148" height="16" font="13">rare accessory pathways.</text>
<text top="876" left="479" width="338" height="16" font="13">The diagnosis of WPW syndrome is reserved for </text>
<text top="893" left="458" width="365" height="16" font="13">patients who demonstrate ventricular pre-excitation </text>
<text top="910" left="458" width="359" height="16" font="13">on their resting ECG that participates in arrhythmias. </text>
<text top="928" left="458" width="356" height="16" font="13">Rapid anterograde accessory pathway conduction during </text>
<text top="945" left="458" width="351" height="16" font="13">AF can result in SCD in patients with a manifest acces-</text>
<text top="962" left="458" width="358" height="16" font="13">sory pathway, with a 10-year risk ranging from 0.15% </text>
<text top="980" left="458" width="60" height="16" font="13">to 0.24%.</text>
<text top="980" left="517" width="28" height="9" font="14">253,254</text>
<text top="980" left="546" width="263" height="16" font="13"> Unfortunately, SCD may be the first pre-</text>
<text top="997" left="458" width="357" height="16" font="13">sentation of patients with undiagnosed WPW. Increased </text>
<text top="1014" left="458" width="356" height="16" font="13">risk of SCD is associated with a history of symptomatic </text>
<text top="1032" left="458" width="356" height="16" font="13">tachycardia, multiple accessory pathways, and a shortest </text>
<text top="1049" left="458" width="356" height="16" font="13">pre-excited R-R interval of &lt;250 ms during AF. The risk </text>
<text top="1066" left="458" width="355" height="16" font="13">of SCD associated with WPW appears highest in the first </text>
<text top="1084" left="458" width="109" height="16" font="13">2 decades of life.</text>
<text top="1084" left="567" width="30" height="9" font="14">254–258</text>
<text top="1084" left="597" width="217" height="16" font="13"> Antiarrhythmic drug treatment of </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e535</i></b></text>
<text top="97" left="69" width="355" height="16" font="13">patients with orthodromic AVRT can be directed at either </text>
<text top="115" left="69" width="357" height="16" font="13">the accessory pathway or the AV node, as both are key </text>
<text top="132" left="69" width="354" height="16" font="13">portions of the reentrant circuit. AV nodal–blocking agents </text>
<text top="149" left="69" width="351" height="16" font="13">may be contraindicated in patients at risk of rapid con-</text>
<text top="166" left="69" width="356" height="16" font="13">duction down the accessory pathway during AF. Catheter </text>
<text top="184" left="69" width="354" height="16" font="13">ablation strategies target the accessory pathway, with high </text>
<text top="201" left="69" width="81" height="16" font="13">success rates.</text>
<text top="97" left="456" width="325" height="18" font="10"><b>6.1. Management of Patients With Symptomatic </b></text>
<text top="115" left="456" width="291" height="18" font="10"><b>Manifest or Concealed Accessory Pathways</b></text>
<text top="135" left="456" width="351" height="16" font="13">See Figure 14 for the algorithm for acute treatment of ortho-</text>
<text top="154" left="456" width="357" height="16" font="13">dromic AVRT and Figure 15 for the algorithm for ongoing </text>
<text top="172" left="456" width="204" height="16" font="13">management of orthodromic AVRT.</text>
<text top="201" left="456" width="250" height="16" font="0"><i><b>6.1.1. Acute Treatment: Recommendations</b></i></text>
<text top="254" left="78" width="339" height="16" font="19"><b>Recommendations for Acute Treatment of Orthodromic AVRT</b></text>
<text top="278" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="278" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="278" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="299" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="299" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="299" left="169" width="443" height="14" font="1"><b>1.   Vagal maneuvers are recommended for acute treatment in patients with orthodromic AVRT.</b></text>
<text top="300" left="612" width="37" height="8" font="20"><b>42,75,235,259</b></text>
<text top="374" left="78" width="20" height="14" font="3">See </text>
<text top="374" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="389" left="78" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="404" left="78" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="404" left="109" width="3" height="14" font="3">.</text>
<text top="321" left="169" width="619" height="14" font="3">For acute conversion of orthodromic AVRT, vagal maneuvers, including Valsalva and carotid sinus massage, can be performed quickly </text>
<text top="336" left="169" width="629" height="14" font="3">and should be the first-line intervention to terminate SVT. These maneuvers should be performed with the patient in the supine position. </text>
<text top="351" left="169" width="590" height="14" font="3">There is no “gold standard” for proper Valsalva maneuver technique, but in general, the patient raises intrathoracic pressure by </text>
<text top="366" left="169" width="452" height="14" font="3">bearing down against a closed glottis for 10 to 30 seconds, equivalent to at least 30 to 40 mm Hg.</text>
<text top="367" left="621" width="16" height="8" font="18">82,84</text>
<text top="366" left="637" width="144" height="14" font="3"> Carotid massage is performed </text>
<text top="381" left="170" width="612" height="14" font="3">after absence of bruit has been confirmed by auscultation, by applying steady pressure over the right or left carotid sinus for 5 to 10 </text>
<text top="396" left="170" width="41" height="14" font="3">seconds.</text>
<text top="397" left="210" width="16" height="8" font="18">83,84</text>
<text top="396" left="226" width="523" height="14" font="3"> Another vagal maneuver based on the classic diving reflex consists of applying an ice-cold, wet towel to the face</text>
<text top="397" left="749" width="7" height="8" font="18">85</text>
<text top="396" left="756" width="17" height="14" font="3">; in </text>
<text top="411" left="170" width="543" height="14" font="3">a laboratory setting, facial immersion in water at 10°C (50°F) has proved effective in terminating tachycardia, as well.</text>
<text top="412" left="712" width="7" height="8" font="18">86</text>
<text top="411" left="719" width="52" height="14" font="3"> One study </text>
<text top="426" left="170" width="609" height="14" font="3">involving 148 patients with SVT demonstrated that Valsalva was more successful than carotid sinus massage, and switching from 1 </text>
<text top="441" left="170" width="310" height="14" font="3">technique to the other resulted in an overall success rate of 27.7%.</text>
<text top="442" left="480" width="7" height="8" font="18">82</text>
<text top="441" left="487" width="286" height="14" font="3"> The practice of applying pressure to the eyeball is potentially </text>
<text top="456" left="169" width="170" height="14" font="3">dangerous and has been abandoned.</text>
<text top="477" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="477" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="477" left="169" width="389" height="14" font="1"><b>2.   Adenosine is beneficial for acute treatment in patients with orthodromic AVRT.</b></text>
<text top="478" left="559" width="30" height="8" font="20"><b>42,260,261</b></text>
<text top="514" left="78" width="20" height="14" font="3">See </text>
<text top="514" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="529" left="78" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="544" left="78" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="544" left="109" width="3" height="14" font="3">.</text>
<text top="499" left="169" width="638" height="14" font="3">Adenosine is effective for conversion of orthodromic AVRT in 90% to 95% of patients, with minor and brief (&lt;1 min) side effects occurring </text>
<text top="514" left="169" width="155" height="14" font="3">in approximately 30% of patients.</text>
<text top="515" left="325" width="31" height="8" font="18">42,260,261</text>
<text top="514" left="356" width="448" height="14" font="3"> Patients often have atrial or ventricular premature complexes immediately after conversion that, </text>
<text top="529" left="169" width="629" height="14" font="3">on occasion, may induce further episodes of AVRT. In this situation, an antiarrhythmic drug may be required to prevent acute reinitiation </text>
<text top="544" left="169" width="591" height="14" font="3">of tachycardia. Because adenosine may precipitate AF that may then conduct rapidly to the ventricle and even cause ventricular </text>
<text top="559" left="169" width="253" height="14" font="3">fibrillation, electrical cardioversion should be available.</text>
<text top="587" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="587" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="579" left="169" width="598" height="14" font="1"><b>3.   Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with AVRT if vagal </b></text>
<text top="594" left="184" width="252" height="14" font="1"><b>maneuvers or adenosine are ineffective or not feasible.</b></text>
<text top="595" left="436" width="29" height="8" font="20"><b>75,262,263</b></text>
<text top="630" left="78" width="20" height="14" font="3">See </text>
<text top="630" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="645" left="78" width="68" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="645" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="615" left="169" width="295" height="14" font="3">Synchronized cardioversion is highly effective in terminating AVRT.</text>
<text top="616" left="465" width="7" height="8" font="18">75</text>
<text top="615" left="472" width="301" height="14" font="3"> Cardioversion avoids complications associated with antiarrhythmic </text>
<text top="630" left="170" width="588" height="14" font="3">drug therapy and should be considered early in the management of hemodynamically unstable patients. Patients often have atrial or </text>
<text top="645" left="170" width="629" height="14" font="3">ventricular premature complexes immediately after cardioversion that, on occasion, may induce further episodes of AVRT. In this situation, an </text>
<text top="660" left="170" width="355" height="14" font="3">antiarrhythmic drug may be required to prevent acute reinitiation of tachycardia.</text>
<text top="688" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="688" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="680" left="170" width="580" height="14" font="1"><b>4.   Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVRT when </b></text>
<text top="695" left="184" width="276" height="14" font="1"><b>pharmacological therapy is ineffective or contraindicated.</b></text>
<text top="696" left="460" width="15" height="8" font="20"><b>87,95</b></text>
<text top="724" left="78" width="20" height="14" font="3">See </text>
<text top="724" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="739" left="78" width="70" height="14" font="21"><a href="">Supplements 3 </a></text>
<text top="754" left="78" width="31" height="14" font="21"><a href="">and 10</a></text>
<text top="754" left="109" width="3" height="14" font="3">.</text>
<text top="716" left="169" width="611" height="14" font="3">Synchronized cardioversion is highly effective in terminating SVT (including AVRT and AVNRT), and when the patient is stable, this is performed </text>
<text top="731" left="169" width="163" height="14" font="3">after adequate sedation or anesthesia.</text>
<text top="732" left="333" width="7" height="8" font="18">94</text>
<text top="731" left="339" width="454" height="14" font="3"> Most stable patients with SVT respond to pharmacological therapy, with success rates of 80% to 98% for </text>
<text top="746" left="169" width="616" height="14" font="3">agents such as verapamil, diltiazem, or adenosine. In some resistant cases, a second drug bolus or higher dose of initial drug agent might prove </text>
<text top="761" left="169" width="39" height="14" font="3">effective.</text>
<text top="762" left="208" width="15" height="8" font="18">87,96</text>
<text top="761" left="223" width="359" height="14" font="3"> Nevertheless, in rare instances, drugs may fail to successfully restore sinus rhythm.</text>
<text top="781" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="781" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="781" left="170" width="616" height="14" font="1"><b>5.  Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with pre-excited AF.</b></text>
<text top="782" left="785" width="15" height="8" font="20"><b>75,94</b></text>
<text top="825" left="78" width="20" height="14" font="3">See </text>
<text top="825" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="840" left="78" width="68" height="14" font="21"><a href="">Supplement 10</a></text>
<text top="840" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="803" left="169" width="337" height="14" font="3">Synchronized cardioversion is highly effective in terminating pre-excited AF.</text>
<text top="803" left="506" width="7" height="8" font="18">75</text>
<text top="803" left="513" width="285" height="14" font="3"> When AF occurs in patients with ventricular pre-excitation, if the </text>
<text top="818" left="170" width="625" height="14" font="3">accessory pathway has a short refractory period, this may allow for rapid pre-excited AV conduction; the resulting fast, often irregular, broad-</text>
<text top="833" left="170" width="611" height="14" font="3">complex tachycardia is often unstable and may lead to ventricular fibrillation. It is therefore important to achieve early restoration of sinus </text>
<text top="848" left="170" width="633" height="14" font="3">rhythm in these patients. Patients often have atrial or ventricular premature complexes immediately after cardioversion that, on occasion, may </text>
<text top="863" left="170" width="181" height="14" font="3">induce AVRT or recurrent pre-excited AF.</text>
<text top="890" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="890" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="883" left="170" width="53" height="14" font="1"><b>6.   Ibutilide</b></text>
<text top="883" left="223" width="10" height="8" font="20"><b>264</b></text>
<text top="883" left="233" width="140" height="14" font="1"><b> or intravenous procainamide</b></text>
<text top="883" left="373" width="10" height="8" font="20"><b>265</b></text>
<text top="883" left="383" width="349" height="14" font="1"><b> is beneficial for acute treatment in patients with pre-excited AF who are </b></text>
<text top="898" left="184" width="118" height="14" font="1"><b>hemodynamically stable.</b></text>
<text top="919" left="78" width="20" height="14" font="3">See </text>
<text top="919" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="934" left="78" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="949" left="78" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="949" left="109" width="3" height="14" font="3">.</text>
<text top="919" left="169" width="636" height="14" font="3">Small observational studies support the use of ibutilide or intravenous procainamide for the treatment of pre-excited AF in patients who are not </text>
<text top="934" left="169" width="144" height="14" font="3">hemodynamically compromised.</text>
<text top="934" left="313" width="22" height="8" font="18">264,265</text>
<text top="934" left="335" width="462" height="14" font="3"> Both medications can decrease ventricular rate by slowing conduction over the accessory pathway and </text>
<text top="949" left="169" width="238" height="14" font="3">have the additional benefit of possibly terminating AF.</text>
<text top="949" left="408" width="22" height="8" font="18">264,265</text>
<text top="999" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="979" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="984" left="169" width="177" height="14" font="1"><b>1.   Intravenous diltiazem, verapamil</b></text>
<text top="985" left="346" width="43" height="8" font="20"><b>42,260,266,267</b></text>
<text top="984" left="390" width="209" height="14" font="1"><b> (<i>Level of Evidence: B-R </i></b><b>), or beta blockers</b></text>
<text top="985" left="599" width="10" height="8" font="20"><b>268</b></text>
<text top="984" left="609" width="165" height="14" font="1"><b> (<i>Level of Evidence: C-LD</i></b><b>) can be </b></text>
<text top="999" left="185" width="610" height="14" font="1"><b>effective for acute treatment in patients with orthodromic AVRT who do not have pre-excitation on their resting ECG during </b></text>
<text top="1014" left="185" width="67" height="14" font="1"><b>sinus rhythm.</b></text>
<text top="1019" left="123" width="26" height="14" font="1"><b> C-LD</b></text>
<text top="1059" left="78" width="20" height="14" font="3">See </text>
<text top="1059" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1074" left="78" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="1089" left="78" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="1089" left="109" width="3" height="14" font="3">.</text>
<text top="1051" left="169" width="634" height="14" font="3">Intravenous diltiazem or verapamil effectively terminate approximately 90% to 95% of AVRT episodes in patients without pre-excitation  </text>
<text top="1066" left="169" width="510" height="14" font="3">on their resting sinus-rhythm ECG, with drug-induced hypotension occurring in approximately 3% of patients.</text>
<text top="1067" left="680" width="44" height="8" font="18">42,260,266,267</text>
<text top="1066" left="723" width="60" height="14" font="3"> Intravenous </text>
<text top="1081" left="170" width="636" height="14" font="3">beta blockers have not been studied in clinical trials; however, clinical experience suggests they are useful for terminating AVRT, with a </text>
<text top="1096" left="170" width="172" height="14" font="3">low risk of associated complications.</text>
<text top="1097" left="342" width="10" height="8" font="18">268</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e536  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="477" left="71" width="285" height="16" font="0"><i><b>6.1.2. Ongoing Management: Recommendations</b></i></text>
<text top="158" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="158" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="150" left="171" width="619" height="14" font="1"><b>1.   Intravenous beta blockers, diltiazem, or verapamil might be considered for acute treatment in patients with orthodromic </b></text>
<text top="165" left="186" width="471" height="14" font="1"><b>AVRT who have pre-excitation on their resting ECG and have not responded to other therapies.</b></text>
<text top="166" left="658" width="44" height="8" font="20"><b>42,266,267,269</b></text>
<text top="225" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="225" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="240" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="255" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="255" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="188" left="171" width="602" height="14" font="3">Intravenous beta blockers, diltiazem, and verapamil have a risk of enhancing conduction over the accessory pathway if the AVRT </text>
<text top="203" left="171" width="609" height="14" font="3">converts to AF during administration of the medication. Should the patient have a rapidly conducting manifest accessory pathway, </text>
<text top="218" left="171" width="591" height="14" font="3">further enhancing accessory-pathway conduction during AF by shortening the refractory period (digoxin) or decreasing BP and </text>
<text top="233" left="171" width="605" height="14" font="3">increasing catecholamines (diltiazem, beta blockers, verapamil) may place the patient at risk of AF degenerating into a malignant </text>
<text top="248" left="171" width="604" height="14" font="3">ventricular arrhythmia. The ability to promptly perform electrical cardioversion must be available should AF with rapid ventricular </text>
<text top="263" left="171" width="629" height="14" font="3">conduction occur. Before intravenous beta blockers, diltiazem, and verapamil were available, intravenous digoxin was commonly used </text>
<text top="278" left="171" width="458" height="14" font="3">for acute treatment of patients with orthodromic AVRT who had pre-excitation on their resting ECG</text>
<text top="279" left="630" width="10" height="8" font="18">270</text>
<text top="278" left="640" width="144" height="14" font="3">; this agent is rarely used now </text>
<text top="293" left="171" width="450" height="14" font="3">because other agents are available and digoxin may put patients at risk of ventricular fibrillation.</text>
<text top="294" left="622" width="10" height="8" font="18">271</text>
<text top="315" left="86" width="18" height="14" font="1"><b>III:  </b></text>
<text top="330" left="80" width="26" height="14" font="1"><b>Harm</b></text>
<text top="322" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="315" left="171" width="613" height="14" font="1"><b>1.   Intravenous digoxin, intravenous amiodarone, intravenous or oral beta blockers, diltiazem, and verapamil are potentially </b></text>
<text top="330" left="186" width="295" height="14" font="1"><b>harmful for acute treatment in patients with pre-excited AF.</b></text>
<text top="330" left="482" width="36" height="8" font="20"><b>269,271–275</b></text>
<text top="375" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="375" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="390" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="405" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="405" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="352" left="171" width="622" height="14" font="3">Patients with pre-excited AF should not receive intravenous digoxin, intravenous amiodarone, or intravenous/oral beta blockers, diltiazem, </text>
<text top="367" left="171" width="623" height="14" font="3">or verapamil because these medications may enhance conduction over the accessory pathway, increase the ventricular rate, and increase </text>
<text top="382" left="171" width="277" height="14" font="3">the risk of provoking a life-threatening ventricular arrhythmia.</text>
<text top="383" left="448" width="36" height="8" font="18">269,271–275</text>
<text top="382" left="484" width="313" height="14" font="3"> Digoxin increases the ventricular rate by shortening refractoriness of </text>
<text top="397" left="171" width="625" height="14" font="3">the accessory pathway, whereas amiodarone, beta blockers, diltiazem, and verapamil may increase the ventricular rate as a result of drug-</text>
<text top="412" left="171" width="635" height="14" font="3">induced hypotension with increased catecholamines. In addition, these medications may enhance conduction over the accessory pathway by </text>
<text top="427" left="171" width="621" height="14" font="3">slowing or blocking conduction through the AV node, preventing competitive concealed retrograde conduction into the accessory pathway.</text>
<text top="104" left="80" width="407" height="16" font="19"><b>Recommendations for Acute Treatment of Orthodromic AVRT (Continued)</b></text>
<text top="128" left="82" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="525" left="80" width="345" height="16" font="19"><b>Recommendations for Ongoing Management of Orthodromic AVRT</b></text>
<text top="549" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="549" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="549" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="571" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="571" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="571" left="171" width="519" height="14" font="1"><b>1.   Catheter ablation of the accessory pathway is recommended in patients with AVRT and/or pre-excited AF.</b></text>
<text top="572" left="690" width="47" height="8" font="20"><b>103,254,276–282</b></text>
<text top="617" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="617" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="632" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="647" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="647" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="594" left="171" width="604" height="14" font="3">Several large series support the use of catheter ablation of the accessory pathway as first-line therapy in patients who have had AF and/or </text>
<text top="609" left="171" width="616" height="14" font="3">AVRT. These series report a success rate of approximately 93% to 95% and a 3% risk of major complications when patients are followed up </text>
<text top="624" left="171" width="102" height="14" font="3">for 6 months to 8 years</text>
<text top="625" left="273" width="58" height="8" font="18">102,103,254,276–282</text>
<text top="624" left="331" width="464" height="14" font="3"> (Table 8). AF in younger patients is usually associated with the accessory pathway and is unlikely to occur </text>
<text top="639" left="171" width="511" height="14" font="3">after ablation; in contrast, older patients may have recurrence of AF from causes unrelated to the accessory pathway.</text>
<text top="640" left="682" width="22" height="8" font="18">283,284</text>
<text top="639" left="704" width="90" height="14" font="3"> Catheter ablation is </text>
<text top="654" left="171" width="566" height="14" font="3">also effective for treating PJRT (Table 3) by ablating the concealed accessory pathway with a success rate of approximately 90%.</text>
<text top="655" left="737" width="22" height="8" font="18">283,284</text>
<text top="654" left="758" width="42" height="14" font="3"> Catheter </text>
<text top="669" left="171" width="607" height="14" font="3">ablation of an atriofascicular (Mahaim) pathway is successful in preventing reentrant tachycardia in approximately 70% to 100% of patients.</text>
<text top="670" left="778" width="22" height="8" font="18">285,286</text>
<text top="699" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="699" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="691" left="171" width="588" height="14" font="1"><b>2.   Oral beta blockers, diltiazem, or verapamil are indicated for ongoing management of AVRT in patients without pre-</b></text>
<text top="706" left="187" width="155" height="14" font="1"><b>excitation on their resting ECG.</b></text>
<text top="707" left="342" width="19" height="8" font="20"><b>46,287</b></text>
<text top="729" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="729" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="744" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="759" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="759" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="729" left="171" width="626" height="14" font="3">Observational studies and clinical experience confirm that beta blockers, diltiazem, and verapamil are effective for preventing recurrent </text>
<text top="744" left="171" width="595" height="14" font="3">tachycardia in approximately 50% of patients without pre-excitation on their resting ECG (concealed accessory pathway) and are </text>
<text top="759" left="171" width="212" height="14" font="3">associated with a favorable side effect profile.</text>
<text top="760" left="383" width="19" height="8" font="18">46,287</text>
<text top="796" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="796" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="781" left="171" width="594" height="14" font="1"><b>1.   Oral flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or </b></text>
<text top="796" left="186" width="612" height="14" font="1"><b>ischemic heart disease who have AVRT and/or pre-excited AF and are not candidates for, or prefer not to undergo, catheter </b></text>
<text top="811" left="186" width="43" height="14" font="1"><b>ablation.</b></text>
<text top="812" left="229" width="56" height="8" font="20"><b>45,108,109,112,288</b></text>
<text top="849" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="849" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="864" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="879" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="879" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="834" left="171" width="615" height="14" font="3">Flecainide and propafenone are beneficial for the treatment of AVRT by directly slowing or blocking conduction over the pathway. These drugs are </text>
<text top="849" left="171" width="406" height="14" font="3">effective in approximately 85% to 90% of patients, with 30% reporting an absence of tachycardia.</text>
<text top="850" left="577" width="51" height="8" font="18">45,108,109,112,288</text>
<text top="849" left="628" width="170" height="14" font="3"> Both drugs have a risk of proarrhythmia </text>
<text top="864" left="171" width="626" height="14" font="3">resulting in VT that is increased in patients with structural heart disease or ischemic heart disease; in such patients, these drugs are generally avoided. </text>
<text top="879" left="171" width="523" height="14" font="3">Side effects occur in up to 60% of patients, and approximately 20% discontinue the medications because of adverse effects.</text>
<text top="880" left="694" width="51" height="8" font="18">45,108,109,112,288</text>
<text top="924" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="924" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="916" left="171" width="630" height="14" font="1"><b>1.   Oral dofetilide or sotalol may be reasonable for ongoing management in patients with AVRT and/or pre-excited AF who are </b></text>
<text top="931" left="187" width="311" height="14" font="1"><b>not candidates for, or prefer not to undergo, catheter ablation.</b></text>
<text top="932" left="498" width="19" height="8" font="20"><b>99,106</b></text>
<text top="962" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="962" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="977" left="80" width="62" height="14" font="21"><a href="">Supplement 9</a></text>
<text top="977" left="141" width="3" height="14" font="3">.</text>
<text top="954" left="171" width="605" height="14" font="3">Unlike flecainide and propafenone, sotalol and dofetilide can be used in patients with structural heart disease or coronary artery disease.</text>
<text top="955" left="776" width="10" height="8" font="18">105</text>
<text top="954" left="786" width="3" height="14" font="3"> </text>
<text top="969" left="171" width="630" height="14" font="3">Given the potential for significant QT prolongation and torsades de pointes, inpatient monitoring with serial ECGs is generally performed when </text>
<text top="984" left="171" width="115" height="14" font="3">these agents are initiated.</text>
<text top="1022" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="1022" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1007" left="171" width="449" height="14" font="1"><b>2.   Oral amiodarone may be considered for ongoing management in patients with AVRT and/or  </b></text>
<text top="1022" left="185" width="595" height="14" font="1"><b>pre-excited AF who are not candidates for, or prefer not to undergo, catheter ablation and in whom beta blockers, diltiazem, </b></text>
<text top="1037" left="185" width="350" height="14" font="1"><b>flecainide, propafenone, and verapamil are ineffective or contraindicated.</b></text>
<text top="1037" left="536" width="22" height="8" font="20"><b>289,290</b></text>
<text top="1059" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1059" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1074" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="1089" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="1089" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="1059" left="171" width="602" height="14" font="3">Small observational studies support the use of amiodarone for preventing recurrent AVRT, but long-term efficacy has not been reported.</text>
<text top="1060" left="773" width="22" height="8" font="18">289,290</text>
<text top="1059" left="795" width="3" height="14" font="3"> </text>
<text top="1074" left="171" width="589" height="14" font="3">Because of the important toxicity associated with long-term use of amiodarone, the drug is usually reserved for patients who are not </text>
<text top="1089" left="171" width="543" height="14" font="3">candidates for catheter ablation and who have failed to respond to or have contraindications to other antiarrhythmic drugs.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e537</i></b></text>
<text top="480" left="69" width="336" height="18" font="10"><b>6.2. Management of Asymptomatic Pre-Excitation</b></text>
<text top="507" left="69" width="196" height="16" font="0"><i><b>6.2.1. PICOTS Critical Questions</b></i></text>
<text top="525" left="69" width="359" height="16" font="13">See the ERC systematic review report, “Risk Stratification </text>
<text top="542" left="69" width="351" height="16" font="13">for Arrhythmic Events in Patients With Asymptomatic Pre-</text>
<text top="559" left="69" width="351" height="16" font="13">Excitation” for the complete evidence review on the manage-</text>
<text top="576" left="69" width="217" height="16" font="13">ment of asymptomatic pre-excitation,</text>
<text top="577" left="285" width="4" height="9" font="14">9</text>
<text top="576" left="289" width="60" height="16" font="13"><a href=""> and see </a></text>
<text top="576" left="349" width="79" height="16" font="15"><a href="">Online Data </a></text>
<text top="594" left="69" width="151" height="16" font="15"><a href="">Supplements 13, 14, and 15</a></text>
<text top="594" left="220" width="203" height="16" font="13"> for additional data on asymptomatic </text>
<text top="611" left="69" width="356" height="16" font="13">pre-excitation, which were reproduced directly from the ERC’s </text>
<text top="628" left="69" width="354" height="16" font="13">systematic review. These recommendations have been designated </text>
<text top="645" left="69" width="355" height="16" font="13">with the notation SR to emphasize the rigor of support from the </text>
<text top="663" left="69" width="356" height="16" font="13">ERC’s systematic review. PICOTS Question 1 did not provide </text>
<text top="680" left="69" width="351" height="16" font="13">adequate data for a recommendation; the other 3 PICOTS ques-</text>
<text top="697" left="69" width="329" height="16" font="13">tions are addressed in the recommendations in Section 6.2.2.</text>
<text top="714" left="90" width="334" height="16" font="13">As noted in Section 1.1, the recommendations in Section </text>
<text top="732" left="69" width="354" height="16" font="13">6.3 are based on a separately commissioned systematic review </text>
<text top="749" left="69" width="356" height="16" font="13">of the available evidence, the results of which were used to </text>
<text top="766" left="69" width="356" height="16" font="13">frame our decision making. Full details are provided in the </text>
<text top="784" left="69" width="188" height="16" font="13">ERC’s systematic review report.</text>
<text top="784" left="257" width="4" height="9" font="14">9</text>
<text top="783" left="262" width="164" height="16" font="13"> The following 4 questions </text>
<text top="801" left="69" width="167" height="16" font="13">were considered by the ERC:</text>
<text top="481" left="470" width="337" height="16" font="13">1.  What is the comparative predictive accuracy of inva-</text>
<text top="498" left="488" width="319" height="16" font="13">sive EP study (without catheter ablation of the acces-</text>
<text top="514" left="488" width="323" height="16" font="13">sory pathway) versus noninvasive testing for predicting </text>
<text top="531" left="488" width="327" height="16" font="13">arrhythmic events (including SCD) in patients with </text>
<text top="548" left="488" width="169" height="16" font="13">asymptomatic pre-excitation?</text>
<text top="565" left="470" width="343" height="16" font="13">2.  What is the usefulness of invasive EP study (without </text>
<text top="582" left="488" width="324" height="16" font="13">catheter ablation of the accessory pathway) versus no </text>
<text top="599" left="488" width="322" height="16" font="13">testing for predicting arrhythmic events (including SCD) </text>
<text top="616" left="488" width="260" height="16" font="13">in patients with asymptomatic pre-excitation?</text>
<text top="633" left="470" width="343" height="16" font="13">3.  What is the usefulness of invasive EP study (without </text>
<text top="649" left="488" width="319" height="16" font="13">catheter ablation of the accessory pathway) or noninva-</text>
<text top="666" left="488" width="319" height="16" font="13">sive EP study for predicting arrhythmic events (includ-</text>
<text top="683" left="488" width="318" height="16" font="13">ing SCD) in patients with asymptomatic pre-excitation?</text>
<text top="700" left="470" width="342" height="16" font="13">4.  What are the efficacy and effectiveness of invasive EP </text>
<text top="717" left="488" width="324" height="16" font="13">study with catheter ablation of the accessory pathway </text>
<text top="734" left="488" width="324" height="16" font="13">as appropriate versus noninvasive tests with treatment </text>
<text top="751" left="488" width="319" height="16" font="13">(including observation) or no testing/ablation as appro-</text>
<text top="768" left="488" width="322" height="16" font="13">priate for preventing arrhythmic events (including SCD) </text>
<text top="784" left="488" width="323" height="16" font="13">and improving outcomes in patients with asymptomatic </text>
<text top="801" left="488" width="85" height="16" font="13">pre-excitation?</text>
<text top="943" left="535" width="255" height="14" font="1"><b>Figure 11.</b> Ongoing management of focal atrial </text>
<text top="956" left="535" width="233" height="14" font="3">tachycardia. Colors correspond to Class of </text>
<text top="970" left="535" width="256" height="14" font="3">Recommendation in Table 1; drugs listed alpha-</text>
<text top="983" left="535" width="269" height="14" font="3">betically. Pt indicates patient; and SHD, structural </text>
<text top="997" left="535" width="259" height="14" font="3">heart disease (including ischemic heart disease).</text>
<text top="158" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="158" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="150" left="170" width="603" height="14" font="1"><b>3.   Oral beta blockers, diltiazem, or verapamil may be reasonable for ongoing management of orthodromic AVRT in patients with pre-</b></text>
<text top="165" left="184" width="460" height="14" font="1"><b>excitation on their resting ECG who are not candidates for, or prefer not to undergo, catheter ablation.</b></text>
<text top="166" left="643" width="18" height="8" font="20"><b>46,287</b></text>
<text top="217" left="78" width="20" height="14" font="3">See </text>
<text top="217" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="232" left="78" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="247" left="78" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="247" left="109" width="3" height="14" font="3">.</text>
<text top="187" left="170" width="604" height="14" font="3">One RCT supports the use of verapamil for prevention of orthodromic AVRT in patients with pre-excitation on their resting ECG (manifest </text>
<text top="202" left="170" width="91" height="14" font="3">accessory pathway).</text>
<text top="203" left="260" width="7" height="8" font="18">46</text>
<text top="202" left="267" width="511" height="14" font="3"> There are no RCTs supporting the use of oral beta blockers or diltiazem for prevention of recurrent AVRT, although </text>
<text top="217" left="170" width="387" height="14" font="3">clinical experience suggests the drugs are effective, with a favorable side effect profile.</text>
<text top="218" left="556" width="10" height="8" font="18">287</text>
<text top="217" left="566" width="232" height="14" font="3"> Patients with pre-excitation may develop AF during </text>
<text top="232" left="170" width="630" height="14" font="3">an episode of AVRT and be exposed to increased risk of rapid conduction over the accessory pathway while receiving beta blockers, diltiazem </text>
<text top="247" left="170" width="254" height="14" font="3">or verapamil, so these agents must be used with caution.</text>
<text top="248" left="424" width="10" height="8" font="18">269</text>
<text top="247" left="434" width="354" height="14" font="3"> The decision to treat with these agents should follow a discussion of risks with </text>
<text top="262" left="170" width="633" height="14" font="3">the patient. Although evidence of poor anterograde conduction via the accessory pathway may be reassuring, rapid conduction in AF has been </text>
<text top="277" left="170" width="304" height="14" font="3">described even in the setting of intermittent anterograde conduction.</text>
<text top="278" left="474" width="10" height="8" font="18">291</text>
<text top="306" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="306" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="298" left="170" width="630" height="14" font="1"><b>4.   Oral digoxin may be reasonable for ongoing management of orthodromic AVRT in patients without pre-excitation on their resting </b></text>
<text top="313" left="184" width="359" height="14" font="1"><b>ECG who are not candidates for, or prefer not to undergo, catheter ablation.</b></text>
<text top="314" left="543" width="10" height="8" font="20"><b>292</b></text>
<text top="343" left="78" width="20" height="14" font="3">See </text>
<text top="343" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="358" left="78" width="68" height="14" font="21"><a href="">Supplement 12</a></text>
<text top="358" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="335" left="170" width="628" height="14" font="3">One small study reported the usefulness of oral digoxin in prevention of recurrent orthodromic AVRT in patients without pre-excitation on their resting </text>
<text top="350" left="170" width="155" height="14" font="3">ECG (concealed accessory pathway).</text>
<text top="351" left="324" width="10" height="8" font="18">293</text>
<text top="350" left="334" width="466" height="14" font="3"> Digoxin has been used clinically for many years, but the low efficacy indicates its use would be best limited to </text>
<text top="365" left="170" width="608" height="14" font="3">patients who are not candidates for catheter ablation or prefer pharmacological therapy and have failed to respond to other antiarrhythmic drugs.</text>
<text top="386" left="85" width="18" height="14" font="1"><b>III:  </b></text>
<text top="401" left="78" width="26" height="14" font="1"><b>Harm</b></text>
<text top="394" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="386" left="170" width="623" height="14" font="1"><b>1.   Oral digoxin is potentially harmful for ongoing management in patients with AVRT or AF and pre-excitation on their resting ECG.</b></text>
<text top="387" left="792" width="10" height="8" font="20"><b>271</b></text>
<text top="423" left="78" width="20" height="14" font="3">See </text>
<text top="423" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="438" left="78" width="68" height="14" font="21"><a href="">Supplement 12</a></text>
<text top="438" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="423" left="170" width="491" height="14" font="3">Digoxin shortens the refractory period of the accessory pathway, such that AF may induce ventricular fibrillation.</text>
<text top="424" left="660" width="10" height="8" font="18">271</text>
<text top="423" left="670" width="119" height="14" font="3"> Even if AF has never been </text>
<text top="438" left="170" width="591" height="14" font="3">documented, AVRT may degenerate into AF. Thus, oral digoxin should not be used to treat patients with a manifest accessory pathway.</text>
<text top="104" left="78" width="413" height="16" font="19"><b>Recommendations for Ongoing Management of Orthodromic AVRT (Continued)</b></text>
<text top="128" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e538  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="406" height="16" font="0"><i><b>6.2.2. Asymptomatic Patients With Pre-Excitation: Recommendations</b></i></text>
<text top="127" left="80" width="457" height="16" font="19"><b>Recommendations for Management of Asymptomatic Patients With Pre-Excitation</b></text>
<text top="152" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="152" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="152" left="172" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="198" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="180" left="121" width="28" height="14" font="1"><b>B-NR </b></text>
<text top="180" left="148" width="8" height="8" font="20"><b>SR</b></text>
<text top="175" left="171" width="607" height="14" font="1"><b>1.   In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over a manifest pathway during </b></text>
<text top="190" left="187" width="158" height="14" font="1"><b>exercise testing in sinus rhythm</b></text>
<text top="191" left="345" width="24" height="8" font="20"><b>294–297</b></text>
<text top="190" left="370" width="131" height="14" font="1"><b> <i>(Level of Evidence: B-NR)</i></b><b> </b></text>
<text top="191" left="500" width="8" height="8" font="20"><b>SR</b></text>
<text top="190" left="508" width="256" height="14" font="1"><b> or intermittent loss of pre-excitation during ECG or </b></text>
<text top="205" left="187" width="113" height="14" font="1"><b>ambulatory monitoring</b></text>
<text top="206" left="299" width="10" height="8" font="20"><b>297</b></text>
<text top="205" left="310" width="129" height="14" font="1"><b> <i>(Level of Evidence: C-LD)</i></b><b> </b></text>
<text top="206" left="439" width="8" height="8" font="20"><b>SR</b></text>
<text top="205" left="447" width="349" height="14" font="1"><b> are useful to identify patients at low risk of rapid conduction over the </b></text>
<text top="220" left="187" width="45" height="14" font="1"><b>pathway.</b></text>
<text top="213" left="122" width="26" height="14" font="1"><b>C-LD </b></text>
<text top="214" left="148" width="8" height="8" font="20"><b>SR</b></text>
<text top="280" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="280" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="295" left="80" width="75" height="14" font="21"><a href="">Supplements 11 </a></text>
<text top="310" left="80" width="31" height="14" font="21"><a href="">and 12</a></text>
<text top="310" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="242" left="171" width="598" height="14" font="3">Noninvasive testing has been shown to identify patients at low risk of developing rapid conduction over the accessory pathway and </text>
<text top="257" left="171" width="612" height="14" font="3">life-threatening ventricular arrhythmias in response to AF. The noninvasive findings that identify a pathway not capable of maintaining </text>
<text top="272" left="171" width="617" height="14" font="3">rapid conduction during AF include intermittent loss of conduction over the accessory pathway on the resting ECG or during ambulatory </text>
<text top="287" left="171" width="357" height="14" font="3">monitoring, or abrupt loss of pre-excitation during exercise testing (Figure 16).</text>
<text top="288" left="528" width="24" height="8" font="18">294–297</text>
<text top="287" left="552" width="247" height="14" font="3"> The ECG should be evaluated closely to make certain </text>
<text top="302" left="171" width="632" height="14" font="3">the delta wave is truly absent, as accessory pathways, especially left lateral pathways, may demonstrate varying degrees of pre-excitation </text>
<text top="317" left="171" width="609" height="14" font="3">because of fusion between conduction over the accessory pathway and through the AV node. This may give the appearance of loss of </text>
<text top="332" left="171" width="619" height="14" font="3">pre-excitation if the subtle delta wave is not identified. Noninvasive tests have an approximately 90% positive predictive value and 30% </text>
<text top="347" left="171" width="372" height="14" font="3">negative predictive value for identifying pathways with life-threatening properties.</text>
<text top="348" left="544" width="34" height="8" font="18">294,295,297</text>
<text top="374" left="87" width="12" height="14" font="1"><b>IIa</b></text>
<text top="380" left="121" width="28" height="14" font="1"><b>B-NR </b></text>
<text top="381" left="148" width="8" height="8" font="20"><b>SR</b></text>
<text top="374" left="171" width="535" height="14" font="1"><b>1.   An EP study is reasonable in asymptomatic patients with pre-excitation to risk-stratify for arrhythmic events.</b></text>
<text top="375" left="707" width="47" height="8" font="20"><b>254,256,298–301</b></text>
<text top="432" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="432" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="447" left="80" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="462" left="80" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="462" left="109" width="3" height="14" font="3"><a href="">.</a></text>
<text top="402" left="171" width="600" height="14" font="3">In the absence of symptoms, a clinical priority is identifying accessory pathways at increased risk of arrhythmic events, including rapid </text>
<text top="417" left="171" width="602" height="14" font="3">conduction during AF and development of life-threatening ventricular arrhythmias, with the most useful findings being the following: an </text>
<text top="432" left="171" width="601" height="14" font="3">R-R interval &lt;250 ms between 2 pre-excited complexes during induced AF; the presence of multiple accessory pathways; the ability to </text>
<text top="447" left="171" width="564" height="14" font="3">induce sustained AVRT; the finding of AVRT precipitating pre-excited AF; and an accessory pathway refractory period &lt;240 ms.</text>
<text top="447" left="735" width="57" height="8" font="18">254,256,298,299,301</text>
<text top="447" left="792" width="3" height="14" font="3"> </text>
<text top="462" left="171" width="627" height="14" font="3">Malignant arrhythmias correlate more with the EP properties of the accessory pathway than with the presence or absence of symptoms. This </text>
<text top="477" left="171" width="610" height="14" font="3">approach is supported by the low risk of complications observed in an EP study in which complication rates among 2169 patients ranged </text>
<text top="492" left="171" width="347" height="14" font="3">from 0.09% to 1% and included pneumothorax and access site complications.</text>
<text top="492" left="518" width="10" height="8" font="18">254</text>
<text top="526" left="91" width="12" height="14" font="1"><b>IIa</b></text>
<text top="532" left="125" width="28" height="14" font="1"><b>B-NR </b></text>
<text top="533" left="153" width="8" height="8" font="20"><b>SR</b></text>
<text top="518" left="171" width="632" height="14" font="1"><b>2.   Catheter ablation of the accessory pathway is reasonable in asymptomatic patients with pre-excitation if an EP study identifies a </b></text>
<text top="533" left="186" width="361" height="14" font="1"><b>high risk of arrhythmic events, including rapidly conducting pre-excited AF.</b></text>
<text top="534" left="547" width="34" height="8" font="20"><b>254,302,303</b></text>
<text top="613" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="613" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="628" left="80" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="643" left="80" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="643" left="109" width="3" height="14" font="3"><a href="">.</a></text>
<text top="561" left="171" width="607" height="14" font="3">In a large prospective cohort study of 756 asymptomatic patients with close to 8 years of follow-up, 9% of patients developed malignant </text>
<text top="576" left="171" width="111" height="14" font="3">AF (shortest R-R interval </text>
<text top="576" left="282" width="231" height="14" font="3">≤250 ms), and 2% developed ventricular fibrillation.</text>
<text top="577" left="513" width="10" height="8" font="18">254</text>
<text top="576" left="523" width="257" height="14" font="3"> Malignant arrhythmias correlated more with high-risk EP </text>
<text top="591" left="171" width="601" height="14" font="3">properties of the accessory pathway than with the presence or absence of symptoms. Ablation of the accessory pathway(s) in high-risk </text>
<text top="606" left="171" width="594" height="14" font="3">patients was also examined in 1 RCT that enrolled 76 patients, showing that arrhythmic events (defined as symptomatic SVT, AF, and </text>
<text top="621" left="171" width="573" height="14" font="3">ventricular fibrillation in this study) occurred in 7% of patients who underwent ablation versus 77% who did not undergo ablation.</text>
<text top="622" left="745" width="10" height="8" font="18">302</text>
<text top="621" left="755" width="40" height="14" font="3"> Another </text>
<text top="636" left="171" width="617" height="14" font="3">study that examined patients on the basis of whether an ablation was performed reported that none of the asymptomatic patients who had </text>
<text top="651" left="171" width="598" height="14" font="3">undergone ablation of the accessory pathway developed a malignant arrhythmia during 8 years of follow-up. The risk of complications </text>
<text top="666" left="171" width="484" height="14" font="3">with ablation ranged from 0.1% (complete heart block) to 0.9% (ablation-induced right bundle-branch block).</text>
<text top="667" left="655" width="10" height="8" font="18">254</text>
<text top="666" left="665" width="115" height="14" font="3"> The risks and benefits of </text>
<text top="681" left="171" width="624" height="14" font="3">proceeding with ablation of pathways found not to have high-risk characteristics should be discussed thoroughly with patients in advance of </text>
<text top="696" left="171" width="79" height="14" font="3">the EP procedure.</text>
<text top="730" left="87" width="12" height="14" font="1"><b>IIa</b></text>
<text top="736" left="121" width="28" height="14" font="1"><b>B-NR </b></text>
<text top="737" left="148" width="8" height="8" font="20"><b>SR</b></text>
<text top="723" left="171" width="620" height="14" font="1"><b>3.   Catheter ablation of the accessory pathway is reasonable in asymptomatic patients if the presence of pre-excitation precludes </b></text>
<text top="738" left="186" width="202" height="14" font="1"><b>specific employment (such as with pilots).</b></text>
<text top="738" left="388" width="72" height="8" font="20"><b>103,254,276–282,302–304</b></text>
<text top="780" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="780" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="795" left="80" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="810" left="80" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="810" left="109" width="3" height="14" font="3"><a href="">.</a></text>
<text top="765" left="171" width="603" height="14" font="3">Patients with asymptomatic pre-excitation whose job activities would place them or others at risk if a hemodynamically significant </text>
<text top="780" left="171" width="580" height="14" font="3">arrhythmia occurred (such as airline pilots) are potential candidates for catheter ablation. Catheter ablation is associated with </text>
<text top="795" left="171" width="564" height="14" font="3">a success rate of approximately 95% and a 3% risk of major complications when patients are followed up for 6 months to </text>
<text top="810" left="171" width="37" height="14" font="3">8 years.</text>
<text top="811" left="208" width="73" height="8" font="18">103,254,276–282,302,303</text>
<text top="810" left="281" width="461" height="14" font="3"> Other documents advise EP study in asymptomatic athletes who engage in moderate- or high-level </text>
<text top="825" left="171" width="88" height="14" font="3">competitive sports.</text>
<text top="826" left="259" width="10" height="8" font="18">305</text>
<text top="852" left="87" width="12" height="14" font="1"><b>IIa</b></text>
<text top="857" left="121" width="28" height="14" font="1"><b>B-NR </b></text>
<text top="857" left="148" width="8" height="8" font="20"><b>SR</b></text>
<text top="852" left="171" width="553" height="14" font="1"><b>4.   Observation, without further evaluation or treatment, is reasonable in asymptomatic patients with pre-excitation.</b></text>
<text top="853" left="725" width="35" height="8" font="20"><b>301,306–309</b></text>
<text top="902" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="902" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="917" left="80" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="932" left="80" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="932" left="109" width="3" height="14" font="3"><a href="">.</a></text>
<text top="880" left="171" width="608" height="14" font="3">Most observational cohort studies suggest that the great majority of adult patients with asymptomatic pre-excitation who do not undergo </text>
<text top="895" left="171" width="592" height="14" font="3">an ablation of the accessory pathway have a benign course with few clinically significant arrhythmic events occurring over time. This </text>
<text top="910" left="171" width="598" height="14" font="3">supports the recommendation that observation without medical therapy or ablation is a reasonable alternative because the risk of SCD </text>
<text top="925" left="171" width="172" height="14" font="3">is small and is seen mainly in children.</text>
<text top="925" left="343" width="47" height="8" font="18">254,301,306–309</text>
<text top="925" left="390" width="360" height="14" font="3"> The choice to observe asymptomatic patients should be preceded by the patient </text>
<text top="940" left="171" width="604" height="14" font="3">being informed of the small risk of life-threatening arrhythmias developing in the absence of treatment, along with the success rate and </text>
<text top="955" left="171" width="329" height="14" font="3">complications associated with catheter ablation of the accessory pathway.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e539</i></b></text>
<text top="97" left="69" width="684" height="18" font="10"><b>6.3. Risk Stratification of Symptomatic Patients With Manifest Accessory Pathways: Recommendations</b></text>
<text top="467" left="186" width="116" height="20" font="12"><b>7. Atrial Flutter</b></text>
<text top="487" left="69" width="354" height="16" font="13">See Figure 17 for a schematic depicting classification of atrial </text>
<text top="505" left="69" width="357" height="16" font="13">flutter/ATs; Figure 18 for the algorithm for acute treatment </text>
<text top="522" left="69" width="356" height="16" font="13">of atrial flutter; and Figure 19 for the algorithm for ongoing </text>
<text top="539" left="69" width="161" height="16" font="13">management of atrial flutter.</text>
<text top="575" left="69" width="340" height="18" font="10"><b>7.1. Cavotricuspid Isthmus–Dependent Atrial Flutter</b></text>
<text top="594" left="69" width="351" height="16" font="13">Atrial flutter is a macroreentrant atrial arrhythmia character-</text>
<text top="611" left="69" width="356" height="16" font="13">ized by regular atrial rate and constant P-wave morphology. </text>
<text top="468" left="456" width="351" height="16" font="13">When the atrial flutter circuit involves the cavotricuspid isth-</text>
<text top="485" left="456" width="357" height="16" font="13">mus (CTI), it is labeled CTI-dependent atrial flutter. When </text>
<text top="503" left="456" width="354" height="16" font="13">CTI-dependent flutter involves a circuit that rotates around the </text>
<text top="521" left="456" width="354" height="16" font="13">tricuspid valve in a counterclockwise direction (up the septum </text>
<text top="538" left="456" width="355" height="16" font="13">and down the free wall), it is called “typical”; less commonly, </text>
<text top="556" left="456" width="351" height="16" font="13">the CTI-dependent flutter circuit rotates in a clockwise direc-</text>
<text top="573" left="456" width="233" height="16" font="13">tion (sometimes called “reverse typical”).</text>
<text top="574" left="689" width="12" height="9" font="14">203</text>
<text top="573" left="701" width="108" height="16" font="13"> Counterclockwise </text>
<text top="591" left="456" width="351" height="16" font="13">CTI-dependent atrial flutter is characterized electrocardio-</text>
<text top="609" left="456" width="355" height="16" font="13">graphically by dominant negative flutter waves in the inferior </text>
<text top="626" left="456" width="356" height="16" font="13">leads (so-called “sawtooth waves”) and a positive P wave in </text>
<text top="644" left="456" width="356" height="16" font="13">lead V1 at atrial rates of 250 bpm to 350 bpm (Figure 17). </text>
<text top="661" left="456" width="351" height="16" font="13">Clockwise isthmus-dependent flutter shows the opposite pat-</text>
<text top="679" left="456" width="355" height="16" font="13">tern (ie, positive flutter waves in the inferior leads and wide, </text>
<text top="697" left="456" width="356" height="16" font="13">negative flutter waves in lead V1) (Figure 17). Although the </text>
<text top="714" left="456" width="357" height="16" font="13">atrial rates for flutter typically range from 250 bpm to 330 </text>
<text top="732" left="456" width="351" height="16" font="13">bpm, the rates may be slower in patients with severe atrial dis-</text>
<text top="750" left="456" width="351" height="16" font="13">ease or in patients taking antiarrhythmic agents or after unsuc-</text>
<text top="767" left="456" width="141" height="16" font="13">cessful catheter ablation.</text>
<text top="768" left="597" width="12" height="9" font="14">310</text>
<text top="785" left="477" width="336" height="16" font="13">Atrial flutter can occur in clinical settings similar to those </text>
<text top="802" left="456" width="356" height="16" font="13">associated with AF, and atrial flutter can be triggered by AT or </text>
<text top="820" left="456" width="20" height="16" font="13">AF.</text>
<text top="821" left="476" width="26" height="9" font="14">121,311</text>
<text top="820" left="501" width="311" height="16" font="13"> It is common for AF and atrial flutter to coexist in the </text>
<text top="838" left="456" width="356" height="16" font="13">same patient. After CTI ablation, 22% to 50% of patients have </text>
<text top="855" left="456" width="356" height="16" font="13">been reported to develop AF after a mean follow-up of 14 to 30 </text>
<text top="873" left="456" width="351" height="16" font="13">months, although 1 study reported a much higher rate of AF devel-</text>
<text top="890" left="456" width="354" height="16" font="13">opment, with 82% of patients treated by catheter ablation for atrial </text>
<text top="908" left="456" width="200" height="16" font="13">flutter manifesting AF within 5 years.</text>
<text top="909" left="656" width="12" height="9" font="14">312</text>
<text top="908" left="667" width="140" height="16" font="13"> Risk factors for the mani-</text>
<text top="926" left="456" width="355" height="16" font="13">festing AF after atrial flutter ablation include prior AF, depressed </text>
<text top="943" left="456" width="356" height="16" font="13">left ventricular function, structural heart disease or ischemic </text>
<text top="961" left="456" width="290" height="16" font="13">heart disease, inducible AF, and increased LA size.</text>
<text top="961" left="746" width="44" height="9" font="14">121,312–316</text>
<text top="978" left="477" width="335" height="16" font="13">Atrial flutter may result from antiarrhythmic therapy of </text>
<text top="996" left="456" width="355" height="16" font="13">AF, particularly when flecainide, propafenone, or amiodarone </text>
<text top="1014" left="456" width="160" height="16" font="13">is used for treatment of AF.</text>
<text top="1014" left="616" width="27" height="9" font="14">317,318</text>
<text top="1014" left="643" width="168" height="16" font="13"> In those patients with atrial </text>
<text top="1031" left="456" width="354" height="16" font="13">flutter resulting from antiarrhythmic therapy of AF, ablation of </text>
<text top="1049" left="456" width="355" height="16" font="13">the CTI-dependent flutter may prevent recurrent flutter while </text>
<text top="1066" left="456" width="248" height="16" font="13">antiarrhythmic therapy for AF is continued.</text>
<text top="1067" left="704" width="12" height="9" font="14">318</text>
<text top="1084" left="477" width="335" height="16" font="13">Patients with atrial flutter are thought to have the same </text>
<text top="1102" left="456" width="359" height="16" font="13">risk of thromboembolism as patients with AF; therefore, </text>
<text top="1048" left="69" width="323" height="14" font="1"><b>Figure 12.</b> Acute treatment of AVNRT. Colors correspond to </text>
<text top="1062" left="69" width="348" height="14" font="3">Class of Recommendation in Table 1; drugs listed alphabetically. </text>
<text top="1075" left="69" width="333" height="14" font="3">*For rhythms that break or recur spontaneously, synchronized </text>
<text top="1089" left="69" width="352" height="14" font="3">cardioversion is not appropriate. AVNRT indicates atrioventricular </text>
<text top="1102" left="69" width="258" height="14" font="3">nodal reentrant tachycardia; and IV, intravenous.</text>
<text top="127" left="78" width="538" height="16" font="19"><b>Recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways</b></text>
<text top="151" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="151" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="151" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="190" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="176" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="172" left="170" width="619" height="14" font="1"><b>1.   In symptomatic patients with pre-excitation, the findings of abrupt loss of conduction over the pathway during exercise testing in </b></text>
<text top="187" left="184" width="61" height="14" font="1"><b>sinus rhythm</b></text>
<text top="188" left="245" width="23" height="8" font="20"><b>294–297</b></text>
<text top="187" left="268" width="467" height="14" font="1"><b> <i>(Level of Evidence: B-NR)</i></b><b> or intermittent loss of pre-excitation during ECG or ambulatory monitoring</b></text>
<text top="188" left="735" width="10" height="8" font="20"><b>297</b></text>
<text top="187" left="745" width="45" height="14" font="1"><b> <i>(Level of </i></b></text>
<text top="202" left="184" width="515" height="14" font="2"><i><b>Evidence: C-LD)</b></i><b> are useful for identifying patients at low risk of developing rapid conduction over the pathway.</b></text>
<text top="204" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="274" left="78" width="20" height="14" font="3">See </text>
<text top="274" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="289" left="78" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="304" left="78" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="304" left="107" width="3" height="14" font="3">.</text>
<text top="229" left="170" width="618" height="14" font="3">An important consideration in the evaluation of patients with pre-excitation is determining risk of developing rapid conduction over the accessory </text>
<text top="244" left="170" width="621" height="14" font="3">pathway and life-threatening ventricular arrhythmias in response to AF. The noninvasive findings that identify a pathway incapable of maintaining </text>
<text top="259" left="170" width="626" height="14" font="3">rapid conduction during AF include intermittent loss of conduction over the accessory pathway on the resting ECG or during ambulatory monitoring </text>
<text top="274" left="170" width="233" height="14" font="3">or abrupt loss of pre-excitation during exercise testing.</text>
<text top="275" left="402" width="23" height="8" font="18">294–297</text>
<text top="274" left="425" width="374" height="14" font="3"> The ECG should be evaluated closely to make certain the delta wave is truly absent, as </text>
<text top="289" left="170" width="628" height="14" font="3">accessory pathways (especially left lateral pathways) may demonstrate varying degrees of pre-excitation because of fusion between conduction over </text>
<text top="304" left="170" width="625" height="14" font="3">the accessory pathway and through the AV node, which may give the appearance of loss of pre-excitation if the subtle delta wave is not identified. </text>
<text top="319" left="170" width="596" height="14" font="3">Noninvasive tests have an approximately 90% positive predictive value and 30% negative predictive value for identifying pathways with life-</text>
<text top="334" left="170" width="96" height="14" font="3">threatening properties.</text>
<text top="335" left="266" width="32" height="8" font="18">294,295,297</text>
<text top="334" left="298" width="497" height="14" font="3"> If noninvasive evaluation suggests that the accessory pathway conducts poorly in the anterograde direction, although </text>
<text top="349" left="170" width="474" height="14" font="3">risk of life-threatening events is likely lower, the EP study still may be useful because of patient symptoms.</text>
<text top="370" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="370" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="370" left="170" width="583" height="14" font="1"><b>2.   An EP study is useful in symptomatic patients with pre-excitation to risk-stratify for life-threatening arrhythmic events.</b></text>
<text top="371" left="753" width="47" height="8" font="20"><b>254,256,298–300</b></text>
<text top="400" left="78" width="20" height="14" font="3">See </text>
<text top="400" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="415" left="78" width="61" height="14" font="21"><a href="">Supplements </a></text>
<text top="430" left="78" width="29" height="14" font="21"><a href="">11–15</a></text>
<text top="430" left="107" width="3" height="14" font="3">.</text>
<text top="392" left="170" width="633" height="14" font="3">Most symptomatic patients with accessory pathways undergo catheter ablation, but in some instances, EP studies are performed to identify whether the </text>
<text top="407" left="170" width="629" height="14" font="3">patient is at increased risk of rapid conduction down the accessory pathway during AF and development of life-threatening ventricular arrhythmias. The </text>
<text top="422" left="170" width="620" height="14" font="3">most useful findings for risk stratification are an R-R interval &lt;250 ms between 2 pre-excited complexes during induced AF; the presence of multiple </text>
<text top="437" left="170" width="517" height="14" font="3">accessory pathways; the finding of AVRT precipitating pre-excited AF; and an accessory pathway refractory period &lt;240 ms.</text>
<text top="438" left="686" width="45" height="8" font="18">254,256,298–300</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e540  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="601" left="71" width="354" height="16" font="13">recommendations for anticoagulation mirror those for patients </text>
<text top="618" left="71" width="49" height="16" font="13">with AF.</text>
<text top="619" left="120" width="37" height="9" font="14">10,121,314</text>
<text top="618" left="157" width="264" height="16" font="13"> Similarly, the recommendations for anticoag-</text>
<text top="636" left="70" width="351" height="16" font="13">ulation with regard to either pharmacological or electrical car-</text>
<text top="654" left="70" width="355" height="16" font="13">dioversion of patients with atrial flutter are the same as those </text>
<text top="672" left="70" width="356" height="16" font="13">for patients with AF, as discussed in the 2014 AF guideline </text>
<text top="689" left="70" width="77" height="16" font="13">(Section 6.1).</text>
<text top="690" left="148" width="8" height="9" font="14">10</text>
<text top="726" left="71" width="296" height="18" font="10"><b>7.2. Non–Isthmus-Dependent Atrial Flutters</b></text>
<text top="745" left="71" width="363" height="16" font="13">Non–isthmus-dependent atrial flutter or atypical flutter </text>
<text top="763" left="71" width="360" height="16" font="13">describes macroreentrant ATs that are not dependent on </text>
<text top="781" left="71" width="356" height="16" font="13">conduction through the CTI. A variety of circuits have been </text>
<text top="799" left="71" width="351" height="16" font="13">described, including a path around the mitral annulus (perimi-</text>
<text top="816" left="71" width="355" height="16" font="13">tral flutter), re-entry involving the left atrial roof, and re-entry </text>
<text top="834" left="71" width="351" height="16" font="13">around regions of scarring in the right or left atrium. Non–</text>
<text top="852" left="71" width="356" height="16" font="13">isthmus-dependent atrial flutters often occur in patients with </text>
<text top="870" left="71" width="354" height="16" font="13">atrial scarring from prior heart surgery or ablation but also may </text>
<text top="888" left="71" width="310" height="16" font="13">occur in any form of heart disease or may be idiopathic.</text>
<text top="888" left="380" width="41" height="9" font="14">134,140,319</text>
<text top="888" left="421" width="4" height="16" font="13"> </text>
<text top="905" left="70" width="351" height="16" font="13">Non–isthmus-dependent atrial flutters can coexist with CTI-</text>
<text top="923" left="70" width="351" height="16" font="13">dependent flutter or involve the presence of multiple atrial re-</text>
<text top="941" left="70" width="77" height="16" font="13">entry circuits.</text>
<text top="942" left="147" width="27" height="9" font="14">133,320</text>
<text top="941" left="174" width="251" height="16" font="13"> The reentrant circuits are classified as either </text>
<text top="959" left="70" width="356" height="16" font="13">macroreentrant AT (large; often several centimeters or longer </text>
<text top="977" left="70" width="200" height="16" font="13">in diameter) or microreentrant AT (</text>
<text top="976" left="270" width="155" height="17" font="13">≤2 cm in diameter), which </text>
<text top="994" left="70" width="226" height="16" font="13">may be indistinguishable from focal AT.</text>
<text top="995" left="296" width="12" height="9" font="14">321</text>
<text top="1012" left="92" width="334" height="16" font="13">In the presence of substantial atrial disease, prior surgery, </text>
<text top="1030" left="71" width="351" height="16" font="13">or prior radiofrequency catheter ablation, the ECG flutter-</text>
<text top="1048" left="71" width="356" height="16" font="13">wave morphology is not a reliable predictor of whether the </text>
<text top="1065" left="71" width="358" height="16" font="13">flutter circuit involves the CTI. Although an ECG with a </text>
<text top="1083" left="71" width="351" height="16" font="13">typical flutter appearance has good predictive value for CTI-</text>
<text top="1101" left="71" width="357" height="16" font="13">dependent flutter in a patient who has not undergone prior </text>
<text top="601" left="458" width="355" height="16" font="13">catheter ablation of AF, the ECG appearance is less useful in </text>
<text top="618" left="458" width="356" height="16" font="13">predicting the flutter circuit in a patient who has previously </text>
<text top="635" left="458" width="139" height="16" font="13">undergone AF ablation.</text>
<text top="636" left="596" width="29" height="9" font="14">322–325</text>
<text top="635" left="626" width="189" height="16" font="13"> The presence of a positive or </text>
<text top="652" left="457" width="351" height="16" font="13">biphasic (but dominantly positive) deflection in V1, accom-</text>
<text top="670" left="457" width="355" height="16" font="13">panied by deflections in other leads inconsistent with typical </text>
<text top="687" left="457" width="357" height="16" font="13">counterclockwise atrial flutter, suggests the presence of an </text>
<text top="704" left="457" width="356" height="16" font="13">atypical flutter (Figure 17). Definitive diagnosis requires EP </text>
<text top="721" left="457" width="183" height="16" font="13">study and intracardiac mapping.</text>
<text top="722" left="640" width="12" height="9" font="14">326</text>
<text top="739" left="479" width="335" height="16" font="13">Catheter ablation of non–CTI-dependent flutter requires </text>
<text top="756" left="458" width="354" height="16" font="13">more extensive mapping than does ablation of CTI-dependent </text>
<text top="773" left="458" width="355" height="16" font="13">flutter, and success rates are lower (Table 8). The location of </text>
<text top="790" left="458" width="287" height="16" font="13">the circuit determines ablation approach and risks.</text>
<text top="808" left="479" width="340" height="16" font="13">The substrate for macroreentrant atrial arrhythmias </text>
<text top="825" left="458" width="351" height="16" font="13">after cardiac surgery is atrial scarring from atriotomy inci-</text>
<text top="842" left="458" width="351" height="16" font="13">sions and cannulation sites and from the underlying myo-</text>
<text top="859" left="458" width="356" height="16" font="13">pathic process of the valve disease itself; this is sometimes </text>
<text top="877" left="458" width="358" height="16" font="13">referred to as incisional atrial reentrant tachycardia. The </text>
<text top="894" left="458" width="351" height="16" font="13">location of the reentrant circuit depends on the type of surgi-</text>
<text top="911" left="458" width="354" height="16" font="13">cal approach, and common populations include patients who </text>
<text top="928" left="458" width="354" height="16" font="13">have undergone mitral valve surgery or have a repaired atrial </text>
<text top="946" left="458" width="77" height="16" font="13">septal defect.</text>
<text top="946" left="535" width="30" height="9" font="14">327–330</text>
<text top="946" left="564" width="248" height="16" font="13"> These arrhythmias are also common after </text>
<text top="963" left="458" width="217" height="16" font="13">surgical or catheter ablation for AF.</text>
<text top="963" left="675" width="27" height="9" font="14">331,332</text>
<text top="963" left="702" width="112" height="16" font="13"> Both single- and </text>
<text top="980" left="457" width="355" height="16" font="13">dual-loop circuits, as well as focal ATs, can be present. It is </text>
<text top="997" left="457" width="354" height="16" font="13">useful to review the procedural notes to identify the location </text>
<text top="1015" left="457" width="354" height="16" font="13">of atrial incisions or prior ablation that can assist with future </text>
<text top="1032" left="457" width="130" height="16" font="13">mapping and ablation.</text>
<text top="1049" left="479" width="335" height="16" font="13">The development of a microreentrant or macroreentrant </text>
<text top="1066" left="457" width="358" height="16" font="13">left AT after AF ablation occurs in approximately 5% of </text>
<text top="1084" left="457" width="48" height="16" font="13">patients.</text>
<text top="1084" left="505" width="42" height="9" font="14">330,333,334</text>
<text top="1084" left="547" width="266" height="16" font="13"> This is less frequent if ablation is limited to </text>
<text top="1101" left="457" width="353" height="16" font="13">pulmonary vein isolation. On the other hand, these arrhythmias </text>
<text top="296" left="536" width="239" height="14" font="1"><b>Figure 13.</b> Ongoing management of AVNRT. </text>
<text top="310" left="536" width="262" height="14" font="3">Colors correspond to Class of Recommendation </text>
<text top="323" left="536" width="268" height="14" font="3">in Table 1; drugs listed alphabetically. AVNRT indi-</text>
<text top="337" left="536" width="269" height="14" font="3">cates atrioventricular nodal reentrant tachycardia; </text>
<text top="350" left="536" width="245" height="14" font="3">pt, patient; and SHD, structural heart disease </text>
<text top="364" left="536" width="184" height="14" font="3">(including ischemic heart disease).</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e541</i></b></text>
<text top="97" left="69" width="355" height="16" font="13">are more common in patients with longer-duration persistent </text>
<text top="115" left="69" width="356" height="16" font="13">AF or more dilated left atria or when linear ablation lesions </text>
<text top="132" left="69" width="53" height="16" font="13">are used.</text>
<text top="133" left="122" width="29" height="9" font="14">333–338</text>
<text top="132" left="151" width="269" height="16" font="13"> Non–reentrant focal arrhythmias often origi-</text>
<text top="150" left="69" width="355" height="16" font="13">nate at lesion edges or reconnected segments of prior isolated </text>
<text top="167" left="69" width="101" height="16" font="13">pulmonary veins.</text>
<text top="168" left="170" width="12" height="9" font="14">333</text>
<text top="167" left="183" width="243" height="16" font="13"> Reisolation of the pulmonary vein and </text>
<text top="185" left="69" width="355" height="16" font="13">ablation of any nonpulmonary vein foci are often effective in </text>
<text top="202" left="69" width="351" height="16" font="13">treating these arrhythmias. Detailed activation and entrain-</text>
<text top="220" left="69" width="356" height="16" font="13">ment mapping of the tachycardia during a second procedure </text>
<text top="237" left="69" width="339" height="16" font="13">result in effective ablation in approximately 90% of patients.</text>
<text top="238" left="408" width="12" height="9" font="14">335</text>
<text top="237" left="420" width="4" height="16" font="13"> </text>
<text top="255" left="69" width="356" height="16" font="13">Although right atrial CTI-dependent flutter may also occur, </text>
<text top="272" left="69" width="296" height="16" font="13">most of the tachycardias originate in the left atrium.</text>
<text top="290" left="90" width="334" height="16" font="13">As with all types of atrial flutter, it may be very difficult </text>
<text top="307" left="69" width="358" height="16" font="13">to achieve rate control in patients with post–AF ablation </text>
<text top="325" left="69" width="355" height="16" font="13">non–CTI-dependent flutter (far more so than in patients with </text>
<text top="97" left="456" width="358" height="16" font="13">preablation AF). When the ventricular response cannot be </text>
<text top="115" left="456" width="357" height="16" font="13">controlled with common rate-control medications, attempts </text>
<text top="132" left="456" width="356" height="16" font="13">at restoration of sinus rhythm with pharmacological therapy </text>
<text top="149" left="456" width="351" height="16" font="13">and cardioversion are often required. Many of the atrial flut-</text>
<text top="166" left="456" width="355" height="16" font="13">ters that are observed during the first 3 months after catheter </text>
<text top="184" left="456" width="356" height="16" font="13">ablation or after cardiac surgery will not recur later on. For </text>
<text top="201" left="456" width="351" height="16" font="13">this reason, it is advised that attempts at ablation of atrial flut-</text>
<text top="218" left="456" width="351" height="16" font="13">ter after AF ablation be deferred until after the 3-month wait-</text>
<text top="235" left="456" width="64" height="16" font="13">ing period.</text>
<text top="236" left="520" width="12" height="9" font="14">339</text>
<text top="235" left="532" width="280" height="16" font="13"> Rarely, pharmacological therapy and attempts </text>
<text top="253" left="456" width="357" height="16" font="13">at rhythm control with antiarrhythmic drug therapy fail to </text>
<text top="270" left="456" width="355" height="16" font="13">adequately control atrial flutter during the 3 months after AF </text>
<text top="287" left="456" width="342" height="16" font="13">ablation. In this situation, early repeat ablation is warranted.</text>
<text top="323" left="456" width="273" height="18" font="10"><b>7.3. Acute Treatment: Recommendations</b></text>
<text top="385" left="78" width="307" height="16" font="19"><b>Recommendations for Acute Treatment of Atrial Flutter</b></text>
<text top="409" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="409" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="409" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="430" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="430" left="133" width="7" height="14" font="1"><b>A</b></text>
<text top="430" left="170" width="573" height="14" font="1"><b>1.   Oral dofetilide or intravenous ibutilide is useful for acute pharmacological cardioversion in patients with atrial flutter.</b></text>
<text top="431" left="743" width="35" height="8" font="20"><b>119,340–346</b></text>
<text top="482" left="78" width="20" height="14" font="3">See </text>
<text top="482" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="497" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="512" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="512" left="109" width="3" height="14" font="3">.</text>
<text top="452" left="170" width="610" height="14" font="3">Pharmacological cardioversion of atrial flutter is generally less effective than synchronized cardioversion and carries the potential risk </text>
<text top="467" left="170" width="596" height="14" font="3">of proarrhythmia but can be an option when sedation is not available or not well tolerated or when indicated by patient preference. </text>
<text top="482" left="170" width="409" height="14" font="3">Intravenous ibutilide converts atrial flutter to sinus rhythm in approximately 60% of cases.</text>
<text top="483" left="579" width="10" height="8" font="18">342</text>
<text top="482" left="589" width="207" height="14" font="3"> The major risk is torsades de pointes, which </text>
<text top="497" left="170" width="612" height="14" font="3">is more likely to occur in patients with reduced left ventricular ejection fraction. Patients receiving ibutilide should undergo continuous </text>
<text top="512" left="170" width="608" height="14" font="3">ECG monitoring during administration and for at least 4 hours after completion of dosing. Pretreatment with magnesium can increase </text>
<text top="527" left="170" width="250" height="14" font="3">the efficacy and reduce the risk of torsades de pointes.</text>
<text top="528" left="420" width="10" height="8" font="18">119</text>
<text top="527" left="430" width="350" height="14" font="3"> Anticoagulation issues for chemical cardioversion are the same as those for </text>
<text top="542" left="170" width="176" height="14" font="3">electrical cardioversion of atrial flutter.</text>
<text top="543" left="345" width="7" height="8" font="18">10</text>
<text top="571" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="571" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="564" left="170" width="623" height="14" font="1"><b>2.   Intravenous or oral beta blockers, diltiazem, or verapamil are useful for acute rate control in patients with atrial flutter who are </b></text>
<text top="579" left="184" width="119" height="14" font="1"><b>hemodynamically stable.</b></text>
<text top="579" left="303" width="24" height="8" font="20"><b>347–354</b></text>
<text top="646" left="78" width="20" height="14" font="3">See </text>
<text top="646" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="661" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="676" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="676" left="109" width="3" height="14" font="3">.</text>
<text top="601" left="170" width="624" height="14" font="3">It is often more difficult to achieve rate control for atrial flutter than for AF. Nonetheless, effective rate control may be achieved with beta </text>
<text top="616" left="170" width="609" height="14" font="3">blockers, diltiazem, or verapamil in patients with atrial flutter through a direct effect on the AV node. Hypotension is the main adverse </text>
<text top="631" left="170" width="589" height="14" font="3">effect. Intravenous diltiazem is the preferred intravenous calcium channel blocker for acute rate control because of its safety and </text>
<text top="646" left="170" width="38" height="14" font="3">efficacy.</text>
<text top="647" left="208" width="10" height="8" font="18">351</text>
<text top="646" left="218" width="564" height="14" font="3"> Diltiazem and verapamil should be avoided in patients with advanced heart failure and in patients with heart block or sinus </text>
<text top="661" left="170" width="604" height="14" font="3">node dysfunction in the absence of pacemaker therapy. Verapamil and diltiazem also should not be used in patients with known pre-</text>
<text top="676" left="170" width="628" height="14" font="3">excitation. The heart rate control achieved with beta blockers is similar to that seen with verapamil and diltiazem. The rate-slowing effect </text>
<text top="691" left="170" width="619" height="14" font="3">of beta blockers is largely related to reduction of sympathetic tone. Esmolol is generally the preferred intravenous beta blocker because </text>
<text top="706" left="170" width="79" height="14" font="3">of its rapid onset.</text>
<text top="707" left="249" width="10" height="8" font="18">353</text>
<text top="706" left="259" width="540" height="14" font="3"> Care should be used in administering beta blockers for rate control in atrial flutter patients with decompensated heart </text>
<text top="721" left="170" width="153" height="14" font="3">failure or reactive airway disease.</text>
<text top="722" left="323" width="10" height="8" font="18">355</text>
<text top="750" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="750" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="743" left="170" width="598" height="14" font="1"><b>3.   Elective synchronized cardioversion is indicated in stable patients with well-tolerated atrial flutter when a rhythm-control </b></text>
<text top="758" left="184" width="124" height="14" font="1"><b>strategy is being pursued.</b></text>
<text top="759" left="308" width="24" height="8" font="20"><b>356–358</b></text>
<text top="788" left="78" width="20" height="14" font="3">See </text>
<text top="788" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="803" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="818" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="818" left="109" width="3" height="14" font="3">.</text>
<text top="780" left="170" width="599" height="14" font="3">Heart rates can be difficult to control in atrial flutter. Cardioversion for atrial flutter can be successful at lower energy levels than for AF.</text>
<text top="781" left="768" width="10" height="8" font="18">356</text>
<text top="780" left="779" width="3" height="14" font="3"> </text>
<text top="795" left="170" width="566" height="14" font="3">Anticoagulation issues for cardioversion are the same as those for patients with AF and are addressed in the 2014 AF guideline.</text>
<text top="796" left="735" width="7" height="8" font="18">10</text>
<text top="795" left="742" width="56" height="14" font="3"> Restoration </text>
<text top="810" left="170" width="598" height="14" font="3">of sinus rhythm is favored to avoid development of tachycardia-mediated cardiomyopathy, which is associated with a rapid ventricular </text>
<text top="825" left="170" width="108" height="14" font="3">response in atrial flutter.</text>
<text top="855" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="855" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="847" left="170" width="592" height="14" font="1"><b>4.   Synchronized cardioversion is recommended for acute treatment of patients with atrial flutter who are hemodynamically </b></text>
<text top="862" left="184" width="281" height="14" font="1"><b>unstable and do not respond to pharmacological therapies.</b></text>
<text top="863" left="466" width="42" height="8" font="20"><b>75,208,356,359</b></text>
<text top="885" left="78" width="20" height="14" font="3">See </text>
<text top="885" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="900" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="915" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="915" left="109" width="3" height="14" font="3">.</text>
<text top="885" left="170" width="580" height="14" font="3">The ventricular rate in atrial flutter can be difficult to control with pharmacological therapy. In patients with any signs or symptoms </text>
<text top="900" left="170" width="582" height="14" font="3">of hemodynamic compromise attributed to atrial flutter, synchronized cardioversion (with appropriate considerations with regard to </text>
<text top="915" left="170" width="220" height="14" font="3">anticoagulation) should be pursued without delay.</text>
<text top="944" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="944" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="936" left="170" width="587" height="14" font="1"><b>5.   Rapid atrial pacing is useful for acute conversion of atrial flutter in patients who have pacing wires in place as part of a </b></text>
<text top="951" left="184" width="550" height="14" font="1"><b>permanent pacemaker or implantable cardioverter-defibrillator or for temporary atrial pacing after cardiac surgery.</b></text>
<text top="952" left="734" width="24" height="8" font="20"><b>360–364</b></text>
<text top="1020" left="78" width="20" height="14" font="3">See </text>
<text top="1020" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1035" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="1050" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="1050" left="109" width="3" height="14" font="3">.</text>
<text top="975" left="170" width="296" height="14" font="3">Atrial pacing is effective at terminating flutter in &gt;50% of cases.</text>
<text top="976" left="466" width="10" height="8" font="18">364</text>
<text top="975" left="476" width="289" height="14" font="3"> Atrial pacing is more commonly applied in situations in which </text>
<text top="990" left="170" width="604" height="14" font="3">atrial wires are already in place, such as in the postoperative setting or in patients with programmable cardiac implanted electrical </text>
<text top="1005" left="170" width="603" height="14" font="3">devices. A temporary pacing wire may also be placed and atrial pacing for termination of atrial flutter can be useful when sedation </text>
<text top="1020" left="170" width="607" height="14" font="3">is contraindicated, or in the setting of digitalis toxicity, in which DC cardioversion is contraindicated. Pace-termination is performed </text>
<text top="1035" left="170" width="594" height="14" font="3">by pacing the atrium at a rate starting approximately 5% to 10% above the atrial flutter rate to achieve atrial entrainment and by </text>
<text top="1050" left="170" width="106" height="14" font="3">maintaining pacing for </text>
<text top="1050" left="276" width="514" height="14" font="3">≥15 seconds, with repeated attempts at incrementally faster rates (reducing the pacing cycle length by 5 to 10 </text>
<text top="1065" left="170" width="198" height="14" font="3">ms until normal sinus rhythm or AF occurs.</text>
<text top="1066" left="368" width="10" height="8" font="18">364</text>
<text top="1065" left="379" width="408" height="14" font="3"> When AF is precipitated, this is often more easily rate-controlled and may subsequently </text>
<text top="1080" left="170" width="623" height="14" font="3">revert to sinus rhythm. Recommendations for anticoagulation with regard to pace-termination of atrial flutter are the same as those for </text>
<text top="1095" left="170" width="181" height="14" font="3">chemical or electrical conversion of AF.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e542  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="556" left="71" width="311" height="18" font="10"><b>7.4. Ongoing Management: Recommendations</b></text>
<text top="159" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="159" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="151" left="171" width="622" height="14" font="1"><b>6.   Acute antithrombotic therapy is recommended in patients with atrial flutter to align with recommended antithrombotic therapy </b></text>
<text top="166" left="186" width="97" height="14" font="1"><b>for patients with AF.</b></text>
<text top="167" left="282" width="10" height="8" font="20"><b>365</b></text>
<text top="244" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="244" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="259" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="274" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="274" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="191" left="171" width="590" height="14" font="3">The risk of stroke associated with AF is well established, and several RCTs have demonstrated the efficacy of anticoagulation  </text>
<text top="206" left="171" width="279" height="14" font="3">for stroke prevention in patients with additional risk factors.</text>
<text top="207" left="450" width="10" height="8" font="18">366</text>
<text top="206" left="461" width="289" height="14" font="3"> Anticoagulation has also been shown to prevent stroke when </text>
<text top="221" left="171" width="350" height="14" font="3">administered during the weeks immediately before and after cardioversion.</text>
<text top="222" left="522" width="10" height="8" font="18">367</text>
<text top="221" left="532" width="257" height="14" font="3"> Whether atrial flutter carries a risk of stroke similar to </text>
<text top="236" left="171" width="619" height="14" font="3">that in patients with AF has been debated in the past but is now supported by limited evidence from mechanistic, observational, and </text>
<text top="251" left="171" width="316" height="14" font="3">prospective studies that include patients primarily with atrial flutter.</text>
<text top="252" left="488" width="24" height="8" font="18">365–369</text>
<text top="251" left="512" width="268" height="14" font="3"> Several reports have suggested that the risk of stroke in </text>
<text top="266" left="171" width="614" height="14" font="3">patients with atrial flutter is mitigated by anticoagulation. Meta-analysis of 13 studies of patients undergoing cardioversion of atrial </text>
<text top="281" left="171" width="602" height="14" font="3">flutter reported short-term stroke risks ranging from 0% to 7%, and the thromboembolism rate in patients with sustained flutter  </text>
<text top="296" left="171" width="164" height="14" font="3">in 4 studies averaged 3% annually.</text>
<text top="297" left="335" width="10" height="8" font="18">365</text>
<text top="296" left="345" width="362" height="14" font="3"> Other studies have reported similar risk and effectiveness of anticoagulation.</text>
<text top="297" left="707" width="10" height="8" font="18">369</text>
<text top="296" left="718" width="72" height="14" font="3"> Therefore, on  </text>
<text top="311" left="171" width="603" height="14" font="3">the basis of the available data, recommendations for antithrombotic therapy for patients with atrial flutter are similar to those for </text>
<text top="326" left="171" width="78" height="14" font="3">patients with AF.</text>
<text top="327" left="249" width="7" height="8" font="18">10</text>
<text top="365" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="365" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="350" left="171" width="498" height="14" font="1"><b>1.   Intravenous amiodarone can be useful for acute control of the ventricular rate (in the absence of  </b></text>
<text top="365" left="186" width="560" height="14" font="1"><b>pre-excitation) in patients with atrial flutter and systolic heart failure, when beta blockers are contraindicated or </b></text>
<text top="380" left="186" width="55" height="14" font="1"><b>ineffective.</b></text>
<text top="381" left="241" width="35" height="8" font="20"><b>350,370,371</b></text>
<text top="441" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="441" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="456" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="471" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="471" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="404" left="171" width="619" height="14" font="3">Amiodarone may be useful for rate control in non–pre-excited atrial flutter because of its slowing of conduction through the AV node </text>
<text top="419" left="171" width="626" height="14" font="3">and prolongation of AV nodal refractoriness. Because it has less negative inotropic effect than beta blockers, diltiazem, and verapamil </text>
<text top="434" left="171" width="634" height="14" font="3">and may produce less hypotension, it may be preferred in critically ill patients or in those with tenuous hemodynamic stability. Because </text>
<text top="449" left="171" width="614" height="14" font="3">of potential toxicity, amiodarone should not be used for long-term rate control in most patients. Although unlikely, amiodarone may </text>
<text top="464" left="171" width="625" height="14" font="3">result in conversion of atrial flutter to sinus rhythm, so potential risks and benefits should be considered for patients with atrial flutter </text>
<text top="479" left="171" width="34" height="14" font="3">lasting </text>
<text top="478" left="205" width="235" height="14" font="3">≥48 hours who are not adequately anticoagulated.</text>
<text top="479" left="441" width="7" height="8" font="18">10</text>
<text top="479" left="448" width="335" height="14" font="3"> However, amiodarone is typically used for rate control only when other </text>
<text top="494" left="171" width="619" height="14" font="3">options are greatly limited. For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile </text>
<text top="509" left="171" width="56" height="14" font="3">used for AF.</text>
<text top="104" left="80" width="375" height="16" font="19"><b>Recommendations for Acute Treatment of Atrial Flutter (Continued)</b></text>
<text top="128" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="613" left="80" width="323" height="16" font="19"><b>Recommendations for Ongoing Management of Atrial Flutter</b></text>
<text top="637" left="82" width="20" height="14" font="1"><b>COR</b></text>
<text top="637" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="637" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="666" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="666" left="129" width="18" height="14" font="1"><b>B-R</b></text>
<text top="659" left="171" width="629" height="14" font="1"><b>1.   Catheter ablation of the CTI is useful in patients with atrial flutter that is either symptomatic or refractory to pharmacological </b></text>
<text top="674" left="186" width="60" height="14" font="1"><b>rate control.</b></text>
<text top="675" left="246" width="36" height="8" font="20"><b>243,372–375</b></text>
<text top="726" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="726" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="741" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="756" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="756" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="696" left="171" width="630" height="14" font="3">Rate control can be difficult to achieve in atrial flutter, and a rhythm control strategy is often chosen. Catheter ablation of CTI-dependent </text>
<text top="711" left="171" width="616" height="14" font="3">atrial flutter is often preferred to long-term pharmacological therapy; in this rhythm, the CTI represents the optimal target for ablation </text>
<text top="726" left="171" width="614" height="14" font="3">because a line of ablation between the tricuspid valve annulus and inferior vena cava can effectively interrupt the circuit. A variety of </text>
<text top="741" left="171" width="613" height="14" font="3">techniques are applicable, including various catheter types, energy delivery systems, and mapping and visualization tools; generally, </text>
<text top="756" left="171" width="624" height="14" font="3">success depends on creation of a complete line of block and permanent interruption of conduction across the CTI (Table 8). Successful </text>
<text top="771" left="171" width="604" height="14" font="3">ablation is often heralded by intraprocedural interruption of the arrhythmia and subsequent EP demonstration of bidirectional block </text>
<text top="786" left="171" width="118" height="14" font="3">across the ablated tissue.</text>
<text top="814" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="814" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="806" left="171" width="616" height="14" font="1"><b>2.   Beta blockers, diltiazem, or verapamil are useful to control the ventricular rate in patients with hemodynamically tolerated </b></text>
<text top="821" left="186" width="61" height="14" font="1"><b>atrial flutter.</b></text>
<text top="822" left="247" width="24" height="8" font="20"><b>347–349</b></text>
<text top="873" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="873" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="888" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="903" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="903" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="843" left="171" width="614" height="14" font="3">In some circumstances of persistent atrial flutter or in patients who have infrequent reasonably well-tolerated episodes of atrial flutter, </text>
<text top="858" left="171" width="609" height="14" font="3">a rate-control strategy may be chosen. In atrial flutter, the relatively slower atrial rate compared with AF often paradoxically results in </text>
<text top="873" left="171" width="624" height="14" font="3">more rapid AV nodal conduction because there is less concealed AV nodal conduction. Therefore, achieving adequate rate control can be </text>
<text top="888" left="171" width="619" height="14" font="3">difficult. Higher doses of beta blockers, diltiazem, or verapamil, and often a combination of agents, may be needed to achieve adequate </text>
<text top="903" left="171" width="618" height="14" font="3">rate control. Beta blockers are generally preferred in patients with heart failure. Avoidance of beta blockers, diltiazem, and verapamil in </text>
<text top="918" left="171" width="615" height="14" font="3">patients with pre-excited atrial flutter is recommended, given the potential for accelerated ventricular rates degenerating to ventricular </text>
<text top="933" left="171" width="340" height="14" font="3">fibrillation, as has been reported to occur rarely in similar patients with AF.</text>
<text top="934" left="511" width="10" height="8" font="18">274</text>
<text top="962" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="962" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="954" left="171" width="593" height="14" font="1"><b>3.   Catheter ablation is useful in patients with recurrent symptomatic non–CTI-dependent flutter after failure of at least 1 </b></text>
<text top="969" left="186" width="105" height="14" font="1"><b>antiarrhythmic agent.</b></text>
<text top="970" left="292" width="22" height="8" font="20"><b>134,327</b></text>
<text top="1029" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1029" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1044" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="1059" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="1059" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="991" left="171" width="619" height="14" font="3">No prospective RCTs have compared the efficacy or safety of antiarrhythmic drugs with that of catheter ablation for non–CTI-dependent </text>
<text top="1006" left="171" width="627" height="14" font="3">atrial flutter. In general, catheter ablation of non–CTI-dependent atrial flutter is substantially more difficult than ablation of CTI-dependent </text>
<text top="1021" left="171" width="609" height="14" font="3">flutter because the anatomic circuits are complex, are often not anatomically defined, and can be difficult to locate. Knowledge of the </text>
<text top="1036" left="171" width="604" height="14" font="3">prior surgical or ablation approach and detailed activation and entrainment mapping of the tachycardia are useful during attempts at </text>
<text top="1051" left="171" width="631" height="14" font="3">ablation (Table 8). The location of the circuit determines ablation approach and risks. Observational data support the relative effectiveness </text>
<text top="1066" left="171" width="247" height="14" font="3">and safety of catheter ablation in experienced centers.</text>
<text top="1067" left="418" width="22" height="8" font="18">134,327</text>
<text top="1066" left="441" width="342" height="14" font="3"> Many of the atrial flutters that are observed during the first 3 months after </text>
<text top="1081" left="171" width="605" height="14" font="3">catheter ablation or cardiac surgery will not persist beyond the periprocedural period, so attempts at ablation can be deferred unless </text>
<text top="1096" left="171" width="291" height="14" font="3">pharmacological therapy and/or cardioversion are unsuccessful.</text>
<text top="1097" left="462" width="10" height="8" font="18">327</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e543</i></b></text>
<text top="157" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="157" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="150" left="170" width="625" height="14" font="1"><b>4.   Ongoing management with antithrombotic therapy is recommended in patients with atrial flutter to align with recommended </b></text>
<text top="165" left="185" width="214" height="14" font="1"><b>antithrombotic therapy for patients with AF.</b></text>
<text top="166" left="399" width="10" height="8" font="20"><b>365</b></text>
<text top="232" left="78" width="20" height="14" font="3">See </text>
<text top="232" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="247" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="262" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="262" left="109" width="3" height="14" font="3">.</text>
<text top="187" left="169" width="619" height="14" font="3">The risk of stroke associated with AF is well established, and several RCTs have demonstrated the efficacy of anticoagulation for stroke </text>
<text top="202" left="169" width="225" height="14" font="3">prevention in patients with additional risk factors.</text>
<text top="202" left="394" width="10" height="8" font="18">366</text>
<text top="202" left="405" width="394" height="14" font="3"> Anticoagulation has also been shown to prevent stroke when administered during the </text>
<text top="217" left="169" width="230" height="14" font="3">weeks immediately before and after cardioversion.</text>
<text top="217" left="400" width="10" height="8" font="18">367</text>
<text top="217" left="410" width="377" height="14" font="3"> Whether atrial flutter carries a risk of stroke similar to that in patients with AF has </text>
<text top="232" left="169" width="624" height="14" font="3">been debated in the past but is now supported by limited evidence from mechanistic, observational, and prospective studies that include </text>
<text top="247" left="169" width="160" height="14" font="3">patients primarily with atrial flutter.</text>
<text top="247" left="330" width="24" height="8" font="18">365–369</text>
<text top="247" left="354" width="448" height="14" font="3"> Several reports have suggested that the risk of stroke in patients with atrial flutter is mitigated by </text>
<text top="262" left="169" width="627" height="14" font="3">anticoagulation. Meta-analysis of 13 studies of patients undergoing cardioversion of atrial flutter reported short-term stroke risks ranging </text>
<text top="277" left="169" width="527" height="14" font="3">from 0% to 7%, and the thromboembolism rate in patients with sustained flutter in 4 studies averaged 3% annually.</text>
<text top="277" left="697" width="10" height="8" font="18">365</text>
<text top="277" left="707" width="91" height="14" font="3"> Other studies have </text>
<text top="292" left="170" width="261" height="14" font="3">reported similar risk and effectiveness of anticoagulation.</text>
<text top="292" left="431" width="10" height="8" font="18">369</text>
<text top="292" left="441" width="360" height="14" font="3"> Therefore, on the basis of available data, recommendations for antithrombotic </text>
<text top="307" left="170" width="352" height="14" font="3">therapy for patients with atrial flutter are similar to those for patients with AF.</text>
<text top="307" left="522" width="7" height="8" font="18">10</text>
<text top="358" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="358" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="328" left="169" width="622" height="14" font="1"><b>1.   The following drugs can be useful to maintain sinus rhythm in patients with symptomatic, recurrent atrial flutter, with the drug </b></text>
<text top="343" left="184" width="311" height="14" font="1"><b>choice depending on underlying heart disease and comorbidities:</b></text>
<text top="358" left="169" width="84" height="14" font="1"><b>  a. Amiodarone</b></text>
<text top="359" left="254" width="10" height="8" font="20"><b>376</b></text>
<text top="373" left="170" width="72" height="14" font="1"><b>  b. Dofetilide</b></text>
<text top="374" left="242" width="22" height="8" font="20"><b>346,377</b></text>
<text top="388" left="170" width="59" height="14" font="1"><b>  c. Sotalol</b></text>
<text top="389" left="229" width="10" height="8" font="20"><b>378</b></text>
<text top="462" left="78" width="20" height="14" font="3">See </text>
<text top="462" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="477" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="492" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="492" left="109" width="3" height="14" font="3">.</text>
<text top="410" left="169" width="607" height="14" font="3">In patients in whom ablation is not being considered because of contraindications (such as underlying medical illness) or because </text>
<text top="425" left="169" width="600" height="14" font="3">of patient preference, a variety of antiarrhythmic drugs are available. These drugs act by suppressing triggers and altering atrial </text>
<text top="440" left="169" width="615" height="14" font="3">tissue refractoriness. Individual properties of each drug need to be considered for proper use. Much of the data pertaining to use of </text>
<text top="455" left="169" width="448" height="14" font="3">amiodarone in management of atrial arrhythmias has been derived from use in patients with AF.</text>
<text top="455" left="617" width="7" height="8" font="18">10</text>
<text top="455" left="624" width="167" height="14" font="3"> Few data are available for patients </text>
<text top="470" left="170" width="611" height="14" font="3">with atrial flutter. Amiodarone has significant toxicities, so it is used only when other treatments are contraindicated or ineffective. </text>
<text top="485" left="170" width="576" height="14" font="3">Nevertheless, administration is reasonable, particularly in patients with heart failure or significant underlying heart disease.</text>
<text top="485" left="745" width="10" height="8" font="18">376</text>
<text top="500" left="169" width="450" height="14" font="3">Dofetilide may be more effective than many other drugs but must be started in an inpatient setting.</text>
<text top="500" left="620" width="22" height="8" font="18">346,377</text>
<text top="500" left="642" width="158" height="14" font="3"> The dose is adjusted on the basis </text>
<text top="515" left="169" width="509" height="14" font="3">of renal function, with close monitoring of the Q-T interval and subsequent monitoring for altered renal function.</text>
<text top="530" left="169" width="618" height="14" font="3">Sotalol, a class III antiarrhythmic, is generally well tolerated but is associated with typical beta blocker side effects, such as fatigue and </text>
<text top="545" left="169" width="56" height="14" font="3">bradycardia.</text>
<text top="545" left="226" width="10" height="8" font="18">378</text>
<text top="545" left="236" width="335" height="14" font="3"> The major potential cardiac toxicity for both drugs is torsades de pointes.</text>
<text top="573" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="573" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="565" left="169" width="625" height="14" font="1"><b>2.   Catheter ablation is reasonable in patients with CTI-dependent atrial flutter that occurs as the result of flecainide, propafenone, </b></text>
<text top="580" left="184" width="191" height="14" font="1"><b>or amiodarone used for treatment of AF.</b></text>
<text top="581" left="375" width="35" height="8" font="20"><b>317,379–381</b></text>
<text top="602" left="78" width="20" height="14" font="3">See </text>
<text top="602" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="617" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="632" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="632" left="109" width="3" height="14" font="3">.</text>
<text top="602" left="169" width="623" height="14" font="3">Some patients with AF treated with propafenone, flecainide, or amiodarone will develop atrial flutter. In this circumstance, if flutter becomes </text>
<text top="617" left="169" width="610" height="14" font="3">the dominant arrhythmia, ablation of the CTI and continued use of the antiarrhythmic drug can decrease the incidence of atrial flutter and </text>
<text top="632" left="169" width="220" height="14" font="3">facilitate the pharmacological management of AF.</text>
<text top="633" left="390" width="22" height="8" font="18">379,380</text>
<text top="661" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="661" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="653" left="169" width="626" height="14" font="1"><b>3.   Catheter ablation of the CTI is reasonable in patients undergoing catheter ablation of AF who also have a history of documented </b></text>
<text top="668" left="184" width="223" height="14" font="1"><b>clinical or induced CTI-dependent atrial flutter.</b></text>
<text top="669" left="407" width="22" height="8" font="20"><b>381,382</b></text>
<text top="698" left="78" width="20" height="14" font="3">See </text>
<text top="698" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="713" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="728" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="728" left="109" width="3" height="14" font="3">.</text>
<text top="690" left="169" width="363" height="14" font="3">The indications for catheter ablation of AF are discussed in the 2014 AF guideline.</text>
<text top="691" left="532" width="7" height="8" font="18">10</text>
<text top="690" left="539" width="246" height="14" font="3"> When AF and atrial flutter coexist, 1 randomized study </text>
<text top="705" left="169" width="629" height="14" font="3">demonstrated that at 1-year follow-up, greater success in terms of arrhythmia suppression and quality-of-life score resulted from AF ablation </text>
<text top="720" left="169" width="332" height="14" font="3">(with or without atrial flutter ablation) than from atrial flutter ablation alone.</text>
<text top="721" left="502" width="10" height="8" font="18">381</text>
<text top="720" left="512" width="267" height="14" font="3"> It may be that AF ablation alone is sufficient to control both </text>
<text top="735" left="169" width="414" height="14" font="3">arrhythmias, although CTI ablation reduced the early postablation arrhythmia recurrence rate.</text>
<text top="736" left="583" width="10" height="8" font="18">382</text>
<text top="771" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="771" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="756" left="169" width="608" height="14" font="1"><b>4.   Catheter ablation is reasonable in patients with recurrent symptomatic non–CTI-dependent flutter as primary therapy, </b></text>
<text top="771" left="185" width="576" height="14" font="1"><b>before therapeutic trials of antiarrhythmic drugs, after carefully weighing potential risks and benefits of treatment </b></text>
<text top="786" left="185" width="40" height="14" font="1"><b>options.</b></text>
<text top="787" left="225" width="10" height="8" font="20"><b>135</b></text>
<text top="823" left="78" width="20" height="14" font="3">See </text>
<text top="823" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="838" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="853" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="853" left="109" width="3" height="14" font="3">.</text>
<text top="808" left="169" width="627" height="14" font="3">No prospective RCTs have compared the efficacy or safety of antiarrhythmic drugs with that of catheter ablation for non–CTI-dependent </text>
<text top="823" left="169" width="604" height="14" font="3">atrial flutter. Observational data, however, support the relative effectiveness and safety of catheter ablation in experienced centers.</text>
<text top="823" left="773" width="22" height="8" font="18">135,327</text>
<text top="823" left="796" width="3" height="14" font="3"> </text>
<text top="838" left="169" width="595" height="14" font="3">Many of the atrial flutters that are observed during the first 3 months after ablation or cardiac surgery will not persist beyond the </text>
<text top="853" left="169" width="588" height="14" font="3">periprocedural period, so attempts at ablation can be deferred unless attempts at pharmacological therapy or cardioversion are </text>
<text top="868" left="169" width="63" height="14" font="3">unsuccessful.</text>
<text top="868" left="233" width="10" height="8" font="18">135</text>
<text top="896" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="896" left="128" width="18" height="14" font="1"><b>B-R</b></text>
<text top="889" left="170" width="624" height="14" font="1"><b>1.   Flecainide or propafenone may be considered to maintain sinus rhythm in patients without structural heart disease or ischemic </b></text>
<text top="904" left="184" width="287" height="14" font="1"><b>heart disease who have symptomatic recurrent atrial flutter.</b></text>
<text top="905" left="471" width="24" height="8" font="20"><b>383–385</b></text>
<text top="948" left="78" width="20" height="14" font="3">See </text>
<text top="948" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="963" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="978" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="978" left="109" width="3" height="14" font="3">.</text>
<text top="926" left="169" width="621" height="14" font="3">Data to support the recommendation for flecainide and propafenone for maintenance of sinus rhythm in patients with atrial flutter is derived </text>
<text top="941" left="169" width="613" height="14" font="3">from trials that pooled patients with AF and atrial flutter, with the vast majority of the patients having AF. It is therefore possible that these </text>
<text top="956" left="169" width="345" height="14" font="3">agents are not as effective for treating isolated atrial flutter as they are for AF.</text>
<text top="956" left="514" width="10" height="8" font="18">386</text>
<text top="956" left="524" width="279" height="14" font="3"> Flecainide and propafenone may result in slowing of the atrial </text>
<text top="971" left="169" width="316" height="14" font="3">flutter cycle length, which may lead to a rapid 1:1 ventricular response.</text>
<text top="971" left="485" width="10" height="8" font="18">387</text>
<text top="971" left="495" width="304" height="14" font="3"> Because of this, caution is advised with flecainide and propafenone </text>
<text top="986" left="169" width="594" height="14" font="3">in patients with atrial flutter at risk of 1:1 conduction. The risk may be reduced by coadministration of medications that slow AV nodal </text>
<text top="1001" left="169" width="261" height="14" font="3">conduction, such as beta blockers, verapamil, or diltiazem.</text>
<text top="1022" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="1022" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1022" left="169" width="451" height="14" font="1"><b>2.   Catheter ablation may be reasonable for asymptomatic patients with recurrent atrial flutter.</b></text>
<text top="1022" left="621" width="34" height="8" font="20"><b>102,121,372</b></text>
<text top="1043" left="78" width="20" height="14" font="3">See </text>
<text top="1043" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1058" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="1073" left="78" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="1073" left="109" width="3" height="14" font="3">.</text>
<text top="1043" left="169" width="418" height="14" font="3">Catheter ablation of atrial flutter is highly effective, with single-procedure success rates &gt;90%</text>
<text top="1044" left="588" width="10" height="8" font="18">102</text>
<text top="1043" left="598" width="139" height="14" font="3"> and an excellent safety profile.</text>
<text top="1044" left="737" width="22" height="8" font="18">102,121</text>
<text top="1043" left="758" width="14" height="14" font="3"> In </text>
<text top="1058" left="170" width="617" height="14" font="3">patients with recurrent atrial flutter, long-term maintenance of sinus rhythm is more likely with ablation than with pharmacological therapy.</text>
<text top="1059" left="786" width="10" height="8" font="18">372</text>
<text top="1058" left="796" width="3" height="14" font="3"> </text>
<text top="1073" left="170" width="396" height="14" font="3">Also, ablation may avoid potential development of tachycardia-mediated cardiomyopathy.</text>
<text top="104" left="78" width="391" height="16" font="19"><b>Recommendations for Ongoing Management of Atrial Flutter (Continued)</b></text>
<text top="128" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="127" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="169" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e544  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="783" left="151" width="190" height="20" font="12"><b>8. Junctional Tachycardia</b></text>
<text top="804" left="71" width="351" height="16" font="13">See Figure 20 for a representative ECG for junctional tachy-</text>
<text top="821" left="71" width="351" height="16" font="13">cardia and Figure 21 for the algorithm for ongoing manage-</text>
<text top="838" left="71" width="177" height="16" font="13">ment of junctional tachycardia.</text>
<text top="97" left="479" width="335" height="16" font="13">Junctional tachycardia is a rapid, occasionally irregular, </text>
<text top="115" left="458" width="355" height="16" font="13">narrow-complex tachycardia (with rates typically of 120 bpm </text>
<text top="132" left="458" width="355" height="16" font="13">to 220 bpm) (Figure 20). AV dissociation (often isorhythmic) </text>
<text top="149" left="458" width="355" height="16" font="13">may be seen, and when present, excludes the misdiagnosis of </text>
<text top="166" left="458" width="357" height="16" font="13">AVRT and makes AVNRT highly unlikely. Other SVTs are </text>
<text top="184" left="458" width="351" height="16" font="13">often misdiagnosed and misclassified as junctional tachycar-</text>
<text top="201" left="458" width="355" height="16" font="13">dia because of the frequent absence of demonstrable P waves </text>
<text top="218" left="458" width="351" height="16" font="13">in reentrant rhythms. Furthermore, when it is irregular, junc-</text>
<text top="235" left="458" width="356" height="16" font="13">tional tachycardia may be misdiagnosed as AF or MAT. The </text>
<text top="253" left="458" width="354" height="16" font="13">mechanism for junctional tachycardia is enhanced (abnormal) </text>
<text top="270" left="458" width="351" height="16" font="13">automaticity from an ectopic focus in the AV junction (includ-</text>
<text top="287" left="458" width="113" height="16" font="13">ing the His bundle).</text>
<text top="288" left="570" width="12" height="9" font="14">388</text>
<text top="304" left="479" width="281" height="16" font="13">Junctional tachycardia is uncommon in adults</text>
<text top="305" left="760" width="12" height="9" font="14">388</text>
<text top="304" left="772" width="44" height="16" font="13">; it is </text>
<text top="322" left="458" width="355" height="16" font="13">typically seen in infants postoperatively, after cardiac surgery </text>
<text top="339" left="458" width="356" height="16" font="13">for congenital heart disease; this is also known as junctional </text>
<text top="356" left="458" width="356" height="16" font="13">ectopic tachycardia. As such, there is limited evidence with </text>
<text top="373" left="458" width="354" height="16" font="13">regard to diagnosis and management of junctional tachycardia </text>
<text top="391" left="458" width="355" height="16" font="13">in adult patients. Adults with junctional tachycardia typically </text>
<text top="408" left="458" width="355" height="16" font="13">have a relatively benign course, whereas infants and children </text>
<text top="425" left="458" width="354" height="16" font="13">with acquired or congenital junctional tachycardia have a high </text>
<text top="442" left="458" width="351" height="16" font="13">rate of death due to heart failure or an uncontrollable, inces-</text>
<text top="460" left="458" width="123" height="16" font="13">sant tachyarrhythmia.</text>
<text top="477" left="479" width="330" height="16" font="13">There are data to support the use of beta blockers, diltia-</text>
<text top="494" left="458" width="357" height="16" font="13">zem, flecainide, procainamide, propafenone, and verapamil </text>
<text top="511" left="458" width="351" height="16" font="13">for the treatment of junctional tachycardia (see recommenda-</text>
<text top="529" left="458" width="355" height="16" font="13">tions and references in Sections 8.1 and 8.2). The efficacy of </text>
<text top="546" left="458" width="324" height="16" font="13">amiodarone has been reported only in pediatric patients.</text>
<text top="546" left="781" width="27" height="9" font="14">389,390</text>
<text top="546" left="809" width="4" height="16" font="13"> </text>
<text top="563" left="457" width="355" height="16" font="13">Digoxin has not been well established as chronic therapy for </text>
<text top="580" left="457" width="130" height="16" font="13">junctional tachycardia.</text>
<text top="598" left="479" width="330" height="16" font="13">A related rhythm, nonparoxysmal junctional tachycar-</text>
<text top="615" left="457" width="357" height="16" font="13">dia (more commonly known as accelerated AV junctional </text>
<text top="632" left="457" width="358" height="16" font="13">rhythm), is far more common in adults than paroxysmal </text>
<text top="649" left="457" width="357" height="16" font="13">junctional tachycardia. The mechanism of nonparoxysmal </text>
<text top="667" left="457" width="351" height="16" font="13">junctional tachycardia is associated with automaticity or trig-</text>
<text top="684" left="457" width="354" height="16" font="13">gered activity. It occurs at a slower rate (70 bpm to 130 bpm) </text>
<text top="701" left="457" width="209" height="16" font="13">and is often due to digoxin toxicity</text>
<text top="702" left="666" width="13" height="9" font="14">391</text>
<text top="701" left="679" width="130" height="16" font="13"> or myocardial infarc-</text>
<text top="718" left="458" width="26" height="16" font="13">tion.</text>
<text top="719" left="484" width="27" height="9" font="14">392,393</text>
<text top="718" left="512" width="300" height="16" font="13"> Treatment of this rhythm centers on addressing the </text>
<text top="736" left="457" width="357" height="16" font="13">underlying condition. In addition, there is some evidence </text>
<text top="753" left="457" width="108" height="16" font="13">that beta blockers,</text>
<text top="753" left="566" width="13" height="9" font="14">394</text>
<text top="753" left="578" width="217" height="16" font="13"> intravenous adenosine, or verapamil</text>
<text top="753" left="796" width="13" height="9" font="14">395</text>
<text top="753" left="809" width="4" height="16" font="13"> </text>
<text top="770" left="457" width="351" height="16" font="13">can terminate an accelerated junctional arrhythmia. A tran-</text>
<text top="787" left="457" width="351" height="16" font="13">sient junction rhythm may be seen after slow-pathway abla-</text>
<text top="805" left="457" width="96" height="16" font="13">tion for AVNRT.</text>
<text top="805" left="554" width="13" height="9" font="14">396</text>
<text top="836" left="458" width="273" height="18" font="10"><b>8.1. Acute Treatment: Recommendations</b></text>
<text top="882" left="80" width="367" height="16" font="19"><b>Recommendations for Acute Treatment of Junctional Tachycardia</b></text>
<text top="906" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="906" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="906" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="928" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="928" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="928" left="171" width="561" height="14" font="1"><b>1.   Intravenous beta blockers are reasonable for acute treatment in patients with symptomatic junctional tachycardia.</b></text>
<text top="928" left="733" width="10" height="8" font="20"><b>388</b></text>
<text top="949" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="949" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="964" left="80" width="67" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="964" left="147" width="3" height="14" font="3">.</text>
<text top="949" left="171" width="612" height="14" font="3">In a series studying junctional tachycardia in adult patients, beta-blocker therapy—specifically intravenous propranolol—was found to be </text>
<text top="964" left="171" width="349" height="14" font="3">modestly effective in terminating and/or reducing the incidence of tachycardia.</text>
<text top="965" left="520" width="10" height="8" font="18">388</text>
<text top="985" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="985" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="985" left="171" width="605" height="14" font="1"><b>2.   Intravenous diltiazem, procainamide, or verapamil is reasonable for acute treatment in patients with junctional tachycardia.</b></text>
<text top="986" left="776" width="10" height="8" font="20"><b>397</b></text>
<text top="1015" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1015" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1030" left="80" width="67" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="1030" left="147" width="3" height="14" font="3">.</text>
<text top="1007" left="171" width="585" height="14" font="3">There may be a limited role for intravenous diltiazem, procainamide, or verapamil in patients in whom beta blockers are ineffective. </text>
<text top="1022" left="171" width="582" height="14" font="3">The literature supports the use of intravenous verapamil, alone or in combination with procainamide; less is known about diltiazem </text>
<text top="1037" left="171" width="61" height="14" font="3">monotherapy.</text>
<text top="1038" left="232" width="10" height="8" font="18">397</text>
<text top="1037" left="242" width="437" height="14" font="3"> The addition of procainamide to propranolol may be more effective than propranolol monotherapy.</text>
<text top="1038" left="680" width="10" height="8" font="18">388</text>
<text top="665" left="71" width="326" height="14" font="1"><b>Figure 14.</b> Acute treatment of orthodromic AVRT. Colors cor-</text>
<text top="678" left="71" width="330" height="14" font="3">respond to Class of Recommendation in Table 1; drugs listed </text>
<text top="692" left="71" width="338" height="14" font="3">alphabetically. *For rhythms that break or recur spontaneously, </text>
<text top="705" left="71" width="335" height="14" font="3">synchronized cardioversion is not appropriate. AVRT indicates </text>
<text top="719" left="71" width="339" height="14" font="3">atrioventricular reentrant tachycardia; ECG, electrocardiogram; </text>
<text top="732" left="71" width="105" height="14" font="3">and IV, intravenous.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e545</i></b></text>
<text top="97" left="69" width="311" height="18" font="10"><b>8.2. Ongoing Management: Recommendations</b></text>
<text top="676" left="164" width="161" height="20" font="12"><b>9. Special Populations</b></text>
<text top="702" left="69" width="95" height="18" font="10"><b>9.1. Pediatrics</b></text>
<text top="723" left="69" width="351" height="16" font="13">As discussed in the Scope (Section 1.4), the present docu-</text>
<text top="741" left="69" width="224" height="16" font="13">ment is aimed at the adult population (</text>
<text top="740" left="294" width="130" height="17" font="13">≥18 years of age) and </text>
<text top="758" left="69" width="357" height="16" font="13">offers no specific recommendations for pediatric patients. </text>
<text top="775" left="69" width="355" height="16" font="13">Nevertheless, a brief discussion of SVT in pediatric patients </text>
<text top="792" left="69" width="357" height="16" font="13">is included below, highlighting major considerations with </text>
<text top="810" left="69" width="358" height="16" font="13">regard to SVT in younger patients, including adolescent </text>
<text top="827" left="69" width="49" height="16" font="13">patients.</text>
<text top="844" left="90" width="337" height="16" font="13">SVT in young patients varies significantly from SVT </text>
<text top="861" left="69" width="356" height="16" font="13">in adult patients in terms of mechanism, risk of developing </text>
<text top="879" left="69" width="351" height="16" font="13">heart failure or cardiac arrest, risks associated with inter-</text>
<text top="896" left="69" width="357" height="16" font="13">ventional therapy, natural history, and psychosocial impact. </text>
<text top="913" left="69" width="356" height="16" font="13">Approximately half of pediatric SVT presents in the first 4 </text>
<text top="930" left="69" width="351" height="16" font="13">months of life, with age-related peaks in occurrence subse-</text>
<text top="948" left="69" width="351" height="16" font="13">quently at 5 to 8 years and after 13 years. Accessory pathway–</text>
<text top="965" left="69" width="356" height="16" font="13">mediated tachycardia accounts for &gt;70% of SVT in infants, </text>
<text top="982" left="69" width="312" height="16" font="13">decreasing to approximately 55% in adolescents.</text>
<text top="983" left="381" width="39" height="9" font="14">56,407–409</text>
<text top="982" left="420" width="4" height="16" font="13"> </text>
<text top="999" left="69" width="358" height="16" font="13">AVNRT increases with age, from 9% to 13% of SVT in </text>
<text top="1017" left="69" width="356" height="16" font="13">infants, to 30% to 50% of SVT in teenagers. After 12 years </text>
<text top="1034" left="69" width="354" height="16" font="13">of age, women are more likely to have AVNRT than men, and </text>
<text top="1051" left="69" width="357" height="16" font="13">overall SVT is less frequent among African American and </text>
<text top="1068" left="69" width="343" height="16" font="13">Hispanic patients than in the general pediatric population.</text>
<text top="1069" left="412" width="8" height="9" font="14">56</text>
<text top="1068" left="420" width="4" height="16" font="13"> </text>
<text top="1086" left="69" width="356" height="16" font="13">Atrial flutter is seen in some neonates and in older children </text>
<text top="1103" left="69" width="355" height="16" font="13">is predominantly observed after congenital heart disease. AF </text>
<text top="672" left="456" width="351" height="16" font="13">is uncommon in childhood, accounting for &lt;3% of supraven-</text>
<text top="689" left="456" width="356" height="16" font="13">tricular arrhythmias, and may be a consequence of AVRT or </text>
<text top="706" left="456" width="357" height="16" font="13">AVNRT in adolescents or may be associated with repaired </text>
<text top="724" left="456" width="357" height="16" font="13">congenital heart disease. Symptoms of SVT vary with age: </text>
<text top="741" left="456" width="358" height="16" font="13">gastrointestinal or respiratory findings in infants, chest or </text>
<text top="758" left="456" width="356" height="16" font="13">abdominal pain in the younger child, and palpitations in the </text>
<text top="775" left="456" width="354" height="16" font="13">adolescent. Congestive heart failure is present in up to 20% of </text>
<text top="793" left="456" width="354" height="16" font="13">infants and in older children with incessant tachycardia and in </text>
<text top="810" left="456" width="351" height="16" font="13">rare cases may necessitate mechanical cardiopulmonary sup-</text>
<text top="827" left="456" width="149" height="16" font="13">port during initial therapy.</text>
<text top="828" left="605" width="12" height="9" font="14">410</text>
<text top="844" left="477" width="334" height="16" font="13">Pre-excitation is present in 20% to 35% of children with </text>
<text top="862" left="456" width="357" height="16" font="13">SVT. The risk of ventricular fibrillation or SCD related to </text>
<text top="879" left="456" width="355" height="16" font="13">WPW in childhood is 1.3% to 1.6% and is highest in the first </text>
<text top="896" left="456" width="102" height="16" font="13">2 decades of life.</text>
<text top="897" left="558" width="39" height="9" font="14">60,254–257</text>
<text top="896" left="597" width="215" height="16" font="13"> The risk of cardiac arrest is higher </text>
<text top="913" left="456" width="351" height="16" font="13">in patients with AVRT precipitating AF, short accessory con-</text>
<text top="931" left="456" width="351" height="16" font="13">nection refractory periods, and posteroseptal accessory path-</text>
<text top="948" left="456" width="33" height="16" font="13">ways.</text>
<text top="948" left="489" width="39" height="9" font="14">60,254–257</text>
<text top="948" left="528" width="282" height="16" font="13"> Notably, the absence of prior symptoms does not </text>
<text top="965" left="456" width="351" height="16" font="13">preclude risk because cardiac arrest may be the initial mani-</text>
<text top="982" left="456" width="152" height="16" font="13">festation of pre-excitation.</text>
<text top="983" left="608" width="42" height="9" font="14">254,257,411</text>
<text top="982" left="650" width="162" height="16" font="13"> Risk stratification, such as </text>
<text top="1000" left="456" width="358" height="16" font="13">with ambulatory 24-hour monitoring or treadmill exercise </text>
<text top="1017" left="456" width="355" height="16" font="13">testing, is often considered for children with pre-excitation to </text>
<text top="1034" left="456" width="203" height="16" font="13">assess persistence of pre-excitation.</text>
<text top="1035" left="659" width="12" height="9" font="14">412</text>
<text top="1051" left="477" width="335" height="16" font="13">Pharmacological therapy of SVT in childhood is largely </text>
<text top="1069" left="456" width="357" height="16" font="13">based on practice patterns because RCTs of antiarrhythmic </text>
<text top="1086" left="456" width="354" height="16" font="13">medications in children are lacking. AV nodal–blocking drugs </text>
<text top="1103" left="456" width="354" height="16" font="13">are widely used for the most common arrhythmias, AVRT, and </text>
<text top="139" left="78" width="396" height="16" font="19"><b>Recommendations for Ongoing Management of Junctional Tachycardia</b></text>
<text top="165" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="165" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="165" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="188" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="188" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="188" left="170" width="487" height="14" font="1"><b>1.   Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia.</b></text>
<text top="188" left="657" width="10" height="8" font="20"><b>388</b></text>
<text top="220" left="78" width="20" height="14" font="3">See </text>
<text top="220" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="235" left="78" width="68" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="235" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="213" left="170" width="624" height="14" font="3">Beta blockers are often used as first-line chronic therapy for junctional tachycardia because of the important proarrhythmic effects and long-</text>
<text top="228" left="170" width="294" height="14" font="3">term toxicity of other agents that have been shown to be effective.</text>
<text top="228" left="463" width="34" height="8" font="18">389,398,399</text>
<text top="228" left="497" width="285" height="14" font="3"> When junctional tachycardia is paroxysmal, attention should be </text>
<text top="243" left="170" width="512" height="14" font="3">directed toward avoiding the potential for bradyarrhythmias and hypotension when beta-blocker therapy is initiated.</text>
<text top="267" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="267" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="267" left="170" width="522" height="14" font="1"><b>2.   Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia.</b></text>
<text top="268" left="692" width="10" height="8" font="20"><b>397</b></text>
<text top="307" left="78" width="20" height="14" font="3">See </text>
<text top="307" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="322" left="78" width="68" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="322" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="292" left="170" width="618" height="14" font="3">Junctional tachycardia caused by enhanced automaticity may be suppressed as effectively by diltiazem and verapamil as by beta blockers. </text>
<text top="307" left="170" width="616" height="14" font="3">In 1 study of an adult patient on a regimen of oral verapamil, procainamide, and digoxin in combination for prophylactic therapy, junctional </text>
<text top="322" left="170" width="587" height="14" font="3">tachycardia could not be induced by either atrial or ventricular overdrive pacing, programmed electrical stimulation, or isoproterenol.</text>
<text top="322" left="757" width="10" height="8" font="18">397</text>
<text top="322" left="767" width="36" height="14" font="3"> Less is </text>
<text top="337" left="170" width="342" height="14" font="3">known about oral diltiazem than verapamil, but it likely has a similar efficacy.</text>
<text top="368" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="368" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="361" left="170" width="625" height="14" font="1"><b>1.   Flecainide or propafenone may be reasonable for ongoing management in patients without structural heart disease or ischemic </b></text>
<text top="376" left="184" width="225" height="14" font="1"><b>heart disease who have junctional tachycardia.</b></text>
<text top="376" left="409" width="22" height="8" font="20"><b>398,399</b></text>
<text top="423" left="78" width="20" height="14" font="3">See </text>
<text top="423" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="438" left="78" width="68" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="438" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="400" left="170" width="461" height="14" font="3">Studies supporting the use of flecainide for long-term control of junctional tachycardia were performed  </text>
<text top="415" left="170" width="219" height="14" font="3">at a time when intravenous flecainide was given  </text>
<text top="430" left="170" width="287" height="14" font="3">for acute control, followed by a transition to chronic oral therapy.</text>
<text top="431" left="457" width="10" height="8" font="18">398</text>
<text top="430" left="467" width="323" height="14" font="3"> Although the only data for propafenone stem from case series in infants </text>
<text top="445" left="170" width="627" height="14" font="3">and children, given that flecainide and propafenone reduce automaticity from the ectopic focus in the AV junction, either agent is reasonable, </text>
<text top="460" left="170" width="358" height="14" font="3">provided patients do not have structural heart disease or ischemic heart disease.</text>
<text top="461" left="528" width="34" height="8" font="18">213,400,401</text>
<text top="492" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="492" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="484" left="170" width="573" height="14" font="1"><b>2.   Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or </b></text>
<text top="499" left="184" width="78" height="14" font="1"><b>contraindicated.</b></text>
<text top="500" left="262" width="59" height="8" font="20"><b>131,132,396,402–405</b></text>
<text top="568" left="78" width="20" height="14" font="3">See </text>
<text top="568" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="583" left="78" width="68" height="14" font="21"><a href="">Supplement 19</a></text>
<text top="583" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="523" left="170" width="617" height="14" font="3">Radiofrequency ablation has been performed as a potentially curative therapy for junctional tachycardia since the early 1990s. However, in </text>
<text top="538" left="170" width="633" height="14" font="3">view of the reported 5% to 10% risk of AV block, catheter ablation is generally reserved for highly symptomatic patients in whom drug therapy </text>
<text top="553" left="170" width="562" height="14" font="3">has been ineffective or not tolerated (Table 8). Many practitioners use cryoablation as an alternative to radiofrequency ablation.</text>
<text top="553" left="732" width="10" height="8" font="18">132</text>
<text top="553" left="742" width="50" height="14" font="3"> Given that </text>
<text top="568" left="170" width="628" height="14" font="3">it is often difficult to distinguish junctional tachycardia from AVNRT on the ECG, EP study with the goal of ablation may be a helpful diagnostic </text>
<text top="583" left="170" width="624" height="14" font="3">and potentially therapeutic intervention. Junctional tachycardia may be observed during and after slow-pathway ablation of AVNRT, because </text>
<text top="598" left="170" width="159" height="14" font="3">of irritation of the compact AV node.</text>
<text top="598" left="329" width="10" height="8" font="18">406</text>
<text top="598" left="339" width="456" height="14" font="3"> This iatrogenic junctional tachycardia is transient and generally benign and can be distinguished from </text>
<text top="613" left="170" width="207" height="14" font="3">AVNRT through pacing maneuvers at EP study.</text>
<text top="613" left="376" width="22" height="8" font="18">396,405</text>
<text top="613" left="398" width="387" height="14" font="3"> It is crucial to recognize this phenomenon at the time of EP study because attempts to </text>
<text top="628" left="170" width="349" height="14" font="3">ablate the junctional tachycardia are unnecessary and could result in AV block.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e546  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="535" left="71" width="351" height="16" font="13">AVNRT. Higher initial doses of adenosine are needed in chil-</text>
<text top="552" left="71" width="355" height="16" font="13">dren than in adults, with children receiving from 150 mcg/kg  </text>
<text top="569" left="71" width="94" height="16" font="13">to 250 mcg/kg.</text>
<text top="570" left="165" width="29" height="9" font="14">413–415</text>
<text top="569" left="194" width="228" height="16" font="13"> Digoxin and propranolol have simi-</text>
<text top="586" left="70" width="339" height="16" font="13">lar efficacy in infants with SVT without pre-excitation.</text>
<text top="587" left="409" width="12" height="9" font="14">416</text>
<text top="586" left="422" width="4" height="16" font="13"> </text>
<text top="604" left="70" width="356" height="16" font="13">Digoxin is avoided in the presence of pre-excitation because </text>
<text top="621" left="70" width="351" height="16" font="13">its use in infancy has been associated with SCD or ventricu-</text>
<text top="638" left="70" width="87" height="16" font="13">lar fibrillation.</text>
<text top="639" left="158" width="27" height="9" font="14">417,418</text>
<text top="638" left="185" width="245" height="16" font="13"> Amiodarone, sotalol, propafenone, or </text>
<text top="535" left="458" width="355" height="16" font="13">flecainide can be used for refractory SVT in infants. In older </text>
<text top="552" left="458" width="357" height="16" font="13">children presenting with SVT, beta-blocker therapy is most </text>
<text top="569" left="458" width="355" height="16" font="13">often the initial therapy used. Because of the rare occurrence </text>
<text top="586" left="458" width="354" height="16" font="13">of adverse events with flecainide, including in patients without </text>
<text top="604" left="458" width="355" height="16" font="13">structural heart disease, ischemic heart disease, or ventricular </text>
<text top="621" left="458" width="354" height="16" font="13">dysfunction, flecainide is not used as a first-line medication in </text>
<text top="638" left="458" width="50" height="16" font="13">children.</text>
<text top="639" left="508" width="12" height="9" font="14">419</text>
<text top="1075" left="71" width="731" height="14" font="1"><b>Figure 16.</b> Abrupt loss of pre-excitation during exercise testing. During exercise treadmill testing, this patient abruptly lost pre-excitation </text>
<text top="1089" left="71" width="731" height="14" font="3">at a heart rate of 117 bpm. Beginning abruptly with the beat under the arrow, the PR interval normalizes, and the QRS changes from pre-</text>
<text top="1102" left="71" width="96" height="14" font="3">excited to narrow.</text>
<text top="472" left="71" width="719" height="14" font="1"><b>Figure 15.</b> Ongoing management of orthodromic AVRT. Colors correspond to Class of Recommendation in Table 1; drugs listed alpha-</text>
<text top="486" left="71" width="718" height="14" font="3">betically. AVRT indicates atrioventricular reentrant tachycardia; ECG, electrocardiogram; pt, patient; and SHD, structural heart disease </text>
<text top="499" left="71" width="184" height="14" font="3">(including ischemic heart disease).</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e547</i></b></text>
<text top="943" left="90" width="330" height="16" font="13">Catheter ablation can be successfully performed in chil-</text>
<text top="960" left="69" width="355" height="16" font="13">dren of all ages, with acute success rates comparable to those </text>
<text top="978" left="69" width="106" height="16" font="13">reported in adults.</text>
<text top="978" left="175" width="56" height="9" font="14">281,282,420,421</text>
<text top="978" left="231" width="194" height="16" font="13"> Success rates are influenced by </text>
<text top="995" left="69" width="351" height="16" font="13">the presence of structural heart disease or ischemic heart dis-</text>
<text top="1013" left="69" width="358" height="16" font="13">ease and are highest in left-sided accessory pathways and </text>
<text top="1031" left="69" width="356" height="16" font="13">lowest for AT. Complications were reported in 4% to 8% of </text>
<text top="1048" left="69" width="356" height="16" font="13">the initial large series, with major complications in 0.9% to </text>
<text top="1066" left="69" width="354" height="16" font="13">3.2%, and complication rates were higher in patients weighing </text>
<text top="1083" left="69" width="44" height="16" font="13">&lt;15 kg.</text>
<text top="1084" left="113" width="44" height="9" font="14">281,420–422</text>
<text top="1083" left="157" width="267" height="16" font="13"> The implications of complications, including </text>
<text top="1101" left="69" width="356" height="16" font="13">AV block requiring pacing, perforation, and coronary artery </text>
<text top="943" left="456" width="322" height="16" font="13">or mitral valve injury, are profound in young patients.</text>
<text top="943" left="778" width="29" height="9" font="14">423–425</text>
<text top="943" left="807" width="4" height="16" font="13"> </text>
<text top="960" left="456" width="355" height="16" font="13">In early series, death was reported in 0.12% of children with </text>
<text top="978" left="456" width="358" height="16" font="13">normal hearts and was associated with lower weight and </text>
<text top="995" left="456" width="228" height="16" font="13">increased number of ablation lesions.</text>
<text top="996" left="684" width="12" height="9" font="14">426</text>
<text top="995" left="697" width="110" height="16" font="13"> Increased institu-</text>
<text top="1013" left="456" width="356" height="16" font="13">tional experience, advanced mapping techniques, and use of </text>
<text top="1031" left="456" width="355" height="16" font="13">cryoablation have reduced the incidence of complications, as </text>
<text top="1048" left="456" width="355" height="16" font="13">well as the radiation exposure associated with the procedure. </text>
<text top="1066" left="456" width="355" height="16" font="13">Although most centers perform elective ablation for children </text>
<text top="1083" left="456" width="351" height="16" font="13">weighing &gt;12 kg to 15 kg, ablation in younger or smaller chil-</text>
<text top="1101" left="456" width="355" height="16" font="13">dren is generally reserved for those with medically refractory </text>
<text top="838" left="69" width="720" height="14" font="1"><b>Figure 17.</b> Classification of atrial flutter/atrial tachycardias. Diagram summarizing types of ATs often encountered in patients with a his-</text>
<text top="852" left="69" width="734" height="14" font="3">tory of atrial fibrillation, including those seen after catheter or surgical ablation procedures. P-wave morphologies are shown for common </text>
<text top="865" left="69" width="721" height="14" font="3">types of atrial flutter; however, the P-wave morphology is not always a reliable guide to the re-entry circuit location or to the distinction </text>
<text top="879" left="69" width="725" height="14" font="3">between common atrial flutter and other macroreentrant ATs. *Exceptions to P-wave morphology and rate are common in scarred atria. </text>
<text top="892" left="69" width="333" height="14" font="3">bpm indicates beats per minute, and ECG, electrocardiogram.</text>
<text top="906" left="69" width="257" height="14" font="3">Reproduced with permission from January et al.</text>
<text top="907" left="326" width="8" height="8" font="18">10</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e548  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="514" left="71" width="351" height="16" font="13">SVT or tachycardia-induced cardiomyopathy or before sur-</text>
<text top="531" left="71" width="351" height="16" font="13">gery that may limit access for subsequent catheter-based pro-</text>
<text top="548" left="71" width="354" height="16" font="13">cedures. Recurrence rates for SVT after successful procedures </text>
<text top="566" left="71" width="354" height="16" font="13">are higher than reported in large adult series, ranging from 7% </text>
<text top="583" left="71" width="351" height="16" font="13">to 17%; whether this reflects technical differences, natural his-</text>
<text top="600" left="71" width="254" height="16" font="13">tory, or more long-term follow-up is unclear.</text>
<text top="601" left="324" width="29" height="9" font="14">427–429</text>
<text top="600" left="353" width="72" height="16" font="13"> Recurrence </text>
<text top="617" left="70" width="233" height="16" font="13">is highest among right-sided accessory  </text>
<text top="617" left="295" width="130" height="16" font="13">pathways, particularly </text>
<text top="634" left="70" width="355" height="16" font="13">anteroseptal or multiple pathways, and in AT in the setting of </text>
<text top="652" left="70" width="192" height="16" font="13">complex congenital heart disease.</text>
<text top="652" left="263" width="29" height="9" font="14">427–429</text>
<text top="669" left="92" width="341" height="16" font="13">Junctional ectopic tachycardia occurs predominantly </text>
<text top="686" left="71" width="356" height="16" font="13">in very young patients either as a congenital form or, more </text>
<text top="514" left="458" width="351" height="16" font="13">commonly, after intracardiac repair of congenital heart dis-</text>
<text top="531" left="458" width="362" height="16" font="13">ease. Nonpostoperative junctional tachycardia has been </text>
<text top="548" left="458" width="357" height="16" font="13">reported to respond to amiodarone or combination therapy </text>
<text top="566" left="458" width="351" height="16" font="13">including beta blockers, flecainide, procainamide, or propafe-</text>
<text top="583" left="458" width="31" height="16" font="13">none.</text>
<text top="583" left="489" width="12" height="9" font="14">130</text>
<text top="583" left="501" width="313" height="16" font="13"> Ablation for patients with refractory tachycardia or </text>
<text top="600" left="458" width="356" height="16" font="13">ventricular dysfunction has shown efficacy of 82% to 85%, </text>
<text top="617" left="458" width="354" height="16" font="13">but inadvertent AV block occurred in 18% and recurrence was </text>
<text top="635" left="458" width="149" height="16" font="13">seen in 14% of patients.</text>
<text top="635" left="606" width="12" height="9" font="14">130</text>
<text top="634" left="619" width="190" height="16" font="13"> Postoperative junctional tachy-</text>
<text top="652" left="458" width="357" height="16" font="13">cardia occurs in 2% to 10% of young patients undergoing </text>
<text top="669" left="458" width="356" height="16" font="13">intracardiac surgery, particularly for ventricular or AV septal </text>
<text top="686" left="458" width="355" height="16" font="13">defects, tetralogy of Fallot, transposition of the great arteries, </text>
<text top="704" left="458" width="153" height="16" font="13">and Norwood procedures.</text>
<text top="704" left="610" width="27" height="9" font="14">430,431</text>
<text top="703" left="637" width="177" height="16" font="13"> Treatment includes sedation </text>
<text top="721" left="458" width="357" height="16" font="13">with muscle relaxation, limitation of inotropic medications, </text>
<text top="738" left="458" width="355" height="16" font="13">reduction of core temperature to 34 to 35°C, atrial overdrive </text>
<text top="755" left="458" width="307" height="16" font="13">pacing, and procainamide or amiodarone infusions.</text>
<text top="756" left="765" width="44" height="9" font="14">416,432–435</text>
<text top="755" left="809" width="4" height="16" font="13"> </text>
<text top="772" left="457" width="356" height="16" font="13">In general, postoperative junctional tachycardia resolves and </text>
<text top="790" left="457" width="191" height="16" font="13">does not require ongoing therapy.</text>
<text top="807" left="479" width="334" height="16" font="13">Although this guideline focuses on adults, it should be </text>
<text top="824" left="457" width="356" height="16" font="13">noted that SVT may occur in the fetus and, if sustained, </text>
<text top="842" left="457" width="351" height="16" font="13">may put the fetus at risk of cardiovascular collapse mani-</text>
<text top="859" left="457" width="356" height="16" font="13">fested by hydrops. Mothers require safety monitoring by </text>
<text top="876" left="457" width="358" height="16" font="13">adult cardiologists during treatment. The most common </text>
<text top="893" left="457" width="338" height="16" font="13">mechanisms for fetal SVT are AVRT and atrial flutter.</text>
<text top="894" left="796" width="13" height="9" font="14">436</text>
<text top="893" left="809" width="4" height="16" font="13"> </text>
<text top="910" left="457" width="355" height="16" font="13">Persistent SVT with hydrops carries a high mortality rate, </text>
<text top="928" left="457" width="351" height="16" font="13">and therefore, prompt and aggressive treatment is war-</text>
<text top="945" left="457" width="357" height="16" font="13">ranted. Maternal administration of antiarrhythmic agents </text>
<text top="962" left="457" width="359" height="16" font="13">has been shown to be effective through transplacental </text>
<text top="980" left="457" width="351" height="16" font="13">delivery. Flecainide, sotalol, and digoxin, alone or in com-</text>
<text top="997" left="457" width="356" height="16" font="13">bination, have demonstrated arrhythmia termination rates </text>
<text top="1014" left="457" width="351" height="16" font="13">of 60% to 90%, depending on whether hydrops is pres-</text>
<text top="1031" left="457" width="22" height="16" font="13">ent.</text>
<text top="1032" left="480" width="28" height="9" font="14">437,438</text>
<text top="1031" left="508" width="306" height="16" font="13"> In cases refractory to the aforementioned drugs, </text>
<text top="1048" left="458" width="355" height="16" font="13">maternal oral loading for 2 to 7 days with amiodarone may </text>
<text top="1066" left="458" width="102" height="16" font="13">prove lifesaving.</text>
<text top="1066" left="560" width="13" height="9" font="14">439</text>
<text top="1066" left="573" width="242" height="16" font="13"> Treatment of fetal SVT has provided </text>
<text top="1083" left="458" width="356" height="16" font="13">safety data for treatment of arrhythmias in women during </text>
<text top="1100" left="458" width="233" height="16" font="13">pregnancy, as addressed in Section 9.3.</text>
<text top="444" left="71" width="693" height="14" font="1"><b>Figure 18.</b> Acute treatment of atrial flutter. Colors correspond to Class of Recommendation in Table 1; drugs listed alphabetically. </text>
<text top="457" left="71" width="739" height="14" font="3">*Anticoagulation as per guideline is mandatory. †For rhythms that break or recur spontaneously, synchronized cardioversion or rapid atrial </text>
<text top="471" left="71" width="272" height="14" font="3">pacing is not appropriate. IV indicates intravenous.</text>
<text top="1008" left="71" width="321" height="14" font="1"><b>Figure 19.</b> Ongoing management of atrial flutter. Colors cor-</text>
<text top="1021" left="71" width="330" height="14" font="3">respond to Class of Recommendation in Table 1; drugs listed </text>
<text top="1035" left="71" width="314" height="14" font="3">alphabetically. *After assuring adequate anticoagulation or </text>
<text top="1048" left="71" width="339" height="14" font="3">excluding left atrial thrombus by transesophageal echocardiog-</text>
<text top="1062" left="71" width="337" height="14" font="3">raphy before conversion. †Should be combined with AV nodal–</text>
<text top="1075" left="71" width="329" height="14" font="3">blocking agents to reduce risk of 1:1 conduction during atrial </text>
<text top="1089" left="71" width="353" height="14" font="3">flutter. AV indicates atrioventricular; SHD, structural heart disease </text>
<text top="1102" left="71" width="184" height="14" font="3">(including ischemic heart disease).</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e549</i></b></text>
<text top="553" left="69" width="335" height="18" font="10"><b>9.2. Patients With Adult Congenital Heart Disease</b></text>
<text top="572" left="69" width="351" height="16" font="13">See Figure 22 for the algorithm for acute treatment of non–</text>
<text top="589" left="69" width="357" height="16" font="13">pre-excited SVT in adult congenital heart disease (ACHD) </text>
<text top="606" left="69" width="351" height="16" font="13">patients; and Figure 23 for the algorithm for ongoing manage-</text>
<text top="624" left="69" width="279" height="16" font="13">ment of non–pre-excited SVT in ACHD patients.</text>
<text top="657" left="69" width="137" height="16" font="0"><i><b>9.2.1. Clinical Features</b></i></text>
<text top="675" left="69" width="351" height="16" font="13">SVT is observed in 10% to 20% of ACHD patients, and is asso-</text>
<text top="692" left="69" width="355" height="16" font="13">ciated with a significantly increased risk of heart failure, stroke, </text>
<text top="709" left="69" width="53" height="16" font="13">and SCD.</text>
<text top="710" left="122" width="28" height="9" font="14">440–444</text>
<text top="709" left="150" width="273" height="16" font="13"> The most common mechanism of SVT in ACHD </text>
<text top="726" left="69" width="353" height="16" font="13">patients is macroreentrant AT (also called flutter), which accounts </text>
<text top="744" left="69" width="355" height="16" font="13">for at least 75% of SVT and frequently involves the CTI. Focal </text>
<text top="761" left="69" width="354" height="16" font="13">AT, AVNRT, and accessory pathway–mediated tachycardia each </text>
<text top="553" left="456" width="356" height="16" font="13">account for less than about 8% of SVT, whereas the incidence </text>
<text top="571" left="456" width="247" height="16" font="13">of AF is about 10% and increases with age.</text>
<text top="571" left="703" width="42" height="9" font="14">133,445–449</text>
<text top="571" left="746" width="65" height="16" font="13"> AT occurs </text>
<text top="588" left="456" width="351" height="16" font="13">in 20% to 45% of adults with Ebstein anomaly, single-ventricle/</text>
<text top="605" left="456" width="357" height="16" font="13">Fontan procedures, tetralogy of Fallot, transposition of the </text>
<text top="622" left="456" width="219" height="16" font="13">great arteries, and atrial septal defects.</text>
<text top="623" left="675" width="29" height="9" font="14">449–451</text>
<text top="640" left="477" width="334" height="16" font="13">The management of SVT in ACHD patients is influenced </text>
<text top="657" left="456" width="351" height="16" font="13">by the underlying cardiac anatomy and surgical repair, the cur-</text>
<text top="674" left="456" width="356" height="16" font="13">rent hemodynamic sequelae of the anatomy and repairs, and </text>
<text top="691" left="456" width="355" height="16" font="13">mechanism of SVT. The ventricular rate during SVT may be </text>
<text top="709" left="456" width="356" height="16" font="13">slowed because of variable AV conduction, which can result </text>
<text top="726" left="456" width="355" height="16" font="13">in a delay in recognizing tachycardia and the development of </text>
<text top="743" left="456" width="351" height="16" font="13">congestive failure. Recognition of severe forms of congeni-</text>
<text top="760" left="456" width="357" height="16" font="13">tal heart disease, including unrepaired or palliated defects, </text>
<text top="97" left="121" width="350" height="16" font="17"><b>Table 8.  Success and Complication Rates for Ablation of SVT*</b></text>
<text top="124" left="132" width="49" height="14" font="3">Arrhythmia</text>
<text top="124" left="321" width="65" height="14" font="3">Acute Success</text>
<text top="124" left="426" width="74" height="14" font="3">Recurrence Rate</text>
<text top="124" left="546" width="90" height="14" font="3">Major Complications</text>
<text top="124" left="684" width="50" height="14" font="3">References</text>
<text top="146" left="132" width="65" height="14" font="3">Common SVTs</text>
<text top="168" left="144" width="30" height="14" font="3">AVNRT</text>
<text top="168" left="319" width="47" height="14" font="3">96%–97%</text>
<text top="169" left="366" width="22" height="8" font="18">102,103</text>
<text top="168" left="456" width="15" height="14" font="3">5%</text>
<text top="169" left="470" width="10" height="8" font="18">103</text>
<text top="168" left="532" width="60" height="14" font="3">•  Overall 3%</text>
<text top="169" left="592" width="10" height="8" font="18">102</text>
<text top="168" left="691" width="37" height="14" font="3">102,103</text>
<text top="186" left="532" width="58" height="14" font="3">•  PPM 0.7%</text>
<text top="187" left="590" width="10" height="8" font="18">102</text>
<text top="203" left="532" width="56" height="14" font="3">•  Death 0%</text>
<text top="204" left="587" width="10" height="8" font="18">102</text>
<text top="226" left="144" width="111" height="14" font="3">AVRT/accessory pathway</text>
<text top="226" left="332" width="21" height="14" font="3">93%</text>
<text top="226" left="353" width="22" height="8" font="18">102,103</text>
<text top="226" left="456" width="15" height="14" font="3">8%</text>
<text top="226" left="470" width="10" height="8" font="18">103</text>
<text top="226" left="532" width="69" height="14" font="3">•  Overall 2.8%</text>
<text top="226" left="601" width="10" height="8" font="18">102</text>
<text top="226" left="691" width="37" height="14" font="3">102,103</text>
<text top="243" left="532" width="58" height="14" font="3">•  PPM 0.3%</text>
<text top="244" left="590" width="10" height="8" font="18">102</text>
<text top="261" left="532" width="64" height="14" font="3">•  Death 0.1%</text>
<text top="262" left="596" width="10" height="8" font="18">102</text>
<text top="278" left="532" width="91" height="14" font="3">•   Tamponade 0.4%</text>
<text top="279" left="622" width="10" height="8" font="18">102</text>
<text top="301" left="144" width="120" height="14" font="3">CTI-dependent atrial flutter</text>
<text top="301" left="338" width="21" height="14" font="3">97%</text>
<text top="302" left="359" width="10" height="8" font="18">102</text>
<text top="301" left="417" width="77" height="14" font="3">10.6% atrial flutter,</text>
<text top="302" left="493" width="10" height="8" font="18">121</text>
<text top="301" left="503" width="5" height="14" font="3">  </text>
<text top="316" left="417" width="82" height="14" font="3">33% atrial fibrillation</text>
<text top="317" left="498" width="10" height="8" font="18">121</text>
<text top="301" left="532" width="69" height="14" font="3">•  Overall 0.5%</text>
<text top="302" left="601" width="10" height="8" font="18">102</text>
<text top="301" left="680" width="58" height="14" font="3">102,103,121</text>
<text top="318" left="532" width="58" height="14" font="3">•  PPM 0.2%</text>
<text top="319" left="590" width="10" height="8" font="18">102</text>
<text top="336" left="532" width="114" height="14" font="3">•   Pericardial effusion 0.3%</text>
<text top="337" left="645" width="10" height="8" font="18">102</text>
<text top="366" left="132" width="87" height="14" font="3">Less common SVTs</text>
<text top="389" left="144" width="38" height="14" font="3">Focal AT</text>
<text top="389" left="327" width="53" height="14" font="3">80%–100%</text>
<text top="389" left="447" width="41" height="14" font="3">4%–27%</text>
<text top="389" left="532" width="43" height="14" font="3">&lt;1%–2%</text>
<text top="389" left="695" width="40" height="14" font="3"><a href="">122–129</a></text>
<text top="411" left="144" width="11" height="14" font="3">JT</text>
<text top="411" left="330" width="47" height="14" font="3">82%–85%</text>
<text top="411" left="452" width="32" height="14" font="3">0–18%</text>
<text top="411" left="532" width="92" height="14" font="3">0–18% CHB (overall </text>
<text top="426" left="532" width="83" height="14" font="3">complications N/A)</text>
<text top="411" left="695" width="40" height="14" font="3">130–132</text>
<text top="448" left="144" width="143" height="14" font="3">Non–CTI-dependent atrial flutter</text>
<text top="448" left="327" width="53" height="14" font="3">73%–100%</text>
<text top="448" left="447" width="41" height="14" font="3">7%–53%</text>
<text top="448" left="548" width="27" height="14" font="3">0–7%</text>
<text top="448" left="679" width="60" height="14" font="3">122,133–140</text>
<text top="469" left="133" width="592" height="14" font="3">*Data in this table are derived from multiple observational studies and registries, and as such may not always reflect current practice.</text>
<text top="484" left="133" width="627" height="14" font="3">AT indicates atrial tachycardia; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; CHB, </text>
<text top="499" left="121" width="637" height="14" font="3">complete  heart  block;  CTI,  cavotricuspid  isthmus;  JT,  junctional  tachycardia;  N/A,  not  available;  PPM,  permanent  pacemaker;  and  SVT, </text>
<text top="514" left="121" width="129" height="14" font="3">supraventricular tachycardia.</text>
<text top="1021" left="69" width="331" height="14" font="1"><b>Figure 20.</b> Surface electrocardiographic recording from leads </text>
<text top="1035" left="69" width="306" height="14" font="3">VI, II, and V5 in a patient with junctional tachycardia. The </text>
<text top="1035" left="375" width="37" height="14" font="1"><b>upper </b></text>
<text top="1048" left="69" width="345" height="14" font="1"><b>panel</b> shows sinus rhythm. The <b>lower panel</b> shows tachycardia </text>
<text top="1062" left="69" width="338" height="14" font="3">onset with the characteristic finding of dissociation of the QRS </text>
<text top="1075" left="69" width="343" height="14" font="3">and P waves (narrow arrows on P waves). The large arrow signi-</text>
<text top="1089" left="69" width="327" height="14" font="3">fies continuous recording. Reproduced with permission from </text>
<text top="1102" left="69" width="146" height="14" font="3">Blomström-Lundqvist et al.</text>
<text top="1103" left="215" width="8" height="8" font="18">11</text>
<text top="1062" left="456" width="320" height="14" font="1"><b>Figure 21.</b> Ongoing management of junctional tachycardia. </text>
<text top="1075" left="456" width="320" height="14" font="3">Colors correspond to Class of Recommendation in Table 1; </text>
<text top="1089" left="456" width="354" height="14" font="3">drugs listed alphabetically. SHD indicates structural heart disease </text>
<text top="1102" left="456" width="184" height="14" font="3">(including ischemic heart disease).</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e550  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="356" height="16" font="13">cyanotic heart disease, single or systemic right ventricles, or </text>
<text top="115" left="71" width="355" height="16" font="13">Ebstein anomaly, is essential to decision making during SVT </text>
<text top="132" left="71" width="356" height="16" font="13">treatment. In certain conditions, the presence of cyanosis or </text>
<text top="149" left="71" width="351" height="16" font="13">severe ventricular dysfunction requires consideration of high-</text>
<text top="166" left="71" width="351" height="16" font="13">risk cardioversion with resuscitation measures at hand; usu-</text>
<text top="184" left="71" width="354" height="16" font="13">ally, this decision is made at centers with specialized expertise. </text>
<text top="201" left="71" width="355" height="16" font="13">Management of ACHD patients should be undertaken only in </text>
<text top="218" left="71" width="355" height="16" font="13">collaboration with a cardiologist who has specialized training </text>
<text top="235" left="71" width="232" height="16" font="13">or experience in managing such patients.</text>
<text top="253" left="92" width="336" height="16" font="13">RCTs assessing antiarrhythmic medication efficacy are </text>
<text top="270" left="71" width="357" height="16" font="13">lacking. Beta-blocking medications offer the advantages of </text>
<text top="287" left="71" width="357" height="16" font="13">outpatient medication initiation and may provide protection </text>
<text top="304" left="71" width="355" height="16" font="13">from tachycardia-mediated hypotension or ischemia. Risks of </text>
<text top="322" left="71" width="355" height="16" font="13">proarrhythmia are increased with the use of sotalol, ibutilide, </text>
<text top="339" left="71" width="356" height="16" font="13">dofetilide, and particularly flecainide and require in-hospital </text>
<text top="356" left="71" width="339" height="16" font="13">initiation. Flecainide is associated with increased risk of SCD</text>
<text top="357" left="409" width="12" height="9" font="14">419</text>
<text top="356" left="422" width="4" height="16" font="13"> </text>
<text top="373" left="70" width="357" height="16" font="13">and is reserved for patients without ventricular dysfunction </text>
<text top="391" left="70" width="355" height="16" font="13">who do not respond to other therapy. Sinus node dysfunction </text>
<text top="408" left="70" width="356" height="16" font="13">may contribute to the development of atrial arrhythmias and </text>
<text top="425" left="70" width="358" height="16" font="13">may become exacerbated with antiarrhythmic medications. </text>
<text top="442" left="70" width="351" height="16" font="13">Atrial antibradycardia pacing to maintain a consistent physi-</text>
<text top="460" left="70" width="355" height="16" font="13">ological heart rate may decrease the frequency of tachycardia </text>
<text top="477" left="70" width="272" height="16" font="13">episodes and may improve functional capacity.</text>
<text top="477" left="343" width="42" height="9" font="14">364,370,371</text>
<text top="477" left="384" width="41" height="16" font="13"> Atrial </text>
<text top="494" left="70" width="355" height="16" font="13">antitachycardia pacing to terminate atrial reentry tachycardia </text>
<text top="511" left="70" width="221" height="16" font="13">is an effective approach when feasible.</text>
<text top="512" left="291" width="42" height="9" font="14">364,370,371</text>
<text top="529" left="92" width="333" height="16" font="13">Overall acute success rates of catheter ablation procedures </text>
<text top="546" left="71" width="357" height="16" font="13">for SVT in ACHD patients range from 70% to 85%, with </text>
<text top="97" left="458" width="322" height="16" font="13">recurrences in 20% to 60% of patients within 2 years.</text>
<text top="98" left="779" width="29" height="9" font="14">452–457</text>
<text top="97" left="809" width="4" height="16" font="13"> </text>
<text top="115" left="457" width="354" height="16" font="13">Catheter ablation is challenged by limitations of venous access </text>
<text top="132" left="457" width="351" height="16" font="13">to the heart, hypertrophied atrial tissue, multiple atrial reen-</text>
<text top="150" left="457" width="355" height="16" font="13">trant circuits, and atrial baffles partitioning the coronary sinus </text>
<text top="167" left="457" width="356" height="16" font="13">and CTI to the pulmonary venous atrium. Because the CTI </text>
<text top="184" left="457" width="351" height="16" font="13">is involved in &gt;60% of atrial reentry circuits, an initial strat-</text>
<text top="202" left="457" width="356" height="16" font="13">egy targeting this region is often used. Highest success rates </text>
<text top="219" left="457" width="351" height="16" font="13">are achieved in patients with atrial septal defects, approach-</text>
<text top="237" left="457" width="355" height="16" font="13">ing 90% to 100%, although subsequent AF has been reported </text>
<text top="254" left="457" width="242" height="16" font="13">in 11% to 30% of patients within 3 years.</text>
<text top="255" left="699" width="42" height="9" font="14">330,449,458</text>
<text top="254" left="741" width="72" height="16" font="13"> Because of </text>
<text top="272" left="457" width="356" height="16" font="13">the need for sophisticated knowledge of anatomy, advanced </text>
<text top="289" left="457" width="351" height="16" font="13">mapping capability, cardiac anesthesia with careful peripro-</text>
<text top="306" left="457" width="354" height="16" font="13">cedural monitoring, and repeat ablations, such patients should </text>
<text top="324" left="457" width="356" height="16" font="13">be referred to centers with extensive experience in complex </text>
<text top="341" left="457" width="195" height="16" font="13">congenital heart disease ablations.</text>
<text top="359" left="479" width="334" height="16" font="13">The development of atrial arrhythmias in ACHD patients </text>
<text top="376" left="457" width="357" height="16" font="13">is often an indicator of progressive hemodynamic changes, </text>
<text top="394" left="457" width="351" height="16" font="13">which require in-depth functional and hemodynamic assess-</text>
<text top="411" left="457" width="363" height="16" font="13">ment. Intervention for residual hemodynamic/structural </text>
<text top="428" left="457" width="351" height="16" font="13">defects may need to be planned as part of chronic arrhyth-</text>
<text top="446" left="457" width="356" height="16" font="13">mia management. Patients with Ebstein anomaly or repaired </text>
<text top="463" left="457" width="351" height="16" font="13">tetralogy of Fallot may have significant pulmonary regurgita-</text>
<text top="481" left="457" width="354" height="16" font="13">tion, tricuspid regurgitation, or both, which might benefit from </text>
<text top="498" left="457" width="354" height="16" font="13">reoperation. In some settings, integration of operative ablation </text>
<text top="516" left="457" width="307" height="16" font="13">techniques with hemodynamic repair may be optimal.</text>
<text top="545" left="457" width="250" height="16" font="0"><i><b>9.2.2. Acute Treatment: Recommendations</b></i></text>
<text top="577" left="80" width="335" height="16" font="19"><b>Recommendations for Acute Treatment of SVT in ACHD Patients</b></text>
<text top="602" left="87" width="20" height="14" font="1"><b>COR</b></text>
<text top="602" left="134" width="18" height="14" font="1"><b>LOE</b></text>
<text top="602" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="631" left="95" width="3" height="14" font="1"><b>I</b></text>
<text top="631" left="131" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="623" left="171" width="592" height="14" font="1"><b>1.   Acute antithrombotic therapy is recommended in ACHD patients who have AT or atrial flutter to align with recommended </b></text>
<text top="638" left="186" width="209" height="14" font="1"><b>antithrombotic therapy for patients with AF.</b></text>
<text top="639" left="395" width="10" height="8" font="20"><b>365</b></text>
<text top="705" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="705" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="720" left="80" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="735" left="80" width="31" height="14" font="21"><a href="">and 17</a></text>
<text top="735" left="111" width="3" height="14" font="3"><a href="">.</a></text>
<text top="660" left="171" width="627" height="14" font="3">The risk of stroke associated with AF is well established, and several RCTs have demonstrated the efficacy of anticoagulation for stroke prevention in </text>
<text top="675" left="171" width="149" height="14" font="3">patients with additional risk factors.</text>
<text top="675" left="320" width="10" height="8" font="18">366</text>
<text top="675" left="330" width="478" height="14" font="3"> Anticoagulation has also been shown to prevent stroke when administered during the weeks immediately before </text>
<text top="690" left="171" width="99" height="14" font="3">and after cardioversion.</text>
<text top="690" left="270" width="18" height="8" font="18">31,367</text>
<text top="690" left="288" width="499" height="14" font="3"> Whether atrial flutter carries a risk of stroke similar to that in patients with AF has been debated in the past but is now </text>
<text top="705" left="171" width="569" height="14" font="3">supported by limited evidence from mechanistic, observational, and prospective studies that include patients primarily with atrial flutter.</text>
<text top="705" left="740" width="23" height="8" font="18">365–369</text>
<text top="705" left="763" width="37" height="14" font="3"> Several </text>
<text top="720" left="171" width="610" height="14" font="3">reports have suggested that the risk of stroke in patients with atrial flutter is mitigated by anticoagulation. Meta-analysis of 13 studies of patients </text>
<text top="735" left="171" width="611" height="14" font="3">undergoing cardioversion of atrial flutter reported short-term stroke risks ranging from 0% to 7%, and the thromboembolism rate in patients with </text>
<text top="750" left="171" width="218" height="14" font="3">sustained flutter in 4 studies averaged 3% annually.</text>
<text top="750" left="389" width="10" height="8" font="18">365</text>
<text top="750" left="399" width="324" height="14" font="3"> Other studies have reported similar risk and effectiveness of anticoagulation.</text>
<text top="750" left="723" width="10" height="8" font="18">369</text>
<text top="750" left="732" width="66" height="14" font="3"> ACHD patients </text>
<text top="765" left="171" width="319" height="14" font="3">with nonfibrillatory atrial tachyarrhythmias appear to be at high risk, as well.</text>
<text top="765" left="490" width="21" height="8" font="18">367,459</text>
<text top="765" left="511" width="269" height="14" font="3"> Therefore, on the basis of available data, recommendations for </text>
<text top="780" left="171" width="481" height="14" font="3">antithrombotic therapy for ACHD patients who also have AT or atrial flutter are similar to those for patients with AF.</text>
<text top="780" left="652" width="7" height="8" font="18">10</text>
<text top="801" left="95" width="3" height="14" font="1"><b>I</b></text>
<text top="801" left="130" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="801" left="171" width="601" height="14" font="1"><b>2.   Synchronized cardioversion is recommended for acute treatment in ACHD patients and SVT who are hemodynamically unstable.</b></text>
<text top="802" left="772" width="18" height="8" font="20"><b>75,460</b></text>
<text top="845" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="845" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="860" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="860" left="147" width="3" height="14" font="3">.</text>
<text top="823" left="171" width="626" height="14" font="3">A small observational study demonstrated safety and efficacy of synchronized cardioversion in ACHD patients, with sinus rhythm achieved in 94% of </text>
<text top="838" left="171" width="36" height="14" font="3">patients.</text>
<text top="838" left="207" width="10" height="8" font="18">460</text>
<text top="838" left="217" width="590" height="14" font="3"> Guideline-directed medical therapy supports this treatment approach, stressing that electrical cardioversion is the safest and most effective </text>
<text top="853" left="171" width="545" height="14" font="3">way of treating SVT associated with hemodynamic instability and should be considered early in the management of such patients.</text>
<text top="853" left="716" width="7" height="8" font="18">75</text>
<text top="853" left="722" width="68" height="14" font="3"> Modification of </text>
<text top="868" left="171" width="614" height="14" font="3">electrode pad placement may be necessary, by using an anterior-posterior configuration in patients with marked atrial enlargement or positioning </text>
<text top="883" left="171" width="555" height="14" font="3">strategically according to the individual arrhythmia and anatomic substrate, including consideration of the possibility of dextrocardia.</text>
<text top="911" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="911" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="904" left="171" width="607" height="14" font="1"><b>3.   Intravenous diltiazem or esmolol (with extra caution used for either agent, observing for the development of hypotension) is </b></text>
<text top="919" left="186" width="451" height="14" font="1"><b>recommended for acute treatment in ACHD patients and SVT who are hemodynamically stable.</b></text>
<text top="919" left="637" width="22" height="8" font="20"><b>461,462</b></text>
<text top="970" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="970" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="985" left="80" width="67" height="14" font="21"><a href="">Supplement 21</a></text>
<text top="985" left="147" width="3" height="14" font="3">.</text>
<text top="940" left="171" width="594" height="14" font="3">Very limited data exist on the use of calcium channel–blocking or beta-blocking medications for rate control or termination of AT or atrial flutter </text>
<text top="955" left="171" width="610" height="14" font="3">specifically associated with ACHD. Rate control of AT or atrial flutter with rapid AV conduction may be useful to improve hemodynamic status while </text>
<text top="970" left="171" width="607" height="14" font="3">planning conversion strategies. Patients with congenital heart disease, particularly single-ventricle physiology or systemic right ventricles, may not </text>
<text top="985" left="171" width="216" height="14" font="3">tolerate ventricular rates &gt;120 bpm for many hours.</text>
<text top="986" left="387" width="7" height="8" font="18">29</text>
<text top="985" left="393" width="388" height="14" font="3"> Either drug may be associated with the development of hypotension in up to 20% of patients.</text>
<text top="986" left="781" width="10" height="8" font="18">462</text>
<text top="985" left="791" width="3" height="14" font="3"> </text>
<text top="1000" left="171" width="635" height="14" font="3">Because of the high incidence of ventricular dysfunction in this population, particular attention should be given to monitoring the patient for development of </text>
<text top="1015" left="171" width="403" height="14" font="3">hypotension, which would necessitate prompt dose adjustments or change of treatment strategy.</text>
<text top="1036" left="91" width="3" height="14" font="1"><b>I</b></text>
<text top="1036" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="1036" left="171" width="412" height="14" font="1"><b>4.   Intravenous adenosine is recommended for acute treatment in ACHD patients and SVT.</b></text>
<text top="1037" left="583" width="34" height="8" font="20"><b>207,463–465</b></text>
<text top="1073" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1073" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1088" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1088" left="147" width="3" height="14" font="3">.</text>
<text top="1058" left="171" width="630" height="14" font="3">Observational studies support the use of adenosine to terminate AVNRT, SVT using an accessory pathway, and some forms of focal AT. These </text>
<text top="1073" left="171" width="361" height="14" font="3">mechanisms account for &lt;25% of SVT in adults with repaired congenital disease.</text>
<text top="1074" left="533" width="22" height="8" font="18">207,463</text>
<text top="1073" left="554" width="234" height="14" font="3"> Intravenous adenosine is unlikely to terminate atrial </text>
<text top="1088" left="171" width="634" height="14" font="3">reentry tachycardia or atrial flutter, which represents &gt;70% of SVT episodes in this population, but it may be diagnostic by producing transient </text>
<text top="1103" left="171" width="237" height="14" font="3">AV block, which would make the atrial activity visible.</text>
<text top="1104" left="409" width="22" height="8" font="18">464,465</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e551</i></b></text>
<text top="617" left="69" width="285" height="16" font="0"><i><b>9.2.3. Ongoing Management: Recommendations</b></i></text>
<text top="646" left="78" width="369" height="16" font="19"><b>Recommendations for Ongoing Management of SVT in ACHD Patients</b></text>
<text top="670" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="670" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="670" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="699" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="699" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="691" left="170" width="594" height="14" font="1"><b>1.   Ongoing management with antithrombotic therapy is recommended in ACHD patients and AT or atrial flutter to align with </b></text>
<text top="706" left="184" width="280" height="14" font="1"><b>recommended antithrombotic therapy for patients with AF.</b></text>
<text top="707" left="464" width="10" height="8" font="20"><b>365</b></text>
<text top="769" left="78" width="20" height="14" font="3"><a href="">See </a></text>
<text top="769" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="784" left="78" width="75" height="14" font="21"><a href="">Supplements 16 </a></text>
<text top="799" left="78" width="34" height="14" font="21"><a href="">and 17.</a></text>
<text top="727" left="170" width="626" height="14" font="3">The risk of stroke associated with AF is well established, and several RCTs have demonstrated the efficacy of anticoagulation for stroke prevention </text>
<text top="742" left="170" width="162" height="14" font="3">in patients with additional risk factors.</text>
<text top="742" left="332" width="10" height="8" font="18">366</text>
<text top="742" left="341" width="454" height="14" font="3"> Anticoagulation has also been shown to prevent stroke when administered during the weeks immediately </text>
<text top="756" left="170" width="130" height="14" font="3">before and after cardioversion.</text>
<text top="756" left="300" width="18" height="8" font="18">31,367</text>
<text top="756" left="318" width="476" height="14" font="3"> Whether atrial flutter carries a risk of stroke similar to that in patients with AF has been debated in the past but </text>
<text top="770" left="170" width="608" height="14" font="3">is now supported by limited evidence from mechanistic, observational, and prospective studies that include patients primarily with atrial flutter.</text>
<text top="771" left="778" width="23" height="8" font="18">365–369</text>
<text top="770" left="800" width="3" height="14" font="3"> </text>
<text top="784" left="170" width="606" height="14" font="3">Several reports have suggested that the risk of stroke in patients with atrial flutter is mitigated by anticoagulation. Meta-analysis of 13 studies </text>
<text top="799" left="170" width="610" height="14" font="3">of patients undergoing cardioversion of atrial flutter reported short-term stroke risks ranging from 0% to 7%, and the thromboembolism rate in </text>
<text top="813" left="170" width="279" height="14" font="3">patients with sustained flutter in 4 studies averaged 3% annually.</text>
<text top="813" left="448" width="10" height="8" font="18">365</text>
<text top="813" left="458" width="329" height="14" font="3"> Other studies have reported similar risk and effectiveness of anticoagulation.</text>
<text top="813" left="787" width="10" height="8" font="18">369</text>
<text top="813" left="796" width="3" height="14" font="3"> </text>
<text top="827" left="170" width="388" height="14" font="3">ACHD patients with nonfibrillatory atrial tachyarrhythmias appear to be at high risk, as well.</text>
<text top="828" left="557" width="21" height="8" font="18">367,459</text>
<text top="827" left="578" width="179" height="14" font="3"> Therefore, on the basis of available data, </text>
<text top="841" left="170" width="581" height="14" font="3">recommendations for antithrombotic therapy for ACHD patients who also have AT or atrial flutter are similar to those for patients with AF.</text>
<text top="842" left="751" width="7" height="8" font="18">10</text>
<text top="868" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="868" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="861" left="170" width="595" height="14" font="1"><b>2.   Assessment of associated hemodynamic abnormalities for potential repair of structural defects is recommended in ACHD </b></text>
<text top="876" left="184" width="166" height="14" font="1"><b>patients as part of therapy for SVT.</b></text>
<text top="877" left="351" width="15" height="8" font="20"><b>25,29</b></text>
<text top="994" left="78" width="20" height="14" font="3">See </text>
<text top="994" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1009" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1009" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="896" left="170" width="606" height="14" font="3">The development of AT, atrial flutter, or AF in ACHD patients is often associated with progressive hemodynamic deterioration of the underlying </text>
<text top="911" left="170" width="608" height="14" font="3">disease. Surgical treatment of the hemodynamic problems does not eliminate atrial arrhythmias, and ablation of atrial arrhythmias alone could </text>
<text top="926" left="170" width="612" height="14" font="3">allow significant hemodynamic issues to progress and potentially deteriorate. Successful treatment involves assessing both the arrhythmia and </text>
<text top="941" left="170" width="594" height="14" font="3">the contributing hemodynamic changes and addressing both when indicated and feasible. Early experience in adults with unoperated atrial </text>
<text top="956" left="170" width="621" height="14" font="3">septal defects and atrial arrhythmias demonstrated the importance of an integrated approach for arrhythmia and hemodynamic problems; similar </text>
<text top="971" left="170" width="631" height="14" font="3">principles apply to patients with tetralogy of Fallot, Ebstein anomaly, and single-ventricle physiology; these patients are at highest risk of arrhythmia </text>
<text top="986" left="170" width="630" height="14" font="3">development, with concurrent hemodynamic abnormalities. For example, patients with ASD who underwent surgery before the age of 25 years had </text>
<text top="1001" left="170" width="500" height="14" font="3">better long-term outcomes and a lower incidence of atrial arrhythmias than those who underwent surgery later in life.</text>
<text top="1002" left="670" width="10" height="8" font="18">475</text>
<text top="1001" left="680" width="119" height="14" font="3"> Closure of significant atrial </text>
<text top="1016" left="170" width="307" height="14" font="3">septal defects in adults even later in life improves morbidity and survival</text>
<text top="1017" left="477" width="10" height="8" font="18">476</text>
<text top="1016" left="486" width="237" height="14" font="3"> but is associated with new (7%) or recurrent (60%) AT.</text>
<text top="1017" left="723" width="10" height="8" font="18">475</text>
<text top="1016" left="732" width="57" height="14" font="3"> Arrhythmias </text>
<text top="1031" left="170" width="604" height="14" font="3">still can be treated successfully when they develop later after surgical corrections; catheter ablation of atrial arrhythmias associated with ASD </text>
<text top="1046" left="170" width="337" height="14" font="3">repair is highly successful, with acute success rates reported as 93% to 100%.</text>
<text top="1047" left="507" width="33" height="8" font="18">449,458,477</text>
<text top="1046" left="539" width="244" height="14" font="3"> Therefore, patients with unoperated significant ASD and </text>
<text top="1061" left="170" width="604" height="14" font="3">arrhythmias should undergo ablation of the AT, as well as closure of the ASD. The choice of catheter versus surgical approaches to therapy is </text>
<text top="1076" left="170" width="608" height="14" font="3">determined by anatomic features of the ASD likely to be successfully addressed with a catheter approach. No randomized comparison trials of </text>
<text top="1091" left="170" width="622" height="14" font="3">catheter versus surgical closure of ASD combined with arrhythmia intervention have been reported. Surgical closure of large ASDs combined with </text>
<text top="1106" left="170" width="554" height="14" font="3">arrhythmia surgery for AT or fibrillation can be safely performed, with 6.5% occurrence of AF reported during 2 years of follow-up.</text>
<text top="1107" left="723" width="10" height="8" font="18">478</text>
<text top="157" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="157" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="150" left="170" width="574" height="14" font="1"><b>1.   Intravenous ibutilide or procainamide can be effective for acute treatment in ACHD patients and atrial flutter who are </b></text>
<text top="165" left="184" width="119" height="14" font="1"><b>hemodynamically stable.</b></text>
<text top="166" left="303" width="24" height="8" font="20"><b>466–468</b></text>
<text top="202" left="78" width="20" height="14" font="3">See </text>
<text top="202" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="217" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="217" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="187" left="170" width="630" height="14" font="3">A small observational study reported that intravenous ibutilide was successful in conversion of 71% of acute episodes of atrial flutter in </text>
<text top="202" left="170" width="403" height="14" font="3">ACHD patients; torsades de pointes or nonsustained VT was reported in 2.7% of episodes.</text>
<text top="202" left="572" width="10" height="8" font="18">468</text>
<text top="202" left="582" width="219" height="14" font="3"> Pretreatment with magnesium may reduce the </text>
<text top="217" left="170" width="621" height="14" font="3">incidence of postibutilide ventricular arrhythmias. Small studies support the use of intravenous procainamide as adjunctive therapy for </text>
<text top="232" left="170" width="425" height="14" font="3">acute therapy of atrial flutter because it improves efficacy of pacing conversion of atrial flutter.</text>
<text top="232" left="594" width="22" height="8" font="18">466,467</text>
<text top="260" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="260" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="253" left="170" width="627" height="14" font="1"><b>2.   Atrial pacing can be effective for acute treatment in ACHD patients and SVT who are hemodynamically stable and anticoagulated  </b></text>
<text top="268" left="184" width="333" height="14" font="1"><b>as per current guidelines for antithrombotic therapy in patients with AF.</b></text>
<text top="269" left="518" width="35" height="8" font="20"><b>466,469–472</b></text>
<text top="297" left="78" width="20" height="14" font="3">See </text>
<text top="297" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="312" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="312" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="290" left="170" width="599" height="14" font="3">Small observational studies support the efficacy of atrial pacing to successfully terminate 54% to 82% of acute episodes of AT or atrial </text>
<text top="305" left="170" width="29" height="14" font="3">flutter.</text>
<text top="305" left="199" width="35" height="8" font="18">466,469–472</text>
<text top="305" left="234" width="510" height="14" font="3"> Atrial pacing is an effective alternative, particularly when concerns about the use of antiarrhythmic medications or </text>
<text top="320" left="170" width="177" height="14" font="3">significant sinus node dysfunction exist.</text>
<text top="348" left="85" width="12" height="14" font="1"><b>IIa</b></text>
<text top="348" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="340" left="170" width="600" height="14" font="1"><b>3.   Elective synchronized cardioversion can be useful for acute termination of AT or atrial flutter in ACHD patients when acute </b></text>
<text top="355" left="184" width="276" height="14" font="1"><b>pharmacological therapy is ineffective or contraindicated.</b></text>
<text top="356" left="460" width="10" height="8" font="20"><b>460</b></text>
<text top="422" left="78" width="20" height="14" font="3">See </text>
<text top="422" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="437" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="437" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="377" left="170" width="581" height="14" font="3">ACHD patients are at increased risk of congestive heart failure and/or atrial thrombus formation with prolonged episodes of AT or </text>
<text top="392" left="170" width="595" height="14" font="3">atrial flutter. Pharmacological conversion in patients with complex anatomy, ventricular dysfunction, or prolonged QTc intervals may </text>
<text top="407" left="170" width="599" height="14" font="3">result in significant proarrhythmia or acute hemodynamic deterioration. Early assessment for cardiac thrombus with transesophageal </text>
<text top="422" left="170" width="618" height="14" font="3">echocardiogram followed by synchronized cardioversion may be preferable to prolonged or multiple attempts to achieve pharmacological </text>
<text top="437" left="170" width="612" height="14" font="3">cardioversion. Because of frequent coexistent sinus node dysfunction and ventricular dysfunction, the need for chronotropic or inotropic </text>
<text top="452" left="170" width="596" height="14" font="3">intervention should be anticipated, with appropriate personnel and support present. Modification of electrode pad placement may be </text>
<text top="467" left="170" width="611" height="14" font="3">necessary, by using an anterior-posterior configuration in patients with marked atrial enlargement or positioning strategically according </text>
<text top="482" left="170" width="491" height="14" font="3">to the individual arrhythmia and anatomic substrate, including consideration of the possibility of dextrocardia.</text>
<text top="511" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="511" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="503" left="170" width="574" height="14" font="1"><b>1.   Oral dofetilide or sotalol may be reasonable for acute treatment in ACHD patients and AT and/or atrial flutter who are </b></text>
<text top="518" left="184" width="119" height="14" font="1"><b>hemodynamically stable.</b></text>
<text top="519" left="303" width="22" height="8" font="20"><b>473,474</b></text>
<text top="555" left="78" width="20" height="14" font="3">See </text>
<text top="555" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="570" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="570" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="540" left="170" width="268" height="14" font="3">Small observational studies support the use of oral dofetilide</text>
<text top="541" left="437" width="10" height="8" font="18">474</text>
<text top="540" left="448" width="44" height="14" font="3"> or sotalol</text>
<text top="541" left="491" width="10" height="8" font="18">473</text>
<text top="540" left="501" width="251" height="14" font="3"> to acutely convert AT to sinus rhythm in 70% to 85% of </text>
<text top="555" left="170" width="599" height="14" font="3">episodes of acute AT or atrial flutter. Proarrhythmic events are more commonly reported with dofetilide. One small study of 20 patients </text>
<text top="570" left="170" width="294" height="14" font="3">reported that 10% experienced torsades de pointes after dofetilide</text>
<text top="571" left="464" width="10" height="8" font="18">474</text>
<text top="570" left="474" width="309" height="14" font="3">; both proarrhythmic events occurred in patients with single-ventricle </text>
<text top="585" left="170" width="497" height="14" font="3">physiology. The risk of proarrhythmia or worsening ventricular function requires arrhythmia monitoring with use.</text>
<text top="104" left="78" width="401" height="16" font="19"><b>Recommendations for Acute Treatment of SVT in ACHD Patients (Continued)</b></text>
<text top="128" left="85" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="132" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e552  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="159" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="159" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="151" left="171" width="613" height="14" font="1"><b>1.   Preoperative catheter ablation or intraoperative surgical ablation of accessory pathways or AT is reasonable in patients with  </b></text>
<text top="166" left="186" width="285" height="14" font="1"><b>SVT who are undergoing surgical repair of Ebstein anomaly.</b></text>
<text top="167" left="471" width="24" height="8" font="20"><b>479–485</b></text>
<text top="287" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="287" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="302" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="302" left="147" width="3" height="14" font="3">.</text>
<text top="190" left="180" width="564" height="14" font="3">The prevalence of SVT among patients with Ebstein anomaly was 33% in 1 large series, the highest noted among ACHD  </text>
<text top="205" left="180" width="40" height="14" font="3">patients,</text>
<text top="205" left="221" width="10" height="8" font="18">440</text>
<text top="205" left="231" width="280" height="14" font="3"> and increased with age. AT, atrial flutter, or AF develops in </text>
<text top="205" left="511" width="258" height="14" font="3">≥50% of patients with Ebstein anomaly and significant </text>
<text top="220" left="180" width="604" height="14" font="3">tricuspid regurgitation. Right-sided accessory pathways are present in 15% to 30% of patients with Ebstein anomaly and may be </text>
<text top="235" left="180" width="79" height="14" font="3">multiple in up to </text>
<text top="235" left="259" width="525" height="14" font="3">≥29% of those patients. Catheter ablation of accessory pathways in patients with Ebstein anomaly is associated </text>
<text top="250" left="180" width="620" height="14" font="3">with lower success rates than for other populations, acute success rate of 75% to 89% of procedures, with acute recurrence in 25% </text>
<text top="265" left="180" width="36" height="14" font="3">to 30%.</text>
<text top="265" left="217" width="23" height="8" font="18">480,481</text>
<text top="265" left="239" width="540" height="14" font="3"> In a series of 83 adults undergoing arrhythmia surgery at the time of surgical repair of Ebstein anomaly, accessory </text>
<text top="280" left="180" width="366" height="14" font="3">pathways were present in 32%, and atrial flutter/fibrillation was noted in 54%,</text>
<text top="280" left="546" width="10" height="8" font="18">483</text>
<text top="280" left="557" width="240" height="14" font="3"> with no recurrence of AP after surgery. Successful </text>
<text top="295" left="180" width="355" height="14" font="3">surgical ablation of accessory pathways has been reported in 92% to 100%.</text>
<text top="295" left="536" width="23" height="8" font="18">483,484</text>
<text top="295" left="559" width="241" height="14" font="3"> In a series of patients undergoing right atrial maze </text>
<text top="310" left="180" width="599" height="14" font="3">procedures or isthmus ablation for atrial flutter/fibrillation in association with repair of Ebstein anomaly, freedom from recurrent </text>
<text top="325" left="180" width="272" height="14" font="3">flutter/fibrillation was 75% during 34 months of follow-up.</text>
<text top="325" left="452" width="10" height="8" font="18">483</text>
<text top="325" left="463" width="330" height="14" font="3"> In a comparison study of combined operative arrhythmia surgery with </text>
<text top="340" left="180" width="604" height="14" font="3">repair, versus catheter ablation followed by surgical repair, the combined approach was effective in 94% of cases versus 76% of </text>
<text top="355" left="180" width="233" height="14" font="3">patients treated with the catheter approach alone.</text>
<text top="355" left="414" width="10" height="8" font="18">484</text>
<text top="355" left="424" width="350" height="14" font="3"> In a series of patients undergoing repair of Ebstein anomaly, patients who </text>
<text top="370" left="180" width="605" height="14" font="3">underwent preoperative EP study with intraoperative ablation of arrhythmia substrate had lower risk of SCD than patients without </text>
<text top="385" left="180" width="111" height="14" font="3">arrhythmia intervention.</text>
<text top="385" left="292" width="10" height="8" font="18">479</text>
<text top="385" left="302" width="477" height="14" font="3"> In patients with Ebstein anomaly undergoing planned surgical intervention, an integrated approach of </text>
<text top="400" left="180" width="337" height="14" font="3">arrhythmia intervention has been demonstrated to be safe and effective.</text>
<text top="421" left="91" width="12" height="14" font="1"><b>IIa</b></text>
<text top="421" left="130" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="421" left="171" width="557" height="14" font="1"><b>2.   Oral beta blockers or sotalol therapy can be useful for prevention of recurrent AT or atrial flutter in ACHD patients.</b></text>
<text top="422" left="729" width="34" height="8" font="20"><b>218,447,486</b></text>
<text top="480" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="480" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="495" left="80" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="495" left="147" width="3" height="14" font="3">.</text>
<text top="443" left="180" width="587" height="14" font="3">Beta blockers may decrease catecholamine-related triggers and provide AV nodal blockade during recurrent atrial arrhythmias. </text>
<text top="458" left="180" width="608" height="14" font="3">One study of adults with transposition of the great arteries and prior atrial switch repairs with implanted defibrillators demonstrated </text>
<text top="473" left="180" width="602" height="14" font="3">SVT preceding VT in 50% of patients; use of beta-blocker medications in this population was associated with decreased incidence </text>
<text top="488" left="180" width="158" height="14" font="3">of appropriate defibrillator shocks.</text>
<text top="488" left="338" width="10" height="8" font="18">486</text>
<text top="488" left="349" width="423" height="14" font="3"> Observational studies on the use of sotalol in ACHD patients report freedom from recurrent </text>
<text top="503" left="180" width="269" height="14" font="3">AT in 41% to 46% of patients during short-term follow-up.</text>
<text top="503" left="450" width="35" height="8" font="18">218,487,488</text>
<text top="503" left="484" width="296" height="14" font="3"> Use of either medication in the setting of significant sinus node </text>
<text top="518" left="180" width="622" height="14" font="3">dysfunction may exacerbate bradycardia and requires careful monitoring. Initiation of sotalol in this population is recommended during </text>
<text top="533" left="180" width="265" height="14" font="3">inpatient monitoring for proarrhythmia for 48 to 72 hours.</text>
<text top="558" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="558" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="558" left="171" width="460" height="14" font="1"><b>3.   Catheter ablation is reasonable for treatment of recurrent symptomatic SVT in ACHD patients.</b></text>
<text top="558" left="631" width="94" height="8" font="20"><b>330,449,452,454,457,458,489–492</b></text>
<text top="662" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="662" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="677" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="677" left="147" width="3" height="14" font="3">.</text>
<text top="583" left="171" width="591" height="14" font="3">Multiple observational and multicenter studies have demon strated acute success rates between 65% and 100% for treatment of SVT </text>
<text top="597" left="171" width="100" height="14" font="3">associated with ACHD.</text>
<text top="598" left="271" width="81" height="8" font="18">452,454,455,457,489,493,494</text>
<text top="597" left="352" width="421" height="14" font="3"> Acute success rates vary by tachycardia mechanism and type of congenital heart disease and </text>
<text top="612" left="171" width="325" height="14" font="3">repair. Success rates are highest for SVT associated with AVNRT (&gt;80%),</text>
<text top="612" left="496" width="22" height="8" font="18">490,494</text>
<text top="612" left="518" width="285" height="14" font="3"> accessory pathways (75% to 89% among patients with Ebstein </text>
<text top="626" left="171" width="43" height="14" font="3">anomaly),</text>
<text top="627" left="214" width="10" height="8" font="18">480</text>
<text top="626" left="225" width="123" height="14" font="3"> or focal AT (80% to 100%).</text>
<text top="627" left="348" width="34" height="8" font="18">492,494,495</text>
<text top="626" left="381" width="394" height="14" font="3"> Success rates for catheter ablation of AT or atrial flutter are significantly lower than that </text>
<text top="640" left="171" width="468" height="14" font="3">reported in patients without ACHD, with overall 65% to 82% acute success in mixed anatomic substrates,</text>
<text top="641" left="639" width="69" height="8" font="18">452,454,455,457,493,494</text>
<text top="640" left="708" width="84" height="14" font="3"> but success rates </text>
<text top="655" left="171" width="286" height="14" font="3">have improved with advanced mapping and ablation techniques.</text>
<text top="655" left="457" width="10" height="8" font="18">494</text>
<text top="655" left="467" width="320" height="14" font="3"> Acute success rates in ablation of AT or atrial flutter varies significantly </text>
<text top="669" left="171" width="416" height="14" font="3">by type of congenital heart disease, ranging from 93% to 100% in patients with repaired ASD,</text>
<text top="670" left="587" width="34" height="8" font="18">330,449,458</text>
<text top="669" left="621" width="164" height="14" font="3"> 85% to 100% in atrial baffle repairs </text>
<text top="684" left="171" width="162" height="14" font="3">of transposition of the great arteries,</text>
<text top="684" left="333" width="22" height="8" font="18">490,492</text>
<text top="684" left="355" width="259" height="14" font="3"> and 54% to 75% of univentricular heart or Fontan repairs.</text>
<text top="684" left="614" width="34" height="8" font="18">457,490,495</text>
<text top="684" left="647" width="123" height="14" font="3"> Older age and presence of </text>
<text top="698" left="171" width="520" height="14" font="3">univentricular heart physiology was associated with decreased acute success rates in a series of 193 ablations of AT.</text>
<text top="699" left="691" width="10" height="8" font="18">457</text>
<text top="698" left="701" width="82" height="14" font="3"> Recurrent AT has </text>
<text top="712" left="171" width="573" height="14" font="3">been reported in 20% to 85% of patients during short-term follow-up, with development of AF reported in 7% to 30% of patients.</text>
<text top="713" left="744" width="45" height="8" font="18">330,449,454,493</text>
<text top="712" left="789" width="3" height="14" font="3"> </text>
<text top="727" left="171" width="629" height="14" font="3">Recurrent SVT may represent the same or a new reentrant circuit, and arrhythmia burden may be decreased by ablation procedures. Ablation </text>
<text top="741" left="171" width="632" height="14" font="3">procedures in patients with complex congenital heart disease are best performed in centers with advanced mapping techniques and expertise </text>
<text top="756" left="171" width="122" height="14" font="3">in congenital heart disease.</text>
<text top="756" left="293" width="27" height="8" font="18">25,29,496</text>
<text top="775" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="775" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="775" left="171" width="530" height="14" font="1"><b>4.   Surgical ablation of AT or atrial flutter can be effective in ACHD patients undergoing planned surgical repair.</b></text>
<text top="776" left="701" width="24" height="8" font="20"><b>497–508</b></text>
<text top="878" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="878" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="893" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="893" left="147" width="3" height="14" font="3">.</text>
<text top="795" left="171" width="606" height="14" font="3">In patients with symptomatic SVT undergoing planned surgical repairs of structural heart disease or ischemic heart disease, observation studies </text>
<text top="810" left="171" width="531" height="14" font="3">report that arrhythmia surgery can be integrated into the operation with high efficacy and without increased surgical morbidity.</text>
<text top="811" left="702" width="23" height="8" font="18">497–500</text>
<text top="810" left="725" width="64" height="14" font="3"> In populations </text>
<text top="825" left="171" width="634" height="14" font="3">including those with tetralogy of Fallot/double-outlet right ventricle, tricuspid valve repairs, and ASD, rates of freedom from recurrent AT or atrial flutter </text>
<text top="840" left="171" width="624" height="14" font="3">have been reported as 73% to 93% without antiarrhythmic medications during medium-term follow-up of 2.5 to 10 years. Catheter ablation may be </text>
<text top="855" left="171" width="634" height="14" font="3">attempted in specialized centersbefore surgical Fontan repair. There are no RCTs comparing efficacy of catheter versus surgical ablation of AT or atrial </text>
<text top="870" left="171" width="617" height="14" font="3">flutter in patients with prior Fontan repairs. The incidence of AT or atrial flutter in patients with prior Fontan repairs approaches 60% and increases </text>
<text top="885" left="171" width="460" height="14" font="3">with advancing age. Catheter ablation success rates in this subset of patients are lower than for other lesions,</text>
<text top="886" left="631" width="10" height="8" font="18">457</text>
<text top="885" left="641" width="155" height="14" font="3"> with acute success in 54% to 75%, </text>
<text top="900" left="171" width="284" height="14" font="3">and with recurrent AT in 27% to 50% of patients within 2 to 4 years</text>
<text top="901" left="455" width="21" height="8" font="18">490,495</text>
<text top="900" left="476" width="307" height="14" font="3">; death or transplantation was reported in 27% during follow-up. Several </text>
<text top="915" left="171" width="617" height="14" font="3">observational studies of surgical resection and ablation for AT or atrial flutter associated with Fontan conversion reported rates of freedom from AT </text>
<text top="930" left="171" width="224" height="14" font="3">of 12% to 16% during follow-up extending to 8 years</text>
<text top="931" left="394" width="23" height="8" font="18">501–505</text>
<text top="930" left="417" width="358" height="14" font="3">; death or transplantation was reported in 6% to 14% during follow-up. Performance </text>
<text top="945" left="171" width="442" height="14" font="3">of a modified right atrial maze procedure versus CTI ablation was associated with lower recurrence rates.</text>
<text top="946" left="613" width="10" height="8" font="18">501</text>
<text top="945" left="623" width="161" height="14" font="3"> Alternatively, surgical repairs without </text>
<text top="960" left="171" width="617" height="14" font="3">arrhythmia intervention are associated with high recurrence rates of AT. Arrhythmia surgery can be combined with hemodynamic surgical revision </text>
<text top="975" left="171" width="491" height="14" font="3">with low mortality rate and improved medium-term freedom from arrhythmia recurrence and deathin this population.</text>
<text top="1003" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="1003" left="126" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="996" left="171" width="548" height="14" font="1"><b>1.   Atrial pacing may be reasonable to decrease recurrences of AT or atrial flutter in ACHD patients and sinus node </b></text>
<text top="1011" left="186" width="59" height="14" font="1"><b>dysfunction.</b></text>
<text top="1011" left="245" width="34" height="8" font="20"><b>472,509,510</b></text>
<text top="1047" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1047" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1062" left="80" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1062" left="147" width="3" height="14" font="3">.</text>
<text top="1032" left="171" width="634" height="14" font="3">Small observational studies support the use of atrial pacing in patients with recurrent AT or atrial flutter to reduce the frequency of tachycardia </text>
<text top="1047" left="171" width="597" height="14" font="3">episodes. The pacing rate is programmed to maintain atrial pacing for the majority of the time in patients with sinus node dysfunction, </text>
<text top="1062" left="171" width="288" height="14" font="3">significantly reducing tachycardia recurrences to 11% in 1 study.</text>
<text top="1063" left="460" width="22" height="8" font="18">509,510</text>
<text top="1062" left="481" width="307" height="14" font="3"> In addition, the implanted pacemaker can be used for termination of </text>
<text top="1077" left="171" width="177" height="14" font="3">recurrent episodes of AT or atrial flutter.</text>
<text top="1078" left="349" width="10" height="8" font="18">472</text>
<text top="104" left="80" width="435" height="16" font="19"><b>Recommendations for Ongoing Management of SVT in ACHD Patients (Continued)</b></text>
<text top="128" left="87" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="134" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e553</i></b></text>
<text top="496" left="69" width="99" height="18" font="10"><b>9.3. Pregnancy</b></text>
<text top="517" left="69" width="361" height="16" font="13">Pregnancy may confer an increased susceptibility to a </text>
<text top="517" left="420" width="4" height="16" font="13"> </text>
<text top="536" left="69" width="354" height="16" font="13">variety of arrhythmias, even in the absence of underlying heart </text>
<text top="555" left="69" width="45" height="16" font="13">disease.</text>
<text top="555" left="114" width="12" height="9" font="14">513</text>
<text top="555" left="126" width="301" height="16" font="13"> Pregnancy is also associated with an increased </text>
<text top="574" left="69" width="356" height="16" font="13">risk of arrhythmia exacerbation, such as more frequent and </text>
<text top="593" left="69" width="354" height="16" font="13">refractory tachycardia episodes, in patients with a pre-existing </text>
<text top="612" left="69" width="124" height="16" font="13">arrhythmic substrate.</text>
<text top="613" left="193" width="12" height="9" font="14">514</text>
<text top="612" left="205" width="222" height="16" font="13"> An important consideration is that </text>
<text top="631" left="69" width="355" height="16" font="13">adverse maternal and fetal outcomes have been reported as a </text>
<text top="650" left="69" width="157" height="16" font="13">result of SVT in pregnancy.</text>
<text top="651" left="226" width="12" height="9" font="14">515</text>
<text top="650" left="239" width="181" height="16" font="13"> Although there is potential tox-</text>
<text top="669" left="69" width="351" height="16" font="13">icity to the fetus with certain pharmacological and nonphar-</text>
<text top="688" left="69" width="355" height="16" font="13">macological therapies, safe options exist to allow for treating </text>
<text top="707" left="69" width="227" height="16" font="13">most cases of maternal SVT effectively.</text>
<text top="496" left="477" width="334" height="16" font="13">The literature on therapeutic options for the management </text>
<text top="513" left="456" width="354" height="16" font="13">of arrhythmias in pregnancy is generally limited to single case </text>
<text top="530" left="456" width="351" height="16" font="13">reports or small series and favors the use of older antiarrhyth-</text>
<text top="547" left="456" width="355" height="16" font="13">mic agents because of more abundant reports on the safe use </text>
<text top="564" left="456" width="357" height="16" font="13">of these drugs. Experience with use of drugs in pregnancy </text>
<text top="581" left="456" width="351" height="16" font="13">also comes from treating a variety of maternal and fetal condi-</text>
<text top="598" left="456" width="354" height="16" font="13">tions, not maternal SVT alone. Although all medications have </text>
<text top="614" left="456" width="356" height="16" font="13">potential side effects to both the mother and the fetus at any </text>
<text top="631" left="456" width="354" height="16" font="13">stage of pregnancy, if possible, drugs should be avoided in the </text>
<text top="648" left="456" width="351" height="16" font="13">first trimester, when risk of congenital malformations is great-</text>
<text top="665" left="456" width="356" height="16" font="13">est. The lowest recommended dose should be used initially, </text>
<text top="682" left="456" width="322" height="16" font="13">accompanied by regular monitoring of clinical response.</text>
<text top="708" left="456" width="250" height="16" font="0"><i><b>9.3.1. Acute Treatment: Recommendations</b></i></text>
<text top="150" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="150" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="150" left="170" width="477" height="14" font="1"><b>2.   Oral dofetilide may be reasonable for prevention of recurrent AT or atrial flutter in ACHD patients.</b></text>
<text top="151" left="646" width="45" height="8" font="20"><b>447,474,487,488</b></text>
<text top="194" left="78" width="20" height="14" font="3">See </text>
<text top="194" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="209" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="209" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="172" left="170" width="618" height="14" font="3">Two small observational studies on the use of oral dofetilide for ACHD patients report a high rate of acute conversion of AT or atrial flutter, with </text>
<text top="187" left="170" width="616" height="14" font="3">longer-term efficacy of the drug (defined by either complete suppression or partial improvement of symptoms) ranging from 70% to 85%. The </text>
<text top="202" left="170" width="317" height="14" font="3">benefit was tempered by an association with torsades de pointes in 10%.</text>
<text top="202" left="486" width="21" height="8" font="18">471,484</text>
<text top="202" left="508" width="293" height="14" font="3"> Although many patients continued to experience recurrence, these </text>
<text top="217" left="170" width="258" height="14" font="3">episodes were better tolerated and were of limited duration.</text>
<text top="217" left="428" width="21" height="8" font="18">471,484</text>
<text top="217" left="449" width="352" height="14" font="3"> Because of the potential risk of proarrhythmia, dofetilide is usually a second-line </text>
<text top="232" left="170" width="571" height="14" font="3">medication after failure of beta blockers and sotalol. Initiation of oral dofetilide is recommended during 72-hour inpatient monitoring.</text>
<text top="260" left="85" width="12" height="14" font="1"><b>IIb</b></text>
<text top="260" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="253" left="170" width="626" height="14" font="1"><b>3.   Amiodarone may be reasonable for prevention of recurrent AT or atrial flutter in ACHD patients for whom other medications and </b></text>
<text top="268" left="184" width="245" height="14" font="1"><b>catheter ablation are ineffective or contraindicated.</b></text>
<text top="269" left="430" width="10" height="8" font="20"><b>447</b></text>
<text top="312" left="78" width="20" height="14" font="3">See </text>
<text top="312" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="327" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="327" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="290" left="170" width="625" height="14" font="3">An observational study reported efficacy of amiodarone in maintaining sinus rhythm, although side effects were noted frequently, including thyroid </text>
<text top="305" left="170" width="93" height="14" font="3">disorders or AV block.</text>
<text top="305" left="263" width="10" height="8" font="18">447</text>
<text top="305" left="272" width="527" height="14" font="3"> The risk of significant side effects increases with chronic use and with higher dosages; using the minimal effective chronic </text>
<text top="320" left="170" width="623" height="14" font="3">dosage is recommended. Observational studies reported thyroid disorders in 13% to 36% of ACHD patients receiving amiodarone; risk factors </text>
<text top="335" left="170" width="598" height="14" font="3">for thyrotoxicosis include female sex, cyanotic heart disease, low body mass index, prior Fontan procedure, or dosages &gt;200 mg daily.</text>
<text top="335" left="767" width="22" height="8" font="18">511,512</text>
<text top="335" left="789" width="3" height="14" font="3"> </text>
<text top="350" left="170" width="617" height="14" font="3">Amiodarone is recommended for short-term use or for patients for whom alternative therapy is not an option for prevention of recurrent AT.</text>
<text top="370" left="85" width="18" height="14" font="1"><b>III:  </b></text>
<text top="385" left="78" width="26" height="14" font="1"><b>Harm</b></text>
<text top="378" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="378" left="170" width="568" height="14" font="1"><b>1.   Flecainide should not be administered for treatment of SVT in ACHD patients and significant ventricular dysfunction.</b></text>
<text top="379" left="738" width="10" height="8" font="20"><b>419</b></text>
<text top="430" left="78" width="20" height="14" font="3">See </text>
<text top="430" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="445" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="445" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="407" left="170" width="601" height="14" font="3">There are no RCTs on the use of flecainide in ACHD patients and ventricular dysfunction. One retrospective study collected data on 579 </text>
<text top="422" left="170" width="611" height="14" font="3">young patients, 369 of whom received flecainide for the treatment of SVT. Efficacy for the treatment of SVT was 71%. Among 12 patients </text>
<text top="437" left="170" width="604" height="14" font="3">with cardiac arrest while receiving flecainide for SVT, 8 had congenital heart disease, and 7 of 8 had either mild to moderate ventricular </text>
<text top="452" left="170" width="616" height="14" font="3">dysfunction or systemic right- or single-ventricle anatomy. The risk associated with flecainide treatment of SVT associated with congenital </text>
<text top="467" left="170" width="473" height="14" font="3">heart disease appears to be highest among patients with complex heart disease or ventricular dysfunction.</text>
<text top="104" left="78" width="435" height="16" font="19"><b>Recommendations for Ongoing Management of SVT in ACHD Patients (Continued)</b></text>
<text top="128" left="85" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="132" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="743" left="78" width="374" height="16" font="19"><b>Recommendations for Acute Treatment of SVT in Pregnant Patients</b></text>
<text top="766" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="766" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="766" left="170" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="787" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="787" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="787" left="170" width="428" height="14" font="1"><b>1.   Vagal maneuvers are recommended for acute treatment in pregnant patients with SVT.</b></text>
<text top="788" left="598" width="22" height="8" font="20"><b>235,516</b></text>
<text top="862" left="78" width="20" height="14" font="3">See </text>
<text top="862" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="877" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="877" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="809" left="170" width="595" height="14" font="3">For acute conversion of SVT, vagal maneuvers, including Valsalva and carotid sinus massage, can be performed quickly and should be the first-line </text>
<text top="824" left="170" width="626" height="14" font="3">intervention to terminate SVT. These maneuvers should be performed with the patient in the supine position. Vagal maneuvers typically will not be effective </text>
<text top="839" left="170" width="597" height="14" font="3">if the rhythm does not involve the AV node as a requisite component of a reentrant circuit. There is no “gold standard” for proper Valsalva maneuver </text>
<text top="854" left="170" width="618" height="14" font="3">technique, but in general, the patient raises intrathoracic pressure by bearing down against a closed glottis for 10 to 30 seconds, equivalent to at least 30 </text>
<text top="869" left="170" width="86" height="14" font="3">mm Hg to 40 mm Hg.</text>
<text top="870" left="255" width="14" height="8" font="18">82,84</text>
<text top="869" left="269" width="515" height="14" font="3"> Carotid massage is performed after absence of bruit has been confirmed by auscultation, by applying steady pressure over the </text>
<text top="884" left="170" width="180" height="14" font="3">right or left carotid sinus for 5 to 10 seconds.</text>
<text top="885" left="350" width="14" height="8" font="18">83,84</text>
<text top="884" left="363" width="439" height="14" font="3"> Another vagal maneuver based on the classic diving reflex consists of applying an ice-cold, wet towel to the </text>
<text top="899" left="170" width="18" height="14" font="3">face</text>
<text top="900" left="187" width="6" height="8" font="18">85</text>
<text top="899" left="193" width="486" height="14" font="3">; in a laboratory setting, facial immersion in water at 10°C (50°F) has proved effective in terminating tachycardia, as well.</text>
<text top="900" left="679" width="6" height="8" font="18">86</text>
<text top="899" left="685" width="103" height="14" font="3"> One study involving 148 </text>
<text top="914" left="170" width="622" height="14" font="3">nonpregnant patients with SVT demonstrated that Valsalva was more successful than carotid sinus massage, and switching from 1 technique to the other </text>
<text top="929" left="170" width="179" height="14" font="3">resulted in an overall success rate of 27.7%.</text>
<text top="930" left="349" width="6" height="8" font="18">82</text>
<text top="929" left="355" width="398" height="14" font="3"> The practice of applying pressure to the eyeball is potentially dangerous and has been abandoned.</text>
<text top="950" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="950" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="950" left="170" width="388" height="14" font="1"><b>2.   Adenosine is recommended for acute treatment in pregnant patients with SVT.</b></text>
<text top="951" left="558" width="10" height="8" font="20"><b>516</b></text>
<text top="987" left="78" width="20" height="14" font="3">See </text>
<text top="987" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1002" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1002" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="972" left="170" width="439" height="14" font="3">When vagal maneuvers fail to terminate SVT, adenosine is a first-line drug option for pregnant patients.</text>
<text top="972" left="609" width="10" height="8" font="18">516</text>
<text top="972" left="618" width="180" height="14" font="3"> Adverse effects to the fetus would not be </text>
<text top="987" left="170" width="463" height="14" font="3">expected, given that it is unlikely the drug will reach the fetal circulation because of adenosine’s short half-life.</text>
<text top="987" left="633" width="10" height="8" font="18">517</text>
<text top="987" left="642" width="157" height="14" font="3"> Maternal side effects, such as chest </text>
<text top="1002" left="170" width="634" height="14" font="3">discomfort and flushing, are usually transient. The initial dose for adenosine is 6-mg rapid bolus IV. If this is ineffective, up to 2 subsequent infusions </text>
<text top="1017" left="170" width="620" height="14" font="3">of 12 mg may be administered. Higher doses of adenosine may be necessary in some cases; safe administration of up to 24 mg has been reported.</text>
<text top="1017" left="790" width="10" height="8" font="18">518</text>
<text top="1045" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="1045" left="125" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1038" left="170" width="630" height="14" font="1"><b>3.   Synchronized cardioversion is recommended for acute treatment in pregnant patients with hemodynamically unstable SVT when </b></text>
<text top="1053" left="184" width="276" height="14" font="1"><b>pharmacological therapy is ineffective or contraindicated.</b></text>
<text top="1054" left="460" width="10" height="8" font="20"><b>516</b></text>
<text top="1082" left="78" width="20" height="14" font="3">See </text>
<text top="1082" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1097" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1097" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="1075" left="170" width="620" height="14" font="3">Synchronized cardioversion has been reported to be safe at all stages of pregnancy. The electrode pads should be applied such that the energy </text>
<text top="1090" left="170" width="243" height="14" font="3">source and trajectory are directed away from the uterus.</text>
<text top="1090" left="413" width="10" height="8" font="18">519</text>
<text top="1090" left="423" width="346" height="14" font="3"> Fetal monitoring during cardioversion (if time allows) and during the immediate </text>
<text top="1105" left="170" width="184" height="14" font="3">postcardioversion period is recommended.</text>
<text top="1105" left="354" width="10" height="8" font="18">519</text>
<text top="1105" left="364" width="365" height="14" font="3"> Energy dosing for pregnant patients should be the same as in nonpregnant patients.</text>
<text top="1105" left="728" width="10" height="8" font="18">520</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e554  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="503" left="71" width="285" height="16" font="0"><i><b>9.3.2. Ongoing Management: Recommendations</b></i></text>
<text top="157" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="157" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="150" left="171" width="596" height="14" font="1"><b>1.   Intravenous metoprolol or propranolol is reasonable for acute treatment in pregnant patients with SVT when adenosine is </b></text>
<text top="165" left="186" width="143" height="14" font="1"><b>ineffective or contraindicated.</b></text>
<text top="166" left="329" width="10" height="8" font="20"><b>516</b></text>
<text top="194" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="194" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="209" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="209" left="147" width="3" height="14" font="3">.</text>
<text top="187" left="171" width="612" height="14" font="3">Beta-adrenergic–blocking drugs are considered the first-line option for a variety of arrhythmias in pregnancy because there are extensive </text>
<text top="202" left="171" width="606" height="14" font="3">reports on their safe use from treating a variety of maternal conditions over many decades. A slow infusion would be less likely to cause </text>
<text top="217" left="171" width="56" height="14" font="3">hypotension.</text>
<text top="217" left="228" width="34" height="8" font="18">516,517,521</text>
<text top="245" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="245" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="238" left="171" width="625" height="14" font="1"><b>1.   Intravenous verapamil may be reasonable for acute treatment in pregnant patients with SVT when adenosine and beta blockers </b></text>
<text top="253" left="186" width="161" height="14" font="1"><b>are ineffective or contraindicated.</b></text>
<text top="254" left="347" width="10" height="8" font="20"><b>516</b></text>
<text top="282" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="282" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="297" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="297" left="147" width="3" height="14" font="3">.</text>
<text top="275" left="171" width="593" height="14" font="3">Intravenous verapamil has been used effectively for the acute treatment of SVT in pregnant women; however, there is a higher risk of </text>
<text top="290" left="171" width="314" height="14" font="3">maternal hypotension with intravenous verapamil than with adenosine.</text>
<text top="290" left="485" width="10" height="8" font="18">516</text>
<text top="290" left="495" width="308" height="14" font="3"> Reports on diltiazem use for acute SVT termination in pregnancy are </text>
<text top="305" left="171" width="287" height="14" font="3">more limited than for verapamil, yet similar effects are expected.</text>
<text top="305" left="458" width="10" height="8" font="18">517</text>
<text top="325" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="325" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="325" left="171" width="474" height="14" font="1"><b>2.   Intravenous procainamide may be reasonable for acute treatment in pregnant patients with SVT.</b></text>
<text top="326" left="645" width="10" height="8" font="20"><b>522</b></text>
<text top="355" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="355" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="370" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="370" left="147" width="3" height="14" font="3">.</text>
<text top="347" left="171" width="622" height="14" font="3">Intravenous procainamide has been used safely to treat a variety of maternal and fetal supraventricular and ventricular arrhythmias and can </text>
<text top="362" left="171" width="199" height="14" font="3">be effective when used for acute conversion.</text>
<text top="363" left="370" width="22" height="8" font="18">517,522</text>
<text top="362" left="392" width="407" height="14" font="3"> Procainamide is generally best avoided as long-term therapy because it can cause a lupus-</text>
<text top="377" left="171" width="309" height="14" font="3">like syndrome, unless other options are contraindicated or ineffective.</text>
<text top="406" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="406" left="126" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="398" left="171" width="624" height="14" font="1"><b>3.   Intravenous amiodarone may be considered for acute treatment in pregnant patients with potentially life-threatening SVT when </b></text>
<text top="413" left="186" width="237" height="14" font="1"><b>other therapies are ineffective or contraindicated.</b></text>
<text top="414" left="422" width="22" height="8" font="20"><b>517,523</b></text>
<text top="443" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="443" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="458" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="458" left="147" width="3" height="14" font="3">.</text>
<text top="435" left="171" width="599" height="14" font="3">Although intravenous amiodarone has been administered safely during pregnancy, multiple adverse effects to the fetus have also been </text>
<text top="450" left="171" width="40" height="14" font="3">reported.</text>
<text top="451" left="211" width="10" height="8" font="18">523</text>
<text top="450" left="221" width="462" height="14" font="3"> An important concern is the possibility of fetal hypothyroidism, reported in approximately 17% of cases.</text>
<text top="451" left="683" width="22" height="8" font="18">517,523</text>
<text top="450" left="705" width="94" height="14" font="3"> With an intravenous </text>
<text top="465" left="171" width="577" height="14" font="3">infusion for short-term use, side effects would be less of a concern, given that most toxicities are related to cumulative drug dose.</text>
<text top="104" left="80" width="440" height="16" font="19"><b>Recommendations for Acute Treatment of SVT in Pregnant Patients (Continued)</b></text>
<text top="128" left="87" width="20" height="14" font="1"><b>COR</b></text>
<text top="128" left="134" width="18" height="14" font="1"><b>LOE</b></text>
<text top="128" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="531" left="80" width="404" height="16" font="19"><b>Recommendations for Ongoing Management of SVT in Pregnant Patients</b></text>
<text top="555" left="83" width="20" height="14" font="1"><b>COR</b></text>
<text top="555" left="129" width="18" height="14" font="1"><b>LOE</b></text>
<text top="555" left="171" width="89" height="14" font="1"><b>Recommendations</b></text>
<text top="637" left="86" width="12" height="14" font="1"><b>IIa</b></text>
<text top="637" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="577" left="171" width="589" height="14" font="1"><b>1.   The following drugs, alone or in combination, can be effective for ongoing management in pregnant patients with highly </b></text>
<text top="592" left="186" width="86" height="14" font="1"><b>symptomatic SVT:</b></text>
<text top="611" left="171" width="63" height="14" font="1"><b>  a. Digoxin</b></text>
<text top="612" left="234" width="22" height="8" font="20"><b>437,517</b></text>
<text top="626" left="171" width="76" height="14" font="1"><b>  b. Flecainide</b></text>
<text top="627" left="247" width="22" height="8" font="20"><b>437,517</b></text>
<text top="640" left="171" width="77" height="14" font="1"><b>  c. Metoprolol</b></text>
<text top="641" left="249" width="22" height="8" font="20"><b>517,521</b></text>
<text top="655" left="171" width="87" height="14" font="1"><b>  d. Propafenone</b></text>
<text top="656" left="258" width="10" height="8" font="20"><b>517</b></text>
<text top="670" left="171" width="81" height="14" font="1"><b>  e. Propranolol</b></text>
<text top="670" left="253" width="22" height="8" font="20"><b>517,521</b></text>
<text top="684" left="171" width="59" height="14" font="1"><b>  f.   Sotalol</b></text>
<text top="685" left="230" width="22" height="8" font="20"><b>437,517</b></text>
<text top="699" left="171" width="75" height="14" font="1"><b>  g. Verapamil</b></text>
<text top="700" left="246" width="10" height="8" font="20"><b>517</b></text>
<text top="766" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="766" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="781" left="80" width="67" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="781" left="147" width="3" height="14" font="3">.</text>
<text top="721" left="171" width="594" height="14" font="3">If possible, antiarrhythmic drugs should be avoided in the first trimester, when risk of congenital malformations is greatest. Almost no </text>
<text top="736" left="171" width="608" height="14" font="3">reports exist on the use of newer antiarrhythmic drugs (such as dofetilide) during pregnancy, yet their use may be justified if the benefits </text>
<text top="751" left="171" width="617" height="14" font="3">outweigh the risk. The lowest recommended dose should be used initially, with dose adjustments made according to clinical response. For </text>
<text top="766" left="171" width="606" height="14" font="3">oral chronic prophylaxis, drugs such as metoprolol, propranolol, and digoxin are considered safe first-line agents because of their longer </text>
<text top="781" left="171" width="597" height="14" font="3">record of safety, yet caution is advised, given that therapy with beta blockers has been associated with intrauterine growth retardation.</text>
<text top="782" left="769" width="22" height="8" font="18">517,524</text>
<text top="781" left="790" width="3" height="14" font="3"> </text>
<text top="796" left="171" width="605" height="14" font="3">This effect appears to be especially pronounced with atenolol, especially in mothers who received atenolol earlier in gestational age and </text>
<text top="811" left="171" width="165" height="14" font="3">who were treated for longer duration.</text>
<text top="812" left="337" width="10" height="8" font="18">525</text>
<text top="811" left="347" width="419" height="14" font="3"> Flecainide and propafenone have been used effectively to treat a variety of maternal and fetal </text>
<text top="826" left="171" width="544" height="14" font="3">tachycardias, yet they are reserved for patients who have no underlying structural heart disease or ischemic heart disease.</text>
<text top="827" left="715" width="10" height="8" font="18">113</text>
<text top="857" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="857" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="849" left="171" width="620" height="14" font="1"><b>1.   Catheter ablation may be reasonable in pregnant patients with highly symptomatic, recurrent, drug-refractory SVT with efforts </b></text>
<text top="864" left="186" width="184" height="14" font="1"><b>toward minimizing radiation exposure.</b></text>
<text top="865" left="370" width="22" height="8" font="20"><b>526,527</b></text>
<text top="935" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="935" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="950" left="80" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="950" left="147" width="3" height="14" font="3">.</text>
<text top="889" left="171" width="621" height="14" font="3">The risk of radiation exposure to the fetus is a concern with catheter ablation in pregnant patients, because high-dose ionizing radiation has been </text>
<text top="904" left="171" width="252" height="14" font="3">linked to excess malignancy and congenital malformations.</text>
<text top="905" left="423" width="10" height="8" font="18">528</text>
<text top="904" left="433" width="346" height="14" font="3"> However, the fetal radiation dose for most common cardiovascular interventions </text>
<text top="919" left="171" width="374" height="14" font="3">is not likely to exceed the 50-mGy negligible-risk threshold dose for excess malignancy.</text>
<text top="920" left="545" width="10" height="8" font="18">529</text>
<text top="919" left="555" width="233" height="14" font="3"> One study that used phantoms to simulate pregnancy </text>
<text top="935" left="171" width="521" height="14" font="3">estimated a low lifetime risk of malignancies from radiation exposure to the conceptus during a typical ablation procedure.</text>
<text top="936" left="692" width="10" height="8" font="18">527</text>
<text top="935" left="702" width="82" height="14" font="3"> Furthermore, with </text>
<text top="950" left="171" width="619" height="14" font="3">current technologies such as electroanatomic mapping systems, catheter ablation procedures using minimal or even zero fluoroscopy have been </text>
<text top="966" left="171" width="130" height="14" font="3">described in pregnant women.</text>
<text top="966" left="301" width="10" height="8" font="18">526</text>
<text top="966" left="311" width="480" height="14" font="3"> Thus, if a catheter ablation procedure is required in a pregnant woman, radiation-reduction technologies should </text>
<text top="981" left="171" width="445" height="14" font="3">be used, and the procedure should be avoided in the first trimester when the teratogenic risk is greatest.</text>
<text top="982" left="616" width="10" height="8" font="18">528</text>
<text top="981" left="626" width="172" height="14" font="3"> Of note, shielding the fetus by covering </text>
<text top="997" left="171" width="563" height="14" font="3">the mother with a lead apron does not eliminate radiation to the fetus because most of the radiation to the fetus comes from scatter.</text>
<text top="1027" left="86" width="12" height="14" font="1"><b>IIb</b></text>
<text top="1027" left="127" width="23" height="14" font="1"><b>C-LD</b></text>
<text top="1019" left="171" width="601" height="14" font="1"><b>2.   Oral amiodarone may be considered for ongoing management in pregnant patients when treatment of highly symptomatic, </b></text>
<text top="1034" left="186" width="379" height="14" font="1"><b>recurrent SVT is required and other therapies are ineffective or contraindicated.</b></text>
<text top="1035" left="565" width="22" height="8" font="20"><b>517,523</b></text>
<text top="1071" left="80" width="20" height="14" font="3"><a href="">See </a></text>
<text top="1071" left="99" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1086" left="80" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1086" left="147" width="3" height="14" font="3">.</text>
<text top="1056" left="171" width="605" height="14" font="3">Although oral amiodarone has been administered safely during pregnancy, multiple adverse effects to the fetus have also been reported.</text>
<text top="1057" left="776" width="10" height="8" font="18">523</text>
<text top="1056" left="786" width="3" height="14" font="3"> </text>
<text top="1071" left="171" width="459" height="14" font="3">An important concern is the possibility of fetal hypothyroidism, reported in approximately 17% of cases.</text>
<text top="1072" left="630" width="22" height="8" font="18">517,523</text>
<text top="1071" left="652" width="139" height="14" font="3"> Therefore, fetal monitoring for </text>
<text top="1086" left="171" width="624" height="14" font="3">development of goiter with ultrasound and for signs of clinical hypothyroidism is advised. In addition, amiodarone has the potential for direct </text>
<text top="1101" left="171" width="302" height="14" font="3">neurotoxicity, which may lead to neurodevelopmental abnormalities.</text>
<text top="1102" left="473" width="10" height="8" font="18">523</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e555</i></b></text>
<text top="611" left="69" width="202" height="18" font="10"><b>9.4. SVT in Older Populations</b></text>
<text top="638" left="69" width="303" height="16" font="0"><i><b>9.4.1. Acute Treatment and Ongoing Management: </b></i></text>
<text top="654" left="69" width="103" height="16" font="0"><i><b>Recommendation</b></i></text>
<text top="671" left="69" width="355" height="16" font="13">The natural history of SVT is steadily changing because most </text>
<text top="688" left="69" width="356" height="16" font="13">patients with SVT undergo ablation at a younger age, but in </text>
<text top="706" left="69" width="351" height="16" font="13">general, the relative proportion of AT is higher in older popu-</text>
<text top="723" left="69" width="358" height="16" font="13">lations, and AVNRT is more prevalent than AVRT among </text>
<text top="740" left="69" width="165" height="16" font="13">patients undergoing ablation.</text>
<text top="741" left="234" width="8" height="9" font="14">49</text>
<text top="740" left="242" width="177" height="16" font="13"> Atypical atrial flutter and mac-</text>
<text top="757" left="69" width="356" height="16" font="13">roreentrant AT are on the rise as consequences of increasing </text>
<text top="775" left="69" width="356" height="16" font="13">AF ablation in this patient population, yet there are limited </text>
<text top="792" left="69" width="355" height="16" font="13">outcome data from RCTs for this segment of the population. </text>
<text top="809" left="69" width="351" height="16" font="13">Therapeutic decisions should be balanced between the over-</text>
<text top="826" left="69" width="355" height="16" font="13">all risks and benefits of the invasive nature of ablation versus </text>
<text top="844" left="69" width="294" height="16" font="13">long-term commitment to pharmacological therapy.</text>
<text top="96" left="505" width="253" height="20" font="12"><b>10. Quality-of-Life Considerations</b></text>
<text top="117" left="456" width="354" height="16" font="13">Patients with SVT may experience recurring symptoms that </text>
<text top="134" left="456" width="351" height="16" font="13">negatively impact their quality of life. Episodes of tachy-</text>
<text top="151" left="456" width="356" height="16" font="13">cardia can cause lightheadedness and syncope, which can </text>
<text top="169" left="456" width="356" height="16" font="13">become an obstacle to the performance of usual activities </text>
<text top="186" left="456" width="170" height="16" font="13">of daily living (eg, driving).</text>
<text top="187" left="626" width="8" height="9" font="14">72</text>
<text top="186" left="634" width="178" height="16" font="13"> However, there are minimal </text>
<text top="203" left="456" width="357" height="16" font="13">data on the effect of treatment on the quality of life for </text>
<text top="220" left="456" width="356" height="16" font="13">patients with SVT. In 1 study that evaluated patients with </text>
<text top="238" left="456" width="356" height="16" font="13">SVT who underwent ablation or received medical therapy, </text>
<text top="255" left="456" width="360" height="16" font="13">questionnaires such as the 36-Item Short-Form Health </text>
<text top="272" left="456" width="356" height="16" font="13">Survey revealed improved quality-of-life scores in several </text>
<text top="289" left="456" width="357" height="16" font="13">categories, including physical role functioning (perceived </text>
<text top="307" left="456" width="351" height="16" font="13">disability from physical limitations), general health percep-</text>
<text top="324" left="456" width="354" height="16" font="13">tions (perceived physical and mental health), and emotional </text>
<text top="341" left="456" width="351" height="16" font="13">role functioning (perceived disability from emotional limi-</text>
<text top="359" left="456" width="48" height="16" font="13">tations).</text>
<text top="359" left="504" width="13" height="9" font="14">540</text>
<text top="358" left="517" width="295" height="16" font="13"> These improvements, measured at 1 to 5 years </text>
<text top="376" left="456" width="351" height="16" font="13">of follow-up, were greater in patients who underwent abla-</text>
<text top="393" left="456" width="351" height="16" font="13">tion than in those treated with medical therapy. Other lit-</text>
<text top="410" left="456" width="354" height="16" font="13">erature, using domains from the 36-Item Short-Form Health </text>
<text top="427" left="456" width="41" height="16" font="13">Survey</text>
<text top="428" left="497" width="30" height="9" font="14">541–543</text>
<text top="427" left="527" width="250" height="16" font="13"> and other quality- of-life questionnaires,</text>
<text top="428" left="777" width="30" height="9" font="14">544–546</text>
<text top="427" left="807" width="4" height="16" font="13"> </text>
<text top="445" left="456" width="356" height="16" font="13">suggests that quality of life is improved after ablation for </text>
<text top="462" left="456" width="351" height="16" font="13">PSVT. However, these data carry important limitations, par-</text>
<text top="479" left="456" width="351" height="16" font="13">ticularly a lack of an appropriate control group, small sam-</text>
<text top="496" left="456" width="356" height="16" font="13">ple sizes, and referral bias. Furthermore, patients affected </text>
<text top="514" left="456" width="351" height="16" font="13">by PSVT carry different experiences. Therefore, firm con-</text>
<text top="531" left="456" width="355" height="16" font="13">clusions cannot be drawn about the effect on quality of life </text>
<text top="548" left="456" width="351" height="16" font="13">provided by medical or ablation therapy, and no recommen-</text>
<text top="565" left="456" width="124" height="16" font="13">dations are provided.</text>
<text top="583" left="477" width="20" height="16" font="16"><i>See</i></text>
<text top="583" left="497" width="4" height="16" font="13"> </text>
<text top="583" left="503" width="166" height="16" font="15"><a href="">Online Data Supplement 22</a></text>
<text top="583" left="669" width="144" height="16" font="13"><a href="">  </a><i>for additional data on </i></text>
<text top="600" left="456" width="169" height="16" font="16"><i>quality-of-life considerations.</i></text>
<text top="634" left="551" width="161" height="20" font="12"><b>11. Cost-Effectiveness</b></text>
<text top="655" left="456" width="357" height="16" font="13">Given the rising costs of health care, there is a growing </text>
<text top="672" left="456" width="351" height="16" font="13">enthusiasm for incorporating economic appraisals of avail-</text>
<text top="689" left="456" width="357" height="16" font="13">able therapies and resources into guidelines. The “2014 </text>
<text top="706" left="456" width="362" height="16" font="13">ACC/AHA Statement on Cost/Value Methodology in </text>
<text top="724" left="456" width="347" height="16" font="13">Clinical Practice Guidelines and Performance Measures”</text>
<text top="724" left="803" width="4" height="9" font="14">6</text>
<text top="724" left="807" width="4" height="16" font="13"> </text>
<text top="741" left="456" width="358" height="16" font="13">called for development of Level of Value categories to </text>
<text top="758" left="456" width="356" height="16" font="13">accompany COR and LOE in future guidelines. Although </text>
<text top="775" left="456" width="356" height="16" font="13">basing recommendations on a cost-effectiveness approach </text>
<text top="793" left="456" width="356" height="16" font="13">to therapy is an important goal for the current and future </text>
<text top="810" left="456" width="355" height="16" font="13">healthcare economy, it also poses considerable challenges. </text>
<text top="827" left="456" width="358" height="16" font="13">For example, the cost of therapy, available technology, </text>
<text top="844" left="456" width="357" height="16" font="13">and practice patterns are highly dynamic, and there may </text>
<text top="883" left="78" width="523" height="16" font="19"><b>Recommendations for Acute Treatment and Ongoing Management of SVT in Older Populations</b></text>
<text top="906" left="81" width="20" height="14" font="1"><b>COR</b></text>
<text top="906" left="128" width="18" height="14" font="1"><b>LOE</b></text>
<text top="906" left="170" width="83" height="14" font="1"><b>Recommendation</b></text>
<text top="934" left="89" width="3" height="14" font="1"><b>I</b></text>
<text top="934" left="124" width="25" height="14" font="1"><b>B-NR</b></text>
<text top="927" left="170" width="630" height="14" font="1"><b>1.   Diagnostic and therapeutic approaches to SVT should be individualized in patients more than 75 years of age to incorporate age, </b></text>
<text top="942" left="184" width="469" height="14" font="1"><b>comorbid illness, physical and cognitive functions, patient preferences, and severity of symptoms.</b></text>
<text top="943" left="653" width="40" height="8" font="20"><b>66,67,530–538</b></text>
<text top="1022" left="78" width="20" height="14" font="3">See </text>
<text top="1022" left="98" width="54" height="14" font="21"><a href="">Online Data </a></text>
<text top="1037" left="78" width="68" height="14" font="21"><a href="">Supplement 20</a></text>
<text top="1037" left="146" width="3" height="14" font="3"><a href="">.</a></text>
<text top="962" left="170" width="465" height="14" font="3">Data have consistently demonstrated that ablation is highly successful (&gt;95%) in selected older patients.</text>
<text top="963" left="635" width="40" height="8" font="18">66,67,531–536</text>
<text top="962" left="675" width="88" height="14" font="3"> Outcomes from 48 </text>
<text top="977" left="170" width="612" height="14" font="3">medical centers in Germany were reported among 3234 consecutive patients undergoing AVNRT ablation from 2007 to 2010; of the total, </text>
<text top="992" left="170" width="186" height="14" font="3">259 patients (8%) were &gt;75 years of age.</text>
<text top="993" left="355" width="10" height="8" font="18">537</text>
<text top="992" left="365" width="402" height="14" font="3"> Acute success was achieved in 98.5% of the older patient group, similar to the 2 younger </text>
<text top="1007" left="170" width="608" height="14" font="3">patient groups (98.7% for the group &lt;50 years of age; 98.8% for the group 50 to 75 years of age). In this study, complication rates were </text>
<text top="1022" left="170" width="611" height="14" font="3">low; hemodynamically stable pericardial effusion was observed in 2 of 259 patients (0.8%), and no pacemakers were needed in the older </text>
<text top="1037" left="170" width="634" height="14" font="3">patient group. Similarly, additional studies from older patient cohorts have consistently shown that older patients have more comorbid medical </text>
<text top="1052" left="170" width="620" height="14" font="3">conditions, have a higher incidence of structural heart disease or ischemic heart disease, and have more severe symptoms associated with </text>
<text top="1067" left="170" width="20" height="14" font="3">SVT.</text>
<text top="1068" left="190" width="34" height="8" font="18">530,538,539</text>
<text top="1067" left="223" width="584" height="14" font="3"> A few studies have shown that complications may be slightly higher in older patients than in younger patients, although the overall </text>
<text top="1082" left="170" width="170" height="14" font="3">complications are low and acceptable.</text>
<text top="1083" left="340" width="34" height="8" font="18">530,538,539</text>
<text top="1082" left="373" width="430" height="14" font="3"> These ablation outcome data should be balanced with the risks and benefits of pharmacological </text>
<text top="1097" left="170" width="296" height="14" font="3">therapy when therapeutic options are reviewed with older patients.</text>
<text top="510" left="70" width="329" height="14" font="1"><b>Figure 22.</b> Acute treatment of SVT in ACHD patients. Colors </text>
<text top="524" left="70" width="351" height="14" font="3">correspond to Class of Recommendation in Table 1; drugs listed </text>
<text top="537" left="70" width="341" height="14" font="3">alphabetically. *For rhythms that break or recur spontaneously, </text>
<text top="551" left="70" width="343" height="14" font="3">synchronized cardioversion is not appropriate. ACHD indicates </text>
<text top="564" left="70" width="341" height="14" font="3">adult congenital heart disease; IV, intravenous; and SVT, supra-</text>
<text top="578" left="70" width="126" height="14" font="3">ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e556  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="318" left="71" width="351" height="16" font="13">be some cost associated with unintended harm or compli-</text>
<text top="336" left="71" width="355" height="16" font="13">cations that result from any intervention. Furthermore, the </text>
<text top="353" left="71" width="351" height="16" font="13">approach toward evaluating the burden of cost in the litera-</text>
<text top="370" left="71" width="356" height="16" font="13">ture is based on varied perspectives (eg, individual, third </text>
<text top="388" left="71" width="168" height="16" font="13">party, stakeholder, societal).</text>
<text top="405" left="92" width="332" height="16" font="13">The small body of literature evaluating cost-effectiveness </text>
<text top="422" left="71" width="351" height="16" font="13">strategies in PSVT has traditionally centered on an evalua-</text>
<text top="440" left="71" width="355" height="16" font="13">tion of medical therapy versus catheter ablation. A rigorous </text>
<text top="457" left="71" width="355" height="16" font="13">cost-effectiveness Markov model was conducted in 2000 to </text>
<text top="474" left="71" width="358" height="16" font="13">compare radiofrequency ablation to medical management </text>
<text top="492" left="71" width="338" height="16" font="13">with generic metoprolol from the societal perspective.</text>
<text top="492" left="409" width="13" height="9" font="14">105</text>
<text top="492" left="422" width="4" height="16" font="13"> </text>
<text top="509" left="70" width="355" height="16" font="13">The estimated population consisted of patients with AVNRT </text>
<text top="526" left="70" width="351" height="16" font="13">(approximately 65%) and AVRT. On the basis of this simula-</text>
<text top="544" left="70" width="357" height="16" font="13">tion, the authors concluded that, for symptomatic patients </text>
<text top="561" left="70" width="358" height="16" font="13">with monthly episodes of PSVT, radiofrequency ablation </text>
<text top="578" left="70" width="357" height="16" font="13">was the more effective and less expensive strategy when </text>
<text top="596" left="70" width="358" height="16" font="13">compared with medical therapy. An observational cohort </text>
<text top="613" left="70" width="356" height="16" font="13">study of patients with atrial flutter supported early ablation </text>
<text top="630" left="70" width="356" height="16" font="13">to significantly reduce hospital-based healthcare utilization </text>
<text top="648" left="70" width="108" height="16" font="13">and the risk of AF.</text>
<text top="648" left="179" width="13" height="9" font="14">547</text>
<text top="665" left="92" width="330" height="16" font="13">These studies, along with other older literature, favor cath-</text>
<text top="682" left="71" width="355" height="16" font="13">eter ablation over medical therapy as the more cost-effective </text>
<text top="700" left="71" width="357" height="16" font="13">approach to treating PSVT and atrial flutter. However, the </text>
<text top="717" left="71" width="356" height="16" font="13">results of these studies were based on cost data and practice </text>
<text top="734" left="71" width="351" height="16" font="13">patterns that do not apply to the current environment and prac-</text>
<text top="752" left="71" width="288" height="16" font="13">tice. Therefore, no recommendations are provided.</text>
<text top="769" left="92" width="20" height="16" font="16"><i>See</i></text>
<text top="769" left="112" width="4" height="16" font="13"> </text>
<text top="769" left="118" width="166" height="16" font="15"><a href="">Online Data Supplement 23</a></text>
<text top="769" left="283" width="144" height="16" font="13">  <i>for additional data on </i></text>
<text top="786" left="70" width="103" height="16" font="16"><i>cost-effectiveness.</i></text>
<text top="820" left="143" width="207" height="20" font="12"><b>12. Shared Decision Making</b></text>
<text top="841" left="71" width="351" height="16" font="13">It is important that the patient be included in clinical decision-</text>
<text top="858" left="71" width="356" height="16" font="13">making processes, with consideration of his/her preferences </text>
<text top="876" left="71" width="358" height="16" font="13">and goals for therapy, as well as his/her unique physical, </text>
<text top="893" left="71" width="351" height="16" font="13">psychological, and social situation. In selected cases, per-</text>
<text top="910" left="71" width="359" height="16" font="13">sonalized, self-directed interventions can be developed in </text>
<text top="928" left="71" width="357" height="16" font="13">partnership with the patient, such as vagal maneuvers and </text>
<text top="945" left="71" width="191" height="16" font="13">“pill-in-the-pocket” drug therapy.</text>
<text top="962" left="92" width="338" height="16" font="13">Shared decision making is especially important for </text>
<text top="980" left="71" width="354" height="16" font="13">patients with SVT. As seen in this guideline, SVT treatment </text>
<text top="997" left="71" width="351" height="16" font="13">can be nuanced and requires expert knowledge of EP pro-</text>
<text top="1014" left="71" width="355" height="16" font="13">cesses and treatment options. Treatment options are highly </text>
<text top="1032" left="71" width="357" height="16" font="13">specific to the exact type of arrhythmia and can depend </text>
<text top="1049" left="71" width="358" height="16" font="13">on certain characteristics of a particular arrhythmia (eg, </text>
<text top="1066" left="71" width="357" height="16" font="13">whether there is pre-excitation). The various choices for </text>
<text top="1084" left="71" width="355" height="16" font="13">therapy, including drugs, cardioversion, invasive treatment, </text>
<text top="1101" left="71" width="356" height="16" font="13">or a combination thereof, can be confusing to the patient, </text>
<text top="318" left="458" width="356" height="16" font="13">so a detailed explanation of the benefits and risks must be </text>
<text top="336" left="458" width="170" height="16" font="13">included in the conversation.</text>
<text top="353" left="479" width="330" height="16" font="13">Patients are encouraged to ask questions with time allot-</text>
<text top="370" left="458" width="354" height="16" font="13">ted for caregivers to respond. Providing a relaxed atmosphere, </text>
<text top="388" left="458" width="358" height="16" font="13">anticipating patient concerns, and encouraging patients to </text>
<text top="405" left="458" width="357" height="16" font="13">keep a notebook with questions could facilitate productive </text>
<text top="422" left="458" width="81" height="16" font="13">conversations.</text>
<text top="440" left="479" width="336" height="16" font="13">It is also important that clinicians use lay terminology </text>
<text top="457" left="458" width="357" height="16" font="13">to explain treatment options to their patients. This involves </text>
<text top="474" left="458" width="351" height="16" font="13">a clear explanation of the risks and benefits of each recom-</text>
<text top="492" left="458" width="357" height="16" font="13">mendation, including how other comorbidities may impact </text>
<text top="509" left="458" width="355" height="16" font="13">each treatment option. Discussions with other physicians and </text>
<text top="526" left="458" width="357" height="16" font="13">healthcare providers caring for the patient will provide the </text>
<text top="544" left="458" width="356" height="16" font="13">broadest picture available. A full discussion about decisions </text>
<text top="561" left="458" width="354" height="16" font="13">for subsequent care and any further instructions is important to </text>
<text top="578" left="458" width="355" height="16" font="13">reinforce these issues before the patient leaves the healthcare </text>
<text top="596" left="458" width="355" height="16" font="13">setting. It is the responsibility of the physician and healthcare </text>
<text top="613" left="458" width="351" height="16" font="13">team to provide the patient with the best possible understand-</text>
<text top="630" left="458" width="355" height="16" font="13">ing of all management options in terms of risks, benefits, and </text>
<text top="648" left="458" width="194" height="16" font="13">potential effects on quality of life.</text>
<text top="682" left="462" width="343" height="20" font="12"><b>13. Evidence Gaps and Future Research Needs</b></text>
<text top="703" left="458" width="361" height="16" font="13">SVTs, even with the exclusion of AF, are among the </text>
<text top="720" left="458" width="351" height="16" font="13">most common arrhythmias that require medical interven-</text>
<text top="737" left="458" width="351" height="16" font="13">tion. The decade before the publication of the “2003 ACC/</text>
<text top="755" left="458" width="356" height="16" font="13">AHA/ESC Guidelines for the Management of Patients With </text>
<text top="772" left="458" width="177" height="16" font="13">Supraventricular Arrhythmias”</text>
<text top="772" left="635" width="8" height="9" font="14">11</text>
<text top="772" left="643" width="171" height="16" font="13"> was characterized by major </text>
<text top="789" left="458" width="357" height="16" font="13">shifts in understanding of the mechanism for SVT, as well </text>
<text top="806" left="458" width="351" height="16" font="13">as a sea change in management (because of catheter abla-</text>
<text top="824" left="458" width="356" height="16" font="13">tion). Since the early 2000s, there have been many iterative </text>
<text top="841" left="458" width="360" height="16" font="13">but important advances in pharmacological and invasive </text>
<text top="858" left="458" width="351" height="16" font="13">management for SVT. Catheter ablation is even better estab-</text>
<text top="876" left="458" width="356" height="16" font="13">lished, with a high degree of success and low complication </text>
<text top="893" left="458" width="356" height="16" font="13">rate, especially for the most common types of SVT, such as </text>
<text top="910" left="458" width="351" height="16" font="13">AVNRT and AVRT. Drug options, on the other hand, are rela-</text>
<text top="928" left="458" width="351" height="16" font="13">tively unchanged since publication of the 2003 guideline, per-</text>
<text top="945" left="458" width="355" height="16" font="13">haps relating to ongoing concern about potential adverse side </text>
<text top="962" left="458" width="184" height="16" font="13">effects of antiarrhythmic agents.</text>
<text top="980" left="479" width="334" height="16" font="13">Areas of uncertainty remain, including interventions for </text>
<text top="997" left="458" width="355" height="16" font="13">which advanced technology is less important. For example, </text>
<text top="1014" left="458" width="356" height="16" font="13">vagal maneuvers are recommended in many circumstances </text>
<text top="1032" left="458" width="359" height="16" font="13">as first-line intervention in patients with SVT, but they </text>
<text top="1049" left="458" width="357" height="16" font="13">are often ineffective. Furthermore, there is great variation </text>
<text top="1066" left="458" width="358" height="16" font="13">in the way these maneuvers are administered. Therefore, </text>
<text top="1084" left="458" width="351" height="16" font="13">research on the best technique of vagal maneuvers, with dis-</text>
<text top="1101" left="458" width="357" height="16" font="13">semination of the findings, is necessary. Clinical trials on </text>
<text top="156" left="536" width="234" height="14" font="1"><b>Figure 23. </b>Ongoing management of SVT in </text>
<text top="169" left="536" width="250" height="14" font="3">ACHD patients. Colors correspond to Class of </text>
<text top="183" left="536" width="256" height="14" font="3">Recommendation in Table 1; drugs listed alpha-</text>
<text top="196" left="536" width="258" height="14" font="3">betically. ACHD indicates adult congenital heart </text>
<text top="210" left="536" width="272" height="14" font="3">disease; intra-op, intraoperative; pre-op, preopera-</text>
<text top="223" left="536" width="231" height="14" font="3">tive; and SVT, supraventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e557</i></b></text>
<text top="97" left="69" width="356" height="16" font="13">antiarrhythmic drugs for SVT have been limited, and data </text>
<text top="115" left="69" width="354" height="16" font="13">are often extrapolated from studies that primarily focused on </text>
<text top="132" left="69" width="354" height="16" font="13">management of patients with AF. The efficacy of a variety of </text>
<text top="150" left="69" width="351" height="16" font="13">drugs is likely to differ according to the tachycardia mech-</text>
<text top="167" left="69" width="356" height="16" font="13">anism, and therefore differentiating the best drug for each </text>
<text top="184" left="69" width="354" height="16" font="13">individual arrhythmia is necessary; for example, the efficacy </text>
<text top="202" left="69" width="356" height="16" font="13">of class III agents might be markedly different in patients </text>
<text top="219" left="69" width="354" height="16" font="13">with AF than in patients with atrial flutter. Limited data exist </text>
<text top="237" left="69" width="355" height="16" font="13">on the optimal management of less common types of SVTs, </text>
<text top="254" left="69" width="354" height="16" font="13">such as junctional tachycardia and multifocal AT. Therefore, </text>
<text top="271" left="69" width="351" height="16" font="13">in view of significant gaps that remain with regard to opti-</text>
<text top="289" left="69" width="354" height="16" font="13">mal management of patients with SVT, we must consider the </text>
<text top="306" left="69" width="357" height="16" font="13">role of electronic medical records, registries, and national </text>
<text top="324" left="69" width="355" height="16" font="13">datasets to better acquire observational data when trials are </text>
<text top="341" left="69" width="355" height="16" font="13">not available or feasible. Multicenter registry studies would </text>
<text top="358" left="69" width="351" height="16" font="13">allow for expansion of our knowledge on the best pharma-</text>
<text top="376" left="69" width="355" height="16" font="13">cological and nonpharmacological approaches to treat these </text>
<text top="393" left="69" width="358" height="16" font="13">arrhythmias. In collaboration with national societies, the </text>
<text top="411" left="69" width="357" height="16" font="13">National Institutes of Health, and the US Food and Drug </text>
<text top="428" left="69" width="354" height="16" font="13">Administration, registries could be developed across selected </text>
<text top="445" left="69" width="351" height="16" font="13">centers to gather important information on safety and long-</text>
<text top="463" left="69" width="354" height="16" font="13">term outcomes where data are lacking (just as such registries </text>
<text top="480" left="69" width="354" height="16" font="13">are being developed for AF ablation). Mandatory postmarket </text>
<text top="498" left="69" width="354" height="16" font="13">surveillance data collection on new drugs for SVT could also </text>
<text top="515" left="69" width="355" height="16" font="13">be considered by the US Food and Drug Administration as a </text>
<text top="532" left="69" width="164" height="16" font="13">condition for drug approval.</text>
<text top="550" left="90" width="333" height="16" font="13">The mechanism and primary etiology of IST remains to be </text>
<text top="567" left="69" width="355" height="16" font="13">defined—advances here would provide a first step on finding </text>
<text top="585" left="69" width="351" height="16" font="13">better therapies for this disorder. It should be noted that medi-</text>
<text top="602" left="69" width="357" height="16" font="13">cal advances have resulted in an increase in the number of </text>
<text top="619" left="69" width="355" height="16" font="13">patients with SVT in specific populations, such as in patients </text>
<text top="637" left="69" width="357" height="16" font="13">after ablation (especially AF), ACHD patients, and patients </text>
<text top="654" left="69" width="355" height="16" font="13">of advanced age. As the numbers of these often-complicated </text>
<text top="672" left="69" width="355" height="16" font="13">patients grow, opportunities arise to perform clinical research </text>
<text top="689" left="69" width="192" height="16" font="13">to guide future recommendations.</text>
<text top="706" left="90" width="333" height="16" font="13">New pharmacological therapies are needed, especially for </text>
<text top="724" left="69" width="357" height="16" font="13">SVT in patients for whom ablation is not an option or has </text>
<text top="741" left="69" width="356" height="16" font="13">been unsuccessful. Newer drugs that selectively target atrial </text>
<text top="759" left="69" width="357" height="16" font="13">channels currently under investigation for patients with AF </text>
<text top="776" left="69" width="355" height="16" font="13">should be investigated for management of AT. Both mapping </text>
<text top="793" left="69" width="358" height="16" font="13">and ablation techniques need to be further investigated to </text>
<text top="811" left="69" width="355" height="16" font="13">maximize the likelihood of successful ablation with minimal </text>
<text top="828" left="69" width="354" height="16" font="13">risk. In the outpatient setting, the added value of new personal </text>
<text top="846" left="69" width="355" height="16" font="13">monitoring and implantable devices needs to be assessed, and </text>
<text top="863" left="69" width="355" height="16" font="13">studies of the impact of shared decision making with patients </text>
<text top="880" left="69" width="355" height="16" font="13">on outcomes are needed for personal monitoring innovations. </text>
<text top="898" left="69" width="351" height="16" font="13">Finally, we encourage investigation of quality-of-life improve-</text>
<text top="915" left="69" width="356" height="16" font="13">ment strategies, in addition to cost-effectiveness studies, for </text>
<text top="933" left="69" width="142" height="16" font="13">the management of SVT.</text>
<text top="967" left="170" width="148" height="20" font="12"><b>Presidents and Staff</b></text>
<text top="992" left="69" width="217" height="18" font="10"><b>American College of Cardiology</b></text>
<text top="1014" left="69" width="294" height="16" font="13">Kim A. Williams, Sr, MD, FACC, FAHA, President</text>
<text top="1031" left="69" width="250" height="16" font="13">Shalom Jacobovitz, Chief Executive Officer</text>
<text top="1049" left="69" width="361" height="16" font="13">William J. Oetgen, MD, MBA, FACC, Executive Vice </text>
<text top="1066" left="81" width="243" height="16" font="13">President, Science, Education, and Quality</text>
<text top="1084" left="69" width="363" height="16" font="13">Amelia Scholtz, PhD, Publications Manager, Science, </text>
<text top="1101" left="81" width="132" height="16" font="13">Education, and Quality</text>
<text top="97" left="456" width="295" height="18" font="10"><b>American College of Cardiology/American  </b></text>
<text top="114" left="456" width="119" height="18" font="10"><b>Heart Association</b></text>
<text top="133" left="456" width="351" height="16" font="13">Lisa Bradfield, CAE, Director, Guidelines and Clinical Policy</text>
<text top="151" left="456" width="358" height="16" font="13">Abdul R. Abdullah, MD, Associate Science and Medicine </text>
<text top="168" left="468" width="46" height="16" font="13">Advisor</text>
<text top="185" left="456" width="344" height="16" font="13">Alexa Papaila, Project Manager, Science and Clinical Policy</text>
<text top="221" left="456" width="190" height="18" font="10"><b>American Heart Association</b></text>
<text top="240" left="456" width="273" height="16" font="13">Mark A. Creager, MD, FACC, FAHA, President</text>
<text top="257" left="456" width="221" height="16" font="13">Nancy Brown, Chief Executive Officer</text>
<text top="275" left="456" width="334" height="16" font="13">Rose Marie Robertson, MD, FAHA, Chief Science Officer</text>
<text top="292" left="456" width="357" height="16" font="13">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice </text>
<text top="310" left="468" width="225" height="16" font="13">President, Office of Science Operations</text>
<text top="327" left="456" width="357" height="16" font="13">Marco Di Buono, PhD, Vice President, Science, Research, </text>
<text top="344" left="468" width="156" height="16" font="13">and Professional Education</text>
<text top="362" left="456" width="357" height="16" font="13">Jody Hundley, Production Manager, Scientific Publications, </text>
<text top="379" left="468" width="165" height="16" font="13">Office of Science Operations</text>
<text top="413" left="564" width="135" height="20" font="12"><b>Acknowledgments</b></text>
<text top="434" left="456" width="351" height="14" font="3">We thank Dr. Daniel B. Mark for his invaluable assistance in review-</text>
<text top="449" left="456" width="357" height="14" font="3">ing studies relating to quality of life and cost-effectiveness. His </text>
<text top="463" left="456" width="354" height="14" font="3">research and insight informed much of the discussion on these topics. </text>
<text top="477" left="456" width="355" height="14" font="3">We also thank Dr. Sarah A. Spinler for her contributions with regard </text>
<text top="492" left="456" width="158" height="14" font="3">to antiarrhythmic drug therapy.</text>
<text top="525" left="591" width="80" height="20" font="12"><b>References</b></text>
<text top="547" left="456" width="356" height="13" font="22"> 1.  Committee on Standards for Developing Trustworthy Clinical Practice </text>
<text top="560" left="476" width="335" height="13" font="22">Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We </text>
<text top="574" left="476" width="278" height="13" font="22">Can Trust. Washington, DC: National Academies Press, 2011.</text>
<text top="587" left="456" width="359" height="13" font="22"> 2. Committee on Standards for Systematic Reviews of Comparative </text>
<text top="601" left="476" width="334" height="13" font="22">Effectiveness Research, Institute of Medicine (US). Finding What Works </text>
<text top="614" left="476" width="337" height="13" font="22">in Health Care: Standards for Systematic Reviews. Washington, DC: </text>
<text top="628" left="476" width="148" height="13" font="22">National Academies Press, 2011.</text>
<text top="642" left="456" width="356" height="13" font="22"> 3.  ACCF/AHA Task Force on Practice Guidelines. Methodology Manual </text>
<text top="655" left="476" width="336" height="13" font="22">and Policies From the ACCF/AHA Task Force on Practice Guidelines. </text>
<text top="669" left="476" width="334" height="13" font="22">American College of Cardiology and American Heart Association. 2010. </text>
<text top="682" left="476" width="331" height="13" font="22">Av<a href="">ailable at: http://assets.cardiosource.com/Methodology_Manual_</a></text>
<text top="696" left="476" width="331" height="13" font="22"><a href="">for_ACC_AHA_Writing_Committees.pdf and http://my.americanheart.</a></text>
<text top="710" left="476" width="331" height="13" font="22"><a href="">org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/</a></text>
<text top="723" left="476" width="207" height="13" font="22"><a href="">ucm_319826.pdf. </a>Accessed January 23, 2015.</text>
<text top="737" left="456" width="354" height="13" font="22">  4.  Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice </text>
<text top="750" left="476" width="335" height="13" font="22">guideline methodology summit report: a report of the American College </text>
<text top="764" left="476" width="336" height="13" font="22">of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="778" left="476" width="237" height="13" font="22">Practice Guidelines. Circulation. 2013;127:268–310.</text>
<text top="791" left="456" width="351" height="13" font="22">  5.  Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/</text>
<text top="805" left="476" width="337" height="13" font="22">AHA clinical practice guidelines: a 30-year journey: a report of the </text>
<text top="818" left="476" width="334" height="13" font="22">American College of Cardiology/American Heart Association Task Force </text>
<text top="832" left="476" width="252" height="13" font="22">on Practice Guidelines. Circulation. 2014;130:1208–17.</text>
<text top="846" left="456" width="354" height="13" font="22">  6.  Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on </text>
<text top="859" left="476" width="335" height="13" font="22">cost/value methodology in clinical practice guidelines and performance </text>
<text top="873" left="476" width="337" height="13" font="22">measures: a report of the American College of Cardiology/American </text>
<text top="886" left="476" width="335" height="13" font="22">Heart Association Task Force on Performance Measures and Task Force </text>
<text top="900" left="476" width="252" height="13" font="22">on Practice Guidelines. Circulation. 2014;129:2329–45.</text>
<text top="913" left="456" width="351" height="13" font="22"> 7.  Halperin JL, Levine GN, Al-Khatib SM. Further evolution of the ACC/</text>
<text top="927" left="476" width="336" height="13" font="22">AHA clinical practice guideline recommendation classification system: </text>
<text top="941" left="476" width="336" height="13" font="22">a report of the American College of Cardiology Foundation/American </text>
<text top="954" left="476" width="334" height="13" font="22">Heart Association Task Force on Clinical Practice Guidelines. Circulation. </text>
<text top="968" left="476" width="88" height="13" font="22">2016;133:1426–28.</text>
<text top="981" left="456" width="359" height="13" font="22"> 8. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS </text>
<text top="995" left="476" width="337" height="13" font="22">strategies to enhance application of clinical practice guidelines in </text>
<text top="1009" left="476" width="336" height="13" font="22">patients with cardiovascular disease and comorbid conditions: from </text>
<text top="1022" left="476" width="337" height="13" font="22">the American Heart Association, American College of Cardiology, </text>
<text top="1036" left="476" width="338" height="13" font="22">and US Department of Health and Human Services. Circulation. </text>
<text top="1049" left="476" width="86" height="13" font="22">2014;130:1662–7.</text>
<text top="1063" left="456" width="351" height="13" font="22">  9.  Al-Khatib SM, Arshad A, Balk EM et al. Risk stratification for arrhyth-</text>
<text top="1077" left="476" width="336" height="13" font="22">mic events in patients with asymptomatic pre-excitation: a systematic </text>
<text top="1090" left="476" width="335" height="13" font="22">review for the 2015 ACC/AHA/HRS guideline for the management of </text>
<text top="1104" left="476" width="334" height="13" font="22">adult patients with supraventricular tachycardia: a report of the American </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e558  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="90" width="338" height="13" font="22">College of Cardiology/American Heart Association Task Force on </text>
<text top="111" left="90" width="334" height="13" font="22">Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. </text>
<text top="125" left="90" width="88" height="13" font="22">2016;133:e575–86.</text>
<text top="138" left="70" width="351" height="13" font="22"> 10. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide-</text>
<text top="152" left="90" width="336" height="13" font="22">line for the management of patients with atrial fibrillation: a report of </text>
<text top="165" left="90" width="336" height="13" font="22">the American College of Cardiology/American Heart Association Task </text>
<text top="179" left="90" width="335" height="13" font="22">Force on Practice Guidelines and the Heart Rhythm Society. Circulation </text>
<text top="192" left="90" width="93" height="13" font="22">2014;130:e199–267.</text>
<text top="206" left="70" width="351" height="13" font="22"> 11.  Blömstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/</text>
<text top="219" left="90" width="337" height="13" font="22">ESC guidelines for the management of patients with supraventricular </text>
<text top="233" left="90" width="338" height="13" font="22">arrhythmias—executive summary: a report of the American College </text>
<text top="247" left="90" width="339" height="13" font="22">of Cardiology/American Heart Association Task Force on Practice </text>
<text top="260" left="90" width="338" height="13" font="22">Guidelines and the European Society of Cardiology Committee for </text>
<text top="274" left="90" width="336" height="13" font="22">Practice Guidelines (Writing Committee to Develop Guidelines for the </text>
<text top="287" left="90" width="335" height="13" font="22">Management of Patients With Supraventricular Arrhythmias). Developed </text>
<text top="301" left="90" width="339" height="13" font="22">in collaboration with NASPE-Heart Rhythm Society. Circulation. </text>
<text top="314" left="90" width="101" height="13" font="22">2003;108:1871–1909.</text>
<text top="328" left="70" width="351" height="13" font="22"> 12.  Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/</text>
<text top="341" left="90" width="335" height="13" font="22">PCNA/SCAI/STS focused update of the guideline for the diagnosis and </text>
<text top="355" left="90" width="335" height="13" font="22">management of patients with stable ischemic heart disease: a report of </text>
<text top="368" left="90" width="336" height="13" font="22">the American College of Cardiology/American Heart Association Task </text>
<text top="382" left="90" width="334" height="13" font="22">Force on Practice Guidelines, and the American Association for Thoracic </text>
<text top="395" left="90" width="339" height="13" font="22">Surgery, Preventive Cardiovascular Nurses Association, Society for </text>
<text top="409" left="90" width="335" height="13" font="22">Cardiovascular Angiography and Interventions, and Society of Thoracic </text>
<text top="423" left="90" width="191" height="13" font="22">Surgeons. Circulation. 2014;130:1749–67.</text>
<text top="436" left="70" width="351" height="13" font="22"> 13.  Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/</text>
<text top="450" left="90" width="337" height="13" font="22">PCNA/SCAI/STS guideline for the diagnosis and management of </text>
<text top="463" left="90" width="335" height="13" font="22">patients with stable ischemic heart disease: a report of the American </text>
<text top="477" left="90" width="335" height="13" font="22">College of Cardiology Foundation/American Heart Association Task </text>
<text top="490" left="90" width="334" height="13" font="22">Force on Practice Guidelines, and the American College of Physicians, </text>
<text top="504" left="90" width="333" height="13" font="22">American Association for Thoracic Surgery, Preventive Cardiovascular </text>
<text top="517" left="90" width="338" height="13" font="22">Nurses Association, Society for Cardiovascular Angiography and </text>
<text top="531" left="90" width="341" height="13" font="22">Interventions, and Society of Thoracic Surgeons. Circulation. </text>
<text top="544" left="90" width="97" height="13" font="22">2012;126:e354–471.</text>
<text top="558" left="70" width="355" height="13" font="22"> 14.  Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline </text>
<text top="571" left="90" width="334" height="13" font="22">for the management of patients with valvular heart disease: a report of the </text>
<text top="585" left="90" width="334" height="13" font="22">American College of Cardiology/American Heart Association Task Force </text>
<text top="598" left="90" width="257" height="13" font="22">on Practice Guidelines. Circulation. 2014;129:e521–643.</text>
<text top="612" left="70" width="353" height="13" font="22"> 15.  Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline </text>
<text top="626" left="90" width="334" height="13" font="22">on the assessment of cardiovascular risk: a report of the American College </text>
<text top="639" left="90" width="339" height="13" font="22">of Cardiology/American Heart Association Task Force on Practice </text>
<text top="653" left="90" width="234" height="13" font="22">Guidelines. Circulation. 2014;129[suppl 2]:S49–73.</text>
<text top="666" left="70" width="356" height="13" font="22"> 16. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline </text>
<text top="680" left="90" width="336" height="13" font="22">for the management of heart failure: a report of the American College </text>
<text top="693" left="90" width="336" height="13" font="22">of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="707" left="90" width="242" height="13" font="22">Practice Guidelines. Circulation. 2013;128:e240–327.</text>
<text top="720" left="70" width="354" height="13" font="22"> 17.  Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic </text>
<text top="734" left="90" width="335" height="13" font="22">therapy for valvular disease: Antithrombotic Therapy and Prevention of </text>
<text top="747" left="90" width="331" height="13" font="22">Thrombosis, 9th ed: American College of Chest Physicians Evidence-</text>
<text top="761" left="90" width="299" height="13" font="22">Based Clinical Practice Guidelines. Chest. 2012;141:e576S–600S.</text>
<text top="774" left="70" width="355" height="13" font="22"> 18.  Camm AJ, Lip GYH, De Caterina R, et al. 2012 Focused update of the </text>
<text top="788" left="90" width="334" height="13" font="22">ESC guidelines for the management of atrial fibrillation: an update of the </text>
<text top="801" left="90" width="334" height="13" font="22">2010 ESC Guidelines for the management of atrial fibrillation. Developed </text>
<text top="815" left="90" width="334" height="13" font="22">with the special contribution of the European Heart Rhythm Association. </text>
<text top="829" left="90" width="139" height="13" font="22">Eur Heart J. 2012;33:2719–47.</text>
<text top="842" left="70" width="351" height="13" font="22"> 19.  European Heart Rhythm Association, European Association for Cardio-</text>
<text top="856" left="90" width="333" height="13" font="22">Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial </text>
<text top="869" left="90" width="333" height="13" font="22">fibrillation: the Task Force for the Management of Atrial Fibrillation of the </text>
<text top="883" left="90" width="327" height="13" font="22">European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.</text>
<text top="896" left="70" width="355" height="13" font="22"> 20.  Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS </text>
<text top="910" left="90" width="335" height="13" font="22">focused update incorporated into the ACCF/AHA/HRS 2008 guidelines </text>
<text top="923" left="90" width="334" height="13" font="22">for device-based therapy of cardiac rhythm abnormalities: a report of the </text>
<text top="937" left="90" width="334" height="13" font="22">American College of Cardiology Foundation/American Heart Association </text>
<text top="950" left="90" width="338" height="13" font="22">Task Force on Practice Guidelines and the Heart Rhythm Society. </text>
<text top="964" left="90" width="149" height="13" font="22">Circulation. 2013;127:e283–352.</text>
<text top="977" left="70" width="356" height="13" font="22"> 21. Verma A, Cairns JA, Mitchell LB, et al. 2014 Focused update of the </text>
<text top="991" left="90" width="334" height="13" font="22">Canadian Cardiovascular Society guidelines for the management of atrial </text>
<text top="1004" left="90" width="203" height="13" font="22">fibrillation. Can J Cardiol. 2014;30:1114–30.</text>
<text top="1018" left="70" width="357" height="13" font="22"> 22. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular </text>
<text top="1032" left="90" width="331" height="13" font="22">Society atrial fibrillation guidelines 2010: prevention of stroke and sys-</text>
<text top="1045" left="90" width="336" height="13" font="22">temic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. </text>
<text top="1059" left="90" width="71" height="13" font="22">2011;27:74–90.</text>
<text top="1072" left="70" width="353" height="13" font="22"> 23.  Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the </text>
<text top="1086" left="90" width="335" height="13" font="22">diagnosis and treatment of hypertrophic cardiomyopathy: a report of the </text>
<text top="1099" left="90" width="334" height="13" font="22">American College of Cardiology Foundation/American Heart Association </text>
<text top="1113" left="90" width="337" height="13" font="22">Task Force on Practice Guidelines. Developed in collaboration with </text>
<text top="98" left="477" width="337" height="13" font="22">the American Association for Thoracic Surgery, American Society of </text>
<text top="111" left="477" width="333" height="13" font="22">Echocardiography, American Society of Nuclear Cardiology, Heart Failure </text>
<text top="125" left="477" width="336" height="13" font="22">Society of America, Heart Rhythm Society, Society for Cardiovascular </text>
<text top="139" left="477" width="338" height="13" font="22">Angiography and Interventions, and Society of Thoracic Surgeons. </text>
<text top="153" left="477" width="149" height="13" font="22">Circulation. 2011;124:e783–831.</text>
<text top="166" left="457" width="356" height="13" font="22"> 24. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary </text>
<text top="180" left="477" width="337" height="13" font="22">prevention and risk reduction therapy for patients with coronary and </text>
<text top="194" left="477" width="337" height="13" font="22">other atherosclerotic vascular disease: 2011 update: a guideline from </text>
<text top="207" left="477" width="336" height="13" font="22">the American Heart Association and American College of Cardiology </text>
<text top="221" left="477" width="201" height="13" font="22">Foundation. Circulation. 2011;124:2458–73.</text>
<text top="235" left="457" width="354" height="13" font="22"> 25.  Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines </text>
<text top="249" left="477" width="335" height="13" font="22">for the management of adults with congenital heart disease: a report of </text>
<text top="262" left="477" width="336" height="13" font="22">the American College of Cardiology/American Heart Association Task </text>
<text top="276" left="477" width="334" height="13" font="22">Force on Practice Guidelines (Writing Committee to Develop Guidelines </text>
<text top="290" left="477" width="334" height="13" font="22">on the Management of Adults With Congenital Heart Disease). Developed </text>
<text top="303" left="477" width="335" height="13" font="22">in Collaboration With the American Society of Echocardiography, Heart </text>
<text top="317" left="477" width="333" height="13" font="22">Rhythm Society, International Society for Adult Congenital Heart Disease, </text>
<text top="331" left="477" width="334" height="13" font="22">Society for Cardiovascular Angiography and Interventions, and Society of </text>
<text top="345" left="477" width="239" height="13" font="22">Thoracic Surgeons. Circulation. 2008;118:e714–833.</text>
<text top="358" left="457" width="356" height="13" font="22"> 26. Chobanian AV, Bakris GL, Black HR, et al. the National High Blood </text>
<text top="372" left="477" width="337" height="13" font="22">Pressure Education Program Coordinating Committee: seventh report </text>
<text top="386" left="477" width="335" height="13" font="22">of the joint national committee on prevention, detection, evaluation, and </text>
<text top="399" left="477" width="300" height="13" font="22">treatment of high blood pressure. Hypertension. 2003;42:1206–52.</text>
<text top="413" left="457" width="355" height="13" font="22"> 27.  PACES/HRS expert consensus statement on the use of catheter ablation </text>
<text top="427" left="477" width="334" height="13" font="22">in children and patients with congenital heart disease. J Am Coll Cardiol. </text>
<text top="441" left="477" width="79" height="13" font="22">2015; IN PRESS.</text>
<text top="454" left="457" width="355" height="13" font="22"> 28.  Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society </text>
<text top="468" left="477" width="336" height="13" font="22">expert consensus statement on the diagnosis and treatment of postural </text>
<text top="482" left="477" width="337" height="13" font="22">tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal </text>
<text top="495" left="477" width="188" height="13" font="22">syncope. Heart Rhythm. 2015;12:e41–63.</text>
<text top="509" left="457" width="356" height="13" font="22"> 29.  Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus </text>
<text top="523" left="477" width="331" height="13" font="22">statement on the recognition and management of arrhythmias in adult con-</text>
<text top="537" left="477" width="334" height="13" font="22">genital heart disease. Developed in partnership between the Pediatric and </text>
<text top="550" left="477" width="336" height="13" font="22">Congenital Electrophysiology Society (PACES) and the Heart Rhythm </text>
<text top="564" left="477" width="223" height="13" font="22">Society (HRS). Heart Rhythm. 2014;11:e102–65.</text>
<text top="578" left="457" width="355" height="13" font="22"> 30.  Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert </text>
<text top="591" left="477" width="334" height="13" font="22">consensus statement on catheter and surgical ablation of atrial fibrillation: </text>
<text top="605" left="477" width="337" height="13" font="22">recommendations for patient selection, procedural techniques, patient </text>
<text top="619" left="477" width="337" height="13" font="22">management and follow-up, definitions, endpoints, and research trial </text>
<text top="633" left="477" width="250" height="13" font="22">design. J Interv Card Electrophysiol. 2012;33:171–257.</text>
<text top="646" left="457" width="354" height="13" font="22"> 31.  Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 </text>
<text top="660" left="477" width="334" height="13" font="22">American Heart Association guidelines for cardiopulmonary resuscitation </text>
<text top="674" left="477" width="308" height="13" font="22">and emergency cardiovascular care. Circulation. 2010;122:S640–56.</text>
<text top="687" left="457" width="351" height="13" font="22"> 32. Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal supraven-</text>
<text top="701" left="477" width="337" height="13" font="22">tricular tachycardia in the general population. J Am Coll Cardiol. </text>
<text top="715" left="477" width="73" height="13" font="22">1998;31:150–7.</text>
<text top="729" left="457" width="351" height="13" font="22"> 33.  Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-</text>
<text top="742" left="477" width="335" height="13" font="22">Parkinson-White syndrome or paroxysmal supraventricular tachycardias </text>
<text top="756" left="477" width="327" height="13" font="22">during a single electrophysiologic test. N Engl J Med. 1991;324:1612–8.</text>
<text top="770" left="457" width="354" height="13" font="22"> 34.  Kay GN, Epstein AE, Dailey SM, et al. Role of radiofrequency ablation in </text>
<text top="783" left="477" width="331" height="13" font="22">the management of supraventricular arrhythmias: experience in 760 con-</text>
<text top="797" left="477" width="282" height="13" font="22">secutive patients. J Cardiovasc Electrophysiol. 1993;4:371–89.</text>
<text top="811" left="457" width="354" height="13" font="22"> 35.  Lindsay BD, Chung MK, Gamache MC, et al. Therapeutic end points for </text>
<text top="825" left="477" width="331" height="13" font="22">the treatment of atrioventricular node reentrant tachycardia by catheter-</text>
<text top="838" left="477" width="306" height="13" font="22">guided radiofrequency current. J Am Coll Cardiol. 1993;22:733–40.</text>
<text top="852" left="457" width="351" height="13" font="22"> 36.  Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supra-</text>
<text top="866" left="477" width="331" height="13" font="22">ventricular tachycardia due to atrioventricular nodal reentry, by radio-</text>
<text top="879" left="477" width="335" height="13" font="22">frequency catheter ablation of slow-pathway conduction. N Engl J Med. </text>
<text top="893" left="477" width="77" height="13" font="22">1992;327:313–8.</text>
<text top="907" left="457" width="351" height="13" font="22"> 37.  Chen SA, Chiang CE, Yang CJ, et al. Accessory pathway and atrioven-</text>
<text top="920" left="477" width="336" height="13" font="22">tricular node reentrant tachycardia in elderly patients: clinical features, </text>
<text top="934" left="477" width="336" height="13" font="22">electrophysiologic characteristics and results of radiofrequency ablation.  </text>
<text top="948" left="477" width="159" height="13" font="22">J Am Coll Cardiol. 1994;23:702–8.</text>
<text top="962" left="457" width="351" height="13" font="22"> 38.  Rodriguez LM, de Chillou C, Schläpfer J, et al. Age at onset and gen-</text>
<text top="975" left="477" width="334" height="13" font="22">der of patients with different types of supraventricular tachycardias. Am J </text>
<text top="989" left="477" width="116" height="13" font="22">Cardiol. 1992;70:1213–5.</text>
<text top="1003" left="457" width="351" height="13" font="22"> 39.  Wu D, Yeh SJ, Wang CC, et al. A simple technique for selective radio-</text>
<text top="1016" left="477" width="334" height="13" font="22">frequency ablation of the slow pathway in atrioventricular node reentrant </text>
<text top="1030" left="477" width="227" height="13" font="22">tachycardia. J Am Coll Cardiol. 1993;21:1612–21.</text>
<text top="1044" left="457" width="353" height="13" font="22"> 40.  Clair WK, Wilkinson WE, McCarthy EA, et al. Spontaneous occurrence of </text>
<text top="1058" left="477" width="331" height="13" font="22">symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricu-</text>
<text top="1071" left="477" width="305" height="13" font="22">lar tachycardia in untreated patients. Circulation. 1993;87:1114–22.</text>
<text top="1085" left="457" width="354" height="13" font="22"> 41.  Wu D, Denes P, Amat-y-Leon F, et al. Clinical, electrocardiographic and </text>
<text top="1099" left="477" width="331" height="13" font="22">electrophysiologic observations in patients with paroxysmal supraventric-</text>
<text top="1112" left="477" width="226" height="13" font="22">ular tachycardia. Am J Cardiol. 1978;41:1045–51.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e559</i></b></text>
<text top="98" left="69" width="351" height="13" font="22"> 42.  DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supra-</text>
<text top="111" left="89" width="336" height="13" font="22">ventricular tachycardia: dose ranging and comparison with verapamil. </text>
<text top="125" left="89" width="335" height="13" font="22">Assessment in placebo-controlled, multicenter trials. The Adenosine for </text>
<text top="138" left="89" width="253" height="13" font="22">PSVT Study Group. Ann Intern Med. 1990;113:104–10.</text>
<text top="152" left="69" width="351" height="13" font="22"> 43. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symp-</text>
<text top="166" left="89" width="337" height="13" font="22">toms with occurrence of paroxysmal supraventricular tachycardia or </text>
<text top="179" left="89" width="337" height="13" font="22">atrial fibrillation: a transtelephonic monitoring study. The Flecainide </text>
<text top="193" left="89" width="331" height="13" font="22">Supraventricular Tachycardia Study Group. Am Heart J. 1992;124:381–6.</text>
<text top="206" left="69" width="351" height="13" font="22"> 44.  Sintetos AL, Roark SF, Smith MS, et al. Incidence of symptomatic tachy-</text>
<text top="220" left="89" width="334" height="13" font="22">cardia in untreated patients with paroxysmal supraventricular tachycardia. </text>
<text top="234" left="89" width="163" height="13" font="22">Arch Intern Med. 1986;146:2205–9.</text>
<text top="247" left="69" width="354" height="13" font="22"> 45.  Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents </text>
<text top="261" left="89" width="338" height="13" font="22">recurrence of symptomatic paroxysmal supraventricular tachycardia. </text>
<text top="274" left="89" width="336" height="13" font="22">The Flecainide Supraventricular Tachycardia Study Group. Circulation. </text>
<text top="288" left="89" width="77" height="13" font="22">1991;83:119–25.</text>
<text top="302" left="69" width="356" height="13" font="22"> 46. Dorian P, Naccarelli GV, Coumel P, et al. A randomized comparison </text>
<text top="315" left="89" width="331" height="13" font="22">of flecainide versus verapamil in paroxysmal supraventricular tachy-</text>
<text top="329" left="89" width="336" height="13" font="22">cardia. The Flecainide Multicenter Investigators Group. Am J Cardiol. </text>
<text top="342" left="89" width="87" height="13" font="22">1996;77:89A–95A.</text>
<text top="356" left="69" width="351" height="13" font="22"> 47.  Lu C-W, Wu M-H, Chen H-C, et al. Epidemiological profile of Wolff-</text>
<text top="369" left="89" width="337" height="13" font="22">Parkinson-White syndrome in a general population younger than 50 </text>
<text top="383" left="89" width="335" height="13" font="22">years of age in an era of radiofrequency catheter ablation. Int J Cardiol. </text>
<text top="397" left="89" width="77" height="13" font="22">2014;174:530–4.</text>
<text top="410" left="69" width="355" height="13" font="22"> 48.  Whinnett ZI, Sohaib SMA, Davies DW. Diagnosis and management of </text>
<text top="424" left="89" width="236" height="13" font="22">supraventricular tachycardia. BMJ. 2012;345:e7769.</text>
<text top="437" left="69" width="353" height="13" font="22"> 49.  Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the </text>
<text top="451" left="89" width="331" height="13" font="22">mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1:393–6.</text>
<text top="465" left="69" width="351" height="13" font="22"> 50.  Campbell RW. Supraventricular tachycardia: occasional nuisance or fre-</text>
<text top="478" left="89" width="226" height="13" font="22">quent threat? Eur Heart J. 1996; 17 Suppl C:21–5.</text>
<text top="492" left="69" width="351" height="13" font="22"> 51.  Cairns CB, Niemann JT. Intravenous adenosine in the emergency depart-</text>
<text top="505" left="89" width="338" height="13" font="22">ment management of paroxysmal supraventricular tachycardia. Ann </text>
<text top="519" left="89" width="135" height="13" font="22">Emerg Med. 1991;20:717–21.</text>
<text top="533" left="69" width="351" height="13" font="22"> 52. Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachy-</text>
<text top="546" left="89" width="331" height="13" font="22">cardia onset in patients with atrioventricular nodal reentrant tachy-</text>
<text top="560" left="89" width="337" height="13" font="22">cardia and accessory pathway-mediated tachycardia. Am Heart J. </text>
<text top="573" left="89" width="80" height="13" font="22">1996;132:765–7.</text>
<text top="587" left="69" width="355" height="13" font="22"> 53.  Maryniak A, Bielawska A, Bieganowska K, et al. Does atrioventricular </text>
<text top="601" left="89" width="335" height="13" font="22">reentry tachycardia (AVRT) or atrioventricular nodal reentry tachycardia </text>
<text top="614" left="89" width="335" height="13" font="22">(AVNRT) in children affect their cognitive and emotional development? </text>
<text top="628" left="89" width="145" height="13" font="22">Pediatr Cardiol. 2013;34:893–7.</text>
<text top="641" left="69" width="351" height="13" font="22"> 54.  González-Torrecilla E, Almendral J, Arenal A, et al. Combined evalu-</text>
<text top="655" left="89" width="336" height="13" font="22">ation of bedside clinical variables and the electrocardiogram for the </text>
<text top="668" left="89" width="339" height="13" font="22">differential diagnosis of paroxysmal atrioventricular reciprocating </text>
<text top="682" left="89" width="337" height="13" font="22">tachycardias in patients without pre-excitation. J Am Coll Cardiol. </text>
<text top="696" left="89" width="79" height="13" font="22">2009;53:2353–8.</text>
<text top="709" left="69" width="351" height="13" font="22"> 55.  Liu S, Yuan S, Hertervig E, et al. Gender and atrioventricular conduc-</text>
<text top="723" left="89" width="331" height="13" font="22">tion properties of patients with symptomatic atrioventricular nodal reen-</text>
<text top="736" left="89" width="334" height="13" font="22">trant tachycardia and Wolff-Parkinson-White syndrome. J Electrocardiol. </text>
<text top="750" left="89" width="82" height="13" font="22">2001;34:295–301.</text>
<text top="764" left="69" width="351" height="13" font="22"> 56.  Anand RG, Rosenthal GL, Van Hare GF, et al. Is the mechanism of supra-</text>
<text top="777" left="89" width="331" height="13" font="22">ventricular tachycardia in pediatrics influenced by age, gender or ethnic-</text>
<text top="791" left="89" width="178" height="13" font="22">ity? Congenit Heart Dis. 2009;4:464–8.</text>
<text top="804" left="69" width="353" height="13" font="22"> 57.  Erdogan A, Schulte B, Carlsson J, et al. [Clinical characteristics of patients </text>
<text top="818" left="89" width="331" height="13" font="22">with AV-nodal reentrant tachycardia (AVNRT): modification by high fre-</text>
<text top="832" left="89" width="331" height="13" font="22">quency catheter ablation. Study of 748 patients after high frequency cath-</text>
<text top="845" left="89" width="236" height="13" font="22">eter ablation]. Med Klin (Munich). 2001;96:708–12.</text>
<text top="859" left="69" width="355" height="13" font="22"> 58.  Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and </text>
<text top="872" left="89" width="337" height="13" font="22">symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol. </text>
<text top="886" left="89" width="71" height="13" font="22">1995;76:675–8.</text>
<text top="900" left="69" width="356" height="13" font="22"> 59. Walfridsson U, Strömberg A, Janzon M, et al. Wolff-Parkinson-White </text>
<text top="913" left="89" width="336" height="13" font="22">syndrome and atrioventricular nodal re-entry tachycardia in a Swedish </text>
<text top="927" left="89" width="336" height="13" font="22">population: consequences on health-related quality of life. Pacing Clin </text>
<text top="940" left="89" width="159" height="13" font="22">Electrophysiol. 2009;32:1299–306.</text>
<text top="954" left="69" width="8" height="13" font="22"> </text>
<text top="954" left="69" width="351" height="13" font="22">60. Cain N, Irving C, Webber S, et al. Natural history of Wolff-</text>
<text top="967" left="89" width="337" height="13" font="22">Parkinson-White syndrome diagnosed in childhood. Am J Cardiol. </text>
<text top="981" left="89" width="79" height="13" font="22">2013;112:961–5.</text>
<text top="995" left="69" width="351" height="13" font="22"> 61.  Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized par-</text>
<text top="1008" left="89" width="334" height="13" font="22">oxysmal supraventricular tachycardia: potential for misdiagnosis as panic </text>
<text top="1022" left="89" width="205" height="13" font="22">disorder. Arch Intern Med. 1997;157:537–43.</text>
<text top="1035" left="69" width="351" height="13" font="22"> 62.  Laurent G, Leong-Poi H, Mangat I, et al. Influence of ventriculoatrial tim-</text>
<text top="1049" left="89" width="334" height="13" font="22">ing on hemodynamics and symptoms during supraventricular tachycardia. </text>
<text top="1063" left="89" width="208" height="13" font="22">J Cardiovasc Electrophysiol. 2009;20:176–81.</text>
<text top="1076" left="69" width="353" height="13" font="22"> 63.  Abe H, Nagatomo T, Kobayashi H, et al. Neurohumoral and hemodynamic </text>
<text top="1090" left="89" width="331" height="13" font="22">mechanisms of diuresis during atrioventricular nodal reentrant tachycar-</text>
<text top="1103" left="89" width="223" height="13" font="22">dia. Pacing Clin Electrophysiol. 1997;20:2783–8.</text>
<text top="97" left="456" width="356" height="13" font="22"> 64. Auricchio A, Klein H, Trappe HJ, et al. Lack of prognostic value of </text>
<text top="111" left="476" width="336" height="13" font="22">syncope in patients with Wolff-Parkinson-White syndrome. J Am Coll </text>
<text top="124" left="476" width="110" height="13" font="22">Cardiol. 1991;17:152–8.</text>
<text top="138" left="456" width="355" height="13" font="22"> 65.  Drago F, Turchetta A, Calzolari A, et al. Reciprocating supraventricular </text>
<text top="152" left="476" width="331" height="13" font="22">tachycardia in children: low rate at rest as a major factor related to propen-</text>
<text top="165" left="476" width="278" height="13" font="22">sity to syncope during exercise. Am Heart J. 1996;132:280–5.</text>
<text top="179" left="456" width="353" height="13" font="22"> 66.  Kalusche D, Ott P, Arentz T, et al. AV nodal re-entry tachycardia in elderly </text>
<text top="192" left="476" width="331" height="13" font="22">patients: clinical presentation and results of radiofrequency catheter abla-</text>
<text top="206" left="476" width="214" height="13" font="22">tion therapy. Coron Artery Dis. 1998;9:359–63.</text>
<text top="220" left="456" width="351" height="13" font="22"> 67. Haghjoo M, Arya A, Heidari A, et al. Electrophysiologic characteris-</text>
<text top="233" left="476" width="336" height="13" font="22">tics and results of radiofrequency catheter ablation in elderly patients </text>
<text top="247" left="476" width="340" height="13" font="22">with atrioventricular nodal reentrant tachycardia. J Electrocardiol. </text>
<text top="260" left="476" width="77" height="13" font="22">2007;40:208–13.</text>
<text top="274" left="456" width="351" height="13" font="22"> 68.  Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricu-</text>
<text top="288" left="476" width="334" height="13" font="22">lar tachycardia: an expression of tachycardia rate or vasomotor response? </text>
<text top="301" left="476" width="138" height="13" font="22">Circulation. 1992;85:1064–71.</text>
<text top="315" left="456" width="353" height="13" font="22"> 69.  Razavi M, Luria DM, Jahangir A, et al. Acute blood pressure changes after </text>
<text top="328" left="476" width="336" height="13" font="22">the onset of atrioventricular nodal reentrant tachycardia: a time-course </text>
<text top="342" left="476" width="255" height="13" font="22">analysis. J Cardiovasc Electrophysiol. 2005;16:1037–40.</text>
<text top="356" left="456" width="351" height="13" font="22"> 70. Sganzerla P, Fabbiocchi F, Grazi S, et al. Electrophysiologic and hae-</text>
<text top="369" left="476" width="338" height="13" font="22">modynamic correlates in supraventricular tachycardia. Eur Heart J. </text>
<text top="383" left="476" width="65" height="13" font="22">1989;10:32–9.</text>
<text top="396" left="456" width="351" height="13" font="22"> 71.  Hamdan MH, Zagrodzky JD, Page RL, et al. Effect of P-wave timing dur-</text>
<text top="410" left="476" width="336" height="13" font="22">ing supraventricular tachycardia on the hemodynamic and sympathetic </text>
<text top="423" left="476" width="214" height="13" font="22">neural response. Circulation. 2001;103:96–101.</text>
<text top="437" left="456" width="351" height="13" font="22"> 72.  Walfridsson U, Walfridsson H. The impact of supraventricular tachycar-</text>
<text top="451" left="476" width="336" height="13" font="22">dias on driving ability in patients referred for radiofrequency catheter </text>
<text top="464" left="476" width="239" height="13" font="22">ablation. Pacing Clin Electrophysiol. 2005;28:191–5.</text>
<text top="478" left="456" width="355" height="13" font="22"> 73.  Brugada P, Brugada J, Mont L, et al. A new approach to the differential </text>
<text top="491" left="476" width="334" height="13" font="22">diagnosis of a regular tachycardia with a wide QRS complex. Circulation. </text>
<text top="505" left="476" width="82" height="13" font="22">1991;83:1649–59.</text>
<text top="519" left="456" width="355" height="13" font="22"> 74.  Vereckei A, Duray G, Szénási G, et al. New algorithm using only lead </text>
<text top="532" left="476" width="335" height="13" font="22">aVR for differential diagnosis of wide QRS complex tachycardia. Heart </text>
<text top="546" left="476" width="107" height="13" font="22">Rhythm. 2008;5:89–98.</text>
<text top="559" left="456" width="351" height="13" font="22"> 75.  Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovas-</text>
<text top="573" left="476" width="331" height="13" font="22">cular life support: 2010 American Heart Association guidelines for cardio-</text>
<text top="587" left="476" width="335" height="13" font="22">pulmonary resuscitation and emergency cardiovascular care. Circulation. </text>
<text top="600" left="476" width="88" height="13" font="22">2010;122:S729–67.</text>
<text top="614" left="456" width="351" height="13" font="22"> 76.  Knight BP, Zivin A, Souza J, et al. Use of adenosine in patients hospital-</text>
<text top="627" left="476" width="294" height="13" font="22">ized in a university medical center. Am J Med. 1998;105:275–80.</text>
<text top="641" left="456" width="354" height="13" font="22"> 77.  Willems S, Shenasa M, Borggrefe M, et al. Atrioventricular nodal reentry </text>
<text top="654" left="476" width="334" height="13" font="22">tachycardia: electrophysiologic comparisons in patients with and without </text>
<text top="668" left="476" width="224" height="13" font="22">2:1 infra-His block. Clin Cardiol. 1993;16:883–8.</text>
<text top="682" left="456" width="351" height="13" font="22"> 78.  Pava LF, Perafán P, Badiel M, et al. R-wave peak time at DII: a new cri-</text>
<text top="695" left="476" width="334" height="13" font="22">terion for differentiating between wide complex QRS tachycardias. Heart </text>
<text top="709" left="476" width="107" height="13" font="22">Rhythm. 2010;7:922–6.</text>
<text top="722" left="456" width="351" height="13" font="22"> 79. Letsas KP, Weber R, Siklody CH, et al. Electrocardiographic differen-</text>
<text top="736" left="476" width="334" height="13" font="22">tiation of common type atrioventricular nodal reentrant tachycardia from </text>
<text top="750" left="476" width="331" height="13" font="22">atrioventricular reciprocating tachycardia via a concealed accessory path-</text>
<text top="763" left="476" width="157" height="13" font="22">way. Acta Cardiol. 2010;65:171–6.</text>
<text top="777" left="456" width="351" height="13" font="22"> 80.  Knight BP, Ebinger M, Oral H, et al. Diagnostic value of tachycardia fea-</text>
<text top="790" left="476" width="331" height="13" font="22">tures and pacing maneuvers during paroxysmal supraventricular tachycar-</text>
<text top="804" left="476" width="184" height="13" font="22">dia. J Am Coll Cardiol. 2000;36:574–82.</text>
<text top="818" left="456" width="354" height="13" font="22"> 81.  Murman DH, McDonald AJ, Pelletier AJ, et al. US emergency department </text>
<text top="831" left="476" width="336" height="13" font="22">visits for supraventricular tachycardia, 1993–2003. Acad Emerg Med. </text>
<text top="845" left="476" width="77" height="13" font="22">2007;14:578–81.</text>
<text top="858" left="456" width="355" height="13" font="22"> 82.  Lim SH, Anantharaman V, Teo WS, et al. Comparison of treatment of </text>
<text top="872" left="476" width="331" height="13" font="22">supraventricular tachycardia by Valsalva maneuver and carotid sinus mas-</text>
<text top="886" left="476" width="171" height="13" font="22">sage. Ann Emerg Med. 1998;31:30–5.</text>
<text top="899" left="456" width="351" height="13" font="22"> 83.  Luber S, Brady WJ, Joyce T, et al. Paroxysmal supraventricular tachycar-</text>
<text top="913" left="476" width="277" height="13" font="22">dia: outcome after ED care. Am J Emerg Med. 2001;19:40–2.</text>
<text top="926" left="456" width="351" height="13" font="22"> 84.  Waxman MB, Wald RW, Sharma AD, et al. Vagal techniques for ter-</text>
<text top="940" left="482" width="331" height="13" font="22">mination of paroxysmal supraventricular tachycardia. Am J Cardiol. </text>
<text top="953" left="482" width="77" height="13" font="22">1980;46:655–64.</text>
<text top="967" left="456" width="42" height="13" font="22"> 85. Tav</text>
<text top="967" left="498" width="309" height="13" font="22">şanoglu S, Ozenel E. Ice-water washcloth rather than facial immer-</text>
<text top="981" left="482" width="331" height="13" font="22">sion (diving reflex) for supraventricular tachycardia in adults. Am J </text>
<text top="994" left="482" width="105" height="13" font="22">Cardiol. 1985;56:1003.</text>
<text top="1008" left="456" width="351" height="13" font="22">  86.  Wayne MA. Conversion of paroxysmal atrial tachycardia by facial im-</text>
<text top="1021" left="482" width="198" height="13" font="22">mersion in ice water. JACEP. 1976;5:434–5.</text>
<text top="1035" left="456" width="351" height="13" font="22">  87.  Brady WJ, DeBehnke DJ, Wickman LL, et al. Treatment of out-of-hos-</text>
<text top="1049" left="482" width="329" height="13" font="22">pital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg </text>
<text top="1062" left="482" width="97" height="13" font="22">Med. 1996;3:574–85.</text>
<text top="1076" left="456" width="354" height="13" font="22">  88.  Gausche M, Persse DE, Sugarman T, et al. Adenosine for the prehospital </text>
<text top="1089" left="482" width="329" height="13" font="22">treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. </text>
<text top="1103" left="482" width="71" height="13" font="22">1994;24:183–9.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e560  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="71" width="351" height="13" font="22">  89.  Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and vera-</text>
<text top="111" left="96" width="328" height="13" font="22">pamil for the treatment of supraventricular tachycardia in the prehospital </text>
<text top="125" left="96" width="193" height="13" font="22">setting. Ann Emerg Med. 1995;25:649–55.</text>
<text top="138" left="71" width="354" height="13" font="22">  90.  McCabe JL, Adhar GC, Menegazzi JJ, et al. Intravenous adenosine in the </text>
<text top="152" left="96" width="330" height="13" font="22">prehospital treatment of paroxysmal supraventricular tachycardia. Ann </text>
<text top="166" left="96" width="135" height="13" font="22">Emerg Med. 1992;21:358–61.</text>
<text top="179" left="70" width="351" height="13" font="22">  91.  Rankin AC, Oldroyd KG, Chong E, et al. Value and limitations of ad-</text>
<text top="193" left="96" width="330" height="13" font="22">enosine in the diagnosis and treatment of narrow and broad complex </text>
<text top="206" left="96" width="196" height="13" font="22">tachycardias. Br Heart J. 1989;62:195–203.</text>
<text top="220" left="70" width="351" height="13" font="22">  92.  Lim SH, Anantharaman V, Teo WS, et al. Slow infusion of calcium chan-</text>
<text top="234" left="96" width="331" height="13" font="22">nel blockers compared with intravenous adenosine in the emergency </text>
<text top="247" left="96" width="325" height="13" font="22">treatment of supraventricular tachycardia. Resuscitation. 2009;80:523–8.</text>
<text top="261" left="70" width="354" height="13" font="22">  93.  Adenoscan IV (adenosine injection) for rapid bolus intravenous use. US </text>
<text top="274" left="96" width="325" height="13" font="22">Food and Drug Administration. 2015. Av<a href="">ailable at: http://www.access-</a></text>
<text top="288" left="96" width="335" height="13" font="22"><a href="">data.fda.gov/drugsatfda_docs/label/2011/019937s026lbl.pdf. Accessed </a></text>
<text top="302" left="96" width="64" height="13" font="22">July 29, 2015.</text>
<text top="315" left="70" width="351" height="13" font="22">  94.  Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital syn-</text>
<text top="329" left="96" width="325" height="13" font="22">chronous direct-current cardioversion for supraventricular tachyar-</text>
<text top="342" left="96" width="332" height="13" font="22">rhythmias causing unstable hemodynamic states. Am J Cardiol. </text>
<text top="356" left="96" width="80" height="13" font="22">2003;91:489–91.</text>
<text top="369" left="70" width="356" height="13" font="22"> 95. Stec S, Kryñski T, Kułakowski P. Efficacy of low energy rectilinear </text>
<text top="383" left="96" width="331" height="13" font="22">biphasic cardioversion for regular atrial tachyarrhythmias. Cardiol J. </text>
<text top="397" left="96" width="65" height="13" font="22">2011;18:33–8.</text>
<text top="410" left="70" width="355" height="13" font="22">  96.  Gupta A, Naik A, Vora A, et al. Comparison of efficacy of intravenous </text>
<text top="424" left="96" width="333" height="13" font="22">diltiazem and esmolol in terminating supraventricular tachycardia.  </text>
<text top="437" left="96" width="193" height="13" font="22">J Assoc Physicians India. 1999;47:969–72.</text>
<text top="451" left="70" width="355" height="13" font="22">  97.  Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel </text>
<text top="465" left="96" width="329" height="13" font="22">blockers in the emergency management of supraventricular tachycardia. </text>
<text top="478" left="96" width="143" height="13" font="22">Resuscitation. 2002;52:167–74.</text>
<text top="492" left="70" width="356" height="13" font="22"> 98.  Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for </text>
<text top="505" left="96" width="326" height="13" font="22">paroxysmal supraventricular tachycardia: a long-term, double-blind ran-</text>
<text top="519" left="96" width="219" height="13" font="22">domized trial. Ann Intern Med. 1982;96:409–12.</text>
<text top="533" left="70" width="354" height="13" font="22">  99.  Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal </text>
<text top="546" left="96" width="328" height="13" font="22">supraventricular tachycardia: a randomized, double-blind comparison of </text>
<text top="560" left="96" width="307" height="13" font="22">digoxin, propranolol and verapamil. Am J Cardiol. 1984;54:1138–9.</text>
<text top="573" left="70" width="9" height="13" font="22"> </text>
<text top="573" left="70" width="360" height="13" font="22">100. Hindricks G. The Multicentre European Radiofrequency Survey </text>
<text top="587" left="96" width="325" height="13" font="22">(MERFS): complications of radiofrequency catheter ablation of ar-</text>
<text top="601" left="96" width="328" height="13" font="22">rhythmias. The Multicentre European Radiofrequency Survey (MERFS) </text>
<text top="614" left="96" width="330" height="13" font="22">Investigators of the Working Group on Arrhythmias of the European </text>
<text top="628" left="96" width="243" height="13" font="22">Society of Cardiology. Eur Heart J. 1993;14:1644–53.</text>
<text top="641" left="70" width="351" height="13" font="22"> 101.  Hindricks G. Incidence of complete atrioventricular block following at-</text>
<text top="655" left="96" width="328" height="13" font="22">tempted radiofrequency catheter modification of the atrioventricular node </text>
<text top="668" left="96" width="330" height="13" font="22">in 880 patients. Results of the Multicenter European Radiofrequency </text>
<text top="682" left="96" width="329" height="13" font="22">Survey (MERFS) The Working Group on Arrhythmias of the European </text>
<text top="696" left="96" width="226" height="13" font="22">Society of Cardiology. Eur Heart J. 1996;17:82–8.</text>
<text top="709" left="70" width="351" height="13" font="22"> 102. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of abla-</text>
<text top="723" left="96" width="331" height="13" font="22">tion of atrial flutter and supraventricular tachycardia. Am J Cardiol. </text>
<text top="736" left="96" width="77" height="13" font="22">2009;104:671–7.</text>
<text top="750" left="70" width="351" height="13" font="22"> 103.  Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory path-</text>
<text top="764" left="96" width="325" height="13" font="22">ways, atrioventricular nodal reentrant tachycardia, and the atrioventricu-</text>
<text top="777" left="96" width="329" height="13" font="22">lar junction: final results of a prospective, multicenter clinical trial. The </text>
<text top="791" left="96" width="311" height="13" font="22">Atakr Multicenter Investigators Group. Circulation. 1999;99:262–70.</text>
<text top="804" left="70" width="351" height="13" font="22"> 104.  Scheinman MM, Huang S. The 1998 NASPE prospective catheter abla-</text>
<text top="818" left="96" width="263" height="13" font="22">tion registry. Pacing Clin Electrophysiol. 2000;23:1020–8.</text>
<text top="832" left="70" width="351" height="13" font="22"> 105.  Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radio-</text>
<text top="845" left="96" width="331" height="13" font="22">frequency ablation for supraventricular tachycardia. Ann Intern Med. </text>
<text top="859" left="96" width="82" height="13" font="22">2000;133:864–76.</text>
<text top="872" left="70" width="353" height="13" font="22"> 106.  Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of </text>
<text top="886" left="96" width="328" height="13" font="22">major complications from contemporary catheter ablation to treat cardiac </text>
<text top="900" left="96" width="200" height="13" font="22">arrhythmias. Heart Rhythm. 2011;8:1661–6.</text>
<text top="913" left="70" width="354" height="13" font="22"> 107.  Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety </text>
<text top="927" left="96" width="329" height="13" font="22">of dofetilide in the prevention of symptomatic episodes of paroxysmal </text>
<text top="940" left="96" width="330" height="13" font="22">supraventricular tachycardia: a 6-month double-blind comparison with </text>
<text top="954" left="96" width="247" height="13" font="22">propafenone and placebo. Am Heart J. 2001;142:93–8.</text>
<text top="967" left="70" width="7" height="13" font="22"> </text>
<text top="967" left="70" width="351" height="13" font="22">108. A randomized, placebo-controlled trial of propafenone in the pro-</text>
<text top="981" left="96" width="331" height="13" font="22">phylaxis of paroxysmal supraventricular tachycardia and paroxysmal </text>
<text top="995" left="96" width="331" height="13" font="22">atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. </text>
<text top="1008" left="96" width="77" height="13" font="22">1995;92:2550–7.</text>
<text top="1022" left="70" width="7" height="13" font="22"> </text>
<text top="1022" left="70" width="358" height="13" font="22">109. Chimienti M, Cullen MT, Casadei G. Safety of flecainide versus </text>
<text top="1035" left="96" width="326" height="13" font="22">propafenone for the long-term management of symptomatic paroxys-</text>
<text top="1049" left="96" width="329" height="13" font="22">mal supraventricular tachyarrhythmias. Report from the Flecainide and </text>
<text top="1063" left="96" width="325" height="13" font="22">Propafenone Italian Study (FAPIS) Group. Eur Heart J. 1995;16:1943–51.</text>
<text top="1076" left="70" width="351" height="13" font="22"> 110.  Anderson JL, Platt ML, Guarnieri T, et al. Flecainide acetate for paroxys-</text>
<text top="1090" left="96" width="329" height="13" font="22">mal supraventricular tachyarrhythmias. The Flecainide Supraventricular </text>
<text top="1103" left="96" width="263" height="13" font="22">Tachycardia Study Group. Am J Cardiol. 1994;74:578–84.</text>
<text top="97" left="458" width="353" height="13" font="22"> 111.  Pritchett EL, DaTorre SD, Platt ML, et al. Flecainide acetate treatment of </text>
<text top="111" left="483" width="325" height="13" font="22">paroxysmal supraventricular tachycardia and paroxysmal atrial fibrilla-</text>
<text top="124" left="483" width="328" height="13" font="22">tion: dose-response studies. The Flecainide Supraventricular Tachycardia </text>
<text top="138" left="483" width="233" height="13" font="22">Study Group. J Am Coll Cardiol. 1991;17:297–303.</text>
<text top="152" left="458" width="355" height="13" font="22"> 112.  Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of </text>
<text top="165" left="483" width="330" height="13" font="22">symptomatic paroxysmal supraventricular arrhythmias. A randomized, </text>
<text top="179" left="483" width="328" height="13" font="22">placebo-controlled, crossover trial in patients tolerating oral therapy. Ann </text>
<text top="192" left="483" width="138" height="13" font="22">Intern Med. 1991;114:539–44.</text>
<text top="206" left="458" width="7" height="13" font="22"> </text>
<text top="206" left="458" width="351" height="13" font="22">113. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbid-</text>
<text top="220" left="483" width="330" height="13" font="22">ity in patients receiving encainide, flecainide, or placebo. The Cardiac </text>
<text top="233" left="483" width="285" height="13" font="22">Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.</text>
<text top="247" left="458" width="355" height="13" font="22"> 114.  Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study </text>
<text top="260" left="483" width="326" height="13" font="22">of the efficacy and safety of sotalol in the prophylactic treatment of pa-</text>
<text top="274" left="483" width="329" height="13" font="22">tients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. </text>
<text top="288" left="483" width="77" height="13" font="22">1997;133:441–6.</text>
<text top="301" left="458" width="351" height="13" font="22"> 115.  Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysi-</text>
<text top="315" left="483" width="328" height="13" font="22">ologic effects and efficacy of single-dose intravenous and long-term oral </text>
<text top="328" left="483" width="331" height="13" font="22">amiodarone therapy in patients with AV nodal reentrant tachycardia. </text>
<text top="342" left="483" width="140" height="13" font="22">Indian Heart J. 1996;48:133–7.</text>
<text top="356" left="458" width="356" height="13" font="22"> 116. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin </text>
<text top="369" left="483" width="332" height="13" font="22">concentration and outcomes in patients with heart failure. JAMA. </text>
<text top="383" left="483" width="77" height="13" font="22">2003;289:871–8.</text>
<text top="396" left="458" width="351" height="13" font="22"> 117. Domanovits H, Laske H, Stark G, et al. Adenosine for the manage-</text>
<text top="410" left="483" width="332" height="13" font="22">ment of patients with tachycardias-a new protocol. Eur Heart J. </text>
<text top="423" left="483" width="79" height="13" font="22">1994;15:589–93.</text>
<text top="437" left="458" width="354" height="13" font="22"> 118.  Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality </text>
<text top="451" left="483" width="329" height="13" font="22">associated with digoxin in contemporary patients with atrial fibrillation: </text>
<text top="464" left="483" width="323" height="13" font="22">findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660–8.</text>
<text top="478" left="458" width="351" height="13" font="22"> 119.  Steinwender C, Hönig S, Kypta A, et al. Pre-injection of magnesium sul-</text>
<text top="491" left="483" width="328" height="13" font="22">fate enhances the efficacy of ibutilide for the conversion of typical but not </text>
<text top="505" left="483" width="293" height="13" font="22">of atypical persistent atrial flutter. Int J Cardiol. 2010;141:260–5.</text>
<text top="519" left="458" width="354" height="13" font="22"> 120.  Tercius AJ, Kluger J, Coleman CI, et al. Intravenous magnesium sulfate </text>
<text top="532" left="483" width="328" height="13" font="22">enhances the ability of intravenous ibutilide to successfully convert atrial </text>
<text top="546" left="483" width="298" height="13" font="22">fibrillation or flutter. Pacing Clin Electrophysiol. 2007;30:1331–5.</text>
<text top="559" left="458" width="351" height="13" font="22"> 121.  Pérez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after cath-</text>
<text top="573" left="483" width="325" height="13" font="22">eter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-</text>
<text top="587" left="483" width="258" height="13" font="22">analysis. Circ Arrhythm Electrophysiol. 2009;2:393–401.</text>
<text top="600" left="458" width="356" height="13" font="22"> 122. de Loma-Osorio F, Diaz-Infante E, et al. Spanish Catheter Ablation </text>
<text top="614" left="483" width="331" height="13" font="22">Registry. 12th Official Report of the Spanish Society of Cardiology </text>
<text top="627" left="483" width="329" height="13" font="22">Working Group on Electrophysiology and Arrhythmias (2012). Rev Esp </text>
<text top="641" left="483" width="163" height="13" font="22">Cardiol (Engl Ed). 2013;66:983–92.</text>
<text top="654" left="458" width="356" height="13" font="22"> 123. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in </text>
<text top="668" left="483" width="333" height="13" font="22">adult patients. Electrophysiological characteristics, pharmacological </text>
<text top="682" left="483" width="329" height="13" font="22">response, possible mechanisms, and effects of radiofrequency ablation. </text>
<text top="695" left="483" width="138" height="13" font="22">Circulation. 1994;90:1262–78.</text>
<text top="709" left="458" width="355" height="13" font="22"> 124.  Biviano AB, Bain W, Whang W, et al. Focal left atrial tachycardias not </text>
<text top="722" left="483" width="331" height="13" font="22">associated with prior catheter ablation for atrial fibrillation: clinical </text>
<text top="736" left="483" width="332" height="13" font="22">and electrophysiological characteristics. Pacing Clin Electrophysiol. </text>
<text top="750" left="483" width="71" height="13" font="22">2012;35:17–27.</text>
<text top="763" left="458" width="354" height="13" font="22"> 125.  Kalman JM, Olgin JE, Karch MR, et al. “Cristal tachycardias”: origin of </text>
<text top="777" left="483" width="325" height="13" font="22">right atrial tachycardias from the crista terminalis identified by intracar-</text>
<text top="790" left="483" width="266" height="13" font="22">diac echocardiography. J Am Coll Cardiol. 1998;31:451–9.</text>
<text top="804" left="457" width="351" height="13" font="22"> 126.  Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electro-</text>
<text top="818" left="483" width="329" height="13" font="22">cardiographic characteristics of focal atrial tachycardia originating from </text>
<text top="831" left="483" width="329" height="13" font="22">the pulmonary veins: acute and long-term outcomes of radiofrequency </text>
<text top="845" left="483" width="186" height="13" font="22">ablation. Circulation. 2003;108:1968–75.</text>
<text top="858" left="457" width="355" height="13" font="22"> 127.  Kistler PM, Fynn SP, Haqqani H, et al. Focal atrial tachycardia from </text>
<text top="872" left="483" width="325" height="13" font="22">the ostium of the coronary sinus: electrocardiographic and electrophysio-</text>
<text top="886" left="483" width="328" height="13" font="22">logical characterization and radiofrequency ablation. J Am Coll Cardiol. </text>
<text top="899" left="483" width="82" height="13" font="22">2005;45:1488–93.</text>
<text top="913" left="457" width="351" height="13" font="22"> 128.  Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left ec-</text>
<text top="926" left="483" width="325" height="13" font="22">topic atrial tachycardias using a three-dimensional nonfluoroscopic map-</text>
<text top="940" left="483" width="202" height="13" font="22">ping system. Am J Cardiol. 1998;82:989–92.</text>
<text top="953" left="457" width="356" height="13" font="22"> 129. Goldberger J, Kall J, Ehlert F, et al. Effectiveness of radiofrequency </text>
<text top="967" left="483" width="331" height="13" font="22">catheter ablation for treatment of atrial tachycardia. Am J Cardiol. </text>
<text top="981" left="483" width="77" height="13" font="22">1993;72:787–93.</text>
<text top="994" left="457" width="354" height="13" font="22"> 130.  Collins KK, Van Hare GF, Kertesz NJ, et al. Pediatric nonpost-operative </text>
<text top="1008" left="483" width="330" height="13" font="22">junctional ectopic tachycardia medical management and interventional </text>
<text top="1021" left="483" width="205" height="13" font="22">therapies. J Am Coll Cardiol. 2009;53:690–7.</text>
<text top="1035" left="457" width="354" height="13" font="22"> 131.  Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter ablation of </text>
<text top="1049" left="483" width="325" height="13" font="22">the tachycardia focus in patients with nonreentrant junctional tachycar-</text>
<text top="1062" left="483" width="162" height="13" font="22">dia. Am J Cardiol. 1996;78:1292–7.</text>
<text top="1076" left="457" width="351" height="13" font="22"> 132.  Law IH, Von Bergen NH, Gingerich JC, et al. Transcatheter cryother-</text>
<text top="1089" left="483" width="328" height="13" font="22">mal ablation of junctional ectopic tachycardia in the normal heart. Heart </text>
<text top="1103" left="483" width="107" height="13" font="22">Rhythm. 2006;3:903–7.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e561</i></b></text>
<text top="98" left="69" width="351" height="13" font="22"> 133.  Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flut-</text>
<text top="111" left="95" width="325" height="13" font="22">ter and intra-atrial re-entrant tachycardia in patients with surgically cor-</text>
<text top="125" left="95" width="308" height="13" font="22">rected congenital heart disease. J Am Coll Cardiol. 2001;38:377–84.</text>
<text top="138" left="69" width="355" height="13" font="22"> 134.  Jaïs P, Shah DC, Haïssaguerre M, et al. Mapping and ablation of left </text>
<text top="152" left="95" width="207" height="13" font="22">atrial flutters. Circulation. 2000;101:2928–34.</text>
<text top="166" left="69" width="353" height="13" font="22"> 135.  Coffey JO, d’Avila A, Dukkipati S, et al. Catheter ablation of scar-related </text>
<text top="179" left="95" width="215" height="13" font="22">atypical atrial flutter. Europace. 2013;15:414–9.</text>
<text top="193" left="69" width="356" height="13" font="22"> 136. Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency </text>
<text top="207" left="95" width="329" height="13" font="22">ablation for control of intraatrial reentrant tachycardia in patients with </text>
<text top="220" left="95" width="277" height="13" font="22">congenital heart disease. J Am Coll Cardiol. 1997;30:1032–8.</text>
<text top="234" left="69" width="354" height="13" font="22"> 137.  Nakagawa H, Shah N, Matsudaira K, et al. Characterization of reentrant </text>
<text top="247" left="95" width="329" height="13" font="22">circuit in macroreentrant right atrial tachycardia after surgical repair of </text>
<text top="261" left="95" width="329" height="13" font="22">congenital heart disease: isolated channels between scars allow “focal” </text>
<text top="275" left="95" width="186" height="13" font="22">ablation. Circulation. 2001;103:699–709.</text>
<text top="288" left="69" width="355" height="13" font="22"> 138.  Chan DP, Van Hare GF, Mackall JA, et al. Importance of atrial flutter </text>
<text top="302" left="95" width="330" height="13" font="22">isthmus in postoperative intra-atrial reentrant tachycardia. Circulation. </text>
<text top="315" left="95" width="82" height="13" font="22">2000;102:1283–9.</text>
<text top="329" left="69" width="356" height="13" font="22"> 139. Stevenson IH, Kistler PM, Spence SJ, et al. Scar-related right atrial </text>
<text top="343" left="95" width="332" height="13" font="22">macroreentrant tachycardia in patients without prior atrial surgery: </text>
<text top="356" left="95" width="329" height="13" font="22">electroanatomic characterization and ablation outcome. Heart Rhythm. </text>
<text top="370" left="95" width="77" height="13" font="22">2005;2:594–601.</text>
<text top="383" left="69" width="351" height="13" font="22"> 140.  Baker BM, Lindsay BD, Bromberg BI, et al. Catheter ablation of clini-</text>
<text top="397" left="95" width="325" height="13" font="22">cal intraatrial reentrant tachycardias resulting from previous atrial sur-</text>
<text top="411" left="95" width="329" height="13" font="22">gery: localizing and transecting the critical isthmus. J Am Coll Cardiol. </text>
<text top="424" left="95" width="71" height="13" font="22">1996;28:411–7.</text>
<text top="438" left="69" width="351" height="13" font="22"> 141.  Haines DE, Beheiry S, Akar JG, et al. Heart Rythm Society expert con-</text>
<text top="451" left="95" width="325" height="13" font="22">sensus statement on electrophysiology laboratory standards: process, pro-</text>
<text top="465" left="95" width="326" height="13" font="22">tocols, equipment, personnel, and safety. Heart Rhythm. 2014;11:e9–51.</text>
<text top="479" left="69" width="354" height="13" font="22"> 142.  Knight BP, Zivin A, Souza J, et al. A technique for the rapid diagnosis of </text>
<text top="492" left="95" width="328" height="13" font="22">atrial tachycardia in the electrophysiology laboratory. J Am Coll Cardiol. </text>
<text top="506" left="95" width="77" height="13" font="22">1999;33:775–81.</text>
<text top="519" left="69" width="355" height="13" font="22"> 143.  Horowitz LN, Kay HR, Kutalek SP, et al. Risks and complications of </text>
<text top="533" left="95" width="331" height="13" font="22">clinical cardiac electrophysiologic studies: a prospective analysis of </text>
<text top="547" left="95" width="283" height="13" font="22">1,000 consecutive patients. J Am Coll Cardiol. 1987;9:1261–8.</text>
<text top="560" left="69" width="355" height="13" font="22"> 144.  Asirvatham S, Narayan O. Advanced catheter mapping and navigation </text>
<text top="574" left="95" width="329" height="13" font="22">system. In: Huang SW, Wood M, editors. Catheter Ablation of Cardiac </text>
<text top="587" left="95" width="292" height="13" font="22">Arrhythmias. Philadelphia, PA: Saunders/Elsevier, 2006:135–61.</text>
<text top="601" left="69" width="351" height="13" font="22"> 145.  Sporton SC, Earley MJ, Nathan AW, et al. Electroanatomic versus fluoro-</text>
<text top="615" left="95" width="325" height="13" font="22">scopic mapping for catheter ablation procedures: a prospective random-</text>
<text top="628" left="95" width="253" height="13" font="22">ized study. J Cardiovasc Electrophysiol. 2004;15:310–5.</text>
<text top="642" left="69" width="351" height="13" font="22"> 146.  Kopelman HA, Prater SP, Tondato F, et al. Slow pathway catheter ab-</text>
<text top="655" left="95" width="326" height="13" font="22">lation of atrioventricular nodal re-entrant tachycardia guided by elec-</text>
<text top="669" left="95" width="330" height="13" font="22">troanatomical mapping: a randomized comparison to the conventional </text>
<text top="683" left="95" width="160" height="13" font="22">approach. Europace. 2003;5:171–4.</text>
<text top="696" left="69" width="354" height="13" font="22"> 147.  Hindricks G, Willems S, Kautzner J, et al. Effect of electroanatomically </text>
<text top="710" left="95" width="330" height="13" font="22">guided versus conventional catheter ablation of typical atrial flutter on </text>
<text top="723" left="95" width="326" height="13" font="22">the fluoroscopy time and resource use: a prospective randomized multi-</text>
<text top="737" left="95" width="267" height="13" font="22">center study. J Cardiovasc Electrophysiol. 2009;20:734–40.</text>
<text top="751" left="69" width="351" height="13" font="22"> 148.  Mah DY, Miyake CY, Sherwin ED, et al. The use of an integrated electro-</text>
<text top="764" left="95" width="329" height="13" font="22">anatomic mapping system and intracardiac echocardiography to reduce </text>
<text top="778" left="95" width="329" height="13" font="22">radiation exposure in children and young adults undergoing ablation of </text>
<text top="791" left="95" width="258" height="13" font="22">supraventricular tachycardia. Europace. 2014;16:277–83.</text>
<text top="805" left="69" width="353" height="13" font="22"> 149.  Alvarez M, Tercedor L, Almansa I, et al. Safety and feasibility of catheter </text>
<text top="819" left="95" width="325" height="13" font="22">ablation for atrioventricular nodal re-entrant tachycardia without fluoro-</text>
<text top="832" left="95" width="224" height="13" font="22">scopic guidance. Heart Rhythm. 2009;6:1714–20.</text>
<text top="846" left="69" width="351" height="13" font="22"> 150.  Casella M, Pelargonio G, Dello RA, et al. “Near-zero” fluoroscopic ex-</text>
<text top="859" left="95" width="328" height="13" font="22">posure in supraventricular arrhythmia ablation using the EnSite NavX™ </text>
<text top="873" left="95" width="331" height="13" font="22">mapping system: personal experience and review of the literature. J </text>
<text top="887" left="95" width="202" height="13" font="22">Interv Card Electrophysiol. 2011;31:109–18.</text>
<text top="900" left="69" width="351" height="13" font="22"> 151.  Razminia M, Manankil MF, Eryazici PLS, et al. Nonfluoroscopic cath-</text>
<text top="914" left="95" width="325" height="13" font="22">eter ablation of cardiac arrhythmias in adults: feasibility, safety, and ef-</text>
<text top="927" left="95" width="245" height="13" font="22">ficacy. J Cardiovasc Electrophysiol. 2012;23:1078–86.</text>
<text top="941" left="69" width="354" height="13" font="22"> 152.  Earley MJ, Showkathali R, Alzetani M, et al. Radiofrequency ablation of </text>
<text top="955" left="95" width="329" height="13" font="22">arrhythmias guided by non-fluoroscopic catheter location: a prospective </text>
<text top="968" left="95" width="213" height="13" font="22">randomized trial. Eur Heart J. 2006;27:1223–9.</text>
<text top="982" left="69" width="355" height="13" font="22"> 153. Xu D, Yang B, Shan Q, et al. Initial clinical experience of remote </text>
<text top="995" left="95" width="333" height="13" font="22">magnetic navigation system for catheter mapping and ablation </text>
<text top="1009" left="95" width="334" height="13" font="22">of supraventricular tachycardias. J Interv Card Electrophysiol. </text>
<text top="1023" left="95" width="74" height="13" font="22">2009;25:171–4.</text>
<text top="1036" left="69" width="351" height="13" font="22"> 154.  Sommer P, Wojdyla-Hordynska A, Rolf S, et al. Initial experience in ab-</text>
<text top="1050" left="95" width="330" height="13" font="22">lation of typical atrial flutter using a novel three-dimensional catheter </text>
<text top="1063" left="95" width="201" height="13" font="22">tracking system. Europace. 2013;15:578–81.</text>
<text top="1077" left="69" width="7" height="13" font="22"> </text>
<text top="1077" left="69" width="358" height="13" font="22">155. Cummings JE, Pacifico A, Drago JL, et al. Alternative energy </text>
<text top="1091" left="95" width="330" height="13" font="22">sources for the ablation of arrhythmias. Pacing Clin Electrophysiol. </text>
<text top="1104" left="95" width="79" height="13" font="22">2005;28:434–43.</text>
<text top="97" left="456" width="353" height="13" font="22"> 156.  Hanninen M, Yeung-Lai-Wah N, Massel D, et al. Cryoablation versus RF </text>
<text top="111" left="482" width="328" height="13" font="22">ablation for AVNRT: a meta-analysis and systematic review. J Cardiovasc </text>
<text top="125" left="482" width="153" height="13" font="22">Electrophysiol. 2013;24:1354–60.</text>
<text top="138" left="456" width="351" height="13" font="22"> 157.  Friedman PL, Dubuc M, Green MS, et al. Catheter cryoablation of su-</text>
<text top="152" left="482" width="328" height="13" font="22">praventricular tachycardia: results of the multicenter prospective “frosty” </text>
<text top="165" left="482" width="164" height="13" font="22">trial. Heart Rhythm. 2004;1:129–38.</text>
<text top="179" left="456" width="10" height="13" font="22"> </text>
<text top="179" left="456" width="361" height="13" font="22">158. Rodriguez-Entem FJ, Expósito V, Gonzalez-Enriquez S, et al. </text>
<text top="193" left="482" width="325" height="13" font="22">Cryoablation versus radiofrequency ablation for the treatment of atrio-</text>
<text top="206" left="482" width="325" height="13" font="22">ventricular nodal reentrant tachycardia: results of a prospective random-</text>
<text top="220" left="482" width="249" height="13" font="22">ized study. J Interv Card Electrophysiol. 2013;36:41–5.</text>
<text top="233" left="456" width="351" height="13" font="22"> 159.  Eckhardt LLL, Leal M, Hollis Z, et al. Cryoablation for AVNRT: im-</text>
<text top="247" left="482" width="332" height="13" font="22">portance of ablation endpoint criteria. J Cardiovasc Electrophysiol. </text>
<text top="261" left="482" width="77" height="13" font="22">2012;23:729–34.</text>
<text top="274" left="456" width="355" height="13" font="22"> 160.  Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll </text>
<text top="288" left="482" width="122" height="13" font="22">Cardiol. 2013;61:793–801.</text>
<text top="302" left="456" width="356" height="13" font="22"> 161.  Marcus B, Gillette PC, Garson A. Intrinsic heart rate in children and </text>
<text top="315" left="482" width="329" height="13" font="22">young adults: an index of sinus node function isolated from autonomic </text>
<text top="329" left="482" width="171" height="13" font="22">control. Am Heart J. 1990;119:911–6.</text>
<text top="342" left="456" width="354" height="13" font="22"> 162.  Jose AD, Collison D. The normal range and determinants of the intrinsic </text>
<text top="356" left="482" width="222" height="13" font="22">heart rate in man. Cardiovasc Res. 1970;4:160–7.</text>
<text top="370" left="456" width="351" height="13" font="22"> 163. Alboni P, Malcarne C, Pedroni P, et al. Electrophysiology of nor-</text>
<text top="383" left="482" width="332" height="13" font="22">mal sinus node with and without autonomic blockade. Circulation. </text>
<text top="397" left="482" width="82" height="13" font="22">1982;65:1236–42.</text>
<text top="410" left="456" width="353" height="13" font="22"> 164.  Winum P-F, Cayla G, Rubini M, et al. A case of cardiomyopathy induced </text>
<text top="424" left="482" width="328" height="13" font="22">by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin </text>
<text top="438" left="482" width="142" height="13" font="22">Electrophysiol. 2009;32:942–4.</text>
<text top="451" left="456" width="351" height="13" font="22"> 165.  Romeo E, Grimaldi N, Sarubbi B, et al. A pediatric case of cardiomyopa-</text>
<text top="465" left="482" width="329" height="13" font="22">thy induced by inappropriate sinus tachycardia: efficacy of ivabradine. </text>
<text top="478" left="482" width="145" height="13" font="22">Pediatr Cardiol. 2011;32:842–5.</text>
<text top="492" left="456" width="351" height="13" font="22"> 166.  Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary ar-</text>
<text top="506" left="482" width="326" height="13" font="22">tery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a ran-</text>
<text top="519" left="482" width="324" height="13" font="22">domised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.</text>
<text top="533" left="456" width="355" height="13" font="22"> 167.  Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in </text>
<text top="546" left="482" width="330" height="13" font="22">chronic heart failure (SHIFT): a randomised placebo-controlled study. </text>
<text top="560" left="482" width="118" height="13" font="22">Lancet. 2010;376:875–85.</text>
<text top="574" left="456" width="353" height="13" font="22"> 168.  Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of  ivabradine </text>
<text top="587" left="482" width="325" height="13" font="22">in patients with inappropriate sinus tachycardia: a prospective, random-</text>
<text top="601" left="482" width="329" height="13" font="22">ized, placebo-controlled, double-blind, crossover evaluation. J Am Coll </text>
<text top="614" left="482" width="116" height="13" font="22">Cardiol. 2012;60:1323–9.</text>
<text top="628" left="456" width="351" height="13" font="22"> 169.  Benezet-Mazuecos J, Rubio JM, Farré J, et al. Long-term outcomes of iv-</text>
<text top="642" left="482" width="328" height="13" font="22">abradine in inappropriate sinus tachycardia patients: appropriate efficacy </text>
<text top="655" left="482" width="313" height="13" font="22">or inappropriate patients. Pacing Clin Electrophysiol. 2013;36:830–6.</text>
<text top="669" left="456" width="356" height="13" font="22"> 170. Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. </text>
<text top="682" left="482" width="325" height="13" font="22">ivabradine in the treatment of inappropriate sinus tachycardia in pa-</text>
<text top="696" left="482" width="332" height="13" font="22">tients unresponsive to previous pharmacological therapy. Europace. </text>
<text top="710" left="482" width="77" height="13" font="22">2013;15:116–21.</text>
<text top="723" left="456" width="355" height="13" font="22"> 171.  Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in the treatment </text>
<text top="737" left="482" width="325" height="13" font="22">of inappropriate sinus tachycardia in patients after successful radiofre-</text>
<text top="750" left="482" width="329" height="13" font="22">quency catheter ablation of atrioventricular node slow pathway. Pacing </text>
<text top="764" left="482" width="159" height="13" font="22">Clin Electrophysiol. 2013;36:42–9.</text>
<text top="778" left="456" width="353" height="13" font="22"> 172.  Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in combination with </text>
<text top="791" left="482" width="328" height="13" font="22">metoprolol succinate in the treatment of inappropriate sinus tachycardia. </text>
<text top="805" left="482" width="214" height="13" font="22">J Cardiovasc Pharmacol Ther. 2013;18:338–44.</text>
<text top="818" left="456" width="354" height="13" font="22"> 173.  Calò L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration </text>
<text top="832" left="482" width="330" height="13" font="22">in patients affected by inappropriate sinus tachycardia. Heart Rhythm. </text>
<text top="846" left="482" width="77" height="13" font="22">2010;7:1318–23.</text>
<text top="859" left="456" width="355" height="13" font="22"> 174.  Kaplinsky E, Comes FP, Urondo LSV, et al. Efficacy of ivabradine in </text>
<text top="873" left="482" width="330" height="13" font="22">four patients with inappropriate sinus tachycardia: a three month-long </text>
<text top="886" left="482" width="330" height="13" font="22">experience based on electrocardiographic, Holter monitoring, exercise </text>
<text top="900" left="482" width="310" height="13" font="22">tolerance and quality of life assessments. Cardiol J. 2010;17:166–71.</text>
<text top="914" left="456" width="353" height="13" font="22"> 175.  Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. </text>
<text top="927" left="482" width="186" height="13" font="22">Wien Klin Wochenschr. 2009;121:715–8.</text>
<text top="941" left="456" width="355" height="13" font="22"> 176.  Zellerhoff S, Hinterseer M, Felix Krull B, et al. Ivabradine in patients </text>
<text top="954" left="482" width="332" height="13" font="22">with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch </text>
<text top="968" left="482" width="130" height="13" font="22">Pharmacol. 2010;382:483–6.</text>
<text top="982" left="456" width="355" height="13" font="22"> 177.  Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of </text>
<text top="995" left="482" width="328" height="13" font="22">inappropriate sinus tachycardia guided by activation mapping. J Am Coll </text>
<text top="1009" left="482" width="110" height="13" font="22">Cardiol. 2000;35:451–7.</text>
<text top="1022" left="456" width="356" height="13" font="22"> 178. Lin D, Garcia F, Jacobson J, et al. Use of noncontact mapping and  </text>
<text top="1036" left="482" width="329" height="13" font="22">saline-cooled ablation catheter for sinus node modification in medically </text>
<text top="1050" left="482" width="330" height="13" font="22">refractory inappropriate sinus tachycardia. Pacing Clin Electrophysiol. </text>
<text top="1063" left="482" width="77" height="13" font="22">2007;30:236–42.</text>
<text top="1077" left="456" width="357" height="13" font="22"> 179. Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter </text>
<text top="1090" left="482" width="330" height="13" font="22">modification of the sinus node for “inappropriate” sinus tachycardia. </text>
<text top="1104" left="482" width="138" height="13" font="22">Circulation. 1995;92:2919–28.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e562  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="71" width="7" height="13" font="22"> </text>
<text top="98" left="71" width="358" height="13" font="22">180. Marrouche NF, Beheiry S, Tomassoni G, et al. Three-dimensional </text>
<text top="111" left="96" width="325" height="13" font="22">nonfluoroscopic mapping and ablation of inappropriate sinus tachycar-</text>
<text top="125" left="96" width="330" height="13" font="22">dia. Procedural strategies and long-term outcome. J Am Coll Cardiol. </text>
<text top="138" left="96" width="82" height="13" font="22">2002;39:1046–54.</text>
<text top="152" left="70" width="355" height="13" font="22"> 181.  Callans DJ, Ren JF, Schwartzman D, et al. Narrowing of the superior </text>
<text top="166" left="96" width="329" height="13" font="22">vena cava-right atrium junction during radiofrequency catheter ablation </text>
<text top="179" left="96" width="325" height="13" font="22">for inappropriate sinus tachycardia: analysis with intracardiac echocar-</text>
<text top="193" left="96" width="220" height="13" font="22">diography. J Am Coll Cardiol. 1999;33:1667–70.</text>
<text top="206" left="70" width="351" height="13" font="22"> 182. Frankel DS, Lin D, Anastasio N, et al. Frequent additional tachyar-</text>
<text top="220" left="96" width="330" height="13" font="22">rhythmias in patients with inappropriate sinus tachycardia undergoing </text>
<text top="234" left="96" width="330" height="13" font="22">sinus node modification: an important cause of symptom recurrence. </text>
<text top="247" left="96" width="202" height="13" font="22">J Cardiovasc Electrophysiol. 2012;23:835–9.</text>
<text top="261" left="70" width="353" height="13" font="22"> 183.  Takemoto M, Mukai Y, Inoue S, et al. Usefulness of non-contact mapping </text>
<text top="274" left="96" width="329" height="13" font="22">for radiofrequency catheter ablation of inappropriate sinus tachycardia: </text>
<text top="288" left="96" width="330" height="13" font="22">new procedural strategy and long-term clinical outcome. Intern Med. </text>
<text top="302" left="96" width="77" height="13" font="22">2012;51:357–62.</text>
<text top="315" left="70" width="351" height="13" font="22"> 184.  Koplan BA, Parkash R, Couper G, et al. Combined epicardial-endocardi-</text>
<text top="329" left="96" width="329" height="13" font="22">al approach to ablation of inappropriate sinus tachycardia. J Cardiovasc </text>
<text top="342" left="96" width="148" height="13" font="22">Electrophysiol. 2004;15:237–40.</text>
<text top="356" left="70" width="356" height="13" font="22"> 185. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. </text>
<text top="369" left="96" width="145" height="13" font="22">N Engl J Med. 2001;344:501–9.</text>
<text top="383" left="70" width="355" height="13" font="22"> 186.  Steinbeck G, Hoffmann E. ‘True’ atrial tachycardia. Eur Heart J. 1998; </text>
<text top="397" left="96" width="85" height="13" font="22">19 Suppl E:E48–9.</text>
<text top="410" left="70" width="341" height="13" font="22"> 187.  Wren C. Incessant tachycardias. Eur Heart J. 1998;19 Suppl E:E54–9.</text>
<text top="424" left="70" width="351" height="13" font="22"> 188.  Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardio-</text>
<text top="437" left="96" width="328" height="13" font="22">myopathy secondary to focal atrial tachycardia: long-term outcome after </text>
<text top="451" left="96" width="245" height="13" font="22">catheter ablation. J Am Coll Cardiol. 2009;53:1791–7.</text>
<text top="465" left="70" width="351" height="13" font="22"> 189.  Tang CW, Scheinman MM, Van Hare GF, et al. Use of P wave configura-</text>
<text top="478" left="96" width="328" height="13" font="22">tion during atrial tachycardia to predict site of origin. J Am Coll Cardiol. </text>
<text top="492" left="96" width="82" height="13" font="22">1995;26:1315–24.</text>
<text top="505" left="70" width="351" height="13" font="22"> 190.  Kistler PM, Roberts-Thomson KC, Haqqani HM, et al. P-wave morphol-</text>
<text top="519" left="96" width="329" height="13" font="22">ogy in focal atrial tachycardia: development of an algorithm to predict </text>
<text top="533" left="96" width="288" height="13" font="22">the anatomic site of origin. J Am Coll Cardiol. 2006;48:1010–7.</text>
<text top="546" left="70" width="351" height="13" font="22"> 191.  Liu X, Dong J, Ho SY, et al. Atrial tachycardia arising adjacent to non-</text>
<text top="560" left="96" width="329" height="13" font="22">coronary aortic sinus: distinctive atrial activation patterns and anatomic </text>
<text top="573" left="96" width="211" height="13" font="22">insights. J Am Coll Cardiol. 2010;56:796–804.</text>
<text top="587" left="70" width="354" height="13" font="22"> 192.  Morton JB, Sanders P, Das A, et al. Focal atrial tachycardia arising from </text>
<text top="601" left="96" width="325" height="13" font="22">the tricuspid annulus: electrophysiologic and electrocardiographic char-</text>
<text top="614" left="96" width="253" height="13" font="22">acteristics. J Cardiovasc Electrophysiol. 2001;12:653–9.</text>
<text top="628" left="70" width="355" height="13" font="22"> 193.  Kistler PM, Sanders P, Hussin A, et al. Focal atrial tachycardia arising </text>
<text top="641" left="96" width="331" height="13" font="22">from the mitral annulus: electrocardiographic and electrophysiologic </text>
<text top="655" left="96" width="242" height="13" font="22">characterization. J Am Coll Cardiol. 2003;41:2212–9.</text>
<text top="668" left="70" width="351" height="13" font="22"> 194.  Gonzalez MD, Contreras LJ, Jongbloed MRM, et al. Left atrial tachy-</text>
<text top="682" left="96" width="330" height="13" font="22">cardia originating from the mitral annulus-aorta junction. Circulation. </text>
<text top="696" left="96" width="91" height="13" font="22">2004;110: 3187–92.</text>
<text top="709" left="70" width="354" height="13" font="22"> 195.  Ouyang F, Ma J, Ho SY, et al. Focal atrial tachycardia originating from </text>
<text top="723" left="96" width="330" height="13" font="22">the non-coronary aortic sinus: electrophysiological characteristics and </text>
<text top="736" left="96" width="245" height="13" font="22">catheter ablation. J Am Coll Cardiol. 2006;48:122–31.</text>
<text top="750" left="70" width="357" height="13" font="22"> 196. Roberts-Thomson KC, Kistler PM, Haqqani HM, et al. Focal atrial </text>
<text top="764" left="96" width="325" height="13" font="22">tachycardias arising from the right atrial appendage: electrocardiograph-</text>
<text top="777" left="96" width="331" height="13" font="22">ic and electrophysiologic characteristics and radiofrequency ablation. </text>
<text top="791" left="96" width="208" height="13" font="22">J Cardiovasc Electrophysiol. 2007;18:367–72.</text>
<text top="804" left="70" width="354" height="13" font="22"> 197.  Walters TE, Kistler PM, Kalman JM. Radiofrequency ablation for atrial </text>
<text top="818" left="96" width="287" height="13" font="22">tachycardia and atrial flutter. Heart Lung Circ. 2012;21:386–94.</text>
<text top="832" left="70" width="355" height="13" font="22"> 198.  Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: </text>
<text top="845" left="96" width="194" height="13" font="22">state of the art. Lancet. 2012;380:1509–19.</text>
<text top="859" left="70" width="355" height="13" font="22"> 199.  Markowitz SM, Nemirovksy D, Stein KM, et al. Adenosine-insensitive </text>
<text top="872" left="96" width="326" height="13" font="22">focal atrial tachycardia: evidence for de novo micro-re-entry in the hu-</text>
<text top="886" left="96" width="227" height="13" font="22">man atrium. J Am Coll Cardiol. 2007;49:1324–33.</text>
<text top="900" left="70" width="354" height="13" font="22"> 200.  Engelstein ED, Lippman N, Stein KM, et al. Mechanism-specific effects </text>
<text top="913" left="96" width="296" height="13" font="22">of adenosine on atrial tachycardia. Circulation. 1994;89:2645–54.</text>
<text top="927" left="70" width="356" height="13" font="22"> 201. Cossú SF, Steinberg JS. Supraventricular tachyarrhythmias involving </text>
<text top="940" left="96" width="332" height="13" font="22">the sinus node: clinical and electrophysiologic characteristics. Prog </text>
<text top="954" left="96" width="145" height="13" font="22">Cardiovasc Dis. 1998;41:51–63.</text>
<text top="967" left="70" width="354" height="13" font="22"> 202.  Goya M, Iesaka Y, Takahashi A, et al. Radiofrequency catheter ablation </text>
<text top="981" left="96" width="329" height="13" font="22">for sinoatrial node reentrant tachycardia: electrophysiologic features of </text>
<text top="995" left="96" width="192" height="13" font="22">ablation sites. Jpn Circ J. 1999;63:177–83.</text>
<text top="1008" left="70" width="355" height="13" font="22"> 203.  Saoudi N, Cosío F, Waldo A, et al. A classification of atrial flutter and </text>
<text top="1022" left="96" width="329" height="13" font="22">regular atrial tachycardia according to electrophysiological mechanisms </text>
<text top="1035" left="96" width="330" height="13" font="22">and anatomical bases: a statement from a joint expert group from the </text>
<text top="1049" left="96" width="329" height="13" font="22">Working Group of Arrhythmias of the European Society of Cardiology </text>
<text top="1063" left="96" width="329" height="13" font="22">and the North American Society of Pacing and Electrophysiology. Eur </text>
<text top="1076" left="96" width="120" height="13" font="22">Heart J. 2001;22:1162–82.</text>
<text top="1090" left="70" width="351" height="13" font="22"> 204.  Gillette PC, Garson A Jr. Electrophysiologic and pharmacologic charac-</text>
<text top="1103" left="96" width="325" height="13" font="22">teristics of automatic ectopic atrial tachycardia. Circulation. 1977;56:571–5.</text>
<text top="97" left="458" width="351" height="13" font="22"> 205.  Mehta AV, Sanchez GR, Sacks EJ, et al. Ectopic automatic atrial tachy-</text>
<text top="111" left="483" width="330" height="13" font="22">cardia in children: clinical characteristics, management and follow-up. </text>
<text top="124" left="483" width="164" height="13" font="22">J Am Coll Cardiol. 1988;11:379–85.</text>
<text top="138" left="458" width="351" height="13" font="22"> 206.  Eidher U, Freihoff F, Kaltenbrunner W, et al. Efficacy and safety of ibu-</text>
<text top="152" left="483" width="328" height="13" font="22">tilide for the conversion of monomorphic atrial tachycardia. Pacing Clin </text>
<text top="165" left="483" width="148" height="13" font="22">Electrophysiol. 2006;29:358–62.</text>
<text top="179" left="458" width="351" height="13" font="22"> 207. Markowitz SM, Stein KM, Mittal S, et al. Differential effects of ad-</text>
<text top="192" left="483" width="331" height="13" font="22">enosine on focal and macroreentrant atrial tachycardia. J Cardiovasc </text>
<text top="206" left="483" width="153" height="13" font="22">Electrophysiol. 1999;10:489–502.</text>
<text top="220" left="458" width="355" height="13" font="22"> 208.  Reisinger J, Gstrein C, Winter T, et al. Optimization of initial energy </text>
<text top="233" left="483" width="329" height="13" font="22">for cardioversion of atrial tachyarrhythmias with biphasic shocks. Am J </text>
<text top="247" left="483" width="135" height="13" font="22">Emerg Med. 2010;28:159–65.</text>
<text top="260" left="458" width="351" height="13" font="22"> 209.  Kunze KP, Kuck KH, Schlüter M, et al. Effect of encainide and fle-</text>
<text top="274" left="483" width="331" height="13" font="22">cainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol. </text>
<text top="288" left="483" width="73" height="13" font="22">1986;7:1121–6.</text>
<text top="301" left="458" width="351" height="13" font="22"> 210.  Creamer JE, Nathan AW, Camm AJ. Successful treatment of atrial tachy-</text>
<text top="315" left="483" width="264" height="13" font="22">cardias with flecainide acetate. Br Heart J. 1985;53:164–6.</text>
<text top="328" left="458" width="351" height="13" font="22"> 211.  von Bernuth G, Engelhardt W, Kramer HH, et al. Atrial automatic tachy-</text>
<text top="342" left="483" width="281" height="13" font="22">cardia in infancy and childhood. Eur Heart J. 1992;13:1410–5.</text>
<text top="356" left="458" width="357" height="13" font="22"> 212. Lucet V, Do Ngoc D, Fidelle J, et al. [Anti-arrhythmia efficacy of </text>
<text top="369" left="483" width="329" height="13" font="22">propafenone in children. Apropos of 30 cases]. Arch Mal Coeur Vaiss. </text>
<text top="383" left="483" width="82" height="13" font="22">1987;80:1385–93.</text>
<text top="396" left="458" width="6" height="13" font="22"> </text>
<text top="396" left="458" width="357" height="13" font="22">213. Heusch A, Kramer HH, Krogmann ON, et al. Clinical experience </text>
<text top="410" left="483" width="330" height="13" font="22">with propafenone for cardiac arrhythmias in the young. Eur Heart J. </text>
<text top="423" left="483" width="77" height="13" font="22">1994;15:1050–6.</text>
<text top="437" left="458" width="351" height="13" font="22"> 214.  Janousek J, Paul T. Safety of oral propafenone in the treatment of ar-</text>
<text top="451" left="483" width="330" height="13" font="22">rhythmias in infants and children (European retrospective multicenter </text>
<text top="464" left="483" width="328" height="13" font="22">study). Working Group on Pediatric Arrhythmias and Electrophysiology </text>
<text top="478" left="483" width="330" height="13" font="22">of the Association of European Pediatric Cardiologists. Am J Cardiol. </text>
<text top="491" left="483" width="77" height="13" font="22">1998;81:1121–4.</text>
<text top="505" left="458" width="355" height="13" font="22"> 215.  Colloridi V, Perri C, Ventriglia F, et al. Oral sotalol in pediatric atrial </text>
<text top="519" left="483" width="226" height="13" font="22">ectopic tachycardia. Am Heart J. 1992;123:254–6.</text>
<text top="532" left="458" width="355" height="13" font="22"> 216.  Guccione P, Paul T, Garson A Jr. Long-term follow-up of amiodarone </text>
<text top="546" left="483" width="329" height="13" font="22">therapy in the young: continued efficacy, unimpaired growth, moderate </text>
<text top="559" left="483" width="226" height="13" font="22">side effects. J Am Coll Cardiol. 1990;15:1118–24.</text>
<text top="573" left="458" width="354" height="13" font="22"> 217.  Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias </text>
<text top="587" left="483" width="326" height="13" font="22">in children: one hundred thirty-five cases. Am Heart J. 1980;100:1063–9.</text>
<text top="600" left="458" width="351" height="13" font="22"> 218.  Miyazaki A, Ohuchi H, Kurosaki K, et al. Efficacy and safety of so-</text>
<text top="614" left="483" width="329" height="13" font="22">talol for refractory tachyarrhythmias in congenital heart disease. Circ J. </text>
<text top="627" left="483" width="93" height="13" font="22">2008;72:1998–2003.</text>
<text top="641" left="458" width="354" height="13" font="22"> 219.  Kang KT, Etheridge SP, Kantoch MJ, et al. Current management of focal </text>
<text top="654" left="483" width="329" height="13" font="22">atrial tachycardia in children: a multicenter experience. Circ Arrhythm </text>
<text top="668" left="483" width="142" height="13" font="22">Electrophysiol. 2014;7:664–70.</text>
<text top="682" left="458" width="354" height="13" font="22"> 220.  Kothari SA, Apiyasawat S, Asad N, et al. Evidence supporting a new rate </text>
<text top="695" left="483" width="325" height="13" font="22">threshold for multifocal atrial tachycardia. Clin Cardiol. 2005;28:561–3.</text>
<text top="709" left="458" width="356" height="13" font="22"> 221. Yokoshiki H, Mitsuyama H, Watanabe M, et al. Swallowing-induced </text>
<text top="722" left="483" width="331" height="13" font="22">multifocal atrial tachycardia originating from right pulmonary veins. </text>
<text top="736" left="483" width="161" height="13" font="22">J Electrocardiol. 2011;44:395.e1–5.</text>
<text top="750" left="458" width="351" height="13" font="22"> 222.  Marchlinski FE, Miller JM. Atrial arrhythmias exacerbated by theophyl-</text>
<text top="763" left="483" width="329" height="13" font="22">line. Response to verapamil and evidence for triggered activity in man. </text>
<text top="777" left="483" width="102" height="13" font="22">Chest. 1985;88:931–4.</text>
<text top="790" left="458" width="355" height="13" font="22"> 223.  Wang K, Goldfarb BL, Gobel FL, et al. Multifocal atrial tachycardia. </text>
<text top="804" left="483" width="158" height="13" font="22">Arch Intern Med. 1977;137:161–4.</text>
<text top="818" left="458" width="351" height="13" font="22"> 224.  Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multi-</text>
<text top="831" left="483" width="298" height="13" font="22">variate analysis of clinical determinants. Chest. 1991;99:1415–20.</text>
<text top="845" left="458" width="354" height="13" font="22"> 225.  Iseri LT, Fairshter RD, Hardemann JL, et al. Magnesium and potassium </text>
<text top="858" left="483" width="319" height="13" font="22">therapy in multifocal atrial tachycardia. Am Heart J. 1985;110:789–94.</text>
<text top="872" left="458" width="348" height="13" font="22"> 226.  Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990;322:1713–7.</text>
<text top="886" left="458" width="357" height="13" font="22"> 227. Hazard PB, Burnett CR. Verapamil in multifocal atrial tachycardia. </text>
<text top="899" left="483" width="284" height="13" font="22">Hemodynamic and respiratory changes. Chest. 1987;91:68–70.</text>
<text top="913" left="458" width="351" height="13" font="22"> 228.  Mukerji V, Alpert MA, Diaz-Arias M, et al. Termination and suppres-</text>
<text top="926" left="483" width="332" height="13" font="22">sion of multifocal atrial tachycardia with verapamil. South Med J. </text>
<text top="940" left="483" width="77" height="13" font="22">1987;80:269–70.</text>
<text top="953" left="458" width="355" height="13" font="22"> 229.  Arsura EL, Solar M, Lefkin AS, et al. Metoprolol in the treatment of </text>
<text top="967" left="483" width="274" height="13" font="22">multifocal atrial tachycardia. Crit Care Med. 1987;15:591–4.</text>
<text top="981" left="458" width="354" height="13" font="22"> 230.  Hazard PB, Burnett CR. Treatment of multifocal atrial tachycardia with </text>
<text top="994" left="483" width="191" height="13" font="22">metoprolol. Crit Care Med. 1987;15:20–5.</text>
<text top="1008" left="458" width="7" height="13" font="22"> </text>
<text top="1008" left="458" width="351" height="13" font="22">231. Kouvaras G, Cokkinos DV, Halal G, et al. The effective treat-</text>
<text top="1021" left="483" width="330" height="13" font="22">ment of multifocal atrial tachycardia with amiodarone. Jpn Heart J. </text>
<text top="1035" left="483" width="79" height="13" font="22">1989;30:301–12.</text>
<text top="1049" left="458" width="351" height="13" font="22"> 232.  Levine JH, Michael JR, Guarnieri T. Treatment of multifocal atrial tachy-</text>
<text top="1062" left="483" width="243" height="13" font="22">cardia with verapamil. N Engl J Med. 1985;312:21–5.</text>
<text top="1076" left="458" width="355" height="13" font="22"> 233.  Salerno DM, Anderson B, Sharkey PJ, et al. Intravenous verapamil for </text>
<text top="1089" left="483" width="326" height="13" font="22">treatment of multifocal atrial tachycardia with and without calcium pre-</text>
<text top="1103" left="483" width="202" height="13" font="22">treatment. Ann Intern Med. 1987;107:623–8.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e563</i></b></text>
<text top="98" left="69" width="351" height="13" font="22"> 234.  Mehta D, Wafa S, Ward DE, et al. Relative efficacy of various physi-</text>
<text top="111" left="95" width="331" height="13" font="22">cal manoeuvres in the termination of junctional tachycardia. Lancet. </text>
<text top="125" left="95" width="71" height="13" font="22">1988;1:1181–5.</text>
<text top="138" left="69" width="354" height="13" font="22"> 235.  Wen ZC, Chen SA, Tai CT, et al. Electrophysiological mechanisms and </text>
<text top="152" left="95" width="325" height="13" font="22">determinants of vagal maneuvers for termination of paroxysmal supra-</text>
<text top="166" left="95" width="247" height="13" font="22">ventricular tachycardia. Circulation. 1998;98:2716–23.</text>
<text top="179" left="69" width="355" height="13" font="22"> 236.  Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of </text>
<text top="193" left="95" width="331" height="13" font="22">adenosine in patients with supraventricular tachycardia. Circulation. </text>
<text top="206" left="95" width="82" height="13" font="22">1999;99:1034–40.</text>
<text top="220" left="69" width="354" height="13" font="22"> 237.  Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of </text>
<text top="234" left="95" width="329" height="13" font="22">paroxysmal supraventricular tachycardia with intravenous diltiazem. IV </text>
<text top="247" left="95" width="253" height="13" font="22">Diltiazem Study Group. Am J Cardiol. 1992;70:587–92.</text>
<text top="261" left="69" width="351" height="13" font="22"> 238.  Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of ven-</text>
<text top="274" left="95" width="325" height="13" font="22">tricular rate in paroxysmal supraventricular tachycardia and atrial fibril-</text>
<text top="288" left="95" width="328" height="13" font="22">lation or flutter: a double-blind randomized cross-over study. Ann Intern </text>
<text top="302" left="95" width="86" height="13" font="22">Med. 1981;94:1–6.</text>
<text top="315" left="69" width="354" height="13" font="22"> 239.  Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective </text>
<text top="329" left="95" width="329" height="13" font="22">beta-adrenergic blockade with intravenously administered metoprolol in </text>
<text top="342" left="95" width="330" height="13" font="22">the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol. </text>
<text top="356" left="95" width="71" height="13" font="22">1991;31:714–8.</text>
<text top="369" left="69" width="354" height="13" font="22"> 240.  Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and </text>
<text top="383" left="95" width="330" height="13" font="22">transfer of patients with supraventricular tachyarrhythmias to alternate </text>
<text top="397" left="95" width="283" height="13" font="22">oral antiarrhythmic agents. J Clin Pharmacol. 1988;28:746–50.</text>
<text top="410" left="69" width="351" height="13" font="22"> 241.  Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-</text>
<text top="424" left="95" width="325" height="13" font="22">hospital self-administered single-dose oral drug treatment in the man-</text>
<text top="437" left="95" width="334" height="13" font="22">agement of infrequent, well-tolerated paroxysmal supraventricular </text>
<text top="451" left="95" width="222" height="13" font="22">tachycardia. J Am Coll Cardiol. 2001;37:548–53.</text>
<text top="465" left="69" width="351" height="13" font="22"> 242.  Yeh SJ, Lin FC, Chou YY, et al. Termination of paroxysmal supraven-</text>
<text top="478" left="95" width="328" height="13" font="22">tricular tachycardia with a single oral dose of diltiazem and propranolol. </text>
<text top="492" left="95" width="127" height="13" font="22">Circulation. 1985;71:104–9.</text>
<text top="505" left="69" width="354" height="13" font="22"> 243.  Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous </text>
<text top="519" left="95" width="326" height="13" font="22">and chronic oral verapamil administration in patients with supraventricu-</text>
<text top="533" left="95" width="242" height="13" font="22">lar tachyarrhythmias. Circulation. 1980;62:996–1010.</text>
<text top="546" left="69" width="354" height="13" font="22"> 244.  D’Este D, Zoppo F, Bertaglia E, et al. Long-term outcome of patients with </text>
<text top="560" left="95" width="326" height="13" font="22">atrioventricular node reentrant tachycardia. Int J Cardiol. 2007;115:350–3.</text>
<text top="573" left="69" width="355" height="13" font="22"> 245.  Langberg JJ, Leon A, Borganelli M, et al. A randomized, prospective </text>
<text top="587" left="95" width="326" height="13" font="22">comparison of anterior and posterior approaches to radiofrequency cath-</text>
<text top="601" left="95" width="330" height="13" font="22">eter ablation of atrioventricular nodal reentry tachycardia. Circulation. </text>
<text top="614" left="95" width="77" height="13" font="22">1993;87:1551–6.</text>
<text top="628" left="69" width="351" height="13" font="22"> 246.  Kalbfleisch SJ, Strickberger SA, Williamson B, et al. Randomized com-</text>
<text top="641" left="95" width="329" height="13" font="22">parison of anatomic and electrogram mapping approaches to ablation of </text>
<text top="655" left="95" width="330" height="13" font="22">the slow pathway of atrioventricular node reentrant tachycardia. J Am </text>
<text top="668" left="95" width="138" height="13" font="22">Coll Cardiol. 1994;23:716–23.</text>
<text top="682" left="69" width="353" height="13" font="22"> 247.  Kay GN, Epstein AE, Dailey SM, et al. Selective radiofrequency ablation </text>
<text top="696" left="95" width="329" height="13" font="22">of the slow pathway for the treatment of atrioventricular nodal reentrant </text>
<text top="709" left="95" width="329" height="13" font="22">tachycardia. Evidence for involvement of perinodal myocardium within </text>
<text top="723" left="95" width="232" height="13" font="22">the reentrant circuit. Circulation. 1992;85:1675–88.</text>
<text top="736" left="69" width="355" height="13" font="22"> 248.  Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients </text>
<text top="750" left="95" width="326" height="13" font="22">with documented but noninducible paroxysmal supraventricular tachy-</text>
<text top="764" left="95" width="198" height="13" font="22">cardia. J Am Coll Cardiol. 1996;28:1000–4.</text>
<text top="777" left="69" width="351" height="13" font="22"> 249.  O’Hara GE, Philippon F, Champagne J, et al. Catheter ablation for car-</text>
<text top="791" left="95" width="328" height="13" font="22">diac arrhythmias: a 14-year experience with 5330 consecutive patients at </text>
<text top="804" left="95" width="328" height="13" font="22">the Quebec Heart Institute, Laval Hospital. Can J Cardiol. 2007;23 Suppl </text>
<text top="818" left="95" width="57" height="13" font="22">B:67B–70B.</text>
<text top="832" left="69" width="354" height="13" font="22"> 250.  Gambhir DS, Bhargava M, Arora R, et al. Electrophysiologic effects and </text>
<text top="845" left="95" width="326" height="13" font="22">therapeutic efficacy of intravenous flecainide for termination of paroxys-</text>
<text top="859" left="95" width="299" height="13" font="22">mal supraventricular tachycardia. Indian Heart J. 1995;47:237–43.</text>
<text top="872" left="69" width="355" height="13" font="22"> 251.  Musto B, Cavallaro C, Musto A, et al. Flecainide single oral dose for </text>
<text top="886" left="95" width="328" height="13" font="22">management of paroxysmal supraventricular tachycardia in children and </text>
<text top="900" left="95" width="197" height="13" font="22">young adults. Am Heart J. 1992;124:110–5.</text>
<text top="913" left="69" width="351" height="13" font="22"> 252.  Wellens HJ. Should catheter ablation be performed in asymptomatic pa-</text>
<text top="927" left="95" width="328" height="13" font="22">tients with Wolff-Parkinson-White syndrome? When to perform catheter </text>
<text top="940" left="95" width="326" height="13" font="22">ablation in asymptomatic patients with a Wolff-Parkinson-White electro-</text>
<text top="954" left="95" width="195" height="13" font="22">cardiogram. Circulation. 2005;112:2201–7.</text>
<text top="967" left="69" width="355" height="13" font="22"> 253.  Munger TM, Packer DL, Hammill SC, et al. A population study of the </text>
<text top="981" left="95" width="329" height="13" font="22">natural history of Wolff-Parkinson-White syndrome in Olmsted County, </text>
<text top="995" left="95" width="242" height="13" font="22">Minnesota, 1953–1989. Circulation. 1993;87:866–73.</text>
<text top="1008" left="69" width="356" height="13" font="22"> 254. Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-White </text>
<text top="1022" left="95" width="328" height="13" font="22">syndrome in the era of catheter ablation: insights from a registry study of </text>
<text top="1035" left="95" width="199" height="13" font="22">2169 patients. Circulation. 2014;130:811–9.</text>
<text top="1049" left="69" width="6" height="13" font="22"> </text>
<text top="1049" left="69" width="351" height="13" font="22">255. Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sud-</text>
<text top="1063" left="95" width="331" height="13" font="22">den death in the Wolff-Parkinson-White syndrome. Am J Cardiol. </text>
<text top="1076" left="95" width="73" height="13" font="22">1995;76:492–4.</text>
<text top="1090" left="69" width="355" height="13" font="22"> 256.  Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the </text>
<text top="1103" left="95" width="309" height="13" font="22">Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080–5.</text>
<text top="97" left="456" width="355" height="13" font="22"> 257.  Bromberg BI, Lindsay BD, Cain ME, et al. Impact of clinical history </text>
<text top="111" left="482" width="325" height="13" font="22">and electrophysiologic characterization of accessory pathways on man-</text>
<text top="124" left="482" width="326" height="13" font="22">agement strategies to reduce sudden death among children with Wolff-</text>
<text top="138" left="482" width="288" height="13" font="22">Parkinson-White syndrome. J Am Coll Cardiol. 1996;27:690–5.</text>
<text top="152" left="456" width="356" height="13" font="22"> 258. Santinelli V, Radinovic A, Manguso F, et al. The natural history of </text>
<text top="165" left="482" width="335" height="13" font="22">asymptomatic ventricular pre-excitation: a long-term prospective </text>
<text top="179" left="482" width="331" height="13" font="22">follow-up study of 184 asymptomatic children. J Am Coll Cardiol. </text>
<text top="192" left="482" width="77" height="13" font="22">2009;53:275–80.</text>
<text top="206" left="456" width="357" height="13" font="22"> 259. Smith GD, Dyson K, Taylor D, et al. Effectiveness of the Valsalva </text>
<text top="220" left="482" width="332" height="13" font="22">manoeuvre for reversion of supraventricular tachycardia. Cochrane </text>
<text top="233" left="482" width="176" height="13" font="22">Database Syst Rev. 2013;3:CD009502.</text>
<text top="247" left="456" width="354" height="13" font="22"> 260.  Delaney B, Loy J, Kelly A-M. The relative efficacy of adenosine versus </text>
<text top="260" left="482" width="325" height="13" font="22">verapamil for the treatment of stable paroxysmal supraventricular tachy-</text>
<text top="274" left="482" width="312" height="13" font="22">cardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18:148–52.</text>
<text top="288" left="456" width="357" height="13" font="22"> 261. Furlong R, Gerhardt RT, Farber P, et al. Intravenous adenosine as </text>
<text top="301" left="482" width="330" height="13" font="22">first-line prehospital management of narrow-complex tachycardias by </text>
<text top="315" left="482" width="331" height="13" font="22">EMS personnel without direct physician control. Am J Emerg Med. </text>
<text top="328" left="482" width="71" height="13" font="22">1995;13:383–8.</text>
<text top="342" left="456" width="355" height="13" font="22"> 262.  Schatz I, Ordog GJ, Karody R, et al. Wolff-Parkinson-White syndrome </text>
<text top="356" left="482" width="292" height="13" font="22">presenting in atrial fibrillation. Ann Emerg Med. 1987;16:574–8.</text>
<text top="369" left="456" width="355" height="13" font="22"> 263.  Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial </text>
<text top="383" left="482" width="329" height="13" font="22">fibrillation: comparison of rectilinear biphasic versus damped sine wave </text>
<text top="396" left="482" width="232" height="13" font="22">monophasic shocks. Circulation. 2000;101:1282–7.</text>
<text top="410" left="456" width="6" height="13" font="22"> </text>
<text top="410" left="456" width="351" height="13" font="22">264. Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological ef-</text>
<text top="423" left="482" width="332" height="13" font="22">fects of ibutilide in patients with accessory pathways. Circulation. </text>
<text top="437" left="482" width="82" height="13" font="22">2001;104:1933–9.</text>
<text top="451" left="456" width="351" height="13" font="22"> 265.  Sellers TD Jr., Campbell RW, Bashore TM, et al. Effects of procain-</text>
<text top="464" left="482" width="330" height="13" font="22">amide and quinidine sulfate in the Wolff-Parkinson-White syndrome. </text>
<text top="478" left="482" width="127" height="13" font="22">Circulation. 1977;55:15–22.</text>
<text top="491" left="456" width="354" height="13" font="22"> 266.  Huycke EC, Sung RJ, Dias VC, et al. Intravenous diltiazem for termination </text>
<text top="505" left="482" width="328" height="13" font="22">of reentrant supraventricular tachycardia: a placebo-controlled, randomized, </text>
<text top="519" left="482" width="311" height="13" font="22">double-blind, multicenter study. J Am Coll Cardiol. 1989;13:538–44.</text>
<text top="532" left="456" width="353" height="13" font="22"> 267.  Hamer A, Peter T, Platt M, et al. Effects of verapamil on supraventricular </text>
<text top="546" left="482" width="328" height="13" font="22">tachycardia in patients with overt and concealed Wolff-Parkinson-White </text>
<text top="559" left="482" width="189" height="13" font="22">syndrome. Am Heart J. 1981;101:600–12.</text>
<text top="573" left="456" width="355" height="13" font="22"> 268.  Hombach V, Braun V, Höpp HW, et al. Antiarrhythmic effects of acute </text>
<text top="587" left="482" width="329" height="13" font="22">beta blockade with atenolol on supraventricular tachycardias at rest and </text>
<text top="600" left="482" width="234" height="13" font="22">during exercise. Klin Wochenschr. 1981;59:123–33.</text>
<text top="614" left="456" width="354" height="13" font="22"> 269.  Morady F, DiCarlo LA Jr., Baerman JM, et al. Effect of propranolol on </text>
<text top="627" left="482" width="330" height="13" font="22">ventricular rate during atrial fibrillation in the Wolff-Parkinson-White </text>
<text top="641" left="482" width="248" height="13" font="22">syndrome. Pacing Clin Electrophysiol. 1987;10:492–6.</text>
<text top="654" left="456" width="354" height="13" font="22"> 270.  Wellens HJ, Durrer D. Effect of digitalis on atrioventricular conduction </text>
<text top="668" left="482" width="325" height="13" font="22">and circus-movement tachycardias in patients with Wolff-Parkinson-</text>
<text top="682" left="482" width="219" height="13" font="22">White syndrome. Circulation. 1973;47:1229–33.</text>
<text top="695" left="456" width="351" height="13" font="22"> 271. Sellers TD Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-ex-</text>
<text top="709" left="482" width="332" height="13" font="22">citation syndrome. Analysis during atrial fibrillation. Circulation. </text>
<text top="722" left="482" width="73" height="13" font="22">1977;56:260–7.</text>
<text top="736" left="456" width="355" height="13" font="22"> 272.  Sheinman BD, Evans T. Acceleration of ventricular rate by fibrillation </text>
<text top="750" left="482" width="330" height="13" font="22">associated with the Wolff-Parkinson-White syndrome. Br Med J (Clin </text>
<text top="763" left="482" width="135" height="13" font="22">Res Ed). 1982;285:999–1000.</text>
<text top="777" left="456" width="351" height="13" font="22"> 273.  Boriani G, Biffi M, Frabetti L, et al. Ventricular fibrillation after intrave-</text>
<text top="790" left="482" width="325" height="13" font="22">nous amiodarone in Wolff-Parkinson-White syndrome with atrial fibril-</text>
<text top="804" left="482" width="170" height="13" font="22">lation. Am Heart J. 1996;131:1214–6.</text>
<text top="818" left="456" width="351" height="13" font="22"> 274.  Shiraishi H, Ishibashi K, Urao N, et al. Two cases of polymorphic ven-</text>
<text top="831" left="482" width="329" height="13" font="22">tricular tachycardia induced by the administration of verapamil against </text>
<text top="845" left="482" width="315" height="13" font="22">paroxysmal supraventricular tachycardia. Intern Med. 2002;41:445–8.</text>
<text top="858" left="456" width="355" height="13" font="22"> 275.  Schützenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway </text>
<text top="872" left="482" width="331" height="13" font="22">conduction following intravenous amiodarone in atrial fibrillation. A </text>
<text top="886" left="482" width="182" height="13" font="22">case report. Int J Cardiol. 1987;16:93–5.</text>
<text top="899" left="456" width="354" height="13" font="22"> 276.  Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory </text>
<text top="913" left="482" width="325" height="13" font="22">atrioventricular pathways (Wolff-Parkinson-White syndrome) by radio-</text>
<text top="926" left="482" width="241" height="13" font="22">frequency current. N Engl J Med. 1991;324:1605–11.</text>
<text top="940" left="456" width="354" height="13" font="22"> 277.  Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation </text>
<text top="953" left="482" width="330" height="13" font="22">of accessory atrioventricular connections in 250 patients. Abbreviated </text>
<text top="967" left="482" width="329" height="13" font="22">therapeutic approach to Wolff-Parkinson-White syndrome. Circulation. </text>
<text top="981" left="482" width="82" height="13" font="22">1992;85:1337–46.</text>
<text top="994" left="456" width="351" height="13" font="22"> 278.  Dagres N, Clague JR, Kottkamp H, et al. Radiofrequency catheter abla-</text>
<text top="1008" left="482" width="330" height="13" font="22">tion of accessory pathways. Outcome and use of antiarrhythmic drugs </text>
<text top="1021" left="482" width="221" height="13" font="22">during follow-up. Eur Heart J. 1999;20:1826–32.</text>
<text top="1035" left="456" width="6" height="13" font="22"> </text>
<text top="1035" left="456" width="351" height="13" font="22">279. Schläpfer J, Fromer M. Late clinical outcome after successful ra-</text>
<text top="1049" left="482" width="332" height="13" font="22">diofrequency catheter ablation of accessory pathways. Eur Heart J. </text>
<text top="1062" left="482" width="71" height="13" font="22">2001;22:605–9.</text>
<text top="1076" left="456" width="355" height="13" font="22"> 280.  Belhassen B, Rogowski O, Glick A, et al. Radiofrequency ablation of </text>
<text top="1089" left="482" width="328" height="13" font="22">accessory pathways: a 14 year experience at the Tel Aviv Medical Center </text>
<text top="1103" left="482" width="221" height="13" font="22">in 508 patients. Isr Med Assoc J. 2007;9:265–70.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e564  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="71" width="351" height="13" font="22"> 281.  Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter abla-</text>
<text top="111" left="96" width="331" height="13" font="22">tion for tachyarrhythmias in children and adolescents. The Pediatric </text>
<text top="125" left="96" width="275" height="13" font="22">Electrophysiology Society. N Engl J Med. 1994;330:1481–7.</text>
<text top="138" left="71" width="7" height="13" font="22"> </text>
<text top="138" left="71" width="351" height="13" font="22">282. Kugler JD, Danford DA, Houston K, et al. Radiofrequency cath-</text>
<text top="152" left="96" width="326" height="13" font="22">eter ablation for paroxysmal supraventricular tachycardia in chil-</text>
<text top="166" left="96" width="332" height="13" font="22">dren and adolescents without structural heart disease. Pediatric EP </text>
<text top="179" left="96" width="332" height="13" font="22">Society, Radiofrequency Catheter Ablation Registry. Am J Cardiol. </text>
<text top="193" left="96" width="82" height="13" font="22">1997;80:1438–43.</text>
<text top="206" left="71" width="351" height="13" font="22"> 283. Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in pa-</text>
<text top="220" left="96" width="325" height="13" font="22">tients with the permanent form of junctional reciprocating tachycar-</text>
<text top="234" left="96" width="331" height="13" font="22">dia treated with radiofrequency ablation. Pacing Clin Electrophysiol. </text>
<text top="247" left="96" width="77" height="13" font="22">1998;21:2073–8.</text>
<text top="261" left="70" width="351" height="13" font="22"> 284.  Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocat-</text>
<text top="274" left="96" width="330" height="13" font="22">ing tachycardia in children: a multicenter experience. Heart Rhythm. </text>
<text top="288" left="96" width="82" height="13" font="22">2014;11:1426–32.</text>
<text top="302" left="70" width="355" height="13" font="22"> 285.  McClelland JH, Wang X, Beckman KJ, et al. Radiofrequency catheter </text>
<text top="315" left="96" width="328" height="13" font="22">ablation of right atriofascicular (Mahaim) accessory pathways guided by </text>
<text top="329" left="96" width="322" height="13" font="22">accessory pathway activation potentials. Circulation. 1994;89:2655–66.</text>
<text top="342" left="70" width="351" height="13" font="22"> 286. Mönnig G, Wasmer K, Milberg P, et al. Predictors of long-term suc-</text>
<text top="356" left="96" width="329" height="13" font="22">cess after catheter ablation of atriofascicular accessory pathways. Heart </text>
<text top="369" left="96" width="107" height="13" font="22">Rhythm. 2012;9:704–8.</text>
<text top="383" left="70" width="351" height="13" font="22"> 287.  Sakurai M, Yasuda H, Kato N, et al. Acute and chronic effects of vera-</text>
<text top="397" left="96" width="331" height="13" font="22">pamil in patients with paroxysmal supraventricular tachycardia. Am </text>
<text top="410" left="96" width="120" height="13" font="22">Heart J. 1983;105:619–28.</text>
<text top="424" left="70" width="351" height="13" font="22"> 288.  Hopson JR, Buxton AE, Rinkenberger RL, et al. Safety and utility of fle-</text>
<text top="437" left="96" width="325" height="13" font="22">cainide acetate in the routine care of patients with supraventricular tachyar-</text>
<text top="451" left="96" width="328" height="13" font="22">rhythmias: results of a multicenter trial. The Flecainide Supraventricular </text>
<text top="465" left="96" width="274" height="13" font="22">Tachycardia Study Group. Am J Cardiol. 1996;77:72A–82A.</text>
<text top="478" left="70" width="356" height="13" font="22"> 289. Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for </text>
<text top="492" left="96" width="325" height="13" font="22">the suppression by amiodarone of orthodromic supraventricular tachy-</text>
<text top="505" left="96" width="332" height="13" font="22">cardias complicating pre-excitation syndromes. J Am Coll Cardiol. </text>
<text top="519" left="96" width="82" height="13" font="22">1984;3:1298–307.</text>
<text top="533" left="70" width="351" height="13" font="22"> 290.  Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysi-</text>
<text top="546" left="96" width="325" height="13" font="22">ologic effects of amiodarone in patients with atrial fibrillation complicat-</text>
<text top="560" left="96" width="325" height="13" font="22">ing the Wolff-Parkinson-White syndrome. Am Heart J. 1988;115:102–7.</text>
<text top="573" left="70" width="354" height="13" font="22"> 291.  Gemma LW, Steinberg LA, Prystowsky EN, et al. Development of rapid </text>
<text top="587" left="96" width="326" height="13" font="22">preexcited ventricular response to atrial fibrillation in a patient with in-</text>
<text top="601" left="96" width="319" height="13" font="22">termittent preexcitation. J Cardiovasc Electrophysiol. 2013;24:347–50.</text>
<text top="614" left="70" width="351" height="13" font="22"> 292.  Bauernfeind RA, Wyndham CR, Dhingra RC, et al. Serial electrophysi-</text>
<text top="628" left="96" width="330" height="13" font="22">ologic testing of multiple drugs in patients with atrioventricular nodal </text>
<text top="641" left="96" width="288" height="13" font="22">reentrant paroxysmal tachycardia. Circulation. 1980;62:1341–9.</text>
<text top="655" left="70" width="351" height="13" font="22"> 293.  Hung JS, Kou HC, Wu D. Digoxin, propranolol, and atrioventricular re-</text>
<text top="668" left="96" width="329" height="13" font="22">entrant tachycardia in the Wolff-Parkinson-White syndrome. Ann Intern </text>
<text top="682" left="96" width="103" height="13" font="22">Med. 1982;97:175–82.</text>
<text top="696" left="70" width="357" height="13" font="22"> 294. Sharma AD, Yee R, Guiraudon G, et al. Sensitivity and specificity </text>
<text top="709" left="96" width="325" height="13" font="22">of invasive and noninvasive testing for risk of sudden death in Wolff-</text>
<text top="723" left="96" width="293" height="13" font="22">Parkinson-White syndrome. J Am Coll Cardiol. 1987;10:373–81.</text>
<text top="736" left="70" width="354" height="13" font="22"> 295.  Gaita F, Giustetto C, Riccardi R, et al. Stress and pharmacologic tests as </text>
<text top="750" left="96" width="330" height="13" font="22">methods to identify patients with Wolff-Parkinson-White syndrome at </text>
<text top="764" left="96" width="239" height="13" font="22">risk of sudden death. Am J Cardiol. 1989;64:487–90.</text>
<text top="777" left="70" width="354" height="13" font="22"> 296.  Spar DS, Silver ES, Hordof AJ, et al. Relation of the utility of exercise </text>
<text top="791" left="96" width="325" height="13" font="22">testing for risk assessment in pediatric patients with ventricular preexci-</text>
<text top="804" left="96" width="271" height="13" font="22">tation to pathway location. Am J Cardiol. 2012;109:1011–4.</text>
<text top="818" left="70" width="351" height="13" font="22"> 297.  Wackel P, Irving C, Webber S, et al. Risk stratification in Wolff-Parkinson-</text>
<text top="832" left="96" width="325" height="13" font="22">White syndrome: the correlation between noninvasive and invasive test-</text>
<text top="845" left="96" width="315" height="13" font="22">ing in pediatric patients. Pacing Clin Electrophysiol. 2012;35:1451–7.</text>
<text top="859" left="70" width="354" height="13" font="22"> 298.  Beckman KJ, Gallastegui JL, Bauman JL, et al. The predictive value of </text>
<text top="872" left="96" width="325" height="13" font="22">electrophysiologic studies in untreated patients with Wolff-Parkinson-</text>
<text top="886" left="96" width="239" height="13" font="22">White syndrome. J Am Coll Cardiol. 1990;15:640–7.</text>
<text top="900" left="70" width="351" height="13" font="22"> 299.  Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhyth-</text>
<text top="913" left="96" width="326" height="13" font="22">mias in initially symptomatic patients with Wolff-Parkinson-White syn-</text>
<text top="927" left="96" width="328" height="13" font="22">drome: results of a prospective long-term electrophysiological follow-up </text>
<text top="940" left="96" width="162" height="13" font="22">study. Circulation. 2012;125:661–8.</text>
<text top="954" left="70" width="351" height="13" font="22"> 300.  Rinne C, Klein GJ, Sharma AD, et al. Relation between clinical presenta-</text>
<text top="967" left="96" width="329" height="13" font="22">tion and induced arrhythmias in the Wolff-Parkinson-White syndrome. </text>
<text top="981" left="96" width="137" height="13" font="22">Am J Cardiol. 1987;60:576–9.</text>
<text top="995" left="70" width="355" height="13" font="22"> 301.  Brembilla-Perrot B, Holban I, Houriez P, et al. Influence of age on the </text>
<text top="1008" left="96" width="329" height="13" font="22">potential risk of sudden death in asymptomatic Wolff-Parkinson-White </text>
<text top="1022" left="96" width="253" height="13" font="22">syndrome. Pacing Clin Electrophysiol. 2001;24:1514–8.</text>
<text top="1035" left="70" width="351" height="13" font="22"> 302.  Pappone C, Santinelli V, Manguso F, et al. A randomized study of pro-</text>
<text top="1049" left="96" width="326" height="13" font="22">phylactic catheter ablation in asymptomatic patients with the Wolff-</text>
<text top="1063" left="96" width="285" height="13" font="22">Parkinson-White syndrome. N Engl J Med. 2003;349:1803–11.</text>
<text top="1076" left="70" width="351" height="13" font="22"> 303.  Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive elec-</text>
<text top="1090" left="96" width="325" height="13" font="22">trophysiologic testing to stratify the risk of arrhythmic events in as-</text>
<text top="1103" left="96" width="330" height="13" font="22">ymptomatic patients with Wolff-Parkinson-White pattern: results from </text>
<text top="97" left="483" width="332" height="13" font="22">a large prospective long-term follow-up study. J Am Coll Cardiol. </text>
<text top="111" left="483" width="77" height="13" font="22">2003;41:239–44.</text>
<text top="124" left="458" width="355" height="13" font="22"> 304.  Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety </text>
<text top="138" left="483" width="328" height="13" font="22">issues related to arrhythmias that may affect consciousness: implications </text>
<text top="152" left="483" width="332" height="13" font="22">for regulation and physician recommendations. A medical/scientific </text>
<text top="165" left="483" width="328" height="13" font="22">statement from the American Heart Association and the North American </text>
<text top="179" left="483" width="325" height="13" font="22">Society of Pacing and Electrophysiology. Circulation. 1996;94:1147–66.</text>
<text top="192" left="458" width="356" height="13" font="22"> 305. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the </text>
<text top="206" left="483" width="329" height="13" font="22">European Society of Cardiology Consensus Recommendations revisited </text>
<text top="220" left="483" width="325" height="13" font="22">a comparison of US and European criteria for eligibility and disqualifica-</text>
<text top="233" left="483" width="328" height="13" font="22">tion of competitive athletes with cardiovascular abnormalities. J Am Coll </text>
<text top="247" left="483" width="116" height="13" font="22">Cardiol. 2008;52:1990–6.</text>
<text top="260" left="458" width="351" height="13" font="22"> 306.  Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assess-</text>
<text top="274" left="483" width="325" height="13" font="22">ment of asymptomatic patients with the Wolff-Parkinson-White electro-</text>
<text top="288" left="483" width="258" height="13" font="22">cardiographic pattern. N Engl J Med. 1989;320:1229–33.</text>
<text top="301" left="458" width="354" height="13" font="22"> 307.  Leitch JW, Klein GJ, Yee R, et al. Prognostic value of electrophysiology </text>
<text top="315" left="483" width="330" height="13" font="22">testing in asymptomatic patients with Wolff-Parkinson-White pattern. </text>
<text top="328" left="483" width="138" height="13" font="22">Circulation. 1990;82:1718–23.</text>
<text top="342" left="458" width="10" height="13" font="22"> </text>
<text top="342" left="458" width="361" height="13" font="22">308. Milstein S, Sharma AD, Klein GJ. Electrophysiologic profile </text>
<text top="356" left="483" width="335" height="13" font="22">of asymptomatic Wolff-Parkinson-White pattern. Am J Cardiol. </text>
<text top="369" left="483" width="88" height="13" font="22">1986;57:1097–100.</text>
<text top="383" left="458" width="355" height="13" font="22"> 309.  Satoh M, Aizawa Y, Funazaki T, et al. Electrophysiologic evaluation of </text>
<text top="396" left="483" width="330" height="13" font="22">asymptomatic patients with the Wolff-Parkinson-White pattern. Pacing </text>
<text top="410" left="483" width="170" height="13" font="22">Clin Electrophysiol. 1989;12:413–20.</text>
<text top="423" left="458" width="162" height="13" font="22"> 310. Havránek S, Simek J, St’oví</text>
<text top="423" left="619" width="195" height="13" font="22">ček P, et al. Distribution of mean cycle </text>
<text top="437" left="483" width="330" height="13" font="22">length in cavo-tricuspid isthmus dependent atrial flutter. Physiol Res. </text>
<text top="451" left="483" width="71" height="13" font="22">2012;61:43–51.</text>
<text top="464" left="458" width="351" height="13" font="22"> 311. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atri-</text>
<text top="478" left="483" width="331" height="13" font="22">al flutter mechanisms and clinical implications. J Am Coll Cardiol. </text>
<text top="491" left="483" width="77" height="13" font="22">2008;51:779–86.</text>
<text top="505" left="458" width="351" height="13" font="22"> 312.  Ellis K, Wazni O, Marrouche N, et al. Incidence of atrial fibrillation post-</text>
<text top="519" left="483" width="326" height="13" font="22">cavotricuspid isthmus ablation in patients with typical atrial flutter: left-</text>
<text top="532" left="483" width="329" height="13" font="22">atrial size as an independent predictor of atrial fibrillation recurrence. J </text>
<text top="546" left="483" width="206" height="13" font="22">Cardiovasc Electrophysiol. 2007;18:799–802.</text>
<text top="559" left="458" width="356" height="13" font="22"> 313. Hsieh M-H, Tai C-T, Chiang C-E, et al. Recurrent atrial flutter and </text>
<text top="573" left="483" width="329" height="13" font="22">atrial fibrillation after catheter ablation of the cavotricuspid isthmus: a </text>
<text top="587" left="483" width="329" height="13" font="22">very long-term follow-up of 333 patients. J Interv Card Electrophysiol. </text>
<text top="600" left="483" width="71" height="13" font="22">2002;7:225–31.</text>
<text top="614" left="458" width="351" height="13" font="22"> 314.  Tai CT, Chen SA, Chiang CE, et al. Long-term outcome of radiofrequen-</text>
<text top="627" left="483" width="329" height="13" font="22">cy catheter ablation for typical atrial flutter: risk prediction of recurrent </text>
<text top="641" left="483" width="262" height="13" font="22">arrhythmias. J Cardiovasc Electrophysiol. 1998;9:115–21.</text>
<text top="654" left="458" width="351" height="13" font="22"> 315.  Paydak H, Kall JG, Burke MC, et al. Atrial fibrillation after radiofre-</text>
<text top="668" left="483" width="329" height="13" font="22">quency ablation of type I atrial flutter: time to onset, determinants, and </text>
<text top="682" left="483" width="204" height="13" font="22">clinical course. Circulation. 1998;98:315–22.</text>
<text top="695" left="458" width="355" height="13" font="22"> 316.  Chinitz JS, Gerstenfeld EP, Marchlinski FE, et al. Atrial fibrillation is </text>
<text top="709" left="483" width="326" height="13" font="22">common after ablation of isolated atrial flutter during long-term follow-</text>
<text top="722" left="483" width="163" height="13" font="22">up. Heart Rhythm. 2007;4:1029–33.</text>
<text top="736" left="458" width="355" height="13" font="22"> 317.  Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of </text>
<text top="750" left="483" width="328" height="13" font="22">atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. </text>
<text top="763" left="483" width="133" height="13" font="22">Eur Heart J. 2000;21:565–72.</text>
<text top="777" left="458" width="351" height="13" font="22"> 318.  Bertaglia E, Bonso A, Zoppo F, et al. Different clinical courses and pre-</text>
<text top="790" left="483" width="326" height="13" font="22">dictors of atrial fibrillation occurrence after transisthmic ablation in pa-</text>
<text top="804" left="483" width="328" height="13" font="22">tients with preablation lone atrial flutter, coexistent atrial fibrillation, and </text>
<text top="818" left="483" width="326" height="13" font="22">drug induced atrial flutter. Pacing Clin Electrophysiol. 2004;27:1507–12.</text>
<text top="831" left="458" width="351" height="13" font="22"> 319.  Satomi K, Chun KRJ, Tilz R, et al. Catheter ablation of multiple un-</text>
<text top="845" left="483" width="330" height="13" font="22">stable macroreentrant tachycardia within the right atrium free wall in </text>
<text top="858" left="483" width="328" height="13" font="22">patients without previous cardiac surgery. Circ Arrhythm Electrophysiol. </text>
<text top="872" left="483" width="65" height="13" font="22">2010;3:24–31.</text>
<text top="886" left="458" width="354" height="13" font="22"> 320.  Seiler J, Schmid DK, Irtel TA, et al. Dual-loop circuits in postoperative </text>
<text top="899" left="483" width="272" height="13" font="22">atrial macro re-entrant tachycardias. Heart. 2007;93:325–30.</text>
<text top="913" left="458" width="351" height="13" font="22"> 321.  Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycar-</text>
<text top="926" left="483" width="330" height="13" font="22">dia I: clinical features, diagnosis, mechanisms, and anatomic location. </text>
<text top="940" left="483" width="203" height="13" font="22">Pacing Clin Electrophysiol. 2006;29:643–52.</text>
<text top="953" left="457" width="351" height="13" font="22"> 322. Barbato G, Carinci V, Tomasi C, et al. Is electrocardiography a reli-</text>
<text top="967" left="483" width="329" height="13" font="22">able tool for identifying patients with isthmus-dependent atrial flutter? </text>
<text top="981" left="483" width="125" height="13" font="22">Europace. 2009;11:1071–6.</text>
<text top="994" left="457" width="355" height="13" font="22"> 323.  Akar JG, Al-Chekakie MO, Hai A, et al. Surface electrocardiographic </text>
<text top="1008" left="483" width="326" height="13" font="22">patterns and electrophysiologic characteristics of atrial flutter fol-</text>
<text top="1021" left="483" width="333" height="13" font="22">lowing modified radiofrequency MAZE procedures. J Cardiovasc </text>
<text top="1035" left="483" width="148" height="13" font="22">Electrophysiol. 2007;18:349–55.</text>
<text top="1049" left="457" width="354" height="13" font="22"> 324.  Chugh A, Latchamsetty R, Oral H, et al. Characteristics of cavotricuspid </text>
<text top="1062" left="483" width="325" height="13" font="22">isthmus-dependent atrial flutter after left atrial ablation of atrial fibrilla-</text>
<text top="1076" left="483" width="162" height="13" font="22">tion. Circulation. 2006;113:609–15.</text>
<text top="1089" left="457" width="356" height="13" font="22"> 325. Shah D. ECG manifestations of left atrial flutter. Curr Opin Cardiol. </text>
<text top="1103" left="483" width="71" height="13" font="22">2009;24:35–41.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e565</i></b></text>
<text top="98" left="69" width="351" height="13" font="22"> 326. Nakagawa H, Jackman WM. Use of a 3-dimensional electroanatomi-</text>
<text top="111" left="95" width="329" height="13" font="22">cal mapping system for catheter ablation of macroreentrant right atrial </text>
<text top="125" left="95" width="325" height="13" font="22">tachycardia following atriotomy. J Electrocardiol. 1999;32 Suppl:16–21.</text>
<text top="138" left="69" width="351" height="13" font="22"> 327.  Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial maco-re-entry cir-</text>
<text top="152" left="95" width="326" height="13" font="22">cuits in adults with repaired congenital heart disease: entrainment map-</text>
<text top="166" left="95" width="329" height="13" font="22">ping combined with three-dimensional electroanatomic mapping. J Am </text>
<text top="179" left="95" width="144" height="13" font="22">Coll Cardiol. 2001;37:1665–76.</text>
<text top="193" left="69" width="355" height="13" font="22"> 328.  Magnin-Poull I, De Chillou C, Miljoen H, et al. Mechanisms of right </text>
<text top="206" left="95" width="325" height="13" font="22">atrial tachycardia occurring late after surgical closure of atrial septal de-</text>
<text top="220" left="95" width="229" height="13" font="22">fects. J Cardiovasc Electrophysiol. 2005;16:681–7.</text>
<text top="234" left="69" width="354" height="13" font="22"> 329.  Kanagasundram AN, Baduashvili A, Liu CF, et al. A novel criterion for </text>
<text top="247" left="95" width="329" height="13" font="22">conduction block after catheter ablation of right atrial tachycardia after </text>
<text top="261" left="95" width="300" height="13" font="22">mitral valve surgery. Circ Arrhythm Electrophysiol. 2013;6:39–47.</text>
<text top="274" left="69" width="355" height="13" font="22"> 330.  Teh AW, Medi C, Lee G, et al. Long-term outcome following ablation </text>
<text top="288" left="95" width="328" height="13" font="22">of atrial flutter occurring late after atrial septal defect repair. Pacing Clin </text>
<text top="302" left="95" width="142" height="13" font="22">Electrophysiol. 2011;34:431–5.</text>
<text top="315" left="69" width="354" height="13" font="22"> 331.  McElderry HT, McGiffin DC, Plumb VJ, et al. Proarrhythmic aspects of </text>
<text top="329" left="95" width="330" height="13" font="22">atrial fibrillation surgery: mechanisms of postoperative macroreentrant </text>
<text top="342" left="95" width="200" height="13" font="22">tachycardias. Circulation. 2008;117:155–62.</text>
<text top="356" left="69" width="351" height="13" font="22"> 332. Wazni OM, Saliba W, Fahmy T, et al. Atrial arrhythmias after sur-</text>
<text top="369" left="95" width="332" height="13" font="22">gical maze: findings during catheter ablation. J Am Coll Cardiol. </text>
<text top="383" left="95" width="77" height="13" font="22">2006;48:1405–9.</text>
<text top="397" left="69" width="354" height="13" font="22"> 333.  Gerstenfeld EP, Callans DJ, Dixit S, et al. Mechanisms of organized left </text>
<text top="410" left="95" width="328" height="13" font="22">atrial tachycardias occurring after pulmonary vein isolation. Circulation. </text>
<text top="424" left="95" width="82" height="13" font="22">2004;110:1351–7.</text>
<text top="437" left="69" width="354" height="13" font="22"> 334.  Chugh A, Oral H, Lemola K, et al. Prevalence, mechanisms, and clinical </text>
<text top="451" left="95" width="330" height="13" font="22">significance of macroreentrant atrial tachycardia during and following </text>
<text top="465" left="95" width="318" height="13" font="22">left atrial ablation for atrial fibrillation. Heart Rhythm. 2005;2:464–71.</text>
<text top="478" left="69" width="351" height="13" font="22"> 335.  Veenhuyzen GD, Knecht S, O’Neill MD, et al. Atrial tachycardias en-</text>
<text top="492" left="95" width="330" height="13" font="22">countered during and after catheter ablation for atrial fibrillation: part </text>
<text top="505" left="95" width="331" height="13" font="22">I: classification, incidence, management. Pacing Clin Electrophysiol. </text>
<text top="519" left="95" width="71" height="13" font="22">2009;32:393–8.</text>
<text top="533" left="69" width="7" height="13" font="22"> </text>
<text top="533" left="69" width="358" height="13" font="22">336. Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial </text>
<text top="546" left="95" width="325" height="13" font="22">tachyarrhythmias after catheter ablation of atrial fibrillation: a random-</text>
<text top="560" left="95" width="332" height="13" font="22">ized comparison between 2 current ablation strategies. Circulation. </text>
<text top="573" left="95" width="88" height="13" font="22">2005;111:2875–80.</text>
<text top="587" left="69" width="353" height="13" font="22"> 337.  Sawhney N, Anousheh R, Chen W, et al. Circumferential pulmonary vein </text>
<text top="601" left="95" width="329" height="13" font="22">ablation with additional linear ablation results in an increased incidence </text>
<text top="614" left="95" width="329" height="13" font="22">of left atrial flutter compared with segmental pulmonary vein isolation </text>
<text top="628" left="95" width="329" height="13" font="22">as an initial approach to ablation of paroxysmal atrial fibrillation. Circ </text>
<text top="641" left="95" width="184" height="13" font="22">Arrhythm Electrophysiol. 2010;3:243–8.</text>
<text top="655" left="69" width="356" height="13" font="22"> 338.  Neumann T, Vogt J, Schumacher B, et al. Circumferential pulmonary </text>
<text top="668" left="95" width="329" height="13" font="22">vein isolation with the cryoballoon technique results from a prospective </text>
<text top="682" left="95" width="228" height="13" font="22">3-center study. J Am Coll Cardiol. 2008;52:273–8.</text>
<text top="696" left="69" width="355" height="13" font="22"> 339.  Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert </text>
<text top="709" left="95" width="328" height="13" font="22">consensus statement on catheter and surgical ablation of atrial fibrillation: </text>
<text top="723" left="95" width="331" height="13" font="22">recommendations for patient selection, procedural techniques, patient </text>
<text top="736" left="95" width="326" height="13" font="22">management and follow-up, definitions, endpoints, and research trial de-</text>
<text top="750" left="95" width="328" height="13" font="22">sign: a report of the Heart Rhythm Society (HRS) Task Force on Catheter </text>
<text top="764" left="95" width="328" height="13" font="22">and Surgical Ablation of Atrial Fibrillation. Developed in partnership with </text>
<text top="777" left="95" width="329" height="13" font="22">the European Heart Rhythm Association (EHRA), a registered branch of </text>
<text top="791" left="95" width="330" height="13" font="22">the European Society of Cardiology (ESC) and the European Cardiac </text>
<text top="804" left="95" width="331" height="13" font="22">Arrhythmia Society (ECAS); and in collaboration with the American </text>
<text top="818" left="95" width="329" height="13" font="22">College of Cardiology (ACC), American Heart Association (AHA), the </text>
<text top="832" left="95" width="328" height="13" font="22">Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic </text>
<text top="845" left="95" width="234" height="13" font="22">Surgeons (STS). Heart Rhythm. 2012;9:632–96.e21.</text>
<text top="859" left="69" width="354" height="13" font="22"> 340.  Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous </text>
<text top="872" left="95" width="330" height="13" font="22">ibutilide for rapid termination of atrial fibrillation and atrial flutter: a </text>
<text top="886" left="95" width="255" height="13" font="22">dose-response study. J Am Coll Cardiol. 1996;28:130–6.</text>
<text top="900" left="69" width="351" height="13" font="22"> 341.  Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiar-</text>
<text top="913" left="95" width="329" height="13" font="22">rhythmic drugs for acute conversion of paroxysmal atrial fibrillation or </text>
<text top="927" left="95" width="270" height="13" font="22">flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722–7.</text>
<text top="940" left="69" width="355" height="13" font="22"> 342.  Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of </text>
<text top="954" left="95" width="326" height="13" font="22">repeated intravenous doses of ibutilide for rapid conversion of atrial flut-</text>
<text top="967" left="95" width="328" height="13" font="22">ter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. </text>
<text top="981" left="95" width="82" height="13" font="22">1996;94:1613–21.</text>
<text top="995" left="69" width="351" height="13" font="22"> 343.  Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibril-</text>
<text top="1008" left="95" width="328" height="13" font="22">lation and flutter: the role of flecainide, propafenone, and verapamil. Am </text>
<text top="1022" left="95" width="134" height="13" font="22">J Cardiol. 1992;70:56A–60A.</text>
<text top="1035" left="69" width="355" height="13" font="22"> 344.  Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new </text>
<text top="1049" left="95" width="331" height="13" font="22">class III agent) over DL-sotalol in converting atrial flutter and atrial </text>
<text top="1063" left="95" width="333" height="13" font="22">fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. </text>
<text top="1076" left="95" width="77" height="13" font="22">1998;79:568–75.</text>
<text top="1090" left="69" width="7" height="13" font="22"> </text>
<text top="1090" left="69" width="351" height="13" font="22">345. Volgman AS, Carberry PA, Stambler B, et al. Conversion effica-</text>
<text top="1103" left="95" width="333" height="13" font="22">cy and safety of intravenous ibutilide compared with intravenous </text>
<text top="97" left="482" width="331" height="13" font="22">procainamide in patients with atrial flutter or fibrillation. J Am Coll </text>
<text top="111" left="482" width="116" height="13" font="22">Cardiol. 1998;31:1414–9.</text>
<text top="124" left="456" width="354" height="13" font="22"> 346.  Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide </text>
<text top="138" left="482" width="329" height="13" font="22">in converting to and maintaining sinus rhythm in patients with chronic </text>
<text top="152" left="482" width="331" height="13" font="22">atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation </text>
<text top="165" left="482" width="331" height="13" font="22">Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. </text>
<text top="179" left="482" width="88" height="13" font="22">2000;102:2385–90.</text>
<text top="192" left="456" width="351" height="13" font="22"> 347.  Blackshear JL, Stambler BS, Strauss WE, et al. Control of heart rate dur-</text>
<text top="206" left="482" width="329" height="13" font="22">ing transition from intravenous to oral diltiazem in atrial fibrillation or </text>
<text top="220" left="482" width="180" height="13" font="22">flutter. Am J Cardiol. 1996;78:1246–50.</text>
<text top="233" left="456" width="351" height="13" font="22"> 348.  Singh BN, Hecht HS, Nademanee K, et al. Electrophysiologic and hemo-</text>
<text top="247" left="482" width="329" height="13" font="22">dynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. </text>
<text top="260" left="482" width="77" height="13" font="22">1982;25:103–32.</text>
<text top="274" left="456" width="353" height="13" font="22"> 349.  Akhtar M, Tchou P, Jazayeri M. Use of calcium channel entry blockers in </text>
<text top="288" left="482" width="302" height="13" font="22">the treatment of cardiac arrhythmias. Circulation. 1989;80:IV31–9.</text>
<text top="301" left="456" width="351" height="13" font="22"> 350.  Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltia-</text>
<text top="315" left="482" width="328" height="13" font="22">zem for rate control in critically ill patients with atrial tachyarrhythmias. </text>
<text top="328" left="482" width="153" height="13" font="22">Crit Care Med. 2001;29:1149–53.</text>
<text top="342" left="456" width="354" height="13" font="22"> 351.  Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of </text>
<text top="356" left="482" width="329" height="13" font="22">continuous intravenous diltiazem infusion for 24-hour heart rate control </text>
<text top="369" left="482" width="329" height="13" font="22">during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll </text>
<text top="383" left="482" width="110" height="13" font="22">Cardiol. 1991;18:891–7.</text>
<text top="396" left="456" width="351" height="13" font="22"> 352.  Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of in-</text>
<text top="410" left="482" width="330" height="13" font="22">travenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. </text>
<text top="423" left="482" width="65" height="13" font="22">1995;75:45–9.</text>
<text top="437" left="456" width="354" height="13" font="22"> 353.  Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil </text>
<text top="451" left="482" width="329" height="13" font="22">in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. </text>
<text top="464" left="482" width="71" height="13" font="22">1989;63:925–9.</text>
<text top="478" left="456" width="351" height="13" font="22"> 354.  Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intra-</text>
<text top="491" left="482" width="331" height="13" font="22">venous diltiazem for treatment of atrial fibrillation and atrial flutter. </text>
<text top="505" left="482" width="331" height="13" font="22">The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. </text>
<text top="519" left="482" width="82" height="13" font="22">1989;63:1046–51.</text>
<text top="532" left="456" width="354" height="13" font="22"> 355.  Basta M, Klein GJ, Yee R, et al. Current role of pharmacologic therapy </text>
<text top="546" left="482" width="329" height="13" font="22">for patients with paroxysmal supraventricular tachycardia. Cardiol Clin. </text>
<text top="559" left="482" width="77" height="13" font="22">1997;15:587–97.</text>
<text top="573" left="456" width="351" height="13" font="22"> 356.  Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, out-</text>
<text top="587" left="482" width="329" height="13" font="22">come and efficiency in direct current cardioversion of atrial fibrillation </text>
<text top="600" left="482" width="227" height="13" font="22">and flutter. J Am Coll Cardiol. 2001;38:1498–504.</text>
<text top="614" left="456" width="8" height="13" font="22"> </text>
<text top="614" left="456" width="351" height="13" font="22">357. Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardiover-</text>
<text top="627" left="482" width="330" height="13" font="22">sion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J. </text>
<text top="641" left="482" width="79" height="13" font="22">2003;145:233–8.</text>
<text top="654" left="456" width="351" height="13" font="22"> 358.  Pizzale S, Lemery R, Green MS, et al. Frequency and predictors of tachy-</text>
<text top="668" left="482" width="329" height="13" font="22">cardia-induced cardiomyopathy in patients with persistent atrial flutter. </text>
<text top="682" left="482" width="144" height="13" font="22">Can J Cardiol. 2009;25:469–72.</text>
<text top="695" left="456" width="354" height="13" font="22"> 359.  Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful </text>
<text top="709" left="482" width="325" height="13" font="22">cardioversion and maintenance of sinus rhythm from direct-current elec-</text>
<text top="722" left="482" width="328" height="13" font="22">trical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. </text>
<text top="736" left="482" width="65" height="13" font="22">1991;68:41–6.</text>
<text top="750" left="456" width="353" height="13" font="22"> 360.  Boriani G, Tukkie R, Manolis AS, et al. Atrial antitachycardia pacing and </text>
<text top="763" left="482" width="329" height="13" font="22">managed ventricular pacing in bradycardia patients with paroxysmal or </text>
<text top="777" left="482" width="326" height="13" font="22">persistent atrial tachyarrhythmias: the MINERVA randomized multicen-</text>
<text top="790" left="482" width="237" height="13" font="22">tre international trial. Eur Heart J. 2014;35:2352–62.</text>
<text top="804" left="456" width="351" height="13" font="22"> 361.  Mitchell ARJ, Spurrell PAR, Cheatle L, et al. Effect of atrial antitachy-</text>
<text top="818" left="482" width="326" height="13" font="22">cardia pacing treatments in patients with an atrial defibrillator: ran-</text>
<text top="831" left="482" width="331" height="13" font="22">domised study comparing subthreshold and nominal pacing outputs. </text>
<text top="845" left="482" width="102" height="13" font="22">Heart. 2002;87:433–7.</text>
<text top="858" left="456" width="351" height="13" font="22"> 362.  Gillis AM, Unterberg-Buchwald C, Schmidinger H, et al. Safety and ef-</text>
<text top="872" left="482" width="329" height="13" font="22">ficacy of advanced atrial pacing therapies for atrial tachyarrhythmias in </text>
<text top="886" left="482" width="329" height="13" font="22">patients with a new implantable dual chamber cardioverter-defibrillator. </text>
<text top="899" left="482" width="164" height="13" font="22">J Am Coll Cardiol. 2002;40:1653–9.</text>
<text top="913" left="456" width="355" height="13" font="22"> 363.  Waldo AL, MacLean WA, Cooper TB, et al. Use of temporarily placed </text>
<text top="926" left="482" width="325" height="13" font="22">epicardial atrial wire electrodes for the diagnosis and treatment of cardi-</text>
<text top="940" left="482" width="329" height="13" font="22">ac arrhythmias following open-heart surgery. J Thorac Cardiovasc Surg. </text>
<text top="953" left="482" width="71" height="13" font="22">1978;76:500–5.</text>
<text top="967" left="456" width="355" height="13" font="22"> 364.  Peters RW, Shorofsky SR, Pelini M, et al. Overdrive atrial pacing for </text>
<text top="981" left="482" width="325" height="13" font="22">conversion of atrial flutter: comparison of postoperative with nonpostop-</text>
<text top="994" left="482" width="207" height="13" font="22">erative patients. Am Heart J. 1999;137:100–3.</text>
<text top="1008" left="456" width="351" height="13" font="22"> 365.  Ghali WA, Wasil BI, Brant R, et al. Atrial flutter and the risk of throm-</text>
<text top="1021" left="482" width="333" height="13" font="22">boembolism: a systematic review and meta-analysis. Am J Med. </text>
<text top="1035" left="482" width="77" height="13" font="22">2005;118:101–7.</text>
<text top="1049" left="456" width="354" height="13" font="22"> 366.  Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy </text>
<text top="1062" left="482" width="328" height="13" font="22">to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann </text>
<text top="1076" left="482" width="138" height="13" font="22">Intern Med. 2007;146:857–67.</text>
<text top="1089" left="456" width="351" height="13" font="22"> 367.  Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complica-</text>
<text top="1103" left="482" width="330" height="13" font="22">tions of direct current cardioversion of atrial arrhythmias: association </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e566  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="96" width="329" height="13" font="22">with low intensity of anticoagulation at the time of cardioversion. J Am </text>
<text top="111" left="96" width="138" height="13" font="22">Coll Cardiol. 2002;40:926–33.</text>
<text top="125" left="70" width="356" height="13" font="22"> 368.  Schmidt H, von der Recke G, Illien S, et al. Prevalence of left atrial </text>
<text top="138" left="96" width="330" height="13" font="22">chamber and appendage thrombi in patients with atrial flutter and its </text>
<text top="152" left="96" width="260" height="13" font="22">clinical significance. J Am Coll Cardiol. 2001;38:778–84.</text>
<text top="166" left="70" width="354" height="13" font="22"> 369.  Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: </text>
<text top="179" left="96" width="293" height="13" font="22">is the risk underestimated? J Am Coll Cardiol. 1997;30:1506–11.</text>
<text top="193" left="70" width="355" height="13" font="22"> 370.  Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for </text>
<text top="206" left="96" width="325" height="13" font="22">acute heart rate control in the critically ill patient with atrial tachyar-</text>
<text top="220" left="96" width="187" height="13" font="22">rhythmias. Am J Cardiol. 1998;81:594–8.</text>
<text top="234" left="70" width="356" height="13" font="22"> 371. Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of </text>
<text top="247" left="96" width="331" height="13" font="22">digoxin treatment for atrial fibrillation and flutter. Am J Cardiol. </text>
<text top="261" left="96" width="80" height="13" font="22">1993;72:567–73.</text>
<text top="274" left="70" width="351" height="13" font="22"> 372.  Natale A, Newby KH, Pisanó E, et al. Prospective randomized compari-</text>
<text top="288" left="96" width="328" height="13" font="22">son of antiarrhythmic therapy versus first-line radiofrequency ablation in </text>
<text top="302" left="96" width="294" height="13" font="22">patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898–904.</text>
<text top="315" left="70" width="355" height="13" font="22"> 373.  Bastani H, Drca N, Insulander P, et al. Cryothermal vs. radiofrequency </text>
<text top="329" left="96" width="330" height="13" font="22">ablation as atrial flutter therapy: a randomized comparison. Europace. </text>
<text top="342" left="96" width="71" height="13" font="22">2013;15:420–8.</text>
<text top="356" left="70" width="351" height="13" font="22"> 374. Poty H, Saoudi N, Nair M, et al. Radiofrequency catheter abla-</text>
<text top="369" left="96" width="325" height="13" font="22">tion of atrial flutter. Further insights into the various types of isth-</text>
<text top="383" left="96" width="329" height="13" font="22">mus block: application to ablation during sinus rhythm. Circulation. </text>
<text top="397" left="96" width="85" height="13" font="22">1996;94:3204–13.</text>
<text top="410" left="70" width="355" height="13" font="22"> 375.  Schwartzman D, Callans DJ, Gottlieb CD, et al. Conduction block in </text>
<text top="424" left="96" width="328" height="13" font="22">the inferior vena caval-tricuspid valve isthmus: association with outcome </text>
<text top="437" left="96" width="330" height="13" font="22">of radiofrequency ablation of type I atrial flutter. J Am Coll Cardiol. </text>
<text top="451" left="96" width="82" height="13" font="22">1996;28:1519–31.</text>
<text top="465" left="70" width="351" height="13" font="22"> 376.  Da Costa A, Thévenin J, Roche F, et al. Results from the Loire-Ardèche-</text>
<text top="478" left="96" width="328" height="13" font="22">Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric </text>
<text top="492" left="96" width="327" height="13" font="22">prospective randomized study comparing amiodarone and radiofrequency </text>
<text top="505" left="96" width="329" height="13" font="22">ablation after the first episode of symptomatic atrial flutter. Circulation. </text>
<text top="519" left="96" width="88" height="13" font="22">2006;114:1676–81.</text>
<text top="533" left="70" width="355" height="13" font="22"> 377.  Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the </text>
<text top="546" left="96" width="325" height="13" font="22">treatment of atrial fibrillation-flutter in patients with reduced left ven-</text>
<text top="560" left="96" width="328" height="13" font="22">tricular function: a Danish Investigations of Arrhythmia and Mortality on </text>
<text top="573" left="96" width="291" height="13" font="22">Dofetilide (DIAMOND) substudy. Circulation. 2001;104:292–6.</text>
<text top="587" left="70" width="354" height="13" font="22"> 378.  Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with </text>
<text top="601" left="96" width="330" height="13" font="22">oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation </text>
<text top="614" left="96" width="330" height="13" font="22">and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. </text>
<text top="628" left="96" width="137" height="13" font="22">Am J Cardiol. 1999;84:270–7.</text>
<text top="641" left="70" width="355" height="13" font="22"> 379.  Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic </text>
<text top="655" left="96" width="328" height="13" font="22">and ablative therapy: a novel and effective approach for the management </text>
<text top="668" left="96" width="288" height="13" font="22">of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:462–9.</text>
<text top="682" left="70" width="355" height="13" font="22"> 380.  Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of </text>
<text top="696" left="96" width="329" height="13" font="22">atrial flutter due to administration of class IC antiarrhythmic drugs for </text>
<text top="709" left="96" width="216" height="13" font="22">atrial fibrillation. Am J Cardiol. 1999;83:710–3.</text>
<text top="723" left="70" width="355" height="13" font="22"> 381.  Mohanty S, Mohanty P, Di Biase L, et al. Results from a single-blind, </text>
<text top="736" left="96" width="328" height="13" font="22">randomized study comparing the impact of different ablation approaches </text>
<text top="750" left="96" width="325" height="13" font="22">on long-term procedure outcome in coexistent atrial fibrillation and flut-</text>
<text top="764" left="96" width="229" height="13" font="22">ter (APPROVAL). Circulation. 2013;127:1853–60.</text>
<text top="777" left="70" width="351" height="13" font="22"> 382.  Wazni O, Marrouche NF, Martin DO, et al. Randomized study compar-</text>
<text top="791" left="96" width="326" height="13" font="22">ing combined pulmonary vein-left atrial junction disconnection and ca-</text>
<text top="804" left="96" width="330" height="13" font="22">votricuspid isthmus ablation versus pulmonary vein-left atrial junction </text>
<text top="818" left="96" width="329" height="13" font="22">disconnection alone in patients presenting with typical atrial flutter and </text>
<text top="832" left="96" width="223" height="13" font="22">atrial fibrillation. Circulation. 2003;108:2479–83.</text>
<text top="845" left="70" width="355" height="13" font="22"> 383.  Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide </text>
<text top="859" left="96" width="325" height="13" font="22">versus propafenone in hospital out-patients with symptomatic paroxys-</text>
<text top="872" left="96" width="328" height="13" font="22">mal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am </text>
<text top="886" left="96" width="134" height="13" font="22">J Cardiol. 1996;77:66A–71A.</text>
<text top="900" left="70" width="355" height="13" font="22"> 384.  Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Efficacy and safety of </text>
<text top="913" left="96" width="330" height="13" font="22">flecainide acetate in the maintenance of sinus rhythm after electrical </text>
<text top="927" left="96" width="329" height="13" font="22">cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. </text>
<text top="940" left="96" width="82" height="13" font="22">1989;64:1317–21.</text>
<text top="954" left="70" width="355" height="13" font="22"> 385.  Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of </text>
<text top="967" left="96" width="330" height="13" font="22">paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide </text>
<text top="981" left="96" width="255" height="13" font="22">Multicenter Study Group. Am J Cardiol. 1991;67:713–7.</text>
<text top="995" left="70" width="351" height="13" font="22"> 386.  Crijns HJ, Van Gelder IC, Kingma JH, et al. Atrial flutter can be termi-</text>
<text top="1008" left="96" width="329" height="13" font="22">nated by a class III antiarrhythmic drug but not by a class IC drug. Eur </text>
<text top="1022" left="96" width="114" height="13" font="22">Heart J. 1994;15:1403–8.</text>
<text top="1035" left="70" width="354" height="13" font="22"> 387.  Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset </text>
<text top="1049" left="96" width="329" height="13" font="22">atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. </text>
<text top="1063" left="96" width="88" height="13" font="22">2004;351:2384–91.</text>
<text top="1076" left="70" width="351" height="13" font="22"> 388.  Ruder MA, Davis JC, Eldar M, et al. Clinical and electrophysiologic char-</text>
<text top="1090" left="96" width="330" height="13" font="22">acterization of automatic junctional tachycardia in adults. Circulation. </text>
<text top="1103" left="96" width="71" height="13" font="22">1986;73:930–7.</text>
<text top="97" left="457" width="351" height="13" font="22"> 389.  Villain E, Vetter VL, Garcia JM, et al. Evolving concepts in the manage-</text>
<text top="111" left="483" width="329" height="13" font="22">ment of congenital junctional ectopic tachycardia. A multicenter study. </text>
<text top="124" left="483" width="133" height="13" font="22">Circulation. 1990;81:1544–9.</text>
<text top="138" left="457" width="354" height="13" font="22"> 390.  Raja P, Hawker RE, Chaikitpinyo A, et al. Amiodarone management of </text>
<text top="152" left="483" width="328" height="13" font="22">junctional ectopic tachycardia after cardiac surgery in children. Br Heart </text>
<text top="165" left="483" width="81" height="13" font="22">J. 1994;72:261–5.</text>
<text top="179" left="457" width="355" height="13" font="22"> 391.  Wyndham CR, Dhingra RC, Smith T, et al. Concealed nonparoxysmal </text>
<text top="192" left="483" width="238" height="13" font="22">junctional tachycardia. Circulation. 1979;60:707–10.</text>
<text top="206" left="457" width="351" height="13" font="22"> 392.  Konecke LL, Knoebel SB. Nonparoxysmal junctional tachycardia com-</text>
<text top="220" left="483" width="304" height="13" font="22">plicating acute myocardial infarction. Circulation. 1972;45:367–74.</text>
<text top="233" left="457" width="354" height="13" font="22"> 393.  Fishenfeld J, Desser KB, Benchimol A. Non-paroxysmal A-V junctional </text>
<text top="247" left="483" width="330" height="13" font="22">tachycardia associated with acute myocardial infarction. Am Heart J. </text>
<text top="260" left="483" width="71" height="13" font="22">1973;86:754–8.</text>
<text top="274" left="457" width="351" height="13" font="22"> 394. Breslow MJ, Evers AS, Lebowitz P. Successful treatment of acceler-</text>
<text top="288" left="483" width="330" height="13" font="22">ated junctional rhythm with propranolol: possible role of sympathetic </text>
<text top="301" left="483" width="330" height="13" font="22">stimulation in the genesis of this rhythm disturbance. Anesthesiology. </text>
<text top="315" left="483" width="71" height="13" font="22">1985;62:180–2.</text>
<text top="328" left="457" width="355" height="13" font="22"> 395.  Lee KL, Chun HM, Liem LB, et al. Effect of adenosine and verapamil </text>
<text top="342" left="483" width="328" height="13" font="22">in catecholamine-induced accelerated atrioventricular junctional rhythm: </text>
<text top="356" left="483" width="331" height="13" font="22">insights into the underlying mechanism. Pacing Clin Electrophysiol. </text>
<text top="369" left="483" width="77" height="13" font="22">1999;22:866–70.</text>
<text top="383" left="457" width="354" height="13" font="22"> 396.  Padanilam BJ, Manfredi JA, Steinberg LA, et al. Differentiating junctional </text>
<text top="396" left="483" width="326" height="13" font="22">tachycardia and atrioventricular node re-entry tachycardia based on re-</text>
<text top="410" left="483" width="318" height="13" font="22">sponse to atrial extrastimulus pacing. J Am Coll Cardiol. 2008;52:1711–7.</text>
<text top="423" left="457" width="351" height="13" font="22"> 397.  Kumagai K, Yamato H, Yamanouchi Y, et al. Automatic junctional tachy-</text>
<text top="437" left="483" width="216" height="13" font="22">cardia in an adult. Clin Cardiol. 1990;13:813–6.</text>
<text top="451" left="457" width="354" height="13" font="22"> 398.  Cook JR, Steinberg JS. An incessant form of junctional ectopic tachycardia </text>
<text top="464" left="483" width="322" height="13" font="22">in an adult responsive to a class 1C agent. Am Heart J. 1991;122:1487–9.</text>
<text top="478" left="457" width="356" height="13" font="22"> 399. Kuck KH, Kunze KP, Schlüter M, et al. Encainide versus flecainide </text>
<text top="491" left="483" width="331" height="13" font="22">for chronic atrial and junctional ectopic tachycardia. Am J Cardiol. </text>
<text top="505" left="483" width="85" height="13" font="22">1988;62:37L–44L.</text>
<text top="519" left="457" width="351" height="13" font="22"> 400. Paul T, Reimer A, Janousek J, et al. Efficacy and safety of propafe-</text>
<text top="532" left="483" width="330" height="13" font="22">none in congenital junctional ectopic tachycardia. J Am Coll Cardiol. </text>
<text top="546" left="483" width="71" height="13" font="22">1992;20:911–4.</text>
<text top="559" left="457" width="355" height="13" font="22"> 401.  Sarubbi B, Musto B, Ducceschi V, et al. Congenital junctional ectopic </text>
<text top="573" left="483" width="331" height="13" font="22">tachycardia in children and adolescents: a 20 year experience based </text>
<text top="587" left="483" width="136" height="13" font="22">study. Heart. 2002;88:188–90.</text>
<text top="600" left="457" width="351" height="13" font="22"> 402.  Mamchur SE, Kurilin MY. High-amplitude pace mapping increases safe-</text>
<text top="614" left="483" width="329" height="13" font="22">ty of radiofrequency catheter ablation of parahisian ectopic foci. Pacing </text>
<text top="627" left="483" width="176" height="13" font="22">Clin Electrophysiol. 2012;35:1458–63.</text>
<text top="641" left="457" width="351" height="13" font="22"> 403.  Scheinman MM, Gonzalez RP, Cooper MW, et al. Clinical and electro-</text>
<text top="654" left="483" width="330" height="13" font="22">physiologic features and role of catheter ablation techniques in adult </text>
<text top="668" left="483" width="331" height="13" font="22">patients with automatic atrioventricular junctional tachycardia. Am J </text>
<text top="682" left="483" width="116" height="13" font="22">Cardiol. 1994;74:565–72.</text>
<text top="695" left="457" width="354" height="13" font="22"> 404.  Fan R, Tardos JG, Almasry I, et al. Novel use of atrial overdrive pacing </text>
<text top="709" left="483" width="328" height="13" font="22">to rapidly differentiate junctional tachycardia from atrioventricular nodal </text>
<text top="722" left="483" width="235" height="13" font="22">reentrant tachycardia. Heart Rhythm. 2011;8:840–4.</text>
<text top="736" left="457" width="351" height="13" font="22"> 405.  Srivathsan K, Gami AS, Barrett R, et al. Differentiating atrioventricu-</text>
<text top="750" left="483" width="331" height="13" font="22">lar nodal reentrant tachycardia from junctional tachycardia: novel </text>
<text top="763" left="483" width="330" height="13" font="22">application of the delta H-A interval. J Cardiovasc Electrophysiol. </text>
<text top="777" left="483" width="62" height="13" font="22">2008;19:1–6.</text>
<text top="790" left="457" width="351" height="13" font="22"> 406. Field ME, Miyazaki H, Epstein LM, et al. Narrow complex tachy-</text>
<text top="804" left="483" width="331" height="13" font="22">cardia after slow pathway ablation: continue ablating? J Cardiovasc </text>
<text top="818" left="483" width="142" height="13" font="22">Electrophysiol. 2006;17:557–9.</text>
<text top="831" left="457" width="354" height="13" font="22"> 407.  Garson A Jr., Gillette PC. Electrophysiologic studies of supraventricular </text>
<text top="845" left="483" width="330" height="13" font="22">tachycardia in children. I. Clinical-electrophysiologic correlations. Am </text>
<text top="858" left="483" width="120" height="13" font="22">Heart J. 1981;102:233–50.</text>
<text top="872" left="457" width="351" height="13" font="22"> 408.  Ko JK, Deal BJ, Strasburger JF, et al. Supraventricular tachycardia mech-</text>
<text top="886" left="483" width="330" height="13" font="22">anisms and their age distribution in pediatric patients. Am J Cardiol. </text>
<text top="899" left="483" width="82" height="13" font="22">1992;69:1028–32.</text>
<text top="913" left="457" width="354" height="13" font="22"> 409.  Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy </text>
<text top="926" left="483" width="330" height="13" font="22">for supraventricular tachycardia in neonates and infants. Am Heart J. </text>
<text top="940" left="483" width="77" height="13" font="22">1996;131:66–72.</text>
<text top="953" left="457" width="351" height="13" font="22"> 410.  Garson A Jr., Gillette PC, McNamara DG. Supraventricular tachycar-</text>
<text top="967" left="483" width="330" height="13" font="22">dia in children: clinical features, response to treatment, and long-term </text>
<text top="981" left="483" width="239" height="13" font="22">follow-up in 217 patients. J Pediatr. 1981;98:875–82.</text>
<text top="994" left="457" width="356" height="13" font="22"> 411. Di Mambro C, Russo MS, Righi D, et al. Ventricular pre-excitation: </text>
<text top="1008" left="483" width="329" height="13" font="22">symptomatic and asymptomatic children have the same potential risk of </text>
<text top="1021" left="483" width="210" height="13" font="22">sudden cardiac death. Europace. 2015:617–21.</text>
<text top="1035" left="457" width="357" height="13" font="22"> 412. Pediatric and Congenital Electrophysiology Society (PACES), Heart </text>
<text top="1049" left="483" width="330" height="13" font="22">Rhythm Society (HRS), American College of Cardiology Foundation </text>
<text top="1062" left="483" width="325" height="13" font="22">(ACCF), et al. PACES/HRS expert consensus statement on the man-</text>
<text top="1076" left="483" width="325" height="13" font="22">agement of the asymptomatic young patient with a Wolff-Parkinson-</text>
<text top="1089" left="483" width="341" height="13" font="22">White (WPW, ventricular preexcitation) electrocardiographic </text>
<text top="1103" left="483" width="329" height="13" font="22">pattern. Developed in partnership between the Pediatric and Congenital </text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e567</i></b></text>
<text top="98" left="95" width="332" height="13" font="22">Electrophysiology Society (PACES) and the Heart Rhythm Society </text>
<text top="111" left="95" width="181" height="13" font="22">(HRS). Heart Rhythm. 2012;9:1006–24.</text>
<text top="125" left="69" width="355" height="13" font="22"> 413.  Dixon J, Foster K, Wyllie J, et al. Guidelines and adenosine dosing in </text>
<text top="138" left="95" width="283" height="13" font="22">supraventricular tachycardia. Arch Dis Child. 2005;90:1190–1.</text>
<text top="152" left="69" width="351" height="13" font="22"> 414.  Díaz-Parra S, Sánchez-Yañez P, Zabala-Argüelles I, et al. Use of adenos-</text>
<text top="166" left="95" width="325" height="13" font="22">ine in the treatment of supraventricular tachycardia in a pediatric emer-</text>
<text top="179" left="95" width="256" height="13" font="22">gency department. Pediatr Emerg Care. 2014;30:388–93.</text>
<text top="193" left="69" width="351" height="13" font="22"> 415.  Losek JD, Endom E, Dietrich A, et al. Adenosine and pediatric supraven-</text>
<text top="206" left="95" width="329" height="13" font="22">tricular tachycardia in the emergency department: multicenter study and </text>
<text top="220" left="95" width="192" height="13" font="22">review. Ann Emerg Med. 1999;33:185–91.</text>
<text top="234" left="69" width="351" height="13" font="22"> 416.  Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medi-</text>
<text top="247" left="95" width="329" height="13" font="22">cations in infancy (SAMIS): a multicenter, randomized controlled trial </text>
<text top="261" left="95" width="331" height="13" font="22">comparing the efficacy and safety of digoxin versus propranolol for </text>
<text top="274" left="95" width="330" height="13" font="22">prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm </text>
<text top="288" left="95" width="142" height="13" font="22">Electrophysiol. 2012;5:984–91.</text>
<text top="302" left="69" width="354" height="13" font="22"> 417.  Deal BJ, Keane JF, Gillette PC, et al. Wolff-Parkinson-White syndrome </text>
<text top="315" left="95" width="326" height="13" font="22">and supraventricular tachycardia during infancy: management and fol-</text>
<text top="329" left="95" width="190" height="13" font="22">low-up. J Am Coll Cardiol. 1985;5:130–5.</text>
<text top="342" left="69" width="351" height="13" font="22"> 418. Villain E, Bonnet D, Acar P, et al. [Recommendations for the treat-</text>
<text top="356" left="95" width="329" height="13" font="22">ment of recurrent supraventricular tachycardia in infants]. Arch Pediatr. </text>
<text top="369" left="95" width="65" height="13" font="22">1998;5:133–8.</text>
<text top="383" left="69" width="355" height="13" font="22"> 419.  Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and </text>
<text top="397" left="95" width="328" height="13" font="22">death in young patients receiving encainide and flecainide. The Pediatric </text>
<text top="410" left="95" width="284" height="13" font="22">Electrophysiology Group. J Am Coll Cardiol. 1991;18:356–65.</text>
<text top="424" left="69" width="351" height="13" font="22"> 420.  Lee P-C, Hwang B, Chen S-A, et al. The results of radiofrequency cath-</text>
<text top="437" left="95" width="331" height="13" font="22">eter ablation of supraventricular tachycardia in children. Pacing Clin </text>
<text top="451" left="95" width="148" height="13" font="22">Electrophysiol. 2007;30:655–61.</text>
<text top="465" left="69" width="355" height="13" font="22"> 421.  Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after </text>
<text top="478" left="95" width="330" height="13" font="22">pediatric cardiac ablation: demographics, medical profiles, and initial </text>
<text top="492" left="95" width="257" height="13" font="22">outcomes. J Cardiovasc Electrophysiol. 2004;15:759–70.</text>
<text top="505" left="69" width="354" height="13" font="22"> 422.  Aiyagari R, Saarel EV, Etheridge SP, et al. Radiofrequency ablation for </text>
<text top="519" left="95" width="328" height="13" font="22">supraventricular tachycardia in children &lt; or =15 kg is safe and effective. </text>
<text top="533" left="95" width="145" height="13" font="22">Pediatr Cardiol. 2005;26:622–6.</text>
<text top="546" left="69" width="355" height="13" font="22"> 423.  Blaufox AD, Felix GL, Saul JP, et al. Radiofrequency catheter ablation in </text>
<text top="560" left="95" width="328" height="13" font="22">infants &lt;/=18 months old: when is it done and how do they fare?: Short-term </text>
<text top="573" left="95" width="324" height="13" font="22">data from the Pediatric Ablation Registry. Circulation. 2001;104:2803–8.</text>
<text top="587" left="69" width="354" height="13" font="22"> 424.  Blaufox AD, Paul T, Saul JP. Radiofrequency catheter ablation in small </text>
<text top="601" left="95" width="329" height="13" font="22">children: relationship of complications to application dose. Pacing Clin </text>
<text top="614" left="95" width="142" height="13" font="22">Electrophysiol. 2004;27:224–9.</text>
<text top="628" left="69" width="351" height="13" font="22"> 425.  Kantoch MJ, Gulamhusein SS, Sanatani S. Short- and long-term out-</text>
<text top="641" left="95" width="330" height="13" font="22">comes in children undergoing radiofrequency catheter ablation before </text>
<text top="655" left="95" width="252" height="13" font="22">their second birthday. Can J Cardiol. 2011;27:523.e3–9.</text>
<text top="668" left="69" width="351" height="13" font="22"> 426.  Schaffer MS, Gow RM, Moak JP, et al. Mortality following radiofre-</text>
<text top="682" left="95" width="330" height="13" font="22">quency catheter ablation (from the Pediatric Radiofrequency Ablation </text>
<text top="696" left="95" width="332" height="13" font="22">Registry). Participating members of the Pediatric Electrophysiology </text>
<text top="709" left="95" width="181" height="13" font="22">Society. Am J Cardiol. 2000;86:639–43.</text>
<text top="723" left="69" width="356" height="13" font="22"> 427. Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment </text>
<text top="736" left="95" width="330" height="13" font="22">after pediatric cardiac ablation: recurrence at 1 year after initially </text>
<text top="750" left="95" width="330" height="13" font="22">successful ablation of supraventricular tachycardia. Heart Rhythm. </text>
<text top="764" left="95" width="74" height="13" font="22">2004;1:188–96.</text>
<text top="777" left="69" width="351" height="13" font="22"> 428.  Buddhe S, Singh H, Du W, et al. Radiofrequency and cryoablation thera-</text>
<text top="791" left="95" width="329" height="13" font="22">pies for supraventricular arrhythmias in the young: five-year review of </text>
<text top="804" left="95" width="246" height="13" font="22">efficacies. Pacing Clin Electrophysiol. 2012;35:711–7.</text>
<text top="818" left="69" width="351" height="13" font="22"> 429.  Chiu S-N, Lu C-W, Chang C-W, et al. Radiofrequency catheter abla-</text>
<text top="832" left="95" width="331" height="13" font="22">tion of supraventricular tachycardia in infants and toddlers. Circ J. </text>
<text top="845" left="95" width="82" height="13" font="22">2009;73:1717–21.</text>
<text top="859" left="69" width="355" height="13" font="22"> 430.  Batra AS, Chun DS, Johnson TR, et al. A prospective analysis of the </text>
<text top="872" left="95" width="325" height="13" font="22">incidence and risk factors associated with junctional ectopic tachy-</text>
<text top="886" left="95" width="330" height="13" font="22">cardia following surgery for congenital heart disease. Pediatr Cardiol. </text>
<text top="900" left="95" width="65" height="13" font="22">2006;27:51–5.</text>
<text top="913" left="69" width="351" height="13" font="22"> 431.  Andreasen JB, Johnsen SP, Ravn HB. Junctional ectopic tachycardia af-</text>
<text top="927" left="95" width="329" height="13" font="22">ter surgery for congenital heart disease in children. Intensive Care Med. </text>
<text top="940" left="95" width="82" height="13" font="22">2008;34:895–902.</text>
<text top="954" left="69" width="354" height="13" font="22"> 432.  Haas NA, Camphausen CK. Impact of early and standardized treatment with </text>
<text top="967" left="94" width="330" height="13" font="22">amiodarone on therapeutic success and outcome in pediatric patients with </text>
<text top="981" left="94" width="323" height="13" font="22">postoperative tachyarrhythmia. J Thorac Cardiovasc Surg. 2008;136:1215–22.</text>
<text top="995" left="69" width="354" height="13" font="22"> 433.  Laird WP, Snyder CS, Kertesz NJ, et al. Use of intravenous amiodarone </text>
<text top="1008" left="94" width="332" height="13" font="22">for postoperative junctional ectopic tachycardia in children. Pediatr </text>
<text top="1022" left="94" width="110" height="13" font="22">Cardiol. 2003;24:133–7.</text>
<text top="1035" left="69" width="355" height="13" font="22"> 434.  Kovacikova L, Hakacova N, Dobos D, et al. Amiodarone as a first-line </text>
<text top="1049" left="94" width="331" height="13" font="22">therapy for postoperative junctional ectopic tachycardia. Ann Thorac </text>
<text top="1063" left="94" width="103" height="13" font="22">Surg. 2009;88:616–22.</text>
<text top="1076" left="69" width="355" height="13" font="22"> 435.  Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment </text>
<text top="1090" left="94" width="330" height="13" font="22">protocol for rapid automatic junctional tachycardia after operation for </text>
<text top="1103" left="94" width="283" height="13" font="22">congenital heart disease. J Am Coll Cardiol. 1997;29:1046–53.</text>
<text top="97" left="456" width="351" height="13" font="22"> 436. van Engelen AD, Weijtens O, Brenner JI, et al. Management out-</text>
<text top="111" left="482" width="328" height="13" font="22">come and follow-up of fetal tachycardia. J Am Coll Cardiol. 1994;24: </text>
<text top="124" left="482" width="38" height="13" font="22">1371–5.</text>
<text top="138" left="456" width="351" height="13" font="22"> 437.  Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacen-</text>
<text top="152" left="482" width="330" height="13" font="22">tal treatment of fetal supraventricular tachyarrhythmias with digoxin, </text>
<text top="165" left="482" width="330" height="13" font="22">flecainide, and sotalol: results of a nonrandomized multicenter study. </text>
<text top="179" left="482" width="144" height="13" font="22">Circulation. 2011;124:1747–54.</text>
<text top="192" left="456" width="351" height="13" font="22"> 438.  van der Heijden LB, Oudijk MA, Manten GTR, et al. Sotalol as first-</text>
<text top="206" left="482" width="329" height="13" font="22">line treatment for fetal tachycardia and neonatal follow-up. Ultrasound </text>
<text top="220" left="482" width="152" height="13" font="22">Obstet Gynecol. 2013;42:285–93.</text>
<text top="233" left="456" width="355" height="13" font="22"> 439.  Strasburger JF, Cuneo BF, Michon MM, et al. Amiodarone therapy for </text>
<text top="247" left="482" width="285" height="13" font="22">drug-refractory fetal tachycardia. Circulation. 2004;109:375–9.</text>
<text top="260" left="456" width="354" height="13" font="22"> 440.  Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with </text>
<text top="274" left="482" width="257" height="13" font="22">congenital heart disease. Circulation. 2009;120:1679–86.</text>
<text top="288" left="456" width="353" height="13" font="22"> 441.  Bernier M, Marelli AJ, Pilote L, et al. Atrial arrhythmias in adult patients </text>
<text top="301" left="482" width="330" height="13" font="22">with right- versus left-sided congenital heart disease anomalies. Am J </text>
<text top="315" left="482" width="122" height="13" font="22">Cardiol. 2010;106:547–51.</text>
<text top="328" left="456" width="351" height="13" font="22"> 442.  Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congen-</text>
<text top="342" left="482" width="328" height="13" font="22">ital heart disease in Europe: morbidity and mortality in a 5 year follow-up </text>
<text top="356" left="482" width="329" height="13" font="22">period. The Euro Heart Survey on Adult Congenital Heart Disease. Eur </text>
<text top="369" left="482" width="120" height="13" font="22">Heart J. 2005;26:2325–33.</text>
<text top="383" left="456" width="351" height="13" font="22"> 443. Trojnarska O, Grajek S, Kramer L, et al. Risk factors of supraven-</text>
<text top="396" left="482" width="330" height="13" font="22">tricular arrhythmia in adults with congenital heart disease. Cardiol J. </text>
<text top="410" left="482" width="77" height="13" font="22">2009;16:218–26.</text>
<text top="423" left="456" width="351" height="13" font="22"> 444.  Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Gender and out-</text>
<text top="437" left="482" width="310" height="13" font="22">come in adult congenital heart disease. Circulation. 2008;118:26–32.</text>
<text top="451" left="456" width="355" height="13" font="22"> 445.  Collins KK, Love BA, Walsh EP, et al. Location of acutely successful </text>
<text top="464" left="482" width="330" height="13" font="22">radiofrequency catheter ablation of intraatrial reentrant tachycardia in </text>
<text top="478" left="482" width="316" height="13" font="22">patients with congenital heart disease. Am J Cardiol. 2000;86:969–74.</text>
<text top="491" left="456" width="354" height="13" font="22"> 446.  de Groot NMS, Zeppenfeld K, Wijffels MC, et al. Ablation of focal atrial </text>
<text top="505" left="482" width="330" height="13" font="22">arrhythmia in patients with congenital heart defects after surgery: role </text>
<text top="519" left="482" width="329" height="13" font="22">of circumscribed areas with heterogeneous conduction. Heart Rhythm. </text>
<text top="532" left="482" width="71" height="13" font="22">2006;3:526–35.</text>
<text top="546" left="456" width="354" height="13" font="22"> 447.  Koyak Z, Kroon B, de Groot JR, et al. Efficacy of antiarrhythmic drugs </text>
<text top="559" left="482" width="328" height="13" font="22">in adults with congenital heart disease and supraventricular tachycardias. </text>
<text top="573" left="482" width="148" height="13" font="22">Am J Cardiol. 2013;112:1461–7.</text>
<text top="587" left="456" width="351" height="13" font="22"> 448.  Mah DY, Alexander ME, Cecchin F, et al. The electroanatomic mecha-</text>
<text top="600" left="482" width="328" height="13" font="22">nisms of atrial tachycardia in patients with tetralogy of Fallot and double </text>
<text top="614" left="482" width="305" height="13" font="22">outlet right ventricle. J Cardiovasc Electrophysiol. 2011;22:1013–7.</text>
<text top="627" left="456" width="354" height="13" font="22"> 449.  Wasmer K, Köbe J, Dechering DG, et al. Isthmus-dependent right atrial </text>
<text top="641" left="482" width="325" height="13" font="22">flutter as the leading cause of atrial tachycardias after surgical atrial sep-</text>
<text top="654" left="482" width="225" height="13" font="22">tal defect repair. Int J Cardiol. 2013;168:2447–52.</text>
<text top="668" left="456" width="116" height="13" font="22"> 450.  Cuypers JAAE, Opi</text>
<text top="668" left="572" width="238" height="13" font="22">ć P, Menting ME, et al. The unnatural history of an </text>
<text top="682" left="482" width="329" height="13" font="22">atrial septal defect: longitudinal 35 year follow up after surgical closure </text>
<text top="695" left="482" width="176" height="13" font="22">at young age. Heart. 2013;99:1346–52.</text>
<text top="709" left="456" width="354" height="13" font="22"> 451.  Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults </text>
<text top="722" left="482" width="330" height="13" font="22">with surgically repaired tetralogy of Fallot: a multi-institutional study. </text>
<text top="736" left="482" width="138" height="13" font="22">Circulation. 2010;122:868–75.</text>
<text top="750" left="456" width="351" height="13" font="22"> 452.  de Groot NMS, Atary JZ, Blom NA, et al. Long-term outcome after ab-</text>
<text top="763" left="482" width="330" height="13" font="22">lative therapy of postoperative atrial tachyarrhythmia in patients with </text>
<text top="777" left="482" width="331" height="13" font="22">congenital heart disease and characteristics of atrial tachyarrhythmia </text>
<text top="790" left="482" width="268" height="13" font="22">recurrences. Circ Arrhythm Electrophysiol. 2010;3:148–54.</text>
<text top="804" left="456" width="353" height="13" font="22"> 453.  Hårdhammar PA, van Beusekom HM, Emanuelsson HU, et al. Reduction </text>
<text top="818" left="482" width="328" height="13" font="22">in thrombotic events with heparin-coated Palmaz-Schatz stents in normal </text>
<text top="831" left="482" width="251" height="13" font="22">porcine coronary arteries. Circulation. 1996;93:423–30.</text>
<text top="845" left="456" width="351" height="13" font="22"> 454.  Tanner H, Lukac P, Schwick N, et al. Irrigated-tip catheter ablation of in-</text>
<text top="858" left="482" width="329" height="13" font="22">traatrial reentrant tachycardia in patients late after surgery of congenital </text>
<text top="872" left="482" width="204" height="13" font="22">heart disease. Heart Rhythm. 2004;1:268–75.</text>
<text top="886" left="456" width="355" height="13" font="22"> 455.  Triedman JK, Saul JP, Weindling SN, et al. Radiofrequency ablation of </text>
<text top="899" left="482" width="330" height="13" font="22">intra-atrial reentrant tachycardia after surgical palliation of congenital </text>
<text top="913" left="482" width="196" height="13" font="22">heart disease. Circulation. 1995;91:707–14.</text>
<text top="926" left="456" width="354" height="13" font="22"> 456.  DeMazumder D, Lake DE, Cheng A, et al. Dynamic analysis of cardiac </text>
<text top="940" left="482" width="325" height="13" font="22">rhythms for discriminating atrial fibrillation from lethal ventricular ar-</text>
<text top="953" left="482" width="261" height="13" font="22">rhythmias. Circ Arrhythm Electrophysiol. 2013;6:555–61.</text>
<text top="967" left="456" width="351" height="13" font="22"> 457.  Yap S-C, Harris L, Silversides CK, et al. Outcome of intra-atrial re-en-</text>
<text top="981" left="482" width="328" height="13" font="22">trant tachycardia catheter ablation in adults with congenital heart disease: </text>
<text top="994" left="482" width="329" height="13" font="22">negative impact of age and complex atrial surgery. J Am Coll Cardiol. </text>
<text top="1008" left="482" width="82" height="13" font="22">2010;56:1589–96.</text>
<text top="1021" left="456" width="356" height="13" font="22"> 458. Scaglione M, Caponi D, Ebrille E, et al. Very long-term results of </text>
<text top="1035" left="482" width="329" height="13" font="22">electroanatomic-guided radiofrequency ablation of atrial arrhythmias </text>
<text top="1049" left="482" width="330" height="13" font="22">in patients with surgically corrected atrial septal defect. Europace. </text>
<text top="1062" left="482" width="64" height="13" font="22">2014:1800–7.</text>
<text top="1076" left="456" width="355" height="13" font="22"> 459.  Feltes TF, Friedman RA. Transesophageal echocardiographic detection </text>
<text top="1089" left="482" width="329" height="13" font="22">of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias </text>
<text top="1103" left="482" width="302" height="13" font="22">and congenital heart disease. J Am Coll Cardiol. 1994;24:1365–70.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e568  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="98" left="71" width="354" height="13" font="22"> 460.  Ammash NM, Phillips SD, Hodge DO, et al. Outcome of direct current </text>
<text top="111" left="96" width="325" height="13" font="22">cardioversion for atrial arrhythmias in adults with congenital heart dis-</text>
<text top="125" left="96" width="163" height="13" font="22">ease. Int J Cardiol. 2012;154:270–4.</text>
<text top="138" left="71" width="351" height="13" font="22"> 461.  Pass RH, Liberman L, Al-Fayaddh M, et al. Continuous intravenous dil-</text>
<text top="152" left="96" width="329" height="13" font="22">tiazem infusion for short-term ventricular rate control in children. Am J </text>
<text top="166" left="96" width="140" height="13" font="22">Cardiol. 2000;86:559–562. A9.</text>
<text top="179" left="71" width="351" height="13" font="22"> 462.  Garnock-Jones KP. Esmolol: a review of its use in the short-term treat-</text>
<text top="193" left="96" width="329" height="13" font="22">ment of tachyarrhythmias and the short-term control of tachycardia and </text>
<text top="206" left="96" width="173" height="13" font="22">hypertension. Drugs. 2012;72:109–32.</text>
<text top="220" left="71" width="353" height="13" font="22"> 463.  diMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use </text>
<text top="234" left="96" width="330" height="13" font="22">of adenosine in patients with supraventricular tachyarrhythmias. J Am </text>
<text top="247" left="96" width="133" height="13" font="22">Coll Cardiol. 1985;6:417–25.</text>
<text top="261" left="71" width="357" height="13" font="22"> 464. Haines DE, DiMarco JP. Sustained intraatrial reentrant tachycardia: </text>
<text top="274" left="96" width="329" height="13" font="22">clinical, electrocardiographic and electrophysiologic characteristics and </text>
<text top="288" left="96" width="267" height="13" font="22">long-term follow-up. J Am Coll Cardiol. 1990;15:1345–54.</text>
<text top="302" left="71" width="351" height="13" font="22"> 465.  Kall JG, Kopp D, Olshansky B, et al. Adenosine-sensitive atrial tachycar-</text>
<text top="315" left="96" width="217" height="13" font="22">dia. Pacing Clin Electrophysiol. 1995;18:300–6.</text>
<text top="329" left="70" width="351" height="13" font="22"> 466.  Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rap-</text>
<text top="342" left="96" width="328" height="13" font="22">id atrial pacing for successful conversion of atrial flutter to sinus rhythm. </text>
<text top="356" left="96" width="164" height="13" font="22">J Am Coll Cardiol. 1988;11:359–64.</text>
<text top="369" left="70" width="351" height="13" font="22"> 467. Heisel A, Jung J, Stopp M, et al. Facilitating influence of procain-</text>
<text top="383" left="96" width="329" height="13" font="22">amide on conversion of atrial flutter by rapid atrial pacing. Eur Heart J. </text>
<text top="397" left="96" width="71" height="13" font="22">1997;18:866–9.</text>
<text top="410" left="70" width="354" height="13" font="22"> 468.  Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and </text>
<text top="424" left="96" width="330" height="13" font="22">in patients with congenital heart disease. Pacing Clin Electrophysiol. </text>
<text top="437" left="96" width="77" height="13" font="22">2007;30:1003–8.</text>
<text top="451" left="70" width="356" height="13" font="22"> 469. Crawford W, Plumb VJ, Epstein AE, et al. Prospective evaluation of </text>
<text top="465" left="96" width="329" height="13" font="22">transesophageal pacing for the interruption of atrial flutter. Am J Med. </text>
<text top="478" left="96" width="71" height="13" font="22">1989;86:663–7.</text>
<text top="492" left="70" width="355" height="13" font="22"> 470.  Rhodes LA, Walsh EP, Saul JP. Conversion of atrial flutter in pediatric </text>
<text top="505" left="96" width="325" height="13" font="22">patients by transesophageal atrial pacing: a safe, effective, minimally in-</text>
<text top="519" left="96" width="215" height="13" font="22">vasive procedure. Am Heart J. 1995;130:323–7.</text>
<text top="533" left="70" width="355" height="13" font="22"> 471.  Brockmeier K, Ulmer HE, Hessling G. Termination of atrial reentrant </text>
<text top="546" left="96" width="331" height="13" font="22">tachycardias by using transesophageal atrial pacing. J Electrocardiol. </text>
<text top="560" left="96" width="106" height="13" font="22">2002;35 Suppl:159–63.</text>
<text top="573" left="70" width="351" height="13" font="22"> 472.  Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycar-</text>
<text top="587" left="96" width="326" height="13" font="22">dia pacing using the Medtronic AT500 pacemaker in patients with con-</text>
<text top="601" left="96" width="233" height="13" font="22">genital heart disease. Am J Cardiol. 2003;92:871–6.</text>
<text top="614" left="70" width="353" height="13" font="22"> 473.  Rao SO, Boramanand NK, Burton DA, et al. Atrial tachycardias in young </text>
<text top="628" left="96" width="330" height="13" font="22">adults and adolescents with congenital heart disease: conversion using </text>
<text top="641" left="96" width="248" height="13" font="22">single dose oral sotalol. Int J Cardiol. 2009;136:253–7.</text>
<text top="655" left="70" width="355" height="13" font="22"> 474.  Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in </text>
<text top="668" left="96" width="328" height="13" font="22">congenital heart disease: a multicenter study. Pacing Clin Electrophysiol. </text>
<text top="682" left="96" width="77" height="13" font="22">2009;32:1313–8.</text>
<text top="696" left="70" width="356" height="13" font="22"> 475.  Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after </text>
<text top="709" left="96" width="328" height="13" font="22">surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. </text>
<text top="723" left="96" width="156" height="13" font="22">N Engl J Med. 1990;323:1645–50.</text>
<text top="736" left="70" width="351" height="13" font="22"> 476.  Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgi-</text>
<text top="750" left="96" width="329" height="13" font="22">cal and medical therapy for atrial septal defect in adults. N Engl J Med. </text>
<text top="764" left="96" width="82" height="13" font="22">1995;333:469–73.</text>
<text top="777" left="70" width="351" height="13" font="22"> 477.  Pfammatter JP, Paul T, Ziemer G, et al. Successful management of junc-</text>
<text top="791" left="96" width="330" height="13" font="22">tional tachycardia by hypothermia after cardiac operations in infants. </text>
<text top="804" left="96" width="160" height="13" font="22">Ann Thorac Surg. 1995;60:556–60.</text>
<text top="818" left="70" width="355" height="13" font="22"> 478.  Giamberti A, Chessa M, Foresti S, et al. Combined atrial septal defect </text>
<text top="832" left="96" width="329" height="13" font="22">surgical closure and irrigated radiofrequency ablation in adult patients. </text>
<text top="845" left="96" width="166" height="13" font="22">Ann Thorac Surg. 2006;82:1327–31.</text>
<text top="859" left="70" width="351" height="13" font="22"> 479. Huang CJ, Chiu IS, Lin FY, et al. Role of electrophysiological stud-</text>
<text top="872" left="96" width="329" height="13" font="22">ies and arrhythmia intervention in repairing Ebstein’s anomaly. Thorac </text>
<text top="886" left="96" width="156" height="13" font="22">Cardiovasc Surg. 2000;48:347–50.</text>
<text top="900" left="70" width="357" height="13" font="22"> 480. Reich JD, Auld D, Hulse E, et al. The Pediatric Radiofrequency </text>
<text top="913" left="96" width="332" height="13" font="22">Ablation Registry’s experience with Ebstein’s anomaly. Pediatric </text>
<text top="927" left="96" width="328" height="13" font="22">Electrophysiology Society. J Cardiovasc Electrophysiol. 1998;9: </text>
<text top="940" left="96" width="38" height="13" font="22">1370–7.</text>
<text top="954" left="70" width="354" height="13" font="22"> 481.  Cappato R, Schlüter M, Weiss C, et al. Radiofrequency current catheter </text>
<text top="967" left="96" width="330" height="13" font="22">ablation of accessory atrioventricular pathways in Ebstein’s anomaly. </text>
<text top="981" left="96" width="133" height="13" font="22">Circulation. 1996;94:376–83.</text>
<text top="995" left="70" width="354" height="13" font="22"> 482.  Misaki T, Watanabe G, Iwa T, et al. Surgical treatment of patients with </text>
<text top="1008" left="96" width="332" height="13" font="22">Wolff-Parkinson-White syndrome and associated Ebstein’s anomaly. </text>
<text top="1022" left="96" width="204" height="13" font="22">J Thorac Cardiovasc Surg. 1995;110:1702–7.</text>
<text top="1035" left="71" width="351" height="13" font="22"> 483.  Khositseth A, Danielson GK, Dearani JA, et al. Supraventricular tachyar-</text>
<text top="1049" left="96" width="331" height="13" font="22">rhythmias in Ebstein anomaly: management and outcome. J Thorac </text>
<text top="1063" left="96" width="162" height="13" font="22">Cardiovasc Surg. 2004;128:826–33.</text>
<text top="1076" left="70" width="351" height="13" font="22"> 484.  Bockeria L, Golukhova E, Dadasheva M, et al. Advantages and disadvan-</text>
<text top="1090" left="96" width="329" height="13" font="22">tages of one-stage and two-stage surgery for arrhythmias and Ebstein’s </text>
<text top="1103" left="96" width="235" height="13" font="22">anomaly. Eur J Cardiothorac Surg. 2005;28:536–40.</text>
<text top="97" left="458" width="354" height="13" font="22"> 485.  Pressley JC, Wharton JM, Tang AS, et al. Effect of Ebstein’s anomaly on </text>
<text top="111" left="483" width="326" height="13" font="22">short- and long-term outcome of surgically treated patients with Wolff-</text>
<text top="124" left="483" width="267" height="13" font="22">Parkinson-White syndrome. Circulation. 1992;86:1147–55.</text>
<text top="138" left="458" width="354" height="13" font="22"> 486.  Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators </text>
<text top="152" left="483" width="328" height="13" font="22">in transposition of the great arteries with intra-atrial baffles: a multicenter </text>
<text top="165" left="483" width="234" height="13" font="22">study. Circ Arrhythm Electrophysiol. 2008;1:250–7.</text>
<text top="179" left="458" width="351" height="13" font="22"> 487.  Banchs JE, Baquero GA, Nickolaus MJ, et al. Clinical efficacy of dofeti-</text>
<text top="192" left="483" width="328" height="13" font="22">lide for the treatment of atrial tachyarrhythmias in adults with congenital </text>
<text top="206" left="483" width="222" height="13" font="22">heart disease. Congenit Heart Dis. 2014;9:221–7.</text>
<text top="220" left="458" width="355" height="13" font="22"> 488.  Tanel RE, Walsh EP, Lulu JA, et al. Sotalol for refractory arrhythmias </text>
<text top="233" left="483" width="325" height="13" font="22">in pediatric and young adult patients: initial efficacy and long-term out-</text>
<text top="247" left="483" width="163" height="13" font="22">come. Am Heart J. 1995;130:791–7.</text>
<text top="260" left="458" width="353" height="13" font="22"> 489.  Lukac P, Pedersen AK, Mortensen PT, et al. Ablation of atrial tachycardia </text>
<text top="274" left="483" width="326" height="13" font="22">after surgery for congenital and acquired heart disease using an electro-</text>
<text top="288" left="483" width="329" height="13" font="22">anatomic mapping system: which circuits to expect in which substrate? </text>
<text top="301" left="483" width="135" height="13" font="22">Heart Rhythm. 2005;2:64–72.</text>
<text top="315" left="458" width="351" height="13" font="22"> 490. Yap S-C, Harris L, Downar E, et al. Evolving electroanatomic sub-</text>
<text top="328" left="483" width="331" height="13" font="22">strate and intra-atrial reentrant tachycardia late after Fontan surgery. </text>
<text top="342" left="483" width="208" height="13" font="22">J Cardiovasc Electrophysiol. 2012;23:339–45.</text>
<text top="356" left="458" width="351" height="13" font="22"> 491.  Wu J, Deisenhofer I, Ammar S, et al. Acute and long-term outcome af-</text>
<text top="369" left="483" width="329" height="13" font="22">ter catheter ablation of supraventricular tachycardia in patients after the </text>
<text top="383" left="483" width="329" height="13" font="22">Mustard or Senning operation for D-transposition of the great arteries. </text>
<text top="396" left="483" width="125" height="13" font="22">Europace. 2013;15:886–91.</text>
<text top="410" left="458" width="351" height="13" font="22"> 492.  Jones DG, Jarman JWE, Lyne JC, et al. The safety and efficacy of trans-</text>
<text top="423" left="483" width="326" height="13" font="22">baffle puncture to enable catheter ablation of atrial tachycardias fol-</text>
<text top="437" left="483" width="329" height="13" font="22">lowing the Mustard procedure: a single centre experience and literature </text>
<text top="451" left="483" width="185" height="13" font="22">review. Int J Cardiol. 2013;168:1115–20.</text>
<text top="464" left="458" width="351" height="13" font="22"> 493.  Kalman JM, VanHare GF, Olgin JE, et al. Ablation of ‘incisional’ re-</text>
<text top="478" left="483" width="332" height="13" font="22">entrant atrial tachycardia complicating surgery for congenital heart </text>
<text top="491" left="483" width="330" height="13" font="22">disease. Use of entrainment to define a critical isthmus of conduction. </text>
<text top="505" left="483" width="133" height="13" font="22">Circulation. 1996;93:502–12.</text>
<text top="519" left="458" width="354" height="13" font="22"> 494.  Ueda A, Suman-Horduna I, Mantziari L, et al. Contemporary outcomes </text>
<text top="532" left="483" width="330" height="13" font="22">of supraventricular tachycardia ablation in congenital heart disease: a </text>
<text top="546" left="483" width="329" height="13" font="22">single-center experience in 116 patients. Circ Arrhythm Electrophysiol. </text>
<text top="559" left="483" width="71" height="13" font="22">2013;6:606–13.</text>
<text top="573" left="458" width="351" height="13" font="22"> 495.  de Groot NMS, Lukac P, Blom NA, et al. Long-term outcome of ab-</text>
<text top="587" left="483" width="329" height="13" font="22">lative therapy of postoperative supraventricular tachycardias in patients </text>
<text top="600" left="483" width="329" height="13" font="22">with univentricular heart: a European multicenter study. Circ Arrhythm </text>
<text top="614" left="483" width="137" height="13" font="22">Electrophysiol. 2009;2:242–8.</text>
<text top="627" left="458" width="354" height="13" font="22"> 496.  Silversides CK, Salehian O, Oechslin E, et al. Canadian Cardiovascular </text>
<text top="641" left="483" width="329" height="13" font="22">Society 2009 Consensus Conference on the management of adults with </text>
<text top="654" left="483" width="331" height="13" font="22">congenital heart disease: complex congenital cardiac lesions. Can J </text>
<text top="668" left="483" width="121" height="13" font="22">Cardiol. 2010;26:e98–117.</text>
<text top="682" left="458" width="353" height="13" font="22"> 497.  Giamberti A, Chessa M, Abella R, et al. Surgical treatment of arrhythmias </text>
<text top="695" left="483" width="315" height="13" font="22">in adults with congenital heart defects. Int J Cardiol. 2008;129:37–41.</text>
<text top="709" left="458" width="354" height="13" font="22"> 498.  Stulak JM, Dearani JA, Puga FJ, et al. Right-sided Maze procedure for </text>
<text top="722" left="483" width="330" height="13" font="22">atrial tachyarrhythmias in congenital heart disease. Ann Thorac Surg. </text>
<text top="736" left="483" width="77" height="13" font="22">2006;81:1780–4.</text>
<text top="750" left="458" width="351" height="13" font="22"> 499. Mavroudis C, Deal BJ, Backer CL, et al. Arrhythmia surgery in pa-</text>
<text top="763" left="483" width="331" height="13" font="22">tients with and without congenital heart disease. Ann Thorac Surg. </text>
<text top="777" left="483" width="77" height="13" font="22">2008;86:857–68.</text>
<text top="790" left="458" width="355" height="13" font="22"> 500.  Karamlou T, Silber I, Lao R, et al. Outcomes after late reoperation in </text>
<text top="804" left="483" width="329" height="13" font="22">patients with repaired tetralogy of Fallot: the impact of arrhythmia and </text>
<text top="818" left="483" width="255" height="13" font="22">arrhythmia surgery. Ann Thorac Surg. 2006;81:1786–93.</text>
<text top="831" left="458" width="351" height="13" font="22"> 501.  Deal BJ, Mavroudis C, Backer CL, et al. Comparison of anatomic isth-</text>
<text top="845" left="483" width="329" height="13" font="22">mus block with the modified right atrial maze procedure for late atrial </text>
<text top="858" left="483" width="274" height="13" font="22">tachycardia in Fontan patients. Circulation. 2002;106:575–9.</text>
<text top="872" left="458" width="351" height="13" font="22"> 502.  Mavroudis C, Backer CL, Deal BJ, et al. Total cavopulmonary conver-</text>
<text top="886" left="483" width="328" height="13" font="22">sion and maze procedure for patients with failure of the Fontan operation. </text>
<text top="899" left="483" width="204" height="13" font="22">J Thorac Cardiovasc Surg. 2001;122:863–71.</text>
<text top="913" left="458" width="357" height="13" font="22"> 503. Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain </text>
<text top="926" left="483" width="330" height="13" font="22">Memorial Paper for congenital heart surgery. 111 Fontan conversions </text>
<text top="940" left="483" width="330" height="13" font="22">with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac </text>
<text top="953" left="483" width="109" height="13" font="22">Surg. 2007;84:1457–65.</text>
<text top="967" left="458" width="354" height="13" font="22"> 504.  Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmia recurrence in </text>
<text top="981" left="483" width="328" height="13" font="22">adult patients with single ventricle physiology following surgical Fontan </text>
<text top="994" left="483" width="213" height="13" font="22">conversion. Congenit Heart Dis. 2010;5:430–4.</text>
<text top="1008" left="458" width="354" height="13" font="22"> 505.  Said SM, Burkhart HM, Schaff HV, et al. Fontan conversion: identifying </text>
<text top="1021" left="483" width="261" height="13" font="22">the high-risk patient. Ann Thorac Surg. 2014;97:2115–21.</text>
<text top="1035" left="458" width="354" height="13" font="22"> 506.  Gutierrez SD, Earing MG, Singh AK, et al. Atrial tachyarrhythmias and </text>
<text top="1049" left="483" width="328" height="13" font="22">the Cox-maze procedure in congenital heart disease. Congenit Heart Dis. </text>
<text top="1062" left="483" width="65" height="13" font="22">2013;8:434–9.</text>
<text top="1076" left="458" width="351" height="13" font="22"> 507.  Terada T, Sakurai H, Nonaka T, et al. Surgical outcome of Fontan con-</text>
<text top="1089" left="483" width="330" height="13" font="22">version and arrhythmia surgery: need a pacemaker? Asian Cardiovasc </text>
<text top="1103" left="483" width="130" height="13" font="22">Thorac Ann. 2013;22:682–6.</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e569</i></b></text>
<text top="98" left="69" width="351" height="13" font="22"> 508.  Theodoro DA, Danielson GK, Porter CJ, et al. Right-sided maze proce-</text>
<text top="111" left="95" width="329" height="13" font="22">dure for right atrial arrhythmias in congenital heart disease. Ann Thorac </text>
<text top="125" left="95" width="103" height="13" font="22">Surg. 1998;65:149–53.</text>
<text top="138" left="69" width="351" height="13" font="22"> 509.  Silka MJ, Manwill JR, Kron J, et al. Bradycardia-mediated tachyarrhyth-</text>
<text top="152" left="95" width="326" height="13" font="22">mias in congenital heart disease and responses to chronic pacing at physi-</text>
<text top="165" left="95" width="200" height="13" font="22">ologic rates. Am J Cardiol. 1990;65:488–93.</text>
<text top="179" left="69" width="351" height="13" font="22"> 510.  Ragonese P, Drago F, Guccione P, et al. Permanent overdrive atrial pac-</text>
<text top="192" left="95" width="328" height="13" font="22">ing in the chronic management of recurrent postoperative atrial reentrant </text>
<text top="206" left="95" width="330" height="13" font="22">tachycardia in patients with complex congenital heart disease. Pacing </text>
<text top="219" left="95" width="176" height="13" font="22">Clin Electrophysiol. 1997;20:2917–23.</text>
<text top="233" left="69" width="351" height="13" font="22"> 511. Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thy-</text>
<text top="246" left="95" width="330" height="13" font="22">roid dysfunction: risk factors in adults with congenital heart disease. </text>
<text top="260" left="95" width="138" height="13" font="22">Circulation. 1999;100:149–54.</text>
<text top="273" left="69" width="351" height="13" font="22"> 512.  Stan MN, Hess EP, Bahn RS, et al. A risk prediction index for amio-</text>
<text top="287" left="95" width="330" height="13" font="22">darone-induced thyrotoxicosis in adults with congenital heart disease. </text>
<text top="300" left="95" width="156" height="13" font="22">J Thyroid Res. 2012;2012:210529.</text>
<text top="314" left="69" width="351" height="13" font="22"> 513.  Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in nor-</text>
<text top="327" left="95" width="328" height="13" font="22">mal pregnancy and relation to palpitations, dizziness, and syncope. Am J </text>
<text top="341" left="95" width="116" height="13" font="22">Cardiol. 1997;79:1061–4.</text>
<text top="354" left="69" width="351" height="13" font="22"> 514.  Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on parox-</text>
<text top="368" left="95" width="305" height="13" font="22">ysmal supraventricular tachycardia. Am J Cardiol. 1993;72:838–40.</text>
<text top="381" left="69" width="351" height="13" font="22"> 515. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of ar-</text>
<text top="395" left="95" width="325" height="13" font="22">rhythmias during pregnancy in women with previous tachyarrhyth-</text>
<text top="408" left="95" width="332" height="13" font="22">mia and impact on fetal and neonatal outcomes. Am J Cardiol. </text>
<text top="422" left="95" width="85" height="13" font="22">2006;97:1206–12.</text>
<text top="435" left="69" width="351" height="13" font="22"> 516.  Ghosh N, Luk A, Derzko C, et al. The acute treatment of maternal su-</text>
<text top="449" left="95" width="329" height="13" font="22">praventricular tachycardias during pregnancy: a review of the literature. </text>
<text top="462" left="95" width="180" height="13" font="22">J Obstet Gynaecol Can. 2011;33:17–23.</text>
<text top="476" left="69" width="351" height="13" font="22"> 517.  Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular phar-</text>
<text top="489" left="95" width="329" height="13" font="22">macotherapeutic considerations during pregnancy and lactation. Cardiol </text>
<text top="503" left="95" width="99" height="13" font="22">Rev. 2004;12:201–21.</text>
<text top="516" left="69" width="357" height="13" font="22"> 518. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. </text>
<text top="530" left="95" width="77" height="13" font="22">1995;130:871–6.</text>
<text top="543" left="69" width="355" height="13" font="22"> 519.  Tromp CHN, Nanne ACM, Pernet PJM, et al. Electrical cardioversion </text>
<text top="557" left="95" width="273" height="13" font="22">during pregnancy: safe or not? Neth Heart J. 2011;19:134–6.</text>
<text top="570" left="69" width="351" height="13" font="22"> 520.  Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac ar-</text>
<text top="584" left="95" width="330" height="13" font="22">rest in special situations: 2010 American Heart Association guidelines </text>
<text top="597" left="95" width="330" height="13" font="22">for cardiopulmonary resuscitation and emergency cardiovascular care. </text>
<text top="611" left="95" width="145" height="13" font="22">Circulation. 2010;122:S829–61.</text>
<text top="624" left="69" width="356" height="13" font="22"> 521. Ersbøll AS, Hedegaard M, Søndergaard L, et al. Treatment with oral </text>
<text top="638" left="95" width="330" height="13" font="22">beta-blockers during pregnancy complicated by maternal heart disease </text>
<text top="651" left="95" width="317" height="13" font="22">increases the risk of fetal growth restriction. BJOG. 2014;121:618–26.</text>
<text top="665" left="69" width="356" height="13" font="22"> 522. Allen NM, Page RL. Procainamide administration during pregnancy. </text>
<text top="678" left="95" width="128" height="13" font="22">Clin Pharm. 1993;12:58–60.</text>
<text top="692" left="69" width="351" height="13" font="22"> 523.  Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone ad-</text>
<text top="705" left="95" width="326" height="13" font="22">ministration during pregnancy on neonatal thyroid function and subse-</text>
<text top="719" left="95" width="286" height="13" font="22">quent neurodevelopment. J Endocrinol Invest. 2001;24:116–30.</text>
<text top="732" left="69" width="306" height="13" font="22"> 524.  Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. </text>
<text top="732" left="375" width="48" height="13" font="22">ß-Blocker </text>
<text top="746" left="95" width="326" height="13" font="22">treatment during pregnancy and adverse pregnancy outcomes: a nation-</text>
<text top="759" left="95" width="255" height="13" font="22">wide population-based cohort study. BMJ Open. 2012;2.</text>
<text top="773" left="69" width="351" height="13" font="22"> 525.  Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in preg-</text>
<text top="786" left="95" width="321" height="13" font="22">nancies complicated by hypertension. Am J Hypertens. 1999;12:541–7.</text>
<text top="800" left="69" width="351" height="13" font="22"> 526.  Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of se-</text>
<text top="813" left="95" width="332" height="13" font="22">vere drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc </text>
<text top="827" left="95" width="148" height="13" font="22">Electrophysiol. 2010;21:877–82.</text>
<text top="840" left="69" width="351" height="13" font="22"> 527.  Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radia-</text>
<text top="854" left="95" width="328" height="13" font="22">tion dose and risk from cardiac catheter ablation procedures. Circulation. </text>
<text top="867" left="95" width="77" height="13" font="22">2001;104:893–7.</text>
<text top="881" left="69" width="6" height="13" font="22"> </text>
<text top="881" left="69" width="351" height="13" font="22">528. McCollough CH, Schueler BA, Atwell TD, et al. Radiation expo-</text>
<text top="894" left="95" width="331" height="13" font="22">sure and pregnancy: when should we be concerned? Radiographics. </text>
<text top="908" left="95" width="77" height="13" font="22">2007;27:909–17.</text>
<text top="921" left="69" width="351" height="13" font="22"> 529.  Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the preg-</text>
<text top="935" left="95" width="247" height="13" font="22">nant patient. AJR Am J Roentgenol. 2013;200:515–21.</text>
<text top="948" left="69" width="351" height="13" font="22"> 530.  Chen SA, Lee SH, Wu TJ, et al. Initial onset of accessory pathway-medi-</text>
<text top="962" left="95" width="328" height="13" font="22">ated and atrioventricular node reentrant tachycardia after age 65: clinical </text>
<text top="98" left="482" width="326" height="13" font="22">features, electrophysiologic characteristics, and possible facilitating fac-</text>
<text top="111" left="482" width="182" height="13" font="22">tors. J Am Geriatr Soc. 1995;43:1370–7.</text>
<text top="125" left="456" width="351" height="13" font="22"> 531.  Chen SA, Chiang CE, Tai CT, et al. Complications of diagnostic electro-</text>
<text top="138" left="482" width="328" height="13" font="22">physiologic studies and radiofrequency catheter ablation in patients with </text>
<text top="152" left="482" width="329" height="13" font="22">tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures </text>
<text top="165" left="482" width="254" height="13" font="22">in a tertiary referral center. Am J Cardiol. 1996;77:41–6.</text>
<text top="179" left="456" width="354" height="13" font="22"> 532.  Zado ES, Callans DJ, Gottlieb CD, et al. Efficacy and safety of catheter </text>
<text top="192" left="482" width="283" height="13" font="22">ablation in octogenarians. J Am Coll Cardiol. 2000;35:458–62.</text>
<text top="206" left="456" width="351" height="13" font="22"> 533.  Rostock T, Risius T, Ventura R, et al. Efficacy and safety of radiofre-</text>
<text top="219" left="482" width="329" height="13" font="22">quency catheter ablation of atrioventricular nodal reentrant tachycardia </text>
<text top="233" left="482" width="272" height="13" font="22">in the elderly. J Cardiovasc Electrophysiol. 2005;16:608–10.</text>
<text top="246" left="456" width="355" height="13" font="22"> 534.  Kihel J, Da Costa A, Kihel A, et al. Long-term efficacy and safety of </text>
<text top="260" left="482" width="325" height="13" font="22">radiofrequency ablation in elderly patients with atrioventricular nodal re-</text>
<text top="273" left="482" width="211" height="13" font="22">entrant tachycardia. Europace. 2006;8:416–20.</text>
<text top="287" left="456" width="351" height="13" font="22"> 535.  Dagres N, Piorkowski C, Kottkamp H, et al. Contemporary catheter abla-</text>
<text top="301" left="482" width="326" height="13" font="22">tion of arrhythmias in geriatric patients: patient characteristics, distribu-</text>
<text top="314" left="482" width="274" height="13" font="22">tion of arrhythmias, and outcome. Europace. 2007;9:477–80.</text>
<text top="328" left="456" width="351" height="13" font="22"> 536.  Pedrinazzi C, Durin O, Agricola P, et al. Efficacy and safety of radio-</text>
<text top="341" left="482" width="329" height="13" font="22">frequency catheter ablation in the elderly. J Interv Card Electrophysiol. </text>
<text top="355" left="482" width="77" height="13" font="22">2007;19:179–85.</text>
<text top="368" left="456" width="351" height="13" font="22"> 537.  Hoffmann BA, Brachmann J, Andresen D, et al. Ablation of atrioventric-</text>
<text top="382" left="482" width="329" height="13" font="22">ular nodal reentrant tachycardia in the elderly: results from the German </text>
<text top="395" left="482" width="220" height="13" font="22">Ablation Registry. Heart Rhythm. 2011;8:981–7.</text>
<text top="409" left="456" width="351" height="13" font="22"> 538.  Yangni N’Da’ O, Brembilla-Perrot B. Clinical characteristics and man-</text>
<text top="422" left="482" width="332" height="13" font="22">agement of paroxysmal junctional tachycardia in the elderly. Arch </text>
<text top="436" left="482" width="151" height="13" font="22">Cardiovasc Dis. 2008;101:143–8.</text>
<text top="449" left="456" width="354" height="13" font="22"> 539.  Boulos M, Hoch D, Schecter S, et al. Age dependence of complete heart </text>
<text top="463" left="482" width="328" height="13" font="22">block complicating radiofrequency ablation of the atrioventricular nodal </text>
<text top="476" left="482" width="203" height="13" font="22">slow pathway. Am J Cardiol. 1998;82:390–1.</text>
<text top="490" left="456" width="354" height="13" font="22"> 540.  Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on </text>
<text top="503" left="482" width="331" height="13" font="22">quality-of-life and health care costs in patients with supraventricular </text>
<text top="517" left="482" width="330" height="13" font="22">tachycardia (radiofrequency catheter ablation versus medical therapy). </text>
<text top="530" left="482" width="143" height="13" font="22">Am J Cardiol. 2002;89:1120–3.</text>
<text top="544" left="456" width="356" height="13" font="22"> 541. Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter </text>
<text top="557" left="482" width="329" height="13" font="22">ablation versus medical therapy for initial treatment of supraventricular </text>
<text top="571" left="482" width="329" height="13" font="22">tachycardia and its impact on quality of life and healthcare costs. Am J </text>
<text top="585" left="482" width="116" height="13" font="22">Cardiol. 1998;82:589–93.</text>
<text top="598" left="456" width="355" height="13" font="22"> 542.  Meissner A, Stifoudi I, Weismüller P, et al. Sustained high quality of </text>
<text top="612" left="482" width="325" height="13" font="22">life in a 5-year long term follow-up after successful ablation for supra-</text>
<text top="626" left="482" width="7" height="12" font="22"> </text>
<text top="625" left="482" width="328" height="13" font="22">ventricular tachycardia: results from a large retrospective patient cohort. </text>
<text top="639" left="482" width="131" height="13" font="22">Int J Med Sci. 2009;6:28–36.</text>
<text top="652" left="456" width="354" height="13" font="22"> 543.  Wood KA, Stewart AL, Drew BJ, et al. Patient perception of symptoms </text>
<text top="666" left="482" width="330" height="13" font="22">and quality of life following ablation in patients with supraventricular </text>
<text top="679" left="482" width="186" height="13" font="22">tachycardia. Heart Lung. 2010;39:12–20.</text>
<text top="693" left="456" width="351" height="13" font="22"> 544.  Yildirim O, Yontar OC, Semiz M, et al. The effect of radiofrequency ab-</text>
<text top="706" left="482" width="325" height="13" font="22">lation treatment on quality of life and anxiety in patients with supraven-</text>
<text top="720" left="482" width="309" height="13" font="22">tricular tachycardia. Eur Rev Med Pharmacol Sci. 2012;16:2108–12.</text>
<text top="733" left="456" width="351" height="13" font="22"> 545.  Farkowski MM, Pytkowski M, Maciag A, et al. Gender-related differ-</text>
<text top="747" left="482" width="326" height="13" font="22">ences in outcomes and resource utilization in patients undergoing radio-</text>
<text top="760" left="482" width="328" height="13" font="22">frequency ablation of supraventricular tachycardia: results from Patients’ </text>
<text top="774" left="482" width="329" height="13" font="22">Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT </text>
<text top="787" left="482" width="141" height="13" font="22">Study. Europace. 2014:1821–7.</text>
<text top="801" left="456" width="354" height="13" font="22"> 546.  Larson MS, McDonald K, Young C, et al. Quality of life before and after </text>
<text top="814" left="482" width="325" height="13" font="22">radiofrequency catheter ablation in patients with drug refractory atrioven-</text>
<text top="828" left="482" width="319" height="13" font="22">tricular nodal reentrant tachycardia. Am J Cardiol. 1999;84:471–3, A9.</text>
<text top="841" left="456" width="355" height="13" font="22"> 547.  Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical </text>
<text top="855" left="482" width="324" height="13" font="22">outcomes after catheter ablation of atrial flutter. PLoS One. 2014;9:e100509.</text>
<text top="885" left="456" width="8" height="13" font="22">K</text>
<text top="888" left="464" width="13" height="9" font="14">EY </text>
<text top="885" left="480" width="11" height="13" font="22">W</text>
<text top="888" left="491" width="22" height="9" font="14">ORDS</text>
<text top="885" left="513" width="145" height="13" font="22">: AHA Scientific Statements </text>
<text top="885" left="658" width="156" height="13" font="22">◼ tachycardia, supraventricular </text>
<text top="897" left="456" width="359" height="13" font="22">◼ tachycardia, atrioventricular nodal reentry ◼ Wolff-Parkinson-White </text>
<text top="911" left="456" width="47" height="13" font="22">syndrome </text>
<text top="910" left="506" width="307" height="13" font="22">◼ catheter ablation ◼ tachycardia, ectopic atrial ◼ tachycardia, </text>
<text top="924" left="456" width="90" height="13" font="22">ectopic junctional </text>
<text top="923" left="546" width="267" height="13" font="22">◼ atrial flutter ◼ anti-arrhythmia agents ◼ accessory </text>
<text top="936" left="456" width="111" height="13" font="22">atrioventricular bundle </text>
<text top="936" left="567" width="246" height="13" font="22">◼ Valsalva maneuver ◼ tachycardia, reciprocating </text>
<text top="949" left="456" width="358" height="13" font="22">◼ electric countershock ◼ heart defects, congenital ◼ death, sudden  </text>
<text top="961" left="456" width="285" height="13" font="22">◼ electrophysiologic techniques, cardiac ◼ sinus tachycardia</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="24" size="8" family="Times" color="#231f20"/>
<text top="47" left="71" width="243" height="17" font="11"><i><b>e570  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="97" left="71" width="740" height="16" font="17"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2015 ACC/AHA/HRS Guideline for the Management of </b></text>
<text top="112" left="71" width="345" height="16" font="17"><b>Adult Patients With Supraventricular Tachycardia (April 2014)</b></text>
<text top="165" left="81" width="45" height="12" font="24">Committee </text>
<text top="178" left="81" width="32" height="12" font="24">Member</text>
<text top="178" left="184" width="48" height="12" font="24">Employment</text>
<text top="178" left="314" width="41" height="12" font="24">Consultant</text>
<text top="165" left="405" width="39" height="12" font="24">Speakers </text>
<text top="178" left="410" width="28" height="12" font="24">Bureau</text>
<text top="152" left="461" width="44" height="12" font="24">Ownership/</text>
<text top="165" left="460" width="47" height="12" font="24">Partnership/</text>
<text top="178" left="467" width="33" height="12" font="24">Principal</text>
<text top="165" left="542" width="38" height="12" font="24">Personal  </text>
<text top="178" left="541" width="36" height="12" font="24">Research</text>
<text top="139" left="626" width="50" height="12" font="24">Institutional, </text>
<text top="152" left="621" width="63" height="12" font="24">Organizational,  </text>
<text top="165" left="634" width="37" height="12" font="24">or Other  </text>
<text top="178" left="617" width="64" height="12" font="24">Financial Benefit</text>
<text top="165" left="704" width="27" height="12" font="24">Expert </text>
<text top="178" left="701" width="31" height="12" font="24">Witness</text>
<text top="165" left="742" width="64" height="12" font="24">Voting Recusals </text>
<text top="178" left="751" width="44" height="12" font="24">by Section*</text>
<text top="199" left="81" width="42" height="12" font="24">Richard L. </text>
<text top="212" left="81" width="44" height="12" font="24">Page, Chair</text>
<text top="199" left="147" width="92" height="12" font="24">University of Wisconsin </text>
<text top="212" left="147" width="119" height="12" font="24">School of Medicine and Public </text>
<text top="224" left="147" width="119" height="12" font="24">Health—Chair, Department of </text>
<text top="237" left="147" width="35" height="12" font="24">Medicine</text>
<text top="199" left="325" width="20" height="12" font="24">None</text>
<text top="199" left="413" width="20" height="12" font="24">None</text>
<text top="199" left="473" width="20" height="12" font="24">None</text>
<text top="199" left="549" width="20" height="12" font="24">None</text>
<text top="199" left="640" width="20" height="12" font="24">None</text>
<text top="199" left="706" width="20" height="12" font="24">None</text>
<text top="199" left="763" width="20" height="12" font="24">None</text>
<text top="258" left="81" width="33" height="12" font="24">José A.  </text>
<text top="271" left="81" width="48" height="12" font="24">Joglar, Vice </text>
<text top="284" left="81" width="20" height="12" font="24">Chair</text>
<text top="258" left="147" width="76" height="12" font="24">University of Texas </text>
<text top="271" left="147" width="125" height="12" font="24">Southwestern Medical Center—</text>
<text top="284" left="147" width="121" height="12" font="24">Professor of Internal Medicine; </text>
<text top="297" left="147" width="102" height="12" font="24">Program Director, Clinical </text>
<text top="309" left="147" width="99" height="12" font="24">Cardiac Electrophysiology</text>
<text top="258" left="325" width="20" height="12" font="24">None</text>
<text top="258" left="413" width="20" height="12" font="24">None</text>
<text top="258" left="473" width="20" height="12" font="24">None</text>
<text top="258" left="549" width="20" height="12" font="24">None</text>
<text top="258" left="640" width="20" height="12" font="24">None</text>
<text top="258" left="706" width="20" height="12" font="24">None</text>
<text top="258" left="763" width="20" height="12" font="24">None</text>
<text top="330" left="81" width="34" height="12" font="24">Sana M. </text>
<text top="343" left="81" width="36" height="12" font="24">Al-Khatib</text>
<text top="330" left="147" width="92" height="12" font="24">Duke Clinical Research </text>
<text top="343" left="147" width="120" height="12" font="24">Institute—Associate Professor </text>
<text top="356" left="147" width="45" height="12" font="24">of Medicine</text>
<text top="330" left="325" width="20" height="12" font="24">None</text>
<text top="330" left="413" width="20" height="12" font="24">None</text>
<text top="330" left="473" width="20" height="12" font="24">None</text>
<text top="330" left="549" width="20" height="12" font="24">None</text>
<text top="330" left="640" width="20" height="12" font="24">None</text>
<text top="330" left="706" width="20" height="12" font="24">None</text>
<text top="330" left="763" width="20" height="12" font="24">None</text>
<text top="377" left="81" width="32" height="12" font="24">Mary A. </text>
<text top="390" left="81" width="33" height="12" font="24">Caldwell</text>
<text top="377" left="147" width="107" height="12" font="24">University of California San </text>
<text top="390" left="147" width="125" height="12" font="24">Francisco—Assistant Professor </text>
<text top="403" left="147" width="33" height="12" font="24">(Retired)</text>
<text top="377" left="325" width="20" height="12" font="24">None</text>
<text top="377" left="413" width="20" height="12" font="24">None</text>
<text top="377" left="473" width="20" height="12" font="24">None</text>
<text top="377" left="549" width="20" height="12" font="24">None</text>
<text top="377" left="640" width="20" height="12" font="24">None</text>
<text top="377" left="706" width="20" height="12" font="24">None</text>
<text top="377" left="763" width="20" height="12" font="24">None</text>
<text top="424" left="81" width="51" height="12" font="24">Hugh Calkins</text>
<text top="424" left="147" width="101" height="12" font="24">Johns Hopkins Hospital—</text>
<text top="437" left="147" width="122" height="12" font="24">Professor of Medicine, Director </text>
<text top="449" left="147" width="78" height="12" font="24">of Electrophysiology</text>
<text top="424" left="281" width="41" height="12" font="24">•  Atricure</text>
<text top="436" left="281" width="93" height="12" font="24">•  Boehringer Ingelheim</text>
<text top="449" left="281" width="69" height="12" font="24">•  Daiichi-Sankyo</text>
<text top="424" left="413" width="20" height="12" font="24">None</text>
<text top="424" left="473" width="20" height="12" font="24">None</text>
<text top="424" left="521" width="80" height="12" font="24">•   St. Jude Medical†</text>
<text top="424" left="640" width="20" height="12" font="24">None</text>
<text top="424" left="706" width="20" height="12" font="24">None</text>
<text top="424" left="750" width="48" height="12" font="24">All Sections </text>
<text top="436" left="742" width="63" height="12" font="24">except 2.4, 5.2, </text>
<text top="449" left="741" width="67" height="12" font="24">6.1.2, 9.3.2, and </text>
<text top="462" left="765" width="15" height="12" font="24">9.4.</text>
<text top="483" left="81" width="39" height="12" font="24">Jamie B.  </text>
<text top="496" left="81" width="20" height="12" font="24">Conti</text>
<text top="483" left="147" width="126" height="12" font="24">University of Florida—Professor </text>
<text top="496" left="147" width="82" height="12" font="24">of Medicine, Chief of </text>
<text top="509" left="147" width="95" height="12" font="24">Cardiovascular Medicine</text>
<text top="483" left="325" width="20" height="12" font="24">None</text>
<text top="483" left="413" width="20" height="12" font="24">None</text>
<text top="483" left="473" width="20" height="12" font="24">None</text>
<text top="483" left="521" width="49" height="12" font="24">•  Medtronic</text>
<text top="483" left="609" width="80" height="12" font="24">•  Boston Scientific‡</text>
<text top="496" left="609" width="54" height="12" font="24">•  Medtronic‡</text>
<text top="509" left="609" width="80" height="12" font="24">•  St. Jude Medical‡</text>
<text top="483" left="706" width="20" height="12" font="24">None</text>
<text top="483" left="750" width="48" height="12" font="24">All Sections </text>
<text top="496" left="739" width="71" height="12" font="24">except 2.4, 6.1.2, </text>
<text top="509" left="744" width="57" height="12" font="24">9.3.2, and 9.4.</text>
<text top="530" left="81" width="43" height="12" font="24">Barbara J. </text>
<text top="543" left="81" width="17" height="12" font="24">Deal</text>
<text top="530" left="147" width="115" height="12" font="24">Feinberg School of Medicine, </text>
<text top="543" left="147" width="103" height="12" font="24">Northwestern University—</text>
<text top="555" left="147" width="110" height="12" font="24">Professor of Pediatrics; Ann </text>
<text top="568" left="147" width="110" height="12" font="24">&amp; Robert H. Lurie Children’s </text>
<text top="581" left="147" width="118" height="12" font="24">Hospital of Chicago—Division </text>
<text top="594" left="147" width="66" height="12" font="24">Head, Cardiology</text>
<text top="530" left="325" width="20" height="12" font="24">None</text>
<text top="530" left="413" width="20" height="12" font="24">None</text>
<text top="530" left="473" width="20" height="12" font="24">None</text>
<text top="530" left="549" width="20" height="12" font="24">None</text>
<text top="530" left="640" width="20" height="12" font="24">None</text>
<text top="530" left="706" width="20" height="12" font="24">None</text>
<text top="530" left="763" width="20" height="12" font="24">None</text>
<text top="615" left="81" width="41" height="12" font="24">N.A. Mark </text>
<text top="627" left="81" width="30" height="12" font="24">Estes III</text>
<text top="615" left="147" width="101" height="12" font="24">Tufts University School of </text>
<text top="627" left="147" width="95" height="12" font="24">Medicine—Professor of </text>
<text top="640" left="147" width="35" height="12" font="24">Medicine</text>
<text top="615" left="281" width="80" height="12" font="24">•  Boston Scientific†</text>
<text top="627" left="281" width="49" height="12" font="24">•  Medtronic</text>
<text top="640" left="281" width="75" height="12" font="24">•  St. Jude Medical</text>
<text top="615" left="413" width="20" height="12" font="24">None</text>
<text top="615" left="473" width="20" height="12" font="24">None</text>
<text top="615" left="521" width="42" height="12" font="24">•   Boston  </text>
<text top="627" left="531" width="36" height="12" font="24">Scientific</text>
<text top="615" left="609" width="80" height="12" font="24">•  Boston Scientific†</text>
<text top="627" left="609" width="54" height="12" font="24">•  Medtronic†</text>
<text top="640" left="609" width="80" height="12" font="24">•  St. Jude Medical†</text>
<text top="615" left="706" width="20" height="12" font="24">None</text>
<text top="615" left="750" width="48" height="12" font="24">All Sections </text>
<text top="627" left="742" width="63" height="12" font="24">except 2.4, 5.2, </text>
<text top="640" left="741" width="67" height="12" font="24">6.1.2, 9.3.2, and </text>
<text top="653" left="765" width="15" height="12" font="24">9.4.</text>
<text top="674" left="81" width="43" height="12" font="24">Michael E. </text>
<text top="687" left="81" width="18" height="12" font="24">Field</text>
<text top="674" left="147" width="92" height="12" font="24">University of Wisconsin </text>
<text top="687" left="147" width="119" height="12" font="24">School of Medicine and Public </text>
<text top="700" left="147" width="122" height="12" font="24">Health—Assistant Professor of </text>
<text top="712" left="147" width="115" height="12" font="24">Medicine, Director of Cardiac </text>
<text top="725" left="147" width="74" height="12" font="24">Arrhythmia Service</text>
<text top="674" left="325" width="20" height="12" font="24">None</text>
<text top="674" left="413" width="20" height="12" font="24">None</text>
<text top="674" left="473" width="20" height="12" font="24">None</text>
<text top="674" left="549" width="20" height="12" font="24">None</text>
<text top="674" left="640" width="20" height="12" font="24">None</text>
<text top="674" left="706" width="20" height="12" font="24">None</text>
<text top="674" left="763" width="20" height="12" font="24">None</text>
<text top="746" left="81" width="44" height="12" font="24">Zachary D. </text>
<text top="759" left="81" width="43" height="12" font="24">Goldberger</text>
<text top="746" left="147" width="98" height="12" font="24">University of Washington </text>
<text top="759" left="147" width="122" height="12" font="24">School of Medicine—Assistant </text>
<text top="772" left="147" width="84" height="12" font="24">Professor of Medicine</text>
<text top="746" left="325" width="20" height="12" font="24">None</text>
<text top="746" left="413" width="20" height="12" font="24">None</text>
<text top="746" left="473" width="20" height="12" font="24">None</text>
<text top="746" left="549" width="20" height="12" font="24">None</text>
<text top="746" left="640" width="20" height="12" font="24">None</text>
<text top="746" left="706" width="20" height="12" font="24">None</text>
<text top="746" left="763" width="20" height="12" font="24">None</text>
<text top="793" left="81" width="45" height="12" font="24">Stephen C. </text>
<text top="806" left="81" width="32" height="12" font="24">Hammill</text>
<text top="793" left="147" width="94" height="12" font="24">Mayo Clinic—Professor </text>
<text top="806" left="147" width="82" height="12" font="24">Emeritus of Medicine</text>
<text top="793" left="325" width="20" height="12" font="24">None</text>
<text top="793" left="413" width="20" height="12" font="24">None</text>
<text top="793" left="473" width="20" height="12" font="24">None</text>
<text top="793" left="549" width="20" height="12" font="24">None</text>
<text top="793" left="640" width="20" height="12" font="24">None</text>
<text top="793" left="706" width="20" height="12" font="24">None</text>
<text top="793" left="763" width="20" height="12" font="24">None</text>
<text top="827" left="81" width="50" height="12" font="24">Julia H. Indik</text>
<text top="827" left="147" width="90" height="12" font="24">University of Arizona—</text>
<text top="840" left="147" width="124" height="12" font="24">Associate Professor of Medicine</text>
<text top="827" left="325" width="20" height="12" font="24">None</text>
<text top="827" left="413" width="20" height="12" font="24">None</text>
<text top="827" left="473" width="20" height="12" font="24">None</text>
<text top="827" left="549" width="20" height="12" font="24">None</text>
<text top="827" left="640" width="20" height="12" font="24">None</text>
<text top="827" left="706" width="20" height="12" font="24">None</text>
<text top="827" left="763" width="20" height="12" font="24">None</text>
<text top="861" left="81" width="36" height="12" font="24">Bruce D. </text>
<text top="874" left="81" width="30" height="12" font="24">Lindsay</text>
<text top="861" left="147" width="117" height="12" font="24">Cleveland Clinic Foundation—</text>
<text top="874" left="147" width="90" height="12" font="24">Professor of Cardiology</text>
<text top="861" left="284" width="80" height="12" font="24">•  Biosense Webster</text>
<text top="874" left="284" width="75" height="12" font="24">•  Boston Scientific</text>
<text top="886" left="284" width="61" height="12" font="24">•  CardioInsight</text>
<text top="899" left="284" width="49" height="12" font="24">•  Medtronic</text>
<text top="861" left="413" width="20" height="12" font="24">None</text>
<text top="861" left="473" width="20" height="12" font="24">None</text>
<text top="861" left="549" width="20" height="12" font="24">None</text>
<text top="861" left="609" width="80" height="12" font="24">•  Boston Scientific†</text>
<text top="874" left="609" width="54" height="12" font="24">•  Medtronic†</text>
<text top="886" left="609" width="80" height="12" font="24">•  St. Jude Medical†</text>
<text top="861" left="706" width="20" height="12" font="24">None</text>
<text top="861" left="750" width="48" height="12" font="24">All Sections </text>
<text top="874" left="743" width="63" height="12" font="24">except 2.4, 5.2, </text>
<text top="886" left="741" width="67" height="12" font="24">6.1.2, 9.3.2, and </text>
<text top="899" left="765" width="15" height="12" font="24">9.4.</text>
<text top="920" left="81" width="23" height="12" font="24">Brian </text>
<text top="933" left="81" width="40" height="12" font="24">Olshansky</text>
<text top="920" left="147" width="117" height="12" font="24">University of Iowa Hospitals—</text>
<text top="933" left="147" width="126" height="12" font="24">Professor Emeritus of Medicine; </text>
<text top="946" left="147" width="88" height="12" font="24">Mercy Hospital Mason </text>
<text top="958" left="147" width="98" height="12" font="24">City—Electrophysiologist</text>
<text top="920" left="284" width="50" height="12" font="24">•  BioControl</text>
<text top="933" left="284" width="45" height="12" font="24">•  Biotronik</text>
<text top="946" left="284" width="94" height="12" font="24">•  Boehringer-Ingelheim</text>
<text top="958" left="284" width="103" height="12" font="24">•   Boston Scientific-Guidant</text>
<text top="971" left="284" width="69" height="12" font="24">•  Daiichi-Sankyo</text>
<text top="984" left="284" width="54" height="12" font="24">•  Medtronic†</text>
<text top="997" left="284" width="66" height="12" font="24">•  Sanofi-aventis</text>
<text top="920" left="413" width="20" height="12" font="24">None</text>
<text top="920" left="473" width="20" height="12" font="24">None</text>
<text top="920" left="521" width="70" height="12" font="24">•   Amarin (DSMB)</text>
<text top="933" left="521" width="78" height="12" font="24">•   Boston Scientific </text>
<text top="946" left="531" width="29" height="12" font="24">(DSMB)</text>
<text top="958" left="521" width="71" height="12" font="24">•    Sanofi-aventis </text>
<text top="971" left="531" width="29" height="12" font="24">(DSMB)</text>
<text top="920" left="609" width="75" height="12" font="24">•  Boston Scientific</text>
<text top="920" left="706" width="20" height="12" font="24">None</text>
<text top="920" left="750" width="48" height="12" font="24">All Sections </text>
<text top="933" left="744" width="60" height="12" font="24">except 2.4 and </text>
<text top="946" left="765" width="15" height="12" font="24">9.4.</text>
<text top="1018" left="81" width="42" height="12" font="24">Andrea M. </text>
<text top="1031" left="81" width="24" height="12" font="24">Russo</text>
<text top="1018" left="147" width="101" height="12" font="24">Cooper Medical School of </text>
<text top="1031" left="147" width="116" height="12" font="24">Rowan University—Professor </text>
<text top="1043" left="147" width="80" height="12" font="24">of Medicine; Cooper </text>
<text top="1056" left="147" width="118" height="12" font="24">University Hospital—Director, </text>
<text top="1069" left="147" width="87" height="12" font="24">Electrophysiology and </text>
<text top="1082" left="147" width="78" height="12" font="24">Arrhythmia Services</text>
<text top="1018" left="284" width="45" height="12" font="24">•  Biotronik</text>
<text top="1031" left="284" width="75" height="12" font="24">•  Boston Scientific</text>
<text top="1043" left="284" width="49" height="12" font="24">•  Medtronic</text>
<text top="1056" left="284" width="75" height="12" font="24">•  St. Jude Medical</text>
<text top="1018" left="413" width="20" height="12" font="24">None</text>
<text top="1018" left="473" width="20" height="12" font="24">None</text>
<text top="1018" left="521" width="54" height="12" font="24">•  Medtronic†</text>
<text top="1018" left="612" width="50" height="12" font="24">•  Biotronik‡</text>
<text top="1031" left="612" width="80" height="12" font="24">•  Boston Scientific†</text>
<text top="1018" left="706" width="20" height="12" font="24">None</text>
<text top="1018" left="750" width="48" height="12" font="24">All Sections </text>
<text top="1031" left="743" width="63" height="12" font="24">except 2.4, 5.2, </text>
<text top="1043" left="741" width="67" height="12" font="24">6.1.2, 9.3.2, and </text>
<text top="1056" left="765" width="15" height="12" font="24">9.4.</text>
<text top="1103" left="763" width="45" height="12" font="24">(Continued )</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e571</i></b></text>
<text top="181" left="80" width="45" height="12" font="24">Win-Kuang </text>
<text top="193" left="80" width="20" height="12" font="24">Shen</text>
<text top="181" left="146" width="126" height="12" font="24">Mayo Clinic Arizona—Professor </text>
<text top="193" left="146" width="118" height="12" font="24">of Medicine; Chair, Division of </text>
<text top="206" left="146" width="95" height="12" font="24">Cardiovascular Diseases</text>
<text top="181" left="323" width="20" height="12" font="24">None</text>
<text top="181" left="412" width="20" height="12" font="24">None</text>
<text top="181" left="472" width="20" height="12" font="24">None</text>
<text top="181" left="547" width="20" height="12" font="24">None</text>
<text top="181" left="638" width="20" height="12" font="24">None</text>
<text top="181" left="704" width="20" height="12" font="24">None</text>
<text top="181" left="761" width="20" height="12" font="24">None</text>
<text top="227" left="80" width="44" height="12" font="24">Cynthia M. </text>
<text top="240" left="80" width="21" height="12" font="24">Tracy</text>
<text top="227" left="146" width="78" height="12" font="24">George Washington </text>
<text top="240" left="146" width="97" height="12" font="24">University—Professor of </text>
<text top="253" left="146" width="113" height="12" font="24">Medicine; Associate Director </text>
<text top="265" left="146" width="122" height="12" font="24">Division of Cardiology, Director </text>
<text top="278" left="146" width="75" height="12" font="24">of Cardiac Services</text>
<text top="227" left="323" width="20" height="12" font="24">None</text>
<text top="227" left="412" width="20" height="12" font="24">None</text>
<text top="227" left="472" width="20" height="12" font="24">None</text>
<text top="227" left="547" width="20" height="12" font="24">None</text>
<text top="227" left="638" width="20" height="12" font="24">None</text>
<text top="227" left="704" width="20" height="12" font="24">None</text>
<text top="227" left="761" width="20" height="12" font="24">None</text>
<text top="297" left="81" width="731" height="14" font="3">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These </text>
<text top="312" left="69" width="741" height="14" font="3">relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. </text>
<text top="327" left="69" width="741" height="14" font="3">The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest </text>
<text top="342" left="69" width="112" height="14" font="3">represents ownership of </text>
<text top="341" left="181" width="630" height="15" font="3">≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds </text>
<text top="357" left="69" width="741" height="14" font="3">received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also </text>
<text top="372" left="69" width="460" height="14" font="3">included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.</text>
<text top="387" left="81" width="729" height="14" font="3">According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property </text>
<text top="402" left="69" width="741" height="14" font="3">or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the </text>
<text top="417" left="69" width="741" height="14" font="3">document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for </text>
<text top="432" left="69" width="500" height="14" font="3">financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="447" left="81" width="726" height="14" font="3">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.</text>
<text top="462" left="81" width="110" height="14" font="3">†Significant relationship.</text>
<text top="477" left="81" width="94" height="14" font="3">‡No financial benefit.</text>
<text top="492" left="81" width="669" height="14" font="3">ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and HRS, Heart Rhythm Society.</text>
<text top="563" left="69" width="739" height="16" font="17"><b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant)—2015 ACC/AHA/HRS Guideline for the Management </b></text>
<text top="579" left="69" width="368" height="16" font="17"><b>of Adult Patients With Supraventricular Tachycardia (March 2015)</b></text>
<text top="656" left="80" width="35" height="12" font="24">Reviewer</text>
<text top="656" left="140" width="57" height="12" font="24">Representation</text>
<text top="656" left="245" width="47" height="12" font="24">Employment</text>
<text top="656" left="354" width="40" height="12" font="24">Consultant</text>
<text top="643" left="445" width="40" height="12" font="24">Speakers  </text>
<text top="656" left="450" width="27" height="12" font="24">Bureau</text>
<text top="631" left="520" width="46" height="12" font="24">Ownership/ </text>
<text top="643" left="519" width="48" height="12" font="24">Partnership/ </text>
<text top="656" left="526" width="32" height="12" font="24">Principal</text>
<text top="643" left="598" width="37" height="12" font="24">Personal  </text>
<text top="656" left="597" width="35" height="12" font="24">Research</text>
<text top="606" left="669" width="49" height="12" font="24">Institutional, </text>
<text top="618" left="664" width="61" height="12" font="24">Organizational,  </text>
<text top="631" left="676" width="35" height="12" font="24">or Other  </text>
<text top="643" left="675" width="39" height="12" font="24">Financial  </text>
<text top="656" left="678" width="26" height="12" font="24">Benefit</text>
<text top="643" left="758" width="29" height="12" font="24">Expert  </text>
<text top="656" left="755" width="30" height="12" font="24">Witness</text>
<text top="677" left="80" width="41" height="12" font="24">Eugene H. </text>
<text top="689" left="80" width="24" height="12" font="24">Chung</text>
<text top="677" left="137" width="29" height="12" font="24">Official </text>
<text top="689" left="137" width="61" height="12" font="24">Reviewer—HRS</text>
<text top="677" left="220" width="105" height="12" font="24">University of North Carolina </text>
<text top="689" left="220" width="82" height="12" font="24">School of Medicine—</text>
<text top="702" left="220" width="86" height="12" font="24">Associate Professor of </text>
<text top="714" left="220" width="34" height="12" font="24">Medicine</text>
<text top="677" left="368" width="19" height="12" font="24">None</text>
<text top="677" left="453" width="19" height="12" font="24">None</text>
<text top="677" left="532" width="19" height="12" font="24">None</text>
<text top="677" left="605" width="19" height="12" font="24">None</text>
<text top="677" left="656" width="60" height="12" font="24">•  Zoll Medical†</text>
<text top="677" left="760" width="19" height="12" font="24">None</text>
<text top="735" left="80" width="33" height="12" font="24">Timm L. </text>
<text top="747" left="80" width="31" height="12" font="24">Dickfeld</text>
<text top="735" left="137" width="29" height="12" font="24">Official </text>
<text top="747" left="137" width="61" height="12" font="24">Reviewer—HRS</text>
<text top="735" left="220" width="89" height="12" font="24">University of Maryland  </text>
<text top="747" left="220" width="82" height="12" font="24">School of Medicine—</text>
<text top="760" left="220" width="86" height="12" font="24">Associate Professor of </text>
<text top="772" left="220" width="80" height="12" font="24">Medicine; Baltimore  </text>
<text top="785" left="220" width="94" height="12" font="24">Veterans Affairs Medical </text>
<text top="797" left="220" width="70" height="12" font="24">Center—Director, </text>
<text top="810" left="220" width="66" height="12" font="24">Electrophysiology</text>
<text top="735" left="337" width="78" height="12" font="24">•  Biosense Webster</text>
<text top="735" left="453" width="19" height="12" font="24">None</text>
<text top="735" left="532" width="19" height="12" font="24">None</text>
<text top="735" left="582" width="47" height="12" font="24">•   Biosense </text>
<text top="747" left="593" width="35" height="12" font="24">Webster*</text>
<text top="760" left="582" width="44" height="12" font="24">•   General  </text>
<text top="772" left="593" width="31" height="12" font="24">Electric*</text>
<text top="735" left="682" width="19" height="12" font="24">None</text>
<text top="735" left="760" width="19" height="12" font="24">None</text>
<text top="831" left="80" width="41" height="12" font="24">Samuel S. </text>
<text top="843" left="80" width="29" height="12" font="24">Gidding</text>
<text top="831" left="137" width="70" height="12" font="24">Official Reviewer—</text>
<text top="843" left="137" width="55" height="12" font="24">ACC/AHA Task </text>
<text top="855" left="137" width="61" height="12" font="24">Force on Clinical </text>
<text top="868" left="137" width="68" height="12" font="24">Practice Guidelines</text>
<text top="831" left="220" width="70" height="12" font="24">Nemours Cardiac  </text>
<text top="843" left="220" width="69" height="12" font="24">Center—Division  </text>
<text top="855" left="220" width="76" height="12" font="24">Chief of Cardiology; </text>
<text top="868" left="220" width="69" height="12" font="24">Jefferson Medical </text>
<text top="880" left="220" width="86" height="12" font="24">College—Professor of </text>
<text top="893" left="220" width="37" height="12" font="24">Pediatrics</text>
<text top="831" left="368" width="19" height="12" font="24">None</text>
<text top="831" left="453" width="19" height="12" font="24">None</text>
<text top="831" left="532" width="19" height="12" font="24">None</text>
<text top="831" left="605" width="19" height="12" font="24">None</text>
<text top="831" left="682" width="19" height="12" font="24">None</text>
<text top="831" left="760" width="19" height="12" font="24">None</text>
<text top="914" left="80" width="40" height="12" font="24">Richard J. </text>
<text top="926" left="80" width="27" height="12" font="24">Kovacs</text>
<text top="914" left="137" width="69" height="12" font="24">Official Reviewer—</text>
<text top="926" left="137" width="52" height="12" font="24">ACC Board of </text>
<text top="939" left="137" width="32" height="12" font="24">Trustees</text>
<text top="914" left="220" width="77" height="12" font="24">Krannert Institute of </text>
<text top="926" left="220" width="97" height="12" font="24">Cardiology—Professor of </text>
<text top="939" left="220" width="64" height="12" font="24">Clinical Medicine</text>
<text top="914" left="337" width="54" height="12" font="24">•   Biomedical </text>
<text top="926" left="347" width="36" height="12" font="24">Systems*</text>
<text top="914" left="453" width="19" height="12" font="24">None</text>
<text top="914" left="532" width="19" height="12" font="24">None</text>
<text top="914" left="582" width="48" height="12" font="24">•  Siemens†</text>
<text top="914" left="656" width="59" height="12" font="24">•   AstraZeneca </text>
<text top="926" left="666" width="28" height="12" font="24">(DSMB)</text>
<text top="939" left="656" width="33" height="12" font="24">•   MED  </text>
<text top="951" left="666" width="34" height="12" font="24">Institute*</text>
<text top="964" left="656" width="41" height="12" font="24">•   Eli Lilly  </text>
<text top="976" left="666" width="32" height="12" font="24">(DSMB)*</text>
<text top="989" left="656" width="31" height="12" font="24">•   Teva </text>
<text top="1001" left="666" width="58" height="12" font="24">Pharmaceuticals</text>
<text top="914" left="760" width="19" height="12" font="24">None</text>
<text top="1022" left="80" width="34" height="12" font="24">Byron K. </text>
<text top="1034" left="80" width="14" height="12" font="24">Lee</text>
<text top="1022" left="137" width="29" height="12" font="24">Official </text>
<text top="1034" left="137" width="61" height="12" font="24">Reviewer—AHA</text>
<text top="1022" left="220" width="104" height="12" font="24">University of California San </text>
<text top="1034" left="220" width="94" height="12" font="24">Francisco—Professor of </text>
<text top="1047" left="220" width="34" height="12" font="24">Medicine</text>
<text top="1022" left="337" width="44" height="12" font="24">•  Biotronik</text>
<text top="1034" left="337" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="1047" left="337" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="1022" left="453" width="19" height="12" font="24">None</text>
<text top="1022" left="532" width="19" height="12" font="24">None</text>
<text top="1022" left="582" width="59" height="12" font="24">•  Zoll Medical*</text>
<text top="1022" left="656" width="46" height="12" font="24">•  CarioNet*</text>
<text top="1022" left="736" width="53" height="12" font="24">•   Defendant, </text>
<text top="1034" left="747" width="44" height="12" font="24">Boehringer </text>
<text top="1047" left="747" width="42" height="12" font="24">Ingelheim, </text>
<text top="1059" left="747" width="25" height="12" font="24">2013†</text>
<text top="1076" left="762" width="45" height="12" font="24">(Continued )</text>
<text top="97" left="69" width="126" height="16" font="17"><b>Appendix 1. Continued</b></text>
<text top="146" left="80" width="45" height="12" font="24">Committee </text>
<text top="159" left="80" width="32" height="12" font="24">Member</text>
<text top="159" left="183" width="48" height="12" font="24">Employment</text>
<text top="159" left="313" width="41" height="12" font="24">Consultant</text>
<text top="146" left="399" width="39" height="12" font="24">Speakers </text>
<text top="159" left="403" width="28" height="12" font="24">Bureau</text>
<text top="133" left="454" width="44" height="12" font="24">Ownership/</text>
<text top="146" left="453" width="47" height="12" font="24">Partnership/</text>
<text top="159" left="460" width="33" height="12" font="24">Principal</text>
<text top="146" left="541" width="38" height="12" font="24">Personal  </text>
<text top="159" left="539" width="36" height="12" font="24">Research</text>
<text top="121" left="624" width="50" height="12" font="24">Institutional, </text>
<text top="133" left="619" width="63" height="12" font="24">Organizational,  </text>
<text top="146" left="632" width="37" height="12" font="24">or Other  </text>
<text top="159" left="616" width="64" height="12" font="24">Financial Benefit</text>
<text top="146" left="702" width="27" height="12" font="24">Expert </text>
<text top="159" left="699" width="31" height="12" font="24">Witness</text>
<text top="146" left="741" width="64" height="12" font="24">Voting Recusals </text>
<text top="159" left="749" width="44" height="12" font="24">by Section*</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e572  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="1076" left="763" width="45" height="12" font="24">(Continued )</text>
<text top="195" left="81" width="41" height="12" font="24">Gregory F. </text>
<text top="207" left="81" width="32" height="12" font="24">Michaud</text>
<text top="195" left="138" width="29" height="12" font="24">Official </text>
<text top="207" left="138" width="61" height="12" font="24">Reviewer—AHA</text>
<text top="195" left="221" width="99" height="12" font="24">Harvard Medical School—</text>
<text top="207" left="221" width="72" height="12" font="24">Assistant Professor</text>
<text top="195" left="338" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="207" left="338" width="48" height="12" font="24">•  Medtronic</text>
<text top="220" left="338" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="195" left="455" width="19" height="12" font="24">None</text>
<text top="195" left="534" width="19" height="12" font="24">None</text>
<text top="195" left="584" width="47" height="12" font="24">•   Biosense </text>
<text top="207" left="594" width="35" height="12" font="24">Webster*</text>
<text top="220" left="584" width="39" height="12" font="24">•   Boston </text>
<text top="232" left="594" width="38" height="12" font="24">Scientific*</text>
<text top="245" left="584" width="44" height="12" font="24">•   St. Jude </text>
<text top="257" left="594" width="33" height="12" font="24">Medical*</text>
<text top="195" left="683" width="19" height="12" font="24">None</text>
<text top="195" left="761" width="19" height="12" font="24">None</text>
<text top="278" left="81" width="31" height="12" font="24">Simone </text>
<text top="291" left="81" width="25" height="12" font="24">Musco</text>
<text top="278" left="138" width="29" height="12" font="24">Official </text>
<text top="291" left="138" width="64" height="12" font="24">Reviewer—ACC </text>
<text top="303" left="138" width="70" height="12" font="24">Board of Governors</text>
<text top="278" left="221" width="88" height="12" font="24">The International Heart </text>
<text top="291" left="221" width="78" height="12" font="24">Institute of Montana </text>
<text top="303" left="221" width="94" height="12" font="24">Foundation—Cardiology </text>
<text top="315" left="221" width="81" height="12" font="24">Research Investigator</text>
<text top="278" left="370" width="19" height="12" font="24">None</text>
<text top="278" left="426" width="66" height="12" font="24">•   Bristol-Myers  </text>
<text top="291" left="436" width="26" height="12" font="24">Squibb</text>
<text top="303" left="426" width="64" height="12" font="24">•  Sanofi-aventis</text>
<text top="278" left="534" width="19" height="12" font="24">None</text>
<text top="278" left="606" width="19" height="12" font="24">None</text>
<text top="278" left="683" width="19" height="12" font="24">None</text>
<text top="278" left="761" width="19" height="12" font="24">None</text>
<text top="336" left="81" width="36" height="12" font="24">Mohan N. </text>
<text top="349" left="81" width="44" height="12" font="24">Viswanathan</text>
<text top="336" left="138" width="29" height="12" font="24">Official </text>
<text top="349" left="138" width="61" height="12" font="24">Reviewer—AHA</text>
<text top="336" left="221" width="96" height="12" font="24">University of Washington </text>
<text top="349" left="221" width="82" height="12" font="24">School of Medicine—</text>
<text top="361" left="221" width="84" height="12" font="24">Assistant Professor of </text>
<text top="374" left="221" width="34" height="12" font="24">Medicine</text>
<text top="336" left="338" width="78" height="12" font="24">•  Biosense Webster</text>
<text top="349" left="338" width="48" height="12" font="24">•  Siemens†</text>
<text top="361" left="338" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="336" left="455" width="19" height="12" font="24">None</text>
<text top="336" left="534" width="19" height="12" font="24">None</text>
<text top="336" left="584" width="52" height="12" font="24">•  Medtronic*</text>
<text top="336" left="683" width="19" height="12" font="24">None</text>
<text top="336" left="761" width="19" height="12" font="24">None</text>
<text top="395" left="81" width="35" height="12" font="24">Seshadri </text>
<text top="407" left="81" width="21" height="12" font="24">Balaji</text>
<text top="395" left="138" width="66" height="12" font="24">Content Reviewer</text>
<text top="395" left="221" width="105" height="12" font="24">Oregon Health and Science </text>
<text top="407" left="221" width="85" height="12" font="24">University—Professor </text>
<text top="420" left="221" width="65" height="12" font="24">of Pediatrics and </text>
<text top="432" left="221" width="80" height="12" font="24">Pediatric Cardiology, </text>
<text top="445" left="221" width="86" height="12" font="24">Director of Pacing and </text>
<text top="457" left="221" width="66" height="12" font="24">Electrophysiology</text>
<text top="395" left="370" width="19" height="12" font="24">None</text>
<text top="395" left="455" width="19" height="12" font="24">None</text>
<text top="395" left="534" width="19" height="12" font="24">None</text>
<text top="395" left="584" width="52" height="12" font="24">•  Medtronic*</text>
<text top="395" left="683" width="19" height="12" font="24">None</text>
<text top="395" left="761" width="19" height="12" font="24">None</text>
<text top="478" left="81" width="36" height="12" font="24">Nancy C. </text>
<text top="490" left="81" width="18" height="12" font="24">Berg</text>
<text top="478" left="138" width="32" height="12" font="24">Content </text>
<text top="490" left="138" width="66" height="12" font="24">Reviewer—ACC  </text>
<text top="503" left="138" width="68" height="12" font="24">Electrophysiology </text>
<text top="515" left="138" width="28" height="12" font="24">Section</text>
<text top="478" left="221" width="77" height="12" font="24">Allina Health System</text>
<text top="478" left="370" width="19" height="12" font="24">None</text>
<text top="478" left="455" width="19" height="12" font="24">None</text>
<text top="478" left="534" width="19" height="12" font="24">None</text>
<text top="478" left="606" width="19" height="12" font="24">None</text>
<text top="478" left="683" width="19" height="12" font="24">None</text>
<text top="478" left="761" width="19" height="12" font="24">None</text>
<text top="536" left="81" width="30" height="12" font="24">Noel G. </text>
<text top="549" left="81" width="21" height="12" font="24">Boyle</text>
<text top="536" left="138" width="32" height="12" font="24">Content </text>
<text top="549" left="138" width="66" height="12" font="24">Reviewer—ACC  </text>
<text top="561" left="138" width="68" height="12" font="24">Electrophysiology </text>
<text top="574" left="138" width="28" height="12" font="24">Section</text>
<text top="536" left="221" width="102" height="12" font="24">University of California Los </text>
<text top="549" left="221" width="108" height="12" font="24">Angeles—Clinical Professor </text>
<text top="561" left="221" width="44" height="12" font="24">of Medicine</text>
<text top="536" left="370" width="19" height="12" font="24">None</text>
<text top="536" left="455" width="19" height="12" font="24">None</text>
<text top="536" left="534" width="19" height="12" font="24">None</text>
<text top="536" left="606" width="19" height="12" font="24">None</text>
<text top="536" left="683" width="19" height="12" font="24">None</text>
<text top="536" left="761" width="19" height="12" font="24">None</text>
<text top="595" left="81" width="31" height="12" font="24">A. John </text>
<text top="607" left="81" width="25" height="12" font="24">Camm</text>
<text top="595" left="138" width="66" height="12" font="24">Content Reviewer</text>
<text top="595" left="221" width="88" height="12" font="24">St. George’s University </text>
<text top="607" left="221" width="95" height="12" font="24">of London—Professor of </text>
<text top="619" left="221" width="69" height="12" font="24">Clinical Cardiology</text>
<text top="595" left="338" width="35" height="12" font="24">•  Bayer*</text>
<text top="607" left="338" width="44" height="12" font="24">•  Biotronik</text>
<text top="619" left="338" width="54" height="12" font="24">•   Boehringer </text>
<text top="632" left="348" width="37" height="12" font="24">Ingelheim</text>
<text top="644" left="338" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="657" left="338" width="39" height="12" font="24">•  ChanRx</text>
<text top="669" left="338" width="67" height="12" font="24">•  Daiichi-Sankyo</text>
<text top="682" left="338" width="48" height="12" font="24">•  Medtronic</text>
<text top="694" left="338" width="43" height="12" font="24">•  Menarini</text>
<text top="707" left="338" width="49" height="12" font="24">•  Mitsubishi</text>
<text top="719" left="338" width="46" height="12" font="24">•  Novartis†</text>
<text top="732" left="338" width="50" height="12" font="24">•   Richmond </text>
<text top="744" left="348" width="57" height="12" font="24">Pharmacology*</text>
<text top="756" left="338" width="64" height="12" font="24">•  Sanofi-aventis</text>
<text top="769" left="338" width="39" height="12" font="24">•   Servier </text>
<text top="781" left="348" width="66" height="12" font="24">Pharmaceuticals*</text>
<text top="794" left="338" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="806" left="338" width="40" height="12" font="24">•   Takeda </text>
<text top="819" left="348" width="62" height="12" font="24">Pharmaceuticals</text>
<text top="831" left="338" width="38" height="12" font="24">•  Xention</text>
<text top="595" left="426" width="34" height="12" font="24">•   Pfizer</text>
<text top="595" left="534" width="19" height="12" font="24">None</text>
<text top="595" left="606" width="19" height="12" font="24">None</text>
<text top="595" left="683" width="19" height="12" font="24">None</text>
<text top="595" left="761" width="19" height="12" font="24">None</text>
<text top="852" left="81" width="39" height="12" font="24">Robert M. </text>
<text top="865" left="81" width="35" height="12" font="24">Campbell</text>
<text top="852" left="138" width="31" height="12" font="24">Content </text>
<text top="865" left="138" width="62" height="12" font="24">Reviewer—ACC </text>
<text top="877" left="138" width="62" height="12" font="24">Adult Congenital </text>
<text top="889" left="138" width="50" height="12" font="24">and Pediatric </text>
<text top="902" left="138" width="67" height="12" font="24">Cardiology Section</text>
<text top="852" left="221" width="70" height="12" font="24">Sibley Heart Center </text>
<text top="865" left="221" width="80" height="12" font="24">Cardiology—Director, </text>
<text top="877" left="221" width="93" height="12" font="24">Chief of Cardiac Services; </text>
<text top="889" left="221" width="96" height="12" font="24">Emory University School of </text>
<text top="902" left="221" width="102" height="12" font="24">Medicine—Division Director </text>
<text top="914" left="221" width="84" height="12" font="24">of Pediatric Cardiology, </text>
<text top="927" left="221" width="79" height="12" font="24">Professor of Pediatrics</text>
<text top="852" left="370" width="19" height="12" font="24">None</text>
<text top="852" left="455" width="19" height="12" font="24">None</text>
<text top="852" left="534" width="19" height="12" font="24">None</text>
<text top="852" left="606" width="19" height="12" font="24">None</text>
<text top="852" left="683" width="19" height="12" font="24">None</text>
<text top="852" left="761" width="19" height="12" font="24">None</text>
<text top="948" left="81" width="35" height="12" font="24">Susan P. </text>
<text top="960" left="81" width="36" height="12" font="24">Etheridge</text>
<text top="948" left="138" width="32" height="12" font="24">Content </text>
<text top="960" left="138" width="63" height="12" font="24">Reviewer—ACC </text>
<text top="973" left="138" width="64" height="12" font="24">Adult Congenital </text>
<text top="985" left="138" width="52" height="12" font="24">and Pediatric </text>
<text top="998" left="138" width="67" height="12" font="24">Cardiology Section</text>
<text top="948" left="221" width="101" height="12" font="24">University of Utah—Training </text>
<text top="960" left="221" width="64" height="12" font="24">Program Director</text>
<text top="948" left="370" width="19" height="12" font="24">None</text>
<text top="948" left="455" width="19" height="12" font="24">None</text>
<text top="948" left="534" width="19" height="12" font="24">None</text>
<text top="948" left="606" width="19" height="12" font="24">None</text>
<text top="948" left="683" width="19" height="12" font="24">None</text>
<text top="948" left="761" width="19" height="12" font="24">None</text>
<text top="1019" left="81" width="29" height="12" font="24">Paul A. </text>
<text top="1031" left="81" width="35" height="12" font="24">Friedman</text>
<text top="1019" left="138" width="66" height="12" font="24">Content Reviewer</text>
<text top="1019" left="221" width="101" height="12" font="24">Mayo Clinic—Professor of </text>
<text top="1031" left="221" width="97" height="12" font="24">Medicine; Cardiovascular </text>
<text top="1043" left="221" width="74" height="12" font="24">Implantable Device </text>
<text top="1056" left="221" width="80" height="12" font="24">Laboratory—Director</text>
<text top="1019" left="338" width="47" height="12" font="24">•  NeoChord</text>
<text top="1019" left="455" width="19" height="12" font="24">None</text>
<text top="1019" left="534" width="19" height="12" font="24">None</text>
<text top="1019" left="584" width="49" height="12" font="24">•  Biotronik†</text>
<text top="1031" left="584" width="48" height="12" font="24">•  Medtronic</text>
<text top="1043" left="584" width="46" height="12" font="24">•   St. Jude  </text>
<text top="1056" left="594" width="29" height="12" font="24">Medical</text>
<text top="1019" left="657" width="50" height="12" font="24">•  Preventice</text>
<text top="1031" left="657" width="33" height="12" font="24">•  Sorin*</text>
<text top="1019" left="761" width="19" height="12" font="24">None</text>
<text top="97" left="71" width="126" height="16" font="17"><b>Appendix 2. Continued</b></text>
<text top="174" left="81" width="35" height="12" font="24">Reviewer</text>
<text top="174" left="142" width="57" height="12" font="24">Representation</text>
<text top="174" left="247" width="47" height="12" font="24">Employment</text>
<text top="174" left="355" width="40" height="12" font="24">Consultant</text>
<text top="161" left="447" width="40" height="12" font="24">Speakers  </text>
<text top="174" left="451" width="27" height="12" font="24">Bureau</text>
<text top="149" left="522" width="46" height="12" font="24">Ownership/ </text>
<text top="161" left="520" width="48" height="12" font="24">Partnership/ </text>
<text top="174" left="527" width="32" height="12" font="24">Principal</text>
<text top="161" left="600" width="37" height="12" font="24">Personal  </text>
<text top="174" left="599" width="35" height="12" font="24">Research</text>
<text top="124" left="670" width="49" height="12" font="24">Institutional, </text>
<text top="136" left="665" width="61" height="12" font="24">Organizational,  </text>
<text top="149" left="678" width="35" height="12" font="24">or Other  </text>
<text top="161" left="676" width="39" height="12" font="24">Financial  </text>
<text top="174" left="680" width="26" height="12" font="24">Benefit</text>
<text top="161" left="759" width="29" height="12" font="24">Expert  </text>
<text top="174" left="756" width="30" height="12" font="24">Witness</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="420" width="387" height="17" font="10"><b>Page et al    2015 ACC/AHA/HRS SVT Guideline    <i>e573</i></b></text>
<text top="195" left="80" width="26" height="12" font="24">Bulent </text>
<text top="207" left="80" width="31" height="12" font="24">Gorenek</text>
<text top="195" left="137" width="31" height="12" font="24">Content </text>
<text top="207" left="137" width="62" height="12" font="24">Reviewer—ACC </text>
<text top="220" left="137" width="66" height="12" font="24">Electrophysiology </text>
<text top="232" left="137" width="27" height="12" font="24">Section</text>
<text top="195" left="220" width="81" height="12" font="24">Eskisehir Osmangazi </text>
<text top="207" left="220" width="101" height="12" font="24">University—Professor and </text>
<text top="220" left="220" width="95" height="12" font="24">Vice Director, Cardiology </text>
<text top="232" left="220" width="44" height="12" font="24">Department</text>
<text top="195" left="368" width="19" height="12" font="24">None</text>
<text top="195" left="453" width="19" height="12" font="24">None</text>
<text top="195" left="532" width="19" height="12" font="24">None</text>
<text top="195" left="605" width="19" height="12" font="24">None</text>
<text top="195" left="682" width="19" height="12" font="24">None</text>
<text top="195" left="760" width="19" height="12" font="24">None</text>
<text top="253" left="80" width="47" height="12" font="24">Jonathan L. </text>
<text top="266" left="80" width="31" height="12" font="24">Halperin</text>
<text top="253" left="137" width="32" height="12" font="24">Content </text>
<text top="266" left="137" width="63" height="12" font="24">Reviewer—ACC/</text>
<text top="278" left="137" width="74" height="12" font="24">AHA Task Force on </text>
<text top="291" left="137" width="63" height="12" font="24">Clinical Practice </text>
<text top="303" left="137" width="39" height="12" font="24">Guidelines</text>
<text top="253" left="220" width="75" height="12" font="24">Mt. Sinai Medical—</text>
<text top="266" left="220" width="82" height="12" font="24">Professor of Medicine</text>
<text top="253" left="337" width="57" height="12" font="24">•  AstraZeneca</text>
<text top="266" left="337" width="75" height="12" font="24">•  Bayer Healthcare</text>
<text top="278" left="337" width="49" height="12" font="24">•  Biotronik†</text>
<text top="291" left="337" width="54" height="12" font="24">•   Boehringer </text>
<text top="303" left="347" width="42" height="12" font="24">Ingelheim†</text>
<text top="315" left="337" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="328" left="337" width="67" height="12" font="24">•  Daiichi-Sankyo</text>
<text top="340" left="337" width="52" height="12" font="24">•   Johnson &amp; </text>
<text top="353" left="347" width="32" height="12" font="24">Johnson</text>
<text top="365" left="337" width="48" height="12" font="24">•  Medtronic</text>
<text top="378" left="337" width="31" height="12" font="24">•  Pfizer</text>
<text top="253" left="453" width="19" height="12" font="24">None</text>
<text top="253" left="532" width="19" height="12" font="24">None</text>
<text top="253" left="605" width="19" height="12" font="24">None</text>
<text top="253" left="682" width="19" height="12" font="24">None</text>
<text top="253" left="760" width="19" height="12" font="24">None</text>
<text top="399" left="80" width="42" height="12" font="24">Warren M. </text>
<text top="411" left="80" width="34" height="12" font="24">Jackman</text>
<text top="399" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="399" left="220" width="89" height="12" font="24">University of Oklahoma </text>
<text top="411" left="220" width="63" height="12" font="24">Health Sciences </text>
<text top="424" left="220" width="85" height="12" font="24">Center—George Lynn </text>
<text top="436" left="220" width="99" height="12" font="24">Cross Research Professor </text>
<text top="448" left="220" width="92" height="12" font="24">Emeritus; Heart Rhythm </text>
<text top="461" left="220" width="104" height="12" font="24">Institute—Senior Scientific </text>
<text top="473" left="220" width="28" height="12" font="24">Advisor</text>
<text top="399" left="337" width="78" height="12" font="24">•  Biosense Webster*</text>
<text top="411" left="337" width="73" height="12" font="24">•  Boston Scientific*</text>
<text top="424" left="337" width="48" height="12" font="24">•  VytronUS*</text>
<text top="399" left="424" width="44" height="12" font="24">•  AtriCure*</text>
<text top="411" left="424" width="76" height="12" font="24">•   Biosense Webster*</text>
<text top="424" left="424" width="47" height="12" font="24">•  Biotronik*</text>
<text top="436" left="424" width="77" height="12" font="24">•   Boston Scientific*</text>
<text top="399" left="532" width="19" height="12" font="24">None</text>
<text top="399" left="605" width="19" height="12" font="24">None</text>
<text top="399" left="682" width="19" height="12" font="24">None</text>
<text top="399" left="760" width="19" height="12" font="24">None</text>
<text top="494" left="80" width="43" height="12" font="24">G. Neal Kay</text>
<text top="494" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="494" left="220" width="92" height="12" font="24">University of Alabama—</text>
<text top="507" left="220" width="71" height="12" font="24">Professor Emeritus</text>
<text top="494" left="368" width="19" height="12" font="24">None</text>
<text top="494" left="453" width="19" height="12" font="24">None</text>
<text top="494" left="532" width="19" height="12" font="24">None</text>
<text top="494" left="605" width="19" height="12" font="24">None</text>
<text top="494" left="682" width="19" height="12" font="24">None</text>
<text top="494" left="760" width="19" height="12" font="24">None</text>
<text top="528" left="80" width="38" height="12" font="24">George J. </text>
<text top="540" left="80" width="19" height="12" font="24">Klein</text>
<text top="528" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="528" left="220" width="93" height="12" font="24">London Health Sciences </text>
<text top="540" left="220" width="101" height="12" font="24">Center—Chief of Cardiology</text>
<text top="528" left="337" width="44" height="12" font="24">•  Biotronik</text>
<text top="540" left="337" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="553" left="337" width="53" height="12" font="24">•  Medtronic†</text>
<text top="528" left="453" width="19" height="12" font="24">None</text>
<text top="528" left="532" width="19" height="12" font="24">None</text>
<text top="528" left="605" width="19" height="12" font="24">None</text>
<text top="528" left="682" width="19" height="12" font="24">None</text>
<text top="528" left="760" width="19" height="12" font="24">None</text>
<text top="574" left="80" width="41" height="12" font="24">Bradley P. </text>
<text top="586" left="80" width="24" height="12" font="24">Knight</text>
<text top="574" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="574" left="220" width="100" height="12" font="24">Northwestern University—</text>
<text top="586" left="220" width="87" height="12" font="24">Professor of Cardiology</text>
<text top="574" left="337" width="73" height="12" font="24">•  Boston Scientific</text>
<text top="586" left="337" width="48" height="12" font="24">•  Medtronic</text>
<text top="574" left="424" width="78" height="12" font="24">•  Biosense Webster</text>
<text top="586" left="424" width="44" height="12" font="24">•  Biotronik</text>
<text top="598" left="424" width="73" height="12" font="24">•   Boston Scientific</text>
<text top="611" left="424" width="48" height="12" font="24">•  Medtronic</text>
<text top="574" left="532" width="19" height="12" font="24">None</text>
<text top="574" left="605" width="19" height="12" font="24">None</text>
<text top="574" left="682" width="19" height="12" font="24">None</text>
<text top="574" left="760" width="19" height="12" font="24">None</text>
<text top="632" left="80" width="31" height="12" font="24">John D. </text>
<text top="644" left="80" width="24" height="12" font="24">Kugler</text>
<text top="632" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="632" left="220" width="87" height="12" font="24">University of Nebraska </text>
<text top="644" left="220" width="99" height="12" font="24">Medical Center—Division </text>
<text top="657" left="220" width="101" height="12" font="24">Chief of Pediatric Cardiology</text>
<text top="632" left="368" width="19" height="12" font="24">None</text>
<text top="632" left="453" width="19" height="12" font="24">None</text>
<text top="632" left="532" width="19" height="12" font="24">None</text>
<text top="632" left="605" width="19" height="12" font="24">None</text>
<text top="632" left="682" width="19" height="12" font="24">None</text>
<text top="632" left="760" width="19" height="12" font="24">None</text>
<text top="678" left="80" width="31" height="12" font="24">Fred M. </text>
<text top="690" left="80" width="38" height="12" font="24">Kusumoto</text>
<text top="678" left="137" width="66" height="12" font="24">Content Reviewer</text>
<text top="678" left="220" width="101" height="12" font="24">Mayo Clinic—Professor of </text>
<text top="690" left="220" width="34" height="12" font="24">Medicine</text>
<text top="678" left="368" width="19" height="12" font="24">None</text>
<text top="678" left="453" width="19" height="12" font="24">None</text>
<text top="678" left="532" width="19" height="12" font="24">None</text>
<text top="678" left="605" width="19" height="12" font="24">None</text>
<text top="678" left="682" width="19" height="12" font="24">None</text>
<text top="678" left="760" width="19" height="12" font="24">None</text>
<text top="711" left="80" width="35" height="12" font="24">Glenn N. </text>
<text top="724" left="80" width="25" height="12" font="24">Levine</text>
<text top="711" left="136" width="32" height="12" font="24">Content </text>
<text top="724" left="136" width="63" height="12" font="24">Reviewer—ACC/</text>
<text top="736" left="136" width="74" height="12" font="24">AHA Task Force on </text>
<text top="748" left="136" width="63" height="12" font="24">Clinical Practice </text>
<text top="761" left="136" width="39" height="12" font="24">Guidelines</text>
<text top="711" left="220" width="66" height="12" font="24">Baylor College of </text>
<text top="724" left="220" width="92" height="12" font="24">Medicine—Professor of </text>
<text top="736" left="220" width="105" height="12" font="24">Medicine; Director, Cardiac </text>
<text top="748" left="220" width="35" height="12" font="24">Care Unit</text>
<text top="711" left="368" width="19" height="12" font="24">None</text>
<text top="711" left="453" width="19" height="12" font="24">None</text>
<text top="711" left="532" width="19" height="12" font="24">None</text>
<text top="711" left="605" width="19" height="12" font="24">None</text>
<text top="711" left="682" width="19" height="12" font="24">None</text>
<text top="711" left="760" width="19" height="12" font="24">None</text>
<text top="782" left="80" width="36" height="12" font="24">Marco A. </text>
<text top="794" left="80" width="36" height="12" font="24">Mercader</text>
<text top="782" left="136" width="66" height="12" font="24">Content Reviewer</text>
<text top="782" left="220" width="76" height="12" font="24">George Washington </text>
<text top="794" left="220" width="86" height="12" font="24">University—Associate </text>
<text top="807" left="220" width="82" height="12" font="24">Professor of Medicine</text>
<text top="782" left="368" width="19" height="12" font="24">None</text>
<text top="782" left="453" width="19" height="12" font="24">None</text>
<text top="782" left="532" width="19" height="12" font="24">None</text>
<text top="782" left="605" width="19" height="12" font="24">None</text>
<text top="782" left="682" width="19" height="12" font="24">None</text>
<text top="782" left="760" width="19" height="12" font="24">None</text>
<text top="828" left="80" width="42" height="12" font="24">William M. </text>
<text top="840" left="80" width="20" height="12" font="24">Miles</text>
<text top="828" left="136" width="66" height="12" font="24">Content Reviewer</text>
<text top="828" left="220" width="85" height="12" font="24">University of Florida—</text>
<text top="840" left="220" width="87" height="12" font="24">Professor of Medicine, </text>
<text top="853" left="220" width="76" height="12" font="24">Silverstein Chair for </text>
<text top="865" left="220" width="100" height="12" font="24">Cardiovascular Education, </text>
<text top="878" left="220" width="86" height="12" font="24">Director of the Clinical </text>
<text top="890" left="220" width="99" height="12" font="24">Cardiac Electrophysiology </text>
<text top="902" left="220" width="75" height="12" font="24">Fellowship Program</text>
<text top="828" left="368" width="19" height="12" font="24">None</text>
<text top="828" left="453" width="19" height="12" font="24">None</text>
<text top="828" left="532" width="19" height="12" font="24">None</text>
<text top="828" left="605" width="19" height="12" font="24">None</text>
<text top="828" left="656" width="53" height="12" font="24">•   Medtronic  </text>
<text top="840" left="666" width="28" height="12" font="24">(DSMB)</text>
<text top="828" left="760" width="19" height="12" font="24">None</text>
<text top="923" left="80" width="19" height="12" font="24">Fred </text>
<text top="936" left="80" width="28" height="12" font="24">Morady</text>
<text top="923" left="136" width="66" height="12" font="24">Content Reviewer</text>
<text top="923" left="220" width="93" height="12" font="24">University of Michigan—</text>
<text top="936" left="220" width="75" height="12" font="24">McKay Professor of </text>
<text top="948" left="220" width="88" height="12" font="24">Cardiovascular Disease</text>
<text top="923" left="368" width="19" height="12" font="24">None</text>
<text top="923" left="453" width="19" height="12" font="24">None</text>
<text top="923" left="532" width="19" height="12" font="24">None</text>
<text top="923" left="605" width="19" height="12" font="24">None</text>
<text top="923" left="682" width="19" height="12" font="24">None</text>
<text top="923" left="760" width="19" height="12" font="24">None</text>
<text top="969" left="80" width="39" height="12" font="24">Melvin M. </text>
<text top="982" left="80" width="42" height="12" font="24">Scheinman</text>
<text top="969" left="136" width="66" height="12" font="24">Content Reviewer</text>
<text top="969" left="220" width="104" height="12" font="24">University of California San </text>
<text top="982" left="220" width="94" height="12" font="24">Francisco—Professor of </text>
<text top="994" left="220" width="34" height="12" font="24">Medicine</text>
<text top="969" left="336" width="37" height="12" font="24">•  Amgen</text>
<text top="982" left="336" width="78" height="12" font="24">•  Biosense Webster</text>
<text top="994" left="336" width="47" height="12" font="24">•  Biotronik*</text>
<text top="1007" left="336" width="77" height="12" font="24">•  Boston Scientific*</text>
<text top="1019" left="336" width="70" height="12" font="24">•  Gilead Sciences</text>
<text top="1032" left="336" width="44" height="12" font="24">•   Janssen </text>
<text top="1044" left="347" width="62" height="12" font="24">Pharmaceuticals</text>
<text top="1056" left="336" width="48" height="12" font="24">•  Medtronic</text>
<text top="1069" left="336" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="969" left="453" width="19" height="12" font="24">None</text>
<text top="969" left="532" width="19" height="12" font="24">None</text>
<text top="969" left="605" width="19" height="12" font="24">None</text>
<text top="969" left="682" width="19" height="12" font="24">None</text>
<text top="969" left="760" width="19" height="12" font="24">None</text>
<text top="1094" left="762" width="45" height="12" font="24">(Continued )</text>
<text top="97" left="69" width="126" height="16" font="17"><b>Appendix 2. Continued</b></text>
<text top="174" left="80" width="35" height="12" font="24">Reviewer</text>
<text top="174" left="140" width="57" height="12" font="24">Representation</text>
<text top="174" left="245" width="47" height="12" font="24">Employment</text>
<text top="174" left="354" width="40" height="12" font="24">Consultant</text>
<text top="161" left="445" width="40" height="12" font="24">Speakers  </text>
<text top="174" left="450" width="27" height="12" font="24">Bureau</text>
<text top="149" left="520" width="46" height="12" font="24">Ownership/ </text>
<text top="161" left="519" width="48" height="12" font="24">Partnership/ </text>
<text top="174" left="526" width="32" height="12" font="24">Principal</text>
<text top="161" left="598" width="37" height="12" font="24">Personal  </text>
<text top="174" left="597" width="35" height="12" font="24">Research</text>
<text top="124" left="669" width="49" height="12" font="24">Institutional, </text>
<text top="136" left="664" width="61" height="12" font="24">Organizational,  </text>
<text top="149" left="676" width="35" height="12" font="24">or Other  </text>
<text top="161" left="675" width="39" height="12" font="24">Financial  </text>
<text top="174" left="678" width="26" height="12" font="24">Benefit</text>
<text top="161" left="758" width="29" height="12" font="24">Expert  </text>
<text top="174" left="755" width="30" height="12" font="24">Witness</text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1174" width="877">
<text top="47" left="71" width="243" height="17" font="11"><i><b>e574  Circulation  </b></i><b>April 5, 2016</b></text>
<text top="195" left="82" width="34" height="12" font="24">Sarah A. </text>
<text top="207" left="82" width="26" height="12" font="24">Spinler</text>
<text top="195" left="139" width="66" height="12" font="24">Content Reviewer</text>
<text top="195" left="222" width="102" height="12" font="24">University of the Sciences, </text>
<text top="207" left="222" width="88" height="12" font="24">Philadelphia College of </text>
<text top="220" left="222" width="95" height="12" font="24">Pharmacy—Professor of </text>
<text top="232" left="222" width="67" height="12" font="24">Clinical Pharmacy</text>
<text top="195" left="339" width="39" height="12" font="24">•   Portola </text>
<text top="207" left="349" width="62" height="12" font="24">Pharmaceuticals</text>
<text top="195" left="455" width="19" height="12" font="24">None</text>
<text top="195" left="534" width="19" height="12" font="24">None</text>
<text top="195" left="607" width="19" height="12" font="24">None</text>
<text top="195" left="684" width="19" height="12" font="24">None</text>
<text top="195" left="762" width="19" height="12" font="24">None</text>
<text top="253" left="82" width="40" height="12" font="24">William G. </text>
<text top="266" left="82" width="39" height="12" font="24">Stevenson</text>
<text top="253" left="139" width="66" height="12" font="24">Content Reviewer</text>
<text top="253" left="222" width="88" height="12" font="24">Brigham and Women’s </text>
<text top="266" left="222" width="105" height="12" font="24">Hospital—Director, Clinical </text>
<text top="278" left="222" width="99" height="12" font="24">Cardiac Electrophysiology </text>
<text top="291" left="222" width="32" height="12" font="24">Program</text>
<text top="253" left="339" width="73" height="12" font="24">•  St. Jude Medical</text>
<text top="253" left="455" width="19" height="12" font="24">None</text>
<text top="253" left="534" width="19" height="12" font="24">None</text>
<text top="253" left="607" width="19" height="12" font="24">None</text>
<text top="253" left="684" width="19" height="12" font="24">None</text>
<text top="253" left="762" width="19" height="12" font="24">None</text>
<text top="311" left="82" width="34" height="12" font="24">Albert L. </text>
<text top="324" left="82" width="23" height="12" font="24">Waldo</text>
<text top="311" left="139" width="66" height="12" font="24">Content Reviewer</text>
<text top="311" left="222" width="84" height="12" font="24">University Hospitals—</text>
<text top="324" left="222" width="70" height="12" font="24">Associate Chief of </text>
<text top="336" left="222" width="95" height="12" font="24">Cardiovascular Medicine </text>
<text top="349" left="222" width="102" height="12" font="24">for Academic Affairs; Case </text>
<text top="361" left="222" width="105" height="12" font="24">Western Reserve University </text>
<text top="374" left="222" width="82" height="12" font="24">School of Medicine—</text>
<text top="386" left="222" width="82" height="12" font="24">Professor of Medicine</text>
<text top="311" left="339" width="41" height="12" font="24">•  AtriCure</text>
<text top="324" left="339" width="76" height="12" font="24">•  Biosense Webster*</text>
<text top="336" left="339" width="59" height="12" font="24">•  CardioInsight</text>
<text top="349" left="339" width="39" height="12" font="24">•  ChanRx</text>
<text top="361" left="339" width="67" height="12" font="24">•  Daiichi-Sankyo</text>
<text top="374" left="339" width="72" height="12" font="24">•  Gilead Sciences </text>
<text top="386" left="339" width="34" height="12" font="24">•  Pfizer </text>
<text top="399" left="339" width="77" height="12" font="24">•  St. Jude Medical*</text>
<text top="312" left="427" width="63" height="12" font="24">•   Bristol-Myers </text>
<text top="324" left="437" width="30" height="12" font="24">Squibb*</text>
<text top="336" left="427" width="44" height="12" font="24">•   Janssen </text>
<text top="349" left="437" width="62" height="12" font="24">Pharmaceuticals</text>
<text top="361" left="427" width="35" height="12" font="24">•  Pfizer*</text>
<text top="312" left="534" width="19" height="12" font="24">None</text>
<text top="312" left="585" width="36" height="12" font="24">•   Gilead </text>
<text top="324" left="595" width="37" height="12" font="24">Sciences*</text>
<text top="312" left="684" width="19" height="12" font="24">None</text>
<text top="312" left="762" width="19" height="12" font="24">None</text>
<text top="420" left="82" width="31" height="12" font="24">Edward </text>
<text top="432" left="82" width="23" height="12" font="24">Walsh</text>
<text top="420" left="139" width="66" height="12" font="24">Content Reviewer</text>
<text top="420" left="222" width="99" height="12" font="24">Harvard Medical School—</text>
<text top="432" left="222" width="89" height="12" font="24">Professor of Pediatrics; </text>
<text top="445" left="222" width="69" height="12" font="24">Boston Children’s </text>
<text top="457" left="222" width="106" height="12" font="24">Hospital—Chief, Division of </text>
<text top="469" left="222" width="97" height="12" font="24">Cardiac Electrophysiology</text>
<text top="420" left="339" width="78" height="12" font="24">•  Biosense Webster†</text>
<text top="420" left="455" width="19" height="12" font="24">None</text>
<text top="420" left="534" width="19" height="12" font="24">None</text>
<text top="420" left="607" width="19" height="12" font="24">None</text>
<text top="420" left="684" width="19" height="12" font="24">None</text>
<text top="420" left="762" width="19" height="12" font="24">None</text>
<text top="490" left="82" width="34" height="12" font="24">Richard  </text>
<text top="503" left="82" width="22" height="12" font="24">C. Wu</text>
<text top="490" left="139" width="66" height="12" font="24">Content Reviewer</text>
<text top="490" left="222" width="68" height="12" font="24">University of Texas </text>
<text top="503" left="222" width="80" height="12" font="24">Southwestern Medical </text>
<text top="515" left="222" width="105" height="12" font="24">Center—Professor of Internal </text>
<text top="528" left="222" width="103" height="12" font="24">Medicine, Director of Cardiac </text>
<text top="540" left="222" width="76" height="12" font="24">Electrophysiology Lab</text>
<text top="490" left="371" width="19" height="12" font="24">None</text>
<text top="490" left="455" width="19" height="12" font="24">None</text>
<text top="490" left="534" width="19" height="12" font="24">None</text>
<text top="490" left="585" width="54" height="12" font="24">•   Boehringer </text>
<text top="503" left="595" width="37" height="12" font="24">Ingelheim</text>
<text top="515" left="585" width="44" height="12" font="24">•   Janssen </text>
<text top="528" left="595" width="54" height="12" font="24">Pharmaceutical</text>
<text top="540" left="585" width="48" height="12" font="24">•  Medtronic</text>
<text top="490" left="684" width="19" height="12" font="24">None</text>
<text top="490" left="762" width="19" height="12" font="24">None</text>
<text top="559" left="84" width="729" height="14" font="3">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to </text>
<text top="574" left="72" width="741" height="14" font="3">this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the </text>
<text top="589" left="72" width="147" height="14" font="3">interest represents ownership of </text>
<text top="589" left="219" width="594" height="14" font="3">≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if </text>
<text top="604" left="72" width="741" height="14" font="3">funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is </text>
<text top="619" left="72" width="741" height="14" font="3">less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in </text>
<text top="634" left="72" width="514" height="14" font="3">this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.</text>
<text top="649" left="84" width="729" height="14" font="3">According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property </text>
<text top="664" left="72" width="741" height="14" font="3">or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the </text>
<text top="679" left="72" width="741" height="14" font="3">document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for </text>
<text top="694" left="72" width="500" height="14" font="3">financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="709" left="84" width="108" height="14" font="3">*Significant relationship.</text>
<text top="724" left="84" width="94" height="14" font="3">†No financial benefit.</text>
<text top="739" left="84" width="669" height="14" font="3">ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and HRS, Heart Rhythm Society.</text>
<text top="858" left="71" width="146" height="16" font="17"><b>Appendix 3. Abbreviations</b></text>
<text top="885" left="82" width="25" height="14" font="3">ACHD</text>
<text top="885" left="160" width="130" height="14" font="3">adult congenital heart disease</text>
<text top="906" left="82" width="11" height="14" font="3">AF</text>
<text top="906" left="160" width="69" height="14" font="3">atrial fibrillation</text>
<text top="927" left="82" width="12" height="14" font="3">AT</text>
<text top="927" left="160" width="76" height="14" font="3">atrial tachycardia</text>
<text top="948" left="82" width="12" height="14" font="3">AV</text>
<text top="948" left="160" width="67" height="14" font="3">atrioventricular</text>
<text top="970" left="82" width="30" height="14" font="3">AVNRT</text>
<text top="970" left="160" width="191" height="14" font="3">atrioventricular nodal reentrant tachycardia</text>
<text top="991" left="82" width="23" height="14" font="3">AVRT</text>
<text top="991" left="160" width="164" height="14" font="3">atrioventricular reentrant tachycardia</text>
<text top="1012" left="82" width="12" height="14" font="3">BP</text>
<text top="1012" left="160" width="66" height="14" font="3">blood pressure</text>
<text top="1033" left="82" width="14" height="14" font="3">CTI</text>
<text top="1033" left="160" width="97" height="14" font="3">cavotricuspid isthmus</text>
<text top="1054" left="82" width="18" height="14" font="3">ECG</text>
<text top="1054" left="160" width="175" height="14" font="3">electrocardiogram/electrocardiographic</text>
<text top="1075" left="82" width="18" height="14" font="3">ERC</text>
<text top="1075" left="160" width="126" height="14" font="3">Evidence Review Committee</text>
<text top="1097" left="82" width="11" height="14" font="3">EP</text>
<text top="1097" left="160" width="88" height="14" font="3">electrophysiological</text>
<text top="97" left="71" width="126" height="16" font="17"><b>Appendix 2. Continued</b></text>
<text top="174" left="82" width="35" height="12" font="24">Reviewer</text>
<text top="174" left="143" width="57" height="12" font="24">Representation</text>
<text top="174" left="248" width="47" height="12" font="24">Employment</text>
<text top="174" left="356" width="40" height="12" font="24">Consultant</text>
<text top="161" left="448" width="40" height="12" font="24">Speakers  </text>
<text top="174" left="452" width="27" height="12" font="24">Bureau</text>
<text top="149" left="523" width="46" height="12" font="24">Ownership/ </text>
<text top="161" left="521" width="48" height="12" font="24">Partnership/ </text>
<text top="174" left="528" width="32" height="12" font="24">Principal</text>
<text top="161" left="601" width="37" height="12" font="24">Personal  </text>
<text top="174" left="599" width="35" height="12" font="24">Research</text>
<text top="124" left="671" width="49" height="12" font="24">Institutional, </text>
<text top="136" left="666" width="61" height="12" font="24">Organizational,  </text>
<text top="149" left="679" width="35" height="12" font="24">or Other  </text>
<text top="161" left="677" width="39" height="12" font="24">Financial  </text>
<text top="174" left="681" width="26" height="12" font="24">Benefit</text>
<text top="161" left="760" width="29" height="12" font="24">Expert  </text>
<text top="174" left="757" width="30" height="12" font="24">Witness</text>
<text top="888" left="468" width="24" height="14" font="3">GWC </text>
<text top="888" left="546" width="124" height="14" font="3">guideline writing committee</text>
<text top="910" left="468" width="14" height="14" font="3">IST</text>
<text top="910" left="546" width="139" height="14" font="3">inappropriate sinus tachycardia</text>
<text top="931" left="468" width="20" height="14" font="3">MAT</text>
<text top="931" left="546" width="123" height="14" font="3">multifocal atrial tachycardia</text>
<text top="953" left="468" width="23" height="14" font="3">PJRT</text>
<text top="953" left="546" width="195" height="14" font="3">permanent form of junctional reciprocating  </text>
<text top="968" left="546" width="51" height="14" font="3">tachycardia</text>
<text top="989" left="468" width="23" height="14" font="3">PSVT</text>
<text top="989" left="546" width="180" height="14" font="3">paroxysmal supraventricular tachycardia</text>
<text top="1010" left="468" width="18" height="14" font="3">RCT</text>
<text top="1010" left="546" width="118" height="14" font="3">randomized controlled trial</text>
<text top="1032" left="468" width="19" height="14" font="3">SCD</text>
<text top="1032" left="546" width="96" height="14" font="3">sudden cardiac death</text>
<text top="1053" left="468" width="17" height="14" font="3">SVT</text>
<text top="1053" left="546" width="126" height="14" font="3">supraventricular tachycardia</text>
<text top="1075" left="468" width="11" height="14" font="3">VT</text>
<text top="1075" left="546" width="101" height="14" font="3">ventricular tachycardia</text>
<text top="1096" left="468" width="23" height="14" font="3">WPW</text>
<text top="1096" left="546" width="100" height="14" font="3">Wolff-Parkinson-White</text>
<text top="859" left="458" width="126" height="16" font="17"><b>Appendix 3. Continued</b></text>
<text top="585" left="30" width="0" height="11" font="9">Downloaded from http://ahajournals.org by on June 16, 2019</text>
</page>
</pdf2xml>
